PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	WOOD, DD; PANG, H; HEMPEL, A; CAMERMAN, N; LANE, BG; MOSCARELLO, MA				WOOD, DD; PANG, H; HEMPEL, A; CAMERMAN, N; LANE, BG; MOSCARELLO, MA			PARTICIPATION OF ACETYLPSEUDOURIDINE IN THE SYNTHESIS OF A PEPTIDE-BOND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBOSOMAL-RNA; TERMINUS; SUBUNIT	Uracil, uridine, and pseudouridine were acetylated by refluxing in acetic anhydride, and the products of acetylation were incubated with a synthetic peptide (1-21) that corresponds to the N-terminal 21 amino acid residues of human myelin basic protein. Peptide bond formation, at the N-alpha terminus in peptide 1-21, was obtained with acetyluracil and acetylpseudouridine, but not with acetyluridine. Transfer of an acetyl group from acetyluracil and acetylpseudouridine depended on acetylation in the N-heterocycle. X-ray crystallographic analysis definitively established N-1 as the site of acetylation in acetyluracil. Mass spectrometry of the acetylation products showed that one acetyl group was transferred to peptide 1-21, in water, by either acetyluracil or acetylpseudouridine at pH similar to 6. Release of the acetyl group by acylaminopeptidase regenerated peptide 1-21 (mass spectrometry) and automated sequencing (for five cycles) of the regenerated (deacetylated) peptide demonstrated that the N terminus was intact. The findings are discussed in the context of a possible role for pseudouridine in ribosome-catalyzed peptidyltransfer, with particular reference being made to similarities between the possible mechanism of acyl transfer by acetyluracil/ pseudouridine and the mechanism of carboxyl transfer by carboxylbiotin in acetyl CoA carboxylase. The possibility that idiosyncratic appearance of a wide range of acyl substituents in myelin basic protein could be related to a peculiar involvement of ribosomal pseudouridine is mentioned.	HOSP SICK CHILDREN,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,CARBOHYDRATE RES CTR,TORONTO,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto								AZAD AA, 1973, CAN J BIOCHEM CELL B, V51, P1195, DOI 10.1139/o73-155; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; COHN WE, 1959, BIOCHIM BIOPHYS ACTA, V32, P569, DOI 10.1016/0006-3002(59)90644-4; COOPERMAN BS, 1995, IN PRESS BIOCH CELL; COSTENTINO M, 1994, BIOCHEMISTRY-US, V33, P4155, DOI 10.1021/bi00180a008; DAVIS FF, 1957, J BIOL CHEM, V227, P907; DETITTA GT, 1980, P NATL ACAD SCI-BIOL, V77, P333, DOI 10.1073/pnas.77.1.333; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FOX JJ, 1952, BIOCHIM BIOPHYS ACTA, V9, P369, DOI 10.1016/0006-3002(52)90181-9; HOAGLAND MB, 1960, NUCL ACIDS, V0003, P00349; LANE BG, 1992, FEBS LETT, V302, P1, DOI 10.1016/0014-5793(92)80269-M; LANE BG, 1965, BIOCHEMISTRY-US, V4, P212, DOI 10.1021/bi00878a006; LANE BG, 1967, J MOL BIOL, V27, P335, DOI 10.1016/0022-2836(67)90024-1; LANE BG, 1961, BIOCHIM BIOPHYS ACTA, V47, P36, DOI 10.1016/0006-3002(61)90826-5; LANE BG, 1995, BIOCHIMIE PARIS, V76, P7; MANDEL NS, 1976, J AM CHEM SOC, V98, P2319, DOI 10.1021/ja00424a054; McCloskey J. A., 1974, BASIC PRINCIPLES NUC, V1, P209; MOSCARELLO MA, 1992, J BIOL CHEM, V267, P9779; NICHOLS JL, 1967, J MOL BIOL, V30, P477, DOI 10.1016/0022-2836(67)90363-4; NICHOLS JL, 1966, BIOCHIM BIOPHYS ACTA, V119, P649, DOI 10.1016/0005-2787(66)90147-X; NICHOLS JL, 1968, CAN J BIOCHEM CELL B, V46, P1487, DOI 10.1139/o68-222; NICHOLS JL, 1967, CAN J BIOCHEM CELL B, V45, P937, DOI 10.1139/o67-104; NICHOLS JL, 1966, CAN J BIOCHEM CELL B, V44, P1633, DOI 10.1139/o66-186; OAKDEN KM, 1976, CAN J BIOCHEM CELL B, V54, P261, DOI 10.1139/o76-039; OFENGAND J, 1965, BIOCHEMISTRY-US, V4, P2832, DOI 10.1021/bi00888a038; OFENGAND J, 1995, IN PRESS BIOCH CELL; PACE NR, 1992, SCIENCE, V256, P1402, DOI 10.1126/science.1376496; RICE JM, 1965, J AM CHEM SOC, V87, P4569, DOI 10.1021/ja00948a029; ROMERO DP, 1990, J BIOL CHEM, V265, P18185; SCANNELL JP, 1959, BIOCHIM BIOPHYS ACTA, V32, P406, DOI 10.1016/0006-3002(59)90613-4; SHELDRICK GM, 1993, SHELXL 93 PROGRAM RE; Sheldrick GM, 1986, SHELXS 86 PROGRAM CR; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SHUGAR D, 1952, BIOCHIM BIOPHYS ACTA, V9, P199, DOI 10.1016/0006-3002(52)90147-9; SPECTOR LB, 1958, J BIOL CHEM, V232, P185; STALLINGS WC, 1980, P NATL ACAD SCI-BIOL, V77, P1260, DOI 10.1073/pnas.77.3.1260; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; STEWART RF, 1967, ACTA CRYSTALLOGR, V23, P1102, DOI 10.1107/S0365110X67004360; STRADE K, 1995, NUCLEIC ACIDS RES, V23, P2371; WRZESINSKI J, 1995, IN PRESS RNA, V1; YU CT, 1959, BIOCHIM BIOPHYS ACTA, V32, P393, DOI 10.1016/0006-3002(59)90612-2	42	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21040	21044		10.1074/jbc.270.36.21040	http://dx.doi.org/10.1074/jbc.270.36.21040			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545664	hybrid			2022-12-25	WOS:A1995RU05400028
J	SARAFIANOS, SG; PANDEY, VN; KAUSHIK, N; MODAK, MJ				SARAFIANOS, SG; PANDEY, VN; KAUSHIK, N; MODAK, MJ			SITE-DIRECTED MUTAGENESIS OF ARGININE-72 OF HIV-1 REVERSE-TRANSCRIPTASE - CATALYTIC ROLE AND INHIBITOR SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DNA-POLYMERASE-I; TRIPHOSPHATE BINDING DOMAIN; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; CROSS-LINKING; STRANDED DNA; IDENTIFICATION; MECHANISM	In order to determine the catalytic role of Arg(72) Of HIV-1 reverse transcriptase (RT), we carried out site-directed mutagenesis at codon 72, Two mutant proteins (R72A and R72K) were purified and characterized. With Arg to Ala substitution the k(cat) of the polymerase reaction was reduced by nearly 100-fold with poly(rA) tem plate, but only about 5-15-fold with poly(rC) and poly(dC) templates, The Arg to Lys substitution exhibited a qualitatively similar pattern, although the overall reduction in k(cat) was less severe, Most interestingly, we noted a large difference in the rate constant of the first and second nucleotide incorporation by R72A, suggesting that Arg(72) participates in the reaction after the formation of the first phosphodiester bond, We propose this step to be the pyrophosphate binding and removal step following the nueleotidyltransferase reaction. Support for this proposal is obtained from the observation that the R72A mutant (i) exhibited a pronounced translocation defect in the processivity analysis, (ii) lacked the ability to catalyze pyrophosphorolysis, and (iii) showed complete resistance to phosphonoformate, an analog of PPi. Arg(72) is the first residue of HIV-1 RT proposed to be involved in the pyrophosphate binding/removal function of RT.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center				Sarafianos, Stefan G/0000-0002-5840-154X; Pandey, Virendra N/0000-0001-6041-6786	PHS HHS [26652] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BOYER PL, 1993, J VIROL, V66, P7533; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CHATTOPADHYAY D, 1992, J BIOL CHEM, V267, P14227; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; HANSEN J, 1987, J BIOL CHEM, V262, P12393; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KEW Y, 1994, J BIOL CHEM, V269, P15331; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEUTHARDT A, 1988, GENE, V68, P35, DOI 10.1016/0378-1119(88)90596-3; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MERRILL BM, 1984, J BIOL CHEM, V259, P850; MOUS J, 1988, J VIROL, V62, P1433, DOI 10.1128/JVI.62.4.1433-1436.1988; MULLER B, 1989, J BIOL CHEM, V264, P13975; PANDEY V, 1994, J BIOL CHEM, V269, P21823; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; Sambrook J., 1989, MOL CLONING; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; SETLOW P, 1972, J BIOL CHEM, V247, P224; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; WU J, 1993, J BIOL CHEM, V268, P9980; YADAV PNS, 1994, J BIOL CHEM, V269, P716	38	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19729	19735		10.1074/jbc.270.34.19729	http://dx.doi.org/10.1074/jbc.270.34.19729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544345	hybrid			2022-12-25	WOS:A1995RQ99100012
J	MEDEMA, JP; DEVRIESSMITS, AMM; BOS, JL				MEDEMA, JP; DEVRIESSMITS, AMM; BOS, JL			CALCIUM INDUCES TYROSINE PHOSPHORYLATION OF A NOVEL P120GAP-ASSOCIATED PROTEIN OF 65 KDA	ONCOGENE			English	Article						KERATINOCYTES; SIGNAL TRANSDUCTION; P2LRAS	GTPASE-ACTIVATING PROTEIN; INDUCED KERATINOCYTE DIFFERENTIATION; MOUSE EPIDERMAL-CELLS; MOLECULAR-CLONING; KINASE-ACTIVITY; GAP; ASSOCIATION; RECEPTOR; SRC; RAS	Several tyrosine-phosphorylated proteins have been identified that associate with p120GAP, the GTPase activating protein of p21ras. In keratinocytes, calcium induced the tyrosine phosphorylation of a 65 kDa p120GAP-associated protein (p65Ca). This protein did not comigrate with two previously reported p120GAP-associated proteins, i.e. a 68 kDa protein from src-transformed cells (p68) and an insulin-induced protein of 60 kDa (p60(2C4)). P65Ca was neither recognized by poly(U)-sepharose, which efficiently precipitates p68, nor did it crossreact with antibodies against p68. In addition, a monoclonal antibody directed to p60(2C4) did not recognize p65Ca. From these results we conclude that p65Ca is different from p68 and p60(2C4) and thus, a novel p120GAP-associated protein. Since calcium has an important, tyrosine kinase dependent, role in the differentiation of keratinocytes, phosphorylation of p65Ca may be important for this differentiation process. However, surprisingly, calcium induced the phosphorylation of a similar-sized p120GAP-associated 65 kDa protein in fibroblast cell lines.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS	Utrecht University				Medema, Jan Paul/0000-0003-3045-2924				BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Buxton R S, 1992, Semin Cell Biol, V3, P157; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FILVAROFF E, 1994, J BIOL CHEM, V269, P21735; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; OGAWA W, 1994, J BIOL CHEM, V269, P29602; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; PRONK GJ, 1992, ONCOGENE, V7, P389; SCHERUBL H, 1990, FEBS LETT, V273, P51, DOI 10.1016/0014-5793(90)81048-S; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; STROOP SD, 1993, J BIOL CHEM, V268, P19927; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298	36	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					757	762						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7544452				2022-12-25	WOS:A1995RQ46900018
J	TEWARI, M; BEIDLER, DR; DIXIT, VM				TEWARI, M; BEIDLER, DR; DIXIT, VM			CRMA-INHIBITABLE CLEAVAGE OF THE 70-KDA PROTEIN-COMPONENT OF THE U1 SMALL NUCLEAR RIBONUCLEOPROTEIN DURING FAS-INDUCED AND TUMOR NECROSIS FACTOR-INDUCED APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODY; CELL-DEATH; C-ELEGANS; ANTIGEN; INDUCTION; ENCODES; ENZYME	Fas and the type I tumor necrosis factor receptor (TNF-R) are two cell surface receptors that, when stimulated with ligand or cross-linking antibody, trigger apoptotic cell death by a mechanism that has yet to be elucidated, The CrmA protein is a serpin family protease inhibitor that can inhibit interleukin-1 beta converting enzyme (ICE) and ICE-Like proteases. We showed previously that expression of CrmA potently blocks apoptosis induced by activation of either Fas or TNF-R, implicating protease involvement in these death pathways (Tewari, M., and Dixit, V. M. (1995) J. Biol. Chem. 270, 3255-3260). Here we report that the 70-kDa component of the U1 small ribonucleoprotein (U1-70 kDa) is a proteolytic substrate rapidly cleaved during both Fas- and TNF-R-induced apoptosis, This cleavage was inhibited by expression of CrmA but not by expression of an inactive point mutant of CrmA, confirming the involvement of an ICE-like protease, These data for the first time identify U1-70 kDa as a death substrate cleaved during Fas- and TNF-R-induced apoptosis and emphasize the importance of protease activation in the cell death pathway.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,GRAD PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA64803] Funding Source: Medline; NHLBI NIH HHS [HL07517] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIONI C, 1991, TUMOR NECROSIS FACTO, P425; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FINKEL TH, 1994, CURR OPIN IMMUNOL, V6, P605, DOI 10.1016/0952-7915(94)90149-X; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; STALDER T, 1994, J IMMUNOL, V152, P1127; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	28	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18738	18741		10.1074/jbc.270.32.18738	http://dx.doi.org/10.1074/jbc.270.32.18738			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7543896	hybrid			2022-12-25	WOS:A1995RN95400008
J	BEIDLER, DR; TEWARI, M; FRIESEN, PD; POIRIER, G; DIXIT, VM				BEIDLER, DR; TEWARI, M; FRIESEN, PD; POIRIER, G; DIXIT, VM			THE BACULOVIRUS P35 PROTEIN INHIBITS FAS-INDUCED AND TUMOR NECROSIS FACTOR-INDUCED APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEATH GENE CED-3; CELL-DEATH; P35-GENE; ENZYME	The baculovirus p35 gene product inhibits virally induced apoptosis, developmental cell death in Caenorhabditis elegans and Drosophila, and neuronal cell death in mammalian systems. Therefore, p35 likely inhibits a component of the death machinery that is both ubiquitous and highly conserved in evolution. We now show for the first time that p35 also inhibits Fas- and tumor necrosis factor (TNF)-induced apoptosis. Additionally, p35 blocks TNF- and Fas-induced proteolytic cleavage of the death substrate poly(ADP-ribose) polymerase from its native 116-kDa form to the characteristic 85-kDa form. This cleavage is thought to be catalyzed by an aspartate-specific protease of the interleukin 1 beta-converting enzyme family designated prICE (Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347), Our data suggest that p35 must directly or indirectly inhibit prICE. Given that p35 inhibits both TNF and Fas killing, along with previous reports of its ability to block developmental, viral, and x-irradiation-induced cell death, the present results indicate that TNF- and Fas-mediated apoptotic pathways must have components in common with these highly conserved death programs.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV WISCONSIN,INST MOLEC VIROL,MADISON,WI 53706; CHU LAVAL,RES CTR,DEPT MOLEC ENDOCRINOL,POLY ADP RIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,ST FOY,PQ G1V 4G2,CANADA	University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison; Laval University; Laval University			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Poirier, Guy/0000-0002-4869-1424	NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64803] Funding Source: Medline; NHLBI NIH HHS [HL 07517Y14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; HAY BA, 1994, DEVELOPMENT, V120, P2121; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; JAATTELA M, 1995, IN PRESS ONCOGENE, V10; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Sambrook J, 1989, MOL CLONING LABORATO; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUGIMOTO A, 1994, EMBO J, V13, P20236; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	23	190	198	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16526	16528		10.1074/jbc.270.28.16526	http://dx.doi.org/10.1074/jbc.270.28.16526			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542648	hybrid			2022-12-25	WOS:A1995RJ34700012
J	KAZANIETZ, MG; LEWIN, NE; BRUNS, JD; BLUMBERG, PM				KAZANIETZ, MG; LEWIN, NE; BRUNS, JD; BLUMBERG, PM			CHARACTERIZATION OF THE CYSTEINE-RICH REGION OF THE CAENORHABDITIS-ELEGANS PROTEIN UNC-13 AS A HIGH-AFFINITY PHORBOL ESTER RECEPTOR - ANALYSIS OF LIGAND-BINDING INTERACTIONS, LIPID COFACTOR REQUIREMENTS, AND INHIBITOR SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; KINASE-C ISOZYMES; REGULATORY DOMAIN; MOUSE-BRAIN; GENE; CALCIUM; DIACYLGLYCEROL; EXPRESSION; CHIMAERIN; CYTOSOL	The Caenorhabditis elegans Unc-13 protein is a novel member of the phorbol ester receptor family having a single cysteine-rich region with high homology to those present in protein kinase C (PKC) isozymes and the chimaerins, We expressed the cysteine-rich region of Unc-13 in Escherichia coli and quantitatively analyzed its interactions with phorbol esters and related analogs, its phospholipid requirements, and its inhibitor sensitivity, [H-3]Phorbol 12,13-dibutyrate [H-3]PDBu bound with high affinity to the cysteine-rich region of Unc-13 (K-d = 1.3 +/- 0.2 nM). This affinity is similar to that of other single cysteine-rich regions from PKC isozymes as well as n-chimaerin, As also described for PKC isozymes and n-chimaerin, Unc-13 bound diacylglycerol with an affinity about 2 orders of magnitude weaker than [H-3]PDBu. Structure activity analysis revealed significant but modest differences between recombinant cysteine-rich regions of Unc-13 and PKC delta. In addition, Unc-13 required slightly higher concentrations of phospholipid for reconstitution of [H-3]PDBu binding. Calphostin C, a compound described as a selective inhibitor of PKC, was also able to inhibit [H-3]PDBu binding to Unc-13, suggesting that this inhibitor is not able to distinguish between different classes of phorbol ester receptors, In conclusion, although our results revealed some differences in ligand and lipid cofactor sensitivities, Unc-13 represents a high affinity cellular target for the phorbol esters as well as for the lipid second messenger diacylglycerol, at least in C. elegans, The use of phorbol esters or some ''specific'' antagonists of PKC does not distinguish between cellular pathways involving different PKC isozymes or novel phorbol ester receptors such as n-chimaerin or Unc-13.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECH TUMOR PROMOT SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ARECES LB, 1994, J BIOL CHEM, V269, P19553; ASHENDEL CL, 1983, CANCER RES, V43, P4333; BLUMBERG PM, 1988, CANCER RES, V48, P1; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BRADSHAW D, 1993, AGENTS ACTIONS, V38, P135, DOI 10.1007/BF02027225; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HA KS, 1993, J BIOL CHEM, V268, P10534; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KAZANIETZ MG, 1994, J CELL BIOCHEM, V18, P90; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LEW KK, 1982, TERATOGEN CARCIN MUT, V2, P19, DOI 10.1002/1520-6866(1990)2:1&lt;19::AID-TCM1770020104&gt;3.0.CO;2-3; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PALANIAPPAN K, 1993, J AM CHEM SOC, V115, P6452; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; Sambrook J, 1989, MOL CLONING LABORATO; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SHARKEY NA, 1985, CANCER RES, V45, P19	37	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10777	10783		10.1074/jbc.270.18.10777	http://dx.doi.org/10.1074/jbc.270.18.10777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537738	hybrid			2022-12-25	WOS:A1995QW60100061
J	OZCELEBI, F; MILLER, LJ				OZCELEBI, F; MILLER, LJ			PHOSPHOPEPTIDE MAPPING OF CHOLECYSTOKININ RECEPTORS ON AGONIST-STIMULATED NATIVE PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; ENZYME-SECRETION; DESENSITIZATION; PHOSPHORYLATION; AFFINITY; CHROMATOGRAPHY; PURIFICATION; ARRESTIN; BINDING	The cholecystokinin (CCK) receptor on the rat pancreatic acinar cell is a G protein-coupled receptor that is phosphorylated in response to homologous and heterologous agonist stimulation. In this work we have studied the stoichiometry of receptor phosphorylation and have utilized one-dimensional phosphopeptide mapping after cyanogen bromide cleavage to demonstrate that the third intracellular loop is the predominant domain of phosphorylation of this receptor in response to these treatments. Of the average 5 mol of phosphate/mol of receptor, greater than 95% was on the third loop, with the remainder residing on the carboxyl-terminal tail. Serine residues were the site of greater than 95% of phosphorylation, with threonine representing the remainder, and no phosphotyrosine was detected. Further, we have utilized two dimensional phosphopeptide mapping after subtilisin cleavage to identify differing sites of CCK receptor phosphorylation which are dependent on the agonist utilized to stimulate this cell. Both qualitative and quantitative differences in phosphorylation sites were observed after acinar cell stimulation with different protein kinase C agonists. Further, distinct phosphopeptides on the map were identified as representing substrate(s) of a staurosporine-insensitive kinase activity stimulated only by receptor occupation with native CCK and were felt to represent site(s) of action of a member of the G protein-coupled receptor kinase family. This represents a sensitive and powerful approach that is applicable to sparse receptors residing in their native cellular environment to assess possible differences in patterns of phosphorylation which may be important in agonist-specific receptor regulation.	MAYO CLIN & MAYO FDN, CTR BASIC RES DIGEST DIS, ROCHESTER, MN 55905 USA	Mayo Clinic					NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMOUMENE S, 1980, AM J PHYSIOL, V239, pG272, DOI 10.1152/ajpgi.1980.239.4.G272; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; DOI R, 1993, J BIOL CHEM, V268, P22436; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GARDNER JD, 1994, PANCREAS BIOL PATHOB, P151; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HONDA T, 1987, AM J PHYSIOL, V252, pG77, DOI 10.1152/ajpgi.1987.252.1.G77; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MILLER LJ, 1992, BIOCHEM BIOPH RES CO, V183, P396, DOI 10.1016/0006-291X(92)90494-6; MILLER LJ, 1981, J BIOL CHEM, V256, P2417; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; POLLO DA, 1993, GASTROENTEROLOGY, V104, pA329; SCHWEINSBERG PD, 1980, J CHROMATOGR, V181, P103, DOI 10.1016/S0378-4347(00)81276-1; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; VINAYEK R, 1990, AM J PHYSIOL, V258, pG107, DOI 10.1152/ajpgi.1990.258.1.G107; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; ZHU ZX, 1994, AM J PHYSIOL, V266, pC904, DOI 10.1152/ajpcell.1994.266.4.C904	34	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3435	3441		10.1074/jbc.270.7.3435	http://dx.doi.org/10.1074/jbc.270.7.3435			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531708	hybrid			2022-12-25	WOS:A1995QG47100081
J	WANG, LL; RICHARD, S; SHAW, AS				WANG, LL; RICHARD, S; SHAW, AS			P62 ASSOCIATION WITH RNA IS REGULATED BY TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-ASSOCIATED PROTEINS; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; NUCLEIC-ACID; T-CELL; BINDING; TARGETS; INCLUDE; KINASE; DOMAIN	The ras-GAP associated protein, p62, is a major tyrosine phosphoprotein in transformed and growth factor treated cells, Although its exact function is not known, it can bind directly to src-family tyrosine kinases and has been implicated as a linker protein bridging activated src family tyrosine kinases with downstream effecters, One novel feature of p62, revealed by its predicted amino acid sequence, is the presence of an RNA-binding region, the KH domain. As p62 becomes tyrosine phosphorylated when src-kinases become activated, we compared the RNA binding ability of p62 in both its phosphorylated and unphosphorylated state, The ability of p62 to bind RNA was severely impaired when p62 was tyrosine phosphorylated. This suggests that the ability of p62 to bind RNA is regulated by tyrosine phosphorylation and implicates the regulation of RNA as a component of tyrosine kinase signaling pathways.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				Shaw, Andrey/0000-0001-5685-0272				ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CHANG JH, 1993, ONCOGENE, V8, P959; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DARBY C, 1994, J IMMUNOL, V152, P5429; DE BK, 1993, NAT GENET, V3, P31; DRUKER B, 1992, BLOOD, V79, P2215; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; EVAN GI, 1985, MOL CELL BIOL, V4, P2843; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FRACKELTON AJ, 1993, LEUK LYMPHOMA, V1, P125; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOLD MR, 1993, J IMMUNOL, V150, P377; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTTSCHALK AR, 1994, J IMMUNOL, V152, P2115; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HUBERT P, 1993, J EXP MED, V178, P1587, DOI 10.1084/jem.178.5.1587; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	35	119	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2010	2013		10.1074/jbc.270.5.2010	http://dx.doi.org/10.1074/jbc.270.5.2010			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530715	hybrid			2022-12-25	WOS:A1995QE49300007
J	YOSHIMURA, M; NISHIKAWA, A; NISHIURA, T; IHARA, Y; KANAYAMA, Y; MATSUZAWA, Y; TANIGUCHI, N				YOSHIMURA, M; NISHIKAWA, A; NISHIURA, T; IHARA, Y; KANAYAMA, Y; MATSUZAWA, Y; TANIGUCHI, N			CELL SPREADING IN COLO-201 BY STAUROSPORIN IS ALPHA-3-BETA-1-INTEGRIN MEDIATED WITH TYROSINE PHOSPHORYLATION OF SRC AND TENSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; RECEPTOR; FIBRONECTIN; COLLAGEN; LAMININ; EXPRESSION; PP60C-SRC; BINDING	Staurosporin, a broad-spectrum kinase inhibitor, induced cell spreading in a human colon cancer cell line, Colo 201. On collagen and laminin, cell spreading was induced in more than 90% of the cells and was dependent on very late activation antigen-3, as shown by an antibody inhibition assay, Cell spreading required divalent cations and showed the order of preference Mn2+ > Mg2+ > Ca2+. On fibronectin, only about 30% of the cells were observed to spread, and spreading occurred via a non-integrin, RGD-independent pathway. Staurosporin-induced spreading was inhibited by treatment with tyrosine kinase inhibitors herbimycin A and methyl 2,5-dihydroxycinnamate. Despite the presence of staurosporin, seven proteins (220, 175, 150, 98, 62, 58, and 45 kDa) showed increased levels of tyrosine phosphorylation in association with cell adhesion. Two of these (58 and 220 kDa) were identified by immunoprecipitation as Src product and tensin, respectively. Flow cytometric analysis showed that the Colo 201 cells expressed the alpha 2, alpha 3, alpha 6, and beta 1 chains of integrin, but expression of these chains was not influenced by staurosporin. Immunofluorescence microscopy revealed that the alpha 3 chain, diffusely expressed on the cell surface in the absence of staurosporin, was concentrated at focal adhesion plaques after staurosporin treatment. Neither alpha 2 nor alpha 6 was focalized by the treatment.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Nishikawa, Atsushi/E-6766-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Nishikawa, Atsushi/0000-0003-4325-1160				BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KANAKURA Y, 1990, BLOOD, V76, P706; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MATSUYAMA T, 1988, J EXP MED, V170, P1133; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; NATHAN C, 1989, J CELL BIOL, V109, P849; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SEMPLE TU, 1978, CANCER RES, V38, P1345; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STREULI CH, 1990, J CELL BIOL, V110, P1405; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; THOUVENIN VM, 1992, J CELL PHYSL, V153, P95; VUORI K, 1993, J BIOL CHEM, V268, P21459; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WILKINS JA, 1987, J CELL BIOL, V105, pA103	44	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2298	2304		10.1074/jbc.270.5.2298	http://dx.doi.org/10.1074/jbc.270.5.2298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530722	hybrid			2022-12-25	WOS:A1995QE49300050
J	XIE, JM; KOLLS, J; BAGBY, G; GREENBERG, SS				XIE, JM; KOLLS, J; BAGBY, G; GREENBERG, SS			INDEPENDENT SUPPRESSION OF NITRIC-OXIDE AND TNF-ALPHA IN THE LUNG OF CONSCIOUS RATS BY ETHANOL	FASEB JOURNAL			English	Article						ALVEOLAR MACROPHAGES; ENDOTOXIN; LOWER RESPIRATORY TRACT INFECTION; PULMONARY HOST DEFENSE	TUMOR-NECROSIS-FACTOR; VASCULAR ENDOTHELIAL-CELLS; L-ARGININE; NITROGEN-OXIDES; POLYMORPHONUCLEAR NEUTROPHILS; ALCOHOLIC HEPATITIS; ENDOTOXIN-SHOCK; HOST DEFENSES; MACROPHAGES; SYNTHASE	Tumor necrosis factor-alpha (TNF alpha) and nitric oxide (NO) mediate in part the microbicidal response of murine and rodent alveolar macrophages (AM) and recruited neutrophils (PMN) to airborne infections. Ethanol (ETOH) suppresses intrapulmonary TNF alpha and NO release and impairs pulmonary host defense mechanisms. We tested the concept that ETOH down-regulates NO by inhibiting production of TNF alpha. Male rats were given intratracheal (i.t.) saline (PBS), a polyclonal anti-TNF alpha antibody (TNFab) or nonimmune IgG (22 mg/kg, i.m.) 2 h before giving i.t. Escherichia coli endotoxin (LPS) to normal rats or rats pretreated with ETOH (5.5 g/kg, i.p.) 30 min before experimentation. AM and PMN were obtained from the bronchoalveolar lavage fluid (BAL) fluid of rats killed 2 and 4 h after administration of LPS. mRNA for inducible NO synthase (iNOS) and TNF alpha were measured in AM and PMN with competitor equalized RT-PCR techniques. The BAL fluid, AM, and PMN were assayed for TNF alpha and NO2-, and NO3- (RNI) with the L929 bioassay and chemiluminescence, respectively. TNFab abolished LPS-induced increases in TNF alpha but did not suppress the NO content of the BAL fluid or gene expression for iNOS by AM or PMN. ETOH suppressed LPS-induced increases in mRNA for iNOS, production of RNI, and BAL fluid TNF alpha but did not affect LPS-induced increases in mRNA for TNF alpha. ETOH-induced attenuation of LPS-induced up-regulation of the iNOS system did not differ in rats pretreated with TNFab or IgG. Thus, ETOH down-regulates iNOS gene expression and RNI production independent of its effects on TNF alpha. Acute ETOH administration suppresses iNOS at the level of transcription and TNF alpha at the level of translation or release of the peptide.	LOUISIANA STATE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,DEPT PHYSIOL,NEW ORLEANS,LA 70112	Louisiana State University System; Louisiana State University System			Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA009803, P60AA009803, R01AA009816] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09803-01, AA09816-01] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADAMS HG, 1984, MED CLIN N AM, V68, P179, DOI 10.1016/S0025-7125(16)31249-4; BAGBY GJ, 1992, AM J PHYSIOL, V262, pR628, DOI 10.1152/ajpregu.1992.262.4.R628; BAGBY GJ, 1993, CIRC SHOCK, V39, P211; BERMUDEZ LE, 1991, J INFECT DIS, V163, P1286, DOI 10.1093/infdis/163.6.1286; BERMUDEZ LE, 1991, LYMPHOKINE CYTOK RES, V10, P413; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; BOMALASKI JS, 1982, ARCH INTERN MED, V142, P2073, DOI 10.1001/archinte.142.12.2073; BRITIGAN BE, 1987, J LEUKOCYTE BIOL, V41, P349, DOI 10.1002/jlb.41.4.349; BUSH PA, 1992, BIOCHEM BIOPH RES CO, V185, P960, DOI 10.1016/0006-291X(92)91720-B; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; COHEN MS, 1988, FREE RADICAL BIO MED, V5, P81, DOI 10.1016/0891-5849(88)90033-0; DEACIUC IV, 1992, ALCOHOL CLIN EXP RES, V16, P533, DOI 10.1111/j.1530-0277.1992.tb01412.x; DECHATELET LR, 1978, J RETICULOENDOTH SOC, V24, P73; Dorio R J, 1990, Prog Clin Biol Res, V325, P135; EIGLER A, 1994, ALCOHOL CLIN EXP RES, V17, P843; EVANS T, 1992, INFECT IMMUN, V60, P4133, DOI 10.1128/IAI.60.10.4133-4139.1992; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GLUCKMAN SJ, 1977, ARCH INTERN MED, V137, P1539; GREEN GM, 1965, BRIT J EXP PATHOL, V46, P360; GREEN SJ, 1990, IMMUNOL LETT, V25, P15, DOI 10.1016/0165-2478(90)90083-3; GREENBERG S, 1993, ALCOHOL, V10, P20; GREENBERG SS, 1994, ALCOHOL, V11, P53, DOI 10.1016/0741-8329(94)90012-4; GREENBERG SS, 1994, ALCOHOL, V11, P539, DOI 10.1016/0741-8329(94)90081-7; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIDALGO HA, 1992, TRANSPLANTATION, V53, P620, DOI 10.1097/00007890-199203000-00024; HOFFMANN H, 1991, AM REV RESPIR DIS, V143, P289, DOI 10.1164/ajrccm/143.2.289; HUNT NCA, 1992, J HEPATOL, V14, P146, DOI 10.1016/0168-8278(92)90150-N; JERRELLS TR, 1993, ADV EXP MED BIOL, V335, P153; JOHNSON A, 1992, J APPL PHYSIOL, V73, P2483, DOI 10.1152/jappl.1992.73.6.2483; JORENS PG, 1991, EUR J PHARMACOL, V200, P205, DOI 10.1016/0014-2999(91)90573-9; KATAKAMI Y, 1988, IMMUNOLOGY, V65, P719; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOLLS J, 1994, P SOC EXP BIOL MED, V205, P220; KOLLS J, 1994, AM J PHYSL; KOLLS JK, 1993, AM J RESP CELL MOL, V8, P370, DOI 10.1165/ajrcmb/8.4.370; KOLLS JK, 1994, CLIN RES, V42, pA147; LEU RW, 1991, J IMMUNOL, V147, P1816; LILLY CM, 1989, AM REV RESPIR DIS, V139, P1361, DOI 10.1164/ajrccm/139.6.1361; Louria D B, 1971, Triangle, V10, P57; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198, DOI 10.1128/AEM.46.1.198-202.1983; MARLETTA MA, 1988, BIOCHEMISTRY-US, V29, P8706; MARTINET Y, 1988, AM REV RESPIR DIS, V138, P659, DOI 10.1164/ajrccm/138.3.659; MARTINEZ F, 1992, ALCOHOL, V9, P455, DOI 10.1016/0741-8329(92)90080-T; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; MCINTYRE IM, 1984, BIOL PSYCHIAT, V19, P1725; MILLS CD, 1991, J IMMUNOL, V146, P2719; MORGAN MJ, 1992, MED HYPOTHESES, V38, P189, DOI 10.1016/0306-9877(92)90092-Q; MORLAND B, 1984, ALCOHOL ALCOHOLISM, V19, P211; NANJI AN, 1994, IN PRESS GASTROENTER; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NELSON S, 1989, LIFE SCI, V44, P673, DOI 10.1016/0024-3205(89)90472-4; NELSON S, 1989, J INFECT DIS, V160, P422, DOI 10.1093/infdis/160.3.422; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; ROSELLE GA, 1984, ALCOHOL CLIN EXP RES, V8, P62; SCHMIDT HHH, 1992, CELL CALCIUM, V13, P427; SEI Y, 1992, LIFE SCI, V50, P419, DOI 10.1016/0024-3205(92)90376-Z; SHI Y, 1993, PEDIATR RES, V34, P345, DOI 10.1203/00006450-199309000-00021; SMITH FE, 1976, J CHRON DIS, V29, P35, DOI 10.1016/0021-9681(76)90066-7; SPOLARICS Z, 1993, BIOCHEM BIOPH RES CO, V97, P606; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, CANCER RES, V47, P5590; THIEMERMANN C, 1993, BRIT J PHARMACOL, V110, P177, DOI 10.1111/j.1476-5381.1993.tb13789.x; TISMAN G, 1973, J CLIN INVEST, V52, P1410, DOI 10.1172/JCI107314; WEISZ A, 1994, J BIOL CHEM, V269, P8324; WOODFORD SL, 1991, J APPL PHYSIOL, V71, P915; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; XIE JM, 1993, AM REV RESPIR DIS, V148, P627, DOI 10.1164/ajrccm/148.3.627; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	74	47	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1995	9	2					253	261		10.1096/fasebj.9.2.7540157	http://dx.doi.org/10.1096/fasebj.9.2.7540157			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QJ249	7540157				2022-12-25	WOS:A1995QJ24900014
J	VONBONIN, A; WIENANDS, J; MANNING, U; ZUBER, JF; BAUMANN, G				VONBONIN, A; WIENANDS, J; MANNING, U; ZUBER, JF; BAUMANN, G			THE BETA-D-SHEET RESIDUES OF THE LCK-DERIVED SH2 DOMAIN DETERMINE SPECIFICITY OF THE INTERACTION WITH TYROSINE-PHOSPHORYLATED LIGANDS IN RAMOS B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GTPASE-ACTIVATING PROTEIN; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; ZETA-CHAIN; BINDING; KINASES; ASSOCIATION; IMMUNOGLOBULIN	Src homology 2 (SH2) domains are noncatalytic regions that are conserved among a group of cellular signaling proteins, SH2 domains share the common property of binding phosphotyrosine-containing peptides, Previously, we showed that SH2 domains expressed as recombinant glutathione S-transferase-fusion proteins (GST-SH2) from GTPase-activating protein, She, zeta-chain-associated protein tyrosine kinase Zap-70, and Src-like tyrosine kinases precipitated distinct sets of phosphoproteins from activated B cells, To determine the intrinsic structural motifs responsible for the binding specificity within the different SH2 domains, we created chimeric SH2 domains especially focusing on crystal structure-defined contact residues, Recombinant SH2 domains of Lck, Zap-70, and She were tested in Ramos B cell lysates for phosphotyrosine-dependent protein binding, Biomolecular interaction analysis (BIAcore) was used to characterize the interaction between the various recombinant SH2 molecules and defined phosphorylated peptides, In agreement with the crystal structure data from the Src and the Lck SH2 domains, our results show that most of the ''specificity information'' of the Lck SH2 domain is provided by the beta D-sheet, located downstream of the SH2 conserved consensus motif GTFLVRES, In addition, the overall affinity is critically influenced by residues located at the N terminus of the SH2 domain.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz								BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MOELLER G, 1993, IMMUNOL REV, V132, P5; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANNOESEL CJM, 1992, J EXP MED, V175, P1511, DOI 10.1084/jem.175.6.1511; VONBONIN A, UNPUB; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33035	33041						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528744				2022-12-25	WOS:A1994QA63800048
J	GLOVER, CJ; FELSTED, RL				GLOVER, CJ; FELSTED, RL			IDENTIFICATION AND CHARACTERIZATION OF MULTIPLE FORMS OF BOVINE BRAIN N-MYRISTOYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE MYRISTOYL-COA; HUMAN IMMUNODEFICIENCY VIRUS-1; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; ACYL-COA; BINDING PROTEIN; ACID ANALOGS; CELL LINE; REPLICATION	N-Myristoyltransferase (NMT) catalyzes the co-translational addition of myristic acid to the N-terminal glycine of many cellular, viral, and fungal proteins which are essential to normal cell functioning and/or are potential therapeutic targets. We have found that bovine brain NMT exists as a heterogeneous mixture of interconvertible high molecular mass multimers involving approximate to 60-kDa NMT subunit(s). Gel filtration chromatography of partially purified NMT at low to moderate ionic strength yields NMT activity eluting as 391 +/- 52 and 126 +/- 17 kDa peaks as well as activity which profiles the protein fractions and Likely results from NMT nonspecifically associating with background proteins and/or column matrix. Chromatography in 1 M NaCl causes 100% of this activity to elute as a single peak of approximate to 391 kDa. Subsequent treatment of the approximate to 391 kDa activity peak with an NMT peptide reaction product (i.e. N-myristoyl-peptide) results in approximate to 75% of the activity re-eluting as a approximate to 126-kDa peak in 1 M NaCl. Rechromatography also yields small amounts of a approximate to 50-kDa NMT monomer which increases with prior storage at 4 degrees C. Up to 5 NMT subunits were identified by SDS-polyacrylamide gel electrophoresis and specific immunoblotting with a human NMT peptide antibody and by cofactor-dependent chemical cross-linking with an I-125-peptide substrate of NMT. The prominent 60 kDa and minor 57-, 53-, 49-, and 47-kDa NMT immunoblotted subunits co-migrate with five of nine silver-stained proteins in an enzyme preparation purified >7,000-fold with approximate to 50% yield by selective elution from octyl-agarose with the myristoyl-CoA analog, S-(2-ketopentadecyl)-CoA. Storage at 4 degrees C also leads to conversion of the larger NMT subunit(s) into 49 and 47 kDa forms with no loss of NMT activity. These results identify two interconvertible forms of NR;IT in bovine brain that result from NMT subunit multimerization and/or complex formation with other cellular proteins. The data also identify a fully active NMT monomer which arises from subunit proteolysis. This study thus reveals a previously unappreciated level of NMT complexity which may have important mechanistic and/or regulatory significance for N-myristoylation in mammalian cells.			GLOVER, CJ (corresponding author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BETHESDA,MD 20892, USA.							BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; DETERMANN H, 1975, CHROMATOGRAPHY, P362; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FELSTED RL, 1989, DEV CANCER CHEMOTHER, V2, P95; GLOVER CG, 1992, 8TH ANN M ONC FRED; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GLOVER CJ, 1991, BIOCHEM PHARMACOL, V41, P1067, DOI 10.1016/0006-2952(91)90215-Q; GLOVER CJ, 1990, FASEB J, V4, pA2058; GLOVER CJ, 1993, FASEB J, V7, P7; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HAMES BD, 1991, GEL ELECTROPHORESIS, V1, P16; HARPER DR, 1993, J GEN VIROL, V74, P1181, DOI 10.1099/0022-1317-74-6-1181; HESLER CB, 1990, J BIOL CHEM, V265, P6600; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON DR, 1983, J BIOL CHEM, V268, P483; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KING MJ, 1992, MOL CELL BIOCHEM, V113, P77; KING MJ, 1994, MOL CELL BIOCHEM, V141, P79, DOI 10.1007/BF00926170; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; MCILHINNEY RAJ, 1994, EUR J BIOCHEM, V222, P137, DOI 10.1111/j.1432-1033.1994.tb18851.x; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; MOSCUFO N, 1991, J VIROL, V65, P2372, DOI 10.1128/JVI.65.5.2372-2380.1991; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; RAJU RVS, 1994, J BIOL CHEM, V269, P12080; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x	52	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23226	23233		10.1074/jbc.270.39.23226	http://dx.doi.org/10.1074/jbc.270.39.23226			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559471	hybrid			2022-12-25	WOS:A1995RY05400091
J	MAEHAMA, T; NISHINA, H; HOSHINO, S; KANAHO, Y; KATADA, T				MAEHAMA, T; NISHINA, H; HOSHINO, S; KANAHO, Y; KATADA, T			NAD(+)-DEPENDENT ADP-RIBOSYLATION OF T-LYMPHOCYTE ALLOANTIGEN RT6.1 REVERSIBLY PROCEEDING IN INTACT RAT LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; BINDING PROTEINS; BOVINE BRAIN; RIBOSYLTRANSFERASE; PURIFICATION; CELLS; GTP; MEMBRANES; SUBSTRATE; SURFACE	Rat T lymphocyte alloantigen 6.1 (RT6.1), which was synthesized as the fusion protein with a maltose-binding protein in Escherichia coli, displayed NAD(+)-dependent auto-ADP-ribosylation in addition to an enzyme activity of NAD(+) glycohydrolase. Such ADP-ribosylation of RT6.1 was also observed in lymphocytes isolated from rat tissues as follows, When intact rat lymphocytes expressing RT6.1 mRNA were incubated with [alpha-P-32]NAD(+), its radioactivity was incorporated into a cell surface protein with the M(r) of 31,000, The radiolabeled 31-kDa protein was released from the cell surface by treatment of the cells with phosphatidylinositol-specific phospholipase C and immunoprecipitated with anti-RT6.1 antiserum, The radioactivity incorporated into the 81-kDa protein was recovered as 5'-[P-32]AMP upon incubation with snake venom phosphodiesterase and also removed by NH2OH treatment, These results suggested that the NAD(+)-dependent modification of the 31-kDa protein was due to ADP-ribosylation of glycosylphosphatidylinositol-anchored RT6.1 at an arginine residue, When intact lymphocytes, in which RT6.1 had been once modified by [P-32]ADP-ribosylation, were further incubated in the absence of NAD(+), there was reduction of the radioactivity in the [P-32]ADP-ribosylated RT6.1, The reduced radioactivity was recovered from the incubation medium as [P-32]ADP-ribose. This reduction was effectively inhibited by the addition of ADP-ribose to the reaction mixture, Moreover, readdition of NAD(+) caused the ADP-ribosylation of RT6.1 again, Thus, the ADP-ribosylation of RT6.1 appeared to proceed reversibly in intact rat lymphocytes.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology			Maehama, Tomohiko/AAX-8926-2020; Maehama, Tomohiko/HGB-4896-2022	Maehama, Tomohiko/0000-0002-9685-2317; Hoshino, Shinichi/0000-0001-6135-7896				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; CRISA L, 1993, DIABETES, V42, P688, DOI 10.2337/diab.42.5.688; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; GREINER DL, 1986, J IMMUNOL, V136, P148; KASHAN A, 1989, IMMUNOL LETT, V23, P133, DOI 10.1016/0165-2478(89)90125-9; KATADA T, 1986, J BIOL CHEM, V261, P8182; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KOCH F, 1988, IMMUNOLOGY, V65, P259; KOSUDA LL, 1994, J TOXICOL ENV HEALTH, V42, P303, DOI 10.1080/15287399409531881; MAEHAMA T, 1994, J BIOCHEM-TOKYO, V116, P1134, DOI 10.1093/oxfordjournals.jbchem.a124639; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; TANUMA S, 1988, J BIOL CHEM, V263, P5485; THIELE HG, 1987, TRANSPLANT P, V19, P3157; TSAI SC, 1988, J BIOL CHEM, V263, P1768; UI M, 1990, ADP RIBOSYLATING TOX, P45; WANG J, 1994, J IMMUNOL, V153, P4048; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	23	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22747	22751		10.1074/jbc.270.39.22747	http://dx.doi.org/10.1074/jbc.270.39.22747			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559400	hybrid			2022-12-25	WOS:A1995RY05400020
J	NAVARRO, JM; CASATORRES, J; JORCANO, JL				NAVARRO, JM; CASATORRES, J; JORCANO, JL			ELEMENTS CONTROLLING THE EXPRESSION AND INDUCTION OF THE SKIN HYPERPROLIFERATION-ASSOCIATED KERATIN K6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-18; RETINOIC ACID; TRANSCRIPTION FACTOR; THYROID-HORMONE; EPIDERMAL DIFFERENTIATION; ENHANCER ELEMENTS; CYTOKERATIN GENES; NUCLEAR RECEPTORS; CARCINOMA-CELLS; C-JUN	The suprabasal keratin 6 (K6) is remarkable among the keratins as, in addition to being constitutively expressed in different stratified epithelia, it is induced in epidermis under hyperproliferative conditions, such as benign or malignant tumors, psoriasis, and wound healing. In addition, this keratin is also induced in skin treated with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid (RA). These characteristics make the study of K6 regulatory elements an especially interesting issue, in particular because these elements could be useful in designing gene constructs for the therapy of skin diseases. We have analyzed by mobility shift and footprinting experiments the cell type-specific enhancer of the bovine K6 beta gene (Blessing, M., Jorcano, J. L., and Franke, W. W. (1989) EMBO J. 8, 117-126) and have identified an AP-2-like element, two AP-1 elements (one of them composite), and a retinoic acid-responsive element (RARE). Mutagenesis experiments and cotransfections with retinoic acid receptors show that the RARE mediates enhancer activation by RA. Chloramphenicol acetyltransferase assays show that under normal culture conditions, the AP-1 element retains most of the enhancer transcriptional activity, while the RARE and AP-2 are weakly active. However, following RA treatment, the AP-1 element is repressed and the RARE is activated, resulting in an overall stimulation of the enhancer by RA in the BMGE+H cells used in our study. These results explain in part the complex and sometimes contradictory response of keratin 6 to hyperproliferative stimuli.	CIEMAT,DEPT CELL & MOLEC BIOL,E-28040 MADRID,SPAIN	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas			Navarro, Manuel/S-1496-2019	Navarro, Manuel/0000-0003-1118-8531				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bernerd Francoise, 1993, Gene Expression, V3, P187; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHUPILO SA, 1984, FEBS LETT, V179, P34; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; Darmon Michel, 1993, P181; EICHNER R, 1992, J INVEST DERMATOL, V98, P154, DOI 10.1111/1523-1747.ep12555767; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HU L, 1994, J BIOL CHEM, V269, P183; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; JORCANO JL, 1984, DIFFERENTIATION, V28, P155, DOI 10.1111/j.1432-0436.1984.tb00278.x; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; KORGE B, 1990, J INVEST DERMATOL, V95, P450, DOI 10.1111/1523-1747.ep12555613; LEASK A, 1991, P NATL ACAD SCI USA, V788, P7948; LU B, 1994, J BIOL CHEM, V269, P7443; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MAGNALDO T, 1993, DNA CELL BIOL, V12, P911, DOI 10.1089/dna.1993.12.911; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLLOY CJ, 1987, CANCER RES, V47, P4674; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RAMIREZ A, 1993, THESIS U COMPLUTENSE; ROOP DR, 1991, RETINOIDS : 10 YEARS ON, P28; ROSENTHAL DS, 1992, J INVEST DERMATOL, V98, P343, DOI 10.1111/1523-1747.ep12499802; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHMID E, 1983, J CELL BIOL, V96, P37, DOI 10.1083/jcb.96.1.37; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHWEIZER J, 1987, J INVEST DERMATOL, V89, P125, DOI 10.1111/1523-1747.ep12470544; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; SNAPE AM, 1991, DEVELOPMENT, V113, P283; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Sun TT, 1984, CANCER CELLS, V1, P169; TOFTGARD R, 1985, CANCER RES, V45, P5845; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; TOMICCANIC M, 1992, J INVEST DERMATOL, V99, P842, DOI 10.1111/1523-1747.ep12614806; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	62	88	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21362	21367		10.1074/jbc.270.36.21362	http://dx.doi.org/10.1074/jbc.270.36.21362			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545670	hybrid			2022-12-25	WOS:A1995RU05400075
J	SANO, S; MIYAKE, C; MIKAMI, B; ASADA, K				SANO, S; MIYAKE, C; MIKAMI, B; ASADA, K			MOLECULAR CHARACTERIZATION OF MONODEHYDROASCORBATE RADICAL REDUCTASE FROM CUCUMBER HIGHLY EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; HYDROGEN-PEROXIDE; SUPEROXIDE-DISMUTASE; SPINACH-CHLOROPLASTS; REDOX PROPERTIES; ENZYME; SEMIDEHYDROASCORBATE; PARTICIPATION; PURIFICATION; INTERMEDIATE	Monodehydroascorbate radical (MDA) reductase, an FAD-enzyme, is the first enzyme to be identified whose substrate is an organic radical and catalyzes the reduction of MDA to ascorbate by NAD(P)H. Its cDNA has been cloned from cucumber seedlings (Sane, S., and Asada, K. (1994) Plant Cell Physiol. 35, 425-437), and a plasmid was constructed in the present study that allowed a high level expression in Escherichia coli of the cDNA-encoding MDA reductase using the T7 RNA polymerase expression system. The recombinant MDA reductase was purified to a crystalline state, with a yield of over 20 mg/liter of culture, and it exhibited spectroscopic properties of the FAD similar to those of the enzyme purified from cucumber fruits during redox reactions with NADH and MDA. The red semiquinone of the FAD of MDA reductase was generated by photoreduction. p-Chloromercuribenzoate inhibited the reduction of the enzyme-FAD by NADH, and dicumarol suppressed electron transfer from the reduced enzyme to MDA. The specificity of electron accepters of the recombinant enzyme appeared to be similar to that of MDA reductase, even though the amino acid sequence encoded by the cDNA was somewhat different from that of the enzyme purified from cucumber fruits. The K-m values for NADH and NADPH of the recombinant enzyme indicated a high affinity of the enzyme for NADH. The reaction catalyzed by the enzyme did not exhibit saturation kinetics with MDA up to 3 mu M. A second order rate constant for the reduction of the enzyme-FAD with NADH was 1.25 x 10(8) M(-1) s(-1), as determined by a stopped-flow method, and its value decreased with increases in ionic strength, an indication of the enhanced electrostatic guidance of NADH to the enzyme-FAD.	KYOTO UNIV, FOOD SCI RES INST, UJI, KYOTO 611, JAPAN	Kyoto University								ARRIGONI O, 1981, FEBS LETT, V125, P242, DOI 10.1016/0014-5793(81)80729-6; Asada K., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P77; ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; BIELSKI BHJ, 1982, AM CHEM SOC ADV CHEM, V200, P81; BORRACCINO G, 1986, PLANTA, V167, P521, DOI 10.1007/BF00391228; BOWDITCH MI, 1990, PLANT PHYSIOL, V94, P531, DOI 10.1104/pp.94.2.531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cornish-Bowden A., 1979, FUNDAMENTALS ENZYME, DOI 10.1016/C2013-0-04130-8; DALTON DA, 1992, ARCH BIOCHEM BIOPHYS, V292, P281, DOI 10.1016/0003-9861(92)90080-G; DAVISON AJ, 1986, J BIOL CHEM, V261, P1193; DHARIWAL KR, 1991, J BIOL CHEM, V266, P12908; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERNSTER L, 1962, BIOCHIM BIOPHYS ACTA, V58, P171, DOI 10.1016/0006-3002(62)90997-6; FORNI LG, 1983, J CHEM SOC PERK T 2, P961, DOI 10.1039/p29830000961; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; HARWOOD HJ, 1986, J BIOL CHEM, V261, P7127; HOSSAIN MA, 1984, PLANT CELL PHYSIOL, V25, P85; HOSSAIN MA, 1985, J BIOL CHEM, V260, P2920; HOSSAIN MA, 1984, PLANT CELL PHYSIOL, V25, P385; IYANAGI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P370, DOI 10.1016/0005-2728(69)90133-9; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; KEIRNS JJ, 1972, J BIOL CHEM, V247, P7374; KITAGAWA T, 1982, J BIOL CHEM, V257, P2075; KOBAYASHI K, 1991, BIOCHEMISTRY-US, V30, P8310, DOI 10.1021/bi00098a005; MARSHALL AG, 1978, BIOPHYSICAL CHEM PRI, P546; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MIYAKE C, 1991, PLANT CELL PHYSIOL, V32, P33; MIYAKE C, 1994, PLANT CELL PHYSIOL, V35, P539, DOI 10.1093/oxfordjournals.pcp.a078628; MURTHY SS, 1994, J BIOL CHEM, V269, P31129; NAKAMURA M, 1993, ARCH BIOCHEM BIOPHYS, V305, P84, DOI 10.1006/abbi.1993.1396; NISHINO H, 1986, J BIOCHEM, V100, P1523, DOI 10.1093/oxfordjournals.jbchem.a121859; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; SANO S, 1994, PLANT CELL PHYSIOL, V35, P425; SCARPA M, 1983, J BIOL CHEM, V258, P6695; SHIGEOKA S, 1987, J GEN MICROBIOL, V133, P227; SPITSBERG VL, 1982, EUR J BIOCHEM, V127, P67, DOI 10.1111/j.1432-1033.1982.tb06838.x; STICH HF, 1976, NATURE, V260, P722, DOI 10.1038/260722a0; STRITTMATTER P, 1965, J BIOL CHEM, V240, P1405; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Svirbely JL, 1933, BIOCHEM J, V27, P279; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; YAMAMOTO HY, 1972, PLANT PHYSIOL, V49, P224, DOI 10.1104/pp.49.2.224; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5	46	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21354	21361		10.1074/jbc.270.36.21354	http://dx.doi.org/10.1074/jbc.270.36.21354			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545669	hybrid			2022-12-25	WOS:A1995RU05400074
J	PENG, H; LEVER, JE				PENG, H; LEVER, JE			POSTTRANSCRIPTIONAL REGULATION OF NA+/GLUCOSE COTRANSPORTER (SGTL1) GENE-EXPRESSION IN LLC-PK1 CELLS - INCREASED MESSAGE STABILITY AFTER CYCLIC-AMP ELEVATION OR DIFFERENTIATION INDUCER TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; DEPENDENT PROTEIN-KINASE; 3' UNTRANSLATED REGION; PHLORIZIN-BINDING; GLUCOSE; TRANSPORT; LINE; TRANSLATION; SIMILARITY; CLONING	We have further investigated the molecular basis of increased differentiation regulated expression of SGTL1, a Na+/glucose cotransporter, in the renal epithelial lial cell line LLC-PK1. Treatment of confluent monolayers either with the differentiation inducer hexamethylene bisacetamide (HMBA) or with cyclic AMP elevating agents promoted increased levels of the SGLT1 mRNA, the immunodetectable 75-kDa cotransporter subunit, and the transport activity. Two molecular species of SGLT1 mRNA (2.2 and 3.9 kilobases (kb)) are transcribed from the same gene in LLC-PK1 cells and differ only in the length of the 3'-untranslated region. The larger transcript is less stable (t(1/2) = 2 h) than the smaller one (t(1/2) = 10 h) in control, confluent monolayers. The 3.9 kb species was stabilized from degradation after either cyclic AMP elevation (t(1/2) = 14 h) or HMBA addition (t(1/2) = 8 h), with negligible effects on the stability of the 2.2-kb species (t(1/2) = 11 h). Inhibition of translation by cycloheximide resulted in a 10-fold increase in the t(1/2) of the 3.9-kb transcript and a 2-fold increase in that of the 2.2-kb species in control monolayers. Our results demonstrate that post-transcriptional regulation of message stability plays a major role in differentiation-dependent SGTL1 expression promoted by either HMBA or cyclic AMP.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027400, R01DK027400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSLER K, 1985, J CELL PHYSIOL, V122, P254, DOI 10.1002/jcp.1041220214; AMSLER K, 1991, AM J PHYSIOL, V260, pC1290, DOI 10.1152/ajpcell.1991.260.6.C1290; ASMLER K, 1982, AM J PHYSIOL, V242, pC94; Battey, 1986, BASIC METHODS MOL BI; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DAWSON WD, 1987, J CELL PHYSIOL, V132, P104, DOI 10.1002/jcp.1041320114; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1989, GENOMICS, V4, P297, DOI 10.1016/0888-7543(89)90333-9; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KONG CT, 1993, J BIOL CHEM, V268, P1509; LEVER JE, 1992, MEMBRANE TRANSPORT B, V5, P56; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; Maniatis T, 1989, DECONTAMINATION DILU; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MORAN A, 1982, AM J PHYSIOL, V243, pC293, DOI 10.1152/ajpcell.1982.243.5.C293; MORAN A, 1988, J BIOL CHEM, V263, P187; MULLIN JM, 1980, J CELL PHYSIOL, V104, P375, DOI 10.1002/jcp.1041040311; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PENG H, 1993, J CELL PHYSIOL, V154, P238, DOI 10.1002/jcp.1041540205; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHIODA T, 1994, P NATL ACAD SCI USA, V91, P11919, DOI 10.1073/pnas.91.25.11919; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; VOLLOCH V, 1981, ORG EXPRESSION GLOBI, P251; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WRIGHT EM, 1993, ANNU REV PHYSIOL, V55, P575, DOI 10.1146/annurev.ph.55.030193.003043; WU JSR, 1989, J CELL BIOCHEM, V40, P83, DOI 10.1002/jcb.240400109; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315; YONEYAMA Y, 1984, J CELL PHYSIOL, V121, P64, DOI 10.1002/jcp.1041210109	33	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20536	20542		10.1074/jbc.270.35.20536	http://dx.doi.org/10.1074/jbc.270.35.20536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7544792	hybrid			2022-12-25	WOS:A1995RR58400048
J	PANDEY, A; DUAN, HJ; DIXIT, VM				PANDEY, A; DUAN, HJ; DIXIT, VM			CHARACTERIZATION OF A NOVEL SRC-LIKE ADAPTER PROTEIN THAT ASSOCIATES WITH THE ECK RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DOMAINS; FAMILY	The Eph family of receptor protein tyrosine kinases (RPTKs) is the largest family of RPTKs, The signal transduction pathways initiated by this family have only recently begun to be explored, Using a yeast two-hybrid screen to identify molecules that interact with the cytoplasmic domain of Eck, it was previously shown that activated Eck RPTK bound to and stimulated phosphatidylinositol 3-kinase (Pandey, A., Lazar, D. F., Saltiel, A. R., and Dixit, V. M. (1994) J. Biol. Chem. 269, 30154-30157), Also isolated from this same screen was a novel protein containing SH3 and SH2 adapter modules that had striking homology to those found in the Src family of non-receptor tyrosine kinases, However, unlike other Src family members, it lacked a catalytic tyrosine kinase domain, Hence, this protein was designated SLAP for Src-like adapter protein, Using glutathione S-transferase fusion proteins, it was demonstrated that SLAP bound to activated Eck receptor tyrosine kinase. Therefore, SLAP is a novel candidate downstream signaling intermediate and the first member of the Src family that resembles an adapter molecule.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012; Pandey, Akhilesh/B-4127-2009	dixit, vishva m/0000-0001-6983-0326; Pandey, Akhilesh/0000-0001-9943-6127	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT BD, 1994, J BIOL CHEM, V269, P14211; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GANJU P, 1994, ONCOGENE, V9, P1613; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU HM, 1994, J BIOL CHEM, V269, P30069; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RUIZ JC, 1994, MECH DEVELOP, V46, P87; Sambrook J, 1989, MOL CLONING LABORATO; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	28	116	123	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19201	19204		10.1074/jbc.270.33.19201	http://dx.doi.org/10.1074/jbc.270.33.19201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7543898	hybrid			2022-12-25	WOS:A1995RP70300002
J	EZUMI, Y; TAKAYAMA, H; OKUMA, M				EZUMI, Y; TAKAYAMA, H; OKUMA, M			DIFFERENTIAL REGULATION OF PROTEIN-TYROSINE PHOSPHATASES BY INTEGRIN ALPHA(IIB)BETA(3) THROUGH CYTOSKELETAL REORGANIZATION AND TYROSINE PHOSPHORYLATION IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PHOSPHOTYROSINE PHOSPHATASE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; SEQUENCE SIMILARITY; GPIIB-IIIA; SH2 DOMAIN; EXPRESSION; THROMBIN; ASSOCIATION	The major platelet integrin alpha(IIb)beta(3) (glycoprotein IIb-IIIa) has been implicated in the regulation of tyrosine phosphorylation and dephosphorylation in activated platelets. To investigate the mechanisms of the alpha(IIb)beta(3)-dependent tyrosine dephosphorylation, normal platelets or thrombasthenic platelets lacking alpha(IIb)beta(3) were stimulated with thrombin and fractionated into Triton X-100-soluble or -insoluble subcellular matrices. We then examined the kinetics of the tyrosine-phosphorylated proteins and distribution of protein-tyrosine phosphatases in these fractions and whole cell lysates. First, alpha(IIb)beta(3)-dependent tyrosine dephosphorylation was re covered mainly in the cytoskeleton with similar kinetics to the whole cell lysate. Second, protein tyrosine phosphatase (PTP) 1B and its cleaved 42 kDa form were associated with the cytoskeleton in an aggregation-dependent manner, whereas association of PTP1C with the cytoskeleton was regulated differentially both by thrombin stimulation and by alpha(IIb)beta(3)-mediated aggregation. Several calpain inhibitors did not affect either tyrosine phosphorylation and dephosphorylation or relocation of PTP1B, but they did inhibit cleavage of PTP1B. Cytochalasin D blocked relocation of both PTP1B and PTP1C but not PTP1B cleavage. SH-PTP2 was distributed in the other fractions than the cytoskeleton and showed no relocation on thrombin stimulation. Finally, the cytoskeleton-associated PTP1C became tyrosine-phosphorylated in an alpha(IIb)beta(3)-mediated aggregation-dependent manner. Thus, integrin alpha(IIb)beta(3) was involved differentially in the regulation of PTP1B and PTP1C.	KYOTO UNIV, FAC MED, DEPT INTERNAL MED, DIV 1, SAKYO KU, KYOTO 606, JAPAN	Kyoto University								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HOLMSEN H, 1990, HEMATOLOGY, P1182; HORAK ID, 1990, ONCOGENE, V5, P597; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; ODA A, 1992, J BIOL CHEM, V267, P20075; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PLUTZKY J, 1992, GENOMICS, V13, P869, DOI 10.1016/0888-7543(92)90172-O; SHAH VO, 1988, J IMMUNOL, V140, P1861; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TAKAYAMA H, 1993, BIOCHEM BIOPH RES CO, V194, P472, DOI 10.1006/bbrc.1993.1843; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	46	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11927	11934		10.1074/jbc.270.20.11927	http://dx.doi.org/10.1074/jbc.270.20.11927			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538126	hybrid			2022-12-25	WOS:A1995QY73600040
J	CHANG, NS				CHANG, NS			TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCTION OF NOVEL EXTRACELLULAR-MATRIX PROTEINS THAT TRIGGER RESISTANCE TO TUMOR-NECROSIS-FACTOR CYTOTOXICITY IN MURINE L929 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIC-CELL-LINES; FACTOR-BETA; FACTOR-ALPHA; BREFELDIN-A; CARCINOMA-CELLS; II RECEPTOR; KINASE-C; INHIBITOR; DIFFERENTIATION; EXPRESSION	The molecular basis by which transforming growth factor (TGF)-beta 1 protects certain tumor cells from tumor necrosis factor (TNF) cytotoxicity was investigated. When pretreated with TGF-beta 1, -beta 2, and -beta 3, murine L929S fibroblasts developed resistance to TNF cytotoxicity, Time course experiments revealed that TGF-beta 1 initially induced both cellular protein-tyrosine phosphorylation and simultaneous secretion of a novel extracellular matrix TNF-resistance triggering (TRT) protein(s), which closely preceded the acquisition of TNF-resistance, TGF-beta 2 and -beta 3 also increased tyrosine phosphorylation, However, both molecules failed to stimulate TRT secretion, The increased levels of phosphorylation, particularly to 9 specific protein tyrosine kinase inhibitor-sensitive cellular proteins, appeared to alter the TNF killing pathway, TGF-beta 1-induced TRT secretion required participation of unknown serum factors, TRT adhered strongly to polystyrene plates and resisted treatment with heat (60 degrees C, 30 min), collagenase, alpha(2)-macroglobulin, heparin, antibodies against TGF-beta s, and limited trypsin digestion, Notably, TRT promoted TNF-resistance via activation of tyrosine and serine/threonine kinase functions in L929S. Thus, the molecular pathway involves TGF-beta 1-mediated initiation of a rapid tyrosine phosphorylation of cellular protein substrates (which alters TNF cytotoxic pathway), and a simultaneous secretion of TRT, which in turn signals the cells to maintain the levels of phosphorylation, thereby sustaining the TNF-resistance.			CHANG, NS (corresponding author), GUTHRIE MED CTR,GUTHRIE RES INST,MOLEC IMMUNOL LAB,SAYRE,PA 18840, USA.				NCI NIH HHS [1R01CA-61879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BEEZHOLD DH, 1992, J LEUKOCYTE BIOL, V51, P59, DOI 10.1002/jlb.51.1.59; BELIZARIO JE, 1991, CANCER RES, V51, P2379; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHANG NS, 1992, BLOOD, V79, P2973; CHANG NS, 1994, J LEUKOCYTE BIOL, V55, P778, DOI 10.1002/jlb.55.6.778; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; DEBENEDETTI F, 1990, BLOOD, V75, P626; DONATO NJ, 1993, CELL GROWTH DIFFER, V4, P411; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESPEVIK T, 1988, J IMMUNOL, V140, P2312; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KAMIJO R, 1990, J IMMUNOL, V144, P1311; KAMIJO R, 1988, BIOCHEM BIOPH RES CO, V158, P155; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNKER R, 1987, BLOOD, V70, P1730; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; SUGAMAN BJ, 1989, CANCER RES, V47, P780; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; YAN ZF, 1994, J BIOL CHEM, V269, P13231	33	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7765	7772		10.1074/jbc.270.13.7765	http://dx.doi.org/10.1074/jbc.270.13.7765			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535777	hybrid			2022-12-25	WOS:A1995QQ43100106
J	RAFFIONI, S; BRADSHAW, RA				RAFFIONI, S; BRADSHAW, RA			STAUROSPORINE CAUSES EPIDERMAL GROWTH-FACTOR TO INDUCE DIFFERENTIATION IN PC12 CELLS VIA RECEPTOR UP-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; INDUCED NEURITE OUTGROWTH; PHEOCHROMOCYTOMA CELLS; TYROSINE KINASE; MAP KINASE; NEURONAL DIFFERENTIATION; SIGNAL TRANSDUCTION; DOWN-REGULATION; PHOSPHORYLATION; ACTIVATION	Although they all utilize tyrosine kinase receptors and activate signaling pathways characterized by a similar set of phosphoproteins, epidermal growth factor (EGF) promotes only cell division while fibroblast growth factor (FGF) and nerve growth factor (NGF) can induce division followed by differentiation in PC12 cells, EGF, in contrast to NGF and FGF, cannot maintain the sustained phosphorylation and activation of mitogen-activated protein (MAP) kinase kinase and MAP kinases, which may account for the difference in phenotypic response. The pretreatment of PC12 cells with staurosporine, a protein kinase inhibitor, causes a substantial increase in both receptor and MAP kinase phosphorylation that results in a differentiative response (neurite proliferation). However, neurites begin to dis appear after 3 days, despite the continual presence of EGP, and are largely gone after 5 days, which is not the case with NGF and FGF. Thus, the effect of staurosporine is not permanent. Northern and Western blots indicate that the staurosporine response mainly results from a substantial up-regulation in EGF receptor synthesis, thus providing a much stronger cell surface signal and supporting the view that quantitative rather than qualitative differences distinguish the EGF versus NGF/FGF signaling pathways in these cells.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER; NIA NIH HHS [AG09735] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERG MM, 1992, J BIOL CHEM, V267, P13; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANDLER LP, 1985, J BIOL CHEM, V260, P3360; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1978, J CELL BIOL, V78, P745; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HASHIMOTO S, 1989, J NEUROCHEM, V53, P1675, DOI 10.1111/j.1471-4159.1989.tb09230.x; HASHIMOTO S, 1989, EXP CELL RES, V184, P351, DOI 10.1016/0014-4827(89)90334-0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HONDERMARCK H, 1994, P NATL ACAD SCI USA, V91, P9377, DOI 10.1073/pnas.91.20.9377; ISONO F, 1994, J NEUROCHEM, V63, P1235; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORIOKA H, 1985, AGR BIOL CHEM TOKYO, V49, P1959, DOI 10.1080/00021369.1985.10867017; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RASOULY D, 1992, MOL PHARMACOL, V42, P35; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SANO M, 1990, BRAIN RES, V510, P269, DOI 10.1016/0006-8993(90)91377-S; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAPLEY P, 1992, ONCOGENE, V7, P371; THEROUX SJ, 1992, MOL ENDOCRINOL, V6, P1849, DOI 10.1210/me.6.11.1849; TISCHLER AS, 1990, J NEUROCHEM, V55, P1159, DOI 10.1111/j.1471-4159.1990.tb03120.x; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WU YY, 1995, IN PRESS J CELL PHYS; ZHANG L, 1994, J BIOL CHEM, V269, P10270; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	46	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7568	7572		10.1074/jbc.270.13.7568	http://dx.doi.org/10.1074/jbc.270.13.7568			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535772	hybrid			2022-12-25	WOS:A1995QQ43100080
J	BORSI, L; BALZA, E; GAGGERO, B; ALLEMANNI, G; ZARDI, L				BORSI, L; BALZA, E; GAGGERO, B; ALLEMANNI, G; ZARDI, L			THE ALTERNATIVE SPLICING PATTERN OF THE TENASCIN-C PRE-MESSENGER-RNA IS CONTROLLED BY THE EXTRACELLULAR PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; LOCALIZATION; ISOFORMS; COMPLEX; TISSUES; REPEAT	Alternative splicing of primary transcripts is an ubiquitous and reversible mechanism for the generation of multiple protein isoforms from single genes, Here we report that in cultured normal human fibroblasts, small pH variations of the culture medium (from 7.2 to 6.9) strikingly modify the alternative splicing pattern of the tenascin-C primary transcript. Since such extracellular pH variations occur in many normal and pathological conditions, microenvironmental pH may be an important element for the regulation of RNA alternative splicing in vivo.	IST NAZL RIC CANC,CELL BIOL LAB,I-16132 GENOA,ITALY	University of Genoa; IRCCS AOU San Martino IST								AUSTIN C, 1993, J PHYSIOL-LONDON, V466, P1; BORSI L, 1994, CELL ADHES COMMUN, V1, P307, DOI 10.3109/15419069409097262; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CARLIN K, 1993, MED HYPOTHESES, V41, P42, DOI 10.1016/0306-9877(93)90032-L; CHIQUETEHRISMANN R, 1993, SEMIN CANCER BIOL, V4, P301; CHUONG CM, 1991, AM J PATHOL, V138, P427; EDELMAN GM, 1992, TRENDS BIOCHEM SCI, V17, P228, DOI 10.1016/0968-0004(92)90383-K; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HARRIS CC, 1980, METHODS CELL BIOL, V21, pCH3; JULIAN JA, 1994, DEVELOPMENT, V120, P661; KAPLONY A, 1991, DEVELOPMENT, V112, P605; LEBOEUF RA, 1992, CANCER RES, V52, P144; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MELLERGARD P, 1994, AM J PHYSIOL, V267, pC581, DOI 10.1152/ajpcell.1994.267.2.C581; OYAMA F, 1991, CANCER RES, V51, P4876; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SRIRAMARAO P, 1993, NUCLEIC ACIDS RES, V21, P163, DOI 10.1093/nar/21.1.163; TUCKER RP, 1993, J CELL SCI, V104, P69	25	71	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6243	6245		10.1074/jbc.270.11.6243	http://dx.doi.org/10.1074/jbc.270.11.6243			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7534307	hybrid			2022-12-25	WOS:A1995QM94500079
J	DING, ZM; CRISTIANO, RJ; ROTH, JA; TAKACS, B; KUO, MT				DING, ZM; CRISTIANO, RJ; ROTH, JA; TAKACS, B; KUO, MT			MALARIAL CIRCUMSPOROZOITE PROTEIN IS A NOVEL GENE DELIVERY VEHICLE TO PRIMARY HEPATOCYTE CULTURES AND CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ASIALOGLYCOPROTEIN RECEPTOR; POLYLYSINE DNA COMPLEXES; PLASMODIUM-FALCIPARUM; DESIALYLATED GLYCOPROTEINS; ADENOVIRUS ENHANCEMENT; RECOMBINANT ADENOVIRUS; MAMMALIAN-CELLS; EXPRESSION; SPOROZOITES; MEMBRANE	In this report we describe a novel gene delivery system using malaria circumsporozoite (CS) protein as a specific ligand, The CS protein covers the entire surface of sporozoites of malaria parasites, Previous studies have demonstrated that intravenously injected CS protein binds specifically to the basolateral surface of hepatocytes within minutes, indicating the high hepatocyte specificity of CS protein, This characteristic of CS protein prompted us to explore the possibility of using this protein as a liver-specific ligand for hepatic gene delivery vehicle, As an initial step, we investigated the efficacy of CS protein-mediated gene transfer into primary hepatocytes as well as established cell lines, Recombinant CS proteins were chemically conjugated to poly(L-lysine), The CS conjugates were complexed with recombinant plasmid DNA carrying a reporter gene, When the DNA complex was used to transfect primary hepatocytes, a very low level of expression of the reporter gene was observed, The level of expression was greatly enhanced when the cells were cotransfected with adenovirus, which presumably releases the internalized DNA from endosomal entrapment, The CS-mediated gene transfer into the cells required region II+, an evolutionarily conserved amino acid sequence conferring the binding of CS protein to its receptor, CS protein also efficiently mediated gene transfer into a number of cell lines, i,e, HepG(2), HeLa, NIH3T3, and K562, but not HL-60, which contains low levels of receptor, Thus, the CS conjugate can be used to deliver DNA into many different cultured cells, Most importantly, the CS conjugate has a potential to be further developed into a liver-specific gene delivery vehicle in vivo.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, THORAC MOLEC ONCOL SECT, HOUSTON, TX 77030 USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES, PRECLIN DERMATOL, CH-4002 BASEL, SWITZERLAND	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Roche Holding					NATIONAL CANCER INSTITUTE [R01CA055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049091] Funding Source: NIH RePORTER; NCI NIH HHS [CA11672, CA 55813] Funding Source: Medline; NIDDK NIH HHS [DK49091] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arima T, 1977, Gastroenterol Jpn, V12, P39; BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; COX FEG, 1992, NATURE, V359, P361, DOI 10.1038/359361a0; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P11548, DOI 10.1073/pnas.90.24.11548; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DODEUR M, 1982, EUR J BIOCHEM, V123, P383, DOI 10.1111/j.1432-1033.1982.tb19780.x; FERKOL T, 1993, FASEB J, V7, P1081, DOI 10.1096/fasebj.7.11.8370479; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; HARBACH PR, 1989, MUTAT RES, V216, P101, DOI 10.1016/0165-1161(89)90010-1; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; KIMURA O, 1994, HUM GENE THER, V5, P845, DOI 10.1089/hum.1994.5.7-845; KUO MT, 1992, CELL GROWTH DIFFER, V3, P531; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MARSHALL JS, 1978, J LAB CLIN MED, V92, P30; MARSHALL JS, 1974, J CLIN INVEST, V54, P555, DOI 10.1172/JCI107792; MASSIE B, 1986, MOL CELL BIOL, V6, P2872, DOI 10.1128/MCB.6.8.2872; MCKEE TD, 1994, BIOCONJUGATE CHEM, V5, P306, DOI 10.1021/bc00028a004; Means G E, 1977, Methods Enzymol, V47, P469; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; NUSSENZWEIG RS, 1994, SCIENCE, V265, P1381, DOI 10.1126/science.8073276; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PLANK C, 1994, J BIOL CHEM, V269, P12918; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1994, J BIOL CHEM, V269, P11542; WU GY, 1991, J BIOL CHEM, V266, P14338; WU GY, 1993, ADV DRUG DELIVER REV, V12, P159, DOI 10.1016/0169-409X(93)90057-B; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	51	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3667	3676		10.1074/jbc.270.8.3667	http://dx.doi.org/10.1074/jbc.270.8.3667			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533154	hybrid			2022-12-25	WOS:A1995QH68800034
J	VELAZQUEZ, L; MOGENSEN, KE; BARBIERI, G; FELLOUS, M; UZE, G; PELLEGRINI, S				VELAZQUEZ, L; MOGENSEN, KE; BARBIERI, G; FELLOUS, M; UZE, G; PELLEGRINI, S			DISTINCT DOMAINS OF THE PROTEIN-TYROSINE KINASE TYK2 REQUIRED FOR BINDING OF INTERFERON-ALPHA/BETA AND FOR SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAIN; RECEPTOR; CELLS; EXPRESSION; PATHWAY; JAK	tyk2 belongs to the JAK family of nonreceptor protein tyrosine kinases recently found implicated in signaling through a large number of cytokine receptors. These proteins are characterized by a large amino-terminal region and two tandemly arranged kinase domains, a kinase-like and a tyrosine kinase domain. Genetic and biochemical evidence supports the requirement for tyk2 in interferon-alpha/beta binding and signaling. To study the rob of the distinct domains of tyk2, constructs lacking one or both kinase domains were stably transfected in recipient cells lacking the endogenous protein. Removal of either or both kinase domains resulted in loss of the in vitro kinase activity. The mutant form truncated of the tyrosine kinase domain was found to reconstitute binding of interferon-alpha 8 and partial signaling. While no contribution of this protein toward interferon-beta binding was evident, increased signaling could be measured. The mutant form lacking both kinase domains did not exhibit any detectable activity. Altogether, these results show that a sequential deletion of domains engenders a sequential loss of function and that the different domains of tyk2 have distinct functions, all essential for full interferon-alpha and -beta binding and signaling.	INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE; INST GENET MOLEC, CNRS, UMR 9942, MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)			Barbieri, Giovanna/AAH-3645-2019; Pellegrini, Sandra/Y-6351-2019; Pellegrini, Sandra -/G-5546-2015; Uzé, Gilles/O-6383-2019	Pellegrini, Sandra/0000-0001-5837-7589; Pellegrini, Sandra -/0000-0001-5837-7589; Uze, Gilles/0000-0002-4150-5772; BARBIERI, GIOVANNA/0000-0002-5895-1795				ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; CHANG CP, 1993, J BIOL CHEM, V268, P19132; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; Maniatis T., 1982, MOL CLONING; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; MOGENSEN KE, 1983, EUR J BIOCHEM, V134, P355, DOI 10.1111/j.1432-1033.1983.tb07575.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RANE SG, 1994, ONCOGENE, V9, P2415; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	43	121	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3327	3334		10.1074/jbc.270.7.3327	http://dx.doi.org/10.1074/jbc.270.7.3327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531704	Green Submitted, hybrid			2022-12-25	WOS:A1995QG47100066
J	SZABO, T; KADISH, JL; CZOP, JK				SZABO, T; KADISH, JL; CZOP, JK			BIOCHEMICAL-PROPERTIES OF THE LIGAND-BINDING 20-KDA SUBUNIT OF THE BETA-GLUCAN RECEPTORS ON HUMAN MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MONOCYTES; TYROSINE PHOSPHORYLATION; PARTICULATE ACTIVATORS; MONOCLONAL-ANTIBODIES; PHORBOL ESTERS; COMPLEMENT; PROTEIN; ZYMOSAN; PARTICLES; CELLS	beta-Glucan receptors are present on mammalian leukocytes and initiate phagocytosis of particulate yeast beta-glucans, such as zymosan particles, Human monocytes and U937 cells express two membrane proteins of 180 and 160 kDa, each of which binds particulate yeast glucan through a 20-kDa polypeptide constituent. In this report, the structural composition of the two beta-glucan receptors and the biochemical properties of their polypeptide constituents were examined, The 180-kDa receptor was composed of three disulfide-linked polypeptides of 95, 60, and 20 kDa, whereas the 160-kDa receptor was a multimer of two polypeptides of 27 and 20 kDa, Unlike other receptor constituents, the 20-kDa polypeptide was nonglycosylated and focused at two distinct isoelectric points. Immunoblots of the focused polypeptides showed the two 20-kDa variants and the 95-kDa subunit to be constitutively tyrosine-phosphorylated, a feature not previously reported for receptors on human mononuclear phagocytes, Dephosphorylation of the receptor proteins resulted in the loss of antigenic phosphotyrosine without affecting the antigenicity of either 20-kDa variant for the anti-idiotypic antibody to beta-glucan receptors, Separate analysis of the 160-kDa receptor showed it contained both variants of the 20-kDa polypeptide, Thus, the 20-kDa subunit constituent of the two beta-glucan receptors is a functionally and chemically unique polypeptide with apparent microheterogeneity in its primary structure.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NIAID NIH HHS [AI23542] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023542] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL G, 1992, INT J IMMUNOPHARMACO, V14, P1363, DOI 10.1016/0192-0561(92)90007-8; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BABINEAU TJ, 1994, ANN SURG, V220, P601, DOI 10.1097/00000658-199411000-00002; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BENACH JL, 1982, INFECT IMMUN, V35, P947, DOI 10.1128/IAI.35.3.947-951.1982; CHAKRAVARTI B, 1988, CELL IMMUNOL, V113, P251, DOI 10.1016/0008-8749(88)90024-X; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CZOP JK, 1985, J IMMUNOL, V134, P2588; CZOP JK, 1991, J EXP MED, V173, P1511, DOI 10.1084/jem.173.6.1511; CZOP JK, 1985, IMMUNOLOGY, V54, P407; CZOP JK, 1980, J IMMUNOL, V125, P124; CZOP JK, 1990, J IMMUNOL, V145, P995; DIAMOND MS, 1993, J CELL BIOL, V120, P1032; DICARLO FJ, 1958, SCIENCE, V120, P279; DIEMANN W, 1979, J EXP MED, V149, P883; DILUZIO NR, 1983, TRENDS PHARMACOL SCI, V4, P344, DOI 10.1016/0165-6147(83)90434-0; DILUZIO NR, 1979, J RETICULOENDOTHEL S, V7, P731; EHLENBERGER AG, 1977, J EXP MED, V145, P357, DOI 10.1084/jem.145.2.357; ELSTAD MR, 1994, J IMMUNOL, V152, P220; FERREIRA A, 1981, J IMMUNOL METHODS, V43, P291, DOI 10.1016/0022-1759(81)90177-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; JANUSZ MJ, 1989, J IMMUNOL, V142, P959; JANUSZ MJ, 1986, J IMMUNOL, V137, P3270; JOHNSON E, 1984, SCAND J IMMUNOL, V19, P31, DOI 10.1111/j.1365-3083.1984.tb00897.x; KELLY BA, 1987, J BIOL CHEM, V262, P17404; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MANNERS DJ, 1974, J GEN MICROBIOL, V80, P411, DOI 10.1099/00221287-80-2-411; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; NEWMAN SL, 1985, J EXP MED, V161, P1414, DOI 10.1084/jem.161.6.1414; ONDERDONK AB, 1992, INFECT IMMUN, V60, P1642, DOI 10.1128/IAI.60.4.1642-1647.1992; RIGGI SJ, 1961, AM J PHYSIOL, V200, P297, DOI 10.1152/ajplegacy.1961.200.2.297; ROSS GD, 1985, J IMMUNOL, V134, P3307; SANGUEDOLCE MV, 1993, J IMMUNOL, V151, P405; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SHARMA A, 1984, INT J IMMUNOPHARMACO, V6, P483, DOI 10.1016/0192-0561(84)90087-0; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	43	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2145	2151		10.1074/jbc.270.5.2145	http://dx.doi.org/10.1074/jbc.270.5.2145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530718	hybrid			2022-12-25	WOS:A1995QE49300027
J	WEERNINK, PAO; RIJKSEN, G				WEERNINK, PAO; RIJKSEN, G			ACTIVATION AND TRANSLOCATION OF C-SRC TO THE CYTOSKELETON BY BOTH PLATELET-DERIVED GROWTH-FACTOR AND EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; ROUS-SARCOMA VIRUS; MORPHOLOGICAL TRANSFORMATION; SIGNAL-TRANSDUCTION; ASSOCIATION; PROTEIN; RECEPTOR; PP60(C-SRC); SUBSTRATE; P60SRC	We have examined the subcellular distribution and catalytic activity of C-Src tyrosine kinase after stimulation of A172 glioblastoma cells with peptide growth factors. Treatment of resting cells with platelet-derived growth factor resulted in an increase (3.5-fold) in the amount of c-Src protein associated with the cytoskeleton, In addition, an increase in specific c-Src kinase activity was observed in the cytoskeleton as well as in the cytosol and the membrane fraction. Similar effects on both c-Src redistribution and activity were seen after stimulation with epidermal growth factor. These data show that, like other signal transducing components, c-Src also becomes activated and associated to the cytoskeleton in response to growth factor stimulation.			WEERNINK, PAO (corresponding author), UNIV UTRECHT HOSP, DEPT HEMATOL, MED ENZYMOL LAB, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; LIEBENHOFF U, 1993, INT CONGR SER, V1042, P171; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; ODA A, 1992, J BIOL CHEM, V267, P20075; OKAMURA H, 1994, ONCOGENE, V9, P2293; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WONG S, 1992, ONCOGENE, V7, P2407; YANG LJ, 1994, J BIOL CHEM, V269, P7156	30	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2264	2267		10.1074/jbc.270.5.2264	http://dx.doi.org/10.1074/jbc.270.5.2264			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530720	hybrid			2022-12-25	WOS:A1995QE49300045
J	WU, WM; BLUMBERG, BM; FAY, PJ; BAMBARA, RA				WU, WM; BLUMBERG, BM; FAY, PJ; BAMBARA, RA			STRAND TRANSFER MEDIATED BY HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE IN-VITRO IS PROMOTED BY PAUSING AND RESULTS IN MISINCORPORATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLONEY MURINE LEUKEMIA; RNASE-H ACTIVITY; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; PROCESSIVE SYNTHESIS; DNA-SYNTHESIS; TEMPLATE; POLYMERIZATION; TERMINATION; GENERATION	Human immunodeficiency virus (HIV-I) is able to recombine by transfer of the growing DNA strand from internal regions of one genome to another. The strand transfer reaction, catalyzed by HIV-1 reverse transcriptase (RT), was conducted in vitro between donor and acceptor RNA templates that were derived from natural HIV-1 nef genes. The donor and acceptor templates shared a nearly homologous region where strand transfer could occur, differing only in that the acceptor had a 36-nucleotide insertion and 6 widely spaced base substitutions compared with the donor. We sequenced elongated primers that underwent transfer, The position of transfer was revealed by the change of sequence from that of the donor to that of the acceptor. Results showed a positive correlation between positions where the RT paused during synthesis and enhancement of strand transfer. Elimination of a pause site, with a minimal change in sequence, decreased the frequency of strand transfer in the immediate area. Analysis of the sequence of DNA products resulting from transfer at a frequently used site showed that mutations had been introduced into the DNA at about the point of transfer. Remarkably, approximately 30% of the products contained mutations. Base substitutions, short additions and deletions were observed. Mutations did not appear in DNA products extended on the donor template without transfer. The identity of the mutations suggests that they were caused by a combination of slippage and non-template-directed nucleotide addition. These results indicated that the detected mutations were related to the process of strand transfer.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NINDS NIH HHS [NS28754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; BLUMBERG BM, 1992, J VIROL, V66, P5256, DOI 10.1128/JVI.66.9.5256-5264.1992; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; Coffin J. M., 1990, VIROLOGY, P1437; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COFFIN JM, 1990, APPLIED VIROLOGY RES, V2; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HOWELL RM, 1991, AIDS RES HUM RETROV, V7, P869, DOI 10.1089/aid.1991.7.869; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SRINIVASAN A, 1989, P NATL ACAD SCI USA, V86, P6388, DOI 10.1073/pnas.86.16.6388; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; Weiss R, 1985, RNA TUMOR VIRUSES; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; ZHANG JY, 1994, J VIROL, V68, P2409, DOI 10.1128/JVI.68.4.2409-2414.1994	36	103	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					325	332		10.1074/jbc.270.1.325	http://dx.doi.org/10.1074/jbc.270.1.325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529228	hybrid			2022-12-25	WOS:A1995QA28700052
J	FLYNN, TR; HOLLENBERG, AN; COHEN, O; MENKE, JB; USALA, SJ; TOLLIN, S; HEGARTY, MK; WONDISFORD, FE				FLYNN, TR; HOLLENBERG, AN; COHEN, O; MENKE, JB; USALA, SJ; TOLLIN, S; HEGARTY, MK; WONDISFORD, FE			A NOVEL C-TERMINAL DOMAIN IN THE THYROID-HORMONE RECEPTOR SELECTIVELY MEDIATES THYROID-HORMONE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-SUBUNIT GENE; DOMINANT-NEGATIVE INHIBITION; RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; GENERALIZED RESISTANCE; PITUITARY RESISTANCE; NUCLEAR RECEPTOR; BASE MUTATION; ERB-A	Resistance to thyroid hormone (RTH) action is due to mutations in the beta-isoform of the thyroid hormone receptor (TR-beta). RTH patients display inappropriate central secretion of thyrotropin-releasing hormone (TRH) from the hypothalamus and thyrotropin (TSH) from the anterior pituitary in association with abnormal peripheral tissue responses to thyroid hormone. Whether TR-beta mutations cause a selective form of RTH, which only leads to abnormal pituitary TSH secretion (PRTH), is unclear. In a patient with PRTH, a novel mutation of a conserved arginine residue adjacent to the ninth heptad of TR-beta selectively disrupts TR homodimer formation. The mutant TR displays normal or enhanced function on stimulatory thyroid hormone response elements found in peripheral tissues, but has defective function on inhibitory thyroid hormone response elements found in the TRH and TSH subunit genes and explains the PRTH phenotype. This is the first report of a mutation in a member of the nuclear receptor superfamily that selectively abolishes hormone dependent inhibition and localizes a novel C-terminal domain necessary for this property.	BETH ISRAEL HOSP,DEPT MED,THYROID UNIT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of North Carolina; East Carolina University				, Stephen/0000-0003-4068-6492	NIDDK NIH HHS [DK-42807, DK-43653] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043653, R29DK042807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS M, 1994, J CLIN INVEST, V94, P506, DOI 10.1172/JCI117362; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GEFFNER ME, 1993, J CLIN INVEST, V91, P538, DOI 10.1172/JCI116233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAYASHI Y, 1994, J CLIN INVEST, V94, P607, DOI 10.1172/JCI117376; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MIXSON AJ, 1993, CLIN ENDOCRINOL, V38, P227, DOI 10.1111/j.1365-2265.1993.tb00999.x; NAGAYA T, 1993, J CLIN ENDOCR METAB, V77, P982, DOI 10.1210/jc.77.4.982; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SASAKI S, 1993, J CLIN ENDOCR METAB, V76, P1254, DOI 10.1210/jc.76.5.1254; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONDISFORD FE, 1988, J BIOL CHEM, V263, P12538; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J CLIN INVEST, V90, P1825, DOI 10.1172/JCI116058; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	39	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32713	32716						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528740				2022-12-25	WOS:A1994QA63800002
J	XIONG, H; VIK, SB				XIONG, H; VIK, SB			ALANINE-SCANNING MUTAGENESIS OF THE EPSILON-SUBUNIT OF THE F-1-F-0 ATP SYNTHASE FROM ESCHERICHIA-COLI REVEALS 2 CLASSES OF MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE ACTIVITY; H+-ATPASE; F1 ATPASE; LAURYLDIMETHYLAMINE OXIDE; ALPHA-SUBUNIT; BETA-SUBUNIT; F1-ATPASE; F1FO-ATPASE; INHIBITION; NUCLEOTIDE	Alanine scanning mutagenesis was applied to the epsilon subunit of the F-1-F-0 ATP synthase from E. coli. Nineteen amino acid residues were changed to alanine, either singly or in pairs, between residues 10 and 93. All mutants, when expressed in the epsilon deletion strain XH1, were able to grow on succinate minimal medium. Membranes were prepared from all mutants and assayed for ATP-driven proton translocation, ATP hydrolysis +/- lauryldiethylamine oxide, and sensitivity of ATPase activity to N,N'-dicyclohexylcarbodiimide (DCCD). Most of the mutants fell into 2 distinct classes. The first group had inhibited ATPase activity, with near normal levels of membrane bound F-1, but decreased sensitivity to DCCD. The second group had stimulated ATPase activity, with a reduced level of membrane-bound F-1, but normal sensitivity to DCCD. Membranes from all mutants were further characterized by immunoblotting using 2 monoclonal antibodies. A model for the secondary structure of epsilon and its role in the function of the ATP synthase has been developed. Some residues are important for the binding of epsilon to F-1 and therefore for inhibition. Other residues, from Glu-59 through Glu-70, are important for the release of inhibition by epsilon that is part of the normal enzyme cycle.	SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA	Southern Methodist University				Vik, Steven/0000-0002-5285-015X	NIGMS NIH HHS [R01 GM040508, GM40508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1990, BIOCHEMISTRY-US, V29, P4335, DOI 10.1021/bi00470a011; DUNN SD, 1982, J BIOL CHEM, V257, P7354; FILLINGAME RH, 1990, BACTERIA; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P87, DOI 10.1016/0003-9861(92)90054-Z; KUKI M, 1988, J BIOL CHEM, V263, P17437; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; LAROE DJ, 1992, J BACTERIOL, V174, P633, DOI 10.1128/jb.174.2.633-637.1992; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J, 1989, MOL CLONING LABORATO; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P272, DOI 10.1006/abbi.1993.1210; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P279, DOI 10.1006/abbi.1993.1211; STANLOTTER H, 1986, EUR J BIOCHEM, V154, P321, DOI 10.1111/j.1432-1033.1986.tb09400.x; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; VIK SB, 1988, J BIOL CHEM, V263, P6599; WANG S, 1994, J BIOL CHEM, V269, P3095; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; XIONG H, 1995, J BACTERIOL, V177, P851, DOI 10.1128/jb.177.3.851-853.1995; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	36	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23300	23304		10.1074/jbc.270.40.23300	http://dx.doi.org/10.1074/jbc.270.40.23300			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559484	hybrid			2022-12-25	WOS:A1995RY90900013
J	LEE, J; JAYARAM, M				LEE, J; JAYARAM, M			FUNCTIONAL ROLES OF INDIVIDUAL RECOMBINASE MONOMERS IN STRAND BREAKAGE AND STRAND UNION DURING SITE-SPECIFIC DNA RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLP RECOMBINASE; HALF-SITE; INTEGRASE FAMILY; MECHANISM; PROTEIN; CLEAVAGE; MUTATIONS; SUBSTRATE; CATALYSIS; SYNAPSIS	The site-specific recombinase Flp from Saccharomyces cerevisiae accomplishes recombination between two target DNA sites by executing a pair of strand exchanges at either end of the strand exchange region. One round of recombination requires the cooperative action of four recombinase monomers. We demonstrate here that, in the presence of the appropriate nucleophiles, a single Flp monomer associated with its binding element can mediate strand cleavage and strand joining at the exchange site phosphate adjacent to it. Our results support a model of recombination in which pairs of FIp monomers reverse catalytic roles to mediate the first and second sets of strand breakage/union reactions. They disfavor a model that involves a relay of recombinase monomers between binding elements to assemble separate active sites for strand cleavage and strand joining. Our data are consistent with the breakage and joining reactions being carried out by a single composite active site in which some residues contribute to both reactions while others contribute to one of the two reactions.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Lee, Jehee/AAS-3229-2021		NIGMS NIH HHS [GM-35654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1992, GENE, V119, P37; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; EVANS BR, 1990, J BIOL CHEM, V265, P18504; JAYARAM M, 1994, NUCLEIC ACIDS MOL BI, V8, P268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; MACK A, 1992, NUCLEIC ACIDS RES, V20, P4451, DOI 10.1093/nar/20.17.4451; Maniatis T., 1982, MOL CLONING; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; QIAN XH, 1990, J BIOL CHEM, V265, P21779; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; WHANG I, 1994, MOL CELL BIOL, V14, P7492, DOI 10.1128/MCB.14.11.7492; YANG SH, 1994, J BIOL CHEM, V269, P12789	29	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23203	23211		10.1074/jbc.270.39.23203	http://dx.doi.org/10.1074/jbc.270.39.23203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559468	hybrid			2022-12-25	WOS:A1995RY05400088
J	LIU, KD; LAI, SY; GOLDSMITH, MA; GREENE, WC				LIU, KD; LAI, SY; GOLDSMITH, MA; GREENE, WC			IDENTIFICATION OF A VARIABLE REGION WITHIN THE CYTOPLASMIC TAIL OF THE IL-2 RECEPTOR BETA-CHAIN THAT IS REQUIRED FOR GROWTH SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; TYROSINE PHOSPHORYLATION; BINDING; PROTEINS; CLONING	Interleukin-2 (IL-2) regulates numerous biological events, including T lymphocyte proliferation. Interleukin-2 receptor (IL-2R)-mediated signaling is triggered by ligand-induced heterodimerization of the IL-2R beta and gamma(c) subunits, which results in the activation of signaling intermediates that are associated with either IL-2R beta or gamma(c). Previous mutagenesis studies of the IL-2R beta cytoplasmic tail demonstrated that the partially conserved box 1 and box 2 motifs and specific tyrosine residues are critical for growth signaling. By deletion and alanine scanning mutagenesis, another set of residues that are critical for IL-2R-mediated signaling has now been identified. These residues lie within the divergent 35-amino acid ''spacer'' region separating box 1 and box 2. The role of this receptor subregion in early phases of IL-2R signaling was evaluated using BA/F3 stable cell lines expressing three functionally impaired mutants from this region. All three cell lines displayed substantially diminished growth responsiveness to IL-2. Receptor-mediated STAT factor activation, IL-2R beta phosphorylation, and Janus kinase activation were also markedly impaired. These findings indicate that this variable spacer region, which we have termed the V-box, is essential for the initiation of IL-2R-mediated signal transduction.	UNIV CALIF SAN FRANCISCO,SCH MED,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lai, Stephen/0000-0001-8301-7286				ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GOLDSMITH M, 1994, INTERLEUKIN 2 INTERL; GOLDSMITH MA, 1995, J IMMUNOL, V154, P2033; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1994, BLOOD, V84, P1501; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	35	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22176	22181		10.1074/jbc.270.38.22176	http://dx.doi.org/10.1074/jbc.270.38.22176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545674	hybrid			2022-12-25	WOS:A1995RW31400020
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			P-GLYCOPROTEIN - ASSOCIATIONS BETWEEN DOMAINS AND BETWEEN DOMAINS AND MOLECULAR CHAPERONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED TRANSMEMBRANE DOMAIN; RESISTANT HUMAN-CELLS; MULTIDRUG-RESISTANCE; FUNCTIONAL CONSEQUENCES; BINDING SITES; MDR1; MUTATIONS; MEMBRANE; GENE; RECONSTITUTION	P-glycoprotein consists of two homologous halves, each composed of a transmembrane domain and a nucleotide-binding domain. In order to understand how the domains interact in P-glycoprotein, we expressed each domain as a separate polypeptide and tested for associations using coimmunoprecipitation assays. We found that the interactions between the two halves of P-glycoprotein were mediated through associations between the two transmembrane domains as well as through the nucleotide-binding domains. In addition, the nucleotide-binding domain also associated with the transmembrane domain in each half of the molecule, By contrast, we could not detect any association either between the first nucleotide-binding domain and the second transmembrane domain, or between the second nucleotide binding domain and the first transmembrane domain. We then tested whether individual domains associated with molecular chaperones, since biogenesis of P-glycoprotein appears to involve the chaperones calnexin and Hsc70. We found that calnexin associated only with the transmembrane domains, while Hsc70 associated only with the nucleotide-binding domains, These results suggest that noncovalent interaction between the domains of P-glycoprotein can contribute to structure and function of P-glycoprotein and that chaperones may participate in the folding of each domain,	UNIV TORONTO, DEPT MED, MRC, MEMBRANE BIOL GRP, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHARUK JHM, 1994, AM J PHYSIOL, V266, pF66, DOI 10.1152/ajprenal.1994.266.1.F66; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; PARMENTIER M, 1987, EUR J BIOCHEM, V170, P207, DOI 10.1111/j.1432-1033.1987.tb13688.x; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAO US, 1995, J BIOL CHEM, V270, P6686; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; VANDERBLIEK AM, 1995, ADV CANCER RES, V52, P165; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	43	126	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21839	21844		10.1074/jbc.270.37.21839	http://dx.doi.org/10.1074/jbc.270.37.21839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545169	hybrid			2022-12-25	WOS:A1995RU75700066
J	HAN, JW; PEARSON, RB; DENNIS, PB; THOMAS, G				HAN, JW; PEARSON, RB; DENNIS, PB; THOMAS, G			RAPAMYCIN, WORTMANNIN, AND THE METHYLXANTHINE SQ20006 INACTIVATE P70(S6K) BY INDUCING DEPHOSPHORYLATION OF THE SAME SUBSET OF SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; P70 S6 KINASE; PROTEIN-KINASE; MAP2 KINASE; LATE PHASE; ACTIVATION; PHOSPHORYLATION; INHIBITION; PHOSPHOPEPTIDE; TRANSFORMATION	Activation of p70(s6k) in cells stimulated with serum correlates with the phosphorylation of seven sites. Pretreatment of Swiss 3T3 cells with the immunosuppressant rapamycin blocks phosphorylation of four of these sites (Thr(229), Thr(389), Ser(404), and Ser(411)), whereas phosphorylation proceeds in the remaining three sites (Ser(418), Thr(421), and Ser(424)). If rapamycin is added post-serum stimulation, the pattern of phosphorylation is qualitatively similar except that Ser(411) is still highly phosphorylated. The inhibitory effect of rapamycin on serum-induced p70(s6k) activation and the phosphorylation of Thr(229), Thr(389), Ser(404), and Ser(411) is rescued by FK506, providing further evidence that the inhibitory effect is exerted through a complex of rapamycin-FKBP12. Wortmannin treatment pre- or post-serum stimulation inhibits phosphorylation of the same set of sites as rapamycin, supporting the argument that both agents act on the same pathway. Likewise, methylxan thine phosphodiesterase inhibitors block p70(s6k) activation and phosphorylation of the same set of sites as wortmannin and rapamycin. However, other agents that raise intracellular cAMP levels have no inhibitory effect, leading to the hypothesis that the inhibitory actions of methylxanthines on p70(s6k) activity are not through activating protein kinase A but through inhibition of an upstream kinase. Together the results indicate that there are two kinase signaling pathways that must converge to activate p70(s6k) and that only one of these pathways is sensitive to rapamycin, wortmannin, and methylxanthine inhibition.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Pearson, Richard Bruce/I-1451-2013	Pearson, Richard Bruce/0000-0001-5919-5090				BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHASIN M, 1972, BIOCHEM PHARMACOL, V21, P2443, DOI 10.1016/0006-2952(72)90414-5; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZMA SC, 1994, SEMIN CANCER BIOL, V5, P255; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LASTICK SM, 1978, CELL REPRODUCTION IC; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MORLEY SJ, 1993, INT ENCY PHARM THERA, P447; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MYERS MG, 1994, J BIOL CHEM, V269, P28783; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIERANDREIAMALDI P, 1985, CELL, V42, P317, DOI 10.1016/S0092-8674(85)80127-6; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1992, J BIOL CHEM, V267, P6905; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; THOMAS G, 1980, CELL, V19, P1015, DOI 10.1016/0092-8674(80)90092-6; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015	51	162	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21396	21403		10.1074/jbc.270.36.21396	http://dx.doi.org/10.1074/jbc.270.36.21396			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545671	hybrid			2022-12-25	WOS:A1995RU05400080
J	MARTENS, CL; CWIRLA, SE; LEE, RYW; WHITEHORN, E; CHEN, EYF; BAKKER, A; MARTIN, EL; WAGSTROM, C; GOPALAN, P; SMITH, CW; TATE, E; KOLLER, KJ; SCHATZ, PJ; DOWER, WJ; BARRETT, RW				MARTENS, CL; CWIRLA, SE; LEE, RYW; WHITEHORN, E; CHEN, EYF; BAKKER, A; MARTIN, EL; WAGSTROM, C; GOPALAN, P; SMITH, CW; TATE, E; KOLLER, KJ; SCHATZ, PJ; DOWER, WJ; BARRETT, RW			PEPTIDES WHICH BIND TO E-SELECTIN AND BLOCK NEUTROPHIL ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ENDOTHELIAL CELL RECOGNITION; LYMPHOCYTE HOMING RECEPTOR; MEDIATED LUNG INJURY; P-SELECTIN; CARBOHYDRATE LIGANDS; GLYCOPROTEIN LIGAND; SIALYL-LEX; AIRWAY INFLAMMATION; MOLECULAR-CLONING	E-selectin is an inducible cell adhesion molecule which mediates rolling of neutrophils on the endothelium, an early event in the development of an inflammatory response, inhibition of selectin-mediated rolling is a possible means for controlling inflammation-induced diseases, and several classes of compounds have been tested for this use. We describe here the use of recombinant peptide library screening for identification and optimization of novel ligands which bind to E-selectin. Several of these peptides bind with K-d values in the low nanomolar range and block E-selectin-mediated adhesion of neutrophils in static and flow cell assays. Administration of the peptide to mice undergoing an acute inflammatory response reduced the extent of neutrophil transmigration to the site of inflammation, demonstrating the utility of this compound as a potential therapeutic. The identification of a peptide ligand for E-selectin suggests that the complete natural ligand for this adhesion molecule may include protein as well as carbohydrate moieties.	BAYLOR UNIV,DEPT LEUKOCYTE BIOL,HOUSTON,TX 77030	Baylor University	MARTENS, CL (corresponding author), AFFYMAX,RES INST,PALO ALTO,CA 94304, USA.		Bakker, Arnold B./F-8494-2010	Bakker, Arnold B./0000-0003-1489-1847				ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889; BARGATZE RF, 1994, J IMMUNOL, V152, P5814; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; COOKE RM, 1994, BIOCHEMISTRY-US, V33, P10591, DOI 10.1021/bi00201a004; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOLDSTEIN A, 1987, MOL PHARMACOL, V31, P603; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GUNDEL RH, 1992, CLIN EXP ALLERGY, V22, P569, DOI 10.1111/j.1365-2222.1992.tb00167.x; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1991, BLOOD, V78, P805; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1991, J CELL BIOCHEM, V45, P139, DOI 10.1002/jcb.240450204; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1992, J IMMUNOL, V149, P331; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; MULLIGAN MS, 1993, J IMMUNOL, V151, P6410; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; PAREKH RB, 1992, J PHARM PHARMACOL, V44, P168; PETERS EA, 1994, J BACTERIOL, V176, P4296, DOI 10.1128/jb.176.14.4296-4305.1994; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RENSCHLER MF, 1994, P NATL ACAD SCI USA, V91, P3623, DOI 10.1073/pnas.91.9.3623; Robinson Martyn K., 1992, Current Opinion in Biotechnology, V3, P662, DOI 10.1016/0958-1669(92)90013-9; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SALMON SE, 1993, P NATL ACAD SCI USA, V90, P11708, DOI 10.1073/pnas.90.24.11708; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STOCKS SC, 1993, BIOCHEM BIOPH RES CO, V195, P478, DOI 10.1006/bbrc.1993.2068; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; ULRICH TR, 1994, INFLAMMATION, V18, P389; WALCHECK B, 1993, J EXP MED, V178, P853, DOI 10.1084/jem.178.3.853; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WELLER A, 1992, J BIOL CHEM, V267, P15176; YUEN CT, 1994, J BIOL CHEM, V269, P195; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	82	139	152	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21129	21136		10.1074/jbc.270.36.21129	http://dx.doi.org/10.1074/jbc.270.36.21129			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545665	hybrid			2022-12-25	WOS:A1995RU05400043
J	SHIBATA, S; TAKAGAKI, K; NAKAMURA, T; IZUMI, J; KOJIMA, K; KATOO, I; ENDO, M				SHIBATA, S; TAKAGAKI, K; NAKAMURA, T; IZUMI, J; KOJIMA, K; KATOO, I; ENDO, M			HNK-1-REACTIVE NOVEL OLIGOSACCHARIDE, SULFATE-O-3GLCA-BETA-1-4XYL-BETA-1-(4-METHYLUMBELLIFERONE), SYNTHESIZED BY CULTURED HUMAN SKIN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSIDE; MYELIN-ASSOCIATED GLYCOPROTEIN; CELL-ADHESION MOLECULES; PROTEOCHONDROITIN SULFATE; GLYCOSAMINOGLYCANS; BIOSYNTHESIS; CARBOHYDRATE; GLYCOLIPIDS; CARTILAGE; L2/HNK-1	4-Methylumbelliferyl-beta-D-xyloside (Xyl-MU) was added to the medium of cultured human skin fibroblasts, After incubation, the culture medium was pooled, and the Xyl-MU-induced oligosaccharides in the medium were purified by gel filtration chromatography, A novel Xyl-MU derivative was obtained, in addition to the previously reported Xyl-MU derivatives such as Gal-Gal-Xyl-MU, Gal-Xyl-MU, Sia-Gal-Xyl-MU, GlcA-Xyl-MU, and Xyl-Xyl-MU. The novel Xyl-MU derivative was purified using gel-filtration chromatography and high performance Liquid chromatography and then subjected to carbohydrate composition analysis, enzymic digestion, Smith degradation, and ion spray mass spectrometric analysis. The results indicated that it was sulfate-O-3GlcA beta 1-4Xyl beta 1-MU. The structure of the nonreducing terminal of this Xyl-MU-induced oligosaccharide was the same as that of the oligosaccharide chain of a human peripheral nerve derived glycolipid, reactive with the mouse monoclonal antibody HNK-1, and this Xyl-MU-induced oligosaccharide also reacted with HNK-1. These results suggest that the oligosaccharide, which is structurally identical to that of human peripheral nerve-derived glycolipid synthesized by nervous tissue and related to cell adhesion, is synthesized also by mesenchymal cells.	HIROSAKI UNIV, SCH MED, DEPT BIOCHEM, HIROSAKI, AOMORI 036, JAPAN; RES INST GLYCOTECHNOL, HIROSAKI, AOMORI 036, JAPAN	Hirosaki University								ARIGA T, 1987, J BIOL CHEM, V262, P848; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; CANTARERO LA, 1980, ANAL BIOCHEM, V105, P375, DOI 10.1016/0003-2697(80)90473-X; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FUKUNAGA Y, 1975, BIOCHIM BIOPHYS ACTA, V381, P443, DOI 10.1016/0304-4165(75)90252-4; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; KARAMANOS NK, 1994, BIOCHIMIE, V76, P79, DOI 10.1016/0300-9084(94)90066-3; KATO Y, 1978, J BIOL CHEM, V253, P2784; KOLSET SO, 1986, BIOCHEM J, V238, P209, DOI 10.1042/bj2380209; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; NAKAMURA T, 1994, BIOCHEM J, V304, P731, DOI 10.1042/bj3040731; NAKAMURA T, 1990, J BIOL CHEM, V265, P5390; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NOBLE DW, 1970, CARBOHYD RES, V12, P448; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SENO N, 1982, CARBOHYD RES, V103, P190; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SORRELL JM, 1988, CELL TISSUE RES, V252, P523, DOI 10.1007/BF00216639; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; TAKAGAKI K, 1990, J BIOCHEM BIOPH METH, V21, P209, DOI 10.1016/0165-022X(90)90014-4; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4	31	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13794	13798		10.1074/jbc.270.23.13794	http://dx.doi.org/10.1074/jbc.270.23.13794			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539793	hybrid			2022-12-25	WOS:A1995RC44800034
J	SHIUE, L; ZOLLER, MJ; BRUGGE, JS				SHIUE, L; ZOLLER, MJ; BRUGGE, JS			SYK IS ACTIVATED BY PHOSPHOTYROSINE-CONTAINING PEPTIDES REPRESENTING THE TYROSINE-BASED ACTIVATION MOTIFS OF THE HIGH-AFFINITY RECEPTOR FOR IGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; T-CELL; ZETA-CHAIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL; SH2 DOMAINS; TCR-ZETA; KINASE; PHOSPHORYLATION	Engagement of the high affinity receptor for immuno globulin E (Fc epsilon RI) on the surface of mast cells induces tyrosine phosphorylation of numerous cellular proteins, Syk, one of several non-receptor protein tyrosine kinases implicated in Fc epsilon RI signaling, is activated following receptor cross-linking and associates with phosphorylated gamma subunits of Fc epsilon RI. We previously showed that the Src homology 2 (SH2) domains of Syk bind with high affinity to the conserved tyrosine-based activation motif (TAM) of the gamma subunit in vitro, In this report, we show that a tyrosine-phosphorylated gamma TAM peptide induced tyrosine phosphorylation of Syk in RBL-2H3 cell lysates and stimulated Syk kinase activity 10-fold in vitro, with half-maximal activation at 1-2 mu M. A similar beta subunit TAM peptide showed much lower stimulation of Syk tyrosine phosphorylation and kinase activity. Phosphopeptide-induced activation was inhibited by an antiserum to the carboxyl-terminal tail of Syk, suggesting that those amino acids are also involved in Syk activation, These results indicate that the catalytic domain of Syk may be regulated by intramolecular interactions with adjacent domains and suggest that Syk binding to phosphorylated gamma subunits following Fc epsilon RI engagement in vivo stimulates Syk kinase activity.	ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology					NATIONAL CANCER INSTITUTE [R01CA027951, R37CA027951] Funding Source: NIH RePORTER; NCI NIH HHS [CA27951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DECHERT U, 1994, J BIOL CHEM, V269, P5602; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	184	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10498	10502		10.1074/jbc.270.18.10498	http://dx.doi.org/10.1074/jbc.270.18.10498			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537732	hybrid			2022-12-25	WOS:A1995QW60100023
J	ANOSTARIO, M; HUANG, KS				ANOSTARIO, M; HUANG, KS			MODULATION OF E-SELECTIN STRUCTURE-FUNCTION BY METAL-IONS - STUDIES ON LIMITED PROTEOLYSIS AND METAL-ION REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE-RECOGNITION; LECTIN DOMAIN; CATION BINDING; CELL-ADHESION; RECEPTOR; IDENTIFICATION; INFLAMMATION; SEQUENCE	E-selection is a member of the selectin family of proteins that recognize carbohydrate ligands in a Ca2+-dependent manner. In order to better understand the role of Ca2+ in E-selectin-ligand interactions, we examined the E-selectin structure by limited proteolysis. Apo-Lec-EGF-CR6, a Ca2+-free form of soluble E-selectin containing the entire extracellular domain, was sensitive to limited proteolysis by Glu-C endoproteinase. Amino-terminal sequencing analysis of the proteolytic fragments revealed that the major cleavage site is at Glu(98) which is in the loop (residues 94-103) adjacent to the Ca2+ binding region of the lectin domain. Upon Ca2+ binding, Lec-EGF-CR6 was protected from proteolysis. This Ca2+-dependent protection was further augmented upon sialyl Lewis x (sLe(x)) ligand binding. These results implied that Ca2+ binding to E-selectin induces a conformational change and perhaps facilitates ligand binding. The sLe(x)-bound complex in turn stabilized Ca2+ binding. Lec-EGF-CR6 contains only one high-affinity Ca2+ site (K-d = approximate to 3.5 mu M) as determined by equilibrium dialysis. In addition, we found that Ba2+ was a potent antagonist in blocking Lec-EGF-CR6-mediated HL-60 cell adhesion. By competitive equilibrium dialysis and proteolysis analysis, we demonstrated that Ba2+ bound to apo-Lec-EGF-CR6 5-fold tighter than Ca2+ and abolished ligand binding activity. Sr2+ also bound to apo-Lec-EGF-CR6 tighter than Ca2+. However, Sr2+-regenerated Lec-EGF-CR6 showed 50% ligand binding activity. Mg2+ bound to apo-Lec-EGF-CR6 with much weaker affinity than Ca2+ and did not show any activity. Thus, E-selectin function can be modulated by different metal ions.	HOFFMANN LA ROCHE INC, DEPT INFLAMMAT AUTOIMMUNE DIS, NUTLEY, NJ 07110 USA	Roche Holding								ANOSTARIO M, 1994, ANAL BIOCHEM, V221, P317, DOI 10.1006/abio.1994.1419; ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P2394, DOI 10.1021/bi00060a034; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GENG JG, 1991, J BIOL CHEM, V266, P22313; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LI SH, 1994, J BIOL CHEM, V269, P4431; LOEB JA, 1988, J BIOL CHEM, V263, P9752; MAHADEVAN D, 1994, BIOCHEMISTRY-US, V33, P746, DOI 10.1021/bi00169a016; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; PIGOTT R, 1991, J IMMUNOL, V147, P130; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STOCKS SC, 1993, BIOCHEM BIOPH RES CO, V195, P478, DOI 10.1006/bbrc.1993.2068; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALLIS CJ, 1993, BIOCHEMISTRY-US, V32, P5045, DOI 10.1021/bi00070a011; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313	31	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8138	8144		10.1074/jbc.270.14.8138	http://dx.doi.org/10.1074/jbc.270.14.8138			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7536194	hybrid			2022-12-25	WOS:A1995QR52600056
J	CARRAWAY, KL; SOLTOFF, SP; DIAMONTI, AJ; CANTLEY, LC				CARRAWAY, KL; SOLTOFF, SP; DIAMONTI, AJ; CANTLEY, LC			HEREGULIN STIMULATES MITOGENESIS AND PHOSPHATIDYLINOSITOL 3-KINASE IN MOUSE FIBROBLASTS TRANSFECTED WITH ERBB2/NEU AND ERBB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION FACTOR; TYROSINE KINASE; TUMOR CELLS; NEU GENE; RECEPTOR; LIGAND; HER4/P180(ERBB4)	Heregulin (HRG) is a pluripotent growth factor that can stimulate the growth of some human mammary tumor cells and the differentiation of others, Two members of the epidermal growth factor receptor family of receptor/tyrosine kinases, p180(erbB3) and p180(erbB4), serve as receptors for the HRG ligand, While HRG appears to be capable of stimulating the autophospholylation activity of p180(erbB4), the co-expression of p185(erbB2/neu) With p180(erbB3) is necessary for the HRG-stimulated tyrosine phosphorylation of both of these receptors, On the basis of the sequences surrounding their putative tyrosine phosphorylation sites, we predict that the different HRG-responsive receptors couple to different intracellular SH2 domain-containing proteins, Hence, the differ ent receptors may mediate different cellular responses to the HRG ligand, In the present study we show that HRG beta 1 is mitogenic for erbB3-transfected DHFR/G8 cells, an NIH3T3 mouse fibroblast derivative that overexpresses p185(erbB2/neu), HRG stimulated the incorporation of [H-3] thymidine into the DNA of these cells with an EC(50) of 70 +/- 7 pm, HRG was not mitogenic for parental DHFR/G8 cells that do not express the ErbB3 protein, Phosphatidylinositol (PI) 3-kinase, an enzyme believed to be important in cellular growth regulation by growth factors and oncogenes, is predicted to couple to tyrosine-phosphorylated ErbB3, We observed that HRG stimulated the association of PI 3-kinase with both p185(erbB2/neu) and ErbB3 in transfected DHFR/G8 cells, but not in the parental cell line, We conclude that the ErbB3 protein is capable of mediating a proliferative response of fibroblasts to HRG, and that the activation of PI 3-kinase is an integral part of the growth signaling mechanism.	BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	CARRAWAY, KL (corresponding author), HARVARD UNIV, SCH MED,DEPT CELL BIOL,WARREN ALPERT BLDG, 1ST FLOOR, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890, GM41890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FENDLY BM, 1990, CANCER RES, V50, P1550; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM HH, 1994, J BIOL CHEM, V269, P24747; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	130	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7111	7116		10.1074/jbc.270.13.7111	http://dx.doi.org/10.1074/jbc.270.13.7111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535767	hybrid			2022-12-25	WOS:A1995QQ43100018
J	MAEGAWA, H; IDE, R; HASEGAWA, M; UGI, S; EGAWA, K; IWANISHI, M; KIKKAWA, R; SHIGETA, Y; KASHIWAGI, A				MAEGAWA, H; IDE, R; HASEGAWA, M; UGI, S; EGAWA, K; IWANISHI, M; KIKKAWA, R; SHIGETA, Y; KASHIWAGI, A			THIAZOLIDINE DERIVATIVES AMELIORATE HIGH GLUCOSE-INDUCED INSULIN-RESISTANCE VIA THE NORMALIZATION OF PROTEIN-TYROSINE-PHOSPHATASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; GROWTH FACTOR-I; ORAL HYPOGLYCEMIC AGENT; HUMAN SKELETAL-MUSCLE; RECEPTOR KINASE; CELLS; CS-045; NIDDM; RATS; DEPHOSPHORYLATION	The mechanisms for the insulin resistance induced by hyperglycemia were investigated by studying the effect of high glucose concentration (HG) and its modulation by thiazolidine derivatives, on insulin signaling using Rat 1 fibroblasts expressing human insulin receptors (HIRc). Incubating HIRc cells in 27 mM D-glucose for 4 days impaired the insulin stimulated phosphorylation of pp185 and receptor beta-subunits. Both protein kinase C activities and phorbol dibutyrate binding to intact cells were unchanged; however, cytosolic protein-tyrosine phosphatase (PTPase) activity increased within 1 h prior to the impairment of insulin receptor kinase in HG cells (Maegawa, H., Tachikawa-Ide, R., Ugi, S., Iwanishi, M., Egawa, K., Kikkawa, R., Shigeta, Y., and Kashiwagi, A. (1993) Biochem. Biophys. Res. Commun. 197, 1078-1082). Increased PTPase activity was consistent with a 2-fold increase in the amount of PTP1B, and anti-PTP1B antibody inhibited this increment of cytosolic PTPase activity in HG cells. Co-incubating cells with pioglitazone prevented these abnormalities in cytosolic PTPase, the PTP1B content and the impaired phosphorylation of pp185 and receptor beta subunits in HG cells. Finally, HG cells had impaired insulin-stimulated alpha-aminoisobutyric acid uptake, which was ameliorated by exposure to thiazolidine derivatives. In conclusion, exposing cells to high glucose levels desensitizes insulin receptor function, and thiazolidine derivatives can reverse the process via the normalization of cytosolic PTPase, but not of protein kinase G.			MAEGAWA, H (corresponding author), SHIGA UNIV MED SCI,DEPT MED 3,OTSU,SHIGA 52021,JAPAN.		Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BEGUM N, 1991, DIABETES, V40, P1620, DOI 10.2337/diabetes.40.12.1620; BERTI L, 1994, J BIOL CHEM, V269, P3381; BUTLER TM, 1990, CANCER RES, V50, P6323; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; GUZMAN NJ, 1991, J AM SOC NEPHROL, V2, P179; HASHIMOTO N, 1992, BIOCHEM BIOPH RES CO, V188, P1305, DOI 10.1016/0006-291X(92)91373-X; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; IDE R, 1994, BIOCHEM BIOPH RES CO, V201, P71, DOI 10.1006/bbrc.1994.1670; IWANISHI M, 1993, METABOLISM, V42, P1017, DOI 10.1016/0026-0495(93)90016-H; KELLERER M, 1994, DIABETES, V43, P447, DOI 10.2337/diabetes.43.3.447; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KOBAYASHI M, 1992, DIABETES, V41, P476, DOI 10.2337/diabetes.41.4.476; KOBAYASHI M, 1988, DIABETES, V37, P657; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; KUZUYA T, 1991, DIABETES RES CLIN PR, V11, P147, DOI 10.1016/S0168-8227(05)80027-0; MAEGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1053, P185, DOI 10.1016/0167-4889(90)90012-3; MAEGAWA H, 1991, DIABETES, V40, P815, DOI 10.2337/diabetes.40.7.815; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V197, P1078, DOI 10.1006/bbrc.1993.2588; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYEROVITCH J, 1987, J CLIN INVEST, V84, P976; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; PERALDI P, 1992, BIOCHEM J, V285, P71, DOI 10.1042/bj2850071; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SUGIYAMA Y, 1990, ARZNEIMITTEL-FORSCH, V40-1, P263; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TAKAYAMA S, 1987, J BIOL CHEM, V263, P3440; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; ECL W BLOTTING PROTO	37	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7724	7730		10.1074/jbc.270.13.7724	http://dx.doi.org/10.1074/jbc.270.13.7724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535776	hybrid			2022-12-25	WOS:A1995QQ43100100
J	MCGINLEY, MD; NARHI, LO; KELLEY, MJ; DAVY, E; ROBINSON, J; ROHDE, MF; WRIGHT, SD; LICHENSTEIN, HS				MCGINLEY, MD; NARHI, LO; KELLEY, MJ; DAVY, E; ROBINSON, J; ROHDE, MF; WRIGHT, SD; LICHENSTEIN, HS			CD14 - PHYSICAL-PROPERTIES AND IDENTIFICATION OF AN EXPOSED SITE THAT IS PROTECTED BY LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE CD14; ACTIVATION; CELLS; ANTIGEN	Soluble CD14 (sCD14) is a 55-kDa serum protein that binds lipopolysaccharide (LPS) and mediates LPS-dependent responses in a variety of cells. Using recombinant sCD14 expressed in Chinese hamster ovary (CHO) cells, we examined the structural characteristics of sCD14 and sCD14 . LPS complexes. The circular dichroism and fluorescence spectra of the sCD14 indicate that it contains substantial beta-sheet (40%) and a well-defined tertiary structure with the tryptophan residues located in environments with different degrees of hydrophobicity and solvent exposure. The spectra of the scD14 . LPS complex are identical within experimental error to the uncomplexed sCD14. Changes in surface accessibility upon LPS binding were examined using limited proteolysis with endoproteinase Asp-N. This analysis revealed that aspartic acid residues at amino acids 57, 59, and 65 are susceptible to cleavage by Asp-N, while the same residues are protected from proteolytic cleavage in the sCD14 LPS complex. These results suggest that a region including amino acids 57 to 64 is involved in LPS binding by sCD14.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University	MCGINLEY, MD (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.				NIAID NIH HHS [AI-30556] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; ATASSI MZ, 1970, J BIOL CHEM, V245, P5122; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DETMERS PA, 1994, J IMMUNOL, V153, P2137; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1993, J IMMUNOL, V151, P1500; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; MALISZEWSKI CR, 1985, J IMMUNOL, V135, P1929; NARHI LO, 1989, J PROTEIN CHEM, V8, P669, DOI 10.1007/BF01025607; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RUPLEY JA, 1967, METHOD ENZYMOL, V2, P903	14	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5213	5218		10.1074/jbc.270.10.5213	http://dx.doi.org/10.1074/jbc.270.10.5213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534290	hybrid			2022-12-25	WOS:A1995QL58000041
J	WEGENER, AMK; HOU, XH; DIETRICH, J; GEISLER, C				WEGENER, AMK; HOU, XH; DIETRICH, J; GEISLER, C			DISTINCT DOMAINS OF THE CD3-GAMMA CHAIN ARE INVOLVED IN SURFACE EXPRESSION AND FUNCTION OF THE T-CELL ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHAIN; TCR/CD3 COMPLEX; ALPHA-CHAIN; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; CD3 COMPLEX; SUBUNITS; PHOSPHORYLATION; CONSEQUENCES; GLYCOPROTEIN	The T cell antigen receptor (TcR) is a multisubunit complex that consists of at least six different polypeptides. We have recently demonstrated that the CD3-delta subunit cannot substitute for the CD3-gamma subunit in TcR cell surface expression, in spite of significant amino acid homology between these two subunits. To identify CD3-gamma-specific domains that are required for assembly of the complete TcR and for surface expression and function of the TcR, chimeric CD3-gamma/CD3-delta molecules were con structed and expressed in T cells devoid of endogenous CD3-gamma. Substitution of the extracellular domain of CD3-gamma with that of CD3-delta did not allow cell surface expression of the TcR, In contrast, substitution of the transmembrane and/or the intracellular domains of CD3-gamma with those of CD3-delta did allow TcR cell surface expression. These results conclusively demonstrate that the extracellular domain of CD3-gamma plays a unique role in TcR assembly. Functional analyses of the transfectants demonstrated that the intracellular domain of CD3-gamma is required for protein kinase C-mediated down-regulation of TcR but is dispensable for the pattern of tyrosine phosphorylation observed following activation through TcR.			WEGENER, AMK (corresponding author), UNIV COPENHAGEN, PANUM INST, INST MED MICROBIOL & IMMUNOL, BLDG 183, BLEGDAMSVEJ 3C, DK-2200 COPENHAGEN, DENMARK.		Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ALEXANDER DR, 1992, BIOCHEM J, V288, P69, DOI 10.1042/bj2880069; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BUFERNE M, 1992, J IMMUNOL, V148, P657; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1988, SCAND J IMMUNOL, V27, P685, DOI 10.1111/j.1365-3083.1988.tb02402.x; GEISLER C, 1992, J IMMUNOL, V148, P3469; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JOHN S, 1989, EUR J IMMUNOL, V19, P335, DOI 10.1002/eji.1830190218; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOH C, 1994, J BIOL CHEM, V269, P8817; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PEREZACIEGO P, 1991, J EXP MED, V174, P319, DOI 10.1084/jem.174.2.319; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SAITO T, 1987, J IMMUNOL, V139, P625; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILLARDGALLO KE, 1990, P NATL ACAD SCI USA, V87, P6713, DOI 10.1073/pnas.87.17.6713	40	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4675	4680		10.1074/jbc.270.9.4675	http://dx.doi.org/10.1074/jbc.270.9.4675			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533164	hybrid			2022-12-25	WOS:A1995QK08400073
J	HASEGAWA, G; HUNTER, AJ; CHARONIS, AS				HASEGAWA, G; HUNTER, AJ; CHARONIS, AS			MATRIX NONENZYMATIC GLYCOSYLATION LEADS TO ALTERED CELLULAR PHENOTYPE AND INTRACELLULAR TYROSINE PHOSPHORYLATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; FOCAL ADHESIONS; CROSS-LINKING; IV COLLAGEN; PROTEIN; FIBRONECTIN; LAMININ; GLUCOSYLATION	The effect of matrix nonenzymatic glycosylation on signal transduction and the cellular phenotype was examined, Human microvascular endothelial cells were plated on control or glycated basement membrane-like matrix. Cells exhibited a decrease in their ability to adhere and spread on modified matrix. The pattern of intracellular tyrosine phosphorylation was examined by Western Immunoblotting; a band with 65 kDa mobility exhibited a marked reduction of tyrosine phosphorylation in cells adherent to modified matrix. Immunoprecipitation experiments provided evidence that this band is paxillin, a member of focal adhesion proteins. Immunoprecipitation with antibodies against focal adhesion kinase (pp125(FAK)), the enzyme that is thought to regulate paxillin tyrosine phosphorylation, also demonstrated a reduction in tyrosine phosphorylation of pp125(FAK). To confirm these biochemical data, adherent cells were examined for the distribution of paxillin, using immunofluorescence microscopy; paxillin was seen in focal points peripherally located in cells on nor mal matrix, but lacked this pattern in cells on modified matrix. Actin filaments were also disorganized in cells plated on modified matrix. These data suggest that matrix nonenzymatic glycosylation can interfere with and potentially alter cellular phenotype and intracellular signaling.	UNIV MINNESOTA, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities				Charonis, Aristidis/0000-0001-9956-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036007, R01DK043569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43569, DK-36007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; EBLE AS, 1983, J BIOL CHEM, V258, P9406; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; HASEGAWA G, 1994, DIABETES RES CLIN PR, V23, P25, DOI 10.1016/0168-8227(94)90123-6; HASKILL S, 1988, J IMMUNOL, V140, P1690; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; INGHER DE, 1990, J CELL BIOL, V110, P1803; IZZARD CS, 1976, J CELL SCI, V21, P129; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105; NEEPER M, 1992, J BIOL CHEM, V267, P14998; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SPORN SA, 1990, J IMMUNOL, V144, P4434; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TANAKA S, 1988, J BIOL CHEM, V263, P17650; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAN SD, 1994, J BIOL CHEM, V269, P9889; Zar JH, 1974, BIOSTATISTICAL ANAL; 1993, N ENG J, V329, P683	40	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3278	3283		10.1074/jbc.270.7.3278	http://dx.doi.org/10.1074/jbc.270.7.3278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531703	hybrid			2022-12-25	WOS:A1995QG47100059
J	CHAMPE, M; MCINTYRE, BW; BERMAN, PW				CHAMPE, M; MCINTYRE, BW; BERMAN, PW			MONOCLONAL-ANTIBODIES THAT BLOCK THE ACTIVITY OF LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 RECOGNIZE 3 DISCRETE EPITOPES IN THE INSERTED DOMAIN OF CD11A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; COMPLEMENT RECEPTOR TYPE-3; CELL-ADHESION; ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; LYMPHOCYTE ADHESION; COUNTER-RECEPTOR; LFA-1; MAC-1; INTEGRINS	The epitopes recognized by eight independently isolated monoclonal antibodies to the alpha chain of human and murine leukocyte function-associated antigen 1 (LFA-1), all able to inhibit receptor function, were identified. Initial localization of epitopes was accomplished using chimeric proteins constructed by splicing fragments of cDNAs encoding the alpha subunit of LFA-1 (CD11a) and the alpha subunit of the closely related leukocyte integrin, Mac-1 (CD11b). Antibody binding to CD11a/CD11b chimeras, expressed in the 293 human kidney cell line, demonstrated that the epitopes recognized by six monoclonal antibodies to human CD11a were located in a similar to 200-amino acid sequence found in all beta(2)-integrin alpha subunits, termed the inserted (I) domain. Three distinct epitopes within the I domain (IdeA, IdeB, and IdeC) were identified using a series of mutants in which sequences from murine CD11a were substituted into human CD11a. A series of mutants incorporating single amino acid substitutions was used to identify individual amino acids essential for antibody binding. The location of these residues accounts for the binding specificity of LFA-1-blocking antibodies and identifies particular conserved sequences (residues 126-150) in the I domain of CD11a and homologous sequences in other beta(2)-integrin alpha subunits that may be important for ligand binding.	GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	Roche Holding; Genentech; University of Texas System; UTMD Anderson Cancer Center								ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1984, J CLIN INVEST, V74, P1291, DOI 10.1172/JCI111539; BERMAN PW, 1980, J BIOL CHEM, V255, P6133; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DANA N, 1986, J IMMUNOL, V137, P3259; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DONGWORTH DW, 1985, EUR J IMMUNOL, V15, P888, DOI 10.1002/eji.1830150905; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DUSTIN ML, 1989, COLD SPRING HARB SYM, V54, P753; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FISCHER A, 1985, J CLIN INVEST, V76, P2385, DOI 10.1172/JCI112251; FISCHER A, 1986, J IMMUNOL, V136, P3198; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KUIJPERS KC, 1990, J IMMUNOL, V144, P3281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TROWBRIDGE IS, 1981, J EXP MED, V154, P1517, DOI 10.1084/jem.154.5.1517; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	55	57	112	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1388	1394		10.1074/jbc.270.3.1388	http://dx.doi.org/10.1074/jbc.270.3.1388			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7530713	hybrid			2022-12-25	WOS:A1995QB15600062
J	KONDOH, G; HAYASAKA, N; LI, Q; NISHIMUNE, Y; HAKURA, A				KONDOH, G; HAYASAKA, N; LI, Q; NISHIMUNE, Y; HAKURA, A			AN IN-VIVO MODEL FOR RECEPTOR TYROSINE KINASE AUTOCRINE/PARACRINE ACTIVATION - AUTO-STIMULATED KIT RECEPTOR ACTS AS A TUMOR-PROMOTING FACTOR IN PAPILLOMAVIRUS-INDUCED TUMORIGENESIS	ONCOGENE			English	Article						HPV16 TRANSGENIC MOUSE; C-KIT SLF; AUTOSTIMULATION; TUMORIGENESIS	STEM-CELL FACTOR; AUTOCRINE GROWTH-FACTORS; C-KIT; W-LOCUS; LUNG-CANCER; TRANSMEMBRANE FORM; PROTO-ONCOGENE; SERTOLI CELLS; GENE-PRODUCT; MUTANT MICE	Constitutive overactivation of growth factor receptors through autocrinelparacrine mechanisms occurs frequently in cancer cells and are thought to play a critical role in carcinogenesis. In the present report, we propose a refined in vivo model which explains the significance of these mechanisms in tumour development. We have previously established transgenic mouse lines containing human papillomavirus type 16 (HPV16) E6E7 oncogenes, in male mice of which a Leydig cell tumor developes with a very high incidence, Not only HPV transgene but also the c-kit proto-oncogene receptor tyrosine kinase and its ligand Steel Factor (SLF) were coexpressed in all tumors analysed. This coexpression of c-kit/SLF was also found in two other Leydig cell tumor lines. Moreover, the proliferation of transgenic tumor cells was attenuated by treatment with a c-kit neutralizing antibody in vitro, strongly suggesting that tumorigenesis is closely related to stimulation of receptors through ligand induction, To confirm the significance of these findings, a defective mutation of the SLF gene in a laboratory mouse, the Steel-Dickey (Sld) mutation, was introduced into a line of transgenic mice showing 100% incidence of the tumor. In Sl(d)-E6E7 transgenic mice, tumorigenesis was initiated but numbers of tumor cells were markedly reduced compared with transgenic mice carrying both wild type SLP allele, showing that c-kit activation through the induction of SLF is essential for testicular tumorigenesis, especially in tumour promotion. This transgenic mice system should be a useful in vivo model for clarifying the implication of growth factor autostimulation in carcinogenesis.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	Osaka University	KONDOH, G (corresponding author), OSAKA UNIV,GENOME INFORMAT RES CTR,SUITA,OSAKA 565,JAPAN.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BERDEL WE, 1992, CANCER RES, V52, P3498; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CACERESCORTES JR, 1992, CANCER RES, V52, P5208; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V13, P2485; HIBI K, 1991, ONCOGENE, V6, P2291; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; INOUE M, 1994, CANCER RES, V54, P3049; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARZIALI G, 1993, DEV BIOL, V157, P182, DOI 10.1006/dbio.1993.1122; MOTRO B, 1991, DEVELOPMENT, V113, P1207; MUNGER K, 1989, J VIROL, V63, P4417; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIE F, 1988, EMBO J, V7, P1003; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENES PHENOTYPES GEN, V5, P105; RUSSELL NH, 1992, BLOOD REV, V6, P149, DOI 10.1016/0268-960X(92)90026-M; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SATO B, 1987, ENDOCRINOLOGY, V120, P1112, DOI 10.1210/endo-120-3-1112; SEKIDO Y, 1991, CANCER RES, V51, P2416; SEKIDO Y, 1993, CANCER RES, V53, P1709; SHIN SI, 1967, ENDOCRINOLOGY, V81, P440, DOI 10.1210/endo-81-3-440; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAJIMA Y, 1991, DEVELOPMENT, V113, P1031; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	46	21	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					341	347						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530826				2022-12-25	WOS:A1995QC62400013
J	LIAO, JK; SHIN, WS; LEE, WY; CLARK, SL				LIAO, JK; SHIN, WS; LEE, WY; CLARK, SL			OXIDIZED LOW-DENSITY-LIPOPROTEIN DECREASES THE EXPRESSION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RELAXING FACTOR; RABBIT AORTA; DEPENDENT RELAXATION; MESSENGER-RNA; CELLS; RECEPTOR; RELEASE; ATHEROSCLEROSIS; INTERLEUKIN-1	The atherogenic effects of low-density lipoprotein (LDL) may be mediated, in part, by its effect(s) on endothelial derived nitric oxide (NO). To determine whether LDL can modulate NO production by changing NO synthase expression, we treated human saphenous vein endothelial cells with increasing concentrations of native or oxidized LDL (0-100 mu g/ml) for various durations (0-72 h). Oxidized, but not native LDL caused a time-dependent decrease in steady state NO synthase mRNA levels. This coincided with a maximal 56% decrease in NOS activity as determined by [H-3]arginine to [SH]citrulline conversion. In the presence of actinomycin D, treatment with oxidized LDL reduced the half-life of NO synthase mRNA from 36 to 10 h, This decrease in NO synthase mRNA correlated with the degree of LDL oxidation and was attenuated by pretreatment with cycloheximide. Nuclear run-off studies showed a biphasic transcriptional pattern of NO synthase gene with an initial 25% decrease during the first 6 h followed by a maximal 2.2-fold increase over baseline during the subsequent 18 h. These results indicate that oxidized LDL regulates endothelial NOS expression through a combination of early transcriptional inhibition and post-transcriptional mRNA destabilization.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School					NHLBI NIH HHS [HL02508] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FORSTERMANN U, 1992, P NATL ACAD SCI USA, V88, P1788; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GHIGO D, 1993, AM J PHYSIOL, V265, pC728, DOI 10.1152/ajpcell.1993.265.3.C728; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GLOVER DM, 1988, DNA CLONING PRACTICA, V1, P49; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1991, CIRC RES, V68, P1027, DOI 10.1161/01.RES.68.4.1027; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LIAO JK, 1994, J BIOL CHEM, V269, P12987; LIBBY P, 1986, AM J PATHOL, V124, P179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; PLANE F, 1992, BRIT J PHARMACOL, V105, P216, DOI 10.1111/j.1476-5381.1992.tb14237.x; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RASBAND W, 1993, NIH V149 IM PROGR; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMON BC, 1990, J CLIN INVEST, V86, P75, DOI 10.1172/JCI114718; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUNDELL CL, 1993, CIRCULATION S, V88, P473; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TIPPING PG, 1993, AM J PATHOL, V142, P1721; WANG J, 1992, J BIOL CHEM, V268, P22255; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; YANG XC, 1994, CIRC RES, V74, P318, DOI 10.1161/01.RES.74.2.318; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; [No title captured]	43	498	550	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					319	324		10.1074/jbc.270.1.319	http://dx.doi.org/10.1074/jbc.270.1.319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529227	hybrid			2022-12-25	WOS:A1995QA28700051
J	MALEK, SN; DESIDERIO, S				MALEK, SN; DESIDERIO, S			A CYCLIN-DEPENDENT KINASE HOMOLOG, P130(PITSLRE), IS A PHOSPHOTYROSINE-INDEPENDENT SH2 LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; MAMMALIAN PROTEIN-KINASE; HIGH-AFFINITY BINDING; SACCHAROMYCES-CEREVISIAE; CDC28 MUTATION; CELL-CYCLE; DOMAIN; GENE; ENCODES; FAMILY	Src-homology 2 (SH2) domains are conserved, globular protein modules that mediate assembly of multicomponent signaling complexes, Phosphoproteins from the B-lymphoid cell line A20 were isolated by SH2 affinity chromatography; the peptide sequence from one of these proteins was used to molecularly clone several related complementary DNAs whose predominant protein product, p130(PITSLRE), is abundant serine/threonine kinase with ubiquitous expression in murine tissues, The sequence of a previously described cyclin-dependent kinase homologue, p58(clk-1), is entirely contained within the p130(PITSLRE) sequence, Specific binding of p130(PITSLRE) to, SH2 domains is mediated by a serine- and glutamic acid-rich cluster of amino acids in the N-terminal region, This interaction is dependent on serine/threonine phosphorylation but independent of tyrosine phosphorylation, Binding is inhibited by free phosphotyrosine and by a phosphotyrosine-containing peptide from polyoma middle T antigen, suggesting that the p130(PITSLRE) binding site in the SH2 domain overlaps the region that binds phosphotyrosine containing peptides, Bacterially expressed p130(PITSLRE) fragments acquire the ability to bind an SH2 domain when phosphorylated in vitro with casein kinase II. A subset of casein kinase II phosphorylation sites may therefore constitute a phosphotyrosine-independent class of SH2 ligands.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University								BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORI K, 1993, CELL, V74, P743; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; OKUDA T, 1992, ONCOGENE, V7, P2249; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; XIANG JL, 1994, J BIOL CHEM, V269, P15786; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33009	33020						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528743				2022-12-25	WOS:A1994QA63800045
J	AZARANI, A; ORLOWSKI, J; GOLTZMAN, D				AZARANI, A; ORLOWSKI, J; GOLTZMAN, D			PARATHYROID-HORMONE AND PARATHYROID HORMONE-RELATED PEPTIDE ACTIVATE THE NA+/H+ EXCHANGER NHE-1 ISOFORM IN OSTEOBLASTIC CELLS (URM-106) VIA A CAMP-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; RAT NA/H EXCHANGER; INTRACELLULAR PH; CYCLIC-AMP; OSTEOSARCOMA CELLS; PHEOCHROMOCYTOMA CELLS; FUNCTIONAL-PROPERTIES; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING	Parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) regulate Na+/H+ exchanger activity in osteoblastic cells, although the signaling components involved are not precisely defined, Since these peptide hormones can stimulate production of diverse second messengers (i.e, cAMP and diacylglycerol) that activate protein kinase A (PKA) and protein kinase C (PHC) in target cells, it is conceivable that either one or both of these pathways can participate in modulating exchanger activity, To discriminate among these possibilities, a series of synthetic PTH and PTHRP fragments were used that stimulate adenylate cyclase and/or PKC, In the osteoblastic cell line UMR-106, human PTH(1-34) and PTHRP(1-34) augmented adenylate cyclase activity, whereas PTH(3-34), PTH(28-42), and PTH(28-48) had no effect, Nevertheless, all these peptide fragments were found to enhance PKC translocation from the cytosol to the membrane in a dose-dependent (10(-11) to 10(-7) M) manner, PTHRP(1-16), a biologically inert fragment, was incapable of influencing either the PRA or PKC pathway, PTH(1-34) and PTHRP(1-34), but not PTR(1-34), PTH(28-42), PTH(28-48), or PTHRP(1-16), elevated Na+/H+ exchanger activity, implicating cAMP as the transducing signal, In accordance with this observation, forskolin (10 mu M), which directly stimulates adenylate cyclase, also activated Na+/H+ exchanger activity, The involvement of PKA was verified when the highly specific PKA inhibitor, H-89, completely abolished the stimulatory effect of PTH(1-34) and forskolin on Na+/H+ exchange, In addition, Northern blot analysis revealed the presence of only the NHE-1 isoform of the Na+/H+ exchanger in UMR-106 cells, In summary, these results indicated that PTH and PTHRP activate the Na+/H+ exchanger NHE-1 isoform in osteoblastic UMR-106 cells exclusively via a cAMP-dependent pathway.	MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; ROYAL VICTORIA HOSP, CALCIUM RES LAB, MONTREAL, PQ H3A 1A1, CANADA	McGill University; McGill University; Royal Victoria Hospital	AZARANI, A (corresponding author), MCGILL UNIV, DEPT PHYSIOL, MCINTYRE MED SCI BLDG, 3655 DRUMMOND ST, MONTREAL, PQ H3G 1Y6, CANADA.			Orlowski, John/0000-0001-7371-175X				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BERNIER SM, 1991, ENDOCRINOLOGY, V128, P2752, DOI 10.1210/endo-128-6-2752; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BOS MP, 1991, J CELL PHYSIOL, V147, P87, DOI 10.1002/jcp.1041470112; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; GRAHAM CS, 1992, BIOCHEM J, V288, P137, DOI 10.1042/bj2880137; GREEN J, 1992, AM J PHYSIOL, V262, pC111, DOI 10.1152/ajpcell.1992.262.1.C111; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GUPTA A, 1994, AM J PHYSIOL, V266, pC1083, DOI 10.1152/ajpcell.1994.266.4.C1083; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITTEN AM, 1994, AM J PHYSIOL, V266, pE897, DOI 10.1152/ajpendo.1994.266.6.E897; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KONG SK, 1989, BIOCHEM BIOPH RES CO, V165, P131, DOI 10.1016/0006-291X(89)91044-9; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LIVESEY SA, 1982, J BIOL CHEM, V257, P4983; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MOULE SK, 1990, EUR J BIOCHEM, V187, P677, DOI 10.1111/j.1432-1033.1990.tb15353.x; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PAUSOVA Z, 1994, GENOMICS, V20, P20, DOI 10.1006/geno.1994.1122; RABBANI SA, 1990, BIOCHEMISTRY-US, V29, P10080, DOI 10.1021/bi00495a010; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; RAO LG, 1989, CALCIFIED TISSUE INT, V45, P354, DOI 10.1007/BF02556006; REDHEAD CR, 1988, CALCIFIED TISSUE INT, V42, P237, DOI 10.1007/BF02553749; REID IR, 1988, AM J PHYSIOL, V255, pE9, DOI 10.1152/ajpendo.1988.255.1.E9; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; ROULEAU MF, 1990, J BONE MINER RES, V5, P1043; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; SUGIMOTO T, 1992, J CELL PHYSIOL, V152, P28, DOI 10.1002/jcp.1041520105; SZPIRER C, 1994, MAMM GENOME, V5, P153, DOI 10.1007/BF00352346; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE M, 1993, J MEMBRANE BIOL, V135, P93; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WINKEL GK, 1993, J BIOL CHEM, V268, P3396; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU FH, 1993, J BIOL CHEM, V268, P25536	56	31	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23166	23172		10.1074/jbc.270.39.23166	http://dx.doi.org/10.1074/jbc.270.39.23166			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559463	hybrid			2022-12-25	WOS:A1995RY05400083
J	LENGYEL, E; STEPP, E; GUM, R; BOYD, D				LENGYEL, E; STEPP, E; GUM, R; BOYD, D			INVOLVEMENT OF A MITOGEN-ACTIVATED PROTEIN-KINASE SIGNALING PATHWAY IN THE REGULATION OF UROKINASE PROMOTER ACTIVITY BY C-HA-RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; MAP KINASE; GENE-EXPRESSION; GROWTH-FACTOR; BASEMENT-MEMBRANE; PHORBOL-ESTER; CELLS; JUN; PHOSPHORYLATION; TRANSCRIPTION	The expression of the urokinase-type plasminogen activator, which plays a crucial role in tissue remodeling by controlling the synthesis of the broadly acting plasmin serine protease, is regulated by several tyrosine kinases. Since the actions of these tyrosine kinases is dependent on the activation of ras proteins, we undertook a study to identify signaling events downstream of ras responsible for the stimulation of urokinase promoter activity. Transient expression of an activated c-Ha-ras in OVCAR-3 cells, which do not harbor the mutated oncogene, led to a dose-dependent transactivation of the urokinase promoter. A sequence residing between -2109 and -1964 was critical for the stimulation of the urokinase promoter by c-Ha-ras. Mutation of an AP-1 and a PEA3 site at -1967 and -1973, respectively, or the co-expression of a transactivation domain-lacking c-jun substantially impaired the ability of c-Ha-ras to stimulate urokinase promoter activity. The induction of the urokinase promoter by ras was completely blocked by expression of a dominant negative c-raf expression vector and substantially reduced in cells made to co-express a catalytically inactive mitogen-activated protein kinase kinase. Further, the expression of an ERK1/ERK2-inactivating phosphatase (CL100) abrogated the stimulation of the urokinase promoter by c-Ha-ras. These data argue for a role of a mitogen-activated protein kinase-dependent signaling pathway in the regulation of urokinase promoter activity by ras.	MD ANDERSON CANC CTR,DEPT TUMOR BIOL HEAD & NECK SURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDREASEN PA, 1990, ENDOCRINOLOGY, V126, P2567, DOI 10.1210/endo-126-5-2567; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GALANG CK, 1994, ONCOGENE, V9, P2913; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; HAMILTON TC, 1983, CANCER RES, V43, P5379; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KASAI S, 1985, J BIOL CHEM, V260, P2382; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LIOTTA LA, 1981, CANCER RES, V41, P4629; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NANBU R, 1995, MOL CELL BIOL, V14, P4920; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NICOLSON GL, 1990, ONCOGENE, V5, P747; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SALO T, 1982, INT J CANCER, V30, P669, DOI 10.1002/ijc.2910300520; SASAOKA T, 1994, J BIOL CHEM, V268, P32621; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SOZERI O, 1992, ONCOGENE, V7, P2259; STACEY DW, 1991, ONCOGENE, V6, P2297; STOPPELLI P, 1986, J CELL BIOL, V102, P1235; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASYLYK C, 1994, ONCOGENE, V9, P3665	51	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23007	23012		10.1074/jbc.270.39.23007	http://dx.doi.org/10.1074/jbc.270.39.23007			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559439	hybrid			2022-12-25	WOS:A1995RY05400059
J	TAYLOR, AH; HEAVNER, G; NEDELMAN, M; SHERRIS, D; BRUNT, E; KNIGHT, D; GHRAYEB, J				TAYLOR, AH; HEAVNER, G; NEDELMAN, M; SHERRIS, D; BRUNT, E; KNIGHT, D; GHRAYEB, J			LIPOPOLYSACCHARIDE (LPS) NEUTRALIZING PEPTIDES REVEAL A LIPID A BINDING-SITE OF LPS BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; ENDOTOXIN; SHOCK	Endotoxic shock follows a cascade of events initiated by release of lipopolysaccharide during infection with Gram-negative organisms. Two overlapping 15-mer peptides were identified, corresponding to residues 91-108 of human lipopolysaccharide binding protein that specifically bound the lipid A moiety of lipopolysaccharide with high affinity. The peptides inhibited binding of lipopolysaccharide to lipopolysaccharide binding protein, inhibited the chromogenic Limulus amebocyte lysate reaction, and blocked release of tumor necrosis factor a following lipopolysaccharide challenge both in vitro and in vivo. These results suggest lipopolysaccharide binding protein residues 91-108 form at least part of the lipopolysaccharide binding site. Moreover, derivatives of lipopolysaccharide binding protein residues 91-108 might modulate lipopolysaccharide toxicity in the clinical setting.			TAYLOR, AH (corresponding author), CENTOCOR INC,DEPT PHARMACEUT RES,200 GREAT VALLEY PKWY,MALVERN,PA 19355, USA.							BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; GALLAY P, 1993, P NATL ACAD SCI USA, V90, P9935, DOI 10.1073/pnas.90.21.9935; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HEAVNER GA, 1993, INT J PEPT PROT RES, V42, P484; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; MARRA MN, 1990, J IMMUNOL, V144, P662; MATHISON JC, 1992, J IMMUNOL, V149, P200; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; THEOFAN G, 1994, J IMMUNOL, V152, P3623; TOBIAS PS, 1992, AM J RESP CELL MOL, V7, P239, DOI 10.1165/ajrcmb/7.3.239; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tracey K J, 1990, Adv Surg, V23, P21; WEISS J, 1984, J IMMUNOL, V132, P3109; WRIGHT SD, 1991, SCIENCE, V249, P1431; YOW E, 1958, ARCH INTERN MED, V92, P248; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	19	73	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17934	17938		10.1074/jbc.270.30.17934	http://dx.doi.org/10.1074/jbc.270.30.17934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543094	hybrid			2022-12-25	WOS:A1995RM26600049
J	ZEMBOWICZ, A; TANG, J; WU, KK				ZEMBOWICZ, A; TANG, J; WU, KK			TRANSCRIPTIONAL INDUCTION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE TYPE-III BY LYSOPHOSPHATIDYLCHOLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; PROTEIN-KINASE-C; CORONARY-ARTERIES; RELAXING FACTOR; DEPENDENT RELAXATION; RABBIT AORTA; VASCULAR REACTIVITY; POTENTIAL ROLE; L-ARGININE; CELLS	Endothelial synthesis of NO is catalyzed by constitutive NO synthase type III (NOS-III). NOS-III has been thought to be regulated mainly at the level of enzyme activity by intracellular calcium. We report that in human umbilical vein endothelial cells lysophosphatidylcholine (lyse-PC), a component of atherogenic lipoproteins and atherosclerotic lesions, increases NOS III mRNA and protein levels. This leads to the augmentation of NOS-III activity and the enhancement of antiplatelet properties of endothelial cells. Importantly, nuclear run-off experiments demonstrate a transcriptional mechanism of regulation of NOS-III expression by lysophosphatidylcholine. As endothelium-derived NO appears to be an anti-atherogenic molecule, induction of NOS-III by lyse-PC may be a protective response that limits the progress of the atherosclerotic lesion and pro motes its regression.	UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, DIV HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	ZEMBOWICZ, A (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV HEMATOL, VASC BIOL RES CTR, HOUSTON, TX 77030 USA.		Wu, Kenneth Kun-Yu/B-1070-2010					BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOSSALLER C, 1987, J CLIN INVEST, V79, P170, DOI 10.1172/JCI112779; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; FLAVAHAN NA, 1993, AM J PHYSIOL, V264, pH722, DOI 10.1152/ajpheart.1993.264.3.H722; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; FORSTERMANN U, 1988, CIRC RES, V62, P185, DOI 10.1161/01.RES.62.2.185; FRIES DM, 1995, BIOCHEM BIOPH RES CO, V207, P231, DOI 10.1006/bbrc.1995.1177; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GALLE J, 1991, ARTERIOSCLER THROMB, V11, P198, DOI 10.1161/01.ATV.11.1.198; GREENBERG ME, 1992, SHORT PROTOCOLS MOL; HARRISON DG, 1987, CIRC RES, V61, P74; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; JAYAKODY L, 1987, CIRC RES, V60, P251, DOI 10.1161/01.RES.60.2.251; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NARUSE K, 1994, ARTERIOSCLER THROMB, V14, P746, DOI 10.1161/01.ATV.14.5.746; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OHARA Y, 1994, ARTERIOSCLER THROMB, V14, P1007, DOI 10.1161/01.ATV.14.6.1007; OHGUSHI M, 1993, ARTERIOSCLER THROMB, V13, P1525, DOI 10.1161/01.ATV.13.10.1525; PARTHASARATHY S, 1989, ARTERIOSCLEROSIS, V9, P398, DOI 10.1161/01.ATV.9.3.398; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; PORTMAN OW, 1969, J LIPID RES, V10, P158; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RADOMSKI MW, 1908, THROMB RES, V30, P383; RESNICK RJ, 1994, J BIOL CHEM, V269, P32336; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SALVEMINI D, 1990, P NATL ACAD SCI USA, V87, P2593, DOI 10.1073/pnas.87.7.2593; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; VERBEUREN TJ, 1986, CIRC RES, V58, P552, DOI 10.1161/01.RES.58.4.552; VIDAVER GA, 1985, J THEOR BIOL, V115, P27, DOI 10.1016/S0022-5193(85)80005-9; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WERNS SW, 1989, CIRCULATION, V79, P287, DOI 10.1161/01.CIR.79.2.287; WU KK, 1988, J BIOL CHEM, V263, P19043; YOKOYAMA M, 1990, BIOCHEM BIOPH RES CO, V168, P301, DOI 10.1016/0006-291X(90)91708-Z; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZEMBOWICZ A, 1993, J PHARMACOL EXP THER, V267, P1112	62	109	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17006	17010		10.1074/jbc.270.28.17006	http://dx.doi.org/10.1074/jbc.270.28.17006			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542654	hybrid			2022-12-25	WOS:A1995RJ34700083
J	BERNINSONE, P; LIN, ZY; KEMPNER, E; HIRSCHBERG, CB				BERNINSONE, P; LIN, ZY; KEMPNER, E; HIRSCHBERG, CB			REGULATION OF YEAST GOLGI GLYCOSYLATION - GUANOSINE DIPHOSPHATASE FUNCTIONS AS A HOMODIMER IN THE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INACTIVATION; SACCHAROMYCES-CEREVISIAE; TARGET ANALYSIS; VESICLES; PURIFICATION; INSITU; SIZE	The Golgi Iumenal GDPase plays an important role in the mannosylation of proteins and Lipids of Saccharomyces cerevisiae by regulating the amount of GDP-mannose available in the Golgi lumen. The enzyme makes available GRIP as an antiporter to be coupled with entry of GDP-mannose into the Golgi lumen from the cytosol. Using radiation inactivation and target analysis, we have now determined the functional molecular mass of the GDPase within the GoIgi membrane and whether or not the enzyme has functional associations with other Golgi membrane proteins, including mannosyltransferases and the GDP-mannose transporter. The functional size of the GDPase was found to be approximately twice the estimated structural target size of the protein; this strongly suggests that the GDPase protein in situ functions as homodimer and does not require association with other membrane proteins for its function.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA; NIAMS, PHYS BIOL LAB, BETHESDA, MD 20892 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)				Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365, R37GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; FLEISCHER B, 1993, BIOCHEMISTRY-US, V32, P2076, DOI 10.1021/bi00059a027; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1989, METHOD ENZYMOL, V172, P410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1987, TARGET SIZE ANAL MEM, P33; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; Maniatis T, 1989, MOL CLONING; NORBY JG, 1989, J BIOL CHEM, V264, P19548; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; STRAKA JG, 1991, J BIOL CHEM, V266, P24637; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	20	18	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14564	14567		10.1074/jbc.270.24.14564	http://dx.doi.org/10.1074/jbc.270.24.14564			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540172	hybrid			2022-12-25	WOS:A1995RD45500051
J	SCHNETKAMP, PPM				SCHNETKAMP, PPM			HOW DOES THE RETINAL ROD NA-CA+K EXCHANGER REGULATE CYTOSOLIC-FREE CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENTS; K EXCHANGE; LIGHT ADAPTATION; CALCIUM; PHOTORECEPTORS; TRANSPORT; INACTIVATION; EXTRUSION; GRADIENTS; SODIUM	The roles of 1) inactivation of Na-Ca+K exchange and 2) Ca2+ release from discs in regulation of cytosolic free Ca2+ were examined in intact rod outer segments (ROS) purified from bovine retinas. Measurements of cytosolic free Ca2+ (with flue-3) were combined with Ca2+ flux measurements (Ca-45) in ROS that contained about 600 mu M total Ca2+. Na+-induced Ca2+ extrusion was measured in a Ca2+-free medium and did not lower cytosolic free Ca2+ to below 1 mu M as expected from a coupling stoichiometry of 4Na(+):(1Ca(2+)+1K(+)). Instead, cytosolic free Ca2+ was rapidly (20 s) lowered from about 1300 nM to 100-150 nM, while at the same time about 35% of total ROS Ca2+ was removed. During the next 40 min cytosolic free Ca2+ remained virtually steady, but total ROS Ca2+ was reduced by a further 50% at a 100-fold lower rate than that observed for the initial fast phase. The steady cytosolic Ca2+ concentration resulted from Ca2+ release from discs and subsequent removal across the plasma membrane by Na-Ca+K exchange operating at a greatly reduced rate. Addition of the alkali cation channel ionophore gramicidin led to a persistent increase in cytosolic free Ca2+ concentration to about 400 nra, presumably caused by an increase in intracellular Na+. It is suggested that cytosolic free Ca2+ is not determined by the Na+:Ca2+ coupling ratio of the exchanger, but rather by a sensor on its cytoplasmic domain that controls inactivation of the Ca2+ extrusion mode and is sensitive to intracellular Ca2+, Na+, and K+.			SCHNETKAMP, PPM (corresponding author), UNIV CALGARY,HLTH SCI CTR,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.							CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; NICOL GD, 1987, J GEN PHYSIOL, V89, P297, DOI 10.1085/jgp.89.2.297; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1980, BIOCHIM BIOPHYS ACTA, V598, P66, DOI 10.1016/0005-2736(80)90266-7; SCHNETKAMP PPM, 1991, J GEN PHYSIOL, V98, P555, DOI 10.1085/jgp.98.3.555; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1985, J MEMBRANE BIOL, V88, P249, DOI 10.1007/BF01871089; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P198; SCHNETKAMP PPM, 1993, J BIOL CHEM, V268, P12449; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1991, ANN NY ACAD SCI, V639, P10, DOI 10.1111/j.1749-6632.1991.tb17285.x; SCHNETKAMP PPM, 1987, J GEN PHYSIOL, V89, P481, DOI 10.1085/jgp.89.3.481; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0	21	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13231	13239		10.1074/jbc.270.22.13231	http://dx.doi.org/10.1074/jbc.270.22.13231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539424	hybrid			2022-12-25	WOS:A1995RB43900045
J	NORGARDSUMNICHT, K; VARKI, A				NORGARDSUMNICHT, K; VARKI, A			ENDOTHELIAL HEPARAN-SULFATE PROTEOGLYCANS THAT BIND TO L-SELECTIN HAVE GLUCOSAMINE RESIDUES WITH UNSUBSTITUTED AMINO-GROUPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-SELECTIN; LEUKOCYTE ADHESION; N-SULFOTRANSFERASE; FLAVOBACTERIUM-HEPARINUM; LINKED OLIGOSACCHARIDES; ANTITHROMBIN-BINDING; MYELOID CELLS; PASTEURELLA-HAEMOLYTICA; SUBSTRATE-SPECIFICITY; VASCULAR ENDOTHELIUM	We earlier reported calcium-dependent, heparin-like L-selectin ligands in cultured bovine endothelial cells (Norgard-Sumnicht, K, E., Varki, N, M., and Varki, A. (1993) Science 261,480-483), Here we show that these are heparan sulfate proteoglycans (HSPGs) associated either with the cultured cells or secreted into the medium and extracellular matrix, Activation of the endothelial cells with bacterial lipopolysaccharide (LPS) does not markedly alter the amount or distribution of this material. A major portion of the glycosaminoglycan (GAG) chains released from these HSPGs by alkaline beta-elimination rebinds to L-selectin in the presence of calcium, indicating that these saccharides alone can mediate the high affinity recognition. Heparin lyase digestions indicate that these GAG chains are enriched in heparan sulfate, not heparin sequences. Current understanding of the biosynthesis of heparan sulfate chains indicates that all glucosamine amino groups must be either N-acetylated or N-sulfated. However, nitrous acid deamination at pH 4.0 suggests the presence of some unsubstituted amino groups in these L-selectin binding GAG chains from endothelial cell HSPGs. This is confirmed by chemical N reacetylation and by reactivity with sulfo-N-hydroxysuccinimide-biotin. These unsubstituted amino groups are also found on HSPGs from human umbilical vein endothelial cells, but are not detected in those from Chinese hamster ovary cells. In both bovine and human endothelial cells, these novel groups are enriched for in the HS-GAG chains which bind to L-selectin. Despite this, studies with N-reacetylation and nitrous acid deamination do not show conclusive evidence for the direct involvement of the unsubstituted amino groups in L-selectin binding. This may be because the chemical reactions used to modify the amino groups do not go to completion. Alternatively, the unsubstituted amino groups may only be indirectly involved in generating binding, by dictating the biosynthesis of another critical group. Regardless, these studies shown that HSPGs from cultured endothelial cells which can bind to L-selectin are enriched with unsubstituted amino groups on their GAG chains. The possible biochemical mechanisms for generation of these novel groups are discussed.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [R01-CA38701] Funding Source: Medline; NHLBI NIH HHS [P50-HL 23594, T32-HL07107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ANJANEYULU PSR, 1987, INT J PEPT PROT RES, V30, P117; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BRITZ JS, 1983, J IMMUNOL, V130, P1848; CAVARI S, 1993, FEBS LETT, V323, P155, DOI 10.1016/0014-5793(93)81469-G; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; EDGE ASB, 1985, ARCH BIOCHEM BIOPHYS, V240, P560, DOI 10.1016/0003-9861(85)90063-3; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1992, ADV EXP MED BIOL, V313, P97; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; IMAI Y, 1993, NATURE, V361, P555; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LINDAHL U, 1991, THROMB HAEMOSTASIS, V66, P44; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; LYON M, 1994, J BIOL CHEM, V269, P11216; MANDON E, 1994, J BIOL CHEM, V269, P11729; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MONTESANO R, 1984, J CELL BIOL, V99, P1706, DOI 10.1083/jcb.99.5.1706; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MUNRO JM, 1992, AM J PATHOL, V141, P1397; NELSON RM, 1993, BLOOD, V82, P3253; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OHMORI K, 1989, BLOOD, V74, P255; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; RIESENFELD J, 1990, ANAL BIOCHEM, V188, P383, DOI 10.1016/0003-2697(90)90624-I; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SENO N, 1978, J BIOCHEM-TOKYO, V83, P953, DOI 10.1093/oxfordjournals.jbchem.a132022; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; SPERTINI O, 1991, J IMMUNOL, V147, P2565; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; UCHIYAMA H, 1991, J BIOL CHEM, V266, P6756; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALKER A, 1994, J BIOL CHEM, V269, P931; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YUEN CT, 1994, J BIOL CHEM, V269, P1595	77	105	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12012	12024		10.1074/jbc.270.20.12012	http://dx.doi.org/10.1074/jbc.270.20.12012			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538130	hybrid			2022-12-25	WOS:A1995QY73600052
J	ROLLING, C; TRETON, D; BECKMANN, P; GALANAUD, P; RICHARD, Y				ROLLING, C; TRETON, D; BECKMANN, P; GALANAUD, P; RICHARD, Y			JAK3 ASSOCIATES WITH THE HUMAN INTERLEUKIN-4 RECEPTOR AND IS TYROSINE-PHOSPHORYLATED FOLLOWING RECEPTOR TRIGGERING	ONCOGENE			English	Article						JAK3; PTK; PTP; IL4R; HUMAN B-CELLS	SIGNAL-TRANSDUCTION; GAMMA-CHAIN; INTERFERON-ALPHA/BETA; FUNCTIONAL COMPONENT; IGE SYNTHESIS; B-CELLS; PROTEIN; KINASE; IL-4; IGG4	In human B cells, interleukin 4 (IL4) acts in regulating proliferation, antigen expression, isotype switching and differentiation. These different effects are mediated through the LL4R complex including the IL2R gamma chain (gamma c) and a specific p130/140 binding unit referred below as human Interleukin 4 Receptor (IL4-R). Here, we studied the signal transduction events following LT4R activation and leading to CD23 expression on resting B cells. We demonstrate that LL4R triggering induced the tyrosine phosphorylation of JAK3 and of a p170 protein. Coimmunoprecipitation of JAK3 with the IL4R suggests a physical association which exists prior to IL4R complex stimulation. Orthovanadate treatment, while having no effect on IL4-induced p130 phosphorylation, leads to the hyperphosphorylation of the p170 and inhibits IL4-induced CD23 expression. These suggest that two mandatory steps exist in early IL4 signaling: one controlled by JAK3 activation and the other by the p170 phosphoprotein.	INST PARIS SUD CYTOKINES,INSERM,U131,CLAMART,FRANCE; IMMUNEX CORP,SEATTLE,WA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Immunex Corporation			RICHARD, Yolande/B-7926-2008	RICHARD, Yolande/0000-0001-8560-9250				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RICHARD Y, 1986, EUR J IMMUNOL, V16, P1303, DOI 10.1002/eji.1830161019; ROLLING CH, 1994, IN PRESS LEUCOCYTE T, V5; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SEDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; VANDERKUUR JA, 1994, J BIOL CHEM, V34, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALTING D, 1993, NATURE, V366, P166; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1992, P NATL ACAD SCI USA, V90, P4032; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	36	26	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1757	1761						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7538655				2022-12-25	WOS:A1995QX46900009
J	AHMAD, M; MARUI, N; ALEXANDER, RW; MEDFORD, RM				AHMAD, M; MARUI, N; ALEXANDER, RW; MEDFORD, RM			CELL-TYPE-SPECIFIC TRANSACTIVATION OF THE VCAM-1 PROMOTER THROUGH AN NF-KAPPA-B ENHANCER MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE; ELAM-1 GENE-TRANSCRIPTION; DNA-BINDING SUBUNIT; CYTOKINE INDUCTION; ENDOTHELIAL-CELLS; PROTEIN SUBUNITS; P65 SUBUNITS; REL FAMILY; ACTIVATION; EXPRESSION	Cytokine activation of vascular cell adhesion molecule-1 (VCAM-1) gene expression by endothelial cells is an important feature in a variety of vascular inflammatory responses. Cytokines transcriptionally activate the VCAM-1 promoter in endothelial cells at least in part through two closely linked NF-kappa B enhancer motifs, kappa L-kappa R (positions -77 and -63). However, cytokine activation of the dimeric NF-kappa B transcriptional factor (p50+p65 subunits) occurs in almost all cell types, whereas VCAM-1 gene expression exhibits a cell type-specific pattern of expression. Tumor necrosis factor-alpha markedly transactivated a transiently transfected minimal kappa L-kappa R motif-driven VCAM-1 promoter, p85VCAMCAT, in passaged human vascular endothelial cells but not in the human epithelial cell line, HeLa suggesting that cell type-specific factors may function through the kappa L-kappa R motif. Both cell types exhibited similar inductions of NF-kappa B DNA binding activity and transcriptional activity. However, co-transfection of HeLa cells with p65 and p50 expression vectors demonstrated that the minimal VCAM-1 promoter was effectively transactivated by p65 alone but that additional co-expression of p50 blocked this activity. Furthermore, cytokine activation of the minimal VCAM-1 promoter in HeLa cells was recovered by inhibition of p50 expression using antisense oligonucleotide. These studies suggest that the NF-kappa B(p50+p65 heterodimer) does not support transactivation of the VCAM-1 promoter with the p50 subunit potentially playing a significant inhibitory role in suppressing cytokine activation of VCAM-1. In addition, p65 associated transcriptional factors other than NF-kappa B may serve as positive, cytokine-inducible, cell type specific regulators of VCAM-1 gene expression.			AHMAD, M (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,1639 PIERCE DR,PO DRAWER LL,ATLANTA,GA 30322, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL48667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V2, P789; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1476; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUTSCH DE, 1994, MOL CELL BIOL, V14, P1939, DOI 10.1128/MCB.14.3.1939; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RON D, 1991, MOL CELL BIOL, V11, P2887, DOI 10.1128/MCB.11.5.2887; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RY A, 1994, P NATL ACAD SCI USA, V91, P752; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCMID RM, 1991, NATURE, V352, P733; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	45	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8976	8983		10.1074/jbc.270.15.8976	http://dx.doi.org/10.1074/jbc.270.15.8976			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7536741	hybrid			2022-12-25	WOS:A1995QT44800087
J	VANDERKUUR, J; ALLEVATO, G; BILLESTRUP, N; NORSTEDT, G; CARTERSU, C				VANDERKUUR, J; ALLEVATO, G; BILLESTRUP, N; NORSTEDT, G; CARTERSU, C			GROWTH-HORMONE PROMOTED TYROSYL PHOSPHORYLATION OF SHC PROTEINS AND SHC ASSOCIATION WITH GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; RAT INSULINOMA CELLS; 3T3-F442A FIBROBLASTS; INTERFERON-GAMMA; KINASE FAMILY; RECEPTOR; DOMAINS; JAK2; ACTIVATION; IDENTIFICATION	Growth hormone (GH) has been shown to stimulate the mitogen-activated protein (MAP) kinases designated ERKs (extracellular signal regulated kinases) 1 and 2. One pathway by which ERKs 1 and 2 are activated by tyrosine kinases involves the Src homology (SH)-2 containing proteins SHC and Grb2. To gain insight into pathways coupling GH receptor (GHR) to MAP kinase activation and signaling molecules that might interact with GHR and its associated tyrosine kinase JAK2, we examined whether SHC and Grb2 proteins serve as signaling molecules for GH, Human GH was shown to promote the rapid tyrosyl phosphorylation of 66-, 52-, and 46-MDa SHC proteins in 3T3-F442A fibroblasts, GH also promoted binding of GHR and JAK2 to the SH2 domain of 46/52-kDa SHC protein fused to glutathione S-transferase (GST). Constitutively phosphorylated JAK2, from COS-7 cells transiently transfected with murine JAJ2 cDNA, bound to SHC SH2-GST fusion protein, demonstrating that the SHC SH2 domain can bind tyrosylphosphorylated JAK2 in the absence of GHR, Regions of GHR required for GH dependent tyrosyl phosphorylation of SHC were examined using Chinese hamster ovary cells expressing mutated rat GHR, In cells expressing GHR1-638 and GHR1-638(Y333,338F), GH stimulated phosphorylation of all 3 SHC proteins whereas GH stimulated phosphorylation of only the 66- and 52-kDa SHC proteins in cells expressing GHR1-454, GH had no effect on SHC phosphorylation in cells expressing GHR1-294 or GHR Delta P, the latter lacking amino acids 297-311 containing the proline-rich motif required for JAK2 activation by GH. In contrast to SHC, Grb2 appeared not to interact directly with GHR or JAK2. However, Grb2 was shown to associate rapidly with SHC proteins in a GH-dependent manner. These findings suggest that GH stimulates: 1) the association of SHC proteins with JAK2 GHR complexes via the SHC SH2 domain, 2) tyrosyl phosphorylation of SHC proteins, and 3) subsequent Grb2 association with SHC proteins. These events are likely to be early events in GH activation of MAP kinases and possibly of other responses to GH.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; HAGEDORN RES LAB, DK-2820 GENTOFTE, DENMARK; KAROLINSKA INST, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN	University of Michigan System; University of Michigan; Novo Nordisk; Hagedorn Research Institute; Karolinska Institutet				Billestrup, Nils/0000-0002-4968-8067	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007245, R01DK034171] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NIDDK NIH HHS [5T32-DK07245, R0I-DK34171, R01 DK034171] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEEK DB, 1974, HDB PHYSIOLOGY END 2, V4, P159; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPUR AG, 1992, ONCOGENE, V7, P1347; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WANG XY, 1992, J BIOL CHEM, V267, P17390; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YIN TG, 1994, J BIOL CHEM, V269, P3731; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	134	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7587	7593		10.1074/jbc.270.13.7587	http://dx.doi.org/10.1074/jbc.270.13.7587			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535773	hybrid			2022-12-25	WOS:A1995QQ43100083
J	BEITNERJOHNSON, D; LEROITH, D				BEITNERJOHNSON, D; LEROITH, D			INSULIN-LIKE GROWTH-FACTOR-I STIMULATES TYROSINE PHOSPHORYLATION OF ENDOGENOUS C-CRK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; RECEPTOR SUBSTRATE-1; PROTEINS; CELLS; IRS-1; SH2; ASSOCIATION; BINDING; GENE; GRB2	Crk, a cellular homolog of v-crk, is an SH2 and SH3 domain-containing adaptor protein related to Grb2 and Nck, two proteins which have been shown to be involved in growth factor signal transduction. Crk proteins have recently been found to associate with two guanine nucleotide releasing proteins, mSos and C3G, and thus appear to lie on the Ras pathway. We investigated whether Crk is a target for the insulin-like growth factor I (IGF-I) receptor tyrosine kinase. We show that IGF-I stimulates tyrosine phosphorylation of Crk II via stimulation of endogenous IGF-I receptors in both 293 cells and NIH-3T3 cells. IGF-I stimulated tyrosine phosphorylation of Crk II in a dose- and time-dependent manner. In 293 cells, which express both IGF-I and insulin receptors, insulin also induced a dose dependent tyrosine phosphorylation of Crk II, but with somewhat reduced sensitivity, compared to IGF-I. In NIH 3T3 cells, IGF-I also stimulated tyrosine phosphorylation of a 45- kDa protein which co immunoprecipitated with Crk II. These findings indicate that Crk II is an endogenous substrate of the IGF-I receptor tyrosine kinase and provide the first demonstration that a mitogenic growth factor induces tyrosine phosphorylation of endogenous c-Crk.			BEITNERJOHNSON, D (corresponding author), NIDDK, DIABET BRANCH,BLDG 10,RM 8S-239,10 CTR DR, MSC 1770, BETHESDA, MD 20892 USA.							AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5187	5190		10.1074/jbc.270.10.5187	http://dx.doi.org/10.1074/jbc.270.10.5187			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534289	hybrid			2022-12-25	WOS:A1995QL58000037
J	WENG, WK; JARVIS, L; LEBIEN, TW				WENG, WK; JARVIS, L; LEBIEN, TW			SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-B; VAV PROTOONCOGENE; PRE-B; MONOCLONAL-ANTIBODY; TYROSINE; ANTIGEN; EXPRESSION; RECEPTOR; DIFFERENTIATION; PROLIFERATION	The B cell-specific cell surface molecule CD19 plays a role in regulating immunoglobulin (Ig) receptor signaling, and cross-linking CD19 activates several signaling molecules in mature human B cells. In surface Ig-negative B cell precursors, a protein tyrosine kinase (PTK)-dependent homotypic aggregation response can be triggered by cross-linking CD19. In the current study, we examined the outcome of PTK-mediated signal transduction following CD19 cross-linking on surface Ig negative and surface Ig positive B cell lines, as well as freshly isolated surface Ig-negative B cell precursors. PIE activation resulted in the tyrosine phosphorylation of multiple protein substrates and peaked at 0.5-1 min following CD19 cross-linking in all B-lineage cells examined. One of the tyrosine-phosphorylated substrates was identified as the hematopoietic-specific protein Vav, a guanine nucleotide exchange factor that activates the Pas pathway. Evidence consistent with Pas pathway activation was also demonstrated by MEK activation and subsequent phosphorylation of a MAP kinase fusion protein. CD19 cross-linking, sequential immunoprecipitation, and Western blotting revealed that: (a) Vav becomes associated with CD19, (b) phosphatidylinositol 3-kinase (PI 3-kinase) becomes associated with CD19, and (c) PI 3-kinase becomes associated with Vav. No such physical interaction occurred following control IgG1 cross-linking or cross-linking of class I major histocompatability complex cell surface molecules. Coupled with a previous report (Tuveson, D. A, Carter, and H., Soltoff, S. P., and Fearon, D. T. (1993) Science 260, 986-988), our data support a model in which CD19 crosslinking induces the formation of a signaling complex that leads to the activation of two pathways involving Pas and PI 3-kinase.	UNIV MINNESOTA, SCH MED, DEPT PATHOL & LAB MED, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities				LeBien, Tucker/0000-0001-5011-2199	NCI NIH HHS [R01 CA-31685] Funding Source: Medline; NIAID NIH HHS [T32 AI-07313] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007313] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BARRETT TB, 1990, EUR J IMMUNOL, V20, P1053, DOI 10.1002/eji.1830200516; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GODING JW, 1986, MONOCLONAL ANTIBODIE, P260; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LEBIEN TW, 1990, LEUKEMIA, V4, P354; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; NADLER LM, 1983, J IMMUNOL, V131, P244; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TEDDER TF, 1989, J IMMUNOL, V143, P712; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1988, BLOOD, V71, P13; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; WOLF ML, 1991, J IMMUNOL, V147, P3324; WOLF ML, 1993, J IMMUNOL, V151, P138; WORMANN B, 1989, J IMMUNOL, V142, P110; ZHOU LJ, 1991, J IMMUNOL, V147, P1424; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	144	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32514	32521						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528218				2022-12-25	WOS:A1994PX30400074
J	HUANG, Y; RANE, SG				HUANG, Y; RANE, SG			POTASSIUM CHANNEL INDUCTION BY THE RAS/RAF SIGNAL-TRANSDUCTION CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAF-1 PROTEIN-KINASE; H-RAS ONCOGENE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; SINGLE-CHANNEL; K+ CHANNELS; CELL-LINE; ACTIVATION; TRANSFORMATION; CONDUCTANCE	p21(ras) plays a critical role in cell growth, differentiation, and oncogenic transformation. However, the final physiological effecters of p21(ras)-mediated signal transduction remain to be determined. We have used patch clamp electrophysiology, pharmacological agents, and transfection with specific Ras or Raf plasmids, to demonstrate that induction of a unique Ca2+-activated K+ channel in murine fibroblast cell lines depends on p21(ras) and its immediate downstream target, the Raf kinase. The importance of this channel in mitogenic signaling is further indicated by its induction in nontransformed cells by epidermal growth factor and platelet-derived growth factor and the ability of K+ channel blockers to inhibit cell proliferation. We suggest that this Ca2+-activated K+ channel is one ultimate physiological target of p21(ras)-mediated signal transduction and that it may play a role in cell proliferation and ras transformation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [R01GM43462] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043462] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ASAI DJ, 1980, J CELL BIOL, V87, P114, DOI 10.1083/jcb.87.1.114; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATARSI S, 1993, NATURE, V363, P353, DOI 10.1038/363353a0; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; DARCANGELO G, 1993, J CELL BIOL, V122, P915, DOI 10.1083/jcb.122.4.915; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; ENOMOTO KI, 1991, J MEMBRANE BIOL, V119, P133, DOI 10.1007/BF01871412; FANGER GR, 1993, J NEUROCHEM, V61, P1977, DOI 10.1111/j.1471-4159.1993.tb09844.x; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLAMM RE, 1990, PFLUG ARCH EUR J PHY, V416, P120, DOI 10.1007/BF00370232; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; HALL A, 1988, COLD SPRING HARB SYM, V53, P855, DOI 10.1101/SQB.1988.053.01.098; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEMMICK LM, 1992, J NEUROSCI, V12, P2007; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG Y, 1993, J PHYSIOL-LONDON, V461, P601, DOI 10.1113/jphysiol.1993.sp019531; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE SC, 1986, J CELL BIOL, V102, P1200, DOI 10.1083/jcb.102.4.1200; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RANE SG, 1991, AM J PHYSIOL, V260, pC104, DOI 10.1152/ajpcell.1991.260.1.C104; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SAUVE R, 1986, J MEMBRANE BIOL, V92, P269, DOI 10.1007/BF01869395; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	54	75	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31183	31189						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527041				2022-12-25	WOS:A1994PV51000069
J	ATFI, A; DROBETSKY, E; BOISSONNEAULT, M; CHAPDELAINE, A; CHEVALIER, S				ATFI, A; DROBETSKY, E; BOISSONNEAULT, M; CHAPDELAINE, A; CHEVALIER, S			TRANSFORMING GROWTH-FACTOR-BETA DOWN-REGULATES SRC FAMILY PROTEIN-TYROSINE KINASE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; II RECEPTOR; SH3 DOMAINS; RAS; PHOSPHORYLATION; ACTIVATION; GRB2; TRANSDUCTION; ASSOCIATION	Transforming growth factor beta (TGF beta) inhibits the proliferation of a wide range of cell types through interaction with its cell surface receptor (R-TGF beta). R-TGF beta possesses serine/threonine kinase activity rather than the tyrosine kinase activity normally associated with peptide growth factor receptors; nevertheless, TGF beta triggers a signaling pathway that leads to the repression of transcription factors, which appear to mediate the action of receptor tyrosine kinases within the nucleus. Accumulating evidence has also shown that the nonreceptor protein tyrosine kinases of the Src family play essential roles in the signal transduction pathways that regulate cell proliferation, differentiation, and function. Here, we investigate whether signals initiated by R-TGF beta are transduced, at least in part, through members of the Src family of tyrosine kinases. Treatment of the responsive human prostate carcinoma cell line PC3 with TGF beta induces a rapid and specific decrease in cellular levels of pp60(Src) and pp53/56(Lyn) and a corresponding decrease in their protein kinase activity when the assays were performed in vitro using the exogenous substrate enolase. Consistent with suppression of pp60(Src) and pp53/56(Lyn) kinase activity, TGF beta also caused a substantial intracellular accumulation of the unphosphorylated form of SH2-containing protein (SHC), a substrate of the Src family kinases. This was paralleled by de creased formation of a complex between the adaptor protein known as growth factor receptor-bound protein 2 and SHC. These results suggest, for the first time, that TGF beta induces down-regulation of Src family kinases, leading to disruption of the SHC-growth factor receptor-bound protein 2 complex. These events may play a crucial role in the negative regulation of Ras, as well as in the control of downstream effector molecules involved in the regulation of cell growth.	MONTREAL GEN HOSP,RES INST,MONTREAL H3G 1A4,PQ,CANADA; MCGILL UNIV,DEPT SURG,DIV UROL,MONTREAL H3G 1A4,PQ,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H1T 2M4,PQ,CANADA; UNIV MONTREAL,DEPT BIOCHEM,MONTREAL H1T 2M4,PQ,CANADA; MAISONNEUVE ROSEMONT HOSP,RES CTR,MONTREAL H1T 2M4,PQ,CANADA	McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal								ATFI A, 1994, PROSTATE, V24, P149, DOI 10.1002/pros.2990240309; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P421; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG XF, 1991, CELL, V67, P795; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	50	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30688	30693						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527036				2022-12-25	WOS:A1994PU52500098
J	ANDREWS, SC; LEBRUN, NE; BARYNIN, V; THOMSON, AJ; MOORE, GR; GUEST, JR; HARRISON, PM				ANDREWS, SC; LEBRUN, NE; BARYNIN, V; THOMSON, AJ; MOORE, GR; GUEST, JR; HARRISON, PM			SITE-DIRECTED REPLACEMENT OF THE COAXIAL HEME LIGANDS OF BACTERIOFERRITIN GENERATES HEME-FREE VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN FERRITIN; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; AZOTOBACTER-VINELANDII; FERROXIDASE-CENTER; CLONING; PURIFICATION; LIGATION; PROTEINS; RELEASE	The bacterioferritin (BFR) of Escherichia coli is a heme-containing iron storage molecule. It is composed of 24 identical subunits, which form a roughly spherical protein shell surrounding a central iron storage cavity. Each of the 12 heme moieties of BFR possesses bis-methionine axial ligation, a heme coordination scheme so far only found in bacterioferritins. Members of the BFR family contain three partially conserved methionine residues (excluding the initiating methionine) and in this study each was substituted by leucine and/or histidine. The Met(52) variants were devoid of heme, whereas the Met(31) and Met(86) variants possessed full heme complements and were spectroscopically indistinguishable from wild-type BFR. The heme-free Met(52) variants appeared to be correctly assembled and were capable of accumulating iron both in vivo and in vitro. No major differences were observed in the overall rate of iron accumulation for BFR-M52H, BFR-M52L, and the wildtype protein. The iron contents of the Met(52) variants, as isolated, were at least 4 times greater than for wild-type BFR. This study is consistent with the reported location of the BFR heme site at the fl-fold axis and shows that heme is unnecessary for BFR assembly and iron uptake.	UNIV E ANGLIA, SCH CHEM SCI, CTR METALLOPROT SPECT & BIOL, NORWICH NR4 7TJ, NORFOLK, ENGLAND	University of East Anglia	ANDREWS, SC (corresponding author), UNIV SHEFFIELD, KREBS INST BIOMOLEC RES, DEPT MOLEC BIOL & BIOTECHNOL, WESTERN BANK, FIRTH COURT, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND.		Andrews, Simon C/H-4758-2019	Andrews, Simon C/0000-0003-4295-2686; Le Brun, Nick/0000-0001-9780-4061	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS SC, 1993, EUR J BIOCHEM, V213, P329, DOI 10.1111/j.1432-1033.1993.tb17766.x; ANDREWS SC, 1989, J BACTERIOL, V171, P3940, DOI 10.1128/jb.171.7.3940-3947.1989; ANDREWS SC, 1991, FEBS LETT, V293, P164, DOI 10.1016/0014-5793(91)81177-A; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHEESMAN MR, 1992, BIOCHEM J, V286, P361, DOI 10.1042/bj2860361; CHEESMAN MR, 1990, NATURE, V346, P771, DOI 10.1038/346771a0; CHEESMAN MR, 1993, BIOCHEM J, V292, P47, DOI 10.1042/bj2920047; DRYSDALE JW, 1965, BIOCHEM J, V95, P851, DOI 10.1042/bj0950851; FALK JE, 1964, PORPHYRINS METALLOPO, V2; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; FROLOW F, 1994, NAT STRUCT BIOL, V1, P453, DOI 10.1038/nsb0794-453; GEORGE GN, 1993, J AM CHEM SOC, V115, P7716, DOI 10.1021/ja00070a015; GROSSMAN MJ, 1992, P NATL ACAD SCI USA, V89, P2419, DOI 10.1073/pnas.89.6.2419; HEMPSTEAD PD, 1994, FEBS LETT, V350, P258, DOI 10.1016/0014-5793(94)00781-0; HUDSON AJ, 1993, EUR J BIOCHEM, V218, P985, DOI 10.1111/j.1432-1033.1993.tb18457.x; INGLIS NF, 1994, GENE, V150, P205, DOI 10.1016/0378-1119(94)90889-3; KADIR FHA, 1992, BIOCHEM J, V282, P867, DOI 10.1042/bj2820867; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROKAWA T, 1989, BIOCHIM BIOPHYS ACTA, V976, P135, DOI 10.1016/S0005-2728(89)80222-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAULHERE JP, 1992, BIOCHEM J, V281, P785, DOI 10.1042/bj2810785; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEBRUN NE, 1993, FEBS LETT, V333, P197, DOI 10.1016/0014-5793(93)80404-I; LEBRUN NE, 1993, THESIS U E ANGLIA NO; LEBRUN NE, 1995, IN PRESS BIOCH J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOORE GR, 1994, BIOCHEM J, V304, P493, DOI 10.1042/bj3040493; PESSOLANI MCV, 1994, J EXP MED, V180, P319, DOI 10.1084/jem.180.1.319; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THOMAS CD, 1988, BIOCHEM SOC T, V16, P838, DOI 10.1042/bst0160838; TREFFRY A, 1978, BIOCHEM J, V171, P313, DOI 10.1042/bj1710313; TRIKHA J, 1994, PROTEINS, V18, P107, DOI 10.1002/prot.340180204; WATT GD, 1986, BIOCHEMISTRY-US, V25, P4330, DOI 10.1021/bi00363a023	38	78	81	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23268	23274		10.1074/jbc.270.40.23268	http://dx.doi.org/10.1074/jbc.270.40.23268			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559480	hybrid			2022-12-25	WOS:A1995RY90900009
J	PENHALLOW, RC; CLASS, K; SONODA, H; BOLEN, JB; ROWLEY, RB				PENHALLOW, RC; CLASS, K; SONODA, H; BOLEN, JB; ROWLEY, RB			TEMPORAL ACTIVATION OF NONTRANSMEMBRANE PROTEIN-TYROSINE KINASES FOLLOWING MAST-CELL FC-EPSILON-RI ENGAGEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; ANTIGEN RECEPTOR-ZETA; SIGNAL-TRANSDUCTION; CROSS-LINKING; HIGH-AFFINITY; T-CELLS; PHOSPHORYLATION; IGE; CHAIN; IMMUNOGLOBULIN	One of the primary responses observed following antigen-induced cross-linking in mast cells is an increase in the phosphorylation of certain cellular proteins on tyrosine residues. Stimulation of protein tyrosine kinase activity appears to be necessary for induction of downstream responses such as degranulation. The role of nonreceptor protein-tyrosine kinases in the signal transduction pathway initiated by Fc epsilon RI engagement in an interleukin-3-dependent mast cell line has been examined. The results presented here show that the enzymatic activity of Lyn is increased within seconds of re receptor engagement. Syk activity also undergoes a rapid and transient increase, reaching a peak at approximately 30 s. Similarly, the activity of Fer, representing a third class of nontransmembrane protein-tyrosine kinase increases as well, with its activity peak reached at 1 min poststimulation. The enzymatic activities of Syk and Fer were found to correspond to anti-phosphotyrosine antibody reactivity. Phosphorylation of tyrosine residues of the beta and gamma chains of Fc epsilon RI increased concomitant with increased protein-tyrosine kinase activity. These results indicate that at least three classes of nontransmembrane protein-tyrosine kinases are involved in mast cell Fc epsilon RI signaling and that the activation of these classes of enzymes is temporally regulated.			PENHALLOW, RC (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.							BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P3982; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; EISEMAN E, 1992, NATURE, V355, P78; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KIHARA H, 1994, J BIOL CHEM, V269, P22427; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YU KT, 1991, J BIOL CHEM, V266, P22564	31	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23362	23365		10.1074/jbc.270.40.23362	http://dx.doi.org/10.1074/jbc.270.40.23362			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559493	hybrid			2022-12-25	WOS:A1995RY90900022
J	ABUSOUD, HM; WANG, JL; ROUSSEAU, DL; FUKUTO, JM; IGNARRO, LJ; STUEHR, DJ				ABUSOUD, HM; WANG, JL; ROUSSEAU, DL; FUKUTO, JM; IGNARRO, LJ; STUEHR, DJ			NEURONAL NITRIC-OXIDE SYNTHASE SELF-INACTIVATES BY FORMING A FERROUS-NITROSYL COMPLEX DURING AEROBIC CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; MACROPHAGE; HEME; CYTOCHROME-P-450; INTERMEDIATE; INHIBITION; OXIDATION; MYOGLOBIN; KINETICS; BINDING	Neuronal NO synthase (NOS) is a flavin-containing hemeprotein that generates NO from L-arginine, NADPH, and O-2. NO has recently been proposed to autoinhibit NOS. We have investigated whether a NOS heme-NO complex forms during aerobic steady-state catalysis, Visible and resonance Raman spectra recorded during steady-state NO synthesis by NOS showed that the majority of enzyme (70-90%) was present as its ferrous-nitrosyl complex, Ferrous-nitrosyl NOS formed only in the coincident presence of NADPH, L-arginine, and O-2. Its level remained constant during NO synthesis until the NADPH was exhausted, after which the complex decayed to regenerate ferric resting NOS. Stopped-flow measurements revealed that the buildup of the ferrous-NO complex was rapid (< 2 s) and caused a 10-fold decrease in the rate of NADPH consumption by NOS. Complex formation and decay could occur several times with no adverse affect on its subsequent formation or on NOS catalytic activity, Neither enzyme dilution nor NO scavengers (superoxide and oxyhemoglobin) diminished formation of ferrous-nitrosyl NOS or prevented the catalytic inhibition attributed to its formation. The ferrous-nitrosyl complex also formed in unfractionated cell cytosol containing neuronal NOS upon initiating NO synthesis, We conclude that a majority of neuronal NOS is converted quickly to a catalytically inactive ferrous-nitrosyl complex during NO synthesis independent of the external NO concentration. Thus, NO binding to the NOS heme may be a fundamental feature of catalysis and functions to down-regulate NO synthesis by neuronal NOS.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; AT&T BELL LABS,MURRAY HILL,NJ 07974; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOLEC PHARMACOL,LOS ANGELES,CA 90024	Case Western Reserve University; AT&T; Nokia Corporation; Nokia Bell Labs; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	ABUSOUD, HM (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT IMMUNOL,CLEVELAND,OH 44195, USA.				NIGMS NIH HHS [GM-48714, GM51491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM048714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; GRISCAVAGE JM, 1994, J BIOL CHEM, V29, P21644; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1993, J BIOL CHEM, V268, P14781; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; POU S, 1992, J BIOL CHEM, V267, P24173; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SCHAAD O, 1993, P NATL ACAD SCI USA, V90, P9547, DOI 10.1073/pnas.90.20.9547; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4527, DOI 10.1021/bi00388a054; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016	37	186	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22997	23006		10.1074/jbc.270.39.22997	http://dx.doi.org/10.1074/jbc.270.39.22997			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559438	hybrid			2022-12-25	WOS:A1995RY05400058
J	JABBOURI, S; FELLAY, R; TALMONT, F; KAMALAPRIJA, P; BURGER, U; RELIC, B; PROME, JC; BROUGHTON, WJ				JABBOURI, S; FELLAY, R; TALMONT, F; KAMALAPRIJA, P; BURGER, U; RELIC, B; PROME, JC; BROUGHTON, WJ			INVOLVEMENT OF NODS IN N-METHYLATION AND NODU IN 6-O-CARBAMOYLATION OF RHIZOBIUM SP NGR234 NOD FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; SYMBIOTIC HOST-SPECIFICITY; STRAIN NGR234; BRADYRHIZOBIUM-JAPONICUM; AZORHIZOBIUM-CAULINODANS; NODULATION SIGNALS; GENES; MELILOTI; PROTEIN; IDENTIFICATION	Although Rhizobium sp, NGR234 and Rhizobium fredii USDA257 share many traits, dysfunctional nodSU genes in the latter prohibit nodulation of Leucaena species, Accordingly, we used R. fredii transconjugants harboring the nodS and nodU genes of NGR234 to study their role in the structural modification of the Lipo-oligosaccharide Nod factors, Differences between the Nod factors mainly concern the length of the oligomer (three to five glucosamine residues in USDA257 and five residues only in NGR234) and the presence of additional substituents in NGR234 (N-linked methyl, one or two carbamoyl groups on the non-reducing moiety, acetyl or sulfate groups on the fucose), R. fredii(nodS) transconjugants produce chitopentamer Nod factors with a N-linked methyl group on the glucosaminyl terminus. Introduction of nodU into USDA257 results in the formation of 6-O-carbamoylated factors. Co-transfer of nodSU directs N-methylation, mono-6-O-carbamoylation, and production of pentameric Nod factors. Mutation of nodU in NGR234 suppresses the formation of bis-carbamoylated species. Insertional mutagenesis of nodSU drastically decreases Nod factor production, but with the exception of sulfated factors (which are partially N-methylated and mono-carbamoylated), they are identical to those of the wild-type strain. Thus, Nod factor levels, their degree of oligomerization, and N-methylation are linked to the activity encoded by nodS.	UNIV GENEVA,LBMPS,CH-1292 CHAMBESY,SWITZERLAND; CNRS,PHARMACOL & TOXICOL FONDAMENTALES LAB,F-31077 TOULOUSE,FRANCE; UNIV GENEVA,DEPT CHIM ORGAN,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; Centre National de la Recherche Scientifique (CNRS); University of Geneva			Jabbouri, Said/N-6672-2014	Jabbouri, Said/0000-0003-1354-494X				ATKINSON EM, 1994, P NATL ACAD SCI USA, V91, P8418, DOI 10.1073/pnas.91.18.8418; BECFERTE MP, 1994, BIOCHEMISTRY-US, V33, P11782, DOI 10.1021/bi00205a014; BECKMANN F, 1995, CARBOHYD RES, V267, pC3, DOI 10.1016/0008-6215(94)00371-L; BLOEMBERG GV, 1994, MOL MICROBIOL, V11, P793, DOI 10.1111/j.1365-2958.1994.tb00357.x; CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; COQUE JJR, 1993, EMBO J, V12, P631, DOI 10.1002/j.1460-2075.1993.tb05696.x; DEBELLE F, 1992, MOL PLANT MICROBE IN, V5, P443, DOI 10.1094/MPMI-5-443; DEMONT N, 1993, J BIOL CHEM, V268, P20134; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; FELLAY R, 1995, PATHOGENESIS HOST PA, V1, P199; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; GEELEN D, 1993, MOL MICROBIOL, V9, P145, DOI 10.1111/j.1365-2958.1993.tb01676.x; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GOTTFERT M, 1990, MOL PLANT MICROBE IN, V3, P308, DOI 10.1094/MPMI-3-308; HERON DS, 1989, MOL PLANT MICROBE IN, V1, P4; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; JONES JDG, 1987, GENE, V61, P299, DOI 10.1016/0378-1119(87)90193-4; KRISHNAN HB, 1992, MOL MICROBIOL, V6, P3321, DOI 10.1111/j.1365-2958.1992.tb02200.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEROUGE P, 1994, GLYCOBIOLOGY, V4, P127, DOI 10.1093/glycob/4.2.127; LEWIN A, 1990, MOL PLANT MICROBE IN, V3, P317, DOI 10.1094/MPMI-3-317; LUKA S, 1993, J BIOL CHEM, V268, P27053; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; RELIC B, 1993, MOL PLANT MICROBE IN, V6, P764, DOI 10.1094/MPMI-6-764; RELIC B, 1994, MOL MICROBIOL, V13, P171, DOI 10.1111/j.1365-2958.1994.tb00412.x; RELIC B, 1994, 1ST P EUR NITR FIX C, P69; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROHRIG H, 1994, P NATL ACAD SCI USA, V91, P3122, DOI 10.1073/pnas.91.8.3122; STACEY G, 1994, J BACTERIOL, V176, P620, DOI 10.1128/jb.176.3.620-633.1994; STAEHELIN C, 1994, P NATL ACAD SCI USA, V91, P2196, DOI 10.1073/pnas.91.6.2196; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VANBRUSSEL AAN, 1992, SCIENCE, V257, P70, DOI 10.1126/science.257.5066.70	35	66	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22968	22973		10.1074/jbc.270.39.22968	http://dx.doi.org/10.1074/jbc.270.39.22968			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559434	Green Published, hybrid			2022-12-25	WOS:A1995RY05400054
J	PAN, JL; MCEVER, RP				PAN, JL; MCEVER, RP			REGULATION OF THE HUMAN P-SELECTIN PROMOTER BY BCL-3 AND SPECIFIC HOMODIMERIC MEMBERS OF THE NF-KAPPA-B/REL FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE PROTOONCOGENE BCL-3; GRANULE MEMBRANE-PROTEIN; CELL-ADHESION; TRANSCRIPTIONAL ACTIVATION; CYTOKINE INDUCTION; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; ONCOPROTEIN BCL-3; P50 HOMODIMERS; B P50	P-selectin, an adhesion receptor for leukocytes, is constitutively expressed by megakaryocytes and endothelial cells. Synthesis of P-selectin is also increased by some inflammatory mediators, We characterized a previously identified kappa B site ((-218)GGGGGTGACCCC(-207)) in the promoter of the human P-selectin gene. The kappa B site was unique in that it bound constitutive nuclear protein complexes containing p50 or p52, but not inducible nuclear protein complexes containing p65. Furthermore, the element bound recombinant p50 or p52 homodimers, but not p65 homodimers. Methylation interference analysis indicated that p50 or p52 homodimers contacted the guanines at positions -218 to -214 on the coding strand and at -210 to -207 on the noncoding strand. Changes in the three central residues at -213 to -211 altered binding specificity for members of the NF-kappa B/Rel family, Mutations that eliminated binding to NF-kappa B/Rel proteins reduced by similar to 40% the expression of a reporter gene driven by the P-selectin promoter in transfected bovine aortic endothelial cells. Overexpression of p52 enhanced P-selectin promoter activity, and co-overexpression of Bcl-3 further induced promoter activity in a kappa B site-dependent manner. In contrast, overexpression of p50 repressed promoter activity; this repression was prevented by co-overexpression of Bcl-3. Similar phenomena were observed with reporter gene constructs driven by two tandem P-selectin kappa B sequences linked to the SV40 minimal promoter. These data suggest that Bcl-3 differentially regulates the effects of p50 and p52 homodimers bound to the kappa B Site of the P-selectin promoter. This site may be a prototype for kappa B elements in other genes that bind specifically to p50 and/or p52 homodimers.	UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,DEPT MED,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation								AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; AUCHAMPACH JA, 1994, GENE, V145, P251, DOI 10.1016/0378-1119(94)90015-9; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CHANG CC, 1994, ONCOGENE, V9, P923; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GOTSCH U, 1994, CELL ADHES COMMUN, V2, P7, DOI 10.3109/15419069409014198; GROBER JS, 1993, J CLIN INVEST, V91, P2609, DOI 10.1172/JCI116500; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JOHNSONTIDEY RR, 1994, AM J PATHOL, V144, P952; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LIOU SC, 1993, CURR OPIN CELL BIOL, V5, P477; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1993, STRUCTURE, FUNCTION, AND REGULATION OF MOLECULES INVOLVED IN LEUKOCYTE ADHESION, P135; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1993, J BIOL CHEM, V268, P22600; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS WE, 1992, BLOOD, V80, P795; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P3557; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SIEBENLIST U, 1995, ANN REV CELL BIOL, V10, P405; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VANHUIJSDUIJNEN RH, 1993, NUCLEIC ACIDS RES, V21, P3711, DOI 10.1093/nar/21.16.3711; WELLER A, 1992, J BIOL CHEM, V267, P15176; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	53	96	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23077	23083		10.1074/jbc.270.39.23077	http://dx.doi.org/10.1074/jbc.270.39.23077			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559449	hybrid			2022-12-25	WOS:A1995RY05400069
J	PARENT, CA; DEVREOTES, PN				PARENT, CA; DEVREOTES, PN			ISOLATION OF INACTIVE AND G-PROTEIN-RESISTANT ADENYLYL-CYCLASE MUTANTS USING RANDOM MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DICTYOSTELIUM-DISCOIDEUM; EXPRESSION; DIVERSITY; SYSTEM; GENES	We used random mutagenesis and phenotypic rescue of adenylyl cyclase-null Dictyostelium cells to isolate loss-of-function mutations in the enzyme. Mutants were (i) catalytically inactive or (ii) resistant to chemoattractant receptor and guanosine 5'-3-O-(thio)triphosphate stimulation. Both classes of mutants harbored substitutions within the cytoplasmic Cia domain. Mutations that inactivated the enzyme were often at highly conserved positions. Those that blocked activation were grouped in two distinct regions: one close to the plane of the plasma membrane and another halfway within the C1 loop. Missense mutations or deletions within the transmembrane domains resulted in missorting of the protein. Our screen provides a simple and efficient method to separately define the sites of catalysis and regulation of this important class of enzymes.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University								BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; HUGHES JE, 1994, MOL CELL BIOL, V14, P6117, DOI 10.1128/MCB.14.9.6117; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung DW, 1989, TECHNIQUE, V1, P11; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	28	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22693	22696		10.1074/jbc.270.39.22693	http://dx.doi.org/10.1074/jbc.270.39.22693			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559391	hybrid			2022-12-25	WOS:A1995RY05400011
J	PARK, CH; BESSHO, T; MATSUNAGA, T; SANCAR, A				PARK, CH; BESSHO, T; MATSUNAGA, T; SANCAR, A			PURIFICATION AND CHARACTERIZATION OF THE XPF-ERCC1 COMPLEX OF HUMAN DNA-REPAIR EXCISION NUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PIGMENTOSUM GROUP-F; RAD10; ENDONUCLEASE; ERCC1	A complex, which consists of ERCC1 (38 kDa) and a 112-kDa protein, was purified from HeLa cells to homogeneity. This complex complemented the nucleotide excision repair defects of rodent ERCC-1, ERCC-4, and human XP-F mutant cell-free extracts, indicating that the 112-kDa protein is XPF/ERCC4 and providing direct biochemical evidence that XPF and ERCC4 are identical. The XPF/ERCC4-ERCC1 complex has an endonuclease activity with preference for single-stranded DNA and a single-stranded region of duplex DNA with a ''bubble'' structure. This complex also nicks supercoiled DNA weakly, and this nicking activity is stimulated by human replication protein A when the DNA contains UV damage.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P317; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12095; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; PARK CH, 1994, P NATL ACAD SCI USA, V1, P5017; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SUNG P, 1993, J BIOL CHEM, V268, P26391; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; THOMPSON LH, 1985, MUTAT RES, V150, P423, DOI 10.1016/0027-5107(85)90139-3; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x	19	111	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22657	22660		10.1074/jbc.270.39.22657	http://dx.doi.org/10.1074/jbc.270.39.22657			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559382	Green Published, hybrid			2022-12-25	WOS:A1995RY05400002
J	RUFF, VA; LEACH, KL				RUFF, VA; LEACH, KL			DIRECT DEMONSTRATION OF NFAT(P) DEPHOSPHORYLATION AND NUCLEAR-LOCALIZATION IN ACTIVATED HT-2 CELLS USING A SPECIFIC NFAT(P) POLYCLONAL ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; T-CELLS; CALCINEURIN; IDENTIFICATION; PROTEIN; CYCLOPHILIN; COMPLEXES; BINDING; TARGET; GENES	Nuclear factor of activated T cells (NFAT) regulates transcription of a number of cytokine genes, and NFAT DNA binding activity is stimulated following T cell activation. Several lines of evidence have suggested that NFAT is a substrate for calcineurin, a serine/threonine phosphatase. Using a polyclonal antibody to murine NFAT(p), Western blot analysis of various mouse tissues demonstrated that the 110-130-kDa NFAT(p) protein was highly expressed in thymus and spleen. Treatment of immunoprecipitated NFAT(p) from untreated HT-2 cells with calcineurin resulted in the dephosphorylation of NFAT(p), demonstrating that NFAT(p) is an in vitro substrate for calcineurin. NFAT(p) immunoprecipitated from P-32-labeled HT-2 cells migrated as an approximately 120-kDa protein that was localized to the cytosol of the cells. Treatment of the cells with ionomycin resulted in a decrease in the molecular weight of NFAT(p) and a loss of P-32, consistent with NFAT(p) dephosphorylation. The dephosphorylation of NFAT(p) was accompanied by localization of the protein to the nuclear fraction. Both of these events were blocked by preincubation of the cells with FK506, a calcineurin inhibitor, consistent with the hypothesis that NFAT(p) is a calcineurin substrate in cells.	UPJOHN CO,DEPT CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001	Pfizer								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HO AM, 1994, J BIOL CHEM, V269, P28181; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KING MM, 1984, J BIOL CHEM, V259, P8080; LI X, 1995, CYTOGENET CELL GENET, V68, P185, DOI 10.1159/000133910; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421	26	110	114	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22602	22607		10.1074/jbc.270.38.22602	http://dx.doi.org/10.1074/jbc.270.38.22602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545680	hybrid			2022-12-25	WOS:A1995RW31400083
J	VUORI, K; RUOSLAHTI, E				VUORI, K; RUOSLAHTI, E			TYROSINE PHOSPHORYLATION OF P130(CAS) AND CORTACTIN ACCOMPANIES INTEGRIN-MEDIATED CELL-ADHESION TO EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; FOCAL ADHESIONS; FIBRONECTIN RECEPTOR; 3T3 CELLS; KINASE; PAXILLIN; BINDING; TRANSFORMATION; IDENTIFICATION; CYTOSKELETON	We show in this report that two v-src substrate proteins, p130(Cas) and cortactin, become tyrosine-phosphoryIated during integrin-mediated cell adhesion to extracellular matrix substrata and upon cell attachment onto immobilized anti-integrin antibodies. This tyrosine phosphorylation does not occur when cells attach to polylysine or through antibodies against major histocompatibility complex. It also does not take place when adhesion-mediated reorganization of the actin cytoskeleton is inhibited with cytochalasin D. Tyrosine phosphorylation of p130(Cas) and cortactin coincides with tyrosine phosphorylation of focal adhesion kinase during integrin-mediated cell adhesion but is independent of cell adhesion in v-src-transformed cells. The tyrosine-phosphorylated sites in p130(Cas) and cortactin may serve as binding sites for proteins containing Src homology 2 domains, as is the case with two other integrin-regulated docking proteins, focal adhesion kinase and paxillin. Thus, these results suggest that ligand binding of integrins regulates the tyrosine phosphorylation state of multiple docking proteins, These proteins may mediate anchorage dependence of growth; their misregulation in v-src-transformed and other tumorigenic cells may be responsible for the anchorage independence of such cells.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA 28896, CA 62042, CA 67224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, R01CA062042, R01CA067224] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PATCH LA, 1995, J CELL SCI, V108, P1371; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VUORI K, 1993, J BIOL CHEM, V268, P21459; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	47	270	270	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22259	22262		10.1074/jbc.270.38.22259	http://dx.doi.org/10.1074/jbc.270.38.22259			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545676	hybrid			2022-12-25	WOS:A1995RW31400032
J	THALL, AD; MALY, P; LOWE, JB				THALL, AD; MALY, P; LOWE, JB			OOCYTE GAL-ALPHA-1,3GAL EPITOPES IMPLICATED IN SPERM ADHESION TO THE ZONA-PELLUCIDA GLYCOPROTEIN ZP3 ARE NOT REQUIRED FOR FERTILIZATION IN THE MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTI-GAL ANTIBODY; O-LINKED OLIGOSACCHARIDES; ALPHA-GALACTOSYL EPITOPES; RECEPTOR ACTIVITY; ALPHA-1,3-GALACTOSYLTRANSFERASE; IDENTIFICATION; EXPRESSION; SEQUENCE; LOCUS; CELLS	The Gal alpha 1-->3Gal structure is displayed on the zona pellucida glycoprotein ZP3 on murine oocytes, This trisaccharide has been implicated in sperm-zona pellucida adhesive events thought to be essential to fertilization in the mouse. To determine directly if this molecule is required for fertilization, we have generated mice that are deficient in a gene (alpha 1,3GT) encoding the UDP-Gal:beta-D-Gal-alpha 1-->3Ga-galactosyltransferase enzyme responsible for Gal alpha 1-->3Gal synthesis and expression, These mice develop normally and exhibit no gross phenotypic abnormalities. The Gal alpha 1-3Gal epitope is absent from the vascular endothelium and other tissues in alpha 1,3GT (-/-) adult mice. By contrast, alpha 1,3GT (-/-) mice, like humans, develop naturally occurring anti-alpha-galactoside antibodies normally absent in wild type mice, Female alpha 1,3GT (-/-) mice yield oocytes that are devoid of the Ga alpha 1-->3Gal epitope; however, these mice are fully fertile, These observations indicate that the Gal alpha 1-->3Gal moiety is not essential to sperm-oocyte interactions leading to fertilization or to essentially normal development, They further suggest that alpha 1,3GT (-/-) mice will find utility for exploring approaches to diminish anti-Gal-dependent hyperacute xenograft rejection, which presents a major barrier to the use of porcine and other non-primate organs for xenotransplantation in humans.	HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute	THALL, AD (corresponding author), UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA.		Malý, Petr/H-5962-2014	Malý, Petr/0000-0001-8118-0581				ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BRADLEY A, 1989, TERATOCARCINOMAS EMB, P113; BRONSON SK, 1994, J BIOL CHEM, V269, P27155; COOPER DKC, 1994, IMMUNOL REV, V141, P31, DOI 10.1111/j.1600-065X.1994.tb00871.x; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCCURRY KR, 1995, TRANSPLANTATION, V59, P1177, DOI 10.1097/00007890-199504270-00017; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SUZUKI E, 1984, J BIOCHEM-TOKYO, V95, P103, DOI 10.1093/oxfordjournals.jbchem.a134571; THALL A, 1990, BIOCHEMISTRY-US, V29, P3959, DOI 10.1021/bi00468a024; THOMAS FT, 1991, XENOTRANSPLANTATION, P139; WASSARMAN PM, 1992, BIOL REPROD, V46, P186, DOI 10.1095/biolreprod46.2.186; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WASSARMAN PM, 1995, CURR TOP DEV BIOL, V30, P1, DOI 10.1016/S0070-2153(08)60562-1; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8; YE Y, 1994, TRANSPLANTATION, V58, P330, DOI 10.1097/00007890-199408000-00014	34	316	327	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21437	21440		10.1074/jbc.270.37.21437	http://dx.doi.org/10.1074/jbc.270.37.21437			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545161	hybrid			2022-12-25	WOS:A1995RU75700003
J	KALLUNKI, P; JENKINSON, S; EDELMAN, GM; JONES, FS				KALLUNKI, P; JENKINSON, S; EDELMAN, GM; JONES, FS			SILENCER ELEMENTS MODULATE THE EXPRESSION OF THE GENE FOR THE NEURON-GLIA CELL-ADHESION MOLECULE, NG-CAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; NERVOUS-SYSTEM; BINDING PROTEINS; PROMOTER ACTIVITY; PAIRED DOMAIN; NR-CAM; SEQUENCE; MEMBER; DNA; TRANSCRIPTION	The combined factors that regulate the expression of cell adhesion molecules (CAMs) during development of the nervous system are largely unknown. To identify such factors for Ng-CAM, the neuron-glia CAM, constructs containing portions of the 5' end of the Ng-CAM gene were examined for activity after transfection into N2A neuroblastoma and NIH3T3 cells. Positive regulatory elements active in both cell types included an Ng-CAM proximal promoter with SP1 and cAMP response element motifs extending 447 base pairs upstream of a single RNA start site and a region within the first exon corresponding to 5'-untranslated sequences, Negative regulatory elements included five neuron-restrictive silencer elements (NRSEs) and a binding site for Pax gene products in a 305-base pair segment of the first intron, Constructs containing the promoter together with the entire first intron were active in N2A cells but were silenced in NIH3T3 cells, This silencer activity was mapped to the NRSEs, In contrast, the Pax motif inhibited activity of Ng-CAM constructs in both cell types, The DNA elements defined in these transfection experiments were examined for their ability to bind nuclear factors. The region within the first exon formed a DNA-protein complex after exposure to nuclear extracts prepared from both NIH3T3 and N2A cells. The NRSE region formed a more prominent complex with proteins prepared from NIH3T3 cells than it did with extracts from N2A cells, A member of the Pax protein family, Pax-3 bound to the Pax motif. Mutations introduced within the Pax motif in its ATTA sequence eliminated this binding whereas mutations in its GTTCC sequence did not, suggesting that paired homeodomain interactions are important for the recognition of Pax-3 by this DNA target sequence, The combined data suggest that negative regulation by NRSEs and Pax proteins may play a key role in the place-dependent expression patterns of Ng-CAM during development.			KALLUNKI, P (corresponding author), SCRIPPS RES INST, DEPT NEUROBIOL, LA JOLLA, CA 92037 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009635, R37HD009635] Funding Source: NIH RePORTER; NICHD NIH HHS [HD09635] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM, 1989, CURRENT PROTOCOL MOL; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V90, P532; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DANILOFF JK, 1986, J NEUROSCI, V6, P739; DANILOFF JK, 1986, J CELL BIOL, V103, P929, DOI 10.1083/jcb.103.3.929; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1987, IMMUNOL REV, V100, P11, DOI 10.1111/j.1600-065X.1987.tb00526.x; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GOOMER RS, 1994, P NATL ACAD SCI USA, V91, P7985, DOI 10.1073/pnas.91.17.7985; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; GRUMET M, 1984, J CELL BIOL, V98, P1746, DOI 10.1083/jcb.98.5.1746; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOLST BD, 1994, J BIOL CHEM, V269, P22245; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; KOHL A, 1992, J NEUROSCI RES, V32, P167, DOI 10.1002/jnr.490320206; LANS MS, 1994, J BIOL CHEM, V269, P14170; Maniatis T, 1989, MOL CLONING; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOASE CE, 1991, DEVELOPMENT, V113, P1049; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINCE JT, 1989, J NEUROSCI, V9, P876; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THIERY JP, 1985, J CELL BIOL, V100, P442, DOI 10.1083/jcb.100.2.442; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	52	76	77	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21291	21298		10.1074/jbc.270.36.21291	http://dx.doi.org/10.1074/jbc.270.36.21291			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545667	hybrid			2022-12-25	WOS:A1995RU05400065
J	PEACH, RJ; BAJORATH, J; NAEMURA, J; LEYTZE, G; GREENE, J; ARUFFO, A; LINSLEY, PS				PEACH, RJ; BAJORATH, J; NAEMURA, J; LEYTZE, G; GREENE, J; ARUFFO, A; LINSLEY, PS			BOTH EXTRACELLULAR IMMUNOGLOBIN-LIKE DOMAINS OF CD80 CONTAIN RESIDUES CRITICAL FOR BINDING T-CELL SURFACE-RECEPTORS CTLA-4 AND CD28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION ANTIGEN B7; INTERLEUKIN-2 PRODUCTION; COUNTER-RECEPTOR; LYMPHOCYTES-T; PROLIFERATION; EXPRESSION; SUPERFAMILY; INDUCTION; CLONING; B7/BB1	The B7-related molecules CD80 and CD86 are expressed on antigen-presenting cells, bind the homologous T cell receptors CD28 and CTLA-4, and trigger costimulatory signals important for optimal T cell activation. All four molecules are immunoglobulin superfamily members, each comprising an extracellular Ig variable-like (IgV) domain, with CD80 and CD86 containing an additional Ig constant-like (IgC) domain. Despite limited sequence identity, CD80 and CD86 share similar overall receptor binding properties and effector functions. We have identified, by site-directed mutagenesis of soluble forms of CD80 and CD86, residues in both the IgV and IgC domains that are important for CTLA4Ig and CD28Ig binding. Mutagenesis in the IgV domain of CD80 identified 11 amino acids that support receptor binding. Many of these residues are conserved in the B7 family, are hydrophobic, and approximately map to the GFCC'C'' beta-sheet face of an IgV fold. Mutagenesis of corresponding residues in CD86 established that some, but not all, of these residues also played a role in CD86 receptor binding. In general, mutations had a similar effect on CTLA4Ig and CD28Ig binding, thereby indicating that both receptors bind to overlapping sites on CD80 and CD86. Further, mutagenesis of several conserved residues in the ABED beta-sheet face of the IgC domain of CD80 completely ablated receptor binding. Point mutagenesis had a more pronounced effect than complete truncation of the IgC domain. Thus, full CTLA4Ig and CD28Ig binding to B7 molecules is dependent upon residues in the GFC'C'' face of the IgV domain and the ABED face of the IgC domain.			PEACH, RJ (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, 3005 1ST AVE, SEATTLE, WA 98121 USA.		Bajorath, Jürgen/F-7493-2014					ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BAJORATH J, 1993, PROTEIN SCI, V2, P1798, DOI 10.1002/pro.5560021103; BAJORATH J, 1994, PROTEIN SCI, V3, P2148, DOI 10.1002/pro.5560031128; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOBE M, 1994, BIOCHEM BIOPH RES CO, V200, P443, DOI 10.1006/bbrc.1994.1469; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; LINSLEY PS, 1994, PROTEIN SCI, V3, P1341, DOI 10.1002/pro.5560030820; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELVAKUMAR A, 1992, IMMUNOGENETICS, V36, P175, DOI 10.1007/BF00661094; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	33	114	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21181	21187		10.1074/jbc.270.36.21181	http://dx.doi.org/10.1074/jbc.270.36.21181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545666	hybrid			2022-12-25	WOS:A1995RU05400050
J	TZFATI, Y; ABELIOVICH, H; AVRAHAMI, D; SHLOMAI, J				TZFATI, Y; ABELIOVICH, H; AVRAHAMI, D; SHLOMAI, J			UNIVERSAL MINICIRCLE SEQUENCE BINDING-PROTEIN, A CCHC-TYPE ZINC-FINGER PROTEIN THAT BINDS THE UNIVERSAL MINICIRCLE SEQUENCE OF TRYPANOSOMATIDS - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA MINICIRCLES; POLYACRYLAMIDE-GEL ELECTROPHORESIS; IMMUNODEFICIENCY-VIRUS TYPE-1; CRITHIDIA-FASCICULATA; TELOMERIC DNA; NUCLEOCAPSID PROTEIN; NUCLEOTIDE-SEQUENCE; VARIABLE REGION; NUCLEIC-ACIDS; REPLICATION	Replication of kinetoplast DNA minicircles of trypanosomatids initiates at a conserved 12-nucleotide sequence, termed the universal minicircle sequence (UMS, 5'-GGGGTTGGTGTA-3'). A single-stranded nucleic acid binding protein that binds specifically to this origin-associated sequence was purified to apparent homogeneity from Crithidia fasciculata cell extracts. This UMS-binding protein (UMSBP) is a dimer of 27.4 kDa with a 13.7-kDa protomer. UMSBP binds single-stranded DNA as well as single-stranded RNA but not double-stranded or four-stranded DNA structures. Stoichiometry analysis indicates the binding of UMSBP as a protein dimer to the UMS site. The five CCHC-type zinc finger motifs of UMSBP, predicted from its cDNA sequence, are similar to the CCHC motifs found in retroviral Gag polyproteins. The remarkable conservation of this motif in a family of proteins found in eukaryotic organisms from yeast and protozoa to mammals is discussed.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PARASITOL,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem				Tzfati, Yehuda/0000-0001-7720-435X				ABELIOVICH H, 1993, MOL CELL BIOL, V13, P7766, DOI 10.1128/MCB.13.12.7766; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANN JR, 1989, J BIOL CHEM, V264, P17032; ENGLUND PT, 1979, J BIOL CHEM, V254, P4895; ENGLUND PT, 1987, CELL, V14, P157; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GUO Q, 1993, BIOCHEMISTRY-US, V32, P3596, DOI 10.1021/bi00065a010; HAMMONDKOSACK MCU, 1993, J MOL ENDOCRINOL, V10, P121, DOI 10.1677/jme.0.0100121; HAOPENG X, 1992, MOL BIOL CELL, V3, P721; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; KITCHIN PA, 1984, J BIOL CHEM, V259, P5532; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; NTAMBI JM, 1985, J BIOL CHEM, V260, P5574; NTAMBI JM, 1986, J BIOL CHEM, V261, P1890; OMICHINSKI JG, 1991, FEBS LETT, V292, P25, DOI 10.1016/0014-5793(91)80825-N; PEREZMORGA D, 1993, J CELL BIOL, V123, P1069, DOI 10.1083/jcb.123.5.1069; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RICHARDSON CC, 1964, J BIOL CHEM, V239, P222; RYAN KA, 1989, J BIOL CHEM, V264, P823; RYAN KA, 1988, P NATL ACAD SCI USA, V85, P5844, DOI 10.1073/pnas.85.16.5844; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P334; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHELINE C, 1989, MOL BIOCHEM PARASIT, V37, P151, DOI 10.1016/0166-6851(89)90147-3; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; SHLOMAI J, 1986, J BIOL CHEM, V261, P6219; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SLOOF P, 1992, MOL BIOCHEM PARASIT, V56, P289, DOI 10.1016/0166-6851(92)90178-M; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TAYLOR FM, 1993, NUCLEIC ACIDS RES, V21, P4610, DOI 10.1093/nar/21.19.4610; TZFATI Y, 1992, P NATL ACAD SCI USA, V89, P6891, DOI 10.1073/pnas.89.15.6891; WALSH K, 1992, J BIOL CHEM, V267, P13714; WEBB JR, 1993, J BIOL CHEM, V268, P13994; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	53	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21339	21345		10.1074/jbc.270.36.21339	http://dx.doi.org/10.1074/jbc.270.36.21339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545668	hybrid			2022-12-25	WOS:A1995RU05400072
J	LAVAU, C; MARCHIO, A; FAGIOLI, M; JANSEN, J; FALINI, B; LEBON, P; GROSVELD, F; PANDOLFI, PP; PELICCI, PG; DEJEAN, A				LAVAU, C; MARCHIO, A; FAGIOLI, M; JANSEN, J; FALINI, B; LEBON, P; GROSVELD, F; PANDOLFI, PP; PELICCI, PG; DEJEAN, A			THE ACUTE PROMYELOCYTIC LEUKEMIA-ASSOCIATED PML GENE IS INDUCED BY INTERFERON	ONCOGENE			English	Article						ACUTE PROMYELOCYTIC LEUKEMIA; T(15-17) TRANSLOCATION; PML-RAR-ALPHA; NUCLEAR BODIES; INTERFERON	PRIMARY BILIARY-CIRRHOSIS; TRANS RETINOIC ACID; T(15-17) TRANSLOCATION; MONOCLONAL-ANTIBODY; NUCLEAR-BODIES; LEUKEMIA FUSES; RAR-ALPHA; EXPRESSION; RECEPTOR; CELLS	The PML protein concentrates within discrete nuclear structures known as nuclear bodies, also called NDs or PODs, which contain several proteins including the interferon (IFN)-inducible SP100 product, The function of these structures remains elusive, We and others have shown recently that they represent specific targets for adenovirus and herpes simplex virus. This prompted us to investigate whether PML, like SP100, might be induced by IFN and to explore the role of PML in viral infection, Here we report that PML mRNA levels increase rapidly in response to interferon treatment, This accumulation of. PML transcripts is a primary IFN response since it does not require de novo protein synthesis, The IFN-induced activation of the PML gene is accompanied by enhanced protein expression as revealed by immunolabelling, Both the intensity of the staining and the number of labelled structures increased upon interferon exposure, To probe the role of PML in IFN action, we compared the antiviral state established by alpha-interferon in embryonic fibroblasts (EFs) derived from null mutant mice for PML and from wild-type control mice, The resistance to viral infection conferred by IFN-alpha was identical in both PML(+/+) and PML(m/m) fibroblasts indicating that PML is not an essential mediator of the antiviral effect of interferon, We also noted that DNA-binding factors are normally activated by IFN in PML(m/m) cells.	UNIV PERUGIA,POLICLIN PERUGIA,IST CLIN MED 1,I-06100 PERUGIA,ITALY; HOP ST VINCENT DE PAUL,SERV BACTERIOL VIROL,F-75674 PARIS 14,FRANCE; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY	University of Perugia; Azienda Ospedaliera di Perugia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; MRC National Institute for Medical Research; Imperial College London; IRCCS European Institute of Oncology (IEO)	LAVAU, C (corresponding author), INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,INSERM,U163,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Dejean, Anne/L-5145-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Lavau, Catherine/Q-2928-2019; Jansen, J.H./H-8054-2014	Jansen, J.H./0000-0001-9459-568X; Lavau, Catherine/0000-0003-4800-1320; FALINI, Brunangelo/0000-0002-7198-5965				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOUTEILLE M, 1974, CELL NUCLEUS, P5; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BREITMAN TR, 1981, BLOOD, V57, P1000; CARVALHO T, 1995, IN PRESS J CELL BIOL; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HORISBERGER MA, 1987, J GEN VIROL, V68, P945, DOI 10.1099/0022-1317-68-3-945; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JANSEN JH, 1995, IN PRESS P NATL ACAD; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PADYKULA HA, 1981, CELL NUCLEUS, V9, P309; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERRIS B, 1995, CANCER RES, V55, P1590; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170	51	224	226	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					871	878						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545807				2022-12-25	WOS:A1995RU79800007
J	LAU, LF; HUGANIR, RL				LAU, LF; HUGANIR, RL			DIFFERENTIAL TYROSINE PHOSPHORYLATION OF N-METHYL-D-ASPARTATE RECEPTOR SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; LONG-TERM POTENTIATION; SRC GENE-PRODUCT; NMDA RECEPTOR; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; GLUTAMATE-RECEPTOR; MOLECULAR-CLONING; PROTEIN; KINASE	Protein-tyrosine phosphorylation has recently been suggested to play an important role in synaptic transmission at the neuromuscular junction. The role of tyrosine phosphorylation in the modulation of synaptic function in the central nervous system, however, is not clear. In this study, immunocytochemical staining with an anti-phosphotyrosine antibody demonstrates that there are high levels of phosphotyrosine, which co localizes with glutamate receptors at excitatory synapses on cultured hippocampal neurons. In addition, the tyrosine phosphorylation of various subtypes of glutamate receptors were examined using subunit-specific antibodies. Glutamate receptors are the major excitatory neurotransmitter receptors in the central nervous system and are classified into three major classes: alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionate, kainate, and N-methyl-D-aspartate (NMDA) receptors, based on their electrophysiological and pharmacological properties. NMDA receptors play a central role in synaptic plasticity, synaptogenesis, and excitotoxicity and are thought to be heteromeric complexes of the two types of subunits: NR1 and NR2(A-D) subunits. Immunoaffinity chromatography of detergent extracts of rat synaptic plasma membranes on anti-phosphotyrosine antibody-agarose showed that the NR2A and NR2B subunits but not the NR1 subunit are tyrosine-phosphorylated. Conversely, immunoprecipitation of the NR1, NR2A, and NR2B subunits with subunit specific antibodies followed by immunoblotting with anti-phosphotyrosine antibodies confirmed that the NR2A and NR2B subunits but not the NR1 subunit were phosphorylated on tyrosine residues. No tyrosine phosphorylation of the AMPA (GluR1-4) and kainate (GluR6/7, KA2) receptor subunits was detected. It was estimated that 2.1 +/- 1.3% of the NR2A subunits and 3.6 +/- 2.4% of the NR2B subunits mere tyrosine-phosphorylated in vivo. In addition, endogenous protein-tyrosine kinases in synaptic plasma membranes phosphorylated the NR2A subunit in vitro, increasing its phosphorylation 6-8-foId but did not phosphorylate NR1 or NR2B. These studies demonstrate that NMDA receptor subunits are differentially tyrosine-phosphorylated and suggest that tyrosine phosphorylation of the NR2 subunits may be important for regulating NMDA receptor function.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROSE N, 1993, J BIOL CHEM, V268, P22663; COOKE M P, 1989, New Biologist, V1, P66; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; FAUNDEZ V, 1992, J BIOL CHEM, V267, P20363; Goslin K., 1991, CULTURING NERVE CELL, P251; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GURD JW, 1985, BRAIN RES, V333, P385, DOI 10.1016/0006-8993(85)91599-9; HANISSIAN SH, 1992, J NEUROSCI RES, V32, P576, DOI 10.1002/jnr.490320413; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; Huganir R L, 1991, Adv Exp Med Biol, V287, P279; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; QU Z, 1994, J NEUROSCI, V14, P6834; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; ROCHE KW, 1995, IN PRESS NEUROSCIENC; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WAGNER K, 1991, J BIOL CHEM, V266, P23784; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; WALLACE BG, 1991, PHILOS T ROY SOC B, V331, P273, DOI 10.1098/rstb.1991.0016; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0	40	247	255	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20036	20041		10.1074/jbc.270.34.20036	http://dx.doi.org/10.1074/jbc.270.34.20036			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544350	hybrid			2022-12-25	WOS:A1995RQ99100055
J	SAKAI, I; NABELL, L; KRAFT, AS				SAKAI, I; NABELL, L; KRAFT, AS			SIGNAL-TRANSDUCTION BY A CD16/CD7/JAK2 FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; EPIDERMAL GROWTH-FACTOR; GM-CSF RECEPTOR; TYROSINE PHOSPHORYLATION; FUNCTIONAL RECEPTORS; HEMATOPOIETIC-CELLS; MULTIPLE CYTOKINES; BETA-SUBUNIT; GENE FAMILY; INTERLEUKIN-3	The addition of interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to hormone-dependent cells induces tyrosine phosphorylation of Janus protein kinase 2 (Jak2) and activates its in vitro kinase activity. To explore the role of Jak2 in IL-3/GM-CSF-mediated signal transduction, we constructed a CD16/CD7/Jak2 (CD16/Jak2) fusion gene containing the external domain of CD16 and the entire Jak2 molecule and expressed this fusion protein using a recombinant vaccinia virus. The clustering of CD16/Jak2 fusion protein by cross-linking with an anti-CD16 antibody induced autophosphorylation of the fusion protein but did not induce the phosphorylation of either the endogenous Jak2 or the beta chain. Cross-linking of CD16/Jak2 stimulates the tyrosine phosphorylation of a large group of proteins that are also phosphorylated after the addition of IL-3 or GM-CSF and include proteins of 145, 97, 67, 52, and 42 kDa. Closer analysis demonstrated that the CD16/Jak2 phosphorylates Shc, a 52-kDa protein, and the 145-kDa protein associated tightly with Shc, as well as mitogen-associated protein kinase (pp42). Electrophoretic mobility shift assays demonstrate that CD16/Jak2 activates the ability of signal transduction and activation of transcription (STAT) proteins to bind to an inferon-gamma-activated sequence oligonucleotide in a manner similar to that seen after IL-3 treatment. Cross-linking of the CD16/Jak2 protein stimulated increases in c-fos and junB similar to IL-3 but did not cause major changes in the levels of the c-myc message, which normally increases after IL-3 treatment, Thus, a transmembrane CD16/Jak2 fusion is capable of activating protein phosphorylation and mRNA transcription in a manner similar but not identical to hematopoietic growth factors.	UNIV ALABAMA, DEPT MED, DIV HEMATOL ONCOL, BIRMINGHAM, AL 35233 USA	University of Alabama System; University of Alabama Birmingham					NIDDK NIH HHS [DK48882, DK44741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741, R01DK048882] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALAI M, 1992, J BIOL CHEM, V267, P18021; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DURONIO V, 1992, J BIOL CHEM, V267, P21856; EARL PL, 1991, CURR PROTOCOLS MOL S, V15; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HE TC, 1994, J BIOL CHEM, V269, P18291; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LAMB P, 1994, BLOOD, V83, P2063; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MIURA Y, 1994, J BIOL CHEM, V269, P29962; OKUDA K, 1992, BLOOD, V79, P2880; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TORIGOE T, 1992, BLOOD, V80, P617; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHU XY, 1994, J BIOL CHEM, V269, P5518	50	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18420	18427		10.1074/jbc.270.31.18420	http://dx.doi.org/10.1074/jbc.270.31.18420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7543102	hybrid			2022-12-25	WOS:A1995RM64200044
J	GERBER, NC; DEMONTELLANO, PRO				GERBER, NC; DEMONTELLANO, PRO			NEURONAL NITRIC-OXIDE SYNTHASE - EXPRESSION IN ESCHERICHIA-COLI, IRREVERSIBLE INHIBITION BY PHENYLDIAZENE, AND ACTIVE-SITE TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; HEME; PHENYLHYDRAZINE; MACROPHAGE; BRAIN; HEMOPROTEIN; MECHANISM; REARRANGEMENT; INACTIVATION	A gene coding for rat neuronal nitric oxide synthase (nNOS) has been cloned into pCWori and the vector has been expressed in Escherichia coli. The expressed enzyme has been purified with a final yield of purified protein of approximately 1 mg/g of wet cells, The recombinant protein reconstituted with calmodulin and Ca2+ exhibits spectroscopic and catalytic properties identical to those reported in the literature for nNOS. Reaction of recombinant nNOS with phenyldiazene produces a phenyl-iron (Fe . Ph) complex with a maximum at 470 nm. Formation of this complex is paralleled by inactivation of the enzyme and is inhibited by arginine, the natural substrate of the enzyme. Phenyl iron complex formation does not alter the rate of electron transfer from the flavin domain to cytochrome c. Addition of ferricyanide triggers migration of the phenyl residue from the iron to the porphyrin nitrogens. The N-phenylprotoporphyrin isomers with the phenyl on the nitrogens of pyrrole rings B, A, C, and D are formed in, respectively, approximately a 14:20:21:45 ratio. The regioisomer pattern indicates that the active site of NOS is open to some extent above all four pyrrole rings but more so above pyrrole ring D. Arylhydrazines are thus not only a new class of inhibitors of nNOS but provide useful information on the active site topology of the enzyme.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARLES IG, 1993, BIOCHEM BIOPH RES CO, V196, P1481, DOI 10.1006/bbrc.1993.2419; CHEN PF, 1994, J BIOL CHEM, V269, P25062; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1995, IN PRESS BIOCHIMIE P; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; FRUETEL JA, 1994, J BIOL CHEM, V269, P28815; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LIU JW, 1994, J BIOL CHEM, V269, P11691; MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; PALACIOS M, 1993, BIOCHEM BIOPH RES CO, V196, P280, DOI 10.1006/bbrc.1993.2246; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SAMOKYSZYN VM, 1991, BIOCHEMISTRY-US, V30, P11646, DOI 10.1021/bi00114a006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; TUCK SF, 1992, J BIOL CHEM, V267, P13175; TUCK SF, 1993, J BIOL CHEM, V268, P269; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	52	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17791	17796		10.1074/jbc.270.30.17791	http://dx.doi.org/10.1074/jbc.270.30.17791			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543092	hybrid			2022-12-25	WOS:A1995RM26600027
J	BEURON, F; LECAHEREC, F; GUILLAM, MT; CAVALIER, A; GARRET, A; TASSAN, JP; DELAMARCHE, C; SCHULTZ, P; MALLOUH, V; ROLLAND, JP; HUBERT, JF; GOURANTON, J; THOMAS, D				BEURON, F; LECAHEREC, F; GUILLAM, MT; CAVALIER, A; GARRET, A; TASSAN, JP; DELAMARCHE, C; SCHULTZ, P; MALLOUH, V; ROLLAND, JP; HUBERT, JF; GOURANTON, J; THOMAS, D			STRUCTURAL-ANALYSIS OF AT MIP FAMILY PROTEIN FROM THE DIGESTIVE-TRACT OF CICADELLA-VIRIDIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; MAJOR INTRINSIC PROTEIN; WATER-SHUNTING COMPLEX; XENOPUS-OOCYTES; CHANNEL; PURIFICATION; EXPRESSION; CLONING; SYSTEM; CDNA	Homopteran insects, and especially Cicadella viridis, display in their digestive tract a specialized epithelial differentiation, the filter chamber (FC) acting as a water-shunting complex. The main intrinsic membrane protein of the FC is a 25,000 Da polypeptide (P25). In this paper we demonstrate that this P25 polypeptide is a member of the MIP family of membrane channel proteins, and that P25 forms homotetramers in the native membranes. Using polymerase chain reaction, a 360-base pair cDNA, named cic, was isolated from RNA of the FC. cic encodes a 119-amino acid polypeptide (CIC) whose homologies with MIP26, AQP1 (CHIP), AQP2, and gamma-TIP are 38, 38, 34, and 20%, respectively. Using a specific antibody raised against a 15-amino acid peptide from the CIC sequence, we concluded that CIC and P25 are identical entities, and hence that P25 belongs to the MIP family. We investigated the quaternary structure of P25 in the membranes of the FC using biophysical analysis of P25 nondenaturing detergent micelles, scanning transmission electron microscopy, and image processing of conventional transmission electron microscopic images. All those different approaches converged to the conclusion that P25 exists as an homotetramer forming a regular two dimensional array in the membranes.	UNIV RENNES 1, BIOCHIM CELLULAIRE LAB, CNRS, U256, F-35042 RENNES, FRANCE; UNIV RENNES 1, BIOL & GENET DEV LAB, CNRS, U256, F-35042 RENNES, FRANCE; IGBMC, F-67400 ILLKIRCH GRAFFENSTADEN, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm)			DELAMARCHE, Christian/A-2138-2010; THOMAS, Danniel/AAJ-5033-2020	DELAMARCHE, Christian/0000-0002-8963-0062; THOMAS, Danniel/0000-0002-9650-0434; schultz, patrick/0000-0002-7310-6186				AERTS T, 1990, J BIOL CHEM, V265, P8675; AGRE P, 1993, AM J PHYSIOL, V265, pF463; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; CLARKE S, 1975, J BIOL CHEM, V250, P5459; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Finkelstein A., 1987, WATER MOVEMENT LIPID; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GOURANTON J, 1968, J MICROSC-PARIS, V7, P559; GUILLAM MT, 1992, EXP CELL RES, V200, P301, DOI 10.1016/0014-4827(92)90176-9; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Helenius A, 1979, Methods Enzymol, V56, P734; HJELMELAND LM, 1984, METHOD ENZYMOL, V104, P305; HOMO JC, 1980, ELECTRON MICROS, V1, P92; HUBERT JF, 1989, BIOL CELL, V66, P155, DOI 10.1016/0248-4900(89)90165-2; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JERICEVIC Z, 1989, METHOD CELL BIOL, V30, P47; JUNG JS, 1994, J BIOL CHEM, V269, P14648; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA TH, 1994, J BIOL CHEM, V269, P21845; MARCHESI SL, 1970, BIOCHEMISTRY-US, V9, P50, DOI 10.1021/bi00803a007; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SAXTON WO, 1980, ELECTRON MICROS, P245; SMITH BL, 1991, J BIOL CHEM, V266, P6407; UNWIN PNT, 1974, J MOL BIOL, V87, P641, DOI 10.1016/0022-2836(74)90075-8; VERBAVATZ JM, 1994, J CELL SCI, V107, P1083; WALZ T, 1994, J BIOL CHEM, V269, P1583; WALZ T, 1994, EMBO J, V13, P2985, DOI 10.1002/j.1460-2075.1994.tb06597.x; ZAMPIGHI G, 1982, J CELL BIOL, V93, P175, DOI 10.1083/jcb.93.1.175; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468; [No title captured]	44	66	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17414	17422		10.1074/jbc.270.29.17414	http://dx.doi.org/10.1074/jbc.270.29.17414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542238	hybrid			2022-12-25	WOS:A1995RK68900059
J	MUTHUSWAMY, SK; MULLER, WJ				MUTHUSWAMY, SK; MULLER, WJ			DIRECT AND SPECIFIC INTERACTION OF C-SRC WITH NEU IS INVOLVED IN SIGNALING BY THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article						NEU; EGFR; C-SRC; SH2; RECEPTOR SIGNALING	TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; AUTOPHOSPHORYLATION SITES; MITOGENIC RESPONSIVENESS; MAMMARY-TUMORS; BREAST-CANCER; ONCOGENE; FAMILY; PHOSPHORYLATION; PROTEIN	Transgenic mice expressing either the activated or wild type neu oncogene heritably develop metastatic mammary tumors. Tumor development in this transgenic mouse model correlates with activation of the Neu tyrosine kinase. Recently, we have shown that these Neu-induced mammary tumors possess elevated c-Src tyrosine kinase activity. Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. By contrast, the c-Src SH2 domain did not interact directly with tyrosine phosphorylated EGFR. Moreover, in established cell lines expressing elevated levels of EGFR, EGF stimulation results in transphosphorylation of Neu and formation of complexes between c-Src and tyrosine phosphorylated Neu. Taken together, these observations suggest that activation of c-Src by these two closely related EGFR family members results from a direct and specific interaction of c-Src with tyrosine phosphorylated Neu.	MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT BIOL, HAMILTON, ON, CANADA; MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT PATHOL, HAMILTON, ON, CANADA	McMaster University; McMaster University			Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; JANES PW, 1994, ONCOGENE, V9, P3601; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROMANO A, 1994, ONCOGENE, V8, P2105; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1993, CELL, V77, P767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	56	105	109	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					271	279						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542762				2022-12-25	WOS:A1995RK95700008
J	SOMMERS, CL; HUANG, K; SHORES, EW; GRINBERG, A; CHARLICK, DA; KOZAK, CA; LOVE, PE				SOMMERS, CL; HUANG, K; SHORES, EW; GRINBERG, A; CHARLICK, DA; KOZAK, CA; LOVE, PE			MURINE TXK - A PROTEIN-TYROSINE KINASE GENE REGULATED BY T-CELL ACTIVATION	ONCOGENE			English	Article						TXK; PROTEIN TYROSINE KINASE; THYMUS; T LYMPHOCYTES; SIGNAL TRANSDUCTION	X-LINKED AGAMMAGLOBULINEMIA; LYMPHOCYTES-T; ZETA-CHAIN; RECEPTOR; MOUSE; EXPRESSION; IDENTIFICATION; INTERLEUKIN-2; CLONING; FAMILY	To identify genes involved in signal transduction pathways that regulate T cell activation and development, murine fetal thymocytes were screened for expression of protein tyrosine kinase family members by the polymerase chain reaction, Using this approach, a nonreceptor protein tyrosine kinase, txk, was identified and cloned. Txk is expressed in thymocytes as early as fetal day 13.5 and its expression at the mRNA level continues throughout development, Txk transcripts are present in thymocytes, peripheral T cells and mast cell lines, but are not detectable in B cell macrophage/monocyte cell lines or in non-hematopoietic fetal or adult tissues, In both thymocytes and T cells, txk transcripts are down-regulated after activation with PMA and ionomycin, concanavalin A or T cell receptor cross-linking, Sequence analysis indicates that txk contains SH2, SH3 and kinase catalytic domains and belongs to the tec family of cytoplasmic protein tyrosine kinases which includes tec, itk and btk, Its unique N-terminus contains a proline-rich region, but unlike the other dec family members, does not contain a pleckstrin homology domain, The restricted expression pattern of txk and its regulation by T cell activation make it an excellent candidate for involvement in signal transduction during thymocyte development.	NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL PROD, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA)	SOMMERS, CL (corresponding author), NICHHD, MAMMALIAN GENES & DEV LAB,BLDG 6B,ROOM 2B-210, 6 CTR DR, MSC 2780, BETHESDA, MD 20892 USA.							ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BROWN T, 1994, CURRENT PROTOCOLS; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DANCIGER M, 1993, GENOMICS, V16, P361, DOI 10.1006/geno.1993.1198; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GIBSON S, 1993, BLOOD, V82, P1561; GODFREY DI, 1992, J IMMUNOL, V149, P2281; Green EL, 1981, GENETICS PROBABILITY, P77; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK CA, 1994, MAMM GENOME, V5, pS65; LEO O, 1987, J IMMUNOL, V139, P1214; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MANO H, 1994, ONCOGENE, V9, P3205; MANO H, 1993, ONCOGENE, V8, P417; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MILLER J, 1985, J IMMUNOL, V134, P4212; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; PALACIOS R, 1992, DEVELOPMENT, V115, P1133; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SATO K, 1994, LEUKEMIA, V8, P1663; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SMITH CIE, 1994, J IMMUNOL, V152, P557; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VONBOEHMER H, 1992, BONE MARROW TRANSPL, V9, P46; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUNIGAPFLUCKER JC, 1993, J EXP MED, V178, P1139, DOI 10.1084/jem.178.4.1139	52	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					245	251						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542761				2022-12-25	WOS:A1995RK95700005
J	SOMASUNDARAM, B; MAHAUTSMITH, MP				SOMASUNDARAM, B; MAHAUTSMITH, MP			A NOVEL MONOVALENT CATION CHANNEL ACTIVATED BY INOSITOL TRISPHOSPHATE IN THE PLASMA-MEMBRANE OF RAT MEGAKARYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC CA2+ OSCILLATION; CYTOSOLIC FREE NA+; CALCIUM RELEASE; HUMAN PLATELETS; 1,4,5-TRISPHOSPHATE RECEPTOR; CURRENT FLUCTUATIONS; MAST-CELLS; SODIUM; LYMPHOCYTES; SPECIFICITY	The activation of a monovalent cation current was studied in rat megakaryocytes using patch clamp techniques combined with photometric measurements of intracellular concentrations of Ca2+ ([Ca2+](i)) and Na+. ADP evoked a release of [Ca2+](i) and transiently activated a monovalent cation-selective channel, which, at negative potentials and under physiological conditions, would be expected to carry an inward Na+ current. The single channel conductance, estimated by noise analysis from whole cell currents at -50 to -60 mV was 9 picosiemens. Thapsigargin induced [Ca2+](i) increases failed to stimulate the monovalent cation current, suggesting that neither [Ca2+](i) nor the depletion of internal Ca2+ stores were activators of this conductance. However, buffering of [Ca2+](i) changes with 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid showed that both activation and inactivation of the current were accelerated by a rise in [Ca2+](i). The monovalent cation conductance was activated by internal perfusion with inositol 1,4,5-trisphosphate, both in the presence and in the absence of a rise in [Ca2+](i). Internal perfusion with inositol 2,4,5-trisphosphate, the poorly metabolizable isomer of inositol trisphosphate, similarly activated the monovalent cation current, whereas 1,3,4,5-tetrakisphosphate neither activated a current nor modified the ADP-induced monovalent current. Heparin, added to the pipette, blocked activation of the channel by ADP. The intracellular concentration of Na+, monitored by sodium-binding benzofuran isopthalate, increased by 10-20 mM in response to ADP under pseudophysiological conditions. We conclude the existence of a novel nonselective cation channel in the plasma membrane of rat megakaryocytes, which is activated by IP3 and can lead to increases in cytosolic Na+ after stimulation by ADP.			SOMASUNDARAM, B (corresponding author), PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.							AKAIKE N, 1994, NEWS PHYSIOL SCI, V9, P49; ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; BALLA T, 1994, TRENDS ENDOCRIN MET, V5, P250, DOI 10.1016/1043-2760(94)P3084-K; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1988, BIOCHEM J, V256, P697, DOI 10.1042/bj2560697; BORIN M, 1990, J BIOL CHEM, V265, P19543; DART C, 1993, J PHYSIOL-LONDON, V471, P767, DOI 10.1113/jphysiol.1993.sp019927; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEVEN RM, 1983, J CELL BIOL, V96, P1234, DOI 10.1083/jcb.96.5.1234; MAK DOD, 1994, J BIOL CHEM, V269, P29375; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MINTA A, 1989, J BIOL CHEM, V264, P19449; MOZHAYEVA GN, 1991, J MEMBRANE BIOL, V124, P113, DOI 10.1007/BF01870456; OKADA Y, 1994, J NEUROPHYSIOL, V71, P595, DOI 10.1152/jn.1994.71.2.595; PENNINGTON DG, 1981, PLATELETS BIOL PATHO, P20; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; RENGASAMY A, 1988, BIOCHEM BIOPH RES CO, V150, P1021, DOI 10.1016/0006-291X(88)90731-0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SAGE SO, 1991, J PHYSIOL-LONDON, V441, P559, DOI 10.1113/jphysiol.1991.sp018767; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SOMASUNDARAM B, 1994, J PHYSIOL-LONDON, V480, P225, DOI 10.1113/jphysiol.1994.sp020355; STENGL M, 1994, J COMP PHYSIOL A, V174, P187; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; UNEYAMA C, 1993, J PHYSIOL-LONDON, V470, P731, DOI 10.1113/jphysiol.1993.sp019885; UNEYAMA H, 1993, J BIOL CHEM, V268, P168; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X	42	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16638	16644		10.1074/jbc.270.28.16638	http://dx.doi.org/10.1074/jbc.270.28.16638			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542650	hybrid			2022-12-25	WOS:A1995RJ34700030
J	RICHTER, MF; SCHWEMMLE, M; HERRMANN, C; WITTINGHOFER, A; STAEHELI, P				RICHTER, MF; SCHWEMMLE, M; HERRMANN, C; WITTINGHOFER, A; STAEHELI, P			INTERFERON-INDUCED MXA PROTEIN - GTP-BINDING AND GTP HYDROLYSIS PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN GTPASE; NUCLEOTIDE-FREE; DOMAINS; P21; MICROTUBULES; EXPRESSION; KINETICS; SHIBIRE; VIRUS	MxA is a GTPase encoded by an interferon-activated human gene which inhibits the multiplication of several RNA viruses. Recombinant histidine-tagged MxA protein (His-MxA) was expressed in Escherichia coli and purified to near homogeneity. Gel filtration showed that it formed high molecular weight oligomers. Purified His-MxA exhibited specific GTP hydrolysis rates of up to 350 nmol of GTP/min/mg of protein, corresponding to a turnover number of 27 min(-1). The K-m for this reaction was 260 mu M. Guanine nucleotides did not copurify with His-MxA. Binding experiments in solution with fluorescent-labeled nucleotides confirmed that His-MxA binds guanine nucleotides rather weakly and further showed that the fluorescent GDP analog N-methylanthraniloyl (mant)-GDP had a much lower affinity for His-MxA (K-d 20 mu M, k(off) 8.5 s(-1)) than the nonhydrolyzable GTP analog mant-5'-guanylyl-beta,gamma-imidotriphosphate (mant-GMP-PNP) (K-d 0.75 mu M, k(off) 0.012 s(-1)). Competitive binding studies with nonlabeled nucleotides revealed a similar binding preference of His-MxA for GTP over GDP: the K-d for GTP was 20 mu M, whereas the K-d for GDP was 100 mu M. Thus, a high percentage of MxA molecules may be complexed with GTP in vivo.	UNIV FREIBURG,INST MED MIKROBIOL & HYG,DEPT VIROL,VIROL ABT,D-79008 FREIBURG,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,STRUKT BIOL ABT,D-44139 DORTMUND,GERMANY	University of Freiburg; Max Planck Society				Richter, Marc Francois/0000-0002-0868-9127				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRESE M, 1995, IN PRESS J VIROL, V69; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; LANDIS H, 1994, IN PRESS VIROLOGY; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; MELEN K, 1994, J BIOL CHEM, V269, P2009; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCHNEIDERSCHAUL.S, 1994, J VIROL, V68, P6910; SCHNORR JJ, 1993, J VIROL, V67, P4760, DOI 10.1128/JVI.67.8.4760-4768.1993; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P246; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; TROWBRIDGE IS, 1993, CURR BIOL, V3, P773, DOI 10.1016/0960-9822(93)90028-M; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	38	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13512	13517		10.1074/jbc.270.22.13512	http://dx.doi.org/10.1074/jbc.270.22.13512			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539429	hybrid			2022-12-25	WOS:A1995RB43900082
J	SARMA, V; LIN, ZW; CLARK, L; RUST, BM; TEWARI, M; NOELLE, RJ; DIXIT, VM				SARMA, V; LIN, ZW; CLARK, L; RUST, BM; TEWARI, M; NOELLE, RJ; DIXIT, VM			ACTIVATION OF THE B-CELL SURFACE-RECEPTOR CD40 INDUCES A20, A NOVEL ZINC-FINGER PROTEIN THAT INHIBITS APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HYPER-IGM SYNDROME; FACTOR-KAPPA-B; DEFECTIVE EXPRESSION; LIGAND; INDUCTION; SIGNAL; ANTIBODY; MOLECULE; KINASE; GENE	CD40 activation is critical for B-cell function, leading to activation and expression of cell surface markers, proliferation, immunoglobulin class switching and inhibition of programmed cell death (PCD). Germinal center B-cells, for example, can be prevented from undergoing PCD by CD40 activation. The mechanism by which PCD is inhibited has been an enigma. A potential role for A20, a novel zinc finger protein, in inhibiting B-cell apoptosis was suggested by our previous finding that it is induced by the Epstein-Barr virus LMP-1 gene product, a potent cell death inhibitor. We now show that CD40 activation induces A20 and that expression of A20 renders B-cell lines resistant to PCD. Additionally, we show that CD40 activation of A20 expression is mediated by inducible binding of NF-kappa B complexes to the A20 promoter and provide evidence for a critical role for Thr(234) (in the CD40 cytoplasmic domain) in activating NF-kappa B.	DARTMOUTH COLL SCH MED,DEPT MICROBIOL,LEBANON,NH 03756	Dartmouth College	SARMA, V (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE ST,ANN ARBOR,MI 48109, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA61348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BERBERICH I, 1994, J IMMUNOL, V153, P4357; COICO R, 1994, CURRENT PROTOCOLS IM; CONLEY ME, 1994, J CLIN INVEST, V94, P1404, DOI 10.1172/JCI117476; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; SARMA V, 1992, J IMMUNOL, V148, P3302; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UHLER MD, 1987, J BIOL CHEM, V262, P15202; ZHANG K, 1991, J IMMUNOL, V146, P1836	29	180	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12343	12346		10.1074/jbc.270.21.12343	http://dx.doi.org/10.1074/jbc.270.21.12343			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7539000	hybrid			2022-12-25	WOS:A1995QZ71100005
J	BALBOA, MA; BALSINDE, J; DENNIS, EA; INSEL, PA				BALBOA, MA; BALSINDE, J; DENNIS, EA; INSEL, PA			A PHOSPHOLIPASE D-MEDIATED PATHWAY FOR GENERATING DIACYLGLYCEROL IN NUCLEI FROM MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; SWISS 3T3 CELLS; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; D ACTIVATION; LOCALIZATION; STIMULATION; MECHANISMS	Many receptors, in response to their specific ligands, trigger activation of phospholipase D (PLD), resulting in the production of phosphatidic acid which, in turn, is acted upon by a specific phosphatase, phosphatidate phosphohydrolase, to produce diacylglycerol. We report here that isolated nuclei from Madin-Darby canine kidneys (MDCK)-D1 cells exhibit a PLD activity that is enhanced by the presence of ATP. PLD activity was measured in the presence of ethanol, by quantitating the production of phosphatidylethanol. Non-phosphorylating ATP analogs were unable to substitute for ATP in activating PLD, indicating that ATP acts as a phosphoryl group donor in a kinase-mediated phosphorylation reaction. The protein kinase C inhibitors chelerythrine and calphostin completely suppressed the ATP-induced nuclear PLD, implicating protein kinase C as the kinase involved in ATP-dependent PLD activity in nuclei from MDCK-D1 cells. In the absence of ethanol, phosphatidic acid was detected in ATP-treated nuclei. Accumulation of phosphatidic acid preceded or closely paralleled that of diacylglycerol, suggesting a precursor-product relationship. Consistent with those results, we detected phosphatidate phosphohydrolase activity in MDCK-D1 cell nuclei. Measurements of phosphatidic acid and diacylglycerol levels at increasing amounts of ethanol demonstrated that PLD and phosphatidate phosphohydrolase are responsible for generating the majority of the diacylglycerol accumulating in MDCK-D1 cell nuclei. The ability of nuclei to generate diacylglycerol from the concerted action of those two enzymes provides a means to regulate nuclear lipid synthesis as well as protein kinase C activity.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT CHEM & BIOCHEM, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019; Balsinde, Jesús/C-7833-2018; Balboa, María A./V-9493-2018	Dennis, Edward A./0000-0003-3738-3140; Balsinde, Jesús/0000-0002-4157-6714; Balboa, María A./0000-0002-2130-5298	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35018] Funding Source: Medline; NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 31487] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGERT G, 1989, J BIOL CHEM, V264, P21689; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; DAY CP, 1992, BIOCHIM BIOPHYS ACTA, V1127, P87, DOI 10.1016/0005-2760(92)90205-A; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; HUANG CF, 1992, J BIOL CHEM, V267, P16859; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P526, DOI 10.1021/bi00168a018; KENNERLY DA, 1990, J IMMUNOL, V144, P3912; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON SC, 1991, J BIOL CHEM, V266, P17236; WHATMORE J, 1994, FEBS LETT, V352, P113, DOI 10.1016/0014-5793(94)00930-9; YORK JD, 1994, J BIOL CHEM, V269, P7847	22	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11738	11740		10.1074/jbc.270.20.11738	http://dx.doi.org/10.1074/jbc.270.20.11738			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538121	hybrid, Green Submitted			2022-12-25	WOS:A1995QY73600010
J	CARROLL, TP; MORALES, MM; FULMER, SB; ALLEN, SS; FLOTTE, TR; CUTTING, GR; GUGGINO, WB				CARROLL, TP; MORALES, MM; FULMER, SB; ALLEN, SS; FLOTTE, TR; CUTTING, GR; GUGGINO, WB			ALTERNATE TRANSLATION INITIATION CODONS CAN CREATE FUNCTIONAL FORMS OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CL CHANNELS; EXPRESSION; IDENTIFICATION; MUTATIONS; PROMOTER; GENE	To evaluate the function of transmembrane domain 1 (TMD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) and the methionines that function in translation initiation, a series of progressive 5' truncations in TMD1 were created to coincide with residues that might serve as translation initiation codons, Expression of the mutants in Xenopus oocytes demonstrated that internal sites in TMD1 can function as initiation codons, In addition, all of the mutants that progressively removed the first four transmembrane segments (M1-M4) of TMD1 expressed functional cAMP-regulated Cl- channels with ion selectivity identical to wild-type CFTR but with reduced open probability and single channel conductance. Further removal of transmembrane segments did not produce functional Cl- channels, These data suggest that segments M1-M4 are not essential components of the conduction pore or the selectivity filter of CFTR.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL & PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR MED GENET, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122, P01HL051811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK048977] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51811, HL47122] Funding Source: Medline; NIDDK NIH HHS [DK48977] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BIENVENU T, 1994, HUM MOL GENET, V3, P365, DOI 10.1093/hmg/3.2.365; BOAT TF, 1989, ACTA PAEDIATR SCAND, P25; CARROLL TP, 1993, CELL PHYSIOL BIOCHEM, V3, P388, DOI 10.1159/000154700; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; HAMOSH A, 1994, NEW ENGL J MED, V330, P866; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KOH J, 1993, J BIOL CHEM, V268, P15912; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; OBLATTMONTAL M, 1994, P NATL ACAD SCI USA, V91, P1495, DOI 10.1073/pnas.91.4.1495; PIAZZACARROLL T, 1994, CELL PHYSIOL BIOCHEM, V4, P10; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1993, J CELL SCI, P235	30	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11941	11946		10.1074/jbc.270.20.11941	http://dx.doi.org/10.1074/jbc.270.20.11941			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538127	hybrid			2022-12-25	WOS:A1995QY73600042
J	KITCHENS, RL; MUNFORD, RS				KITCHENS, RL; MUNFORD, RS			ENZYMATICALLY DEACYLATED LIPOPOLYSACCHARIDE (LPS) CAN ANTAGONIZE LPS AT MULTIPLE SITES IN THE LPS RECOGNITION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-LINE THP-1; LIPID-A; BINDING-PROTEIN; BACTERIAL LIPOPOLYSACCHARIDE; GENE-EXPRESSION; HUMAN MONOCYTES; SOLUBLE CD14; MODULATION; RECEPTOR	Like other tetraacyl partial structures of lipopolysaccharide (LPS) and lipid A, LPS that has been partially deacylated by acyloxyacyl hydrolase can inhibit LPS-induced responses in human cells, To identify the site(s) of inhibition in the LPS recognition pathway, we analyzed the apparent binding affinities and interactions of H-3-labeIed enzymatically deacylated LPS (dLPS) and [H-3]LPS with CD14, the LPS receptor, on THP-1 cells. Using (i) incubation conditions that prevented ligand internalization and (ii) defined concentrations of LPS binding protein (LBP), which facilitates LPS and dLPS binding to CD14, we found that dLPS can antagonize LPS in at least three ways, 1) When the concentration of LBP in the medium was suboptimal for promoting LPS-CD14 binding, low concentrations of dLPS were able to compete with LPS for binding CD14, suggesting competition between LPS and dLPS for engaging LBP. 2) When LBP was present in excess, dLPS could compete with LPS for binding CD14, but only at dLPS concentrations that were at or above its K-D for binding CD14 (100 ng/ml). 3) In contrast, substoichiometric concentrations of dLPS (1 ng/ml) inhibited LPS-induced (3 ng/ml) interleukin-8 release without blocking LPS binding to CD14. Functional antagonism was possible without competition for cell-surface binding because both LPS-induced interleukin-8 release and dLPS inhibition occurred at concentrations that were far below their respective CD14 binding K-D values. In addition to its expected ability to compete with-LPS far binding LBP and CD14, dLPS thus potently antagonizes LPS at an undiscovered site that is distal to LPS CD14 binding in the LPS recognition pathway.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GRAD PROGRAM IMMUNOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KITCHENS, RL (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018188, R56AI018188, R01AI018188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DALNOGARE AR, 1990, J IMMUNOL, V144, P1404; DUCHOW J, 1993, INFECT IMMUN, V61, P4280, DOI 10.1128/IAI.61.10.4280-4285.1993; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; FEIST W, 1992, FEMS MICROBIOL IMMUN, V89, P73, DOI 10.1016/0378-1097(92)90264-O; FERRERO E, 1990, J IMMUNOL, V145, P331; FLAD HD, 1993, IMMUNOBIOLOGY, V187, P303, DOI 10.1016/S0171-2985(11)80346-3; FLEIT HB, 1991, J LEUKOCYTE BIOL, V49, P556, DOI 10.1002/jlb.49.6.556; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HARAKUGE S, 1990, J BIOL CHEM, V265, P6606; HEINE H, 1994, J ENDOTOXIN RES, V1, P14; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOTANI S, 1985, INFECT IMMUN, V49, P225, DOI 10.1128/IAI.49.1.225-237.1985; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; LYNN WA, 1991, J IMMUNOL, V147, P3072; MANTHEY CL, 1993, INFECT IMMUN, V61, P3518, DOI 10.1128/IAI.61.8.3518-3526.1993; Manthey CL, 1994, J ENDOTOXIN RES, V1, P84; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; POHLMAN TH, 1987, J EXP MED, V165, P1393, DOI 10.1084/jem.165.5.1393; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RIEDO FX, 1990, J IMMUNOL, V144, P3506; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TAKADA H, 1985, INFECT IMMUN, V48, P219, DOI 10.1128/IAI.48.1.219-227.1985; TAKADA H, 1992, BACTERIAL ENDOTOXIC, V1, P107; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; ULMER AJ, 1992, INFECT IMMUN, V60, P5145, DOI 10.1128/IAI.60.12.5145-5152.1992; ULMER AJ, 1992, INFECT IMMUN, V60, P3309, DOI 10.1128/IAI.60.8.3309-3314.1992; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	41	126	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9904	9910		10.1074/jbc.270.17.9904	http://dx.doi.org/10.1074/jbc.270.17.9904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537270	hybrid			2022-12-25	WOS:A1995QV41700033
J	KANAMORI, T; HAYAKAWA, T; SUZUKI, M; TITANI, K				KANAMORI, T; HAYAKAWA, T; SUZUKI, M; TITANI, K			IDENTIFICATION OF 2 17-KDA RAT PAROTID-GLAND PHOSPHOPROTEINS, SUBJECTS FOR DEPHOSPHORYLATION UPON BETA-ADRENERGIC STIMULATION, AS DESTRIN-LIKE AND COFILIN-LIKE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN DEPOLYMERIZING FACTOR; SODIUM DODECYL-SULFATE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; NUCLEAR TRANSPORT; PORCINE BRAIN; ACINAR-CELLS; PEPTIDE; CDNA; ACID	We previously reported that when P-32(i)-loaded rat parotid slices are incubated with the beta-adrenergic agonist isoproterenol, the level of a soluble P-32-labeled 17-kDa protein (pp17) decreases rapidly (Kanamori, T., and Hayakawa, T. (1982) Biochem. Int. 4, 517-523). Here we show that pp17 consists of two distinct phosphoproteins (pp17a and pp17b), identify their unphosphorylated forms (p17a and p17b, respectively), and provide evidence for their beta-adrenergic stimulation-induced dephosphorylation. Since p17a and p17b were predominant forms even in nonstimulated cells, peptides were generated from them with Staphylococcus aureus V8 protease or cyanogen bromide; subsequent sequencing of these peptides and homology search allowed identification of p17a and p17b as destrin- and cofilin-like proteins, respectively. Interestingly, they were also dephosphorylated in response to cholinergic stimulation. Because destrin and cofilin are actin-depolymerizing proteins whose activities are possibly regulated by their phosphorylation/dephosphorylation, the two parotid proteins reported here might be involved in cortical F-actin disruption observed in parallel with exocytotic amylase secretion.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University	KANAMORI, T (corresponding author), AICHI GAKUIN UNIV,SCH DENT,DEPT BIOCHEM,1-100 KUSUMOTO CHO,NAGOYA,AICHI 464,JAPAN.							ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; ARMSTRONG IL, 1980, ANAL BIOCHEM, V106, P469, DOI 10.1016/0003-2697(80)90549-7; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BAUM BJ, 1981, J BIOL CHEM, V256, P9731; BREITHAUPT TB, 1978, ANAL BIOCHEM, V84, P579, DOI 10.1016/0003-2697(78)90078-7; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HIRS CHW, 1967, METHOD ENZYMOL, V11, P199; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KANAMORI T, 1984, BIOMED RES-TOKYO, V5, P77, DOI 10.2220/biomedres.5.77; KANAMORI T, 1982, BIOCHEM INT, V4, P517; KANAMORI T, 1987, ANAL BIOCHEM, V167, P372, DOI 10.1016/0003-2697(87)90179-5; KANAMORI T, 1980, BIOCHEM INT, V1, P395; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; MORIYAMA K, 1990, J BIOL CHEM, V265, P5771; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHTA Y, 1989, J BIOL CHEM, V264, P16143; PERRIN D, 1992, J CELL BIOL, V116, P127, DOI 10.1083/jcb.116.1.127; PLAXTON WC, 1989, ANAL BIOCHEM, V178, P391, DOI 10.1016/0003-2697(89)90658-1; RAY WJ, 1985, ANAL BIOCHEM, V146, P307, DOI 10.1016/0003-2697(85)90544-5; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRAMM M, 1968, BIOCHIM BIOPHYS ACTA, V165, P546, DOI 10.1016/0304-4165(68)90238-9; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SPEARMAN TN, 1984, J CELL BIOL, V99, P1354, DOI 10.1083/jcb.99.4.1354; SPEARMAN TN, 1989, HDB PHYSL GASTROINTE, V3, P63; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STARK GR, 1960, J BIOL CHEM, V235, P3177; SWANSTROM R, 1978, ANAL BIOCHEM, V86, P184, DOI 10.1016/0003-2697(78)90333-0; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	55	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8061	8067		10.1074/jbc.270.14.8061	http://dx.doi.org/10.1074/jbc.270.14.8061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7536193	hybrid			2022-12-25	WOS:A1995QR52600045
J	UDDIN, S; KATZAV, S; WHITE, MF; PLATANIAS, LC				UDDIN, S; KATZAV, S; WHITE, MF; PLATANIAS, LC			INSULIN-DEPENDENT TYROSINE PHOSPHORYLATION OF THE VAV PROTOONCOGENE PRODUCT IN CELLS OF HEMATOPOIETIC ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNALING PATHWAYS; SH2 DOMAIN; IRS-1; RECEPTOR; PROTEINS; MITOGENESIS; ASSOCIATION; ACTIVATION	Insulin activates the ras signaling pathway and promotes hematopoietic cell proliferation. One possible mediator in such signaling is the vav proto oncogene product (p95(vav)), which is specifically expressed in cells of hematopoietic origin and contains domains typical of guanine nucleotide exchange factors as well as Src homology 2 and Src homology 3 domains, We studied the tyrosine phosphorylation of p95(vav) in hematopoietic cells expressing insulin receptors. Immunoblotting experiments with an antiphosphotyrosine monoclonal antibody disclosed that insulin induces rapid and transient tyrosine phosphorylation of p95(vav) in the human U-266 myeloma cell line. These findings were confirmed by immunoprecipitation experiments performed with P-32-labeled cells and phosphoamino acid analysis of the bands corresponding to p95(vav). Similarly, insulin dependent tyrosine phosphorylation of p95(vav) was observed in the human IM-9 and mouse J558L hematopoietic cell lines. Furthermore, insulin treatment of cells led to the association of the Src homology 2 domain of p95(vav) with the activated P-subunit of the insulin receptor in vitro. Altogether, these data suggest that p95(vav) is a substrate for the insulin receptor tyrosine kinase and may be involved in an insulin signaling pathway linking receptor-generated signals to Pas or other GTP-binding proteins in cells of hematopoietic origin.	EDWARD HINES VET ADM MED CTR, HINES, IL 60141 USA; SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, TERRY FOX MOLEC ONCOL GRP, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Lady Davis Institute; McGill University; McGill University; McGill University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	UDDIN, S (corresponding author), LOYOLA UNIV, DIV HEMATOL ONCOL, BLDG 112, 2160 S 1ST AVE, MAYWOOD, IL 60153 USA.			Uddin, Shahab/0000-0003-1886-6710	NIDDK NIH HHS [DK-43808, DK-38712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK038712, R29DK038712, R01DK038712, R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FREUND GG, 1993, J IMMUNOL, V151, P1811; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PFEFFER LM, 1987, J BIOL CHEM, V262, P3665; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7712	7716		10.1074/jbc.270.13.7712	http://dx.doi.org/10.1074/jbc.270.13.7712			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535775	hybrid			2022-12-25	WOS:A1995QQ43100098
J	YU, H; DIAMANDIS, EP; MONNE, M; CROCE, CM				YU, H; DIAMANDIS, EP; MONNE, M; CROCE, CM			ORAL CONTRACEPTIVE-INDUCED EXPRESSION OF PROSTATE-SPECIFIC ANTIGEN IN THE FEMALE BREAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER; SERUM	Prostate-specific antigen (PSA) is widely used as a tumor marker of prostatic adenocarcinoma. We recently found that 30% of breast tumors produce PSA and that PSA is a favorable prognostic marker in female breast cancer. We measured immunoreactive PSA in cytosolic extracts of normal breast tissue from eight women receiving no medication and one woman who was receiving the progestin-containing oral contraceptive Brevicon. None of the eight cytosolic extracts of normal breast tissue contained appreciable amounts of immunoreactive PSA. However, left and right breast tissues from the woman receiving Brevicon contained high levels of PSA. This immunoreactive species was shown to have a molecular weight identical to that of seminal PSA. Furthermore, reverse transcription of RNA and polymerase chain reaction amplification produced a 571-base pair cDNA that hybridized to a labeled cDNA PSA probe. Upon sequencing, the cDNA polymerase chain reaction product was found to have 100% homology with cDNA from prostatic tissue. PSA production by breast carcinoma cell lines was achieved after in vitro stimulation with norethindrone and ethinylestradiol. Our data suggest that PSA can no longer be regarded as a specific prostatic protein because it is produced by breast tumors with good prognosis and by normal breast tissue after steroid hormone stimulation.	TORONTO WESTERN HOSP,DEPT CLIN BIOCHEM,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT IMMUNOL MICROBIOL,PHILADELPHIA,PA 19107	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Jefferson University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; MONNE, MARIA/0000-0003-4978-4427; Diamandis, Eleftherios/0000-0002-1589-820X				ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181; BELANGER A, 1994, 76TH END SOC ANN M A, P493; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DIAMANDIS EP, 1994, BREAST CANCER RES TR, V32, P301, DOI 10.1007/BF00666007; KANETY H, 1993, J CLIN ENDOCR METAB, V77, P229, DOI 10.1210/jc.77.1.229; KILLIAN CS, 1993, BIOCHEM BIOPH RES CO, V192, P940, DOI 10.1006/bbrc.1993.1506; MORENO JG, 1992, CANCER RES, V52, P6110; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Sambrook J, 1989, MOL CLONING LABORATO; YU H, 1995, CLIN CHEM, V41, P54; YU H, 1994, BREAST CANCER RES TR, V32, P291, DOI 10.1007/BF00666006; YU H, 1995, CLIN CHEM, V41, P204; YU H, 1993, CLIN CHEM, V39, P2108; YU H, 1994, CLIN BIOCHEM, V27, P75, DOI 10.1016/0009-9120(94)90015-9	16	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6615	6618		10.1074/jbc.270.12.6615	http://dx.doi.org/10.1074/jbc.270.12.6615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7534765	hybrid			2022-12-25	WOS:A1995QQ85500031
J	NAVON, A; SCHULZE, AJ; GUILLOU, Y; ZYLINSKI, CA; BALEUX, F; EXPERTBEZANCON, N; FRIGUET, B; DJAVADIOHANIANCE, L; GOLDBERG, ME				NAVON, A; SCHULZE, AJ; GUILLOU, Y; ZYLINSKI, CA; BALEUX, F; EXPERTBEZANCON, N; FRIGUET, B; DJAVADIOHANIANCE, L; GOLDBERG, ME			IMPORTANCE OF RESIDUES-2-9 IN THE IMMUNOREACTIVITY, SUBUNIT INTERACTIONS, AND ACTIVITY OF THE BETA(2)-SUBUNIT OF ESCHERICHIA-COLI TRYPTOPHAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BETA-2 SUBUNIT; MONOCLONAL-ANTIBODIES; TRUE AFFINITY; PROTEINS; ANTIGEN; CONFORMATION; SYNTHETASE; KINETICS; DOMAINS; CHAIN	The epitope recognized by a monoclonal antibody (mAb19) directed against the beta(2) subunit of Escherichia coli tryptophan synthase was found to be carried by residues 2-9 of the beta chain. The affinities of mAb19 for peptides of different lengths containing the 2-9 sequence were close to 0.6 x 10(9) M(-1), the affinity of mAb19 for native beta(2). In view of these results, a model is proposed to account for the kinetics of appearance of the epitope during in vitro renaturation of beta(2) (Murry-Brelier, A., and Goldberg, M. E. (1988) Biochemistry 27, 7633-7640). A mutant producing beta chains lacking residues 1-9 (beta(Delta 1-9)) was prepared. The beta(Delta 1-9) protein was able to fold into a heat stable homodimer resembling wild type beta(2). Isolated beta(Delta 1-9) had no detectable enzymatic activity. It could bind alpha chains extremely weakly and be slightly activated. In the presence of the 1-9 peptide, the beta(Delta 1-9) protein could bind alpha chains much more strongly and generate a 50% active enzyme, Thus, although having little role in the overall folding and stability of the protein, the 1-9 sequence of the beta chain appears strongly involved in the alpha-beta interactions and in the enzymatic activity.	INST PASTEUR, CNRS, URA 1129, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE; BAR ILAN UNIV, DEPT LIFE SCI, RAMAT GAN, ISRAEL; INST PASTEUR, CNRS, URA 487, UNITE CHIM ORGAN, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Bar Ilan University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Friguet, Bertrand/0000-0001-8085-1961				BLONDELGUINDI S, 1990, BIOCHEMISTRY-US, V29, P2409, DOI 10.1021/bi00461a026; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAFFOTTE AF, 1987, J MOL BIOL, V197, P131, DOI 10.1016/0022-2836(87)90615-2; CRAWFORD IP, 1978, BIOCHEM BIOPH RES CO, V85, P309, DOI 10.1016/S0006-291X(78)80044-8; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P391; DJAVADIOHANIANC.L, 1991, IMMUNOCHEMISTRY SOLI, P201; DJAVADIOHANIANCE L, 1984, BIOCHEMISTRY-US, V23, P97, DOI 10.1021/bi00296a016; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FRIGUET B, 1993, ANAL BIOCHEM, V210, P344, DOI 10.1006/abio.1993.1206; FRIGUET B, 1989, RES IMMUNOL, V140, P355, DOI 10.1016/0923-2494(89)90142-9; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FRIGUET B, 1993, J IMMUNOL METHODS, V158, P243, DOI 10.1016/0022-1759(93)90220-2; GOLDBERG ME, 1990, FEBS LETT, V263, P51, DOI 10.1016/0014-5793(90)80703-L; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARVOR MP, 1991, MOL IMMUNOL, V28, P523, DOI 10.1016/0161-5890(91)90167-I; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; Onoue K, 1965, Immunochemistry, V2, P401, DOI 10.1016/0019-2791(65)90039-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; ULLMANN A, 1967, J MOL BIOL, V24, P839; ZETINA CR, 1980, J BIOL CHEM, V255, P4381	31	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4255	4261		10.1074/jbc.270.9.4255	http://dx.doi.org/10.1074/jbc.270.9.4255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533160	hybrid			2022-12-25	WOS:A1995QK08400015
J	AVILA, MA; VELASCO, JA; CHO, C; LUPU, R; WEN, DZ; NOTARIO, V				AVILA, MA; VELASCO, JA; CHO, C; LUPU, R; WEN, DZ; NOTARIO, V			HYPERACTIVE AUTOCRINE LOOP MEDIATED BY A NDF-RELATED FACTOR IN NEOPLASTIC HAMSTER-EMBRYO FIBROBLASTS EXPRESSING AN ACTIVATED CPH ONCOGENE	ONCOGENE			English	Article						MITOGENIC FACTORS; ERBB-2 TYROSINE KINASE; NEOPLASTIC CONVERSION; CELL PROLIFERATION; CPH TRANSFORMATION	NEU DIFFERENTIATION FACTOR; HUMAN-BREAST-CANCER; GROWTH-FACTOR; PROTO-ONCOGENE; EGF RECEPTOR; SIGNAL TRANSDUCTION; TYROSINE KINASE; POINT MUTATION; LIGAND; CELLS	We described previously the characterization of a novel oncogene, cph, activated in primary Syrian hamster embryo fibroblasts by exposure to 3-methylcholanthrene (Velasco et al., Oncogene 9: 2065-2069, 1994). The present report describes the participation in the neoplastic conversion of cph-expressing (81C=39) hamster fibroblasts of a hyperactive autocrine loop involving a nea differentiation factor [NDF]-like protein, The tyrosine phosphorylation of the p185(erbB-2) receptor in the human breast carcinoma MDA-MB-453 cells was stimulated by conditioned medium from neoplastic 81C39 cells. The extent of this stimulatory effect was much greater than that induced by conditioned medium from normal 84-3 hamster cells. The p185(erbB-2) tyrosine phosphorylation-stimulating activity was partially blocked by the heparin analogue pentosan polysulfate [PPS], a known antagonist of p185(erbB-2) ligands, and was partially purified from 81C39 conditioned medium by heparin-Sepharose chromatography. The level of p185(erbB-2) tyrosine phosphorylation-stimulating activity in the heparin-Sepharose fractions correlated directly with their content in NDF-like protein as immunodetected with an anti-rat NDF antibody, Consistently, the steady-state level of NDF-related mRNA was found to be four times greater in neoplastic 81C39 cells than in normal 84-3 cells. However, the levels of erbB-2 mRNA were similar in both cell types, while the expression of erbB-4 mRNA was upregulated in the neoplastic fibroblasts. The ability of 81C39 conditioned medium to stimulate protein tyrosine phosphorylation and to induce other PPS-sensitive growth responses on 81C39 cells themselves suggested the involvement of an autocrine loop in their neoplastic conversion, The participation of a NDF-related factor in this autocrine loop was confirmed by the ability of an anti-NDF antibody to block the mitogenic activity present in their own conditioned medium. The involvement of the cpk oncogene in the upregulation of NDF-related expression was evidenced when cph-transformed NIH3T3 fibroblasts showed elevated levels of NDF-related mRNA, and their conditioned medium induced tyrosine phosphorylation on MDA-MB-453 cells, reproducing the effect of the medium from 81C39 hamster cells.	GEORGETOWN UNIV, MED CTR, DEPT RADIAT MED, DIV EXPTL CARCINOGENESIS, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Georgetown University; Georgetown University; Amgen			Avila, Matias A/Y-6342-2019; /AAB-6461-2022; /AFP-0764-2022	Avila, Matias A/0000-0001-6570-3557; 	NCI NIH HHS [CA49858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BERWALD Y, 1965, J NATL CANCER I, V35, P641; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIRAKAWA T, 1991, ONCOGENE, V6, P289; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; KRAUS MH, 1988, ANN NY ACAD SCI, V551, P320, DOI 10.1111/j.1749-6632.1988.tb22358.x; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; NOTARIO V, 1990, ONCOGENE, V5, P1425; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELASCO JA, 1994, ONCOGENE, V9, P2065; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTERMARK B, 1991, CANCER RES, V51, P5087; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	51	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7534900				2022-12-25	WOS:A1995QL03800018
J	LECABEC, V; MARIDONNEAUPARINI, I				LECABEC, V; MARIDONNEAUPARINI, I			COMPLETE AND REVERSIBLE INHIBITION OF NADPH OXIDASE IN HUMAN NEUTROPHILS BY PHENYLARSINE OXIDE AT A STEP DISTAL TO MEMBRANE TRANSLOCATION OF THE ENZYME SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; SUPEROXIDE GENERATION; MICROBICIDAL OXIDASE; HEAT-SHOCK	The effects of the trivalent arsenical phenylarsine oxide (PAO) on the activity of NADPH oxidase in human neutrophils were studied. PAO caused a rapid dose-dependent inhibition of superoxide generation which was maximal at a concentration of 1 mu M, irrespective of the stimulating agent. This inhibitory effect was not due to impaired transduction of activation signals since neither degranulation nor phagocytosis were modified. When cytosolic and membrane fractions from resting neutrophils were combined to reconstitute the NADPH oxidase, O-2(radical anion) generation was inhibited by PAO while translocation of the NADPH oxidase components to the plasma membrane fraction was not affected. The inhibition was completely and specifically reversed by 2,3-dimercaptopropanol, not by dithiothreitol or beta-mercaptoethanol, indicating that PAO binds covalently to spatially vicinal thiol groups. PAO inhibited the plasma membrane's capacity to initiate O-2(radical anion) generation while it apparently did not affect the cytosol. When PAO was added subsequently to NADPH oxidase activation, no inhibition was observed, indicating that PAO cannot reach its target once the oxidase is functionally assembled. In conclusion, PAO is the first complete and reversible inhibitor of NADPH oxidase which could provide the basis for new therapeutical approaches in inflammatory diseases.	CNRS, UPR 8221, F-31077 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Maridonneau-Parini, Isabelle/F-1985-2011; le cabec, veronique/U-2712-2019	Maridonneau-Parini, Isabelle/0000-0003-0189-0976				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; AKARD LP, 1988, BLOOD, V72, P322; ANDERSON R, 1991, MOL PHARMACOL, V40, P427; ASAHI M, 1993, J BIOL CHEM, V268, P23334; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BALLOTTI R, 1991, EXP CELL RES, V197, P300, DOI 10.1016/0014-4827(91)90436-X; BELLAVITE P, 1992, J LEUKOCYTE BIOL, V51, P329, DOI 10.1002/jlb.51.4.329; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOULET I, 1992, ONCOGENE, V7, P703; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CONSEILLER EC, 1989, EUR J BIOCHEM, V187, P107; COX JA, 1987, J IMMUNOL, V138, P1884; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELENNA J, 1994, J BIOL CHEM, V269, P6729; FROST SC, 1989, J CELL PHYSIOL, V141, P467, DOI 10.1002/jcp.1041410304; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HETHERINGTON SV, 1983, J IMMUNOL METHODS, V65, P183, DOI 10.1016/0022-1759(83)90314-9; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; JHUN BH, 1991, J BIOL CHEM, V266, P22260; KATO Y, 1992, P NATL ACAD SCI USA, V89, P8507, DOI 10.1073/pnas.89.18.8507; KILPATRICK L, 1992, J IMMUNOL, V149, P3059; Klebanoff S. J., 1988, INFLAMMATION BASIC P; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LEWIS CT, 1993, J BIOL CHEM, V268, P1628; LIAO K, 1991, J BIOL CHEM, V266, P6544; MADEMA RH, 1991, J BIOL CHEM, V266, P21186; MARIDONNEAUPARINI I, 1989, J CLIN INVEST, V83, P1936, DOI 10.1172/JCI114101; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; MARIDONNEAUPARINI I, 1993, J CELL PHYSIOL, V156, P204, DOI 10.1002/jcp.1041560127; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARIDONNEAUPARINI I, 1988, BIOCHEM BIOPH RES CO, V154, P179, DOI 10.1016/0006-291X(88)90667-5; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SCHUSTER MG, 1992, J BIOL CHEM, V267, P5056; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V146, P1296, DOI 10.1016/0006-291X(87)90790-X; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TAMURA M, 1992, J BIOL CHEM, V267, P7529; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILSON E, 1986, J BIOL CHEM, V261, P2616; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018	66	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2067	2073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530716				2022-12-25	WOS:A1995QE49300016
J	BOEUF, H; MURPHY, J; BIBBINS, KB; VARMUS, HE				BOEUF, H; MURPHY, J; BIBBINS, KB; VARMUS, HE			BINDING IN-VITRO OF PHOSPHOTYROSINE-CONTAINING PROTEINS TO PP60(C-SRC) SH2 DOMAIN DOES NOT CORRELATE WITH CEF CELL-TRANSFORMATION	ONCOGENE			English	Article						SH2; SH3; SRC; TRANSFORMATION; PHOSPHOTYROSINE	GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; SRC HOMOLOGY REGION-2; C-SRC; V-SRC; SIGNAL TRANSDUCTION; PP60(SRC) SUBSTRATE; DEPENDENT MANNER; TYROSINE KINASE; HIGH-AFFINITY	We have previously described pp60(c-src) SH2 mutants that are host-range-dependent for cell transformation; most of these mutants can transform CEF cells but not NIH3T3 cells, and others transform NM3T3 cells more efficiently than CEF (Hirai and Varmus, 1990c). In an attempt to understand the molecular basis of these phenotypes, we analysed the ability of mutant SH2 domains in GST fusion-proteins to bind to tyrosine phosphorylated proteins in lysates from CEF and NIH3T3 cells. The relative affinity of mutated versions of the SH2 domain for phosphotyrosine-containing proteins from CEF and NM3T3 cells was compared with the relative ability of the mutant Src proteins to transform the two cell types. While the affinity of the SH2 domain for phosphotyrosine-containing proteins was closely correlated with transformation in NIH3T3 cells, there was no correlation between phosphotyrosine binding and transformation of CEF cells, and none of the host range mutant SH2 domains showed significant differences in their ability to bind phosphotyrosine-containing proteins from lysates from either cell type. In addition, the SH3 domain was shown to augment the capacity of mutant SH2 domain to bind phosphotyrosine-containing proteins.	CU, STRASBOURG, FRANCE; CHIRON CORP, DEPT VIROL, EMERYVILLE, CA 94608 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; NIH, BETHESDA, MD 20892 USA	Novartis; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA	BOEUF, H (corresponding author), IGBMC, BP 163, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEELE RE, 1992, TRENDS BIOCHEM SCI, V17, P205, DOI 10.1016/0968-0004(92)90375-J; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					433	438						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7531318				2022-12-25	WOS:A1995QF64800003
J	KATAGIRI, Y; HIROYAMA, T; AKAMATSU, N; SUZUKI, H; YAMAZAKI, H; TANOUE, K				KATAGIRI, Y; HIROYAMA, T; AKAMATSU, N; SUZUKI, H; YAMAZAKI, H; TANOUE, K			INVOLVEMENT OF ALPHA(V)BETA(3) INTEGRIN IN MEDIATING FIBRIN GEL RETRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT CYTOPLASMIC DOMAINS; PLATELET GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; VITRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; ADHESION RECEPTORS; CELL-SURFACE; BETA-SUBUNIT	Platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa) plays important roles in platelet-mediated clot retraction. However, little is known about the mechanisms of clot retraction mediated by nucleated cells, In this report, we demonstrate that another member of the beta(3) integrin family, alpha(v) beta(3), is involved in clot retraction mediated by nucleated cells. Retraction of fibrin clots was observed using a human melanoma cell line, C32TG, which contains no alpha(IIb)beta(3) complex. This retraction was inhibited by RGD-containing peptide, monoclonal anti-beta(3), and anti-alpha(v) beta(3) antibodies. Immunoelectron microscopic studies revealed a direct interaction between beta(3) integrin and fibrin fibers at an early stage of clot retraction. We found that another human embryonal cell line, 293, which is known to express alpha(v) beta(1), but no alpha(v) beta(3), lacks fibrin gel retractile activity. Upon transfection of beta(3) DNA into 293 cells, the beta(3) subunit formed a complex with an endogenous alpha(v) subunit. The beta(3)-bearing transfectants were found to retract fibrin gels, which was specifically inhibited by anti-beta(3) antibody. In addition, a point mutation at Asp(119) in the beta(3) ligand binding domain abolished the clot retractile activity of 293 transfectants, indicating the requirement of alpha(v) beta(3) ligand-binding activity, Our findings suggest that alpha(v) beta(3) is involved in mediating the interaction between the three dimensional fibrin network and nucleated cells and in promoting ''post-receptor occupancy'' events.			KATAGIRI, Y (corresponding author), TOKYO METROPOLITAN INST MED SCI, DEPT CARDIOVASC RES, BUNKYO KU, 3-18-22 HONKOMAGOME, TOKYO 113, JAPAN.							ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BATES RC, 1991, J BIOL CHEM, V266, P18593; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BRAATEN JV, 1994, BLOOD, V83, P982; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARR ME, 1991, AM J MED SCI, V302, P13, DOI 10.1097/00000441-199107000-00004; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; COHEN I, 1989, BLOOD, V73, P1880; COHEN I, 1982, J CELL BIOL, V93, P775, DOI 10.1083/jcb.93.3.775; COHEN I, 1985, PLATELET MEMBRANE GL, P299; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; FOURNIER DJ, 1989, THROMB HAEMOSTASIS, V62, P977; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARTNER TK, 1988, THROMB RES, V49, P43; GARTNER TK, 1991, BIOCHEM BIOPH RES CO, V180, P1446; HANTGAN RR, 1985, BLOOD, V65, P1299, DOI 10.1182/blood.V65.6.1299.bloodjournal6561299; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KATAGIRI Y, 1991, CANCER RES, V51, P1286; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KOUNS WC, 1992, BLOOD, V80, P2539; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACIEIRACOELHO A, 1990, J CELL PHYSIOL, V142, P610, DOI 10.1002/jcp.1041420322; MCGREGOR JL, 1983, EUR J BIOCHEM, V131, P427, DOI 10.1111/j.1432-1033.1983.tb07281.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NIEWIAROWSKI S, 1973, THROMB DIATH HAEMOST, P51; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUZUKI H, 1992, HISTOCHEMISTRY, V97, P381, DOI 10.1007/BF00270384; TAYLOR DB, 1994, P SOC EXP BIOL MED, V205, P35; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YAMAMOTO N, 1985, THROMB RES, V39, P751, DOI 10.1016/0049-3848(85)90259-2; YAMAMOTO N, 1989, BLOOD, V73, P1552; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	52	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1785	1790		10.1074/jbc.270.4.1785	http://dx.doi.org/10.1074/jbc.270.4.1785			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530248	hybrid			2022-12-25	WOS:A1995QD20400048
J	HALL, AV; ANTONIOU, H; WANG, Y; CHEUNG, AH; ARBUS, AM; OLSON, SL; LU, WC; KAU, CL; MARSDEN, PA				HALL, AV; ANTONIOU, H; WANG, Y; CHEUNG, AH; ARBUS, AM; OLSON, SL; LU, WC; KAU, CL; MARSDEN, PA			STRUCTURAL ORGANIZATION OF THE HUMAN NEURONAL NITRIC-OXIDE SYNTHASE GENE (NOS1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA; NADPH-DIAPHORASE; Z-DNA; TRANSCRIPTION; BRAIN; PROMOTER; CELLS; EXPRESSION; SEQUENCES	Neuronal nitric oxide (NO) synthase, localized to human chromosome 12, uniquely participates in diverse biologic processes; neurotransmission, the regulation of body fluid homeostasis, neuroendocrine physiology, control of smooth muscle motility, sexual function, and myocyte/myoblast biology, among others. Restriction enzyme mapping, subcloning, and DNA sequence analysis of bacteriophage- and yeast artificial chromosome-derived human genomic DNA indicated that the mRNA for neuronal NO synthase is dispersed over a minimum of 160 kilobases of human genomic DNA. Analysis of intron-exon splice junctions predicted that the open reading frame is encoded by 28 exons, with translation initiation and termination in exon 2 and exon 29, respectively. Determination of transcription initiation sites in brain poly(A) RNA with primer extension analysis and RNase protection revealed a major start site 28 nucleotides downstream from a TATA box. Sequence inspection of 5'-flanking regions revealed potential cis-acting DNA elements: AP-2, TEF-1/MCBF, CREB/ATF/c-Fos, NRF-1, Ets, NF-1, and NF-kappa B-like sequences. Diversity appears to represent a major theme apparent upon analysis of human neuronal NO synthase mRNA transcripts. A microsatellite of the dinucleotide variety was detected within the S'-untranslated region of exon 29. Multiple alleles were evident in normal individuals indicating the existence of allelic mRNA sequence variation. Characterization of variant human neuronal NO synthase cDNAs indicated the existence of casette exon 9/10 and exon 10 deletions as examples of structural mRNA diversity due to alternative splicing. The latter deletion of a 175-nucleotide exon introduces a frameshift and premature stop codon indicating the potential existence of a novel NH2 terminus protein. In summary, analysis of the human neuronal NO synthase locus reveals a complex genomic organization and mRNA diversity that is both allelic and structural.	UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,ST MICHAELS HOSP,DIV RENAL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto			Marsden, Philip A/B-1441-2012					ABU SH, 1993, P NATL ACAD SCI USA, V90, P10769; AFEWORK M, 1992, NEUROREPORT, V3, P893, DOI 10.1097/00001756-199210000-00018; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREDT DS, 1991, J BIOL CHEM, V267, P10976; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DUN NJ, 1993, NEUROSCI LETT, V158, P51, DOI 10.1016/0304-3940(93)90610-W; ELOFSSON R, 1993, NEUROREPORT, V4, P279, DOI 10.1097/00001756-199303000-00013; ELPHICK MR, 1993, BRAIN RES, V619, P344, DOI 10.1016/0006-8993(93)91632-3; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; LEE KH, 1994, J BIOL CHEM, V269, P14371; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN XH, 1993, J BIOL CHEM, V268, P17334; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARSDEN PA, 1994, GENOMICS, V19, P183, DOI 10.1006/geno.1994.1039; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MUNDEL P, 1992, KIDNEY INT, V42, P1017, DOI 10.1038/ki.1992.382; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RETTORI V, 1993, P NATL ACAD SCI USA, V90, P10130, DOI 10.1073/pnas.90.21.10130; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SHIMOSEGAWA T, 1992, NEUROSCI LETT, V148, P67, DOI 10.1016/0304-3940(92)90806-I; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VERGE VMK, 1992, P NATL ACAD SCI USA, V89, P11617, DOI 10.1073/pnas.89.23.11617; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; XU WM, 1993, CYTOGENET CELL GENET, V64, P62, DOI 10.1159/000133562; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	68	266	284	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33082	33090						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528745				2022-12-25	WOS:A1994QA63800053
J	NASO, MF; ZIMMERMANN, DR; IOZZO, RV				NASO, MF; ZIMMERMANN, DR; IOZZO, RV			CHARACTERIZATION OF THE COMPLETE GENOMIC STRUCTURE OF THE HUMAN VERSICAN GENE AND FUNCTIONAL-ANALYSIS OF ITS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR-BETA-1; TRANSCRIPTION FACTOR AP-2; MESSENGER-RNA LEVELS; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; LINK PROTEIN; CORE PROTEIN; FIBROBLAST PROTEOGLYCAN; C4B-BINDING PROTEIN	Versican is a modular proteoglycan involved in the control of cellular growth and differentiation. To understand versican gene regulation and transcriptional control, we have isolated genomic clones spanning the entire gene locus including 5'- and 3'-flanking sequences, Versican was encoded by 15 exons encompassing over 90 kilobase pairs of continuous DNA, The exon organization corresponded to the protein subdomains encoded by homologous proteins, with a remarkable conservation of exon size and intron phase. We discovered an additional exon just proximal to the glycosaminoglycan-binding region that was identical to a recently identified splice variant of versican (Dours-Zimmermann, M, T., and Zimmermann, D. R. (1994) J. Biol. Chem. 269, 32992-32998). The versican promoter harbored a typical TATA box located approximately 16 base pairs upstream of the transcription start site and binding sites for a number of transcription factors involved in regulated gene expression, This promoter was shown to be highly functional in transiently transfected cells of both mesenchymal and epithelial origin. Stepwise 5' deletions identified a strong enhancer element between -209 and -445 base pairs and a strong negative element between -445 and -632 base pairs. This study provides the molecular basis for discerning the transcriptional control of the versican gene and offers the opportunity to investigate genetic disorders linked to this important human gene.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA; UNIV ZURICH, INST CLIN PATHOL, DEPT PATHOL, CH-8091 ZURICH, SWITZERLAND	Jefferson University; Jefferson University; University of Zurich			Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA-47282, CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, BIOCHEM BIOPH RES CO, V171, P1402, DOI 10.1016/0006-291X(90)90841-A; ALEXANDER F, 1984, J MOL BIOL, V173, P159, DOI 10.1016/0022-2836(84)90187-6; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BARTA E, 1993, BIOCHEM J, V292, P947, DOI 10.1042/bj2920947; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CRAWFORD TJ, 1993, DEV BRAIN RES, V76, P264, DOI 10.1016/0165-3806(93)90216-W; DECORDOBA SR, 1991, J EXP MED, V173, P1073, DOI 10.1084/jem.173.5.1073; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FULOP C, 1993, J BIOL CHEM, V268, P17377; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HERDEGEN T, 1992, NEUROSCI LETT, V142, P57, DOI 10.1016/0304-3940(92)90619-I; HILLARP A, 1993, J BIOL CHEM, V268, P15017; IOZZO RV, 1992, GENOMICS, V14, P845, DOI 10.1016/S0888-7543(05)80103-X; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KRUEGER RC, 1992, J BIOL CHEM, V267, P12149; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; POST TW, 1990, J IMMUNOL, V144, P740; QWARNSTROM EE, 1993, BIOCHEM J, V294, P613, DOI 10.1042/bj2940613; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RHODES C, 1988, J BIOL CHEM, V263, P6063; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANTRA M, 1994, J BIOL CHEM, V269, P579; SATOBIGBEE C, 1993, J NEUROCHEM, V60, P2106, DOI 10.1111/j.1471-4159.1993.tb03495.x; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TAN EML, 1991, LAB INVEST, V64, P474; TONA A, 1993, J HISTOCHEM CYTOCHEM, V41, P593, DOI 10.1177/41.4.8450198; UPHOLT WB, 1993, EXPERIENTIA, V49, P384, DOI 10.1007/BF01923583; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	65	142	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32999	33008						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528742				2022-12-25	WOS:A1994QA63800044
J	MEHINDATE, K; ALDACCAK, R; SCHALL, TJ; MOURAD, W				MEHINDATE, K; ALDACCAK, R; SCHALL, TJ; MOURAD, W			INDUCTION OF CHEMOKINE GENE-EXPRESSION BY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II LIGANDS IN HUMAN FIBROBLAST-LIKE SYNOVIOCYTES - DIFFERENTIAL REGULATION BY INTERLEUKIN-4 AND DEXAMETHASONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; RHEUMATOID-ARTHRITIS; MESSENGER-RNA; FACTOR-ALPHA; MICROBIAL SUPERANTIGENS; GLUCOCORTICOID RECEPTOR; INFLAMMATORY CYTOKINES; SIGNAL TRANSDUCTION; T-CELLS	Chemokines play a key role in recruiting leukocytes into inflamed synovial environment, and the cells of the synovial membrane, which express high levels of major histocompatibility complex (MHC) class LI molecules, are a major source of these chemokines. Our data indicated that engagement of MHC class II molecules by staphylococcal enterotoxin A superantigen resulted in the induction of chemokine gene expression as well as protein synthesis. Pretreatment of the cells with cycloheximide potentiated the effect of superantigen on chemokine mRNA induction, suggesting that the expression of these genes may occur independently of prior protein synthesis. Ligation of MHC class II molecules in fibroblast-like synoviocytes by other ligands such as Mycoplasma arthritidis-derived superantigen and anti class II antibody could also trigger an increase in the mRNA level of RANTES, MCP-1, and interleukin (IL)-8. The addition of dexamethasone to superantigen-treated fibroblast-like synoviocytes inhibited the mRNA expression of all three chemokines. IL-4 treatment decreased only the stimulating effect of superantigen on RANTES messanger suggesting that different mechanisms are involved in regulating these genes. The inhibitory effect of dexamethasone did not require a de nova protein synthesis, whereas that of IL-4 was protein-dependent. This report demonstrates that MHC class II ligands (superantigens and anti-MHC class II antibodies) may represent an important agent by which inflammatory chemokines can be induced and shows that this response can be modulated by the anti-inflammatory agents dexamethasone and IL-4.	UNIV LAVAL,CHUL,CTR RECH RHUMATOL & IMMUNOL,ST FOY G1V 4G2,PQ,CANADA; GENENTECH INC,SAN FRANCISCO,CA 94080	Laval University; Roche Holding; Genentech			Al-Daccak, Reem/L-8804-2018	Mourad, Walid/0000-0002-1859-9387; Al-Daccak, Reem/0000-0002-6146-2845				ALDACCAK R, 1994, INFECT IMMUN, V62, P2409, DOI 10.1128/IAI.62.6.2409-2416.1994; ALDACCAK R, 1994, BIOCHEM BIOPH RES CO, V201, P855, DOI 10.1006/bbrc.1994.1779; ANTTILA HSI, 1992, CLIN EXP IMMUNOL, V89, P509; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BAGGIOLILNI M, 1994, ADV IMMUNOL, V55, P98; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; CALMAN AF, 1987, J IMMUNOL, V139, P2489; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; COLE BC, 1971, INFECT IMMUN, V4, P344, DOI 10.1128/IAI.4.4.344-355.1971; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DONNELLY RP, 1993, J IMMUNOL, V151, P5603; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; HACHICHA M, 1993, ARTHRITIS RHEUM, V36, P26, DOI 10.1002/art.1780360106; HARIGAI M, 1993, CLIN IMMUNOL IMMUNOP, V69, P83, DOI 10.1006/clin.1993.1153; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HART PH, 1993, J IMMUNOL, V151, P3370; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; HOWELL MD, 1991, P NATL ACAD SCI USA, V88, P10921, DOI 10.1073/pnas.88.23.10921; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LEW W, 1988, J IMMUNOL, V140, P1895; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MIOSSEC P, 1990, ARTHRITIS RHEUM, V33, P1180; MOURAD W, 1989, J EXP MED, V170, P2011, DOI 10.1084/jem.170.6.2011; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; Mourad W, 1993, Semin Immunol, V5, P47, DOI 10.1006/smim.1993.1007; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; OHASHI PS, 1991, CELL, V65, P309; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PHILLIPS PE, 1988, CLIN EXP RHEUMATOL, V6, P87; POON M, 1991, J BIOL CHEM, V266, P22375; Posnett D N, 1993, Semin Immunol, V5, P65, DOI 10.1006/smim.1993.1009; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; RINK L, 1994, INFECT IMMUN, V62, P462, DOI 10.1128/IAI.62.2.462-467.1994; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHOLL P, 1989, P NATL ACAD SCI USA, V86, P4210, DOI 10.1073/pnas.86.11.4210; SEARLES RP, 1988, ARTHRITIS RHEUM-US, V31, P834, DOI 10.1002/art.1780310703; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; TOBLER A, 1992, BLOOD, V79, P45; TREDE NS, 1991, J IMMUNOL, V146, P2310; TREDE NS, 1993, EUR J IMMUNOL, V23, P2129, DOI 10.1002/eji.1830230913; TSUJI K, 1992, HLA 1991 DISEASE COM, V1, P693; TUMANG JR, 1990, J EXP MED, V171, P2153, DOI 10.1084/jem.171.6.2153; VILLIGER PM, 1992, J IMMUNOL, V149, P722; WONG HL, 1992, J IMMUNOL, V148, P2118; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	59	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32063	32069						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528208				2022-12-25	WOS:A1994PX30400011
J	NAKANISHI, S; UEDA, T; HORI, H; YAMAZAKI, N; OKADA, N; WATANABE, K				NAKANISHI, S; UEDA, T; HORI, H; YAMAZAKI, N; OKADA, N; WATANABE, K			A UGU SEQUENCE IN THE ANTICODON LOOP IS A MINIMUM REQUIREMENT FOR RECOGNITION BY ESCHERICHIA-COLI TRANSFER-RNA-GUANINE TRANSGLYCOSYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; TRANSFER-RNA TRANSGLYCOSYLASE; MODIFIED NUCLEOSIDE-Q; BIOSYNTHESIS; INSERTION; QUEUINE; LIVER; GENES	Escherichia coli tRNA-guanine transglycosylase is an enzyme which catalyzes replacement of guanine (G(34)) Of tRNA(Asp), tRNA(Asn), tRNA(His) and tRNA(Tyr) by free guanine or free preQ(1) base by a base exchange reaction in the biosynthesis of queuosine (Q) (Okada, N., and Nishimura, S. (1979) J. Biol. Chem. 254, 3061-3066). The gene encoding for this enzyme was amplified from the E. coli genome by polymerase chain reaction and inserted into an overexpression vector, pJLA503, The enzyme was overexpressed by heat induction in E. coli transformed by this recombinant plasmid and purified to homogeneity by two column chromatographies. The sequence requirement in tRNA for recognition by this enzyme was investigated using minihelices corresponding to the anticodon arm of E. coli tRNA(His). Two uridine residues (U-33, U-35) were found to be prerequisite for such recognition by this enzyme, Position 32 required pyrimidines, because the enzyme activity toward the minihelices was markedly reduced or entirely lost when this residue was replaced by purines or was deleted, Adenosine at position 37 and the G(30)-C-40 base pair were not essential despite their conservation. Our results suggest that the enzyme recognizes the U-33-G(34)-U-35 sequence in the anticodon loop and not the tertiary structure of tRNA itself.	UNIV TOKYO,FAC ENGN,DEPT CHEM & BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOL SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology			Ueda, Takuya/K-5217-2014; Hori, Hiroyuki/AAB-3911-2021	Ueda, Takuya/0000-0002-7760-8271; 				BIENZ M, 1981, NATURE, V294, P188, DOI 10.1038/294188a0; CARBON P, 1988, EMBO J, V2, P1093; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; FREY B, 1989, J BACTERIOL, V171, P1524, DOI 10.1128/jb.171.3.1524-1530.1989; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; KASAI H, 1975, NUCLEIC ACIDS RES, V2, P1931, DOI 10.1093/nar/2.10.1931; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; NISHIMURA S, 1979, TRANSFER RNA STRUCTU, P59; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P415, DOI 10.1093/nar/4.2.415; OKADA N, 1976, NUCLEIC ACIDS RES, V3, P2593, DOI 10.1093/nar/3.10.2593; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1979, J BIOL CHEM, V254, P3061; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028	21	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32221	32225						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528209				2022-12-25	WOS:A1994PX30400034
J	PAN, Y; WILSON, P; GITSCHIER, J				PAN, Y; WILSON, P; GITSCHIER, J			THE EFFECT OF 8 V2 VASOPRESSIN RECEPTOR MUTATIONS ON STIMULATION OF ADENYLYL-CYCLASE AND BINDING TO VASOPRESSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; PROTEIN-COUPLED RECEPTORS; CLONING; GENE; MUTAGENESIS; EXPRESSION	We previously identified six V2 vasopressin receptor mutations in five unrelated nephrogenic diabetes insipidus (NDI) families. In order to elucidate the effect of these mutations on the function of the V2 vasopressin receptor, we introduced these six and two additional, naturally occurring mutations into the V2 vasopressin receptor gene by in vitro mutagenesis. Five of the mutants (two frameshift, one nonsense, and two missense) failed to stimulate adenylyl cyclase due to their inability to bind vasopressin under the experimental conditions. In contrast, ligand binding and cAMP accumulation were normal for two other mutations, a A61V missense mutation and an in-frame deletion of four amino acids (Arg-247 to Gly-250), suggesting that they are not the cause of NDI in these families. The deletion mutation was found in a family in conjunction with a second mutation, R181C, which yielded a much reduced ligand binding capacity. The K-D of R181C was at least 26 times higher than that of the wild type. Further characterization by an immunofluorescent assay showed that the R181C mutant receptor is expressed and distributed on the cell surface in a manner similar to that of the wild type. This finding indicates that the inability of this mutant to stimulate adenylyl cyclase is caused by the reduced capacity for vasopressin binding and that the R181C mutation is responsible for NDI in this family.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	PAN, Y (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.							BICHET DG, 1993, J CLIN INVEST, V92, P1262, DOI 10.1172/JCI116698; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BIRNBAUMER M, 1992, J BIOL CHEM, V267, P11783; BROWNSTEIN MJ, 1993, 4TH I8NT VAS C, P33; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNOERS N, 1993, 4TH INT VAS C, P571; KOJRA E, 1993, 4TH INT VAS C, P582; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MERENDINO JJ, 1993, NEW ENGL J MED, V328, P1538, DOI 10.1056/NEJM199305273282106; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	26	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31933	31937						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527400				2022-12-25	WOS:A1994PX30300092
J	SHERMAN, M; GOLDBERG, AL				SHERMAN, M; GOLDBERG, AL			HEAT SHOCK-INDUCED PHOSPHORYLATION OF GROEL ALTERS ITS BINDING AND DISSOCIATION FROM UNFOLDED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONES; DNAK; STABILITY; ATPASE; HSP70; HSP60	During heat shock of Escherichia coli, the expression of the major molecular chaperone, GroEL, increases; in addition, a small fraction of the GroEL becomes phosphorylated (Sherman, M. Yu., and Goldberg, A. L. (1992) Nature 367, 166-1692). This heat shock-induced phosphorylation was found to enhance 50-100-fold the capacity of GroEL to bind to several denatured proteins, including casein and fetuin, The phosphorylated species in the cell extract bound quantitatively to affinity columns containing these ligands, and treatment of the extract with alkaline phosphatase markedly reduced this binding, Like heat shock (42 degrees C), overproduction of GroEL (5-10-fold) from the multicopy plasmid at low temperature (25 degrees C) increased the phosphorylated fraction, which bound strongly to denatured fetuin, Heat shock of these cells further enhanced phosphorylation, and about 15% of the induced level of GroEL could bind tightly to the fetuin column, The predominant form of the GroEL that bound to the denatured protein columns appeared to contain at least one phosphate on each of its subunits, although multiple phosphorylated subunits were also observed, With fetuin and casein as affinity ligands, only the phosphorylated species bound, and this material dissociated quantitatively upon addition of ATP-Mg2+. With CRAG and histone as the ligands, some unphosphorylated GroEL also bound, but this species (unlike the phosphorylated form) was not released by ATP alone; its release required the addition of the cofactor GroES together with ATP. Thus, the phosphorylation of GroEL during heat shock greatly enhances its ability to bind to certain denatured proteins and stimulates its ATP-dependent dissociation in the absence of GroES, Presumably, these alterations in the properties of a fraction of GroEL aid in the refolding or the degradation of specific damaged polypeptides.			SHERMAN, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.							BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CRAIG E, 1990, TRENDS BIOCHEM SCI, V16, P135; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hartl F U, 1991, Semin Immunol, V3, P5; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HELLEBUST H, 1989, J BIOTECHNOL, V12, P275, DOI 10.1016/0168-1656(89)90047-3; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; SHERMAN M, 1991, J BACTERIOL, V173, P4249; SHERMAN MY, 1992, EMBO J, V11, P71; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SHERMAN MY, 1992, NATURE, V367, P166; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	25	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31479	31483						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527389				2022-12-25	WOS:A1994PX30300026
J	VANDERGOOT, FG; HARDIE, KR; PARKER, MW; BUCKLEY, JT				VANDERGOOT, FG; HARDIE, KR; PARKER, MW; BUCKLEY, JT			THE C-TERMINAL PEPTIDE PRODUCED UPON PROTEOLYTIC ACTIVATION OF THE CYTOLYTIC TOXIN AEROLYSIN IS NOT INVOLVED IN CHANNEL FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE; AEROMONAS; SITE	The channel-forming toxin aerolysin is secreted by Aeromonas hydrophila as a protoxin that can be activated by nicking with endoproteinase Lys-C after Lys-427 near the C terminus of the protein. The fate of the 43-amino acid peptide distal to the activation site was investigated. A cysteine was introduced into the C-terminal region by replacing Ile-445, and another replaced Gly-202, which is on the proximal side of the activation site. In a double mutant, the two new cysteines were close enough in the folded molecule to form an intrachain 202-445 disulfide bond. Tryptophan fluorescence measurements on wild type and the 2 single cysteine mutants indicated that activation results in exposure of at least 1 tryptophan residue, leading to the conclusion that the peptide moves with respect to the protein when it is produced. This was supported by the observation that upon activation there was a decrease in energy transfer between a tryptophan in the bulk of the protein and a probe attached to Cys-445. The peptide could be separated from active toxin by several methods, indicating that it leaves the protein when it is produced, and that it plays no further role in the process of channel formation.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA; UNIV GENEVA,DEPT BIOCHIM,CH-1211 GENEVA,SWITZERLAND; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA	University of Victoria; University of Geneva; St. Vincent's Institute of Medical Research			van der Goot, Gisou G/B-2279-2012; Parker, Michael W/F-9069-2013	van der Goot, Gisou G/0000-0002-8522-274X; Parker, Michael W/0000-0002-3101-1138; Hardie, Kim/0000-0002-4892-2739	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTWEGG M, 1989, CRC CR REV MICROBIOL, V16, P253, DOI 10.3109/10408418909105478; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; BUCKLEY JT, 1992, FEBS LETT, V307, P30, DOI 10.1016/0014-5793(92)80896-O; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKEY J, 1992, BACTERIOCINS MICROCI, P127; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Stern O, 1919, PHYS Z, V20, P183; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272	15	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30496	30501						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527031				2022-12-25	WOS:A1994PU52500071
J	BEYAERT, R; VANHAESEBROECK, B; DECLERCQ, W; VANLINT, J; VANDENABEELE, P; AGOSTINIS, P; VANDENHEEDE, JR; FIERS, W				BEYAERT, R; VANHAESEBROECK, B; DECLERCQ, W; VANLINT, J; VANDENABEELE, P; AGOSTINIS, P; VANDENHEEDE, JR; FIERS, W			CASEIN KINASE-1 PHOSPHORYLATES THE P75 TUMOR-NECROSIS-FACTOR RECEPTOR AND NEGATIVELY REGULATES TUMOR-NECROSIS-FACTOR SIGNALING FOR APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; TRANSDUCTION PATHWAY; TNF RECEPTOR; KAPPA-B; CELLS; INTERLEUKIN-1; PHOSPHATASE; IDENTIFICATION	Cellular responses initiated by tumor necrosis factor (TNF) are mediated by two different cell surface receptors with respective molecular masses of 55 kDa (p55) and 75 kDa (p75), p55 is functional in almost every cell type and can independently transmit most biological activities of TNF. In contrast, TNF signaling via p75 seems so far largely restricted to cells of lymphoid origin, where it can induce proliferation, cytokine production, and/or apoptosis. The mechanisms that regulate TNF receptor activity are largely unknown. Here we report that the p75 of unstimulated p75-responsive PC60 T cells is phosphorylated on serine by a kinase activity present in p75 immune complexes. Several lines of evidence indicate that the latter kinase is casein kinase-1 (CK-1). Previous results have shown that the p75 TNF receptor is constitutively phosphorylated in vivo. Our data show that the latter in vivo phosphorylation is also at least partially due to CK-1. Pretreatment of cells with TNF had no detectable effect on p75 phosphorylation in vitro or in vivo. However, a specific CK-1 inhibitor potentiated TNF-induced apoptosis mediated by p75, suggesting an inhibitory role for phosphorylation by CK-1. Although in vivo p75 phosphorylation could be seen in both p75-unresponsive and p75-responsive cell lines, in vitro p75 phosphorylation in p75 coimmunoprecipitates could not be observed in cell lines that were biologically unresponsive to p75 stimulation. The latter observation further indicates a regulatory role for p75 phosphorylation in p75-mediated signaling. Taken together, our data demonstrate that the p75 TNF receptor is phosphorylated and associated with CK-1, which negatively regulates p75-mediated TNF signaling.	STATE UNIV GHENT VIB, MOLEC BIOL LAB, B-9000 GHENT, BELGIUM; CATHOLIC UNIV LEUVEN, FAC MED, BIOCHEM LAB, B-3000 LOUVAIN, BELGIUM	Flanders Institute for Biotechnology (VIB); Ghent University; KU Leuven			Van Lint, Johan/P-9073-2019; Beyaert, Rudi/B-2589-2009; Agostinis, Patrizia/ABI-1177-2020; Vandenabeele, Peter/C-8597-2009; Agostinis, Patrizia/AAO-2468-2020; Vandenabeele, Peter/AAD-5793-2022	Agostinis, Patrizia/0000-0003-1314-2115; Vandenabeele, Peter/0000-0002-6669-8822; Van Lint, Johan/0000-0002-0275-571X; Beyaert, Rudi/0000-0002-5704-582X				AGOSTINIS P, 1987, FEBS LETT, V224, P385, DOI 10.1016/0014-5793(87)80489-1; AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BEYAERT R, 1993, CANCER RES, V53, P2623; BEYAERT R, 1990, FEBS LETT, V262, P93, DOI 10.1016/0014-5793(90)80161-B; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHAUCHEREAU A, 1992, BIOL REPROD, V46, P174, DOI 10.1095/biolreprod46.2.174; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; Fiers W, 1995, BIOL THERAPY CANC, P295; GEHR G, 1992, J IMMUNOL, V149, P911; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1993, J BIOL CHEM, V268, P2141; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HELLER RA, 1992, CELL, V70, P47; HEPBURN A, 1988, FEBS LETT, V227, P175, DOI 10.1016/0014-5793(88)80892-5; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIM MY, 1991, J BIOL CHEM, V266, P484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; PENNICA D, 1992, J BIOL CHEM, V267, P21172; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TAN YH, 1993, SCIENCE, V262, P376, DOI 10.1126/science.7692598; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TOTPAL K, 1992, CANCER RES, V52, P2557; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VANOSTADE X, 1993, NATURE, V361, P266; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VANROY F, 1981, J VIROL, V40, P28, DOI 10.1128/JVI.40.1.28-44.1981; VASSALLI P, 1993, CURR BIOL, V3, P607, DOI 10.1016/0960-9822(93)90010-L; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	55	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23293	23299		10.1074/jbc.270.40.23293	http://dx.doi.org/10.1074/jbc.270.40.23293			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559483	Green Published, hybrid			2022-12-25	WOS:A1995RY90900012
J	CORONEOS, E; MARTINEZ, M; MCKENNA, S; KESTER, M				CORONEOS, E; MARTINEZ, M; MCKENNA, S; KESTER, M			DIFFERENTIAL REGULATION OF SPHINGOMYELINASE AND CERAMIDASE ACTIVITIES BY GROWTH-FACTORS AND CYTOKINES - IMPLICATIONS FOR CELLULAR PROLIFERATION AND DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MESANGIAL CELLS; PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; FREE SYSTEM; PATHWAY; SPHINGOSINE; ENDOTHELIN; FOS	Sphingosine is a product of sphingolipid metabolism that has been linked to a protein kinase C-independent mitogenic response. In previously published data, utilizing an in vitro model system for platelet-derived growth factor (PDGF)-induced vascular smooth muscle proliferation, we have demonstrated that sphingosine is increased at the expense of a concomitant decrease in ceramide formation, implicating an altered ceramidase activity. To explore mechanisms of growth factor stimulated sphingosine formation, we have developed and investigated a cell free model system assessing ceramidase activity. We now report that an alkaline, membrane-associated, ceramidase activity in the rat glomerular mesangial cell, a smooth muscle-like pericyte, is up-regulated by growth factors, apparently via a tyrosine kinase phosphorylation mechanism. PDGF also stimulated sphingomyelinase activity which generates sufficient substrate to drive the subsequent ceramidase reaction, Inflammatory cytokines, including interleukin-1, and tumor necrosis factor-alpha, stimulated sphingomyelinase but not ceramidase activity, a result consistent with the cellular accumulation of the ceramide, apoptidic, differentiating second messenger, Mitogenic vasoconstrictor peptides such as endothelin-1 stimulated neither sphingomyelinase nor ceramidase activities, An inhibitor of ceramidase activity, N-oleoylethanolamine, reduced PDGF- but not endothelin-1-stimulated proliferation. Thus, we conclude that, in mesangial cells, growth factors but not vasoconstrictor peptides or cytokines induce mitogenesis, in part, through ceramidase-mediated sphingosine formation.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University								DESAI NN, 1992, J BIOL CHEM, V267, P23122; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KESTER M, 1992, J CELL PHYSIOL, V150, P578, DOI 10.1002/jcp.1041500319; KESTER M, 1993, J CELL PHYSL, V153, P244; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PRENSKY AL, 1967, P SOC EXP BIOL MED, V126, P725; RAO BG, 1976, J LIPID RES, V17, P506; SEDOR JR, 1992, KIDNEY INT, V41, P595, DOI 10.1038/ki.1992.89; SHARMA RV, 1993, AM J PHYSIOL, V264, pC71, DOI 10.1152/ajpcell.1993.264.1.C71; SHAYMAN JA, 1992, J AM SOC NEPHROL, V3, pA766; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SU Y, 1994, J BIOL CHEM, V269, P16512; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; ZHANG H, 1990, J BIOL CHEM, V265, P76	26	205	217	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23305	23309		10.1074/jbc.270.40.23305	http://dx.doi.org/10.1074/jbc.270.40.23305			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559485	hybrid			2022-12-25	WOS:A1995RY90900014
J	BENBARUCH, A; XU, LL; YOUNG, PR; BENGALI, K; OPPENHEIM, JJ; WANG, JM				BENBARUCH, A; XU, LL; YOUNG, PR; BENGALI, K; OPPENHEIM, JJ; WANG, JM			MONOCYTE CHEMOTACTIC PROTEIN-3 (MCP3) INTERACTS WITH MULTIPLE LEUKOCYTE RECEPTORS - C-C-CKR1, A RECEPTOR FOR MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA, RANTES, IS ALSO A FUNCTIONAL RECEPTOR FOR MCP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; MOLECULAR-CLONING; CYTOKINE FAMILY; EXPRESSION; IDENTIFICATION; CHEMOKINES; BIOLOGY; BINDING; CELLS; CDNA	Monocyte chemotactic protein-3 (MCP3) is a recently identified and molecularly cloned C-C chemokine that is chemotactic for and activates a great variety of inflammatory cell types. MCP3 has been reported to interact with several C-C chemokine receptors, which can be simultaneously or selectively expressed on leukocyte subpopulations. In order to isolate receptor(s) for MCP3, a cDNA library was constructed using mRNA from a human Mt-like cell line, YT. These cells showed high affinity binding sites for I-125-MCP3 and migrated in response to MCP3. A chemokine receptor cDNA clone, designated YT4, was sequenced and found to be identical to the known C-C CKR1 or macrophage inflammatory protein-1 alpha (MIP1 alpha)/Rantes receptor. YT4 cDNA was subcloned into a mammalian expression vector, and stable transfectants were prepared using the embryonic kidney cell line 293. The transfectants (YT4/293) showed high affinity binding for I-125-MCP3 in addition to specifically binding I-125-MIP1 alpha and I-125-Rantes. All three C-C chemokines were able to cross compete for binding sites on YT4/293 cells and induced directional migration of YT4/293 cells in vitro, with MCP3 being the most potent chemoattractant. MCP3, MTP1 alpha, and Rantes were equally able to cross-attenuate the migratory response of YT4/293 cells to one another. In contrast, MCP1 and MIP1 beta had very limited capacity to compete for MCP3 binding on YT4/293 cells and had only a minor attenuating effect on MCP3-induced migration. Since MCP3 has been reported to use MCP1 receptor(s), our results with transfected 293 cells expressing only C-C CKR1 clearly establish that C-C CKR1 is also a functional receptor for MCP3.	NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,MOLEC IMMUNOREGULAT LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; SMITHKLINE BEECHAM PHARMACEUT INC,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; GlaxoSmithKline								ALAM R, 1994, J IMMUNOL, V153, P3155; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, P9121; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHARO IF, 1994, CHEMOTACTIC CYTOKINE, P444; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAO JL, 1994, J BIOL CHEM, V269, P28539; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NOSO N, 1994, BIOCHEM BIOPH RES CO, V200, P1470, DOI 10.1006/bbrc.1994.1616; OPDENAKKER G, 1994, GENOMICS, V21, P403, DOI 10.1006/geno.1994.1283; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; SOZZANI S, 1994, J IMMUNOL, V152, P3615; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WANG JM, 1993, J IMMUNOL, V150, P1; YODOI J, 1985, J IMMUNOL, V134, P1623	32	121	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22123	22128		10.1074/jbc.270.38.22123	http://dx.doi.org/10.1074/jbc.270.38.22123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545673	hybrid			2022-12-25	WOS:A1995RW31400013
J	MANZELLA, SM; DHARMESH, SM; BERANEK, MC; SWANSON, P; BAENZIGER, JU				MANZELLA, SM; DHARMESH, SM; BERANEK, MC; SWANSON, P; BAENZIGER, JU			EVOLUTIONARY CONSERVATION OF THE SULFATED OLIGOSACCHARIDES ON VERTEBRATE GLYCOPROTEIN HORMONES THAT CONTROL CIRCULATORY HALF-LIFE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGALACTOSAMINE-TRANSFERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; ALPHA-SUBUNIT; SIALYLATED OLIGOSACCHARIDES; ANIONIC OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION; BOVINE LUTROPIN; RECEPTOR; SO4-4GALNAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA	The circulatory half-life of the mammalian glycoprotein hormone lutropin is controlled by its unique Asn-linked oligosaccharides, which terminate with the sequence SO4-4-GalNAc beta 1,4GlcNAc. A cluster of basic amino acids essential for recognition of the alpha subunit by the glycoprotein hormone:N-acetylgalactosaminyltransferase is located within two turns of an alpha helix (Mengeling, B. J., Manzella, S. M., and Baenziger, J. U. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 502-506). The amino acids within this region are virtually invariant in the alpha subunits of all vertebrates, indicating that the recognition determinant utilized by the N-acetylgalactosaminyltransferase has been conserved in species ranging from teleost fish to mammals. We demonstrate that the glycoprotein hormone:N-acetylgalactosaminyltransferase and the N-acetylgalactosamine-4-sulfotransferase responsible for the synthesis of these unique sulfated oligosaccharides are expressed in the pituitaries of vertebrates ranging from teleost fish to mammals. Furthermore, we show that Asn-linked oligosaccharides terminating with SO4-4-GalNAc beta 1,4GlcNAc are present on the alpha and beta subunits of the salmon glycoprotein hormone GTH II. Asn-linked oligosaccharides terminating with SO4-4-GalNAc beta 1,4GlcNAc are unique structural features of the glycoprotein hormones that have been conserved during vertebrate evolution, suggesting they are critical for the expression of hormone biologic activity.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; UNIV WASHINGTON,SCH FISHERIES,SEATTLE,WA 98195	Washington University (WUSTL); University of Washington; University of Washington Seattle			Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [T32CA009547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09547-09] Funding Source: Medline; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSON DS, 1993, BIOCHEM J, V294, P657, DOI 10.1042/bj2940657; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1994, METHOD ENZYMOL, V230, P237; BAENZIGER JU, 1993, GUIDE TECHNIQUES GLY; BIELINSKA M, 1992, MOL ENDOCRINOL, V6, P267; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FONTAINE YA, 1984, ACTES C INRA PHYSL P, P10; FOSTER DN, 1992, J MOL ENDOCRINOL, V8, P21, DOI 10.1677/jme.0.0080021; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1986, ANAL BIOCHEM, V158, P42, DOI 10.1016/0003-2697(86)90585-3; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; KRYSTEK SR, 1991, BIOCHEMISTRY-US, V30, P1858, DOI 10.1021/bi00221a019; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LITJENS T, 1991, BIOCHEM INT, V24, P209; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; QUERAT B, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P27; REED DK, 1991, J BIOL CHEM, V266, P14251; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SWANSON P, 1991, BIOL REPROD, V44, P29, DOI 10.1095/biolreprod44.1.29; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688	37	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21665	21671		10.1074/jbc.270.37.21665	http://dx.doi.org/10.1074/jbc.270.37.21665			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545167	hybrid			2022-12-25	WOS:A1995RU75700039
J	WOFSY, C; KENT, UM; MAO, SY; METZGER, H; GOLDSTEIN, B				WOFSY, C; KENT, UM; MAO, SY; METZGER, H; GOLDSTEIN, B			KINETICS OF TYROSINE PHOSPHORYLATION WHEN IGE DIMERS BIND TO FC-EPSILON RECEPTORS ON RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RBL-2H3 MAST-CELLS; IMMUNOGLOBULIN-E; SIGNAL TRANSDUCTION; HISTAMINE-RELEASE; ANTIGEN-BINDING; CROSS-LINKING; DESENSITIZATION; AFFINITY; AGGREGATION; COMPLEXES	Previously, we demonstrated that aggregates of the high affinity receptor for IgE (Fc epsilon RI), formed by the binding of chemically cross-linked oligomers of IgE, continue to signal early and late cellular responses long after the formation of new aggregates is blocked. In the present work, we explore quantitatively the relationship between aggregation of the receptors and one of the earliest biochemical changes this initiates. We compare the time course of aggregate formation, inferred from studies of the binding of dimers of IgE, and the time course of phosphorylation of tyrosines on receptor subunits when the receptors are aggregated. A simple model does not fit the data. It appears that aggregates formed late in the response are less effective signaling units than those formed initially. We propose new explanations for the persistence of the response and the unusual kinetics.	LOS ALAMOS NATL LAB,DIV THEORET,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545; UNIV NEW MEXICO,DEPT MATH & STAT,ALBUQUERQUE,NM 87131; NIAMS,BETHESDA,MD 20892	United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)					NIGMS NIH HHS [GM35556] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035556, R01GM035556] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER G, 1992, J IMMUNOL, V149, P2428; APGAR JR, 1990, J IMMUNOL, V145, P3814; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BAZIN H, 1974, IMMUNOLOGY, V26, P713; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CONRAD DH, 1975, J IMMUNOL, V114, P1688; DEMBO M, 1980, CELL, V22, P59, DOI 10.1016/0092-8674(80)90154-3; DEMBO M, 1982, MOL IMMUNOL, V19, P421, DOI 10.1016/0161-5890(82)90208-5; EISEMAN E, 1992, NATURE, V355, P78; FEWTRELL C, 1980, J IMMUNOL, V125, P701; FEWTRELL C, 1985, CALCIUM BIOL SYSTEMS, P129; HOLOWKA D, 1990, CELLULAR MOL MECHANI, V1, P173; HOLOWKA D, 1982, MOL IMMUNOL, V112, P1909; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KANELLOPOULOS JM, 1980, J BIOL CHEM, V255, P9060; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KEIZER J, 1985, ACCOUNTS CHEM RES, V18, P235, DOI 10.1021/ar00116a002; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LABRECQUE GF, 1989, J IMMUNOL, V142, P236; LIU FT, 1980, J IMMUNOL, V124, P2728; MACGLASHAN D, 1983, J IMMUNOL, V130, P2337; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MAO SY, 1991, J IMMUNOL, V146, P958; MAO SY, 1992, P NATL ACAD SCI USA, V89, P222, DOI 10.1073/pnas.89.1.222; MATTHYSSENS GE, 1975, MOL CELL BIOCHEM, V7, P119, DOI 10.1007/BF01792078; MCCLOSKEY MA, 1984, J CELL BIOL, V99, P778, DOI 10.1083/jcb.99.3.778; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; MENON AK, 1986, J CELL BIOL, V102, P534, DOI 10.1083/jcb.102.2.534; METZGER H, 1992, J IMMUNOL, V149, P1477; METZGER H, 1976, IMMUNOCHEMISTRY, V13, P417, DOI 10.1016/0019-2791(76)90377-3; OLIVER JM, 1988, PROG ALLERGY, V42, P185; ORTEGA E, 1991, BIOCHEMISTRY-US, V30, P3473, DOI 10.1021/bi00228a018; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; POSNER RG, 1992, BIOCHEMISTRY-US, V31, P5350, DOI 10.1021/bi00138a015; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; SEAGRAVE J, 1990, J CELL PHYSIOL, V144, P128, DOI 10.1002/jcp.1041440117; SEAGRAVE JC, 1987, CYTOMETRY, V8, P287, DOI 10.1002/cyto.990080309; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; STERK AR, 1982, J IMMUNOL, V128, P838; TAUROG JD, 1977, J IMMUNOL, V119, P1757; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOLF DE, 1980, P NATL ACAD SCI-BIOL, V77, P2043, DOI 10.1073/pnas.77.4.2043; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	54	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20264	20272		10.1074/jbc.270.35.20264	http://dx.doi.org/10.1074/jbc.270.35.20264			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7544786	hybrid			2022-12-25	WOS:A1995RR58400008
J	AMIN, T; LARKINS, A; JAMES, RFL; HIRST, TR				AMIN, T; LARKINS, A; JAMES, RFL; HIRST, TR			GENERATION OF A MONOCLONAL-ANTIBODY THAT RECOGNIZES THE AMINO-TERMINAL DECAPEPTIDE OF THE B-SUBUNIT OF ESCHERICHIA-COLI HEAT-LABILE ENTEROTOXIN - A NEW PROBE FOR STUDYING TOXIN ASSEMBLY INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; VIBRIO-CHOLERAE; CARBOXYL TERMINUS; PEPTIDE-SYNTHESIS; MEMBRANE-PROTEIN; CONFORMATION; SECRETION; EPITOPES; DETERMINANTS; ANTIGEN	Cholera toxin and the related Escherichia coli heat-labile enterotoxin are hexameric proteins comprising one B-subunit and five B-subunits. In this paper we report the generation and characterization of a monoclonal antibody, designated LDS47, that recognizes and precipitates in vivo assembly intermediates of the B-subunit (EtxB) of E. coli heat-labile enterotoxin. The monoclonal antibody is unable to precipitate native B-subunit pentamers, thus making LDS47 a useful probe for studying the early stages of enterotoxin biogenesis. The use of LDS47 to monitor the in vivo turnover of newly synthesized B-subunits in the periplasm off. coli demonstrated that (i) the turnover of unassembled B-subunits followed an apparent first order process and (ii) it occurred concomitantly with the assembly of native B-pentamers (k = 0.317 +/- 0.170 min(-1); t(1/2) = 2.2 min). No other proteins were co-precipitated with the newly synthesized B-subunits; a finding that implies that unassembled B-subunits do not stably associate with other periplasmic proteins prior to their assembly into a macromolecular complex. The use of overlapping synthetic peptides corresponding to the entire EtxB polypeptide demonstrated that the epitope recognized by LDS47 is located within the amino-terminal decapeptide of the B-subunit. From the x-ray structural analysis of the toxin (Sixma, T., Kalk, K., van Zanten, B., Dauter, Z., Kingma, J., Witholt, B., and Hol, W. G. J. (1993) J. Mel. Biol. 230, 890-918), this region appears to resemble a curved finger that clasps the adjacent B-subunit. Thus, this region might be expected to be exposed in the unfolded or unassembled subunit, but to become partially buried upon assembly and thus inaccessible to recognition by the monoclonal antibody.	UNIV KENT, RES SCH BUSINESS, CANTERBURY CT2 7NJ, KENT, ENGLAND; UNIV LEICESTER, DEPT SURG, LEICESTER LE2 7LX, LEICS, ENGLAND	University of Kent; University of Leicester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERT MJ, 1993, LANCET, V342, P387, DOI 10.1016/0140-6736(93)92811-7; AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; APPEL JR, 1990, J IMMUNOL, V144, P976; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BELISLE BW, 1984, INFECT IMMUN, V43, P1027, DOI 10.1128/IAI.43.3.1027-1032.1984; BLACK RE, 1986, DEV VACCINES DRUGS D, P23; CREIGHTON TE, 1978, J MOL BIOL, V123, P129, DOI 10.1016/0022-2836(78)90317-0; DAVID V, 1993, J BIOL CHEM, V268, P9585; DJAVADIOHANIANCE L, 1986, BIOCHEMISTRY-US, V25, P2502, DOI 10.1021/bi00357a033; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FINKELSTEIN RA, 1987, REV INFECT DIS, V9, P544; FOUREL D, 1992, EUR J BIOCHEM, V206, P109, DOI 10.1111/j.1432-1033.1992.tb16907.x; FRIGUET B, 1986, EUR J BIOCHEM, V160, P593, DOI 10.1111/j.1432-1033.1986.tb10079.x; FRIGUET B, 1994, J BIOL CHEM, V269, P15945; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GEYSEN HM, 1985, IMMUNOL TODAY, V6, P364, DOI 10.1016/0167-5699(85)90096-9; GLASS RI, 1986, CLIN TROPICAL MED CO, V1, P603; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HAMLIN J, 1972, P NATL ACAD SCI USA, V69, P412, DOI 10.1073/pnas.69.2.412; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; HIRST TR, 1984, J BACTERIOL, V157, P637, DOI 10.1128/JB.157.2.637-642.1984; HIRST TR, 1984, P NATL ACAD SCI-BIOL, V81, P7752, DOI 10.1073/pnas.81.24.7752; HIRST TR, 1995, HDB NATURAL TOXINS, V8, P123; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOFSTRA H, 1985, J BIOL CHEM, V260, P6037; HOFSTRA H, 1984, J BIOL CHEM, V259, P5182; HOLMES RK, 1983, INFECT IMMUN, V42, P914, DOI 10.1128/IAI.42.3.914-923.1983; HOLMGREN J, 1973, INFECT IMMUN, V8, P208, DOI 10.1128/IAI.8.2.208-214.1973; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KAZEMI M, 1990, INFECT IMMUN, V58, P2352, DOI 10.1128/IAI.58.7.2352-2360.1990; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEONG J, 1985, INFECT IMMUN, V48, P73, DOI 10.1128/IAI.48.1.73-77.1985; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; LINDHOLM L, 1983, INFECT IMMUN, V40, P570, DOI 10.1128/IAI.40.2.570-576.1983; LUI J, 1990, P NATL ACAD SCI USA, V87, P4028; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MOSS J, 1978, J CLIN INVEST, V62, P281, DOI 10.1172/JCI109127; NEILL RJ, 1983, SCIENCE, V221, P289, DOI 10.1126/science.6857285; PALVA ET, 1981, J BACTERIOL, V146, P325, DOI 10.1128/JB.146.1.325-330.1981; QU ZH, 1993, ELECTROPHORESIS, V14, P899, DOI 10.1002/elps.11501401143; REMMERS EF, 1982, INFECT IMMUN, V37, P70, DOI 10.1128/IAI.37.1.70-76.1982; ROBB M, 1982, INFECT IMMUN, V38, P267, DOI 10.1128/IAI.38.1.267-272.1982; SANDKVIST M, 1987, J BACTERIOL, V169, P4570, DOI 10.1128/jb.169.10.4570-4576.1987; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; SHARIF KA, 1994, J BIOL CHEM, V269, P23655; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SVENNERHOLM AM, 1986, MED BIOL, V64, P23; YAMAMOTO T, 1987, J BACTERIOL, V169, P1352, DOI 10.1128/jb.169.3.1352-1357.1987; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x	61	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20143	20150		10.1074/jbc.270.34.20143	http://dx.doi.org/10.1074/jbc.270.34.20143			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544352	hybrid			2022-12-25	WOS:A1995RQ99100069
J	GUNZL, A; TSCHUDI, C; NAKAAR, V; ULLU, E				GUNZL, A; TSCHUDI, C; NAKAAR, V; ULLU, E			ACCURATE TRANSCRIPTION OF THE TRYPANOSOMA-BRUCEI U2 SMALL NUCLEAR-RNA GENE IN A HOMOLOGOUS EXTRACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION SITE; POLYMERASE; PROMOTER; INVITRO	In vitro transcription systems are a classic means to dissect mechanisms of gene expression at the molecular level. To begin an analysis of the biochemistry of gene expression in trypanosomes, we established an in vitro transcription system from cultured insect forms of Trypanosoma brucei. As a model we used the U2 snRNA gene which in vivo is transcribed by an RNA polymerase with characteristics of animal RNA polymerase III. To obtain maximum sensitivity in our assay, we adapted the so-called G-less cassette approach to the U2 snRNA gene promoter. Since an intragenic control region is required for accurate expression in vivo, we generated a series of mutations to substitute all guanosine residues in the intragenic control region. These mutants were shown to retain full transcriptional activity in vivo after transient expression in insect-form trypanosomes. In a cell-free extract, synthesis of the U2 G-less cassette RNA is correctly initiated, is mediated by RNA polymerase III as determined by RNA polymerase inhibitor studies, and is dependent on the integrity of the upstream B box element.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University; Yale University				Gunzl, Arthur/0000-0002-7487-2261	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028798, R01AI028798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; GUNZL A, 1992, MOL CELL BIOL, V12, P468; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	19	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17287	17291		10.1074/jbc.270.29.17287	http://dx.doi.org/10.1074/jbc.270.29.17287			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542235	hybrid			2022-12-25	WOS:A1995RK68900038
J	SCHUMANN, MA; LEUNG, CC; RAFFIN, TA				SCHUMANN, MA; LEUNG, CC; RAFFIN, TA			ACTIVATION OF NADPH-OXIDASE AND ITS ASSOCIATED WHOLE-CELL H+ CURRENT IN HUMAN NEUTROPHILS BY RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR-ALPHA AND FORMYL-METHIONYL-LEUCYL-PHENYLALANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTRACELLULAR PH MEASUREMENT; RESPIRATORY BURST OXIDASE; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE; TNF-ALPHA; PHAGOCYTES; CHANNEL; CONDUCTANCE; MECHANISMS	Proton accumulation and efflux associated specifically with NADPH oxidation in neutrophils remains to be elucidated. Using confocal fluorescence and patch-clamp recordings from single human neutrophils, in the presence of protein kinase C inhibitors, we studied the transient cytosolic acidification and whole cell H+ current induced by N-formyl-methionyl-leucyl-phenylalanine (fMLP) and recombinant human tumor necrosis factor alpha (rhTNF alpha). Intracellular pH changes mere monitored utilizing the ratiometric imaging of the dual emission fluoroprobe, carboxyseminaphthorhodafluor-1, AM acetate. Bath application of 1000 units/ml rhTNF alpha or 0.1 mu M fMLP changed the fluorescence of fluoroprobe-loaded cells, indicating generation of cytosolic H+ ions. In the absence of Ca2+ in the pipette solution, exposure of cells to rhTNF alpha or fMLP for 10 s activated voltage dependent HC currents. From tail current analysis, the threshold voltage for H+ current activation was approximate to -50 mV. These fMLP- or rhTNF alpha-activated voltage-dependent H+ currents were augmented further in the presence of 0.1 mM of NADPH in the pipette solution, and they were inhibited by bath application of 50 mu M of apocynin, an NADPH oxidase inhibitor. These results indicate that rhTNF alpha- or fMLP-induced NADPH oxidase in human neutrophils gives rise to the activation of voltage-dependent H+ currents.			SCHUMANN, MA (corresponding author), STANFORD UNIV,SCH MED,DIV PULM & CRIT CARE MED,STANFORD,CA 94305, USA.				NHLBI NIH HHS [HL455330] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALOBAIDI T, 1981, BIOCHIM BIOPHYS ACTA, V675, P316, DOI 10.1016/0304-4165(81)90020-9; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BASSNETT S, 1990, AM J PHYSIOL, V258, pC171, DOI 10.1152/ajpcell.1990.258.1.C171; BECKSPEIER I, 1993, FREE RADICAL BIO MED, V14, P661, DOI 10.1016/0891-5849(93)90148-N; BERKOW RL, 1987, J LEUKOCYTE BIOL, V41, P441, DOI 10.1002/jlb.41.5.441; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; FUJISHIMA S, 1993, J CELL PHYSIOL, V154, P478, DOI 10.1002/jcp.1041540305; GELDER VBF, 1962, BIOCHIM BIOPHYS ACTA, V58, P590; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; GRINSTEIN S, 1992, AM J PHYSIOL, V263, pC78, DOI 10.1152/ajpcell.1992.263.1.C78; GRZESKOWIAK M, 1986, BIOCHEM BIOPH RES CO, V135, P785, DOI 10.1016/0006-291X(86)90997-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HIKADA H, 1979, MOL PHARMACOL, V15, P49; HIKADA H, 1984, BIOCHEMISTRY-US, V23, P5036; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; KAPUS A, 1993, BIOCHEM J, V292, P445, DOI 10.1042/bj2920445; KRAUSE KH, 1990, J CLIN INVEST, V85, P491, DOI 10.1172/JCI114464; LIANG B, 1992, J CELL PHYSIOL, V152, P145, DOI 10.1002/jcp.1041520119; LIANG SL, 1990, J CELL PHYSIOL, V145, P295, DOI 10.1002/jcp.1041450214; LU DJ, 1990, J BIOL CHEM, V265, P13721; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NAGATA S, 1992, INT ARCH ALLERGY IMM, V97, P194, DOI 10.1159/000236118; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; ORRTMEYER J, 1993, AM J PHYSIOL, V264, pC402; OWEN CS, 1992, ANAL BIOCHEM, V204, P65, DOI 10.1016/0003-2697(92)90140-3; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SCHUMANN MA, 1992, BIOCHEM BIOPH RES CO, V185, P531, DOI 10.1016/0006-291X(92)91657-C; SCHUMANN MA, 1994, J BIOL CHEM, V269, P2389; SCHUMANN MA, 1993, J BIOL CHEM, V268, P2134; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SIMCHOWITZ L, 1985, J CLIN INVEST, V76, P1079, DOI 10.1172/JCI112061; SIMCHOWITZ L, 1979, J IMMUNOL, V123, P2428; SUZUKI Y, 1980, J CLIN INVEST, V66, P1409, DOI 10.1172/JCI109994; SUZUKI Y, 1992, AM REV RESPIR DIS, V145, P338; SWALLOW CJ, 1990, CURR TOP MEMBR TRANS, V35, P227; TANIGAKI T, 1993, J APPL PHYSIOL, V93, P2155; TAUBER AI, 1987, BLOOD, V69, P711; THART BA, 1992, BIOTECHNOL THER, V3, P119; THOMAS JA, 1979, BIOCHEMISTRY-US, V81, P2210; UTSUMI T, 1992, ARCH BIOCHEM BIOPHYS, V294, P271, DOI 10.1016/0003-9861(92)90168-V; WHITAKER JE, 1991, ANAL BIOCHEM, V194, P330, DOI 10.1016/0003-2697(91)90237-N; YONEMARU M, 1991, J APPL PHYSIOL, V71, P342, DOI 10.1152/jappl.1991.71.1.342	60	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13124	13132		10.1074/jbc.270.22.13124	http://dx.doi.org/10.1074/jbc.270.22.13124			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539423	hybrid			2022-12-25	WOS:A1995RB43900030
J	DECLERCK, PJ; CARMELIET, P; VERSTREKEN, M; DECOCK, F; COLLEN, D				DECLERCK, PJ; CARMELIET, P; VERSTREKEN, M; DECOCK, F; COLLEN, D			GENERATION OF MONOCLONAL-ANTIBODIES AGAINST AUTOLOGOUS PROTEINS IN GENE-INACTIVATED MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMINOGEN-ACTIVATOR; AFFINITY; DELETION; MUTANTS; CELLS; SPECIFICITY; DUPLICATION; EXPRESSION; SELECTION; CLONING	Induction of an immune response is strongly dependent on the phylogenetic distance between antigen and recipient. In general, antibodies will not be raised against self-antigens nor against highly conserved domains. In the present study we describe the production and characterization of murine monoclonal ''auto-antibodies'' against murine tissue type plasminogen activator (t-PA) raised in ''knock-out'' mice, homozygously deficient of the functional gene. 203 stable hybridomas were obtained producing murine monoclonal antibodies against murine t-PA. Analysis of the species reactivity revealed that 182 cross-reacted with one or more (t-)PAs originating from other species including rat t-PA, human t-PA, and vampire bat-PA. 121 reacted with epitopes conserved among murine, rat, and human t-PA. In addition, 31 of the monoclonal antibodies were directed against domains present in all four species. Epitope mapping indicated a high frequency of specificity toward diverse epitopes that are highly conserved across species. Comparative analysis of their influence on the enzymatic activity of t-PA and their species cross-reactivity clearly demonstrated that the domains required for the biological activity of plasminogen activators are more conserved (p < 0.02) than non-functional domains. The availability of such unique antibodies against a wide variety of conserved epitopes may facilitate studies on the structural homologies between (t-)PAs isolated from various species. The present approach should also apply to various other classes of proteins, allowing the generation of monoclonal antibodies, against conserved epitopes, which could not be raised in wild-type animals because of their ''self-antigen'' nature.	CATHOLIC UNIV LEUVEN,CTR MOLEC & VASC BIOL,B-3000 LOUVAIN,BELGIUM	KU Leuven			Declerck, Paul J/A-2330-2017; Carmeliet, Peter/AAQ-5140-2020	Declerck, Paul J/0000-0003-1259-9105; Carmeliet, Peter/0000-0001-7961-1821				BULENS F, 1992, FIBRINOLYSIS, V6, P243, DOI 10.1016/0268-9499(92)90077-U; BURNET FM, 1959, CLONAL SELECTION THE; CAJOT JF, 1987, THROMB RES, V46, P141, DOI 10.1016/0049-3848(87)90214-3; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; COLLEN D, 1988, BLOOD, V71, P216; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GODING JW, 1983, MONOCLONAL ANTIBODIE, P5; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1992, EUR J IMMUNOL, V22, P867, DOI 10.1002/eji.1830220336; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRATZSCHMAR J, 1991, GENE, V105, P229, DOI 10.1016/0378-1119(91)90155-5; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; LIJNEN HR, 1992, THROMB HAEMOSTASIS, V67, P239; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; NELLES L, 1990, THROMB HAEMOSTASIS, V64, P53; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; POHL G, 1991, FIBRINOLYSIS, V5, P17, DOI 10.1016/0268-9499(91)90074-E; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VERHEIJEN JH, 1982, THROMB HAEMOSTASIS, V48, P266; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; [No title captured]	21	46	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8397	8400		10.1074/jbc.270.15.8397	http://dx.doi.org/10.1074/jbc.270.15.8397			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7536737	hybrid			2022-12-25	WOS:A1995QT44800007
J	WALSH, MJ; SHUE, GL; SPIDONI, K; KAPOOR, A				WALSH, MJ; SHUE, GL; SPIDONI, K; KAPOOR, A			E2F-1 AND A CYCLIN-LIKE DNA-REPAIR ENZYME, URACIL-DNA GLYCOSYLASE, PROVIDE EVIDENCE FOR AN AUTOREGULATORY MECHANISM FOR TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; E2F-CYCLIN-A COMPLEX; REGULATORY ELEMENT; BINDING ACTIVITY; PROTEIN; TRANSACTIVATION; FACTOR-E2F; COMPONENT; CLONING	The cell cycle-dependent transcription factor, E2F-1, regulates the cyclin-like species of the DNA repair enzyme uracil-DNA glycosylase (UDG) gene in human osteosarcoma (Saos-2) cells. We demonstrate, through the deletion of the human UDG promoter sequences, that expression of E2F-1 activates the UDG promoter through several E2F sites. The major putative downstream site for E2F, located in the first exon, serves as a target for E2F-1/DP1 complex binding in vitro. We also provide evidence for the functional relationship between the cyclin-like UDG gene product and E2F. High levels of UDG expression in a transient transfection assay result in the down-regulation of transcriptional activity through elements specific for E2F-mediated transcription. Overexpression of UDG in Saos 2 cells was observed to delay growth late in G(1) phase and transiently arrest these cells from progressing into the S phase. This hypothetical model integrates one mechanism of DNA repair with the cell cycle control of gene transcription, likely through E2F. This implicates E2F as a multifunctional target for proteins and enzymes, possibly, responsive to DNA damage through the negative effect of UDG on E2F-mediated transcriptional activity.			WALSH, MJ (corresponding author), CUNY MT SINAI SCH MED, DEPT PEDIAT, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.				NIADDK NIH HHS [AM07420] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CORMACK B, 1992, SHORT PROTOCOLS MOL; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FRIEDBERG EC, 1985, DNA REPAIR, P141; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P197, DOI 10.1016/0167-4781(91)90055-Q; MULLER SJ, 1993, J BIOL CHEM, V268, P1310; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; TEDDER TF, 1989, J IMMUNOL, V143, P712; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; WALSH MJ, 1990, MOL CELL BIOL, V10, P4356, DOI 10.1128/MCB.10.8.4356; WALSH MJ, 1992, J BIOL CHEM, V267, P7026; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	56	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5289	5298		10.1074/jbc.270.10.5289	http://dx.doi.org/10.1074/jbc.270.10.5289			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534293	hybrid			2022-12-25	WOS:A1995QL58000053
J	MUNDSCHAU, LJ; FALLER, DV				MUNDSCHAU, LJ; FALLER, DV			PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION THROUGH THE INTERFERON-INDUCIBLE KINASE PKR - IMMEDIATE-EARLY GENE INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DEPENDENT EIF-2-ALPHA KINASE; INITIATION FACTOR-II; GCN2 PROTEIN-KINASE; EJ-RAS ONCOGENE; C-FOS; NIH-3T3 CELLS; RECEPTOR AUTOPHOSPHORYLATION; GLUCOCORTICOID RECEPTOR; SELECTIVE-INHIBITION	The interferon-inducible, double-stranded RNA (dsRNA)-dependent eukaryotic initiation factor-2 alpha kinase PKR has primarily been characterized as a component of the interferon-mediated cellular antiviral response. Several lines of evidence now exist that suggest that PKR plays a role in the regulation of growth in uninfected cells. The most direct examples are the finding of an oncogenic variant of PKR and the effects of activators and inhibitors of PKR phosphorylation on the expression of platelet-derived growth factor (PDGF)-inducible genes. Previous reports have shown that 1) dsRNA, a direct activator of PKR, induces the genes c-myc, c-fos, and JE; 2) 2-aminopurine, a chemical inhibitor of PKR, blocks the induction of these genes by serum; and 3) activated p21(ras) induces a cellular inhibitor of PKR. We report here that activation of PKR was correlated with the induction of the immediate early genes c-fos, c-myc, and JE by PDGF in the following situations: 1) PDGF induction of these genes, also inducible by dsRNA, was blocked by two inhibitors of PKR activation: 2-aminopurine and v-ras; 2) PDGF induction of another immediate early gene, egr-1, which could not be induced by dsRNA, was not blocked by 2-aminopurine or v-ras; 3) agents that reverse v-ras inhibition of PKR activation also reversed the v-ras block of PDGF induction of c-myc, c-fos, and JE; 4) down-regulation of PKR protein levels by antisense inhibition of translation blocked the induction of c-myc, c-fos, and JE by PDGF, but had no effect on egr-1 induction; and finally, 5) PHR was autophosphorylated in vivo in response to PDGF. These results provide direct evidence that PKR activation functions as a second messenger in a growth factor signal transduction pathway. Thus, PKR may serve as a common mediator of growth-promoting and growth inhibitory signals.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118	Boston University			Kasman, Laura/AAF-3536-2021	Kasman, Laura/0000-0002-8661-2918				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; CARCHMAN RA, 1974, CELL, V1, P59, DOI 10.1016/0092-8674(74)90156-1; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1993, J INTERFERON RES, V13, P241, DOI 10.1089/jir.1993.13.241; CLEMENS MJ, 1994, BIOCHIMIE PARIS, V8, P770; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALLER DV, 1994, J BIOL CHEM, V269, P5022; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GIANTINI M, 1989, J VIROL, V63, P2415, DOI 10.1128/JVI.63.6.2415-2421.1989; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUNDSCHAU LJ, 1991, MOL CELL BIOL, V11, P3148, DOI 10.1128/MCB.11.6.3148; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; MUNDSCHAU LJ, 1994, BIOCHIMIE PARIS, V8, P792; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; OLINGER PL, 1989, J CELL PHYSIOL, V139, P335, DOI 10.1002/jcp.1041390216; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PRATT WB, 1988, J BIOL CHEM, V263, P267; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RICE AP, 1989, J BIOL CHEM, V264, P20632; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	59	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3100	3106		10.1074/jbc.270.7.3100	http://dx.doi.org/10.1074/jbc.270.7.3100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531699	hybrid			2022-12-25	WOS:A1995QG47100034
J	PLUSKEY, S; WANDLESS, TJ; WALSH, CT; SHOELSON, SE				PLUSKEY, S; WANDLESS, TJ; WALSH, CT; SHOELSON, SE			POTENT STIMULATION OF SH-PTP2 PHOSPHATASE-ACTIVITY BY SIMULTANEOUS OCCUPANCY OF BOTH SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; PHOSPHORYLATION; BINDING; ASSOCIATION; ACTIVATION; 3-KINASE	Src homology 2 (SH2) domains are phosphotyrosine binding modules found within many cytoplasmic proteins. A major function of SR2 domains is to bring about the physical assembly of signaling complexes, We now show that, in addition, simultaneous occupancy of both SH2 domains of the phosphotyrosine phosphatase SH-PTP2 (Syp, PTP 1D, PTP-2C) by a tethered peptide with two IRS-1-derived phosphorylation sites potently stimulates phosphatase activity. The concentration required for activation by the tethered peptide is 80-160-fold lower than either corresponding monophosphorylated peptide. Moreover, the diphosphorylated peptide stimulates catalytic activity 37-fold, compared with 9-16-fold for the monophosphorylated peptides. Mutational analyses of the SH2 domains of SH-PTP2 confirm that both SH2 domains participate in this effect. Binding studies with a tandem construct comprising the N- plus C-terminal SH2 domains show that the diphosphorylated peptide binds with 60-90-fold higher affinity than either monophosphorylated sequence. These results demonstrate that SH-PTP2 activity can be potently regulated by interacting via both of its SH2 domains with phosphoproteins having two cognate phosphorylation sites.	JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836] Funding Source: Medline; NIGMS NIH HHS [GM 20011] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Morrison M, 1980, Methods Enzymol, V70, P214; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TONKS NK, 1988, J BIOL CHEM, V263, P6731; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XIAO S, 1994, J BIOL CHEM, V269, P21244; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	25	227	229	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2897	2900		10.1074/jbc.270.7.2897	http://dx.doi.org/10.1074/jbc.270.7.2897			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531695	hybrid			2022-12-25	WOS:A1995QG47100005
J	PERRONE, CE; FENWICKSMITH, D; VANDENBURGH, HH				PERRONE, CE; FENWICKSMITH, D; VANDENBURGH, HH			COLLAGEN AND STRETCH MODULATE AUTOCRINE SECRETION OF INSULIN-LIKE GROWTH-FACTOR-I AND INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS FROM DIFFERENTIATED SKELETAL-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLICATION-STIMULATING ACTIVITY; LIVER TRANSCRIPTION FACTORS; RAT MYOBLASTS RELEASE; I IGF-I; GENE-EXPRESSION; SATELLITE CELLS; TISSUE-CULTURE; SOMATOMEDIN; RECEPTOR; INVITRO	Stretch-induced skeletal muscle growth may involve increased autocrine secretion of insulin-like growth factor-1 (IGF-1) since IGF-1 is a potent growth factor for skeletal muscle hypertrophy, and stretch elevates IGF-1 mRNA levels in vivo, In tissue cultures of differentiated avian pectoralis skeletal muscle cells, nanomolar concentrations of exogenous IGF-1 stimulated growth in mechanically stretched but not static cultures, These cultures released up to 100 pg of endogenously produced IGF-1/mu g of protein/day, as well as three major IGF binding proteins of 31, 36, and 43 kilodaltons (kDa), IGF-1 was secreted from both myofibers and fibroblasts coexisting in the muscle cultures, Repetitive stretch/relaxation of the differentiated skeletal muscle cells stimulated the acute release of IGF-1 during the first 4 h after initiating mechanical activity, but caused no increase in the long-term secretion over 24-72 h of IGF-1, or its binding proteins, Varying the intensity and frequency of stretch had no effect on the long-term efflux of IGF-1, In contrast to stretch, embedding the differentiated muscle cells in a three-dimensional collagen (Type I) matrix resulted in a 2-5-fold increase in long-term IGF-1 efflux over 24-72 h, Collagen also caused a 2-5-fold increase in the release of the IGF binding proteins, Thus, both the extracellular matrix protein type I collagen and stretch stimulate the autocrine secretion of IGF-1, but with different time kinetics, This endogenously produced growth factor may be important for the growth response of skeletal myofibers to both types of external stimuli.	BROWN UNIV, SCH MED, DEPT PATHOL, PROVIDENCE, RI 02906 USA	Brown University	PERRONE, CE (corresponding author), MIRIAM HOSP, DEPT LAB MED, 164 SUMMIT AVE, PROVIDENCE, RI 02906 USA.				NIAMS NIH HHS [R0I AR 39998] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039998] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGREZ MV, 1991, CELL REGUL, V2, P1035, DOI 10.1091/mbc.2.12.1035; ALLEN RE, 1990, P SOC EXP BIOL MED, V194, P81; ARMSTRONG DG, 1989, J ENDOCRINOL, V120, P373, DOI 10.1677/joe.0.1200373; BREIER BH, 1991, J ENDOCRINOL, V128, P347, DOI 10.1677/joe.0.1280347; CLEMMONS DR, 1991, ADV EXP MED BIOL, V293, P113; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DODSON MV, 1985, ENDOCRINOLOGY, V117, P2357, DOI 10.1210/endo-117-6-2357; DUCLOS MJ, 1991, J ENDOCRINOL, V128, P35, DOI 10.1677/joe.0.1280035; EDWALL D, 1989, ENDOCRINOLOGY, V124, P820, DOI 10.1210/endo-124-2-820; ERNST CW, 1992, ENDOCRINOLOGY, V130, P607, DOI 10.1210/en.130.2.607; EWTON DZ, 1990, P SOC EXP BIOL MED, V194, P76; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FURLANETTO RW, 1977, J CLIN INVEST, V60, P648, DOI 10.1172/JCI108816; GILLERY P, 1992, J CELL PHYSIOL, V152, P389, DOI 10.1002/jcp.1041520221; HILL DJ, 1985, ENDOCRINOLOGY, V117, P2061, DOI 10.1210/endo-117-5-2061; HILL DJ, 1984, J CELL PHYSIOL, V119, P349, DOI 10.1002/jcp.1041190314; HOPPELER H, 1992, INT J SPORTS MED, V13, pS166, DOI 10.1055/s-2007-1024628; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JANECZKO RA, 1984, J BIOL CHEM, V259, P6292; JENNISCHE E, 1989, ACTA ENDOCRINOL-COP, V121, P733, DOI 10.1530/acta.0.1210733; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V130, P327, DOI 10.1111/j.1748-1716.1987.tb08144.x; JENNISCHE E, 1992, ACTA PHYSIOL SCAND, V146, P79, DOI 10.1111/j.1748-1716.1992.tb09395.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOWE WL, 1992, MOL ENDOCRINOL, V6, P741, DOI 10.1210/me.6.5.741; MAGRI KA, 1991, ADV EXP MED BIOL, V293, P57; MANGAT H, 1993, ENDOCRINOLOGY, V133, P1398, DOI 10.1210/en.133.3.1398; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; RUTANEN EM, 1990, ACTA ENDOCRINOL-COP, V123, P7, DOI 10.1530/acta.0.1230007; Sambrook J, 1989, MOL CLONING LABORATO; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SWADISON S, 1992, J CELL SCI, V102, P643; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VANDENBURGH H, 1980, J BIOL CHEM, V255, P5826; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475	45	125	127	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2099	2106		10.1074/jbc.270.5.2099	http://dx.doi.org/10.1074/jbc.270.5.2099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530717	Green Submitted, hybrid			2022-12-25	WOS:A1995QE49300020
J	BOLDIN, MP; METT, IL; VARFOLOMEEV, EE; CHUMAKOV, I; SHEMERAVNI, Y; CAMONIS, JH; WALLACH, D				BOLDIN, MP; METT, IL; VARFOLOMEEV, EE; CHUMAKOV, I; SHEMERAVNI, Y; CAMONIS, JH; WALLACH, D			SELF-ASSOCIATION OF THE DEATH DOMAINS OF THE P55 TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR AND FAS/APO1 PROMPTS SIGNALING FOR TNF AND FAS/APO1 EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; FAS ANTIGEN; EXPRESSION; INDUCTION; APOPTOSIS; INTERLEUKIN-1; PROMOTERS; PROTEINS; FAMILY	Signaling by the p55 tumor necrosis factor (TNF) receptor and by the structurally related receptor Fas/APO1 is initiated by receptor clustering. Data presented here and in other recent studies (Wallach, D., Boldin, M., Varfolomeev, E. E., Bigda, Y., Camonis, H. J. and Mett, I. (1994) Cytokine 6, 556; Song, H. Y., Dunbar, J. D., and Bonner, D. B. (1994) J. Biol. Chem. 269, 22492-22495) indicate that part of that region within the intracellular domains of the two receptors that is involved in signaling for cell, death, as well as for some other effects (the ''death domain'', specifically self-associates. We demonstrate also the expected functional consequence of this association; a mere increase in p55 TNF receptor expression, or the expression just of its intracellular domain, is shown to trigger signaling for cytotoxicity as well as for interleukin 8 gene induction, while expression of the intracellular domain of Fas/APO1 potentiates the cytotoxicity of co-expressed p55 TNF receptor. These findings indicate that the p55 TNF and Fas/APO1 receptors play active roles in their own clustering and suggest the existence of cellular mechanisms that restrict the self-association of these receptors, thus preventing constitutive signaling.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; DENIS DIDEROT UNIV,INSERM,U248,F-75010 PARIS,FRANCE	Weizmann Institute of Science; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			AVNI, YONAT SHEMER/F-1772-2012	Boldin, Mark/0000-0003-4593-0669				ADERKA D, 1991, CANCER RES, V51, P5602; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; DHEIN J, 1992, J IMMUNOL, V149, P3166; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HALEY JD, 1989, ONCOGENE, V4, P273; HELLER RA, 1992, CELL, V70, P47; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; ITOH N, 1993, J BIOL CHEM, V268, P10932; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LONARDO F, 1990, New Biologist, V2, P992; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SONG HY, 1994, J BIOL CHEM, V268, P22492; STAMENKOVIC I, 1989, EMBO J, V8, P1408; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALLACH D, 1984, J IMMUNOL, V132, P2464; WALLACH D, 1994, CYTOKINE, V6, P558; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	33	348	375	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					387	391		10.1074/jbc.270.1.387	http://dx.doi.org/10.1074/jbc.270.1.387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529234	hybrid			2022-12-25	WOS:A1995QA28700061
J	ORTEN, DJ; STRAWHECKER, JM; SANDERSON, SD; HUANG, DY; PRYSTOWSKY, MB; HINRICHS, SH				ORTEN, DJ; STRAWHECKER, JM; SANDERSON, SD; HUANG, DY; PRYSTOWSKY, MB; HINRICHS, SH			DIFFERENTIAL-EFFECTS OF MONOCLONAL-ANTIBODIES ON ACTIVATING TRANSCRIPTION FACTOR-I AND CAMP RESPONSE ELEMENT-BINDING PROTEIN INTERACTIONS WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; RNA-POLYMERASE; CREB BINDING; TAX PROTEIN; FACTOR ATF; PROMOTER; GENE; EXPRESSION; COMPLEX; PHOSPHORYLATION	Activating transcription factor-1 (ATF1) and cAMP response element binding protein (CREB) have been implicated in cAMP-, calcium-, and virus-induced transcriptional alterations. Although CREB and ATF1 share extensive homology, they appear to mediate distinct cellular functions. We investigated the effect on DNA binding and in vitro transcription of four monoclonal antibodies (mAb) that bound to domains in either the regulatory region (mAb 1 and 3) or unique regions near the DNA-binding domains (mAb 4 and 5) of ATF1. mAb 1 and 3 supershifted both ATF1 and CREB in a DNA binding assay but did not affect in vitro transcription. mAb 4 prevented ATF1-DNA binding while supershifting CREB.DNA complexes and inhibited in vitro transcription by 95% from the CRE-containing murine proliferating cell nuclear antigen promoter. mAb 5 reacted specifically with ATF1 and did not prevent DNA binding or affect in vitro transcription. The mAb 4 epitope was located within ATF1 amino acid residues 205-219, including the first 3 basic residues in the putative DNA-binding domain. Secondary structural analysis predicted that this region comprises a transition site from alpha-helix to a turn-like conformation in ATF1. The transition to turn-like motifs is predicted to occur in CREB after 5 additional residues, with a correspondingly longer Ly-helical domain. Although regulatory domains distinct from DNA binding regions are thought to account for most of the differences in activity of members of the CREB subfamily, our results suggest that small structural variations adjacent to DNA binding regions may also contribute to the distinct functional activities of ATF1 and CREB.	UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT MICROBIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10467	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [CA49624] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049624] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; DASH PK, 1993, CELL MOL BIOL, V39, P35; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMBER JA, 1992, J IMMUNOL, V148, P3165; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KELLY D, 1994, IN PRESS MOL REPROD; KLIEWER S, 1990, J VIROL, V64, P4507, DOI 10.1128/JVI.64.9.4507-4515.1990; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MANTOVANI R, 1992, EMBO J, V11, P3316; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P1163, DOI 10.1093/nar/21.5.1163; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; QUINN PG, 1993, J BIOL CHEM, V268, P16999; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SETH A, 1993, ONCOGENE, V8, P1783; Shipman-Appasamy P M, 1991, DNA Seq, V2, P181, DOI 10.3109/10425179109039688; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; SZILVAY AM, 1993, ARCH VIROL, V131, P393, DOI 10.1007/BF01378640; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WALZ DA, 1974, THROMB RES, V4, P713, DOI 10.1016/0049-3848(74)90226-6; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	48	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32254	32263						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528210				2022-12-25	WOS:A1994PX30400039
J	MEACOCK, S; PESCINIGOBERT, R; DELAMARTER, JF; VANHUIJSDUIJNEN, RH				MEACOCK, S; PESCINIGOBERT, R; DELAMARTER, JF; VANHUIJSDUIJNEN, RH			TRANSCRIPTION FACTOR-INDUCED, PHASED BENDING OF THE E-SELECTIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LEUKOCYTE-ADHESION MOLECULE-1; CURVED DNA; REGULATORY PROTEINS; CYTOKINE INDUCTION; GENE-TRANSCRIPTION; ESCHERICHIA-COLI; BINDING; FAMILY; ELAM-1	E-selectin is an endothelial adhesion molecule that is critically involved in neutrophil adhesion and recruitment. All DNA elements required for interleukin-l inducibility have been located in the proximal promoter: an NF-ELAM1/ATF site, two NF-kappa B sites (I and II), the NF-ELAM2 element and a TATA box We show here that interleukin-1 induced promoter activity is exquisitely sensitive to the spatial arrangements of these elements. Phasing of the ATF and NF-kappa B II elements indicates that their relative helix orientation is more important than distance per se. This sensitivity is partly due to a requirement for correctly oriented, transcription factor-induced DNA-bending. (i) Band shift analyses with permuted ATF- and NF-kappa B elements show that their associated factors all bend DNA (ii) One can functionally replace the NF-ELAM1/ATF element by a subset of a panel of DNA fragments that contain defined bends in various planes, We conclude that the main role of the factors binding at the NF-ELAM1/ATF element is to alter the conformation of the E-selectin promoter, presumably looping distant enhancer elements into each other's proximity,	GLAXO,INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline			van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424; Pescini Gobert, Rosanna/0000-0002-2434-7530				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; GASTON K, 1992, NUCLEIC ACIDS RES, V20, P3391, DOI 10.1093/nar/20.13.3391; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GHERSA P, 1994, J BIOL CHEM, V269, P29129; GHERSA P, GENE AMST, V151, P331; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HUBER HE, 1994, J BIOL CHEM, V269, P6999; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LARIGAN JD, 1992, DNA CELL BIOL, V11, P149, DOI 10.1089/dna.1992.11.149; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MARTIN JP, 1993, SCIENCE, V260, P805; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MUROI M, 1993, J BIOL CHEM, V268, P19534; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PESCINI R, 1994, J BIOL CHEM, V269, P1159; PESCINI R, 1994, BIOCHEM BIOPH RES CO, V202, P1664, DOI 10.1006/bbrc.1994.2125; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SHPIGELMAN ES, 1993, COMPUT APPL BIOSCI, V9, P435; SMITH GM, 1993, BIOCHEM BIOPH RES CO, V194, P215, DOI 10.1006/bbrc.1993.1806; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; VANHUIJSDUIJNEN RAMH, 1992, BIOTECHNIQUES, V12, P830; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VANHUIJSDUIJNEN RH, 1993, NUCLEIC ACIDS RES, V21, P3711, DOI 10.1093/nar/21.16.3711; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31756	31762						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527395				2022-12-25	WOS:A1994PX30300067
J	ADLER, M; SETO, MH; NITECKI, DE; LIN, JH; LIGHT, DR; MORSER, J				ADLER, M; SETO, MH; NITECKI, DE; LIN, JH; LIGHT, DR; MORSER, J			THE STRUCTURE OF A 19-RESIDUE FRAGMENT FROM THE C-LOOP OF THE 4TH EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF THROMBOMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE MODULE; PROTEIN-C; 3-DIMENSIONAL STRUCTURE; NMR-SPECTROSCOPY; COUPLING-CONSTANTS; COFACTOR ACTIVITY; H-1-NMR SPECTRA; ALPHA; THROMBIN; MACROMOLECULES	The solution structure has been determined for a 19-residue peptide that is fully folded at room temperature. The sequence of this peptide is based on the C-loop, residues 371-389, of the fourth epidermal growth factor-like domain of thrombomodulin, a protein that acts as a cofactor for the thrombin activation of protein C. Despite its small size, the peptide forms a compact structure with almost no repeating secondary structure. The results indicate the structure is held together by hydrophobic interactions, which in turn stabilize the two beta-turns in the structure. The first beta-turn in the C-loop represents a conserved motif that is found in the published structures of five other epidermal growth factor-like proteins. The critical role of Phe(376) in the stabilization tion of the first beta-turn is consistent with mutagenesis data with soluble thrombomodulin. The results also show that a small subdomain of a larger protein can fold independently, and therefore it could act as an initiation site for further folding.			ADLER, M (corresponding author), BERLIX BIOSCI INC,15049 SAN PABLO AVE,RICHMOND,CA 94804, USA.							ADLER M, 1992, BIOCHEMISTRY-US, V31, P1031, DOI 10.1021/bi00119a011; BARON M, 1992, PROTEIN SCI, V1, P81; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON NL, 1982, J BIOL CHEM, V257, P859; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LIN JH, 1994, J BIOL CHEM, V269, P25021; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SRINIVASAN J, 1994, BIOCHEMISTRY-US, V33, P13553, DOI 10.1021/bi00250a007; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; ULLNER M, 1992, BIOCHEMISTRY-US, V31, P5974, DOI 10.1021/bi00141a004; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	34	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23366	23372		10.1074/jbc.270.40.23366	http://dx.doi.org/10.1074/jbc.270.40.23366			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559494	hybrid			2022-12-25	WOS:A1995RY90900023
J	REUMANN, S; MAIER, E; BENZ, R; HELDT, HW				REUMANN, S; MAIER, E; BENZ, R; HELDT, HW			THE MEMBRANE OF LEAF PEROXISOMES CONTAINS A PORIN-LIKE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; MATRIX PROTEIN PORIN; OUTER-MEMBRANE; CHLOROPLAST ENVELOPE; RAT-LIVER; FORMING PROTEIN; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; MALATE-DEHYDROGENASE; SPINACH-CHLOROPLASTS	Spinach leaf peroxisomes were purified by Percoll density gradient centrifugation. After several freeze-thaw cycles, the peroxisomal membranes were separated from the matrix enzymes by sucrose density gradient centrifugation. The purity of the peroxisomal membranes was checked by measuring the activities of marker enzymes and by using antibodies. Lipid bilayer membrane experiments with the purified peroxisomal membranes, solubilized with a detergent, demonstrated that the membranes contain a channel-forming component, which may represent the major permeability pathway of these membranes. Control experiments with membranes of other cell organelles showed that the peroxisomal channel was not caused by the contamination of the peroxisomes with mitochondria or chloroplasts. The peroxisomal channel had a comparatively small single channel conductance of 350 pS in 1 M KCl as compared with channels from other cell organelles. The channel is slightly anion selective, which is in accordance with its physiological function. The single channel conductance was found to be only moderately dependent on the salt concentration in the aqueous phase. This may be explained by the presence of positive point net charges in or near the channel or by the presence of a saturable binding site inside the channel. The possible role of the channel in peroxisomal metabolism is discussed.	UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST,LEHRSTUHL BIOTECHNOL,D-97074 WURZBURG,GERMANY	University of Wurzburg	REUMANN, S (corresponding author), UNIV GOTTINGEN,INST BIOCHEM PFLANZE,UNTERE KARSPULE 2,D-37073 GOTTINGEN,GERMANY.			Benz, Roland/0000-0002-9510-9265				ALJAMAL JA, 1993, PLANT PHYSIOL, V102, P615, DOI 10.1104/pp.102.2.615; ANDREWS J, 1983, PLANT PHYSIOL, V72, P75; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1980, J MEMBRANE BIOL, V56, P19, DOI 10.1007/BF01869348; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; Benz R., 1994, BACTERIAL CELL WALL, P397; BLOCK MA, 1983, J BIOL CHEM, V258, P3273; BLOCK MA, 1983, FEBS LETT, V153, P377, DOI 10.1016/0014-5793(83)80647-4; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; CASTELLAN GW, 1983, PHYSICAL CHEM, P769; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; CHAPMAN KD, 1992, PLANT PHYSIOL BIOCH, V30, P1; DOUCE R, 1973, BIOCHIM BIOPHYS ACTA, V292, P105, DOI 10.1016/0005-2728(73)90255-7; DOUCE R, 1973, J BIOL CHEM, V248, P7215; DOUMA AC, 1987, ARCH MICROBIOL, V147, P42, DOI 10.1007/BF00492903; FISCHER K, 1994, J BIOL CHEM, V269, P25754; FISCHER K, 1995, PLANT MOL BIOL, V25, P167; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; FRENTZEN M, 1990, EUR J BIOCHEM, V187, P395, DOI 10.1111/j.1432-1033.1990.tb15317.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GERHARDT B, 1986, PHYSIOL VEG, V24, P397; GERHARDT R, 1984, PLANT PHYSIOL, V75, P542, DOI 10.1104/pp.75.3.542; HELDT HW, 1971, BIOCHIM BIOPHYS ACTA, V234, P83, DOI 10.1016/0005-2728(71)90133-2; HEUPEL R, 1991, PLANT PHYSIOL, V96, P971, DOI 10.1104/pp.96.3.971; HEUPEL R, 1994, EUR J BIOCHEM, V220, P165, DOI 10.1111/j.1432-1033.1994.tb18611.x; ICHIHARA K, 1993, PLANT CELL PHYSIOL, V34, P557; JANK B, 1993, TRENDS BIOCHEM SCI, V18, P427; JOYARD J, 1981, PLANT PHYSIOL, V67, P250, DOI 10.1104/pp.67.2.250; KALDI K, 1993, FEBS LETT, V315, P217, DOI 10.1016/0014-5793(93)81167-X; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; LABARCA P, 1986, J MEMBRANE BIOL, V94, P285, DOI 10.1007/BF01869724; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMENS M, 1989, BIOCHIM BIOPHYS ACTA, V984, P351, DOI 10.1016/0005-2736(89)90302-7; LESSIRE R, 1979, PLANT SCI LETT, V16, P31, DOI 10.1016/0304-4211(79)90005-1; LUDWIG B, 1976, H-S Z PHYSIOL CHEM, V357, P177, DOI 10.1515/bchm2.1976.357.1.177; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; NICOLAY K, 1987, ARCH MICROBIOL, V147, P37, DOI 10.1007/BF00492902; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PREISIGMULLER R, 1994, EUR J BIOCHEM, V219, P57, DOI 10.1111/j.1432-1033.1994.tb19914.x; REUMANN S, 1994, PLANTA, V193, P167, DOI 10.1007/BF00192526; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; SAUER A, 1985, PLANTA, V166, P227, DOI 10.1007/BF00397353; SCHMID A, 1992, BIOCHIM BIOPHYS ACTA, V1112, P174, DOI 10.1016/0005-2736(92)90389-4; SCHMITT MR, 1983, PLANT PHYSIOL, V72, P728, DOI 10.1104/pp.72.3.728; STRUGLICS A, 1993, PHYSIOL PLANTARUM, V88, P19, DOI 10.1111/j.1399-3054.1993.tb01755.x; SUKUMAR V, 1987, BIOCHEM INT, V14, P719; SULTER GJ, 1993, YEAST, V9, P733, DOI 10.1002/yea.320090707; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOLINS NE, 1994, J BIOL CHEM, V269, P1149; YU C, 1986, ARCH BIOCHEM BIOPHYS, V245, P125, DOI 10.1016/0003-9861(86)90196-7	56	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17559	17565		10.1074/jbc.270.29.17559	http://dx.doi.org/10.1074/jbc.270.29.17559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542242	hybrid			2022-12-25	WOS:A1995RK68900078
J	HEMMERICH, S; LEFFLER, H; ROSEN, SD				HEMMERICH, S; LEFFLER, H; ROSEN, SD			STRUCTURE OF THE O-GLYCANS IN GLYCAM-1, AN ENDOTHELIAL-DERIVED LIGAND FOR L-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; P-SELECTIN; SIALYLATED OLIGOSACCHARIDES; MECONIUM GLYCOPROTEINS; EXPRESSION CLONING; EPITHELIAL-CELLS; LINKED GLYCANS; CORE; IDENTIFICATION; LECTIN	L-selectin, the leukocyte selectin, mediates the carbohydrate dependent attachment of circulating leukocytes to endothelium, preceding emigration into tissues, It functions in inflammatory leukocyte trafficking and in lymphocyte homing to lymph nodes, From previous work, the binding of L-selectin to endothelial-associated glycoprotein ligands, GlyCAM-1 and CD34, requires oligosaccharide sialylation, sulfation, and probably fucosylation, We have recently identified a major capping group in GlyCAM-1 as 6' sulfated sialyl Lewis x, a novel structure which potentially satisfies all of these requirements, In the present study, we define the complete structure of beta-eliminated chains of GlyCAM-1 using metabolic radiolabeling, plant lectin binding, and glycosidase digestions in conjunction with high pH anion-exchange chromatography. The majority of the O-glycans in GlyCAM-1 contain the T-antigen, i.e. Gal beta 1-->GalNAc, which is incorporated into the core-a structure, i.e. Gal beta 1-->3[GlcNAc beta 1-->6]GalNAc or larger core structures with additional GlcNAc residues, The structures of two O-glycans, based on core-2, were determined to be: [GRAPHICS] The implications of these structures and more complex O-glycans for binding by L-selectin are discussed,	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,PROGRAM IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	HEMMERICH, S (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM023547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA M, 1974, J BIOCHEM, V75, P707, DOI 10.1093/oxfordjournals.jbchem.a130443; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BOLAND CR, 1991, CANCER RES, V51, P657; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; BROCKHAUSEN I, 1984, CAN J BIOCHEM CELL B, V75, P1081; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GREEN ED, 1988, J BIOL CHEM, V263, P25; HANISCH FG, 1992, EUR J BIOCHEM, V205, P527, DOI 10.1111/j.1432-1033.1992.tb16809.x; HANISCH FG, 1993, EUR J BIOCHEM, V217, P645, DOI 10.1111/j.1432-1033.1993.tb18288.x; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HOUNSELL EF, 1985, EUR J BIOCHEM, V148, P367, DOI 10.1111/j.1432-1033.1985.tb08848.x; HOUNSELL EF, 1989, EUR J BIOCHEM, V186, P597, DOI 10.1111/j.1432-1033.1989.tb15250.x; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, GLYCOCONJUGATE J, V10, P34, DOI 10.1007/BF00731184; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KIKUTA A, 1994, BLOOD, V84, P3766, DOI 10.1182/blood.V84.11.3766.bloodjournal84113766; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LI SC, 1975, J BIOL CHEM, V250, P6786; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOTAN R, 1975, J BIOL CHEM, V250, P8518; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NELSON RM, 1993, BLOOD, V82, P3253; OEHRLEIN R, 1993, CARBOHYD RES, V244, P149, DOI 10.1016/0008-6215(93)80011-3; PFEIFFER G, 1992, GLYCOBIOLOGY, V2, P411, DOI 10.1093/glycob/2.5.411; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosen S D, 1993, Semin Immunol, V5, P237, DOI 10.1006/smim.1993.1028; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SCHACHNER HS, 1989, S SOC EXP BIOL, V63, P1; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; STOOLMAN LM, 1992, CELL SURFACE CARBOHY; VANHALBEEK H, 1985, FEBS LETT, V187, P81, DOI 10.1016/0014-5793(85)81219-9; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; YUREWICZ EC, 1987, J BIOL CHEM, V262, P4733	61	269	276	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12035	12047		10.1074/jbc.270.20.12035	http://dx.doi.org/10.1074/jbc.270.20.12035			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538131	hybrid			2022-12-25	WOS:A1995QY73600054
J	MATSUDA, T; FUKADA, T; TAKAHASHITEZUKA, M; OKUYAMA, Y; FUJITANI, Y; HANAZONO, Y; HIRAI, H; HIRANO, T				MATSUDA, T; FUKADA, T; TAKAHASHITEZUKA, M; OKUYAMA, Y; FUJITANI, Y; HANAZONO, Y; HIRAI, H; HIRANO, T			ACTIVATION OF FES TYROSINE KINASE BY GP130, AN INTERLEUKIN-6 FAMILY CYTOKINE SIGNAL TRANSDUCER, AND THEIR ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							X-LINKED AGAMMAGLOBULINEMIA; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; RECEPTOR; EXPRESSION; PROTEIN; DIFFERENTIATION; CNTF; GENE	gp130 is a signal-transducing subunit of receptors for the interleukin-6 (IL-6)-related cytokine subfamily including IL-6, leukemia inhibitory factor, oncostatin M, IL-11, and ciliary neurotrophic factor, indicating that gp130-mediated signals are involved in the immune response, hematopoiesis, inflammation, and endocrine and nervous system activity. We previously showed that gp130 stimulation rapidly activates Jak, Btk, and Tec tyrosine kinases, all of which constitutively associate with gp130, To further elucidate intracellular signal transduction through gp130, we examined the possible involvement of another nonreceptor tyrosine kinase, p92(c-fes) (Fes). We showed that gp130 stimulation rapidly induced tyrosine phosphorylation of Fes and actually activated its kinase activity in hematopoietic lineage cells. Furthermore, Fes associated with gp130 independently of ligand stimulation like Jak, Btk, and Tec tyrosine kinases. These results indicate that multiple nonreceptor tyrosine kinases are involved in the gp130-mediated signal transduction pathway. Because both gp130 and Fes are expressed not only in hematopoietic lineage cells but also in heart and nerve cells, Fes may play a role in signal transduction through gp130 in these tissues.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV MOLEC ONCOL,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	Osaka University; University of Tokyo			Hirano, Toshio/C-8194-2009; Matsuda, Tadashi/A-3835-2012	Matsuda, Tadashi/0000-0002-3089-3757				BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; CARE A, 1994, ONCOGENE, V9, P739; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; LUTTICKEN C, 1993, SCIENCE, V263, P89; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1994, BLOOD, V83, P3457; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V202, P637, DOI 10.1006/bbrc.1994.1975; MATSUDA T, 1995, BLOOD, V84, P627; MURAKAMI M, 1991, P NATL ACAD SCI USA, V99, P11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OGAWA M, 1993, BLOOD, V81, P2844; ORITANI K, 1992, BLOOD, V80, P2298; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; RAWLINGS DJ, 1993, SCIENCE, V358, P358; SAITO M, 1992, J IMMUNOL, V148, P4066; STAHL N, 1993, SCIENCE, V263, P92; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873; YIN TG, 1993, J IMMUNOL, V151, P2555	38	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11037	11039		10.1074/jbc.270.19.11037	http://dx.doi.org/10.1074/jbc.270.19.11037			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7538109	hybrid			2022-12-25	WOS:A1995QX86500004
J	ANAGNOU, NP; PEREZSTABLE, C; GELINAS, R; COSTANTINI, F; LIAPAKI, K; CONSTANTOPOULOU, M; KOSTEAS, T; MOSCHONAS, NK; STAMATOYANNOPOULOS, G				ANAGNOU, NP; PEREZSTABLE, C; GELINAS, R; COSTANTINI, F; LIAPAKI, K; CONSTANTOPOULOU, M; KOSTEAS, T; MOSCHONAS, NK; STAMATOYANNOPOULOS, G			SEQUENCES LOCATED 3' TO THE BREAKPOINT OF THE HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN-3 DELETION EXHIBIT ENHANCER ACTIVITY AND CAN MODIFY THE DEVELOPMENTAL EXPRESSION OF THE HUMAN FETAL A-GAMMA-GLOBIN GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN; ERYTHROLEUKEMIA-CELLS; THALASSEMIA; CHAIN; TRANSCRIPTION; PROMOTER; ELEMENTS; ACTIVATION; CLUSTER; REGION	Expression of fetal gamma-globin genes in individuals with the deletion forms of hereditary persistence of fetal hemoglobin (HPFH) has been attributed either to enhancement by 3' regulatory elements juxtaposed to gamma-globin genes or to deletion of gamma-gene silencers normally residing within the beta-globin gene cluster, In the present study, we tested the hypothesis of imported enhancers downstream of beta-globin gene using the HPFH-3 deletion as a model, The abnormal bridging fragment of 13.6 kilobases (kb) containing the A gamma-gene with its flanking sequences and 6.2 kb of the juxtaposed region was microinjected into fertilized mouse eggs, Twelve transgenic mice positive for the fragment were generated, Samples hom 11.5-day yolk sacs, 16-day fetal liver, and adult blood were analyzed for A gamma-mRNA using RNase protection assays, Three mice lacked A gamma expression in the yolk sac indicating non-optimal integration site, Four expressed A gamma-mRNA at the embryonic stage only, while two expressed A gamma-mRNA in both embryonic and fetal Liver erythroid cells, Since the A gamma gene with its normal flanking sequences and in the absence of the locus control region is expressed only in embryonic cells of transgenic mice, these data suggest that the juxtaposed sequences have altered the developmental specificity of the fetal gamma-gIobin gene, These sequences were further tested for the presence of an enhancer element, by their ability to activate a fusion reporter gene consisting of the CAT gene linked to the gamma-gIobin gene promoter, in erythroid (K562) and non-erythroid (HeLa) cells, A 0.7-kb region located immediately 3' to the breakpoint, enhanced chloramphenicol acetyltransferase activity by 3-fold in erythroid cells, The enhancer also activated the embryonic epsilon-globin gene promoter by 2-fold but not the adult beta- or delta-globin gene promoters, The enhancer represents a region of previously known complex tandem repeats; in this study we have completed the sequencing of the region encompassing the 0.7-kb enhancer element, Multiple areas of the enhancer region exhibit homology to the core element of the simian virus 40 enhancer and to the sequences of the human 3' A gamma- and the chicken 3' beta-globin enhancers, A consensus binding site for the erythroid specific GATA-1 transcription factor and seven consensus sites for the ubiquitous CP1 transcription factor are also included within the enhancer, These data suggest that these sequences located immediately 3' to the breakpoint of the HPFH-3 deletion, exhibit both the structure and the function of an enhancer, and can modify the developmental specificity of the fetal gamma-globin genes, resulting in their continued expression during adult life,	UNIV CRETE,SCH MED,DEPT BIOTECHNOL,GR-71110 IRAKLION,GREECE; UNIV CRETE,SCH BIOL,GR-71110 IRAKLION,GREECE; COLUMBIA UNIV,DEPT HUMAN GENET & DEV,NEW YORK,NY 10032; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Crete; University of Crete; Columbia University; University of Washington; University of Washington Seattle	ANAGNOU, NP (corresponding author), UNIV CRETE,SCH MED,INST MOLEC BIOL,GR-71110 IRAKLION,GREECE.		Anagnou, Nicholas/GLR-3609-2022	Kosteas, Theodoros/0000-0003-2174-911X; Moschonas, Nicholas/0000-0002-2556-537X	NIDDK NIH HHS [DK 45365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045365, R56DK045365, R01DK045365] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEHRINGER RR, 1987, P NATL ACAD SCI USA, V84, P7056, DOI 10.1073/pnas.84.20.7056; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BORELLI E, 1984, NATURE, V312, P608; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CAMASCHELLA C, 1990, BLOOD, V75, P1000; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1988, MOL CELL BIOL, V8, P4917, DOI 10.1128/MCB.8.11.4917; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; FEINGOLD EA, 1989, BLOOD, V74, P2178; FLAVELL RA, 1987, ORG EXPRESSION GLOBI, P119; FORDIS MC, 1985, PROG CLIN BIOL RES, V191, P281; GORMAN C, 1982, MOL CELL BIOL, V2, P1099; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HENTHORN PS, 1986, P NATL ACAD SCI USA, V83, P5194, DOI 10.1073/pnas.83.14.5194; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; HOGAN B, 1986, MANIPULATING MOUSE E; HUISMAN THJ, 1974, ANN NY ACAD SCI, V232, P107, DOI 10.1111/j.1749-6632.1974.tb20576.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JONES RW, 1981, NUCLEIC ACIDS RES, V9, P6813, DOI 10.1093/nar/9.24.6813; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; KOSTEAS T, 1993, CLIN RES, V41, P308; KOSTEAS T, 1991, CLIN RES, V39, P259; KUTLAR A, 1984, BIOCHEM GENET, V22, P21, DOI 10.1007/BF00499284; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAMALAKI A, 1990, ACTA HAEMATOL-BASEL, V84, P30; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; ORKIN SH, 1992, BLOOD, V80, P575; PALENA A, 1994, BLOOD, V83, P3738; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAMATOYANNOPOU.G, 1993, MOL CELL BIOL, V13, P7636; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DISE, P107; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TUAN D, 1983, P NATL ACAD SCI-BIOL, V80, P6937, DOI 10.1073/pnas.80.22.6937; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WINICHAGOON P, 1990, HEMOGLOBIN, V14, P185, DOI 10.3109/03630269009046960; ZHANG JW, 1993, BLOOD, V81, P1624	48	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10256	10263		10.1074/jbc.270.17.10256	http://dx.doi.org/10.1074/jbc.270.17.10256			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537267	hybrid			2022-12-25	WOS:A1995QV41700078
J	WATERS, MJ; DANIEL, N; BIGNON, C; DJIANE, J				WATERS, MJ; DANIEL, N; BIGNON, C; DJIANE, J			THE RABBIT MAMMARY-GLAND PROLACTIN RECEPTOR IS TYROSINE-PHOSPHORYLATED IN RESPONSE TO PROLACTIN IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITIES; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; PHOSPHATASE; INTERLEUKIN-3; EXPRESSION; JAK2	We report the first in vivo study demonstrating tyrosine phosphorylation of mammary gland proteins including the prolactin receptor, in response to the injection of prolactin. Immunoblotting of mammary gland membrane extracts revealed that subunits of 200, 130, 115, 100, 90, 70, and 45 kDa display increased tyrosine phosphorylation within 5 min of prolactin administration. The 100-kDa component was identified as the full-length prolactin receptor by a variety of means including immunoprecipitation and immunoblotting with monoclonal (U5, 917, 110, and 82) and polyclonal (46) antibodies to the prolactin receptor. Maximal receptor phosphorylation was seen within 1 min of hormone injection, and to obtain a strong response it was necessary to deprive rabbits of their endogenous prolactin for 36 h, Rapid tyrosine phosphorylation of the full-length receptor was verified by its demonstration in Chinese hamster ovary cells stably transfected with rabbit prolactin receptor cDNA. Both in vivo and in vitro, the phosphorylation signal was transient, being markedly reduced within 10 min of exposure to prolactin. Tyrosine-phosphorylated receptor was shown to be associated with JAK 2 by immunoblotting of receptor immunoprecipitated from transfected Chinese hamster ovary cells with polyclonal 46. A 48-kDa ATP-binding protein was also shown to be associated with the mammary gland receptor by U5 or polyclonal 46 immunoprecipitation of receptor complexes following covalent labeling with [alpha-P-32]azido-ATP. Our demonstration of prolactin receptor tyrosine phosphorylation raises the possibility of signaling pathways regulated by receptor/SH2 protein interaction, which would facilitate prolactin specific responses. The fact that a period of hormone deprivation is needed for significant hormone triggered receptor phosphorylation indicates that the mammary gland receptor exists in a largely desensitized state in vivo, analogous to the related growth hormone receptor.	UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,ST LUCIA,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,ST LUCIA,QLD 4072,AUSTRALIA	University of Queensland; University of Queensland	WATERS, MJ (corresponding author), INRA,UNITE ENDOCRINOL MOLEC,F-78352 JOUY EN JOSAS,FRANCE.		waters, michael j/C-9582-2014					ALI S, 1991, J BIOL CHEM, V266, P20110; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGATSINGER LS, 1993, CELL, V74, P237; BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BAYATSARMADI M, 1993, MOL CELL ENDOCRINOL, V92, P127, DOI 10.1016/0303-7207(93)90083-V; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1993, J BIOL CHEM, V267, P6074; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DJIANE J, 1985, J BIOL CHEM, V260, P1430; DUSANTERFOURT I, 1984, ENDOCRINOLOGY, V114, P1021, DOI 10.1210/endo-114-3-1021; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FENG GS, 1993, SCIENCE, V250, P1607; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V258, P1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GALA RR, 1991, P SOC EXP BIOL MED, V198, P513; HERNANDEZSOTOMA.SM, 1992, J MEMBRANE BIOL, V128, P81; HERNANDEZSOTOMA.SM, 1993, P NATL ACAD SCI USA, V90, P7691; KATOH M, 1986, J BIOL CHEM, V260, P11422; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESNEUR L, 1990, MOL CELL ENDOCRINOL, V71, P7; LESUEUR L, 1991, P NATL ACAD SCI USA, V86, P824; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MAYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLLER C, 1993, J BIOL CHEM, V267, P23403; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; NICOLL CS, 1980, FED PROC, V39, P2563; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; PREVARSKAYA N, 1994, AM J PHYSIOL, V267, pC554, DOI 10.1152/ajpcell.1994.267.2.C554; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; SATOH T, 1992, J BIOL CHEM, V267, P2537; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATERS MJ, 1988, PROG ENDOCRINOL, V1, P601; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	54	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5136	5143		10.1074/jbc.270.10.5136	http://dx.doi.org/10.1074/jbc.270.10.5136			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534288	hybrid			2022-12-25	WOS:A1995QL58000030
J	THOMPSON, NE; STRASHEIM, LA; NOLAN, KM; BURGESS, RR				THOMPSON, NE; STRASHEIM, LA; NOLAN, KM; BURGESS, RR			ACCESSIBILITY OF EPITOPES ON HUMAN TRANSCRIPTION FACTOR IIB IN THE NATIVE PROTEIN AND IN A COMPLEX WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; BOX-BINDING-PROTEIN; FACTOR-TFIIB; CRYSTAL-STRUCTURE; FUNCTIONAL DOMAINS; INITIATION-FACTORS; MINIMAL SET; GENE; IDENTIFICATION; ACTIVATOR	Transcription factor IIB (TFIIB) plays a central role in the assembly of the RNA polymerase If initiation complex. Monoclonal antibodies (mAbs) that react with human TFIIB were prepared and used as probes to identify portions of TFIIB that are accessible when the factor is in solution and when it is contained in a complex with DNA. Seven mAbs were examined and were mapped to three regions of the TFIIB molecule. Only the mAbs that mapped to residues 52-105 inhibited transcription, immunoprecipitated recombinant TFIIB and TFIIB from HeLa cell nuclear extract (NE), and supershifted a complex containing TFIIB, the TATA-binding protein and DNA. The mAbs that mapped to residues 1-51 and the mAb that mapped to residues 106-316 did not show activity in the functional assays, with the exception of the far N-terminal mAbs (residues 151), which immunoprecipitated recombinant TFIIB, but not TFIIB from HeLa cell NE. These data indicate that the region containing residues 52-105 is exposed in solution and when TFIIB is part of the preinitiation complex and that some far N-terminal epitopes are accessible on the purified protein, but become blocked when TFIIB is in HeLa cell NE or in the preinitiation complex.			THOMPSON, NE (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.			Burgess, Richard/0000-0001-9545-3165	NATIONAL CANCER INSTITUTE [R01CA060896, P01CA023076, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA60896, CA23076, CA07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; ING NH, 1992, J BIOL CHEM, V267, P17617; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; THOMPSON NE, 1994, PROTEIN EXPRES PURIF, V5, P468, DOI 10.1006/prep.1994.1066; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	33	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4735	4740		10.1074/jbc.270.9.4735	http://dx.doi.org/10.1074/jbc.270.9.4735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533165	hybrid			2022-12-25	WOS:A1995QK08400081
J	JAMESPEDERSON, M; YOST, S; SHEWCHUK, B; ZEIGLER, T; MILLER, R; HARDISON, R				JAMESPEDERSON, M; YOST, S; SHEWCHUK, B; ZEIGLER, T; MILLER, R; HARDISON, R			FLANKING AND INTRAGENIC SEQUENCES REGULATING THE EXPRESSION OF THE RABBIT ALPHA-GLOBIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; HUMAN BETA-GLOBIN; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION UNIT; DNA METHYLATION; CONTROL REGION; BINDING-SITES; ENHANCER; ELEMENT; EVOLUTION	Despite their descent from a common ancestral gene and the requirement for coordinated, tissue-specific regulation, the alpha- and beta-globin genes in many mammals are regulated in distinctly different ways. Unlike the beta-globin gene, the rabbit alpha-globin gene is transiently expressed at a high level without an added enhancer in transfected erythroid and non-erythroid cells. By examining a series of alpha/beta fusion genes, we show that internal sequences of the rabbit alpha-globin gene (within the first two exons and introns) are required along with the 5' flank for this enhancer-independent expression. Furthermore, deletion of the introns of the alpha-globin gene, or replacement by introns of the beta-globin gene, results in severely decreased expression of the transfecting genes, Hybrid constructs between segments of the alpha-globin gene and a luciferase gene confirm that internal alpha-globin sequences are needed for high level production of RNA in transfected cells, The flanking and internal sequences implicated in regulation of the rabbit alpha-globin gene coincide with a prominent CpG-rich island and may comprise an extended promoter (including both flanking and intragenic sequences) that is active in transfected cells without an enhancer,	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Hardison, Ross C/G-1142-2010; Shewchuk, Brian/AAA-3388-2021	Hardison, Ross C/0000-0003-4084-7516; Yost, Susan/0000-0002-9422-0316	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001589, R01DK027635] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44491] Funding Source: Medline; NIDDK NIH HHS [DK-01589, DK-27635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BENTLEY DL, 1984, NATURE, V307, P77, DOI 10.1038/307077a0; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BRICKNER HE, 1991, J BIOL CHEM, V266, P15363; CHAO MV, 1983, CELL, V32, P483, DOI 10.1016/0092-8674(83)90468-3; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHENG JF, 1988, J BIOL CHEM, V263, P9981; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; DEISSEROTH A, 1978, CELL, V15, P55, DOI 10.1016/0092-8674(78)90082-X; Favaloro J, 1980, Methods Enzymol, V65, P718; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARDISON R, 1991, J MOL BIOL, V222, P233, DOI 10.1016/0022-2836(91)90209-O; HARDISON R, 1993, MOL BIOL EVOL, V10, P73; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HUMPHRIES RK, 1982, CELL, V30, P173; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; MARGOT JB, 1989, J MOL BIOL, V205, P15, DOI 10.1016/0022-2836(89)90362-8; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PYATI J, 1980, P NATL ACAD SCI USA, V79, P4337; REN SC, 1993, BLOOD, V81, P1058; ROHRBAUGH ML, 1985, MOL CELL BIOL, V5, P147, DOI 10.1128/MCB.5.1.147; Sambrook J, 1989, MOL CLONING LABORATO; SHEN CKJ, 1980, P NATL ACAD SCI-BIOL, V77, P6634, DOI 10.1073/pnas.77.11.6634; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; Tuan D, 1987, DEV CONTROL GLOBIN G, P211; VANDENBERGH DJ, 1991, J MOL BIOL, V220, P255, DOI 10.1016/0022-2836(91)90011-T; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; WHITELAW E, 1989, MOL CELL BIOL, V9, P241, DOI 10.1128/MCB.9.1.241; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLING MC, 1979, NATURE, V277, P534, DOI 10.1038/277534a0; WRIGHT S, 1983, NATURE, V305, P333, DOI 10.1038/305333a0; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YOST SE, 1993, MOL CELL BIOL, V13, P5439, DOI 10.1128/MCB.13.9.5439	45	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3965	3973		10.1074/jbc.270.8.3965	http://dx.doi.org/10.1074/jbc.270.8.3965			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533158	hybrid			2022-12-25	WOS:A1995QH68800076
J	HERBST, R; MUNEMITSU, S; ULLRICH, A				HERBST, R; MUNEMITSU, S; ULLRICH, A			ONCOGENIC ACTIVATION OF V-KIT INVOLVES DELETION OF A PUTATIVE TYROSINE-SUBSTRATE INTERACTION SITE	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; ONCOGENIC MUTATION; V-KIT; SIGNAL TRANSDUCTION	EPIDERMAL GROWTH-FACTOR; FMS PROTO-ONCOGENE; STEM-CELL FACTOR; MALIGNANT HUMAN HEMATOPOIESIS; ACUTE MYELOBLASTIC-LEUKEMIA; C-KIT; KINASE RECEPTOR; SIGNAL TRANSDUCTION; NEU ONCOGENE; SRC FAMILY	The transforming gene of the Hardy-Zuckerman-4 strain of feline sarcoma virus, v-kit, arose by transduction of the cellular c-kit gene, which encodes the receptor tyrosine kinase (RTK) p145(c-kit). To gain insight into the molecular basis of the v-kit transforming potential, we characterized the feline c-kit by cDNA cloning. Comparison of the feline v-kit and c-kit sequences revealed, in addition to deletions of the extracellular and transmembrane domains, three additional mutations in the v-kit oncogene product: deletion of tyrosine-569 and valine-570, the exchange of aspartate at position 761 to glycine, and replacement of the C-terminal 50 amino acids by five unrelated residues, Examinations of individual v-kit mutations in the context of chimeric receptors yielded inhibitory effects for some mutants on both autophosphorylation and substrate phosphorylation functions. In contrast, deletion of tyrosine-569 and valine-570 significantly enhanced transforming and mitogenic activities of p145(c-kit), while the other mutations had no significant effects. Conservation in subclass III RTKs and the identification of the corresponding residue in beta PDGF-R, Y579, as a binding site for src family tyrosine kinases suggests an important role for Y568 in kit signal regulation and the definition of its oncogenic potential, Repositioning of Y571 by an in-frame two codon deletion may be the crucial alteration resulting in enhancement of v-kit oncogenic activity.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOLEC,D-82152 MARTINSRIED,GERMANY	Max Planck Society								ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERRETI A, 1991, BLOOD S, V78, pA373; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; BUHRING HJ, 1993, CANCER RES, V53, P4424; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FENDLY BM, 1990, CANCER RES, V50, P1550; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HERBST R, 1991, J BIOL CHEM, V266, P19908; HERBST R, 1992, J BIOL CHEM, V267, P13210; HIBI K, 1991, ONCOGENE, V6, P2291; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUANG E, 1990, CELL, V63, P223; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LASSAM N, 1992, ONCOGENE, V7, P51; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MAJUMDER S, 1990, ONCOGENE RES, V5, P329; Maniatis T., 1982, MOL CLONING; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOSTOV KE, 1984, NATURE, V318, P37; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; RATAJCZAK MZ, 1992, INT J CELL CLONING, V10, P205; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1990, ONCOGENE, V5, P25; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIDO Y, 1991, CANCER RES, V51, P2416; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG C, 1989, LEUKEMIA, V3, P699; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	67	37	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					369	379						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530827				2022-12-25	WOS:A1995QC62400016
J	COLE, PA; BURN, P; TAKACS, B; WALSH, CT				COLE, PA; BURN, P; TAKACS, B; WALSH, CT			EVALUATION OF THE CATALYTIC MECHANISM OF RECOMBINANT HUMAN CSK (C-TERMINAL SRC KINASE) USING NUCLEOTIDE ANALOGS AND VISCOSITY EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FAMILY TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; KINETIC MECHANISM; ESCHERICHIA-COLI; SUBUNIT; PHOSPHORYLATION; PHOSPHOTRANSFER; HYDROLYSIS; SUBSTRATE	Tyrosine kinases catalyze phosphoryl transfers from ATP to tyrosine residues in proteins. Despite their growing importance, their kinetic mechanism has remained largely unexplored. In this study we have investigated the tyrosine kinase reaction catalyzed by purified human recombinant Csk (C-terminal Src kinase). Poly(Glu,Tyr) 4:1 was used as the tyrosine containing substrate. Both ATP and poly(Glu,Tyr) were shown to be well behaved saturable substrates for recombinant Csk, with K-m values that were in reasonable agreement with Literature values reported for the non-recombinant enzyme and with k(cat) about 40 min(-1). A sequential kinetic mechanism is suggested by a steady state kinetic analysis. Inhibitor studies with ADP and beta,gamma-imidoadenosine 5'-triphosphate were performed, and these results provided evidence against the possibility that ordered binding of peptide prior to ATP occurs. While a suitable competitive inhibitor of poly(Glu,Tyr) has not yet been identified, other evidence pointed to a rapid equilibrium random mechanism. Csk utilized adenosine 5'-O-(3-thiotriphosphate) in place of ATP. The phosphorothioyl transfer occurred with a k(cat) about 15-20-fold lower than the ATP reaction but with similar K-m values. Deuterium solvent isotope effects on k(cat) were small for both reactions in a pH-independent range, consistent with the possibility that proton transfer is asymmetric in the reaction transition state. Using viscosity effects, ADP product release was suggested to be partially rate determining for catalysis in the standard ATP reaction. A comparison of the Csk kinetic mechanism with that of protein kinase A is discussed.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND	Harvard University; Harvard Medical School; Roche Holding; Roche Holding								ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; AMREIN KE, 1994, IN PRESS P NATL ACAD, V91; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOUGERET C, 1993, ONCOGENE, V8, P1241; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BRUNATI AM, 1992, FEBS LETT, V313, P291, DOI 10.1016/0014-5793(92)81212-5; BUDDE RJA, 1993, J BIOL CHEM, V268, P24868; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CASPERS P, 1994, CELL MOL BIOL, V40, P635; CHLEBOWSKI JF, 1974, J BIOL CHEM, V249, P7192; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; ECKSTEIN F, 1983, ANGEW CHEM INT EDIT, V22, P423, DOI 10.1002/anie.198304233; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HEATH DF, 1956, J CHEM SOC, P3796, DOI 10.1039/jr9560003796; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1989, J BIOL CHEM, V264, P20886; QAMAR R, 1993, BIOCHEMISTRY-US, V32, P6802, DOI 10.1021/bi00077a035; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; Segel I.H., 1975, ENZYME KINETICS; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WONG TW, 1984, J BIOL CHEM, V259, P3127; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	42	87	88	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30880	30887						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527038				2022-12-25	WOS:A1994PV51000025
J	WANG, H; PETERS, GA; ZENG, X; TANG, ML; WALLACE, I; KHAN, SA				WANG, H; PETERS, GA; ZENG, X; TANG, ML; WALLACE, I; KHAN, SA			YEAST 2-HYBRID SYSTEM DEMONSTRATES THAT ESTROGEN-RECEPTOR DIMERIZATION IS LIGAND-DEPENDENT IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA RESPONSE ELEMENT; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; PROGESTERONE RECEPTORS; STEROID BINDING; GENE-EXPRESSION; TERMINAL DOMAIN	Previous studies using in vitro procedures have not clearly established whether the estrogen receptor (ER) acts as a monomer or dimer in the cell. We have used the yeast two-hybrid system as an in vivo approach to investigate the dimerization of the estrogen receptor in the absence and presence of estrogen and anti-estrogens. This system is independent of ER binding to the estrogen response element. Two vectors, expressing GAL4 DNA binding domain-human ER and GAL4 transactivation domain-human ER, were constructed. Control experiments showed that each fusion protein had a high affinity binding site for estradiol-17 beta and could transactivate an ERE-LacZ reporter gene in yeast similar to the wild type ER. The two fusion proteins, GAL4 DB-hER and GAL 4 TA-hER, were expressed in the yeast strain, PCY2, which carries a GAL1 promoter lacZ reporter. ER dimerization was measured via reconstitution of GALA through interaction of the fusion proteins, which transactivates LacZ through the GAL1 promoter. When both ER fusion proteins were expressed, beta-galactosidase activity was estradiol 17 beta-inducible. Furthermore, we showed that both tamoxifen and ICI 182,780 also induced beta-galactosidase activity, albeit lower than that induced by estradiol 17 beta. These results strongly argue that ER dimerization is ligand-dependent and the dimer can be induced by estradiol-17 beta, tamoxifen, or ICI 182,780. We also treated the yeast containing the two fusion proteins with estradiol-17 beta and tamoxifen or ICI 182,780 simultaneously to determine the effects on ER dimerization. beta-Galactosidase activity was lower when the yeast was treated with a higher ratio of tamoxifen or ICI 182,780 to estrogen than estradiol-17 beta alone. Taken together, we conclude that ER dimerization is ligand (estradiol-17 beta, tamoxifen, or ICI 182, 780)-dependent, and we suggest that estradiol-17 beta-induced dimers are destabilized when estradiol-17 beta is used with tamoxifen or ICI 182,780 simultaneously.	UNIV CINCINNATI, COLL MED, DEPT CELL BIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT NEUROBIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT ANAT, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			Wang, Hong/H-6298-2012	Khan, Sohaib/0000-0002-0792-9109; Peters, Gregory/0000-0001-6914-7316	NICHD NIH HHS [HD22918] Funding Source: Medline; NIEHS NIH HHS [P30-ES06096] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ARBUCKLE ND, 1992, NUCLEIC ACIDS RES, V20, P3839, DOI 10.1093/nar/20.15.3839; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; EMMAS CE, 1992, J STEROID BIOCHEM, V41, P291, DOI 10.1016/0960-0760(92)90354-L; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMAN B M, 1990, New Biologist, V2, P587; FREEDMAN PP, 1993, STEROID HORMONE ACTI, P141; FRITSCH M, 1992, J BIOL CHEM, V267, P1823; FURLOW JD, 1993, J BIOL CHEM, V268, P12519; GIBSON MK, 1991, ENDOCRINOLOGY, V129, P2000, DOI 10.1210/endo-129-4-2000; GILBERT DM, 1992, NUCLEIC ACIDS RES, V20, P4525, DOI 10.1093/nar/20.17.4525; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GORSKI J, 1993, BIOL REPROD, V48, P8, DOI 10.1095/biolreprod48.1.8; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GRONEMEYER H, 1993, STEROID HORMONE ACTI, P94; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HIRST MA, 1992, P NATL ACAD SCI USA, V89, P5527, DOI 10.1073/pnas.89.12.5527; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLINGE CM, 1992, J STEROID BIOCHEM, V43, P249, DOI 10.1016/0960-0760(92)90159-G; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; LYTTLE CR, 1992, J STEROID BIOCHEM, V42, P677, DOI 10.1016/0960-0760(92)90108-U; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MAK P, 1989, J BIOL CHEM, V264, P21613; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MEDICI N, 1991, MOL ENDOCRINOL, V5, P555, DOI 10.1210/mend-5-4-555; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; REDEUILH G, 1987, J BIOL CHEM, V262, P6969; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, J BIOL CHEM, V266, P10880; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; SALOMONSSON M, 1994, J STEROID BIOCHEM, V48, P447, DOI 10.1016/0960-0760(94)90192-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIKORSKI RS, 1989, GENETICS, V122, P19; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WEATHERILL PJ, 1988, J STEROID BIOCHEM, V30, P263, DOI 10.1016/0022-4731(88)90103-3; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WHITE JH, 1988, COLD SPRING HARB SYM, V53, P819, DOI 10.1101/SQB.1988.053.01.093; WHITE R, 1991, J STEROID BIOCHEM, V40, P333, DOI 10.1016/0960-0760(91)90199-F; WOOGE CH, 1992, MOL ENDOCRINOL, V6, P861, DOI 10.1210/me.6.6.861; WRANGE O, 1989, J BIOL CHEM, V264, P5253; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763	62	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23322	23329		10.1074/jbc.270.40.23322	http://dx.doi.org/10.1074/jbc.270.40.23322			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559488	hybrid			2022-12-25	WOS:A1995RY90900017
J	MCMURRY, LM; LEVY, SB				MCMURRY, LM; LEVY, SB			THE NH2-TERMINAL HALF OF THE TN10-SPECIFIED TETRACYCLINE EFFLUX PROTEIN TETA CONTAINS A DIMERIZATION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESISTANCE PROTEIN; GLUCOSE-TRANSPORTER; MEMBRANE-PROTEIN; GENE-EXPRESSION; INNER MEMBRANE; TN10; SEQUENCE; TOPOLOGY; FUSIONS	The 43.1-kDa tetracycline-cation/proton antiporter TetA from Tn10 comprises two equal-sized domains, alpha and beta (amino-terminal and carboxyl-terminal halves, respectively). An inactivating mutation in the alpha domain can complement a mutation on a second polypeptide in the beta domain to restore partial tetracycline resistance in bacterial cells, suggesting that intermolecular interactions permit this transport protein to act as a multimer. In the present studies, multimer formation was examined in mixtures of dodecylmaltoside extracts of membranes from Escherichia coli cells containing different TetA derivatives. TetA, TetA(alpha), and TetA(beta) were each fused genetically to a six-histidine carboxyl-terminal tail. The ability of these fusions, immobilized on a nickel affinity column, to bind wild type TetA or other Tet fusions was determined. An interaction between cu domains on different polypeptides which resulted in multimerization was seen. The binding was specific for Tet protein and did not occur with other membrane proteins or another polyhistidine fusion protein, No alpha-beta interactions were detected by this method, although they are postulated to occur in the intact cell based on the alpha-beta genetic complementations. A dimeric model for TetA having intermolecular alpha-alpha and alpha-beta interactions is presented.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University	MCMURRY, LM (corresponding author), TUFTS UNIV, SCH MED, CTR ADAPTAT GENET & DRUG RESISTANCE, BOSTON, MA 02111 USA.				NIAID NIH HHS [AI30646] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030646] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLARD JD, 1993, J BACTERIOL, V175, P4554, DOI 10.1128/JB.175.14.4554-4560.1993; ALLARD JD, 1992, J BIOL CHEM, V267, P17809; COLEMAN DC, 1983, J BACTERIOL, V153, P921, DOI 10.1128/JB.153.2.921-929.1983; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; CURIALE MS, 1982, J BACTERIOL, V151, P209, DOI 10.1128/JB.151.1.209-215.1982; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; ECKERT B, 1989, J BIOL CHEM, V264, P11663; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; HICKMAN RK, 1990, MOL MICROBIOL, V4, P1241, DOI 10.1111/j.1365-2958.1990.tb00703.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY SB, 1989, J ANTIMICROB CHEMOTH, V24, P1, DOI 10.1093/jac/24.1.1; LINDENTHAL S, 1991, P NATL ACAD SCI USA, V88, P6540, DOI 10.1073/pnas.88.15.6540; MANEEWANNAKUL K, 1992, MOL MICROBIOL, V6, P2961, DOI 10.1111/j.1365-2958.1992.tb01755.x; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; Miller J.H., 1972, EXPT MOL GENETICS; MILLER KW, 1993, ANAL BIOCHEM, V215, P118, DOI 10.1006/abio.1993.1563; MOYED HS, 1983, J BACTERIOL, V155, P549, DOI 10.1128/JB.155.2.549-556.1983; POSTLE K, 1984, NUCLEIC ACIDS RES, V12, P4849, DOI 10.1093/nar/12.12.4849; RUBIN RA, 1990, J BACTERIOL, V172, P2303, DOI 10.1128/jb.172.5.2303-2312.1990; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1993, FEBS LETT, V324, P131, DOI 10.1016/0014-5793(93)81378-D	29	22	22	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22752	22757		10.1074/jbc.270.39.22752	http://dx.doi.org/10.1074/jbc.270.39.22752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559401	hybrid			2022-12-25	WOS:A1995RY05400021
J	NIGHTINGALE, KP; WOLFFE, AP				NIGHTINGALE, KP; WOLFFE, AP			THE INTERACTION OF TFIIIA WITH SPECIFIC RNA-DNA HETERODUPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; 5S RNA; ZINC FINGERS; 5S-RNA GENE; BINDING-SITE; B-FORM; PROTEIN; COMPLEX; POLYMERASE	We examine the association of transcription factor TFIIIA with RNA-DNA heteroduplexes containing sequences from the Xenopus borealis 5 S rRNA gene. Under conditions where TFIIIA selectively binds to 5 S rRNA or the internal control region of the 5 S rRNA gene, no specific association of TFIIIA with DNA-RNA heteroduplexes containing either strand of 5 S DNA could be detected. We discuss our results with respect to specific models of TFIIIA recognition of the internal control region and of DNA-RNA hybrids by zinc finger proteins.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; CAMPBELL FE, 1991, MOL CELL BIOL, V11, P3978, DOI 10.1128/MCB.11.8.3978; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DALY TJ, 1989, J BIOL CHEM, V264, P20394; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DUNN K, 1980, NUCLEIC ACIDS RES, V8, P555, DOI 10.1093/nar/8.3.555; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GOTTESFELD JM, 1987, NATURE, V329, P460, DOI 10.1038/329460a0; HALL KB, 1993, CURR OPIN STRUC BIOL, V3, P336, DOI 10.1016/S0959-440X(05)80103-4; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HAYES J, 1989, J BIOL CHEM, V264, P6009; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HOVATTER KR, 1987, P NATL ACAD SCI USA, V84, P1162, DOI 10.1073/pnas.84.5.1162; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MAO XZ, 1993, MOL CELL BIOL, V13, P7496, DOI 10.1128/MCB.13.12.7496; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SANDS MS, 1991, NUCLEIC ACIDS RES, V19, P1791, DOI 10.1093/nar/19.8.1791; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	43	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22665	22668		10.1074/jbc.270.39.22665	http://dx.doi.org/10.1074/jbc.270.39.22665			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559384	hybrid			2022-12-25	WOS:A1995RY05400004
J	POUCH, MN; PETIT, F; BURI, J; BRIAND, Y; SCHMID, HP				POUCH, MN; PETIT, F; BURI, J; BRIAND, Y; SCHMID, HP			IDENTIFICATION AND INITIAL CHARACTERIZATION OF A SPECIFIC PROTEASOME (PROSOME) ASSOCIATED RNASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MESSENGER-RNA; MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; DUCK ERYTHROBLASTS; XENOPUS-LAEVIS; HELA-CELLS; SUBUNIT; PURIFICATION; TRANSLATION	We have identified and characterized a specific nuclease activity to be tightly associated with proteasomes. Using tobacco mosaic virus RNA (TMV-RNA) as substrate to analyze and quantify the cleavage reaction, we supply several lines of evidence that this nuclease activity is an integral part of proteasomes. Thus, RNase activity was coincident with the elution profiles of proteasomes at each stage of purification. Proteasomal nuclease activity was resistant to strong dissociation conditions using 480 mM KCl, 0.5% sodium lauroylsarcosinate, and 6 M urea. This nuclease activity remained associated with an urea-resistant subcomplex of the proteasome comprising a specific set of proteins. Finally the digestion of TMV-RNA led to a well defined pattern of RNA fragments while 5 S ribosomal RNA and globin mRNA were not degraded. These results provide further evidence that proteasomes are able to discriminate between different RNAs, and the possible involvement of proteasomes in translation control is discussed.	UNIV CLERMONT FERRAND,F-63177 CLERMONT FERRAND,FRANCE; INRA,VIROL & IMMUNOL MOLEC STN,F-78350 JOUY EN JOSAS,FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay				Pelissier, Marie-Noelle/0000-0002-2787-4360				ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; ARRIGO AP, 1985, EMBO J, V4, P399, DOI 10.1002/j.1460-2075.1985.tb03642.x; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BEY F, 1993, MOL GEN GENET, V237, P193, DOI 10.1007/BF00282801; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CASTANO JG, 1986, CELL, V46, P377, DOI 10.1016/0092-8674(86)90658-6; DESA CM, 1986, J MOL BIOL, V187, P479, DOI 10.1016/0022-2836(86)90328-1; DINEVA B, 1989, MOL BIOL REP, V13, P207, DOI 10.1007/BF00788172; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GAEDIK R, 1988, THESIS U STUTTGART F; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOMMA S, 1994, MOL BIOL REP, V20, P57, DOI 10.1007/BF00996354; HORSCH A, 1990, FEBS LETT, V269, P336, DOI 10.1016/0014-5793(90)81188-T; HORSCH A, 1989, FEBS LETT, V246, P131, DOI 10.1016/0014-5793(89)80268-6; HOUGH R, 1987, J BIOL CHEM, V262, P8303; IMAIZUMISCHERRE.MT, 1982, DEV BIOL, V93, P126; KLEINSCHMIDT JA, 1983, EUR J CELL BIOL, V32, P143; KUHN L, 1990, FEBS LETT, V261, P274; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; NOTHWANG HG, 1992, NUCLEIC ACIDS RES, V20, P1959, DOI 10.1093/nar/20.8.1959; NOTHWANG HG, 1992, EUR J BIOCHEM, V207, P621, DOI 10.1111/j.1432-1033.1992.tb17089.x; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERRY RP, 1972, BIOCHIM BIOPHYS ACTA, V262, P220, DOI 10.1016/0005-2787(72)90236-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Sambrook J, 1989, MOL CLONING LABORATO; SCHLIEPHACKE M, 1991, EUR J CELL BIOL, V55, P114; SCHMID HP, 1983, FEBS LETT, V157, P105, DOI 10.1016/0014-5793(83)81125-9; SCHMID HP, 1984, EMBO J, V3, P29, DOI 10.1002/j.1460-2075.1984.tb01757.x; SCHMID HP, 1983, MOL BIOL REP, V9, P87, DOI 10.1007/BF00777478; SKILTON HE, 1991, FEBS LETT, V279, P351, DOI 10.1016/0014-5793(91)80185-6; TANAKA K, 1992, NEW BIOL, V4, P173; TOMEK W, 1990, J CHROMATOGR, V521, P221, DOI 10.1016/0021-9673(90)85046-X; TSUKAHARA T, 1989, FEBS LETT, V255, P179, DOI 10.1016/0014-5793(89)81086-5; VINCENT A, 1983, EMBO J, V2, P1869, DOI 10.1002/j.1460-2075.1983.tb01673.x; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WHITE K, 1988, J BIOL CHEM, V263, P8938; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YAJNIK V, 1993, J BIOL CHEM, V268, P13253	48	39	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22023	22028		10.1074/jbc.270.37.22023	http://dx.doi.org/10.1074/jbc.270.37.22023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545175	hybrid			2022-12-25	WOS:A1995RU75700089
J	MOHAN, S; NAKAO, Y; HONDA, Y; LANDALE, E; LESER, U; DONY, C; LANG, K; BAYLINK, DJ				MOHAN, S; NAKAO, Y; HONDA, Y; LANDALE, E; LESER, U; DONY, C; LANG, K; BAYLINK, DJ			STUDIES ON THE MECHANISMS BY WHICH INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING PROTEIN-4 (IGFBP-4) AND IGFBP-5 MODULATE IGF ACTIONS IN BONE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; CONDITIONED MEDIUM; MOLECULAR-CLONING; PURIFICATION; FIBROBLASTS; LINE; IDENTIFICATION; POTENTIATION; INHIBITOR; TURNOVER	The growth potentiating effects of the insulin-like growth factor (IGF)-I and IGF-II are modulated by a family of six insulin-like growth factor binding proteins (IGFBPs). Despite the similarity in amino acid sequences of the IGFBPs, their effects on the growth of bone cells differ. Studies on the molecular mechanisms for IGFBP-4 actions revealed that coincubation of bone cells with IGFBP-4 and I-125-IGF-I or I-125-IGF-II decreased the binding of both of these ligands in a dose-dependent manner. In addition, IGFBP-4 decreased the binding of IGF-I tracer to purified type I IGF receptor. These data in conjunction with data showing that IGFBP-4 had no effect on cell proliferation induced by analogs of IGF-I or IGF-II, which exhibited > 100-fold reduced affinity for binding to IGFBP-4 suggest that IGFBP-4 may inhibit IGF action by preventing the binding of ligand to its membrane receptor. In contrast to IGFBP-4, IGFBP-5 treatment increased the binding of IGF tracer to bone cells but did not increase the binding of I-125-IGF-I to, type I IGF receptor. Studies on the mechanism by which IGFBP-5 increased the binding of I-125-IGF tracer to bone cells suggest that IGFBP-5 could facilitate IGF binding by a mechanism in which IGFBP-5 has cell surface binding sites independent of IGF receptors. These data in conjunction with the findings that IGFBP-5 potentiated cell proliferation even in the presence of those same IGF analogs that exhibited > 200-fold reduced affinity for binding to IGFBP-5, suggest that IGFBP-5 may in part stimulate bone cell proliferation by an IGF-independent mechanism involving IGFBP-5 specific cell surface binding sites.	LOMA LINDA UNIV,DEPT MED,LOMA LINDA,CA 92357; LOMA LINDA UNIV,DEPT BIOCHEM,LOMA LINDA,CA 92357; LOMA LINDA UNIV,DEPT PHYSIOL,LOMA LINDA,CA 92357; BOEHRINGER MANNHEIM GMBH,BIOCHEM RES CTR,D-82377 PENZBERG,GERMANY	Loma Linda University; Loma Linda University; Loma Linda University	MOHAN, S (corresponding author), JERRY L PETTIS MEM VET ADM MED CTR,RES SERV 151,MINERAL METAB LAB,11201 BENTON ST,LOMA LINDA,CA 92357, USA.		HONDA, Yoko/F-4558-2018	HONDA, Yoko/0000-0002-9978-8672	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031062, T32AR007543] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 07543, AR 31062] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BALLARD J, 1992, ENDOCRINOLOGY, V130, P1736; BAUTISTA CM, 1990, METABOLISM, V39, P96, DOI 10.1016/0026-0495(90)90154-5; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAYLINK DJ, 1993, J BONE MINER RES, V8, pS565; BLAT C, 1989, J BIOL CHEM, V264, P12449; CANALIS E, 1988, CALCIFIED TISSUE INT, V43, P346, DOI 10.1007/BF02553277; Canalis Ernesto, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P155; CHEUNG PT, 1991, ENDOCRINOLOGY, V129, P1006, DOI 10.1210/endo-129-2-1006; CLEMMONS DR, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P381; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHICK WS, 1993, ANN REV PHYSL, V155, P131; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; EBELING PR, 1993, J CLIN ENDOCR METAB, V77, P1384, DOI 10.1210/jc.77.5.1384; FARLEY JR, 1991, METABOLISM, V40, P664, DOI 10.1016/0026-0495(91)90081-7; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; JOHANSSON AG, 1992, LANCET, V339, P1619, DOI 10.1016/0140-6736(92)91889-G; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; MOHAN S, 1986, BIOCHIM BIOPHYS ACTA, V884, P234, DOI 10.1016/0304-4165(86)90168-6; MOHAN S, 1990, ENDOCRINOLOGY, V126, P2534, DOI 10.1210/endo-126-5-2534; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; MOHAN S, 1991, GROWTH REGULAT, V1, P110; MOHAN S, 1991, CLIN ORTHOP RELAT R, V263, P30; MOHAN S, 1993, GROWTH REGULAT, V3, P65; MUELLER K, 1994, AM J PHYSIOL, V267, pE1, DOI 10.1152/ajpendo.1994.267.1.E1; OH Y, 1992, ENDOCRINOLOGY, V181, P3123; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; RUDOLPH R, 1990, MODERN METHDOS PROTE; SCHILTZ PM, 1993, J BONE MINER RES, V8, P391; SCHMID C, 1993, J BONE MINER RES, V8, pS293; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, PROG GROWTH FACTOR R, V1, P243; SPENCER EM, 1991, MODERN CONCEPTS INSU; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAGA T, 1992, FASEB J, V7, P3387; VILLAUDY J, 1994, GROWTH FACTORS, V10, P107, DOI 10.3109/08977199409010984; WERGEDAL JE, 1984, P SOC EXP BIOL MED, V176, P60	46	259	267	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20424	20431		10.1074/jbc.270.35.20424	http://dx.doi.org/10.1074/jbc.270.35.20424			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7544787	hybrid			2022-12-25	WOS:A1995RR58400031
J	UMANS, L; SERNEELS, L; OVERBERGH, L; LORENT, K; VANLEUVEN, F; VANDENBERGHE, H				UMANS, L; SERNEELS, L; OVERBERGH, L; LORENT, K; VANLEUVEN, F; VANDENBERGHE, H			TARGETED INACTIVATION OF THE MOUSE ALPHA(2)-MACROGLOBULIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PULMONARY FIBROSIS; ALPHA-MACROGLOBULIN; HUMAN ALPHA-2-MACROGLOBULIN; HOMOLOGOUS RECOMBINATION; LIPOPROTEIN-LIPASE; MOLECULAR-CLONING; SUBUNIT STRUCTURE; CDNA; MICE; SEQUENCE	The mouse alpha(2)-macroglobulin gene was inactivated in embryonic stem cells by homologous recombination, Liver alpha(2)-macroglobulin mRNA and plasma protein was absent in homozygotes and reduced to 50% in heterozygotes, alpha(2)-Macroglobulin-deficient mice were viable and produced normally sized litters with normal sex ratio over 3 generations, Characterization of adult homozygotes included diets with different fat content, treatments with endotoxin, bleomycin, carbon tetrachloride, and ethionine to test for immune system, lung, Liver, and pancreas toxicity, respectively, Knock-out mice were more resistant to endotoxin but more sensitive to a choline-free diet supplemented with ethionine, Regulation of murinoglobulin mRNA expression during pregnancy was analyzed as a possible back-up mechanism for the deficiency in alpha(2)-macroglobulin. In addition, expression of mRNA was studied, coding for alpha(2)-macroglobulin receptor/lipoprotein receptor-related protein, low density Lipoprotein receptor, and very low density lipoprotein receptor and for some common ligands, i,e, apolipoprotein E, lipoprotein Lipase, and the 44-kDa heparin binding protein, Their differential regulation in the knockout mice relative to C57Bl mice was evident and is discussed, The impressive 15-fold increase in maternal liver murinoglobulin mRNA at partum in the knock-out mice indicated increased consumption, compared to only 4-fold in normal mice, Thus, murinoglobulin appears as the major proteinase inhibitor around partum, obviously solicited to a much greater extend in alpha(2)-macroglobulin-deficient mice.	KATHOLIEKE UNIV LEUVEN, DEPT HUMAN GENET, EXPTL GENET GRP, B-3000 LOUVAIN, BELGIUM	KU Leuven			Overbergh, Lut/AAC-3515-2020	Serneels, Lutgarde/0000-0002-5463-4231				ABE K, 1989, J BIOCHEM-TOKYO, V106, P564; ADAMSON IYR, 1974, AM J PATHOL, V77, P185; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BELYAEV ND, 1992, HEPATOLOGY, V15, P525, DOI 10.1002/hep.1840150327; BOHE M, 1986, SCAND J GASTROENTERO, V21, P598, DOI 10.3109/00365528609003106; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GIL G, 1991, J BIOL CHEM, V266, P20512; GONIAS SL, 1983, BIOCHEM J, V209, P99, DOI 10.1042/bj2090099; HEREMANS H, 1987, J IMMUNOL, V138, P4175; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HORIUCHI K, 1989, J BIOCHEM-TOKYO, V106, P98, DOI 10.1093/oxfordjournals.jbchem.a122828; ISHIDA BY, 1991, J LIPID RES, V32, P559; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; LAMARRE J, 1991, LAB INVEST, V65, P3; LOMBARDI B, 1975, AM J PATHOL, V79, P465; LORENT K, 1994, DIFFERENTIATION, V55, P213, DOI 10.1046/j.1432-0436.1994.5530213.x; Mao-Hua Mei, 1993, Hepatology, V17, P638, DOI 10.1002/hep.1840170418; MCMAHON MJ, 1984, AM J SURG, V147, P164, DOI 10.1016/0002-9610(84)90052-7; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Myant N., 2012, CHOLESTEROL METABOLI, DOI [10.1016/B978-0-12-512300-6.50007-7, DOI 10.1016/B978-0-12-512300-6.50007-7]; NISHINA PM, 1990, J LIPID RES, V31, P859; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OVERBERGH L, 1994, GENOMICS, V22, P530, DOI 10.1006/geno.1994.1426; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SAITO A, 1985, J BIOL CHEM, V260, P775; SCHRIER DJ, 1983, AM REV RESPIR DIS, V127, P63, DOI 10.1164/arrd.1983.127.1.63; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; UMANS L, 1994, GENOMICS, V22, P519, DOI 10.1006/geno.1994.1425; VANDERZEE A, 1994, GENOMICS, V23, P256, DOI 10.1006/geno.1994.1489; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; VANLEUVEN F, 1987, J BIOCHEM-TOKYO, V101, P1181, DOI 10.1093/oxfordjournals.jbchem.a121982; VANLEUVEN F, 1982, TRENDS BIOCHEM SCI, V7, P185, DOI 10.1016/0968-0004(82)90135-9; VANLEUVEN F, 1993, BIOCHIM BIOPHYS ACTA, V1173, P71, DOI 10.1016/0167-4781(93)90244-8; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; YAMAMOTO K, 1985, BIOCHEM INT, V10, P463	42	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19778	19785		10.1074/jbc.270.34.19778	http://dx.doi.org/10.1074/jbc.270.34.19778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544347	hybrid			2022-12-25	WOS:A1995RQ99100018
J	AGARWAL, S; CORBLEY, MJ; ROBERTS, TM				AGARWAL, S; CORBLEY, MJ; ROBERTS, TM			RECONSTITUTION OF SIGNAL-TRANSDUCTION FROM THE MEMBRANE TO THE NUCLEUS IN A BACULOVIRUS EXPRESSION SYSTEM - ACTIVATION OF RAF-1 LEADS TO HYPERMODIFICATION OF C-JUN AND C-FOS VIA MULTIPLE PATHWAYS	ONCOGENE			English	Article						SIGNALING PATHWAYS; KINASES; RAF-1; ERK-1; NUCLEAR ONCOGENES; C-FOS; C-JUN; POSTTRANSLATIONAL MODIFICATIONS	GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; MAP KINASE; HA-RAS; COMPLEX-FORMATION; GROWTH-FACTORS; INSECT CELLS; S6 KINASE; 3T3 CELLS	We have attempted to dissect signaling pathways involved in transmitting activating signals from the cell surface to the nucleus by reconstituting them in the baculovirus/Sf9 cell system. We have used this system to coexpress different combinations of the critical signaling proteins pp60(v-src), p21(v-ras), Raf-1 and ERK-1 and assayed the effects of resulting signaling cascades on the modifications of coexpressed transcription factors c-jun or c-fos. We observe that activation of ERK-1 via Raf-1 and p21(ras) dependent signals can result in the hyperphosphorylation of c-jun. In contrast, c-fos appears to be the target of two Raf-1 activated modifying signals: one independent of ERK-1 and the other dependent on ERK-1 stimulation. Thus, coexpression of c-fos with pp60(v-src), p21(v-ras) or constitutively active forms of Raf-1 results in a dramatic reduction of its electrophoretic mobility in the absence of coexpressed ERK-1. Activation of this ERK-1-independent pathway together with the ERK-1 dependent pathway that modifies c-jun results in additional modification of c-fos. Our observation of a Raf-1 activated, ERK-independent signaling pathway is consistent with previous reports that constitutively active Raf-1 can, in some cell types, result in transformation or differentiation without activation of ERKs. Our data indicate the presence of multiple Raf-1 activated pathways that lead to modification of transcription factors.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA43803] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AHN NG, 1992, CIBA F SYMP, V164, P113; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHUNG J, 1991, P NATL ACAD SCI USA, V58, P4981; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1984, CELL, V36, P259; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1993, ONCOGENE, V8, P841; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HERRERA R, 1990, CELL GROWTH DIFFER, V1, P483; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEEK DW, 1992, BIOCHEM J, V287, P1; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SETH A, 1992, J BIOL CHEM, V267, P24796; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Summers MD, 1987, MANUAL METHODS BACUL; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	92	22	23	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					427	438						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543194				2022-12-25	WOS:A1995RN53000002
J	OGILVIE, P; SCHILLING, K; BILLINGSLEY, ML; SCHMIDT, HHHW				OGILVIE, P; SCHILLING, K; BILLINGSLEY, ML; SCHMIDT, HHHW			INDUCTION AND VARIANTS OF NEURONAL NITRIC-OXIDE SYNTHASE TYPE-I DURING SYNAPTOGENESIS	FASEB JOURNAL			English	Article						EXPRESSION; DEVELOPMENT; NITRO-L-ARGININE; SYNAPTOGENESIS	SOLUBLE GUANYLYL CYCLASE; LONG-TERM POTENTIATION; CYCLIC-GMP FORMATION; NADPH-DIAPHORASE; MESSENGER-RNA; L-ARGININE; INSITU HYBRIDIZATION; SIGNAL-TRANSDUCTION; NERVOUS-SYSTEM; RAT	In the adult central nervous system, nitric oxide (NO) is formed from L-arginine by the so-called constitutive or type I NO synthase (NOS-I-155) However, expression of NOS-I-155 immunoreactivity and activity was low or not detectable in developing mouse and rat brain. NOS-I-155 was sharply induced coincident with the onset of synaptogenesis in specific brain regions, This was followed by a second phase in which total NOS-I-155 expression decreased both in specific cell populations and in the total synaptosomal subcellular fraction, Furthermore, two putative variants of NOS-I were transiently observed: an NOS-I-immunoreactive protein with increased electrophoretic mobility (NOS-I-144) and a transient hypersensitivity of NOS-I-155 to the competitive substrate inhibitor N-omega-nitro-L-arginine. It is concluded that NOS-I expression is not constitutive but locally induced. In the central nervous system, this regionally specific, biphasic pattern of postnatal NOS-I induction is consistent with a role for NO in synaptogenesis and synaptic plasticity.	UNIV WURZBURG,MED KLIN,D-97078 WURZBURG,GERMANY; UNIV ULM,ANAT & ZELLBIOL ABT,D-89081 ULM,GERMANY; PENN STATE UNIV,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,CTR CELL & MOLEC BIOL,HERSHEY,PA 17033	University of Wurzburg; Ulm University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Schmidt, Harald HHW/B-1549-2008	Schmidt, Harald HHW/0000-0003-0419-5549	NIEHS NIH HHS [R0I ES 05450] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005450] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BLUE ME, 1987, J NEUROCYTOL, V16, P599; Bohme E, 1978, Adv Cyclic Nucleotide Res, V9, P131; BOHME GA, 1993, P NATL ACAD SCI USA, V90, P9191, DOI 10.1073/pnas.90.19.9191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1993, SOC NEUR ABSTR, V19, P374; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; EAST SJ, 1990, EUR J PHARMACOL, V184, P311, DOI 10.1016/0014-2999(90)90623-E; FIALLOSESTRADA CE, 1993, NEUROSCI LETT, V150, P169, DOI 10.1016/0304-3940(93)90528-S; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FUJISAWA H, 1994, IN PRESS J NEUROCHEM; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; ISHII K, 1990, EUR J PHARMACOL, V176, P219; KIMOTO M, 1993, ARCH BIOCHEM BIOPHYS, V300, P657, DOI 10.1006/abbi.1993.1091; KRISTT DA, 1978, BRAIN RES, V150, P467, DOI 10.1016/0006-8993(78)90814-4; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larramendi LMH, 1969, NEUROBIOLOGY CEREBEL, P803; MAHALIK TJ, 1992, DEV BRAIN RES, V67, P75, DOI 10.1016/0165-3806(92)90027-T; MATSUMOTO T, 1993, DEV BRAIN RES, V73, P199, DOI 10.1016/0165-3806(93)90139-2; MAYER B, 1989, FEBS LETT, V256, P211, DOI 10.1016/0014-5793(89)81750-8; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; NORTH AJ, 1994, AM J PHYSIOL, V266, pL635, DOI 10.1152/ajplung.1994.266.6.L635; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; PURO DG, 1977, EXP BRAIN RES, V28, P427; SCHILLING K, 1994, NEUROSCIENCE, V59, P893, DOI 10.1016/0306-4522(94)90293-3; SCHILLING K, 1991, NEURON, V7, P891, DOI 10.1016/0896-6273(91)90335-W; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SOLODKIN A, 1992, NEUROSCIENCE, V51, P495, DOI 10.1016/0306-4522(92)90290-I; VALLANCE P, 1992, LANCET, V339, P572; VERGE VMK, 1992, P NATL ACAD SCI USA, V89, P11617, DOI 10.1073/pnas.89.23.11617; WU WT, 1993, EXP NEUROL, V121, P279, DOI 10.1006/exnr.1993.1097	57	87	91	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1995	9	9					799	806		10.1096/fasebj.9.9.7541381	http://dx.doi.org/10.1096/fasebj.9.9.7541381			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7541381				2022-12-25	WOS:A1995RH98200013
J	BOISJOYEUX, B; DENISSENKO, M; THOMASSIN, H; GUESDON, S; IKONOMOVA, R; BERNUAU, D; FELDMANN, G; DANAN, JL				BOISJOYEUX, B; DENISSENKO, M; THOMASSIN, H; GUESDON, S; IKONOMOVA, R; BERNUAU, D; FELDMANN, G; DANAN, JL			THE C-JUN PROTOONCOGENE DOWN-REGULATES THE RAT ALPHA-FETOPROTEIN PROMOTER IN HEPG2 HEPATOMA-CELLS WITHOUT BINDING TO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC FACTOR; TRANS-ACTING FACTOR; GENE-EXPRESSION; ALPHA-1-FETOPROTEIN GENE; TRANSCRIPTION ACTIVATION; FUNCTIONAL-ANALYSIS; ALBUMIN GENES; PHORBOL ESTER; FOS PROTEINS; CIS ELEMENT	The effects of a phorbol ester (TPA) and of members of the Jun and Fos oncoprotein family on the activity of the rat alpha-fetoprotein (AFP) promoter were checked by using transient expression experiments in HepG2 hepatoma cells. TPA blocked the activity of the rat AFP promoter in a dose-dependent manner. Overexpression of c-Jun specifically repressed the rat AFP promoter but not the albumin promoter. JunB and JunD were poorer inhibitors. c-Fos expression did not potentiate the negative effect of Jun, The Jun-induced repression does not require binding of c-Jun to the AFP promoter. DNase 1 footprinting experiments did not display any high affinity binding site for Jun on the AFP promoter. Integrity of the c-Jun DNA binding domain is not required for the c-Jun protein to block the AFP promoter. The N-terminal part of Jun, which contains the activating domain, is responsible for the repression as shown by using Jun-Gal4 chimera. Jun likely exerts its negative control on the AFP promoter via protein-protein interactions with a not yet identified trans-activating factor within the -134 to +6 region or with a component of the general machinery of transcription. Jun proteins can thus be key intermediates in regulatory cascades which result in the differential modulation of the AFP and albumin gene expression in the course of liver development and carcinogenesis.	CTR RECH ENDOCRINOL MOLEC & DEV, CNRS, UPR 1511, F-92190 MEUDON, FRANCE; UNIV PARIS 07, INSERM, U327, F-75018 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				THOMASSIN, Helene/0000-0003-4613-5587				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BERNUAU D, 1988, HEPATOLOGY, V8, P997, DOI 10.1002/hep.1840080504; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOISJOYEUX B, 1994, BIOCHEM J, V301, P49, DOI 10.1042/bj3010049; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; CURRAN T, 1992, TOHOKU J EXP MED, V168, P169, DOI 10.1620/tjem.168.169; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FAUSTO N, 1989, LAB INVEST, V60, P4; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1990, ONCOGENE, V5, P39; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HU JM, 1994, MOL CELL BIOL, V14, P1531, DOI 10.1128/MCB.14.3.1531; JOSEESTANYOL M, 1989, EUR J BIOCHEM, V181, P761, DOI 10.1111/j.1432-1033.1989.tb14789.x; JOSEESTANYOL M, 1988, J BIOL CHEM, V263, P10865; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIU Y, 1994, NUCLEIC ACIDS RES, V22, P1079, DOI 10.1093/nar/22.6.1079; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCBRIDE K, 1993, MOL CELL BIOL, V13, P600, DOI 10.1128/MCB.13.1.600; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NAHON JL, 1987, J BIOL CHEM, V262, P12479; NAHON JL, 1987, BIOCHIMIE, V69, P445, DOI 10.1016/0300-9084(87)90082-4; NAKAO K, 1990, MOL CELL BIOL, V10, P1461, DOI 10.1128/MCB.10.4.1461; NAKATA K, 1992, J BIOL CHEM, V267, P1331; PAPACONSTANTINOU J, 1990, DEV GROWTH DIFFER, V32, P205; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; POLIARD A, 1990, J BIOL CHEM, V265, P2137; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RYSECK RP, 1991, ONCOGENE, V6, P533; SAEGUSA M, 1994, J TUMOR MARKER ONCOL, V9, P29; SARGENT TD, 1981, MOL CELL BIOL, V1, P871, DOI 10.1128/MCB.1.10.871; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELL S, 1978, JNCI-J NATL CANCER I, V60, P19, DOI 10.1093/jnci/60.1.19; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; TAMAOKI T, 1984, RECOMBINANT DNA CELL, P145; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TURCOTTE B, 1990, MOL CELL BIOL, V10, P5002, DOI 10.1128/MCB.10.9.5002; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; ZHANG DE, 1990, J BIOL CHEM, V265, P3382; ZHANG XK, 1991, J BIOL CHEM, V266, P8248	55	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10204	10211		10.1074/jbc.270.17.10204	http://dx.doi.org/10.1074/jbc.270.17.10204			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537266	hybrid			2022-12-25	WOS:A1995QV41700072
J	JAJU, M; BEARD, WA; WILSON, SH				JAJU, M; BEARD, WA; WILSON, SH			HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE - 3'-AZIDODEOXYTHYMIDINE 5'-TRIPHOSPHATE INHIBITION INDICATES 2-STEP BINDING FOR TEMPLATE-PRIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; 3'-AZIDO-3'-DEOXYTHYMIDINE 5'-TRIPHOSPHATE; THYMIDINE 5'-TRIPHOSPHATE; MECHANISM; PROCESSIVITY; MUTANT; LENGTH; REGION; ACID	Human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT) catalyzes DNA synthesis by an ordered sequential mechanism, After template-primer (T . P) binds to free enzyme, the deoxynucleoside triphosphate to be incorporated binds to the RT and T . P binary complex (RT(T . P)). After incorporation of the bound nucleotide, catalytic cycling is limited either by a conformational change (for processive synthesis) or release of the enzyme from the extended T . P (for single-nucleotide incorporation), To explore cycling through these alternate rate-limiting steps, we determined kinetic parameters for single-nucleotide incorporation by HXB2R HIV-1 RT with chain-terminating nucleotide substrates 3'-azido-3'-deoxythymidine triphosphate (AZTTP) and dideoxythymidine triphosphate on a homopolymeric T . P system, poly(rA)-oligo(dT)(16). Inhibition of processive deoxythymidine monophosphate in corporation by these chain-terminating substrates was also examined Because AZTTP is a substrate, its K-m should be equivalent to K-i, and since K-m for AZTTP should be influenced by the dissociation rate constant for RT(T . P), we examined the effect of altering RT(T .) P dissociation on AZTTP kinetic parameters, The dissociation rate constant was modulated by making use of different T . P substrates, viral sources of RT, and a mutant RT altered at a residue that perturbs T . P binding, As expected from earlier work, the time course of AZTMP incorporation on poly(rA)-oligo(dT)(16) was biphasic, with a burst followed by a slower steady-state phase representing k(cat) (0.42 min(-1)) which was similar to the rate constant for RT(T . P) dissociation. Additionally, K-m for AZTTP (110 nM) was lower than its equilibrium dissociation constant (1200 nM). AZTTP inhibition (K-i,K-AZTTP) of processive dTMP incorporation and incorporation of a single nucleotide were similar, However, a simple correlation between the RT(T . P) dissociation rate constant and K-i,K-AZTTP was not observed, These results indicate that a simple ordered model for single-nucleotide incorporation is inadequate and that different forms of RT(T . P) exist which can limit catalysis, The results are discussed in the context of a two-step binding reaction for T . P where the binary RT(T . P) complex undergoes an isomerization before binding of the deoxynucleotide substrate.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; NCI,BIOCHEM LAB,BETHESDA,MD 20892	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Hottiger, Michael O./J-7747-2013; Wilson, Samuel H/E-6644-2019	Hottiger, Michael O./0000-0002-7323-2270; Wilson, Samuel H/0000-0002-1702-5293				ALTMAN S, 1970, J MOL BIOL, V50, P235, DOI 10.1016/0022-2836(70)90190-7; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11708; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KATI WM, 1992, J BIOL CHEM, V267, P25988; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUHOFFER M, 1993, NUCLEIC ACIDS RES, V21, P3943, DOI 10.1093/nar/21.17.3943; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; MA QF, 1992, BIOCHEMISTRY-US, V31, P1375, DOI 10.1021/bi00120a013; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MATTHES E, 1987, BIOCHEM BIOPH RES CO, V148, P78, DOI 10.1016/0006-291X(87)91078-3; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; REARDON JE, 1991, J BIOL CHEM, V266, P14128; Segel I.H., 1975, ENZYME KINETICS; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; Wharton C. W., 1981, MOL ENZYMOLOGY, V1	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9740	9747		10.1074/jbc.270.17.9740	http://dx.doi.org/10.1074/jbc.270.17.9740			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537269	hybrid			2022-12-25	WOS:A1995QV41700010
J	RAINGEAUD, J; GUPTA, S; ROGERS, JS; DICKENS, M; HAN, JH; ULEVITCH, RJ; DAVIS, RJ				RAINGEAUD, J; GUPTA, S; ROGERS, JS; DICKENS, M; HAN, JH; ULEVITCH, RJ; DAVIS, RJ			PRO-INFLAMMATORY CYTOKINES AND ENVIRONMENTAL-STRESS CAUSE P38 MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION BY DUAL PHOSPHORYLATION ON TYROSINE AND THREONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION PATHWAY; C-JUN; NUCLEAR-LOCALIZATION; ESCHERICHIA-COLI; MAP KINASE; YEAST; EXPRESSION; AFFINITY; DOMAIN	Protein kinases activated by dual phosphorylation on Tyr and Thr (MAP kinases) can be grouped into two major classes: ERK and JNK. The ERR group regulates multiple targets in response to growth factors via a Ras-dependent mechanism, In contrast, JNK activates the transcription factor c-Jun in response to pro-inflammatory cytokines and exposure of cells to several forms of environmental stress, Recently, a novel mammalian protein kinase (p38) that shares sequence similarity with mitogen-activated protein (MAP) kinases was identified, Here, we demonstrate that p38, like JNK, is activated by treatment of cells with pro-inflammatory cytokines and environmental stress, The mechanism of p38 activation is mediated by dual phosphorylation on Thr-180 and Tyr-182, Immunofluorescence microscopy demonstrated that p38 MAP kinase is present in both the nucleus and cytoplasm of activated cells, Together, these data establish that p38 is a member of the mammalian MAP kinase group.	SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	RAINGEAUD, J (corresponding author), UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & BIOCHEM, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.		Han, J/G-4671-2010; Ulevitch, Richard J/Q-3393-2017; Dickens, Martin/B-2001-2012		NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI KY, 1994, CELL, V78, P499; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; ERREDE B, 1993, CURR OPIN CELL BIOL, V2, P283; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SETH A, 1992, J BIOL CHEM, V267, P24796; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0	53	2013	2073	2	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7420	7426		10.1074/jbc.270.13.7420	http://dx.doi.org/10.1074/jbc.270.13.7420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535770	hybrid			2022-12-25	WOS:A1995QQ43100061
J	EYCHENE, A; DUSANTERFOURT, I; BARNIER, JV; PAPIN, C; CHARON, M; GISSELBRECHT, S; CALOTHY, G				EYCHENE, A; DUSANTERFOURT, I; BARNIER, JV; PAPIN, C; CHARON, M; GISSELBRECHT, S; CALOTHY, G			EXPRESSION AND ACTIVATION OF B-RAF KINASE ISOFORMS IN HUMAN AND MURINE LEUKEMIA-CELL LINES	ONCOGENE			English	Article						B-RAF; C-RMIL; RAF-1; SERINE THREONINE KINASE; HEMATOPOIETIC CELLS	COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; PROTEIN-KINASE; GROWTH-FACTOR; RAPID PHOSPHORYLATION; C-RAF; SIGNAL TRANSDUCTION; PROTOONCOGENE; ERYTHROPOIETIN; INTERLEUKIN-3	The B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases. It encodes multiple protein isoforms previously shown to be expressed predominantly in neural tissues. We report here that B-Raf proteins of 95 and 72 kDa are also expressed in various human and murine hematopoietic cell lines. Their relative level of expression is variable depending on the cell line examined. The highest level of expression of p95(B-raf) was found in UT-7 cells, a human pluripotent cell line established from a patient with a megakaryoblastic leukemia. These cells are able to differentiate toward erythroid or myeloid lineage phenotypes in presence of erythropoietin (EPO) or granulocyte-macrophage colony-stimulating factor (GM-CSF) respectively. We show that treatment of UT-7 cells with EPO, GM-CSF or stem cell factor (SCF) rapidly induces phosphorylation of p95(B-raf) as indicated by a shift of electrophoretic mobility. This increase in phosphorylation is correlated with a three-fold increase of B-Raf kinase activity. B-Raf activation also increases in a dose-dependent manner in response to EPO and GM-CSF. We also show that both p95(B-raf) and p72(B-raf) can be activated by IL-3 in murine BAF-3 pro-B cells and by anti-CD3 in human Jurkat cells, respectively. These observations provide the first evidence that the B-Raf kinase is involved in signal transduction pathways regulating proliferation and differentiation of hematopoietic cells of both myeloid and lymphoid lineages.	HOP COCHIN,ICGM,INSERM,U363,F-75674 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	EYCHENE, A (corresponding author), CTR UNIV ORSAY,INST CURIE,LAB 110,CNRS,URA 1443,F-91405 ORSAY,FRANCE.		Eychene, Alain/M-8838-2017; Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; EYCHENE, Alain/0000-0002-6818-7225				BRENNSCHEIDT U, 1994, CELL GROWTH DIFFER, V5, P367; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSCHER D, 1993, ONCOGENE, V8, P3323; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EYCHENE A, 1992, ONCOGENE, V7, P1657; EYCHENE A, 1992, ONCOGENE, V7, P1315; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; HEIDECKER G, 1991, ADV CANCER RES, V58, P53; HERMINE O, 1992, BLOOD, V80, P3060; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KANAKURA Y, 1991, BLOOD, V77, P243; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOMATSU N, 1991, CANCER RES, V51, P341; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MIHALY A, 1993, BRAIN RES, V627, P225, DOI 10.1016/0006-8993(93)90325-H; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RAMOSMORALES F, 1994, IN PRESS ONCOGENE, V9; RAPP UR, 1991, ONCOGENE, V6, P495; RIEDEL D, 1993, EUR J IMMUNOL, V23, P3146, DOI 10.1002/eji.1830231216; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; TAMAKI T, 1992, CANCER RES, V52, P566; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1159	1165						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535416				2022-12-25	WOS:A1995QN35300017
J	HARRISON, L; ASCIONE, AG; WILSON, DM; DEMPLE, B				HARRISON, L; ASCIONE, AG; WILSON, DM; DEMPLE, B			CHARACTERIZATION OF THE PROMOTER REGION OF THE HUMAN APURINIC ENDONUCLEASE GENE (APE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR USF; RNA POLYMERASE-II; DNA-REPAIR ENZYME; APYRIMIDINIC ENDONUCLEASE; UPSTREAM ELEMENT; BINDING PROTEINS; EXONUCLEASE-III; EXPRESSION; HAP1	Apurinic/apyrimidinic (AP) sites are mutagenic and block DNA synthesis in vitro, Repair of AP sites is initiated by AP endonucleases that cleave just 5' to the damage. We linked a 4.1-kilobase pair HindIII DNA fragment from the region upstream of the human AP endonuclease gene (APE) to the chloramphenicol acetyltransferase (CAT) gene. Deletions generated constructs containing 1.9 kilobase pairs to 50 base pairs (bp) of the APE upstream region. Transient transfection studies in HeLa cells established that the basal APE promoter is contained within a 500-bp fragment. The major transcriptional start site in HeLa, hepatoma (HepG2), and myeloid leukemic (K562) cells was mapped to a cluster of sites similar to 130 bp downstream of a putative ''CCAAT box,'' similar to 130 bp 5' of the first splice junction in APE. Deletion of 5' sequences to within 10 bp of the CCAAT box reduced the CAT activity by only about half, and removal of the CCAAT box region left a residual promoter activity similar to 9%. Deletion to 31 bp upstream of the transcriptional start site abolished APE promoter activity. DNA sequence analysis revealed potential transcription factor recognition sites in the APE promoter. Gel mobility-shift assays showed that both human upstream factor and Spl can bind their respective sites in the APE promoter. However, DNase I footprinting using HeLa nuclear extract showed that the binding of Sp1 and upstream factor is blocked by the binding of other proteins to the nearby CCAAT box region.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40000] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA K, 1994, BBA-GENE STRUCT EXPR, V1219, P15, DOI 10.1016/0167-4781(94)90241-0; BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3229; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Harrison Lynn, 1992, Human Molecular Genetics, V1, P677, DOI 10.1093/hmg/1.9.677; HENNER WD, 1983, J BIOL CHEM, V258, P711; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; KONECKI DS, 1992, BIOCHEMISTRY-US, V31, P8363, DOI 10.1021/bi00150a033; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RIVKEES SA, 1994, BRAIN RES, V666, P137, DOI 10.1016/0006-8993(94)90296-8; ROBSON CN, 1992, NUCLEIC ACIDS RES, V20, P4417, DOI 10.1093/nar/20.17.4417; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WINTERS TA, 1994, NUCLEIC ACIDS RES, V22, P1866, DOI 10.1093/nar/22.10.1866; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHAO B, 1992, NUCLEIC ACIDS RES, V20, P4097, DOI 10.1093/nar/20.15.4097	40	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5556	5564		10.1074/jbc.270.10.5556	http://dx.doi.org/10.1074/jbc.270.10.5556			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534297	hybrid			2022-12-25	WOS:A1995QL58000091
J	TIMERMAN, AP; WIEDERRECHT, G; MARCY, A; FLEISCHER, S				TIMERMAN, AP; WIEDERRECHT, G; MARCY, A; FLEISCHER, S			CHARACTERIZATION OF AN EXCHANGE-REACTION BETWEEN SOLUBLE FKBP-12 AND THE FKBP RYANODINE RECEPTOR COMPLEX - MODULATION BY FKBP MUTANTS DEFICIENT IN PEPTIDYL-PROLYL ISOMERASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL TERMINAL CISTERNAE; MUSCLE SARCOPLASMIC-RETICULUM; CYTOSOLIC BINDING-PROTEIN; CALCIUM-RELEASE CHANNEL; RABBIT SKELETAL-MUSCLE; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; FK-506-BINDING PROTEIN; MOLECULAR-CLONING; CYCLOPHILIN	FKBP-12 (FKBP), the soluble receptor for the immunosuppresant drug FK-506, is tightly bound to the calcium release channel (CRC)/ryanodine receptor (RyR) of skeletal muscle terminal cisternae (TC) of sarcoplasmic reticulum with a stoichiometry of 4 mol of FKBP per tetrameric RyR complex. FKBP displays cis/trans-peptidyl-prolyl isomerase (PPIase) activity which is inhibited by FK-590 or rapamycin. In skeletal muscle TC, FK-590 or rapamycin binds to and dissociates FKBP from the RyR in a time- and temperature-dependent manner which increases the open probability of the channel. Therefore, the net energized Ca2+ uptake rate of TC vesicles devoid of FKBP is reduced due to the increased leak of Ca2+ from the TC specifically via the RyR, which is reversed upon rebinding of FKBP. Thus, the RyR is modulated by FKBP (Timerman, A. P., Ogunbumni, E., Freund, E. A., Wiederrecht, G., Marks, A. R., and Fleischer, S., (1993) J. Biol. Chem. 268, 22922-22999; Mayrleitner, M., Timerman, A. P., Wiederrecht, G., and Fleischer S. (1994) Cell Calcium 15, 99-108). We now find that FKBP can be displaced from the FKBP RyR complex by exchange with FKBP in solution. The EC(50) for exchange is 0.30 mu M for wild type FKBP versus 0.6 to 2.4 mu M for three different site-directed mutants that are practically devoid of any measurable PPIase activity. Substitution of wild-type FKBP on the RyR complex with these PPIase-deficient mutants did not alter the Ca2+ flux of TC vesicles, whereas dissociation of FKBP from TC with FK-590 increased the Ca2+ leak rate. Our studies show that, in vivo, the FKBP.RyR complex is in equilibrium with the cytosolic pool of FKBP (similar to 3 mu M) and suggest that modulation of the CRC by FKBP is independent of PPIase activity.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT IMMUNOL, RAHWAY, NJ 07065 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT BIOPHYS CHEM, RAHWAY, NJ 07065 USA	Vanderbilt University; Merck & Company; Merck & Company					NHLBI NIH HHS [HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHU A, 1988, METHOD ENZYMOL, V157, P36; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Eisenberg B. R., 2010, COMPREHENSIVE PHYSL, P73; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P105; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACK MM, 1994, J BIOL CHEM, V269, P23236; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; SAITO A, 1989, Biophysical Journal, V55, p206A; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	32	129	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2451	2459		10.1074/jbc.270.6.2451	http://dx.doi.org/10.1074/jbc.270.6.2451			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531689	hybrid			2022-12-25	WOS:A1995QF53500011
J	SEIBERT, FS; TABCHARANI, JA; CHANG, XB; DULHANTY, AM; MATHEWS, C; HANRAHAN, JW; RIORDAN, JR				SEIBERT, FS; TABCHARANI, JA; CHANG, XB; DULHANTY, AM; MATHEWS, C; HANRAHAN, JW; RIORDAN, JR			CAMP-DEPENDENT PROTEIN KINASE-MEDIATED PHOSPHORYLATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR RESIDUE SER-753 AND ITS ROLE IN CHANNEL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CL CHANNEL; R-DOMAIN; BINDING; PHOSPHATASES; DELTA-F508; MODULATION; SEQUENCES; GENE; SITE	Hormonal regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is largely mediated via cAMP-dependent protein kinase (PKA), CFTR contains 10 dibasic consensus sites for potential PKA phosphorylation ((R/K)(R/K)X(S*/T*)). Previous studies (Chang, X-B., Tabcharani, J. A., Hou, Y.-X., Jensen, T. J., Kartner, N., Alon, N., Hanrahan, J.W., and Riordan, J.R (1993) J. Biol. Chem. 268, 11304-11311) showed that approximately 25% of the CFTR wild-type response to PKA activation remained upon inhibition of most detectable phosphorylation by in vitro mutagenesis of all 10 dibasic consensus sites (10SA CFTR), To identify potential additional sites responsible for the residual activity, large amounts of this mutant CFTR were phosphorylated with PKA using high specific activity [gamma-P-32]ATP. Cyanogen bromide cleavage indicated that a large portion of the observed PKA phosphorylation occurred within a 5.8-kDa fragment of the R domain between residues 722-773. Removal of serines at potential PKA sites in this fragment showed that Ser-753 accounted for all of the gamma-P-32 labeling of the 5.8-kDa peptide. Replacement of Ser-753 with alanine reduced the level of residual CFTR activity by a further 40%, indicating that phosphorylation at this previously unidentified site contributes to the activation of 10SA CFTR.	MAYO CLIN SCOTTSDALE, SC JOHNSON MED RES CTR, SCOTTSDALE, AZ 85259 USA; HOSP SICK CHILDREN, RES INST, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON M5G 1X8, CANADA; MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McGill University			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECQ F, 1994, IN PRESS P NATL ACAD; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; BERGER HA, 1993, J BIOL CHEM, V268, P2037; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HANRAHAN JW, 1994, ADV COMP ENV PHYSL, V19, P193; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RICH DP, 1993, J BIOL CHEM, V268, P20259; Riordan J. R., 1993, CYSTIC FIBROSIS CURR, VI, P157; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1994, IN PRESS J EXP BIOL; RIORDAN JR, 1992, CURRENT OPINION NEPH, P34; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937	34	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2158	2162		10.1074/jbc.270.5.2158	http://dx.doi.org/10.1074/jbc.270.5.2158			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530719	hybrid			2022-12-25	WOS:A1995QE49300029
J	CAMPOS, KL; GIOVANELLI, J; KAUFMAN, S				CAMPOS, KL; GIOVANELLI, J; KAUFMAN, S			CHARACTERISTICS OF THE NITRIC-OXIDE SYNTHASE-CATALYZED CONVERSION OF ARGININE TO N-HYDROXYARGININE, THE FIRST OXYGENATION STEP IN THE ENZYMATIC-SYNTHESIS OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; BRAIN; HEME; INTERMEDIATE; OXIDATION; REDUCTION; CYTOCHROME-P-450; BIOSYNTHESIS; HEMOPROTEIN; COFACTOR	The nitric oxide synthase-catalyzed conversion of L-arginine to L-citrulline and nitric oxide is known to be the sum of two partial reactions: oxygenation of arginine to N-hydroxyarginine, followed by oxygenation of N-hydroxyarginine to citrulline and nitric oxide, Whereas the conversion of N-hydroxyarginine to citrulline and nitric oxide has been the subject of a number of studies, the oxygenation of arginine to N-hydroxyarginine has received little attention, Here we show that substrate amounts of rat cerebellar nitric oxide synthase, in the absence of added NADPH, catalyze the conversion of arginine to N-hydroxyarginine as the dominant product, The product appears not to be tightly bound to the enzyme. A maximum of 0.16 mol of N-hydroxyarginine/mol of nitric oxide synthase subunit was formed. The reaction requires oxygen and the addition of Ca2+/calmodulin and is stimulated 3-fold by tetrahydrobiopterin. Upon addition of NADPH, citrulline is formed exclusively, Conversion of N-hydroxyarginine to citrulline, like the first partial reaction, requires Ca2+/calmodulin and is stimulated by tetrahydrobiopterin but differs from the first partial reaction in being completely dependent upon addition of NADPH, These results indicate that brain nitric oxide synthase contains an endogenous reductant that can support oxygenation of arginine but not of N-hydroxyarginine, The reductant is not NADPH, since the amount of nitric oxide synthase-bound NADPH is appreciably less than the amount required for N-hydroxyarginine synthesis. Possible candidates for this role are discussed in relation to proposed mechanisms of action of nitric oxide synthase.	NIMH, NEUROCHEM LAB, BETHESDA, MD 20895 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ARCHER MC, 1972, CAN J BIOCHEM CELL B, V50, P1174, DOI 10.1139/o72-160; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHENAIS B, 1993, BIOCHEM BIOPH RES CO, V196, P1558, DOI 10.1006/bbrc.1993.2429; CHENAIS B, 1991, J CHROMATOGR, V539, P433, DOI 10.1016/S0021-9673(01)83952-2; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; ESTABROOK RW, 1970, ANN NY ACAD SCI, V174, P218, DOI 10.1111/j.1749-6632.1970.tb49788.x; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GUENGERICH FP, 1984, ACCOUNTS CHEM RES, V17, P9, DOI 10.1021/ar00097a002; Gunsalus I C, 1972, Biochem Soc Symp, V34, P135; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRAAK JC, 1977, J CHROMATOGR, V142, P671, DOI 10.1016/S0021-9673(01)92076-X; Lai C Y, 1977, Methods Enzymol, V47, P236; LOWRY OH, 1961, J BIOL CHEM, V236, P2746; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYUZUMI H, 1994, ARCH BIOCHEM BIOPHYS, V310, P367, DOI 10.1006/abbi.1994.1180; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; PIERRE J, 1982, EUR J BIOCHEM, V124, P533; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; PUFAHL RA, 1994, FASEB J, V8, pA1382; SALET C, 1981, PHOTOCHEM PHOTOBIOL, V33, P753, DOI 10.1111/j.1751-1097.1981.tb05485.x; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; VERMILION JL, 1981, J BIOL CHEM, V256, P266; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	36	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1721	1728		10.1074/jbc.270.4.1721	http://dx.doi.org/10.1074/jbc.270.4.1721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530247	hybrid			2022-12-25	WOS:A1995QD20400039
J	ABUSOUD, HM; FELDMAN, PL; CLARK, P; STUEHR, DJ				ABUSOUD, HM; FELDMAN, PL; CLARK, P; STUEHR, DJ			ELECTRON-TRANSFER IN THE NITRIC-OXIDE SYNTHASES - CHARACTERIZATION OF L-ARGININE ANALOGS THAT BLOCK HEME IRON REDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-L-ARGININE; PERITONEAL-MACROPHAGES; MOLECULAR-CLONING; BRAIN; CALMODULIN; ENZYME; FLAVOPROTEIN; INHIBITION; MECHANISM; COMPLEXES	Heme iron reduction in the nitric-oxide syntheses (NOSs) requires calmodulin binding and is associated with increased NO synthesis and NADPH oxidation (Abu-Soud, H. M., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci., U. S. A. 90, 10769-10772). Here, we examined how L-arginine and the analogs N-w-methyl-L-arginine (NMA), N-w-nitro-L-arginine methyl ester (NAME), and d-(thioureido)-L-norvaline (thiocitrulline) affect electron flux through neuronal and macrophage NOS. L-Arginine and NMA increased or decreased NOS NADPH consumption depending on the isoform, while thiocitrulline and NAME decreased NADPH oxidation in both NOS by 73-86% relative to their ligand-free rates. Kinetic studies showed that thiocitrulline and NAME inhibited NOS NADPH consumption through binding within the substrate binding site. Thiocitrulline and NAME did not affect the NADPH-dependent reduction of NOS flavins nor NOS cytochrome c reduction, indicating that they blocked electron flux at a point beyond the flavins in the electron transfer sequence. Thiocitrulline and NAME inhibited both NADPH-dependent and dithionite-mediated heme iron reduction in the NOS isoforms relative to the substrate-free NOS, whereas L-arginine and NMA did not. Thus, L-arginine and NMA increase or decrease electron flux through the NOS by coupling NADPH oxidation to NO synthesis (L-arginine), or by occupying the substrate binding site with minimal catalytic coupling (NMA). In contrast, thiocitrulline and NAME decrease electron nux through both NOS isoforms by decreasing the reduction potential of the heme iron. Inhibition of heme iron reduction by substrate analogs is unusual and represents a new means to modulate electron now through the NOS.	CLEVELAND CLIN, DEPT IMMUNOL, CLEVELAND, OH 44195 USA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; GLAXO INC, RES INST, DEPT CHEM, RES TRIANGLE PK, NC 27709 USA	Cleveland Clinic Foundation; Case Western Reserve University; GlaxoSmithKline					NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DENG WL, 1993, J IMMUNOL, V151, P322; DING AH, 1988, J IMMUNOL, V141, P2407; FELDMAN PL, 1991, TETRAHEDRON LETT, V32, P875, DOI 10.1016/S0040-4039(00)92109-9; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HINTZ MJ, 1980, J BIOL CHEM, V255, P7317; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, J BIOL CHEM, V267, P11374; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LAMBERT LE, 1991, LIFE SCI, V48, P69, DOI 10.1016/0024-3205(91)90426-C; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MANSUY D, 1978, EUR J BIOCHEM, V86, P573, DOI 10.1111/j.1432-1033.1978.tb12341.x; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MORIKAWA E, 1992, AM J PHYSIOL, V263, pH1632, DOI 10.1152/ajpheart.1992.263.5.H1632; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PETERSON JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P654, DOI 10.1016/0003-9861(92)90738-I; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POU S, 1992, J BIOL CHEM, V267, P24173; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SONO M, 1982, J BIOL CHEM, V257, P8308; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; WANG JL, 1993, J BIOL CHEM, V268, P22255; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	51	125	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32318	32326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528212				2022-12-25	WOS:A1994PX30400048
J	BRIZZI, MF; ZINI, MG; ARONICA, MG; BLECHMAN, JM; YARDEN, Y; PEGORARO, L				BRIZZI, MF; ZINI, MG; ARONICA, MG; BLECHMAN, JM; YARDEN, Y; PEGORARO, L			CONVERGENCE OF SIGNALING BY INTERLEUKIN-3, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, AND MAST-CELL GROWTH-FACTOR ON JAK2 TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; C-KIT; GM-CSF; TRANSCRIPTION FACTOR; FACTOR RECEPTOR; HEMATOPOIETIC-CELLS; EXPRESSION CLONING; INTERFERON-GAMMA; STEEL FACTOR; PHOSPHORYLATION	Mast cell growth factor (MGF) (also called stem cell factor) synergizes with several lymphokines, including interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM CSF), to promote proliferation and differentiation of certain hemopoietic progenitor cells. Although similar patterns of tyrosine-phosphorylated proteins characterize cells stimulated by MGF, IL-3, and GM-CSF, only the MGF receptor is a tyrosine kinase, and the heterodimeric receptors for IL-3 and GM-CSF share a common beta subunit that is devoid of enzymatic activity. Here we show that signaling pathways utilized by all three cytokines include the cytoplasmic tyrosine kinase JAK2. Analysis of several factor-dependent myeloid cell lines indicated that JAK2 is physically associated with the common beta subunit and with MGF receptor (c-Kit) even prior to ligand binding. However, each of the ligands induced elevated tyrosine phosphorylation of JAK2 and a consequent increase in its catalytic activity. These results demonstrate for the first time the convergence within the same myeloid cells of signaling pathways originating in two distinct lymphokine receptors and a tyrosine kinase receptor on activation of a cytoplasmic tyrosine kinase.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			Brizzi, Maria Felice/J-7882-2016; YARDEN, YOSEF/K-1467-2012					ALAI M, 1992, J BIOL CHEM, V267, P18021; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; AVANZI GC, 1991, CANCER RES, V51, P1741; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HORIE M, 1993, J BIOL CHEM, V268, P968; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KANAKURA Y, 1990, BLOOD, V76, P706; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LANGE B, 1987, BLOOD, V70, P192; LEV S, 1992, J BIOL CHEM, V267, P10866; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; OKUDA K, 1991, BLOOD, V78, P1928; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TORTI M, 1992, J BIOL CHEM, V267, P8293; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	54	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31680	31684						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527392				2022-12-25	WOS:A1994PX30300056
J	MOLLER, NPH; MOLLER, KB; LAMMERS, R; KHARITONENKOV, A; HOPPE, E; WIBERG, FC; SURES, I; ULLRICH, A				MOLLER, NPH; MOLLER, KB; LAMMERS, R; KHARITONENKOV, A; HOPPE, E; WIBERG, FC; SURES, I; ULLRICH, A			SELECTIVE DOWN-REGULATION OF THE INSULIN-RECEPTOR SIGNAL BY PROTEIN-TYROSINE PHOSPHATASE-ALPHA AND PHOSPHATASE-EPSILON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; HIGH-EFFICIENCY; RAT-LIVER; DEPHOSPHORYLATION; KINASE; PHOSPHORYLATION; DOMAIN; CELLS	Binding of insulin to its receptor (IR) causes rapid autophosphorylation with concomitant activation of its tyrosine kinase which transmits the signal by phosphorylating cellular substrates. The IR activity is controlled by protein-tyrosine phosphatases, but those directly involved in regulating the insulin receptor and its signaling pathways have not yet been identified. Using baby hamster kidney cells overexpressing the IR and a novel insulin-based selection principle, we established stable cell lines with functionally coupled expression of the IR and protein-tyrosine phosphatases. The two closely related protein-tyrosine phosphatases alpha and epsilon were identified as negative regulators of IR tyrosine kinase.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society	MOLLER, NPH (corresponding author), NOVO NORDISK AS,SIGNAL TRANSDUCT,BLDG 6A1086,DK-2880 BAGSVAERD,DENMARK.							ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; BOYLAN JM, 1992, J CLIN INVEST, V90, P174, DOI 10.1172/JCI115833; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FAURE R, 1993, GLIA, V9, P311, DOI 10.1002/glia.440090409; FAURE R, 1992, J BIOL CHEM, V267, P11215; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FENDLY BM, 1990, CANCER RES, V50, P1550; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MEYEROVITCH J, 1992, BIOCHEMISTRY-US, V31, P10338, DOI 10.1021/bi00157a023; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SALE GJ, 1991, ADV PROTEIN PHOSPHAT, V6, P159; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SU J, 1994, J BIOL CHEM, V269, P18731; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAN H, 1993, J BIOL CHEM, V268, P24880; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHANG WR, 1991, BIOCHEM BIOPH RES CO, V178, P1291, DOI 10.1016/0006-291X(91)91034-A; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	61	134	138	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23126	23131		10.1074/jbc.270.39.23126	http://dx.doi.org/10.1074/jbc.270.39.23126			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559456	hybrid			2022-12-25	WOS:A1995RY05400076
J	ONEILL, RE; JASKUNAS, R; BLOBEL, G; PALESE, P; MOROIANU, J				ONEILL, RE; JASKUNAS, R; BLOBEL, G; PALESE, P; MOROIANU, J			NUCLEAR IMPORT OF INFLUENZA-VIRUS RNA CAN BE MEDIATED BY VIRAL NUCLEOPROTEIN AND TRANSPORT FACTORS REQUIRED FOR PROTEIN IMPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HERPES-SIMPLEX VIRUS; MOLECULAR-GENETICS; PORE COMPLEX; CELLS; RIBONUCLEOPROTEINS; NUCLEOCAPSIDS; LOCALIZATION; ACCUMULATION; INFECTION; RAN/TC4	We have fluorescently labeled one of the eight genomic segments of influenza virus RNA and a recombinant influenza viral protein, the nucleoprotein (NP), to investigate the requirement for their uptake into nuclei of digitonin-permeabilized cells. We found that the influenza viral NP behaves like a nuclear localization sequence (NLS) containing protein. Thus, at 0 degrees C it docks at the nuclear envelope only in the presence of the heterodimeric karyopherin (either karyopherin alpha 1 beta or karyopherin alpha 2 beta), and docking is competitively inhibited by an unlabeled NLS containing substrate. Like other NLS-containing proteins, at 20 degrees C NP is imported into the nucleus after further addition of the GTPase Ran and of p10, In contrast, the fluorescently labeled, 890-nucleotide-long viral RNA segment does not dock to the nuclear envelope or enter the nucleus either in the presence of exogenous cytosol or of karyopherin heterodimer, Ran, and p10, However, in the presence of NP the RNA is able to dock and enter the nucleus with transport requirements indistinguishable from those for docking and entry of NP. These data indicate that uptake of the influenza virus RNA segment is not via a signal in the RNA but via an NLS of a viral protein such as NP.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA; CUNY MT SINAI SCH MED, DEPT MICROBIOL, NEW YORK, NY 10029 USA	Howard Hughes Medical Institute; Rockefeller University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Palese, Peter/0000-0002-0337-5823	NIAID NIH HHS [AI-18998] Funding Source: Medline; PHS HHS [P7-3593] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018998, R01AI018998] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTERSON W, 1983, J VIROL, V45, P397, DOI 10.1128/JVI.45.1.397-407.1983; BAUDIN F, 1994, EMBO J, V13, P3158, DOI 10.1002/j.1460-2075.1994.tb06614.x; BLUMBERG BM, 1983, CELL, V32, P559, DOI 10.1016/0092-8674(83)90475-0; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; COMPANS RW, 1972, J VIROL, V10, P795, DOI 10.1128/JVI.10.4.795-800.1972; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HERZ C, 1981, CELL, V26, P391, DOI 10.1016/0092-8674(81)90208-7; JONES IM, 1986, EMBO J, V5, P2371, DOI 10.1002/j.1460-2075.1986.tb04506.x; KEMLER I, 1994, VIROLOGY, V202, P1028, DOI 10.1006/viro.1994.1432; KOBAYASHI M, 1994, J VIROL, V68, P8433, DOI 10.1128/JVI.68.12.8433-8436.1994; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOYER SA, 1991, J VIROL, V65, P2170, DOI 10.1128/JVI.65.5.2170-2178.1991; MURTI KG, 1988, VIROLOGY, V164, P562, DOI 10.1016/0042-6822(88)90574-0; NIETO A, 1994, J GEN VIROL, V75, P29, DOI 10.1099/0022-1317-75-1-29; ONEILL RE, 1994, INFECT AGENT DIS, V3, P77; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; PALESE P, 1977, CELL, V10, P1, DOI 10.1016/0092-8674(77)90133-7; PARVIN JD, 1989, J VIROL, V63, P5142, DOI 10.1128/JVI.63.12.5142-5152.1989; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REES PJ, 1981, J GEN VIROL, V53, P125, DOI 10.1099/0022-1317-53-1-125; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; RUIGROK RWH, 1989, VIROLOGY, V173, P311, DOI 10.1016/0042-6822(89)90248-1; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOGNON M, 1981, J VIROL, V40, P870, DOI 10.1128/JVI.40.3.870-880.1981; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEISS B, 1989, J VIROL, V63, P5310, DOI 10.1128/JVI.63.12.5310-5318.1989; YAMANAKA K, 1990, J BIOL CHEM, V265, P11151	45	178	186	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22701	22704		10.1074/jbc.270.39.22701	http://dx.doi.org/10.1074/jbc.270.39.22701			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559393	hybrid			2022-12-25	WOS:A1995RY05400013
J	STEINER, H; ZOLLNER, A; HAID, A; NEUPERT, W; LILL, R				STEINER, H; ZOLLNER, A; HAID, A; NEUPERT, W; LILL, R			BIOGENESIS OF MITOCHONDRIAL HEME LYASES IN YEAST - IMPORT AND FOLDING IN THE INTERMEMBRANE SPACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; PRECURSOR PROTEINS; NEUROSPORA-CRASSA; APOCYTOCHROME-C; CYCLOSPORINE-A; 2 STEPS; TRANSLOCATION; MEMBRANE	Heme lyases are components of the mitochondrial intermembrane space facilitating the covalent attachment of heme to the apoforms of c-type cytochromes. The precursors of heme lyases are synthesized in the cytosol without the typical N-terminal mitachondrial targeting signal. Here, we have analyzed the mode of import and folding of the two heme lyases of the yeast Saccharomyces cerevisiae, namely of cytochrome c heme lyase and of cytochrome c, heme lyase. For transport into mitochondria, both proteins use the general protein import machinery of the outer membrane, import occurred independently of a membrane potential, Delta psi, across the inner membrane and ATP in the matrix space, suggesting that the inner membrane is not required for transport along this direct sorting pathway. The presence of a large folded domain in heme lyases was utilized to study their folding in the intermembrane space. Formation of this domain occurred at the same rate as import, indicating that heme lyases fold either during or immediately after their transfer across the membrane. Folding was not affected by depletion of ATP and Delta psi or by inhibitors of peptidylprolyl cis-trans isomerases, i.e. it does not involve homologs of known folding factors (Like Hsp60 and Hsp70). The energy derived from folding cannot be regarded as a major driving force for import, since the folded domain could be imported into mitochondria with the same efficiency as the intact protein. We conclude that protein folding in the intermembrane space obeys principles different from those established for other subcellular compartments.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHE & ZELLBIOL, D-80336 MUNICH, GERMANY; UNIV MUNICH, INST GENET & MIKROBIOL, D-80638 MUNICH, GERMANY	University of Munich; University of Munich				Lill, Roland/0000-0002-8345-6518				BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; DAUM G, 1982, J BIOL CHEM, V257, P3075; DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1995, ADV MOL CELL BIOL; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; LILL R, 1992, MEMBRANE BIOGENESIS, P265; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19804; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1987, EMBO J, V6, P2635, DOI 10.1002/j.1460-2075.1987.tb02554.x; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; STUART RA, 1990, J BIOL CHEM, V265, P20210; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; THONYMEYER L, 1994, BBA-BIOENERGETICS, V1187, P260, DOI 10.1016/0005-2728(94)90123-6; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	50	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22842	22849		10.1074/jbc.270.39.22842	http://dx.doi.org/10.1074/jbc.270.39.22842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559417	hybrid			2022-12-25	WOS:A1995RY05400037
J	CROMMIE, D; ROSEN, SD				CROMMIE, D; ROSEN, SD			BIOSYNTHESIS OF GLYCAM-1, A MUCIN-LIKE LIGAND FOR L-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; HIGH ENDOTHELIAL VENULES; VICIA-VILLOSA SEEDS; L BARK LECTIN; BREFELDIN-A; CELL-SURFACE; LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; MAACKIA-AMURENSIS	L-selectin, a member of the selectin family of leukocyte endothelial adhesion proteins, mediates the initial attachment of lymphocytes to lymph node high endothelial venules during lymphocyte recirculation. One of the endothelial-associated Ligands for L-selectin is Gly-CAM-1, a mucin-like glycoprotein, which presents novel sulfated, sialylated and fucosylated O-glycans. In order to understand the generation of these glycans, we have examined the biosynthesis of GlyCAM-1 in lymph node organ culture. Using peptide-specific antibodies, lectins, and recombinant L-selectin, we detected the following species of GlyCAM-1: unglycosylated (<28 kDa); modified with GalNAc only (28-33 kDa); modified with sialic acid, fucose, and sulfate but lacking L-selectin reactivity (40-50 kDa); and mature (L-selectin-reactive) ligand (50-60 kDa). Pulse-chase labeling at 15 degrees C suggested that GalNAc is added in a pre-Golgi compartment. Treatment with brefeldin A almost completely blocked sulfation, indicating that this modification occurs in the trans-Golgi network. Two distinct sialylation events occurred in the presence of brefeldin A, while fucosylation was partially blocked. We conclude that sialylation precedes both fucosylation and sulfation during biosynthesis. This ordering will help to identify the critical acceptor structures recognized by lymph node glycosyltransferases and sulfotransferases.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BAUMHUETER S, 1994, BLOOD, V84, P2554; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BOLAND CR, 1991, CANCER RES, V51, P657; BRISKIN MJ, 1993, NATURE, V363, P451; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; CALABRO A, 1994, J BIOL CHEM, V269, P22764; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DOWBENKO D, 1993, J CLIN INVEST, V92, P952, DOI 10.1172/JCI116671; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HAMANN A, 1988, J IMMUNOL, V140, P693; HANOVER JA, 1982, J BIOL CHEM, V257, P172; HARLOW E, 1988, ANTIBODIES LABORATOR; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; HOURIHAN H, 1993, J CELL SCI, V104, P1049; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, GLYCOCONJUGATE J, V10, P34, DOI 10.1007/BF00731184; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JAIN RK, 1994, J AM CHEM SOC, V116, P12123, DOI 10.1021/ja00105a091; KALADAS PM, 1981, MOL IMMUNOL, V18, P969, DOI 10.1016/0161-5890(81)90114-0; KIKUTA A, 1994, BLOOD, V84, P3766, DOI 10.1182/blood.V84.11.3766.bloodjournal84113766; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MILLER RL, 1987, METHOD ENZYMOL, V138, P527; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PILLER V, 1990, J BIOL CHEM, V265, P9264; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; ROTH J, 1982, J CELL BIOL, V92, P223; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHACHNER HS, 1989, S SOC EXP BIOL, V63, P1; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SHITE S, 1990, J BIOL CHEM, V265, P17385; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SPIELMAN J, 1988, J BIOL CHEM, V263, P9621; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; STROUS GJAM, 1979, P NATL ACAD SCI USA, V76, P2694, DOI 10.1073/pnas.76.6.2694; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TOLLEFSEN SE, 1983, J BIOL CHEM, V258, P5172; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WANG WC, 1988, J BIOL CHEM, V263, P4576; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688; YAMASHITA K, 1992, BIOCHEMISTRY-US, V31, P11647, DOI 10.1021/bi00161a052	85	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22614	22624		10.1074/jbc.270.38.22614	http://dx.doi.org/10.1074/jbc.270.38.22614			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545681	hybrid			2022-12-25	WOS:A1995RW31400085
J	HOLZ, GG; LEECH, CA; HABENER, JF				HOLZ, GG; LEECH, CA; HABENER, JF			ACTIVATION OF A CAMP-REGULATED CA2+-SIGNALING PATHWAY IN PANCREATIC BETA-CELLS BY THE INSULINOTROPIC HORMONE GLUCAGON-LIKE PEPTIDE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; CYCLIC ADENOSINE-MONOPHOSPHATE; ADENYLATE-CYCLASE; FUNCTIONAL EXPRESSION; SIGNAL TRANSDUCTION; GENE-EXPRESSION; ELECTRICAL-ACTIVITY; DIABETES-MELLITUS; INCRETIN HORMONE; CYTOSOLIC CA-2+	Glucagon-like peptide-1 (GLP-1) is an intestinally derived insulinotropic hormone that is currently under investigation for use in the treatment of diabetes mellitus. To investigate the Ca2+ signaling pathways by which GLP-1 may stimulate the secretion of insulin from pancreatic beta-cells, we examined its effects on the concentration of free intracellular Ca2+ ([Ca2+](i)) while simultaneously determining what action it exerts on ion channel function. Measurements of [Ca2+](i) were obtained from single rat beta-cells and from beta TC6 and HIT-T15 insulinoma cells loaded with the Ca2+ indicator fura-2, and changes in membrane potential and current were monitored using the perforated patch clamp technique. We report a previously undocumented action of GLP-1 and analogs of cAMP (8-bromo-cAMP, Sp- or Rp-adenosine 3',5'-cyclic monophosphothionate triethylamine) to raise [Ca2+](i) that is attributable to the activation of a prolonged inward current designated here as I-cAMP. Activation of I-cAMP is associated with an increased membrane conductance, membrane depolarization, and triggers large increases of [Ca2+]. I-cAMP is primarily a Na+ current that is blocked by extracellularly applied La3+ or by intracellular administration of Ca2+ chelators (1,2-bis(2- aminophenoxy)ethane N,N,N',N'-tetraacetic acid/acetoxy-methyl EGTA) and which exhibits a reversal potential of about -26 mV. We propose that I-cAMP results from the opening of nonselective cation channel that are activated by intracellular Ca2+ and cAMP and which might play an important role in the regulation of insulin secretion from pancreatic beta-cells.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,MOLEC ENDOCRINOL LAB,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	HOLZ, GG (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,WELLMAN 320,50 BLOSSOM ST,BOSTON,MA 02114, USA.		Holz, George G/A-3386-2012	Holz, George/0000-0002-1781-3580	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045817, R01DK030834, R29DK045817] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK030834, DK30834, DK45817, R01 DK045817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; BLUME AJ, 1979, P NATL ACAD SCI USA, V76, P5626, DOI 10.1073/pnas.76.11.5626; COOPER DMF, 1982, FEBS LETT, V138, P157, DOI 10.1016/0014-5793(82)80431-6; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; DALESSIO DA, 1989, DIABETES, V38, P1534, DOI 10.2337/diabetes.38.12.1534; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; DILLON JS, 1993, ENDOCRINOLOGY, V133, P1907, DOI 10.1210/en.133.4.1907; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; EDDLESTONE GT, 1985, AM J PHYSIOL, V248, pC145, DOI 10.1152/ajpcell.1985.248.1.C145; EFRAT S, 1994, TRENDS BIOCHEM SCI, V19, P535, DOI 10.1016/0968-0004(94)90056-6; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FEHMANN HC, 1991, ENDOCRINOLOGY, V128, P2880, DOI 10.1210/endo-128-6-2880; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FEHMANN HC, 1992, TRENDS ENDOCRIN MET, V3, P158, DOI 10.1016/1043-2760(92)90165-W; FOURNIER L, 1994, J BIOL CHEM, V269, P1120; FRIDOLF T, 1993, MOL CELL ENDOCRINOL, V96, P85, DOI 10.1016/0303-7207(93)90098-5; FRIDOLF T, 1991, BIOCHEM BIOPH RES CO, V179, P701, DOI 10.1016/0006-291X(91)91429-G; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GILLIS KD, 1993, PFLUG ARCH EUR J PHY, V424, P195, DOI 10.1007/BF00374612; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HABENER JF, 1993, ENDOCRIN METAB CLIN, V22, P775, DOI 10.1016/S0889-8529(18)30135-X; HAHN HJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P425, DOI 10.1016/0304-4165(80)90291-3; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IKEUCHI M, 1984, LIFE SCI, V35, P685, DOI 10.1016/0024-3205(84)90264-9; JACOBS KH, 1984, ADV CYCLIC NUCLEOTID, V17, P135; JACOBS KH, 1981, ADV CYCLIC NUCLEOTID, V14, P173; JACOBS KH, 1983, J RECEPTOR RES, V3, P137; KAWAI K, 1989, ENDOCRINOLOGY, V124, P1768, DOI 10.1210/endo-124-4-1768; KLEE WA, 1984, ADV CYCLIC NUCL PROT, V17, P153; KOSKI G, 1982, J BIOL CHEM, V257, P4035; KREYMANN B, 1987, LANCET, V2, P1300; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LU M, 1993, ENDOCRINOLOGY, V132, P94, DOI 10.1210/en.132.1.94; MALAISSE WJ, 1984, ENDOCRINOLOGY, V115, P2015, DOI 10.1210/endo-115-5-2015; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; PRENTKI M, 1987, FEBS LETT, V220, P103, DOI 10.1016/0014-5793(87)80884-0; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; REALE V, 1994, J MEMBRANE BIOL, V141, P101; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; SALA S, 1991, J MEMBRANE BIOL, V122, P177, DOI 10.1007/BF01872640; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHMIDTLER J, 1994, AM J PHYSIOL, V266, pG775, DOI 10.1152/ajpgi.1994.266.5.G775; STURGESS NC, 1986, FEBS LETT, V208, P397, DOI 10.1016/0014-5793(86)81056-0; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; WANG JL, 1993, J BIOL CHEM, V268, P7785; WATSON EL, 1989, BIOCHEM PHARMACOL, V38, P1069, DOI 10.1016/0006-2952(89)90250-5; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X	67	156	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17749	17757		10.1074/jbc.270.30.17749	http://dx.doi.org/10.1074/jbc.270.30.17749			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543091	hybrid			2022-12-25	WOS:A1995RM26600021
J	CRAPARO, A; ONEILL, TJ; GUSTAFSON, TA				CRAPARO, A; ONEILL, TJ; GUSTAFSON, TA			NON-SH2 DOMAINS WITHIN INSULIN-RECEPTOR SUBSTRATE-1 AND SHC MEDIATE THEIR PHOSPHOTYROSINE-DEPENDENT INTERACTION WITH THE NPEY MOTIF OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; PROTEIN; IRS-1; CELLS; PHOSPHORYLATION; PHOSPHATASE; BINDING; SITES	Insulin receptor substrate-1 (IRS-1) and SHC become rapidly phosphorylated upon tyrosines after insulin-like growth factor I receptor (IGFIR) activation. In this study we demonstrate that IRS-1, SHC, and the p85 sub unit of phosphatidylinositol 3-kinase interact directly and specifically with the IGFIR. The interaction of all three proteins is dependent upon IGFIR kinase activity and, furthermore, substitution of Tyr-950 with Phe within the NPEY motif of the IGFIR eliminated interaction with both SHC and IRS-1 but had no effect upon p85 interaction. We show that residues 160-516 of IRS-1 and 1-238 of SHC are sufficient and necessary for receptor interaction in the yeast two-hybrid assay. We also demonstrate a direct in vitro interaction between the IGFIR and a fusion protein containing SHC amino acids 1-238. No interaction was observed with a SHC protein containing only the SH2 domain. We conclude that SHC and IRS-1 interact with the tyrosine-phosphorylated NPEY motif of the IGFIR, and that both proteins interact via related motifs located in their amino termini. We conclude that the interactions of SHC and IRS-1 with the IGFIR are similar to those which we have previously defined with the insulin receptor.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44093] Funding Source: Medline; NIGMS NIH HHS [GM08181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; GIORGETTIS, 1994, EUR J BIOCHEM, V223, P195; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Miller J.H., 1972, EXPT MOL GENETICS; MIURA M, 1995, CANCER RES, V55, P663; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WHITE MF, 1994, J BIOL CHEM, V269, P1; WU R, 1983, METHOD ENZYMOL, V100, P293; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	142	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15639	15643		10.1074/jbc.270.26.15639	http://dx.doi.org/10.1074/jbc.270.26.15639			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541045	hybrid			2022-12-25	WOS:A1995RG53800033
J	MUNICIO, MM; LOZANO, J; SANCHEZ, P; MOSCAT, J; DIAZMECO, MT				MUNICIO, MM; LOZANO, J; SANCHEZ, P; MOSCAT, J; DIAZMECO, MT			IDENTIFICATION OF HETEROGENEOUS RIBONUCLEOPROTEIN A1 AS A NOVEL SUBSTRATE FOR PROTEIN-KINASE-C-ZETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-ANNEALING ACTIVITY; MITOGENIC SIGNAL; ACTIVATION; PHOSPHORYLATION; TRANSFORMATION; MATURATION; ISOFORM; OOCYTES	The zeta isoform of protein kinase C (zeta PKC) has been shown to be an important step in mitogenic signal transduction. Using a yeast interaction screen to search for potential novel substrates of zeta PKC, we identified the heterogeneous ribonucleoprotein A1 (hnRNPA1). This protein specifically interacts with the catalytic domain of zeta PKC but not with its regulatory region or with the full-length protein, or with a kinase-defective mutant of the zeta PKC catalytic domain. In addition, no interaction was detected with other kinases such as Raf-1 or Mos, that, like zeta PKC, are critically involved in signal transduction, or with the catalytic domain of epsilon PKC, which is the PKC isotype with the highest homology to zeta PKC. hnRNPAI is directly phosphorylated by both recombinant and native zeta PKC, and this phosphorylation is increased when zeta PKC is immunoprecipitated from mitogen-activated fibroblasts. As an additional control, hnRNPA1 is not phosphorylated appreciably by catalytic epsilon PKC or by a mixture of highly purified classical PRC isotypes maximally activated by phosphatidylserine and Ca2+. Treatment of quiescent cell cultures with a potent mitogen such as platelet-derived growth factor promotes a significant phosphorylation of hnRNPA1 in vivo that is impaired by expression of a dominant negative mutant of zeta PKC. Furthermore, expression of a catalytically active zeta PKC mutant phosphorylates hnRNPA1 in vivo. These findings suggest that zeta PKC could be critically involved in a novel pathway that connects membrane signaling to nuclear regulatory events, at the level of RNA transport and processing, Results also shown here by using different zeta PKC mutants suggesting the control of the cytoplasmic localization of hnRNPA1 by zeta PKC. Also of potential functional relevance are the results demonstrating that the phosphorylation by zeta PKC severely impairs both hnRNPA1 RNA binding and its ability to promote strand annealing in vitro.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Sánchez-Gómez, Pilar/K-8256-2014; Moscat, Jorge/A-7011-2009; Lozano, José/C-2760-2014	Sánchez-Gómez, Pilar/0000-0002-0709-4973; Lozano, José/0000-0002-8187-2833; Diaz-Meco, Maria/0000-0003-0147-0998				BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FUMAGALLI S, 1994, NATURE, V368, P872; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IDRISS H, 1994, BIOCHEMISTRY-US, V33, P11382, DOI 10.1021/bi00203a037; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395	41	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15884	15891		10.1074/jbc.270.26.15884	http://dx.doi.org/10.1074/jbc.270.26.15884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541049	hybrid			2022-12-25	WOS:A1995RG53800068
J	PHILIPSON, LH; KUZNETSOV, A; TOTH, PT; MURPHY, JF; SZABO, G; MA, GH; MILLER, RJ				PHILIPSON, LH; KUZNETSOV, A; TOTH, PT; MURPHY, JF; SZABO, G; MA, GH; MILLER, RJ			FUNCTIONAL EXPRESSION OF AN EPITOPE-TAGGED G-PROTEIN-COUPLED K+ CHANNEL (GIRK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; POTASSIUM CHANNEL; CELL LINES; ION CHANNELS; SOMATOSTATIN; INSULINOMA; INHIBITION; RECEPTORS; MEMBRANES; SEQUENCE	An epitope-tagged form of an inwardly rectifying and G protein-coupled K+ channel (GIRK1-cp) was expressed at high levels in transfected mammalian cells. Immunoblot analysis of transfected human embryonic kidney cells (HEK293 and mouse insulinoma cells (beta TC3) revealed several GIRK1-cp polypeptides, including the major 59-kDa band, corresponding to the predicted mass of the GIRK1 polypeptide plus the epitope tag. Immunohistochemical staining using two anti-tag antibodies showed abundant immunoreactive material, which was predominantly concentrated in the perinuclear area in both transfected cell types. While functional GIRK1-cp message was present in poly(A)+ RNA prepared from HEK293 cells expressing GIRK1-cp protein, appropriate K+ currents could not be detected. In contrast, whole cell recordings made directly from transfected beta TC3 cells expressing GIRK1-cp revealed inwardly rectifying, pertussis toxin-sensitive currents activated by norepinephrine and galanin. Single channel recordings in excised patches of beta TC3 cells expressing GIRK1-cp showed rectifying K+ currents when activated by 50 mu M guanosine 5'-O-(thiotriphosphate), with a slope conductance of 39.1 +/- 1.0 picosiemens. This is the first report of stable heterologous expression of a functional G protein-coupled K+ channel in mammalian cells. The activity of an epitope-tagged channel in insulinoma cells demonstrates the utility of this system for further biochemical and biophysical analyses of G protein-K+ channel interactions.	UNIV CHICAGO,DEPT PHYSIOL & PHARMACOL,CHICAGO,IL 60637; UNIV VIRGINIA,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908	University of Chicago; University of Virginia	PHILIPSON, LH (corresponding author), UNIV CHICAGO,DEPT MED,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.			Toth, Peter/0000-0003-2168-0124	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037127, R37HL037127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002575] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37127] Funding Source: Medline; NIDA NIH HHS [DA-02575] Funding Source: Medline; NIDDK NIH HHS [P01 DK44840] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BAFFY G, 1993, DIABETES, V42, P1878, DOI 10.2337/diabetes.42.12.1878; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN AM, 1991, J BIOENERG BIOMEMBR, V23, P499, DOI 10.1007/BF00785808; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DEWEILLE JR, 1989, P NATL ACAD SCI USA, V86, P2971; DUNNE MJ, 1989, EMBO J, V8, P412; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GILLISON SL, 1994, DIABETES, V43, P24, DOI 10.2337/diabetes.43.1.24; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KONTANI K, 1992, ARCH BIOCHEM BIOPHYS, V294, P527, DOI 10.1016/0003-9861(92)90720-H; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SF, 1993, J BIOL CHEM, V268, P10721; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LEWIS DL, 1990, MAYO CLIN PROC, V65, P1127, DOI 10.1016/S0025-6196(12)62726-8; MA GH, 1995, IN PRESS MOL PHARM; MADSEN OD, 1985, ENDOCRINOLOGY, V113, P2135; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; MURPHY JF, 1993, FASEB J, V7, pA1138; NAKAYAMA K, 1991, BRIT J PHARMACOL, V103, P1641, DOI 10.1111/j.1476-5381.1991.tb09841.x; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PHILIPSON L, 1994, P NATL ACAD SCI USA, V269, P27787; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; STOFFEL M, 1994, GENOMICS, V21, P254, DOI 10.1006/geno.1994.1253; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; UEDA N, 1994, J BIOL CHEM, V269, P4388; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	46	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14604	14610		10.1074/jbc.270.24.14604	http://dx.doi.org/10.1074/jbc.270.24.14604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540174	hybrid			2022-12-25	WOS:A1995RD45500057
J	KAMATA, T; WRIGHT, R; TAKADA, Y				KAMATA, T; WRIGHT, R; TAKADA, Y			CRITICAL THREONINE AND ASPARTIC-ACID RESIDUES WITHIN THE I-DOMAINS OF BETA-2 INTEGRINS FOR INTERACTIONS WITH INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) AND C3BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; VONWILLEBRAND-FACTOR; ALPHA-SUBUNIT; VI COLLAGEN; FACTOR-B; CDNA; SEQUENCE; MAC-1; SITE; HOMOLOGY	Integrins mediate signal transduction through interactions with multiple cellular or extracellular matrix ligands. Evidence is accumulating that the I (or A) do main, a similar to 200-residue inserted sequence in some integrin alpha subunits, mediates ligand binding, We have previously shown that Thr-221 of the putative ligand binding sites within alpha 2 I domain of alpha 2 beta 1 is critical for binding to collagen (Kamata, T., and Takada, Y. (1994) J. Biol. Chem. 269, 26006-26010), Here we report that the mutation of Thr-206 of alpha L blocks intercellular adhesion molecule 1 (ICAM-1) binding to alpha L beta 2 and mutation of Thr-209 of alpha M blocks ICAM-1 and C3bi binding to alpha M beta 2. The data indicate the Thr residues of alpha M and alpha L corresponding to Thr-221 of alpha 2 are critically involved in the ligand interaction with beta 2 integrins. The mutations of the Asp-137 and Asp-239 of alpha L also block ICAM-1 binding to alpha L beta 2, as do the corresponding Asp residues of alpha 2 or alpha M in collagen/alpha 2 beta 1 or C3bi/alpha M beta 2 interactions, respectively, These data suggest that these Thr and Asp residues, conserved among I domains, are critical for interaction with structurally distinct ligands (e.g. ICAMs, C3bi, and collagen),	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; SANDOZ PHARMACEUT CORP, SANDOZ RES INST, PRECLIN RES, ONCOL RES PROGRAM, E HANOVER, NJ 07936 USA	Scripps Research Institute; Novartis; Sandoz				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM049899] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157, GM49899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BACK AL, 1990, BIOCHEM BIOPH RES CO, V171, P787, DOI 10.1016/0006-291X(90)91215-E; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DANA N, 1994, INTEGRINS BIOL PROBL, P37; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RANDI M, 1994, J BIOL CHEM, V269, P12395; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	44	87	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12531	12535		10.1074/jbc.270.21.12531	http://dx.doi.org/10.1074/jbc.270.21.12531			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7539004	hybrid			2022-12-25	WOS:A1995QZ71100033
J	SHOR, J; BENASHER, E; ALONI, Y				SHOR, J; BENASHER, E; ALONI, Y			TRANSCRIPTION ELONGATION OF THE MURINE ORNITHINE DECARBOXYLASE (ODC) GENE IS REGULATED IN-VITRO AT 2 DOWNSTREAM ELEMENTS BY DIFFERENT ATTENUATION MECHANISMS	ONCOGENE			English	Article						ELONGATION FACTORS; IN VITRO TRANSCRIPTION; NUCLEAR EXTRACT; ODC TRANSCRIPTION; TRANSCRIPTION ELONGATION	RNA POLYMERASE-II; HAMSTER OVARY CELLS; C-MYC GENE; CALF THYMUS; MESSENGER-RNA; FACTOR-SII; TERMINATION; DNA; PURIFICATION; SEQUENCE	Ornithine decarboxylase (ODC) plays an important role in cell proliferation. Its expression is tightly regulated at the mRNA and protein levels and is found to be deregulated in various malignancies. The rapid acid dramatic induction of cellular ODC mRNA upon serum addition raised the possibility that a transcriptional attenuation mechanism may be involved in the regulation of ODC gene expression, Using transcription in HeLa nuclear extract acid isolated transcription complexes, we have identified two sites of transcription arrest downstream to the transcription start site: Attenuator 1 (Att.1) located at +220, near two repeats of a USF/ Myc-Max binding consensus sequence and attenuator 2 (Att.2) located at +1590 near a long stretch of T-residues, The two attenuators exhibit distinct properties as revealed by elongation of briefly initiated and partially purified transcription complexes: Att.l serves as transient pause site while arrest at Att,2 is more prolonged. The arrest at both attenuators is modulated by the general elongation factor TFIIS. In a promoter independent transcription system, using partially purified RNA polymerase II, only Att.2 was recognized efficiently. This suggests that the recognition of Att.2 is an intrinsic property of the polymerase while Att.1 recognition has to be facilitated by an auxiliary factor/s.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science					NCI NIH HHS [CA 14995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BAEK KH, 1986, P NATL ACAD SCI USA, V83, P7623, DOI 10.1073/pnas.83.20.7623; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLORES O, 1990, J BIOL CHEM, V265, P5629; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KESSLER M, 1991, J BIOL CHEM, V266, P13019; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1988, GENE, V72, P91, DOI 10.1016/0378-1119(88)90130-8; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SPENCER CA, 1990, ONCOGENE, V5, P777; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TONIN PN, 1989, ONCOGENE, V4, P1117; UNEO A, 1992, P NATL ACAD SCI USA, V89, P3676; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YANOFSKY C, 1988, J BIOL CHEM, V263, P609	47	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1587	1596						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7537363				2022-12-25	WOS:A1995QU68100015
J	SABATINI, R; HAJDUK, SL				SABATINI, R; HAJDUK, SL			RNA LIGASE AND ITS INVOLVEMENT IN GUIDE RNA/MRNA CHIMERA FORMATION - EVIDENCE FOR A CLEAVAGE-LIGATION MECHANISM OF TRYPANOSOMA-BRUCEI MESSENGER-RNA EDITING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA MINICIRCLES; MESSENGER-RNA; 3',5'-PHOSPHODIESTER LINKAGE; WHEAT-GERM; MITOCHONDRIA; INVITRO; MOLECULES; 2'-PHOSPHOMONOESTER; COMPLEXES; SITES	RNA editing in Trypanosoma brucei results in the addition and deletion of uridine residues within several mitochondrial mRNAs. Editing is thought to be directed by guide RNAs and may proceed via a chimeric guide RNA/mRNA intermediate. We have previously shown that chimera-forming activity sediments with 19 S and 35-40 S mitochondrial ribonucleoprotein particles (RNPs). In this report we examine the involvement of RNA ligase in the production of chimeric molecules in vitro. Two adenylylated proteins of 50 and 57 kDa cosediment on glycerol gradients with RNA ligase activity as components of the ribonucleoprotein particles. The two adenylylated proteins differ in sequence and contain AMP linked via a phosphoamide bond. Both proteins are deadenylylated by the addition of ligatable RNA substrate with the concomitant release of AMP and by the addition of pyrophosphate to yield ATP. Incubation with nonligatable RNA substrate results in an accumulation of the adenylylated RNA intermediate. These experiments identify the adenylylated proteins as RNA ligases. AMP release from the mitochondrial RNA ligase is also concomitant with chimera formation. Inhibition by nonhydrolyzable analogs indicates that both RNA ligase and chimera-forming activities require alpha-beta bond hydrolysis of ATP. Deadenylylation of the ligase inhibits chimera formation. These results strongly suggest the involvement of RNA ligase in in vitro chimera formation and support the cleavage-ligation mechanism for kinetoplastid RNA editing.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOLEC GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI21401] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, R21AI021401] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; BRUN R, 1979, ACTA TROP, V36, P289; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DOUTHWAITE S, 1983, EUR J BIOCHEM, V131, P261, DOI 10.1111/j.1432-1033.1983.tb07258.x; FRAENKELCONRAT H, 1967, METHODS ENZYMOLOGY B, V12, P243; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; KAUFMANN G, 1974, P NATL ACAD SCI USA, V71, P3741, DOI 10.1073/pnas.71.9.3741; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1974, SCIENCE, V186, P790; OHTSUKA E, 1976, NUCLEIC ACIDS RES, V3, P1613, DOI 10.1093/nar/3.6.1613; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; POLLARD VW, 1991, MOL CELL BIOL, V11, P1668, DOI 10.1128/MCB.11.3.1668; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; ROHRER SP, 1987, CELL, V49, P625, DOI 10.1016/0092-8674(87)90538-1; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; SNINSKY JJ, 1976, NUCLEIC ACIDS RES, V3, P3157, DOI 10.1093/nar/3.11.3157; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]	33	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7233	7240		10.1074/jbc.270.13.7233	http://dx.doi.org/10.1074/jbc.270.13.7233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535769				2022-12-25	WOS:A1995QQ43100035
J	WOLKOWICZ, R; ELKIND, NB; RONEN, D; ROTTER, V				WOLKOWICZ, R; ELKIND, NB; RONEN, D; ROTTER, V			THE DNA-BINDING ACTIVITY OF WILD-TYPE P53 IS MODULATED BY BLOCKING ITS VARIOUS ANTIGENIC EPITOPES	ONCOGENE			English	Article						DNA-BINDING; P53; ANTIGENIC EPITOPES	CELL-CYCLE CONTROL; A MOUSE CELLS; MUTANT P53; MONOCLONAL-ANTIBODY; GROWTH SUPPRESSION; CONTROL PROTEIN; TUMOR-ANTIGEN; NORMAL 3T3; EXPRESSION; GENE	Interaction of wild type p53 with specific DNA target sequences, which is dictated by several structural domains, can be modified by blocking the different antigenic epitopes of the protein. Comparison of p53 protein expressed by recombinant bacteria (wtp53-Bac) to that produced in an eukaryotic system by a vaccinia expression vector (wtp53-Vac), indicated that only the later exhibited spontaneous DNA-binding activity. Furthermore, DNA-binding patterns of these wild type p53 proteins were affected differently by their interactions with monoclonal anti-p53 antibodies recognizing individual antigenic epitopes of the molecule. While the vaccinia derived p53 that spontaneously bound DNA is supershifted by the N'-terminal specific antibodies PAb-248, the bacterial derived p53 protein that retains this antigenic epitope but does not bind DNA spontaneously, is not affected. The C'-terminal specific PAb-421 antibodies accelerated binding of the bacterial p53 protein and modified the pattern of the interaction of the vaccinia derived p53 DNA. DNA-binding patterns generated by PAb-421 and PAb-248, suggest that either interaction of wild type p53 is dependent on modification of the p53 protein or that it interacts with cellular factors which their activity can be mimicked by PAb-421. Saturation of both types of wild type p53 with several anti-p53 monoclonal antibodies directed against the wild type p53 specific epitope that maps to the N'-terminal border of the DNA-binding region, blocked specific DNA-binding. The fact that most p53 mutants have lost the wild type p53 conformation specific epitope coupled with the observation that blocking of this site by binding specific antibodies, prevents the interaction of wild type p53 with DNA, suggests that maintaining the correct structural conformation of this site is central for DNA-binding activity. The wild type specific epitope which maps to the N'-terminal border of the DNA-binding region is neighboring the first P-strand detected by the recent crystallographic analysis.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRISON SC, 1991, NATURE, V353; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KELMAN Z, 1989, BLOOD, V74, P2318; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHALOVITZ D, 1989, P NATL ACAD SCI USA, V86, P8763; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RONEN D, 1992, NUCLEIC ACIDS RES, V20, P3435, DOI 10.1093/nar/20.13.3435; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, J IMMUNOL METHODS, V151, P237; WADEHARPER J, 1993, CELL, V75, P805; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	73	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1167	1174						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535417				2022-12-25	WOS:A1995QN35300018
J	WEBER, P; ZIMMERMANN, DR; WINTERHALTER, KH; VAUGHAN, L				WEBER, P; ZIMMERMANN, DR; WINTERHALTER, KH; VAUGHAN, L			TENASCIN-C BINDS HEPARIN BY ITS FIBRONECTIN TYPE-III DOMAIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; CYTOTACTIN; SEQUENCES; RNA	Two sites on tenascin mediate interactions with glycosaminoglycan chains of proteoglycans. One is situated on the fibrinogen-like domain, whereas the other lies within the fibronectin type III homology region (Aukhil, I., Joshi, P., Yan, Y.Z., and Erickson, H.P. (1993) J. Biol. Chem. 268, 2542-2553.). We now characterize the latter binding site more closely by means of recombinant protein fragments derived from the type III homology region of tenascin, Using a heparin-Sepharose column we localize the second heparin binding site to the fifth fibronectin type III domain, This is confirmed in solid phase assays by incubation of fusion proteins with biotin-labeled heparin. In addition, we demonstrate the binding of heparan sulfate and dermatan sulfate to domain five, Molecular modelling of this domain reveals a conserved heparin-binding motif that we propose as the putative binding site, The fact, that different glycosaminoglycans may bind to this domain, implies that different classes of proteoglycans may in vivo compete for the same site.	ETH ZENTRUM, BIOCHEM LAB 1, CH-8092 ZURICH, SWITZERLAND; UNIV ZURICH, INST KLIN PATHOL, DEPT PATHOL, CH-8091 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich			Vaughan, Lloyd/GNP-4888-2022; Vaughan, L/E-6528-2011	Vaughan, L/0000-0003-3474-9426				AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BARNEA G, 1994, J BIOL CHEM, V269, P14349; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; DEBBAGE PL, 1988, J HISTOCHEM CYTOCHEM, V36, P1097, DOI 10.1177/36.9.2900263; ERICKSON HP, 1994, PERSPECT DEV NEUROBI, V2, P9; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KAPLONY A, 1991, DEVELOPMENT, V112, P605; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOLLOUCH AC, 1992, BIOCHEMISTRY-US, V31, P2279; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MARTON LS, 1989, J BIOL CHEM, V264, P13145; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TUCKER RP, 1993, DEVELOPMENT, V117, P347; VAUGHAN L, 1994, PERSPECT DEV NEUROBI, V2, P43; VAUGHAN L, 1994, CONTRIB NEPHROL, V107, P80; VAUGHAN L, 1987, EMBO J, V6, P349, DOI 10.1002/j.1460-2075.1987.tb04761.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	27	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4619	4623		10.1074/jbc.270.9.4619	http://dx.doi.org/10.1074/jbc.270.9.4619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533163	hybrid			2022-12-25	WOS:A1995QK08400066
J	NAKAMURA, K; SUZUKI, H; HIRABAYASHI, Y; SUZUKI, A				NAKAMURA, K; SUZUKI, H; HIRABAYASHI, Y; SUZUKI, A			IV3 ALPHA(NEUGC-ALPHA-2-8NEUGC)-GG(4)CER IS RESTRICTED TO CD4(+) T-CELLS PRODUCING INTERLEUKIN-2 AND A SMALL POPULATION OF MATURE THYMOCYTES IN MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTE SUBPOPULATIONS; MONOCLONAL-ANTIBODIES; STRUCTURAL CHARACTERIZATION; DIFFERENTIATION ANTIGEN; MOUSE SPLEEN; ASIALO GM1; NK-CELLS; B-CELLS; GANGLIOSIDES; SURFACE	Monoclonal antibody YK-3 was established by immunization with IV3 alpha(NeuGc alpha 2-8NeuGc)-Gg(4)Cer (GD(D1c) (NeuGc-NeuGc-)), and its epitope was determined to be NeuGc alpha 2-8NeuGc alpha 23Gal beta 1. Thin layer chromatography immunostaining with YK-3 detected only G(D1c) (NeuGc-NeuGc-) among the gangliosides of mouse thymocytes and splenocytes. Immunohistochemical staining with YK-3 visualized the medulla of mouse thymus and T cell-dependent areas of mouse spleen and mesenteric lymph nodes. Two-color flow cytometry demonstrated that G(D1c)(NeuGc-NeuGc-) was expressed on a quarter of CD3(+) mature thymocytes and strongly expressed on three quarters of CD4(+) T cells in the spleen, lymph nodes, and peripheral blood but not on CD8(+) T cells or B cells. G(D1c)(NeuGc-NeuGc-)-positive cells and negative cells were separated by panning with YK-3 on Petri dishes into adherent and nonadherent fractions. Following stimulation with concanavalin A, adherent cells, predominantly G(D1c)(NeuGc-NeuGc-)(+), produced more interleukin-2 (IL-2) and markedly less interleukin-4 (IL-4) than nonadherent cells. This conclusion is supported by data obtained by lysis of cells by YK-3 and complement. These data indicate that the cell surface expression of G(D1c)(NeuGc-NeuGc-) is restricted to a small number of mature thymocytes and a subset of CD4(+) T cells, which produce abundant IL-2 and very little IL-4, suggesting that G(D1c)(NeuGc-NeuGc-) is an excellent marker for mouse naive T or T helper 1-like cells in vivo.	TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT CARDIOVASC RES,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,GLYCO CELL BIOL LAB,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; RIKEN				Hirabayashi, Yoshio/0000-0002-5774-7354				ABO T, 1981, J IMMUNOL, V127, P1024; ARIGA T, 1987, J BIOL CHEM, V262, P848; BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; COMMISSION II, 1978, J LIPID RES, V19, P114; DITTRICH F, 1994, BIOCHEM BIOPH RES CO, V200, P1557, DOI 10.1006/bbrc.1994.1628; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P118; EBEL F, 1992, BIOCHEMISTRY-US, V31, P12190, DOI 10.1021/bi00163a031; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GREER JM, 1993, GLYCOBIOLOGY, V3, P391, DOI 10.1093/glycob/3.4.391; HABU S, 1980, J IMMUNOL, V125, P2284; HANDA S, 1964, JPN J EXP MED, V34, P293; HANSSON GC, 1983, J BIOL CHEM, V258, P4091; HASHIMOTO Y, 1986, SEIKAGAKU, V58, P862; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HAYAKAWA K, 1991, IMMUNOL REV, V123, P145, DOI 10.1111/j.1600-065X.1991.tb00609.x; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HERSEY P, 1986, CANCER RES, V46, P6083; HOLMGREN J, 1973, INFECT IMMUN, V8, P851, DOI 10.1128/IAI.8.6.851-859.1973; KASAI M, 1980, EUR J IMMUNOL, V10, P175, DOI 10.1002/eji.1830100304; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KNIEP B, 1992, BIOCHEM BIOPH RES CO, V187, P1343, DOI 10.1016/0006-291X(92)90450-Y; KNIEP B, 1990, LEUCOCYTE TYPING, V4, P362; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; MADASSERY J V, 1991, Journal of Immunology, V147, P823; MAKITA A, 1963, JPN J EXP MED, V33, P361; MERCURIO AM, 1984, J EXP MED, V160, P1114, DOI 10.1084/jem.160.4.1114; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUTHING J, 1989, BIOCHEMISTRY-US, V28, P2923; NAKAMURA K, 1987, J BIOCHEM-TOKYO, V101, P825, DOI 10.1093/oxfordjournals.jbchem.a121949; NAKAMURA K, 1984, J BIOCHEM-TOKYO, V96, P949, DOI 10.1093/oxfordjournals.jbchem.a134954; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; NOHARA K, 1994, BIOCHEMISTRY-US, V33, P4661, DOI 10.1021/bi00181a601; NOHARA K, 1991, J BIOCHEM-TOKYO, V110, P274, DOI 10.1093/oxfordjournals.jbchem.a123570; NORIHISA Y, 1994, J IMMUNOL, V152, P485; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; OHASHI M, 1981, GLYCOCONJUGATES, P33; OSHANNESSY DJ, 1984, IMMUNOL LETT, V8, P273, DOI 10.1016/0165-2478(84)90008-7; OZAWA H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P184, DOI 10.1016/0005-2760(92)90110-H; PORTNER A, 1993, BIOCHEMISTRY-US, V32, P12685; RIEBER EP, 1990, LEUCOCYTE TYPING, V4, P361; ROSSIBERGMANN B, 1993, INFECT IMMUN, V61, P2266, DOI 10.1128/IAI.61.5.2266-2269.1993; SCHWARTING GA, 1983, J BIOL CHEM, V258, P5893; SEKINE M, 1988, J BIOCHEM-TOKYO, V103, P722, DOI 10.1093/oxfordjournals.jbchem.a122335; SHARON N, 1983, ADV IMMUNOL, V34, P213, DOI 10.1016/S0065-2776(08)60380-6; STEINDOUGLAS KE, 1976, J EXP MED, V143, P822, DOI 10.1084/jem.143.4.822; SUTTLES J, 1986, J IMMUNOL, V136, P1586; SUZUKI M, 1986, CARBOHYD RES, V151, P213, DOI 10.1016/S0008-6215(00)90342-2; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; WELTE K, 1987, J IMMUNOL, V139, P1763; YOSHINO H, 1993, J NEUROCHEM, V61, P658; YOUNG WW, 1980, J IMMUNOL, V124, P199	54	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3876	3881		10.1074/jbc.270.8.3876	http://dx.doi.org/10.1074/jbc.270.8.3876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533156	hybrid			2022-12-25	WOS:A1995QH68800063
J	MURAKAMI, M; MATSUMOTO, R; URADE, Y; AUSTEN, KF; ARM, JP				MURAKAMI, M; MATSUMOTO, R; URADE, Y; AUSTEN, KF; ARM, JP			C-KIT LIGAND MEDIATES INCREASED EXPRESSION OF CYTOSOLIC PHOSPHOLIPASE A(2), PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1, AND HEMATOPOIETIC PROSTAGLANDIN D-2 SYNTHASE AND INCREASED IGE-DEPENDENT PROSTAGLANDIN D-2 GENERATION IN IMMATURE MOUSE MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; D SYNTHETASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; MOLECULAR-CLONING; LEUKOTRIENE C-4; MESSENGER-RNA; G/H SYNTHASE; SI-LOCUS; RAT; RELEASE	We have examined the cytokine regulation of IgE-dependent prostaglandin (PG) D-2 generation in mouse mast cells by assessing the changes in the levels of the transcript, translated protein, and activity of the enzymes involved in the synthesis of PGD(2) from endogenous arachidonic acid. When mouse mast cells, derived by culture of bone marrow cells with WEHI-3 cell-conditioned medium as a source of interleukin (IL)-3 (BMMC) were cultured in recombinant c-kit ligand (KL), sensitized with IgE, and stimulated with antigen, PGD(2) generation increased 3-fold; when KL was combined with IL-3, IL-9, or IL-10, PGD(2) generation increased 6-8-fold above that produced by the cells cultured in IL -3 alone. The increased IgE-dependent PGD(2) generation by BMMC was apparent after 1 day of culture, reached a maximum after 2-4 days of culture, and was dose-dependent for KL and for each of the accessory cytokines. IgE-dependent generation of leukotriene C-4 increased 2-fold after the cells were cultured with KL and was not increased by the addition of IL-3, IL-9, or IL-10. Assays for steady-state transcripts by RNA blotting, for protein by SDS-PAGE/immunoblotting, and for function by enzymatic activities revealed that KL alone stimulated the increased expression of cytosolic phospholipase A(2) (cPLA(2)), prostaglandin endoperoxide synthase (PGHS)-1, and the terminal enzyme, hematopoietic PGD(2) synthase, without a change in expression of 5-lipoxygenase. IL-3, IL-9, and IL-10 each enhanced the KL-induced expression of PGHS-1. In contrast, transcripts for PGHS-2, which were detected transiently after the cells had been cultured for 5 h in KL + IL-3, were not expressed during the period of subsequent increase in IgE-dependent PGD(2) generation. These findings demonstrate that KL up-regulates expression of cPLA(2), PGHS-1, and hematopoietic PGD, synthase, leading to a relatively selective increase in IgE-dependent production of PGD(2) from endogenously released arachidonic acid in BMMC, and they provide the first example of cytokine regulation of hematopoietic PGD(2) synthase.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; OSAKA BIOSCI INST, SUITA, OSAKA 565, JAPAN	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI022531, U19AI031599, R37AI022531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI22531, AI31599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COLEMAN JW, 1993, J IMMUNOL, V150, P556; COLUMBO M, 1992, J IMMUNOL, V149, P599; DASTYCH J, 1994, J IMMUNOL, V152, P213; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; EKLUND KK, 1993, J IMMUNOL, V151, P4266; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GALLI SJ, 1993, J CLIN INVEST, V91, P148, DOI 10.1172/JCI116164; GALLI SJ, 1994, ADV IMMUNOL, V55, P11; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HEAVEY DJ, 1988, J IMMUNOL, V140, P1953; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; JONES DA, 1993, J BIOL CHEM, V268, P9049; KATZ HR, 1992, J IMMUNOL, V148, P868; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; REDDY ST, 1994, J BIOL CHEM, V269, P15473; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROTTEM M, 1993, J IMMUNOL, V151, P4950; ROUZER CA, 1988, J BIOL CHEM, V263, P10135; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1990, J BIOL CHEM, V265, P371; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	72	137	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3239	3246		10.1074/jbc.270.7.3239	http://dx.doi.org/10.1074/jbc.270.7.3239			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531701	hybrid			2022-12-25	WOS:A1995QG47100054
J	VOJTESEK, B; DOLEZALOVA, H; LAUEROVA, L; SVITAKOVA, M; HAVLIS, P; KOVARIK, J; MIDGLEY, CA; LANE, DP				VOJTESEK, B; DOLEZALOVA, H; LAUEROVA, L; SVITAKOVA, M; HAVLIS, P; KOVARIK, J; MIDGLEY, CA; LANE, DP			CONFORMATIONAL-CHANGES IN P53 ANALYZED USING NEW ANTIBODIES TO THE CORE DNA-BINDING DOMAIN OF THE PROTEIN	ONCOGENE			English	Note						P53; DNA BINDING; CONFORMATION; ANTIBODIES; MUTANTS	MONOCLONAL-ANTIBODIES; IMMUNOCHEMICAL ANALYSIS; CANCER; MUTATIONS; EXPRESSION; SUPPRESSOR; APOPTOSIS; FORM	The p53 protein contains a protease resistant core section that binds to DNA in a sequence specific manner and whose crystal structure has been determined. This core is flanked at the N-terminus by the transcriptional transactivation domain and at the C-terminus by sequences involved in the oligomerisation of the protein. Extensive immunochemical analysis of p53 has shown that dominant antigenic sites lie within these N- and C-terminal domains while few antibodies to the central core have been identified; One of these, PAb240, has been extensively characterised as its epitope is cryptic in the native DNA binding core structure but is exposed by denaturation. This epitope is also exposed on many p53 proteins that contain point mutations in the core domain suggesting that these mutations may have a common affect on the structure of the core. To investigate this further we have generated several new antibodies to novel sites on p53 and mapped their epitopes using synthetic peptides. We find that antibodies to two other discrete sites in the core can also, like PAb240, recognize cryptic epitopes and distinguish mutant from wild-type conformations implying that the point mutations found in p53 in human tumours have widespread effects on the folding pattern of the DNA binding domain.	MASARYK MEM CANC INST,DEPT CELLULAR & MOLEC ONCOL,CR-65653 BRNO,CZECH REPUBLIC; UNIV DUNDEE,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND	Masaryk Memorial Cancer Institute; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BARTEK J, 1990, ONCOGENE, V5, P893; CHO Y, 1994, SCIENCE, V256, P346; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLMAN PM, 1987, IMMUNOL TODAY, V8, P44; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1993, ONCOGENE, V8, P2001; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x	24	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					389	393						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530828				2022-12-25	WOS:A1995QC62400018
J	STEWART, N; HICKS, GG; PARASKEVAS, F; MOWAT, M				STEWART, N; HICKS, GG; PARASKEVAS, F; MOWAT, M			EVIDENCE FOR A 2ND CELL-CYCLE BLOCK AT G2/M BY P53	ONCOGENE			English	Article						P53; RAS; CELL CYCLE	WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; BINDING PROTEIN; DNA-BINDING; ERYTHROLEUKEMIA-CELLS; NUCLEAR-LOCALIZATION; DEPENDENT KINASES	Wild type p53 can induce cell cycle arrest at specific points in the cell cycle, in particular G1/S, an ability lost by most p53 mutants. We have previously reported that p53 mutant genes can rescue REF52 cells from ras-induced growth arrest and that over expression of wild type p53 inhibits cell growth in these cells. In this paper we examined whether p53 can also induce cell cycle arrest at the G2/M boundary of the cell cycle. To accomplish this we used the REF52 cell line and the temperature sensitive p53val(135) mutant allele. Cells were enriched in the late G1 and early S phases before the temperature shift. REF52 cells expressing mutant-p53val(135) alone with an activated H-vas gene arrest primarily at the G1/S and G2/M parts of the cell cycle at the restrictive temperature, as determined by flow cytometry analysis. These results suggest that the antiproliferative activity of p53 may be involved in regulation of the cell cycle at the G2/M restriction point as well as transit through G1/S and initiation of DNA synthesis.	MANITOBA CANC TREATMENT & RES FDN,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT HUMAN GENET,WINNIPEG,MB R3E 0V9,CANADA	University of Manitoba; University of Manitoba				Hicks, Geoffrey/0000-0003-4688-2312				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BASERGA R, 1985, BIOL CELL REPRODUCTI; BEISKER W, 1987, CYTOMETRY, V8, P235, DOI 10.1002/cyto.990080218; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1993, BIOL CHEM H-S, V374, P227; LI Y, 1994, ONCOGENE, V9, P2261; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; ROUACH EY, 1991, NATURE, V353, P345; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1987, ONCOGENE, V1, P201; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1984, P NATL ACAD SCI USA, V82, P790; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	79	347	349	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					109	115						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529916				2022-12-25	WOS:A1995QA98000013
J	STAN, R; MCLAUGHLIN, MM; CAFFERKEY, R; JOHNSON, RK; ROSENBERG, M; LIVI, GP				STAN, R; MCLAUGHLIN, MM; CAFFERKEY, R; JOHNSON, RK; ROSENBERG, M; LIVI, GP			INTERACTION BETWEEN FKBP12-RAPAMYCIN AND TOR INVOLVES A CONSERVED SERINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDYL-PROLYL ISOMERASE; SACCHAROMYCES-CEREVISIAE; CYCLOSPORINE-A; PHOSPHATIDYLINOSITOL 3-KINASE; IMMUNOSUPPRESSANT FK506; SIGNAL TRANSDUCTION; PROTEIN; RAPAMYCIN; YEAST; CYCLOPHILIN	The yeast TOR1 and TOR2 proteins were previously discovered as putative targets of the immunosuppressive drug rapamycin, Although their cellular function is unknown, they are predicted to be at least 215 kDa in size and possess a C-terminal phosphatidylinositol (PI) kinase-related domain. We previously identified a conserved Ser residue, within the PI kinase-related domain of both yeast TOR proteins (Ser(1972) in TOR1; Ser(1975) in TOR2), as being the site of missense mutations conferring dominant rapamycin resistance. The Ser(1972/1975) res. residue of yeast TOR is conserved in mammalian TOR homologs. One possibility is that this residue is critical for a direct interaction between TOR and the FKBP12-rapamycin complex. There is very recent biochemical evidence for an interaction between mammalian TOR and FKBP12-rapamycin (Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., and Schreiber, S. L. (1994) Nature 369, 756-758; Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. (1994) Cell 78, 35-43). Using the yeast two-hybrid system, we now have obtained genetic proof of a physical interaction between FKBP12-rapamycin and TOR and have demonstrated that this interaction requires the conserved Ser residue. We have found that a small fragment of wild-type yeast TOR2 spanning Ser(1975) is capable of interacting with human FKBP12 in the presence of rapamycin, whereas an Arg(1975) mutant fails to interact, This effect is dependent upon rapamycin and is antagonized by FK506.	SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOMOLEC DISCOVERY,KING OF PRUSSIA,PA 19406; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	GlaxoSmithKline; GlaxoSmithKline; Rutgers State University New Brunswick; Rutgers State University Medical Center								Bartel P. L., 1993, CELLULAR INTERACTION, P153; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BOSSARD MJ, 1994, BIOCHEM J, V297, P365, DOI 10.1042/bj2970365; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KOSER PL, 1993, GENE, V129, P159, DOI 10.1016/0378-1119(93)90264-4; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Miller J.H., 1972, EXPT MOL GENETICS; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P139; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STEARNS T, 1988, GENETICS, V119, P249; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WEIDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029	34	114	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32027	32030						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528205				2022-12-25	WOS:A1994PX30400002
J	KOHLER, M; KORNAU, HC; SEEBURG, PH				KOHLER, M; KORNAU, HC; SEEBURG, PH			THE ORGANIZATION OF THE GENE FOR THE FUNCTIONALLY DOMINANT ALPHA-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID RECEPTOR SUBUNIT GLUR-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUTAMATE-OPERATED CHANNELS; KAINATE BINDING-PROTEIN; MOLECULAR-CLONING; GLIAL-CELLS; RNA; EXPRESSION; CALCIUM; PERMEABILITY; FAMILY; BRAIN	The murine gene encoding the GluR-B subunit of alpha-amino-3-hydroxy-5-methylisoxazole- 4-propionic acid receptors was characterized with respect to exon-intron organization, transcriptional start site, alternatively spliced transcripts, and adenosine to guanosine substitutions between gene and complementary DNA sequence. The GluR-B gene spans >90 kilobase pairs and harbors 17 exons. Transcription appears to initiate approximately 430 nucleotides upstream of the translational start codon, with no intron in the 5'-untranslated region of the gene. Pour alternatively spliced mRNAs are generated from the primary GluR-B transcript, two containing the modules Flip and Flop, and another two with alternate C-terminal coding sequence. The major GluR-B mRNAs in murine brain, 4 and 6 kilobase differ in the length of their 3'-untranslated region.	UNIV HEIDELBERG, CTR BIOL MOLEC ZMBH, MOLEC NEUROENDOCRINOL LAB, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ESHHAR N, 1992, FEBS LETT, V297, P257, DOI 10.1016/0014-5793(92)80551-Q; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLO V, 1992, J NEUROSCI, V12, P1010; GREGOR P, 1992, MOL BRAIN RES, V16, P179, DOI 10.1016/0169-328X(92)90223-X; HAMPSON DR, 1992, NEUROSCIENCE, V50, P11, DOI 10.1016/0306-4522(92)90378-F; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1994, IN PRESS NEURON, V12; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MULLER T, 1992, SCIENCE, V256, P1563, DOI 10.1126/science.1317969; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	35	106	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17367	17370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7545935				2022-12-25	WOS:A1994NU12800003
J	GOLJER, I; KUMAR, S; BOLTON, PH				GOLJER, I; KUMAR, S; BOLTON, PH			REFINED SOLUTION STRUCTURE OF A DNA HETERODUPLEX CONTAINING AN ALDEHYDIC ABASIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE-III; DEOXYADENOSINE STACKS; ESCHERICHIA-COLI; REPAIR ENZYMES; RNA-POLYMERASE; HELIX OPPOSITE; DUPLEX DNA; DAMAGE; MECHANISM; NMR	The solution structure of the DNA duplex d(C(1)G(2)C(3)G(4) A(5)D(6)A(7)C(8)G(9)C(10)C(11))-d(G(22)C(21)G(20)C(19)T(18)A(17)T(16)G(15)C(14)G(13)G(12)), with D indicating a deoxyribose aldehyde abasic site and numbering from 5' to 3', has been determined by the combined use of NMR and restrained molecular dynamics. The P-31 and P-31-H-1 correlation data indicate that the backbones of these duplex DNAs are regular. One- and two-dimensional H-1 NMR data indicate that the duplexes are right-handed and B-form. Conformational changes due to the presence of the abasic site extends to the base pairs adjacent to the lesion site with the local conformation of the DNA being dependent on whether the abasic site is in the alpha or beta configuration. When the sugar of the abasic site is in the beta configuration the deoxyribose is within the helix, whereas when the sugar is in the cu configuration the deoxyribose is out of the helix. The base of residue A(17) in the position opposite the abasic site is predominantly stacked in the helix in both cases. A water molecule can apparently form a hydrogen bond bridge between the beta abasic site and A(17).	WESLEYAN UNIV,DEPT CHEM,MIDDLETOWN,CT 06459	Wesleyan University					NCRR NIH HHS [RR02781, RR08438, RR02301] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008438, S10RR002781, P41RR002301] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABSALON MJ, 1995, BIOCHEMISTRY-US, V34, P2065, DOI 10.1021/bi00006a029; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; CAI H, 1993, J BIOL CHEM, V268, P23567; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FREDERICO LA, 1990, BIOCHEMISTRY-US, P2532; FREIDBERG EC, 1975, J VIROL, V16, P315; FREIDBERG EC, 1985, DNA REPAIR; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; GOLDBERG IH, 1987, FREE RADICAL BIO MED, V3, P41, DOI 10.1016/0891-5849(87)90038-4; GOLJER I, 1992, BIOCHEMISTRY-US, V31, P11614, DOI 10.1021/bi00161a047; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HOLMES GE, 1992, MUTAT RES, V275, P305, DOI 10.1016/0921-8734(92)90034-M; Ide H, 1992, Nucleic Acids Symp Ser, P167; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; KAPPEN LS, 1992, BIOCHEMISTRY-US, V31, P9081, DOI 10.1021/bi00152a052; KLUPP BG, 1994, J VIROL, V68, P3868, DOI 10.1128/JVI.68.6.3868-3878.1994; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KOZARICH JW, 1989, SCIENCE, V245, P1396, DOI 10.1126/science.2476851; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1994, NATURE, V362, P709; LOEB LA, 1987, ANNU REV GENET, V20, P201; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8209; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; RAO KS, 1992, MUTAT RES, V275, P317; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCHEZ G, 1994, ENVIRON MOL MUTAGEN, V23, P32, DOI 10.1002/em.2850230106; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SERIANNI AS, 1990, J AM CHEM SOC, V112, P5886, DOI 10.1021/ja00171a042; SHAAPER RM, 1983, P NATL ACAD SCI USA, V80, P487; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; TARTAGLIA J, 1990, J GEN VIROL, V71, P1517, DOI 10.1099/0022-1317-71-7-1517; TESSMAN I, 1994, GENETICS, V16, P439; WANG KY, 1994, J MAGN RESON SER B, V103, P192, DOI 10.1006/jmrb.1994.1030; WEEDA G, 1993, BIOESSAYS, V15, P249, DOI 10.1002/bies.950150405; WILDE JA, 1989, J AM CHEM SOC, V111, P1894, DOI 10.1021/ja00187a062; Young MA, 1995, METHOD ENZYMOL, V261, P121; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	53	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22980	22987		10.1074/jbc.270.39.22980	http://dx.doi.org/10.1074/jbc.270.39.22980			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559436	hybrid			2022-12-25	WOS:A1995RY05400056
J	VANDERKUUR, JA; WANG, XY; ZHANG, LY; ALLEVATO, G; BILLESTRUP, N; CARTERSU, C				VANDERKUUR, JA; WANG, XY; ZHANG, LY; ALLEVATO, G; BILLESTRUP, N; CARTERSU, C			GROWTH HORMONE-DEPENDENT PHOSPHORYLATION OF TYROSINE-333 AND/OR TYROSINE-338 OF THE GROWTH-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM BINDING-PROTEIN; RAT INSULINOMA CELLS; SECONDARY-STRUCTURE; 3T3-F442A FIBROBLASTS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; KINASE-ACTIVITY; MESSENGER-RNA; SH3 DOMAINS; EXPRESSION	Many signaling pathways initiated by ligands that activate receptor tyrosine kinases have been shown to involve the binding of SH2 domain-containing proteins to specific phosphorylated tyrosines in the receptor. Although the receptor for growth hormone (GH) does not contain intrinsic tyrosine kinase activity, GH has recently been shown to promote the association of its receptor with JAK2 tyrosine kinase, to activate JAK2, and to promote the tyrosyl phosphorylation of both GH receptor (GHR) and JAK2. In this work, we examined whether tyrosines 333 and/or 338 in GHR are phosphorylated by JAK2 in response to GH. Tyrosines 333 and 338 in rat full-length (GHR(1-638)) and truncated (GHR(1-454)) receptor were replaced with phenylalanines and the mutated GHRs expressed in Chinese hamster ovary cells. These substitutions caused a loss of GH-dependent tyrosyl phosphorylation of truncated receptor and a reduction of GH dependent phosphorylation of the full-length receptor. Consistent with Tyr(333) and/or Tyr(338) serving as substrates of JAK2, these substitutions resulted in a loss of tyrosyl phosphorylation of truncated receptor in an in vitro kinase assay using substantially purified GH . GHR . JAK2 complexes. The Tyr to Phe substitutions did not substantially alter GH-dependent JAK2 association with GHR or tyrosyl phosphorylation of JAK2. These results suggest that Tyr(333) and/or Tyr(338) in GHR are phosphorylated in response to GH and may therefore serve as binding sites for SH2 domain-containing proteins in GH signal transduction pathways.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; HAGEDORN RES LAB, DK-2820 GENTOFTE, DENMARK	University of Michigan System; University of Michigan; Novo Nordisk; Hagedorn Research Institute				Billestrup, Nils/0000-0002-4968-8067	NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NIDDK NIH HHS [R01 DK034171, DK34171, DK48283] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048283, R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BURNSIDE J, 1991, ENDOCRINOLOGY, V128, P3183, DOI 10.1210/endo-128-6-3183; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CIOFFI JA, 1990, NUCLEIC ACIDS RES, V18, P6451, DOI 10.1093/nar/18.21.6451; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LI CH, 1982, MOL CELL BIOCHEM, V46, P31; LOHIE PE, 1995, J BIOL CHEM, V270, P21745; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NISHIKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V748, P285, DOI 10.1016/0167-4838(83)90306-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21738	21744		10.1074/jbc.270.37.21738	http://dx.doi.org/10.1074/jbc.270.37.21738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545168	hybrid			2022-12-25	WOS:A1995RU75700051
J	LOCKERT, DH; KAUFMAN, KM; CHANG, CP; HUSLER, T; SODETZ, JM; SIMS, PJ				LOCKERT, DH; KAUFMAN, KM; CHANG, CP; HUSLER, T; SODETZ, JM; SIMS, PJ			IDENTITY OF THE SEGMENT OF HUMAN-COMPLEMENT C8 RECOGNIZED BY COMPLEMENT REGULATORY PROTEIN CD59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; C9; C5B-9; IDENTIFICATION; COMPONENT; DOMAIN; LYSIS; CHAIN	CD59 antigen is a membrane glycoprotein that inhibits the activity of the C5b-9 membrane attack complex (MAC), thereby protecting human cells from lysis by human complement, The inhibitory function of CD59 derives from its capacity to interact with both the C8 and C9 components of MAC, preventing assembly of membrane-inserted C9 polymer, MAC-inhibitory activity of CD59 is species-selective and is most effective when both C8 and C9 derive from human or other primate plasma, Rabbit CS and C9, which can substitute for human CS and C9 in MAC, mediate virtually unrestricted lysis of human cells expressing CD59, In order to identify the segment of human C8 that is recognized by CD59, recombinant peptides containing human or rabbit C8 sequence were expressed in Escherichia coli and purified. CD59 was found to specifically bind to a peptide corresponding to residues 334-385 of the human CS alpha-subunit, and to require a disulfide bond between Cys(345) and Cys(369). NO specific binding was observed to the corresponding sequence from rabbit C8 alpha (residues 334-386). To obtain functional evidence that this segment of human C8 alpha is selectively recognized by CD59, recombinant C8 proteins were prepared by co-transfecting COS-7 cells with human/rabbit chimeras of the C8 alpha cDNA, and cDNAs encoding the C8 beta and C8 gamma chains. Hemolytic activity of MAC formed with chimeric C8 was analyzed using target cells reconstituted with CD59. These experiments confirmed that CD59 recognizes a conformationally sensitive epitope that is within a segment of human C8 alpha internal to residues 320-415, Our data also suggest that optimal interaction of CD59 with this segment of human C8 alpha is influenced by N-terminal flanking sequence in C8 alpha and by human C8 beta, but is unaffected by CS gamma.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; UNIV S CAROLINA, SCH MED, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA	Versiti Blood Center of Wisconsin; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036061, R37HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042898] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36061] Funding Source: Medline; NIGMS NIH HHS [GM42898] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG CP, 1994, J BIOL CHEM, V269, P26424; DAVE SJ, 1990, J IMMUNOL, V144, P3087; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HATANAKA M, 1994, BBA-PROTEIN STRUCT M, V1209, P117, DOI 10.1016/0167-4838(94)90146-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; HUSLER T, 1995, FASEB J, V9, pA490; HUSLER T, 1995, J BIOL CHEM, V270, P3483; LEHTO T, 1993, J IMMUNOL, V151, P4941; MERI S, 1990, IMMUNOLOGY, V71, P1; NG SC, 1987, BIOCHEMISTRY-US, V26, P5229, DOI 10.1021/bi00391a003; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; SCHALLER J, 1994, J PROTEIN CHEM, V13, P472; SODETZ JM, 1989, CURR TOP MICROBIOL, V140, P19; STEWART JL, 1985, BIOCHEMISTRY-US, V24, P4598, DOI 10.1021/bi00338a018; WHITE RV, 1994, J IMMUNOL, V152, P2501; WIEDMER T, 1985, J MEMBRANE BIOL, V84, P249, DOI 10.1007/BF01871388; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	25	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19723	19728		10.1074/jbc.270.34.19723	http://dx.doi.org/10.1074/jbc.270.34.19723			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544344	hybrid			2022-12-25	WOS:A1995RQ99100011
J	JAATTELA, M; BENEDICT, M; TEWARI, M; SHAYMAN, JA; DIXIT, VM				JAATTELA, M; BENEDICT, M; TEWARI, M; SHAYMAN, JA; DIXIT, VM			BCL-X AND BCL-2 INHIBIT TNF AND FAS-INDUCED APOPTOSIS AND ACTIVATION OF PHOSPHOLIPASE A(2) IN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article						CELL DEATH; CERAMIDE; FAS; TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION	TUMOR-NECROSIS-FACTOR; FACTOR-MEDIATED CYTOTOXICITY; MOLECULAR-CLONING; FACTOR-ALPHA; MONOCLONAL-ANTIBODY; CYTO-TOXICITY; EXPRESSION; RECEPTOR; PROTEIN; DEATH	Tumor necrosis factor (TNF) induces cell death in several tumor cell lines by undefined mechanisms. Using a cDNA expression cloning strategy we identified two cDNAs that completely inhibit the TNF-induced death pathway in MCF7 breast carcinoma cells. These cDNAs encoded for Bcl-2 and Bcl-x. To compare the cytotoxic signal transduction pathway induced by the TNF receptor versus that induced by Fas, we transfected MCF7 cells with a Fas expression construct. The resulting cell line, MCF-Fas, was highly sensitive to cytotoxicity induced by TNF or anti-Fas. Expression of either bcl-2 or bcl-x in these cells rendered them completely resistant to lysis induced by either TNF or Pas. Interestingly, exposure of MCF-Pas cells to anti-Fas or TNF induced activation of phospholipase A(2) (PLA(2)), while only TNF activated NF-kappa B. Activation of PLA(2) was completely blocked whereas activation of NF-kappa B was unaffected by overexpression of either bcl-x or bcl-2. Moreover, PLA(2)-inhibitors, quinacrine and dexamethasone, partially inhibited cytotoxicity induced by either TNF or anti-Pas. These data suggest an involvement of PLA(2) in both TNF- and Fas-mediated cytotoxicity and a novel mechanism of action for bcl-2 and bcl-x, i.e. inhibition of arachidonic acid metabolism, by which they may, in addition of apoptosis, modulate inflammation.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JAATTELA, M (corresponding author), DANISH CANC SOC,RES CTR,DEPT TUMOR CELL BIOL,DK-2100 COPENHAGEN,DENMARK.		Jäättelä, Marja/AAT-7932-2021; dixit, vishva m/A-4496-2012	Jäättelä, Marja/0000-0001-5950-7111; dixit, vishva m/0000-0001-6983-0326				BETTS JC, 1994, J BIOL CHEM, V269, P8455; BOISE LH, 1993, CELL, V744, P597; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CIFONE MG, 1993, J EXP MED, V177, P1547; EICHEN CM, 1994, J IMMUNOL, V153, P1947; HASHIZUME T, 1991, ARCH BIOCHEM BIOPHYS, V289, P47, DOI 10.1016/0003-9861(91)90440-T; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HENNET T, 1993, CANCER RES, V53, P1456; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1991, LAB INVEST, V64, P724; JAATTELA M, 1991, LYMPHOKINE CYTOK RES, V10, P119; JAATTELA M, 1989, EUR J IMMUNOL, V19, P1413, DOI 10.1002/eji.1830190810; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J IMMUNOL, V151, P4286; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; PREISS J, 1986, J BIOL CHEM, V261, P8597; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	60	299	307	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2297	2305						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7540278				2022-12-25	WOS:A1995RE54300004
J	TANIDA, I; HASEGAWA, A; IIDA, H; OHYA, Y; ANRAKU, Y				TANIDA, I; HASEGAWA, A; IIDA, H; OHYA, Y; ANRAKU, Y			COOPERATION OF CALCINEURIN AND VACUOLAR H+-ATPASE IN INTRACELLULAR CA2+ HOMEOSTASIS OF YEAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-T ACTIVATION; SACCHAROMYCES-CEREVISIAE; CALCIUM HOMEOSTASIS; SECRETORY PATHWAY; GENE-PRODUCT; TRANSPORT; SUBUNIT; ACIDIFICATION; CYCLOSPORINE; PHOSPHATASE	Saccharomyces cerevisiae VMA genes, encoding essential components for the expression of vacuolar membrane H+-ATPase activity, are involved in intracellular ionic homeostasis and vacuolar biogenesis. We report here that the immunosuppressants FK506 and cyclosporin A cause general growth inhibition of the vma3 mutant. Upon addition of the drugs, the mutant grew neither in the presence of more than 5 mM Ca2+ nor above pH 6.0. The action of the immunosuppressants is dependent on their binding proteins and ascribable to inhibition of calcineurin activity; a mutation of a calcineurin subunit (cnb1) shows synthetic lethal interaction with the vma mutation. The addition of FK506 decreases the cytosolic free concentration of Ca2+ in the vma3 mutant cells. Consequently, FK506 induces an 8.9-fold elevation of a nonexchangeable Ca2+ pool. These results suggest that calcineurin controls calcium homeostasis by repression of Ca2+ flux into a cellular compartment(s) and that the vacuolar H+-ATPase is essential for cell growth cooperating with calcineurin to regulate the cytosolic free concentration of Ca2+.	UNIV TOKYO, GRAD SCH SCI, DEPT PLANT SCI, BUNKYO KU, TOKYO 113, JAPAN; TONEN CORP, CORP RES & DEV LAB, OI, SAITAMA 356, JAPAN; NATL INST BASIC BIOL, DIV CELL PROLIFERAT, OKAZAKI, AICHI 444, JAPAN	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Tanida, Isei/C-8277-2009	Tanida, Isei/0000-0001-8999-3990				ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Anraku Y, 1987, PLANT VACUOLES, P255; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; EILAM Y, 1982, BIOCHIM BIOPHYS ACTA, V687, P8, DOI 10.1016/0005-2736(82)90164-X; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; FOOR F, 1992, NATURE, V360, P682; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALACHMI D, 1993, FEBS LETT, V316, P73, DOI 10.1016/0014-5793(93)81739-M; HIRATA R, 1990, J BIOL CHEM, V265, P6726; IIDA H, 1990, J BIOL CHEM, V265, P13391; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Maniatis T., 1982, MOL CLONING; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MYERS M, 1993, J BIOL CHEM, V268, P9184; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sherman F., 1986, METHODS YEAST GENETI; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; TANIDA I, 1991, TRANSPL P, V23, P2856; TREWAVAS A, 1991, TRENDS GENET, V7, P356, DOI 10.1016/0168-9525(91)90255-O; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447	38	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10113	10119		10.1074/jbc.270.17.10113	http://dx.doi.org/10.1074/jbc.270.17.10113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537264	hybrid			2022-12-25	WOS:A1995QV41700061
J	HUSLER, T; LOCKERT, DH; KAUFMAN, KM; SODETZ, JM; SIMS, PJ				HUSLER, T; LOCKERT, DH; KAUFMAN, KM; SODETZ, JM; SIMS, PJ			CHIMERAS OF HUMAN-COMPLEMENT C9 REVEAL THE SITE RECOGNIZED BY COMPLEMENT REGULATORY PROTEIN CD59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE ATTACK COMPLEX; INHIBITORY ACTIVITY; C5B-9; DOMAIN; LYSIS; INSERTION; C8	CD59 antigen is a membrane glycoprotein that inhibits the activity of the C9 component of the C5b-9 membrane attack complex, thereby protecting human cells from lysis by human complement. The complement-inhibitory activity of CD59 is species-selective and is most effective toward C9 derived from human or other primate plasma. By contrast, rabbit C9, which can substitute for human C9 in the membrane attack complex, mediates unrestricted lysis of human cells. To identify the peptide segment of human C9 that is recognized by CD59, rabbit C9 cDNA clones were isolated, characterized, and used to construct hybrid cDNAs for expression of full-length human/rabbit C9 chimeras in COS-7 cells. Ah resulting chimeras were hemolytically active, when tested against chicken erythrocytes bearing C5b-8 complexes. Assays performed in the presence or absence of CD59 revealed that this inhibitor reduced the hemolytic activity of those chimeras containing human C9 sequence between residues 334-415, irrespective of whether the remainder of the protein contained human or rabbit sequence. By contrast, when this segment of C9 contained rabbit sequence, lytic activity was unaffected by CD59. These data establish that human C9 residues 334-415 contain the site recognized by CD59, and they suggest that sequence variability within this segment of C9 is responsible for the observed species-selective inhibitory activity of CD59.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53201 USA; UNIV S CAROLINA, SCH MED, COLUMBIA, SC 29208 USA; UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA	Versiti Blood Center of Wisconsin; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NHLBI NIH HHS [HL36061] Funding Source: Medline; NIGMS NIH HHS [GM42898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036061, R37HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAGA LL, 1992, J CLIN INVEST, V90, P1131, DOI 10.1172/JCI115931; CHANG CP, 1994, J BIOL CHEM, V269, P26424; DALMASSO AP, 1992, IMMUNOPHARMACOLOGY, V24, P149, DOI 10.1016/0162-3109(92)90020-D; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DUPUIS M, 1993, MOL IMMUNOL, V30, P95, DOI 10.1016/0161-5890(93)90430-J; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; HUGHES TR, 1992, BIOCHEM J, V284, P169, DOI 10.1042/bj2840169; MERI S, 1990, IMMUNOLOGY, V71, P1; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PARIZADE M, 1994, J EXP MED, V179, P1625, DOI 10.1084/jem.179.5.1625; PEITSCH MC, 1990, MOL IMMUNOL, V27, P589, DOI 10.1016/0161-5890(90)90001-G; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; ROSSE WF, 1992, CURR TOP MICROBIOL, V178, P163; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; STANLEY KK, 1989, CURR TOP MICROBIOL, V140, P49; TOMLINSON S, 1994, J IMMUNOL, V152, P1927; VANDENBERG CW, 1993, IMMUNOLOGY, V78, P349; WHITE RV, 1994, J IMMUNOL, V152, P2501; WIEDMER T, 1985, J MEMBRANE BIOL, V84, P249, DOI 10.1007/BF01871388; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	23	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3483	3486						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533152				2022-12-25	WOS:A1995QH68800006
J	ASHMARINA, LI; RUSNAK, N; MIZIORKO, HM; MITCHELL, GA				ASHMARINA, LI; RUSNAK, N; MIZIORKO, HM; MITCHELL, GA			3-HYDROXY-3-METHYLGLUTARYL-COA LYASE IS PRESENT IN MOUSE AND HUMAN LIVER PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HYPEROXALURIA TYPE-1; RAT-LIVER; GLYOXYLATE AMINOTRANSFERASE; COENZYME; CHOLESTEROL; LOCALIZATION; BIOSYNTHESIS; FIBROBLASTS; METABOLISM; MICROSOMES	3-Hydroxy-3-methylglutaryl (HMG)-CoA metabolism is compartmentalized in mitochondria, endoplasmic reticulum, and peroxisomes. We investigated the subcellular distribution of HMG-CoA lyase (HL), which is found principally in mitochondria but in which we observed the potential peroxisomal targeting motif cysteine-lysine/arginine-leucine at the carboxyl terminus. We used differential and density gradient centrifugation to separate peroxisomes and mitochondria in liver homogenates of outbred CD-1 mice. Peroxisomal fractions contained 6.4% of total HL activity in mouse liver and 5.6% in human liver. Liver peroxisomal HL activity increased 2.3-2.5 times following induction of peroxisomal proliferation by clofibrate administration. Western blotting with anti-human HL antibodies confirmed the presence of immunoreactive HL in peroxisomal fractions, Mouse liver peroxisomal HL is distinct from mitochondrial HL, measuring similar to 2.5 kDa more by sodium dodecyl sulfate polyacrylamide gel electrophoresis. By fast protein liquid chromatofocusing analysis, the pi of peroxisomal. HL is 7.3, in contrast to 6.2 for mitochondrial HL. These results are consistent with noncleavage of the mitochondrial leader peptide in peroxisomal HL. A distinct species of enzymatically active HL exists in peroxisomes and may play a role in HMG-CoA metabolism in that organelle.	HOP ST JUSTINE, SERV GENET MED, MONTREAL H3T 1C5, PQ, CANADA; UNIV MONTREAL, FAC MED, DEPT PEDIAT, MONTREAL H3T 1C5, PQ, CANADA; MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA	Universite de Montreal; Universite de Montreal; Medical College of Wisconsin					NIDDK NIH HHS [DK 21491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; DANPURE CJ, 1993, BIOCHIMIE, V75, P309, DOI 10.1016/0300-9084(93)90091-6; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ENDO A, 1989, ADV ENZYME REGUL, V28, P53; ERICSSON J, 1993, BIOCHIMIE, V75, P167, DOI 10.1016/0300-9084(93)90074-3; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1987, J INHERIT METAB DIS, V10, P11, DOI 10.1007/BF01812843; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MITCHELL GA, 1993, J BIOL CHEM, V268, P4376; MIURA S, 1984, J BIOL CHEM, V259, P6397; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SHMIDT E, 1974, METHOD ENZYMAT AN, P650; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; SWEETMAN L, 1989, METABOLIC BASIS INHE, P791; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WANDERS RJA, 1988, CLIN CHIM ACTA, V171, P95, DOI 10.1016/0009-8981(88)90294-X; Wang S., 1994, American Journal of Human Genetics, V55, pA248; WANG SP, 1993, MAMM GENOME, V4, P382, DOI 10.1007/BF00360589; WYSYNSKI AM, 1993, HUM EXP TOXICOL, V12, P337, DOI 10.1177/096032719301200413	31	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31929	31932						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527399				2022-12-25	WOS:A1994PX30300091
J	TERADA, Y; TOMITA, K; HOMMA, MK; NONOGUCHI, H; YANG, TX; YAMADA, T; YUASA, Y; KREBS, EG; SASAKI, S; MARUMO, F				TERADA, Y; TOMITA, K; HOMMA, MK; NONOGUCHI, H; YANG, TX; YAMADA, T; YUASA, Y; KREBS, EG; SASAKI, S; MARUMO, F			SEQUENTIAL ACTIVATION OF RAF-1 KINASE, MITOGEN-ACTIVATED PROTEIN (MAP) KINASE KINASE, MAP KINASE, AND S6 KINASE BY HYPEROSMOLALITY IN RENAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DIRECT PHOSPHORYLATION; SIGNAL; OSMOREGULATION; EXPRESSION; PATHWAY; VOLUME; YEAST; NACL; GENE	In the renal medulla during antidiuresis, the extracellular fluid becomes hyperosmotic. Madin-Darby canine kidney (MDCK) epithelial cells adapt in hyperosmotic conditions and serve as a useful tissue culture model for cellular responses to hyperosmolality, We demonstrate that hyperosmolality stimulates phospholipase C, Raf-1 kinase mitogen-activated protein (MAP) kinase kinase, MAP kinase, and S6 kinase activities and that it increases phosphorylation of Raf-1 kinase, and p42 MAP kinase in MDCK cells. Stimulation of these kinases is osmolality-dependent (from 300 to 600 mosm/kg H2O). The time course of activation is sequential; the peak stimulation for Raf-1 kinase is at 5 min, at 10 min for MAP kinase kinase and MAP kinase, and at 20 min for S6 kinase. The activation of Raf-1 kinase and MAP kinase is inhibited by phorbol 12-myristate 13-acetate pretreatment in the presence of calphostin C or H-7. Tyrosine kinase inhibitors (genistein, herbimycin) do not significantly suppress hyperosmolality-induced MAP kinase activity. The increase of Ins-1,4,5-P-s levels by hyperosmolality suggests that activation of these kinases is mediated at least partially via activation of phospholipase C. Thus, hyperosmolality stimulates the serine/threonine kinases, Raf-1 kinase, MAP kinase kinase, MAP kinase, and S6 kinase, via predominantly protein kinase C-dependent, tyrosine kinase-independent pathways in MDCK cells.	TOKYO MED & DENT UNIV,DEPT HYG & ONCOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT PHARMACOL,SEATTLE,WA 98195	Tokyo Medical & Dental University (TMDU); Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	TERADA, Y (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,BUNKYO KU,5-45 YUSHIMA 1-CHOME,TOKYO 113,JAPAN.			Nonoguchi, Hiroshi/0000-0001-7831-7380				AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BECK F, 1985, PFLUG ARCH EUR J PHY, V405, pS28, DOI 10.1007/BF00581776; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURG MB, 1992, J AM SOC NEPHROL, V3, P121; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; GRINSTEIN S, 1986, J BIOL CHEM, V261, P8009; HATGUELDEMOUZON S, 1992, J CELL PHYSL, V150, P180; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LONGECARTER CA, 1993, SCIENCE, V260, P315; LYTLE C, 1992, J BIOL CHEM, V267, P25438; NAKANISHI T, 1989, AM J PHYSIOL, V257, pC795, DOI 10.1152/ajpcell.1989.257.4.C795; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SEGER R, 1992, J BIOL CHEM, V267, P14373; SELDIN DW, 1992, KIDNEY PHYSL PATHOPH; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; TILLY BC, 1993, J BIOL CHEM, V268, P19919; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1987, AM J PHYSIOL, V253, pC230, DOI 10.1152/ajpcell.1987.253.2.C230; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	31	115	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31296	31301						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527042				2022-12-25	WOS:A1994PV51000084
J	HUNTER, JJ; TANAKA, N; ROCKMAN, HA; ROSS, J; CHIEN, KR				HUNTER, JJ; TANAKA, N; ROCKMAN, HA; ROSS, J; CHIEN, KR			VENTRICULAR EXPRESSION OF A MLC-2V-RAS FUSION GENE INDUCES CARDIAC-HYPERTROPHY AND SELECTIVE DIASTOLIC DYSFUNCTION IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTIVE PHYSIOLOGICAL-RESPONSE; ATRIAL-NATRIURETIC-FACTOR; CONTRACTILE PROTEIN GENE; RAT MYOCARDIAL-CELLS; LIGHT CHAIN-2 GENE; ADRENERGIC STIMULATION; INDUCIBLE EXPRESSION; HEART; IDENTIFICATION; INDUCTION	p21(ras) has been implicated in the hypertrophic response of cultured cardiac myocytes to defined growth stimuli, To determine if activation of ras-dependent intracellular signaling pathways is sufficient to induce in vivo hypertrophy, transgenic mice were created that express oncogenic ras in the cardiac ventricular chamber. Mice homozygous for the transgene displayed morphological, physiological, and genetic markers of marked cardiac muscle hypertrophy. Miniaturized catheterization technology documented a selective prolongation of cardiac relaxation, similar to that seen in early human hypertrophic heart disease, An increase in left atrial mass, in the absence of transgene expression in that chamber, further supported physiologically abnormal left ventricular diastolic function. Histological analysis revealed myofibrillar disarray, indistinguishable from that in hypertrophic cardiomyopathy in man, These studies establish a ras-dependent pathway for hypertrophic heart disease and document the feasibility of mapping in vivo signaling pathways for cardiac hypertrophy and dysfunction by applying in vivo micro-physiological assays to genetically manipulated mice, ras-dependent pathways may also be a rational target for developing new approaches to inhibit the genesis of hypertrophy in certain pathological settings.	UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR GENET MOLEC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED,AMER HEART ASSOC,BUGHER FDN, CTR MOLEC BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL036139] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36139, HL40569, HL46345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HOGAN B, 1986, MANIPULATING MOUSE E; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LITWIN SE, 1990, J CLIN INVEST, V86, P481, DOI 10.1172/JCI114734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; METZGER JM, 1993, P NATL ACAD SCI USA, V90, P9036, DOI 10.1073/pnas.90.19.9036; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NISHIMURA RA, 1989, MAYO CLIN PROC, V64, P71, DOI 10.1016/S0025-6196(12)65305-1; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; ROCKMAN HA, 1994, AM J PHYSIOL, V266, pH2468, DOI 10.1152/ajpheart.1994.266.6.H2468; ROCKMAN HA, 1993, CIRCULATION, V87, P14; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; THORBURN A, 1993, J BIOL CHEM, V268, P2244; WEISS JL, 1976, J CLIN INVEST, V58, P751, DOI 10.1172/JCI108522; YELLIN EL, 1986, AM J PHYSIOL, V250, pH620, DOI 10.1152/ajpheart.1986.250.4.H620; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	33	258	265	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23173	23178		10.1074/jbc.270.39.23173	http://dx.doi.org/10.1074/jbc.270.39.23173			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559464	hybrid			2022-12-25	WOS:A1995RY05400084
J	CHLUMSKY, LJ; ZHANG, LN; JORNS, MS				CHLUMSKY, LJ; ZHANG, LN; JORNS, MS			SEQUENCE-ANALYSIS OF SARCOSINE OXIDASE AND NEARBY GENES REVEALS HOMOLOGIES WITH KEY ENZYMES OF FOLATE ONE-CARBON METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-CLEAVAGE SYSTEM; AMINO-ACID-SEQUENCE; T-PROTEIN; MOLECULAR-CLONING; RAT-LIVER; DIMETHYLGLYCINE DEHYDROGENASE; ESCHERICHIA-COLI; ELECTRON-TRANSFER; EXPRESSION; FLAVIN	Corynebacterial sarcosine oxidase, a heterotetrameric (alpha beta gamma delta) enzyme containing covalent and noncovalent FAD, catalyzes the oxidative demethylation of sarcosine to yield glycine, H2O2, and 5,10-CH2-tetrahydrofolate (H-4 folate) in a reaction requiring H-4 folate and O-2. The sarcosine oxidase operon contains at least five closely packed genes encoding sarcosine oxidase subunits and serine hydroxymethyltransferase (glyA), arranged in the order glyAsoxBDAG. The operon status of a putative purU gene, found 340 nucleotides downstream from soxG, is not known, No homology with other proteins is observed for the smallest sarcosine oxidase subunits gamma and delta. The beta subunit (405 residues) contains an ADP-binding motif near its NH2 terminus, the covalent FAD attachment site (H175), and exhibits homology with the NH2-terminal half of dimethylglycine dehydrogenase (857 residues) and monomeric, bacterial sarcosine oxidases (similar to 388 residues), enzymes that contain a single covalent FAD, The alpha subunit (967 residues) contains a second ADP-binding motif within an similar to 280 residue region near the NH2 terminus that exhibits homology with subunit A from octopine and nopaline oxidases, heterodimeric enzymes that catalyze analogous oxidative cleavage reactions with N-substituted arginine derivatives, An similar to 380 residue region near the COOH terminus of alpha exhibits homology with T-protein and the COOH terminal half of dimethylglycine dehydrogenase. These enzymes catalyze the formation of 5,10-CH2-H(4)folate, using different one-carbon donors. The results suggest that the alpha subunit and dimethylglycine dehydrogenase contain an NH2-terminal domain that binds noncovalent or covalent FAD, respectively, and a carboxyl-terminal H(4)folate-binding domain,	HAHNEMANN UNIV, SCH MED, DEPT BIOL CHEM, PHILADELPHIA, PA 19102 USA	Drexel University					NIGMS NIH HHS [GM 31704] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031704] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041; ALI SN, 1991, BIOCHEMISTRY-US, V30, P10980, DOI 10.1021/bi00109a024; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACHMANN BJ, 1983, MICROBIOL REV, V47, P180, DOI 10.1128/MMBR.47.2.180-230.1983; BOSL M, 1994, J BACTERIOL, V176, P221; BOURGUIGNON J, 1993, EUR J BIOCHEM, V217, P377, DOI 10.1111/j.1432-1033.1993.tb18256.x; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHLUMSKY LJ, 1993, BIOCHEMISTRY-US, V32, P11132, DOI 10.1021/bi00092a024; CLAVERIE JM, 1993, COMPUT CHEM, V17, P191, DOI 10.1016/0097-8485(93)85010-A; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1985, J BIOL CHEM, V260, P2998; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG DF, 1990, METHOD ENZYMOL, V183, P375; HAYASAKA K, 1993, BIOCHEM BIOPH RES CO, V192, P766, DOI 10.1006/bbrc.1993.1480; HROMOCKYJ AE, 1992, MOL MICROBIOL, V6, P2113, DOI 10.1111/j.1365-2958.1992.tb01385.x; KOPRIVA S, 1994, PLANT PHYSIOL, V104, P1079, DOI 10.1104/pp.104.3.1079; KOYAMA Y, 1991, AGR BIOL CHEM TOKYO, V55, P1259, DOI 10.1080/00021369.1991.10870758; KVALNESKRICK K, 1987, BIOCHEMISTRY-US, V26, P7391, DOI 10.1021/bi00397a029; KVALNESKRICK K, 1986, BIOCHEMISTRY-US, V25, P6061, DOI 10.1021/bi00368a034; KVALNESKRICK K, 1991, CHEM BIOCH FLAVOENZY, V2, P425; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; MAIZEL JV, 1981, P NATL ACAD SCI-BIOL, V78, P7665, DOI 10.1073/pnas.78.12.7665; MASKELL D, 1993, GENE, V129, P155, DOI 10.1016/0378-1119(93)90713-D; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; MIHALIK SJ, 1991, J BIOL CHEM, V266, P4822; MIYATA A, 1993, EUR J BIOCHEM, V212, P745, DOI 10.1111/j.1432-1033.1993.tb17713.x; NAGY PL, 1993, J BACTERIOL, V175, P7066, DOI 10.1128/jb.175.21.7066-7073.1993; NAGY PL, 1995, J BACTERIOL, V177, P1292, DOI 10.1128/jb.177.5.1292-1298.1995; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NISHIYA Y, 1993, J FERMENT BIOENG, V75, P239, DOI 10.1016/0922-338X(93)90145-X; NORMARK S, 1983, ANNU REV GENET, V17, P499, DOI 10.1146/annurev.ge.17.120183.002435; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; OKAMURAIKEDA K, 1992, J BIOL CHEM, V267, P18284; OKAMURAIKEDA K, 1991, J BIOL CHEM, V266, P4917; PORTER DH, 1985, ARCH BIOCHEM BIOPHYS, V243, P396, DOI 10.1016/0003-9861(85)90516-8; SANS N, 1987, EUR J BIOCHEM, V167, P81, DOI 10.1111/j.1432-1033.1987.tb13306.x; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHIGA Y, 1983, BIOCHEM INT, V6, P737; Stauffer L T, 1993, DNA Seq, V3, P339, DOI 10.3109/10425179309020835; STEENKAMP DJ, 1982, BIOCHEM J, V203, P707, DOI 10.1042/bj2030707; SUZUKI H, 1991, J BIOCHEM-TOKYO, V109, P909, DOI 10.1093/oxfordjournals.jbchem.a123479; SUZUKI H, 1988, BIOCHEM INT, V17, P577; SUZUKI K, 1992, BIOSCI BIOTECH BIOCH, V56, P432, DOI 10.1271/bbb.56.432; SUZUKI K, 1994, J FERMENT BIOENG, V77, P231, DOI 10.1016/0922-338X(94)90224-0; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; VONLINTIG J, 1994, J BACTERIOL, V176, P495, DOI 10.1128/JB.176.2.495-503.1994; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZANKER H, 1994, J BACTERIOL, V176, P4511, DOI 10.1128/JB.176.15.4511-4517.1994; ZELLER HD, 1989, BIOCHEMISTRY-US, V28, P5145, DOI 10.1021/bi00438a035	52	75	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18252	18259		10.1074/jbc.270.31.18252	http://dx.doi.org/10.1074/jbc.270.31.18252			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7543100	hybrid			2022-12-25	WOS:A1995RM64200018
J	HIESBERGER, T; HERMANN, M; JACOBSEN, L; NOVAK, S; HODITS, RA; BUJO, H; MEILINGER, M; HUTTINGER, M; SCHNEIDER, WJ; NIMPF, J				HIESBERGER, T; HERMANN, M; JACOBSEN, L; NOVAK, S; HODITS, RA; BUJO, H; MEILINGER, M; HUTTINGER, M; SCHNEIDER, WJ; NIMPF, J			THE CHICKEN OOCYTE RECEPTOR FOR YOLK PRECURSORS AS A MODEL FOR STUDYING THE ACTION OF RECEPTOR-ASSOCIATED PROTEIN AND LACTOFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NEPHRITIS ANTIGENIC COMPLEX; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; FAMILIAL HYPERCHOLESTEROLEMIA; MULTIFUNCTIONAL RECEPTOR; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE	Receptor-associated protein (RAP) was originally described as a 39-kDa intracellular protein copurifying with mammalian low density lipoprotein (LDL) receptor-related protein/alpha(2)-macroglobulin receptor (LRP/alpha(2)MR), RAP has a high affinity for LRP/alpha(2)MR and interferes with the receptor's ability to bind a variety of ligands, The laying hen expresses, in a tissue-specific manner, at least four different proteins which belong to the same family of receptors as LRP/alpha(2)MR. Here we show that the chicken also produces RAP, so far thought to be expressed only in mammals, Studies on the interaction of recombinant human RAP with the LDL receptor family in the chicken revealed that RAP binds with high affinity to the abundant oocyte receptor for yolk precursors (OVR) as well as to the somatic cell-specific LRP/alpha(2)MR. Significantly, RAP interacts with a lower affinity with the LDL receptor, but does not bind to the oocyte-specific form of LRP. Binding of RAP to OVR inhibits the interaction of the receptor with all known physiological ligands, i.e. the yolk precursors very low density lipoprotein, vitellogenin, and alpha(2)-macroglobulin. In COS cells transfected with OVR, RAP is internalized and degraded in a concentration-dependent and saturable manner, Lactoferrin, another protein with a high affinity for mammalian LRP/alpha(2)MR, also binds to OVR and abolishes its interaction with yolk precursors, Cross-competition experiments show that RAP and lactoferrin recognize sites different from those involved in yolk precursor binding, The availability of pure OVR and LDLR enabled us to determine kinetic parameters for the binding of BAP and lactoferrin to these receptors by surface plasmon resonance, Taken together, our results strongly suggest that chicken OVR, which is easily accessible and highly abundant in growing oocytes, represents a superior system for studying mechanistic and structural aspects of the interaction of ligands and modulating proteins with members of the LDL receptor gene family.	BIOCTR,DEPT MOLEC GENET,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,DEPT MED CHEM,A-1030 VIENNA,AUSTRIA; BIOCTR,DEPT MED BIOCHEM,A-1030 VIENNA,AUSTRIA	University of Vienna				Hermann, Marcela/0000-0003-2298-4269; Nimpf, Johannes/0000-0002-9273-3492				ABBATE M, 1993, EUR J CELL BIOL, V61, P139; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; DIJK MCM, 1992, EUR J BIOCHEM, V205, P775; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HO KJ, 1974, ARCH PATHOL, V98, P161; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HUTTINGER M, 1988, CLIN BIOCHEM, V21, P87; HUTTINGER M, 1992, J BIOL CHEM, V267, P18551; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; JONES DG, 1975, POULTRY SCI, V54, P1780; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NIMPF J, 1994, J BIOL CHEM, V269, P212; NIMPF J, 1994, ANN NY ACAD SCI, V737, P145, DOI 10.1111/j.1749-6632.1994.tb44308.x; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; SOTTRUPJENSEN L, 1983, ANN NY ACAD SCI, V421, P41, DOI 10.1111/j.1749-6632.1983.tb18091.x; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, SCIENCE, V264, P1171; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	80	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18219	18226		10.1074/jbc.270.31.18219	http://dx.doi.org/10.1074/jbc.270.31.18219			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7543099	hybrid			2022-12-25	WOS:A1995RM64200013
J	COFFER, PJ; BURGERING, BMT; PEPPELENBOSCH, MP; BOS, JL; KRUIJER, W				COFFER, PJ; BURGERING, BMT; PEPPELENBOSCH, MP; BOS, JL; KRUIJER, W			UV ACTIVATION OF RECEPTOR TYROSINE KINASE-ACTIVITY	ONCOGENE			English	Article						UV; GROWTH FACTOR; RECEPTORS; EGF; INSULIN; SIGNAL TRANSDUCTION	ARACHIDONIC-ACID; EGF RECEPTOR; DNA-BINDING; NF-KAPPA; PROTEIN; INSULIN; CELLS; PHOSPHORYLATION; EXPRESSION; SIGNAL	The exposure of mammalian cells to ultraviolet radiation (UV) may lead to DNA damage resulting in mutation and thus possibly cancer, while irradiation can further act as a potent tumour promoter. In addition UV induces p21ras-mediated signalling leading to activation of transcription factors such as AP-1 and NF-kappa B, as well as activation of the Src tyrosine kinase. This 'UV-response' has been well studied in mammalian cells and furthermore is conserved in yeast, however the most upstream components of this signal transduction pathway have remained elusive. Here we show that UV rapidly activates both the EGF receptor and insulin receptor, as shown by tyrosine phosphorylation of these receptors. We demonstrate that this activation is due to autophosphorylation as it only occurs in cells containing receptors with a functional kinase domain. We have further analysed the propagation of the UV-induced signal to downstream events such as, IRS-1 and Shc tyrosine phosphorylation, phosphatidylinositol 3-kinase activation, leukotriene synthesis, MAP kinase activation and gene induction all of which are activated by UV irradiation. Importantly, we demonstrate that in cells expressing a 'kinase-dead' receptor mutant the UV-response is inhibited, blocking leukotriene synthesis, MAP kinase activation and transcriptional induction. Furthermore, prior-stimulation of cells with UV appears to reduce further responsiveness to addition of growth factor suggesting a common signaling pathway. These data demonstrate a critical role for receptor-mediated events in regulating the response of mammalian cells to UV exposure.	UNIV UTRECHT,3508 TA UTRECHT,NETHERLANDS; UNIV GRONINGEN,CTR BIOL,DEPT GENET,9750 AA HAREN,NETHERLANDS	Utrecht University; University of Groningen	COFFER, PJ (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020	Peppelenbosch, Maikel/0000-0001-9112-6028				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1985, DNA REPAIR; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALDENHOVEN E, 1994, J BIOL CHE3M, V269, P22146; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; COFFER P, 1994, ONCOGENE, V9, P911; COHEN D, 1993, PHOTOCHEM PHOTOBIOL, V57, P383, DOI 10.1111/j.1751-1097.1993.tb02306.x; DEEG HJ, 1989, BLOOD, V73, P369; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FISHER SM, 1989, PROGR CLIN BIOL RES, V298, P249; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fursin G. I., 1990, Engineering Information in Data Bases and Knowledge Based Systems. Techno-Data '90. Proceedings of the International Conference Techno-Data '90, P107; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HAWK JLM, 1983, J INVEST DERMATOL, V80, P496, DOI 10.1111/1523-1747.ep12535038; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HURZA LL, 1993, J INVEST DERMATOL, V100, P35; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KRAMER M, 1993, J BIOL CHEM, V257, P13193; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVINE L, 1981, ADV CANCER RES, V35, P49, DOI 10.1016/S0065-230X(08)60908-2; MAHER VM, 1988, DNA REPLICATION MUTA, P465; MATSUI MS, 1989, J INVEST DERMATOL, V93, P617; MATSUI MS, 1991, CANCER CELLS, V31, P8; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKADATE T, 1990, EICOSANOIDS SKIN, P185; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Romerdahl C A, 1989, Cancer Commun, V1, P209; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WARMUTH I, 1994, CANCER RES, V54, P374; WHITMAN M, 1990, BIOCHEM J, V247, P165; YAMAMOTO S, 1992, CANCER CHEMOPREVENTION, P141; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	147	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					561	569						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543196				2022-12-25	WOS:A1995RN53000017
J	JUAN, TSC; HAILMAN, E; KELLEY, MJ; WRIGHT, SD; LICHENSTEIN, HS				JUAN, TSC; HAILMAN, E; KELLEY, MJ; WRIGHT, SD; LICHENSTEIN, HS			IDENTIFICATION OF A DOMAIN IN SOLUBLE CD14 ESSENTIAL FOR LIPOPOLYSACCHARIDE (LPS) SIGNALING BUT NOT LPS BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; CELLS; ACTIVATION; EXPRESSION; COMPLEXES; ENDOTOXIN; ANTIGEN	CD14 is a 55-kDa glycoprotein that binds lipopolysaccharide (LPS) and enables LPS dependent responses in a variety of cells. Monoclonal antibodies of CD14 such as 3C10 and MEM-18 are known to neutralize biological activity of CD14. Recently, it has been demonstrated that MEM-18 recognizes the LPS-binding site of CD14, between amino acids 57 and 64. It has also been shown that 3C10 recognizes a distinct epitope from that of MEM-18, indicating that 3C10 may yet define another functional domain of CD14. In order to identify the epitope for 3C10, we constructed a series of alanine substitution mutants of soluble CD14 (sCD14). BIAcore analyses showed that regions between amino acids 7 and 10 and between amino acids 11 and 14 are required for 3C10 binding. To assess the effect of altering the 3C10 epitope in CD14, we generated a stable cell line expressing a mutant sCD14 containing alanine substitutions in the region between amino acids 7 and 10, sCD14((7-10)A), and purified this protein to homogeneity. sCD14((7-10)A) has impaired ability to mediate LPS-dependent IL-6 up-regulation in U373 cells, integrin activation in neutrophils, and NF-kappa B activation in U373 cells. Purified sCD14((7-10)A) was, however, capable of forming a stable complex with LPS in an LPS binding protein-facilitated and LPS binding protein-independent fashion. The ability of sCD14((7-10)A) to bind LPS was also demonstrated in assays in which excess sCD14((7-10)A) inhibited LPS-mediated tumor necrosis factor-alpha production in whole blood and adhesion of polymorphonuclear leukocytes to fibrinogen. These data strongly suggest that a region recognized by neutralizing monoclonal antibody 3C10 contains a domain required for cellular signaling but not for LPS binding.	AMGEN INC,THOUSAND OAKS,CA 91320; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Amgen; Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30556] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; BAGASRA O, 1992, P NATL ACAD SCI USA, V89, P6285, DOI 10.1073/pnas.89.14.6285; BAZIL V, 1989, MOL IMMUNOL, V26, P657, DOI 10.1016/0161-5890(89)90048-5; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DETMERS PA, 1994, J IMMUNOL, V153, P2137; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRUNWALD U, 1992, J IMMUNOL METHODS, V155, P225, DOI 10.1016/0022-1759(92)90289-6; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1994, J IMMUNOL, V152, P5868; HAZIOT A, 1993, J IMMUNOL, V151, P1500; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LETURCQ DJ, 1994, 3RD SAT M C INT END, P22; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIMMONS DL, 1989, BLOOD, V73, P284; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743	27	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17237	17242		10.1074/jbc.270.29.17237	http://dx.doi.org/10.1074/jbc.270.29.17237			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542233	hybrid			2022-12-25	WOS:A1995RK68900030
J	IWATA, K; SEYA, T; YANAGI, Y; PESANDO, JM; JOHNSON, PM; OKABE, M; UEDA, S; ARIGA, H; NAGASAWA, S				IWATA, K; SEYA, T; YANAGI, Y; PESANDO, JM; JOHNSON, PM; OKABE, M; UEDA, S; ARIGA, H; NAGASAWA, S			DIVERSITY OF SITES FOR MEASLES-VIRUS BINDING AND FOR INACTIVATION OF COMPLEMENT C3B AND C4B ON MEMBRANE COFACTOR PROTEIN CD46	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C3B/C4B RECEPTOR CR-1; MONOCLONAL-ANTIBODY; MEDIATES PHAGOCYTOSIS; HUMAN TROPHOBLAST; HUMAN MONOCYTES; LIGAND-BINDING; CELL-DAMAGE; FACTOR-I; MCP; CLEAVAGE	The complement system membrane cofactor protein (MCP) CD46 serves as a C3b/C4b inactivating factor for the protection of host cells from autologous complement attack and as a receptor for measles virus (MV). MCP consists of four short consensus repeats (SCR) which are the predominant extracellular structural motif. In the present study, we determined which of the four SCR of MCP contribute to its function using Chinese hamster ovary cell clones expressing each SCR deletion mutants. The results were as follows: 1) SCR1 and SCR2 are mainly involved in MV binding and infection; 2) SCR2, SCR3, and SCR4 contribute to protect Chinese hamster ovary cells from human alternative complement pathway-mediated cytolysis; and 3) SCR2 and SCR3 are essential for protection of host cells from the classical complement pathway. These results on cell protective activity of the mutants against the human classical and the alternative complement pathways were compatible with factor I-mediated inactivation profiles of C4b and C3b, respectively, in the fluid-phase assay using solubilized mutants and factor I; the results were mostly consistent with those reported by Adams et al, (Adams, E. M., Brown, M. C., Nunge, M., Krych, M., and Atkinson, J. P. (1991) J. Immunol. 147, 3005-3011). SCR2 and SCR3 were required for C3b and C4b inactivation, and SCR4-deleted MCP showed weak cofactor activity for C4b cleavage but virtually no cofactor activity for C3b cleavage. The functional domains of MCP for the three natural ligands C3b, C4b, and MV, therefore, map to different, although partly overlapping, SCR domains.	HOKKAIDO UNIV, DEPT PHARMACEUT SCI, DIV HYG CHEM, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, DEPT PHARMACEUT SCI, DIV MOLEC BIOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; UNIV TOKYO, FAC MED, DEPT BACTERIOL, BUNKYO KU, TOKYO 113, JAPAN; ONCOMEMBRANE INC, CLIN IMMUNOL, SEATTLE, WA 98102 USA; ROYAL LIVERPOOL UNIV HOSP, DEPT IMMUNOL, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND; OSAKA UNIV, MICROBIAL DIS RES INST, DEPT NEUROVIROL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, MICROBIAL DIS RES INST, DEPT EXPTL ANIM, SUITA, OSAKA 565, JAPAN; CTR ADULT DIS, DEPT IMMUNOL, HIGASHINARI KU, OSAKA 537, JAPAN	Hokkaido University; Hokkaido University; University of Tokyo; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Osaka University; Osaka University			Seya, Tsukasa/A-4336-2012; Ariga, Hiroyoshi/B-5895-2013; Okabe, Masaru/B-6917-2015	Ariga, Hiroyoshi/0000-0001-7384-2143; Okabe, Masaru/0000-0002-0803-9044; Yanagi, Yusuke/0000-0001-7815-1667				ADAMS EM, 1991, J IMMUNOL, V147, P3005; BELLINGERKAWAHARA C, 1990, J EXP MED, V172, P1201, DOI 10.1084/jem.172.4.1201; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BORA NS, 1989, J EXP MED, V169, P597, DOI 10.1084/jem.169.2.597; CAREL JC, 1990, J BIOL CHEM, V265, P12293; COLE JL, 1985, P NATL ACAD SCI USA, V82, P859, DOI 10.1073/pnas.82.3.859; DIERICH MP, 1993, IMMUNOL TODAY, V14, P435, DOI 10.1016/0167-5699(93)90246-H; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; HARA T, 1992, CLIN EXP IMMUNOL, V89, P490; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HSI BL, 1988, AM J REPROD IMMUNOL, V18, P21; IWATA K, 1994, J IMMUNOL, V152, P3436; IWATA K, 1994, BIOCHEM J, V304, P169, DOI 10.1042/bj3040169; JOHNSTONE RW, 1993, MOL IMMUNOL, V30, P1231, DOI 10.1016/0161-5890(93)90038-D; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P4104, DOI 10.1073/pnas.88.10.4104; KOJIMA A, 1993, J IMMUNOL, V151, P1519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MASAKI T, 1992, J BIOCHEM-TOKYO, V111, P573, DOI 10.1093/oxfordjournals.jbchem.a123799; MATSUMOTO M, 1992, BIOCHEM J, V281, P493, DOI 10.1042/bj2810493; MOORE MD, 1991, J VIROL, V65, P3559, DOI 10.1128/JVI.65.7.3559-3565.1991; NAGASAWA S, 1977, IMMUNOCHEMISTRY, V14, P749, DOI 10.1016/0019-2791(77)90345-7; NAGASAWA S, 1980, J IMMUNOL, V125, P578; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NANICHE D, 1992, J GEN VIROL, V73, P2617, DOI 10.1099/0022-1317-73-10-2617; NICKELLS MW, 1990, J IMMUNOL, V144, P4262; Oglesby T., 1993, Molecular Immunology, V30, P40, DOI 10.1016/0161-5890(93)90318-6; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PESANDO JM, 1986, J IMMUNOL, V137, P3689; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; SCHLESINGER LS, 1991, J EXP MED, V174, P1031, DOI 10.1084/jem.174.5.1031; SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581; SEYA T, 1985, J BIOCHEM-TOKYO, V97, P373, DOI 10.1093/oxfordjournals.jbchem.a135064; SEYA T, 1990, J IMMUNOL, V145, P238; SEYA T, 1990, J EXP MED, V172, P1673, DOI 10.1084/jem.172.6.1673; SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837; SEYA T, 1990, J BIOCHEM, V107, P310, DOI 10.1093/oxfordjournals.jbchem.a123044; SPARROW RL, 1983, HUM IMMUNOL, V7, P1, DOI 10.1016/0198-8859(83)90002-2; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STERN PL, 1986, J IMMUNOL, V137, P1604; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERPUYE OA, 1992, BIOCHIM BIOPHYS ACTA, V1121, P301, DOI 10.1016/0167-4838(92)90161-6; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WILD TF, 1991, J GEN VIROL, V72, P439, DOI 10.1099/0022-1317-72-2-439; WONG TC, 1991, J VIROL, V65, P2191, DOI 10.1128/JVI.65.5.2191-2199.1991; YAMAZAKI M, 1986, FEBS LETT, V208, P147, DOI 10.1016/0014-5793(86)81550-2; YANAGI Y, 1992, VIROLOGY, V187, P280, DOI 10.1016/0042-6822(92)90316-H; [No title captured]	53	118	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15148	15152		10.1074/jbc.270.25.15148	http://dx.doi.org/10.1074/jbc.270.25.15148			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541036	hybrid			2022-12-25	WOS:A1995RE66600047
J	WANG, DH; ZHOU, GH; BIRKENMEIER, TM; GONG, JG; SUN, LZ; BRATTAIN, MG				WANG, DH; ZHOU, GH; BIRKENMEIER, TM; GONG, JG; SUN, LZ; BRATTAIN, MG			AUTOCRINE TRANSFORMING GROWTH-FACTOR BETA(1) MODULATES THE EXPRESSION OF INTEGRIN ALPHA(5)BETA(1) IN HUMAN COLON-CARCINOMA FET CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; DIFFERENTIAL SENSITIVITY; COLORIMETRIC ASSAY; TGF-BETA; LINE; FACTOR-BETA-1; PHENOTYPE; ADHESION; GENE	Transforming growth factor beta (TGF-beta) has been extensively studied as an exogenous agent that stimulates the expression of extracellular matrix proteins and their cell-surface integrin receptors in a variety of cell types, However, the recent demonstration of autocrine TGF-beta growth effects in a number of cell types suggests that the steady-state expression of extracellular matrix and integrin proteins and their biological activity may also be under autocrine TGF-beta control, Previously, we reported that repression of autocrine TGF-beta(1) activity by constitutive expression of a full-length TGF-beta(1) antisense cDNA led to abrogation of autocrine negative TGF-beta and, as a result, increased tumorigenicity and anchorage-independent growth of a poorly tumorigenic, well differentiated colon carcinoma cell line designated FET (Wu, S., Theodorescu, D., Kerbel, R. S., Willson, J. K. V., Mulder, K. M., Humphrey, L. E., and Brattain, M. G. (1992) J. Cell Biol. 116, 187-196), Consequently, we have used this model system to study the effects of repression of autocrine TGF-beta(1) activity on the expression of integrin alpha(5) beta(1) and integrin alpha(5) beta(1)-mediated cell adhesion to fibronectin, The expression of the integrin alpha(5) subunit was reduced in TGF-beta(1) antisense transfected FET cells at both mRNA and protein levels as determined by RNase protection assays and immunoprecipitation, respectively. Autocrine TGF-beta(1) had no effect on the transcription of integrin alpha(5) and beta(1) subunits, indicating that autocrine TGF-beta(1) may regulate integrin alpha(5) beta(1) expression at the post transcriptional level. The diminished expression of integrin alpha(5) beta(1) on the cell surface led to the reduced adhesion of TGF-beta(1) antisense transfected cells to fibronectin, This phenomenon could be reversed by treatment with exogenous TGF-beta(1).	MED COLL OHIO,DEPT BIOCHEM & MOLEC BIOL,TOLEDO,OH 43699; BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110	Baylor College of Medicine; Washington University (WUSTL)			, LuZhe/AAW-4095-2021		NCI NIH HHS [CA38173, CA50457, CA63480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA038173, R29CA063480, R01CA038173, R01CA050457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BOYD D, 1988, CANCER RES, V48, P2825; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHAKRABARTY S, 1989, CANCER RES, V49, P2112; CHAKRABARTY S, 1988, CANCER RES, V48, P4059; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOWELL GM, 1993, CANCER METAST REV, V12, P275, DOI 10.1007/BF00665958; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; JANAT MF, 1992, J CELL PHYSIOL, V151, P588, DOI 10.1002/jcp.1041510319; MANNING AM, 1991, ONCOGENE, V6, P1471; MILAM SB, 1991, J CELL PHYSIOL, V149, P173, DOI 10.1002/jcp.1041490202; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; ROBERTS AB, 1990, ANN NY ACAD SCI, V593, P1; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SCHREINER C, 1991, CANCER RES, V51, P1738; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SING GK, 1990, CELL GROWTH DIFFER, V1, P549; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; WANG D, 1995, IN PRESS J CELL PHYS; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187	38	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14154	14159		10.1074/jbc.270.23.14154	http://dx.doi.org/10.1074/jbc.270.23.14154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539800	hybrid			2022-12-25	WOS:A1995RC44800082
J	WELLBROCK, C; LAMMERS, R; ULLRICH, A; SCHARTL, M				WELLBROCK, C; LAMMERS, R; ULLRICH, A; SCHARTL, M			ASSOCIATION BETWEEN THE MELANOMA-INDUCING RECEPTOR TYROSINE KINASE XMRK AND SRC FAMILY TYROSINE KINASES IN XIPHOPHORUS	ONCOGENE			English	Article						GROWTH FACTOR RECEPTOR; MELANOMA; PLC-GAMMA; SIGNAL TRANSDUCTION; SH2 DOMAIN; TYROSINE KINASES	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; FAINT-LITTLE-BALL; EGF RECEPTOR; ELEVATED EXPRESSION; SIGNAL-TRANSDUCTION; MALIGNANT-MELANOMA; SH2 DOMAINS; PROTEIN; GENE	Melanoma formation in the fish Xiphophorus is an in vivo model for the function of receptor tyrosine kinases (RTKs) in tumor development. The overexpression and high activity of the RTK Xmrk (Xiphophorus melanoma receptor kinase) is responsible for the formation of hereditary malignant melanoma in this fish, but the mechanism by which Xmrk signals cell proliferation has not been elucidated. Remarkably, in earlier experiments an elevated level of a pp60(c-src) related kinase activity was found in the melanomas. In order to evaluate the significance of src family SH2 domain interactions in the intracellular signalling of Xmrk, we determined its relative binding affinity to the ubiquitous general RTK substrate, PLC gamma, and to the Xiphophorus cytoplasmic kinases Xsrc, Xfyn and Xyes. Recombinant Xmrk purified from baculovirus infected Sf9 cells bound with high affinity to the SH2 domains of PLC gamma and Xfyn in vitro. The affinity of Xmrk to Xsrc and Xyes SH2 domains was 5- to 10-fold lower. Coprecipitation experiments revealed that the Xmrk/Xfyn interaction occurred also in melanoma cells. Moreover, stimulation of the Xmrk kinase activity was paralleled by an increase in Xfyn activity. These results suggest that in malignant melanoma of Xiphophorus the highly activated Xmrk may enhance the activity of Xfyn through direct interaction and that both kinases are linked in a signal transduction pathway.	UNIV WURZBURG, THEODOR BOVERI INST, BIOCTR, DEPT PHYSIOL CHEM 1, D-97074 WURZBURG, GERMANY; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	University of Wurzburg; Max Planck Society				Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; ALTSCHMIED J, 1994, LEGACY CELL FUSION, P199; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARNEKOW A, 1982, CANCER RES, V42, P2429; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FENDLY BM, 1990, CANCER RES, V50, P1550; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNIG G, 1991, ONCOGENE, V6, P361; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOGANZO F, 1993, ONCOGENE, V8, P2637; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MALITSCHEK B, 1994, J BIOL CHEM, V269, P10423; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MAUELER W, 1988, ONCOGENE, V3, P113; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RATH HM, 1990, J BIOL CHEM, V265, P3080; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1982, CANCER RES, V42, P4222; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIERKE SL, 1983, BIOL BIOPHYS RES COM, V191, P45; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V73, P321; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1993, J BIOL CHEM, V268, P1775; ZHU GC, 1994, ONCOGENE, V9, P1379	41	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7540277				2022-12-25	WOS:A1995RB70300008
J	TU, GF; REID, GE; ZHANG, JG; MORITZ, RL; SIMPSON, RJ				TU, GF; REID, GE; ZHANG, JG; MORITZ, RL; SIMPSON, RJ			C-TERMINAL EXTENSION OF TRUNCATED RECOMBINANT PROTEINS IN ESCHERICHIA-COLI WITH A 10SA RNA DECAPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL STABLE RNA; MURINE INTERLEUKIN-6; SYNTHETIC GENE; PURIFICATION; EXPRESSION; SEQUENCE	When murine interleukin-6 is overexpressed in Escherichia coli, a small population of molecules exhibits a novel C-terminal modification. Peptide mapping, electrospray ionization-mass spectrometry, and automated N- and C-terminal sequencing identified a peptide (''tag'' peptide), Ala-Ala-Asn-Asp-Glu-Asn-Tyr-Aza-Leu-Ala COOH, encoded by a small metabolically stable RNA of E. coli (10Sa RNA) attached to truncated C termini of the recombinant protein. A mutant strain of E. coli in which the chromosomal 10Sa RNA gene (ssrA) is disrupted does not produce this C-terminal modification, confirming that the tag peptide originates from the ssrA gene.	LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,PARKVILLE,VIC 3050,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute			Moritz, Robert L/B-9222-2011	Reid, Gavin/0000-0002-9675-1444; Simpson, Richard/0000-0002-9834-0796				BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BOGOSIAN G, 1989, J BIOL CHEM, V264, P531; BRUMLIK MJ, 1992, MOL MICROBIOL, V6, P337, DOI 10.1111/j.1365-2958.1992.tb01476.x; CHAUHAN AK, 1989, MOL MICROBIOL, V3, P1481, DOI 10.1111/j.1365-2958.1989.tb00133.x; DANLEY DE, 1991, FEBS LETT, V283, P135, DOI 10.1016/0014-5793(91)80571-J; DAUMY GO, 1989, BIOCHIM BIOPHYS ACTA, V998, P32, DOI 10.1016/0167-4838(89)90115-5; JESPERSEN AM, 1994, EUR J BIOCHEM, V219, P365, DOI 10.1111/j.1432-1033.1994.tb19948.x; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; MILLER CG, 1995, METHODS PROTEIN STRU; Miller J. H., 1992, SHORT COURSE BACTERI, P263; MORITZ RL, 1992, J MICROCOLUMN SEP, V4, P485, DOI 10.1002/mcs.1220040604; Moritz Robert L., 1994, Methods (Orlando), V6, P213, DOI 10.1006/meth.1994.1024; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; RAY BK, 1979, MOL GEN GENET, V174, P25, DOI 10.1007/BF00433301; REID GE, 1992, ANAL BIOCHEM, V200, P301, DOI 10.1016/0003-2697(92)90470-R; Sambrook J, 1989, MOL CLONING LABORATO; SEETHARAM R, 1988, BIOCHEM BIOPH RES CO, V155, P518, DOI 10.1016/S0006-291X(88)81117-3; SIMPSON RJ, 1988, BIOCHEM BIOPH RES CO, V157, P364, DOI 10.1016/S0006-291X(88)80056-1; SIMPSON RJ, 1988, EUR J BIOCHEM, V176, P187, DOI 10.1111/j.1432-1033.1988.tb14267.x; TU GF, 1992, AM J PHYSIOL, V263, pR195, DOI 10.1152/ajpregu.1992.263.1.R195; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; ZHANG JG, 1992, EUR J BIOCHEM, V207, P903, DOI 10.1111/j.1432-1033.1992.tb17123.x	24	203	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9322	9326		10.1074/jbc.270.16.9322	http://dx.doi.org/10.1074/jbc.270.16.9322			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7536743	hybrid			2022-12-25	WOS:A1995QU08900042
J	KARLSSON, T; ZHOU, SY; LANDGREN, E; LAVERGNE, C; DIFIORE, PP; ANAFI, M; PAWSON, T; CANTLEY, LC; CLAESSONWELSH, L; WELSH, M				KARLSSON, T; ZHOU, SY; LANDGREN, E; LAVERGNE, C; DIFIORE, PP; ANAFI, M; PAWSON, T; CANTLEY, LC; CLAESSONWELSH, L; WELSH, M			MOLECULAR-INTERACTIONS OF THE SRC HOMOLOGY-2 DOMAIN PROTEIN SHB WITH PHOSPHOTYROSINE RESIDUES, TYROSINE KINASE RECEPTORS AND SRC HOMOLOGY-3 DOMAIN PROTEINS	ONCOGENE			English	Article						SRC HOMOLOGY 2 (SH2) DOMAIN; SRC HOMOLOGY 3 (SH3) DOMAIN; TYROSINE KINASE RECEPTORS; PROLINE-RICH MOTIFS; MITOGENIC SIGNAL TRANSDUCTION; ADAPTER SH2 DOMAIN PROTEIN	GROWTH-FACTOR RECEPTOR; PDGF BETA-RECEPTOR; SIGNAL TRANSDUCTION; AUTOPHOSPHORYLATION SITES; POINT MUTATION; C-SRC; RAS; IDENTIFICATION; GRB2; ASSOCIATION	The molecular interactions of the Src homology 2 (SH2) domain and the N-terminal proline-rich sequence motifs (pro-1 to pro-5) of the SH2 protein Shb with other components were presently characterised, Using a degenerate phosphopeptide library the preferred binding site for the Shb SH2 domain was determined to pTyr-Thr/Val/Ile-X-Leu at positions +1 to +3 relative the phosphotyrosine residue, Experiments with competing peptides and platelet-derived growth factor (PDGF) beta-receptor mutants with Y to F substitutions in autophosphorylation sites revealed multiple binding sites for the Shb SH2 domain in the receptor, The Shb SH2 domain also binds to in vitro phosphorylated fibroblast growth factor receptor-1 (FGFR-1) mainly through position Y776, The receptor experiments suggest that other residues besides the +1 to +3 positions may also be of significance for Shb binding, The pro-4/pro-5 motif of Shb binds in vitro particularly well to the Src, p85 alpha PI3-kinase and Eps8 SH3 domains expressed as GST fusion proteins, However, the GST-SH3 domain fusion proteins tested bind in vitro to peptides corresponding to the pro-1 to pro-5 motifs of Shb with low affinity and selectivity, suggesting that sequences outside the core proline motif may also be important for Shb-SH3 domain interactions, In vivo association between Shb-SH3 domain proteins v-Src and Eps8 was detected by coimmunoprecipitation. PDGF treatment did not affect the association between Eps8 and Shb. The data suggest that Shb is an adaptor protein linking SH3 domain proteins to tyrosine kinases or other tyrosine phosphorylated proteins.	UNIV UPPSALA, DEPT MED CELL BIOL, UPPSALA, SWEDEN; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA USA; UPPSALA UNIV, LUDWIG INST CANC RES, UPPSALA, SWEDEN; HOP ROBERT DEBRE, INSERM, CJF 93-13, F-75019 PARIS, FRANCE; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	Uppsala University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Ludwig Institute for Cancer Research; Uppsala University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Di Fiore, Pier Paolo/K-2130-2012; Cantley, Lewis C/D-1800-2014; Pawson, Tony J/E-4578-2013	Di Fiore, Pier Paolo/0000-0002-2252-0950; Cantley, Lewis C/0000-0002-1298-7653; Welsh, Michael/0000-0002-5467-9755				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASTAGNINO P, 1995, IN PRESS ONCOGENE; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELSH M, 1994, ONCOGENE, V9, P19; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1475	1483						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7537362				2022-12-25	WOS:A1995QU68100002
J	CASTAGNINO, P; BIESOVA, Z; WONG, WT; FAZIOLI, F; GILL, GN; DIFIORE, PP				CASTAGNINO, P; BIESOVA, Z; WONG, WT; FAZIOLI, F; GILL, GN; DIFIORE, PP			DIRECT BINDING OF EPS8 TO THE JUXTAMEMBRANE DOMAIN OF EGFR IS PHOSPHOTYROSINE-INDEPENDENT AND SH2-INDEPENDENT	ONCOGENE			English	Article						EPS8; EGFR; JUXTAMEMBRANE; BINDING	GROWTH-FACTOR RECEPTOR; SIGNALING PROTEINS; TYROSINE KINASES; SH3 DOMAINS; PHOSPHORYLATION; SPECIFICITY; THREONINE; ERBB-2	Several signal transducers bind through their SH2 domains to phosphotyrosine-containing motifs present in receptor tyrosine kinases (RTKs). However, the juxtamembrane regions of the epidermal growth factor receptor (EGFR) and of the related erbB-2 protein, while important in mitogenic signaling, lack demonstrable tyrosine phosphorylation sites, suggesting that other modalities of receptor-transducer interactions exist. A candidate for investigating this type of association is p97(eps8), a recently described substrate for RTKs. p97(eps8) is phosphorylated by several RTKs, associates with EGFR in vivo and, upon overexpression, enhances the transduction of EGFR-mediated mitogenic signals. Here we report that eps8 binds directly to the juxtamembrane region of EGFR through a domain that does not bear resemblance to SH2 domains and by a mechanism that does not require the presence of phosphotyrosine residues. Thus, the physical association between EGFR and eps8 represents a novel interaction between RTKs and their substrates.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; FAC MED & CHIRURG BARI, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; Universita degli Studi di Bari Aldo Moro			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COCHET C, 1991, J BIOL CHEM, V266, P637; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WONG WT, 1994, ONCOGENE, V9, P3057; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					723	729						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7532293				2022-12-25	WOS:A1995QH61200012
J	CONRAD, R; KERANEN, LM; ELLINGTON, AD; NEWTON, AC				CONRAD, R; KERANEN, LM; ELLINGTON, AD; NEWTON, AC			ISOZYME-SPECIFIC INHIBITION OF PROTEIN-KINASE-C BY RNA APTAMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATION	In vitro selection technology has been used to purify RNA aptamers from a random sequence pool that can bind to, and specifically inhibit, protein kinase C beta IL. Two of the selected RNA aptamers bind to this isozyme of protein kinase C with nanomolar affinities and inhibit activation with unprecedented selectivity; the highly related, alternatively spliced beta I isozyme, which differs by 23 residues, is inhibited with 1 order of magnitude lower potency; the next most similar isozyme, alpha, shows no detectable inhibition. The production of isozyme-specific inhibitors of protein kinase C opens the possibilities for dissecting the roles of specific protein kinase Cs in the myriad of intracellular signaling pathways.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; JAEGER JA, 1989, METHOD ENZYMOL, V183, P281; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; WALKER JM, 1988, J BIOL CHEM, V263, P4537; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	16	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32051	32054						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528207				2022-12-25	WOS:A1994PX30400008
J	BIRD, TA; KYRIAKIS, JM; TYSHLER, L; GAYLE, M; MILNE, A; VIRCA, GD				BIRD, TA; KYRIAKIS, JM; TYSHLER, L; GAYLE, M; MILNE, A; VIRCA, GD			INTERLEUKIN-1 ACTIVATES P54 MITOGEN-ACTIVATED PROTEIN (MAP) KINASE KINASE STRESS-ACTIVATED PROTEIN-KINASE BY A PATHWAY THAT IS INDEPENDENT OF P21(RAS), RAF-1, AND MAP KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; MYELIN BASIC-PROTEIN; SMOOTH-MUSCLE CELLS; SUBSTRATE RECOGNITION; HUMAN-FIBROBLASTS; SIGNAL TRANSDUCTION; FACTOR-ALPHA; C-MYC; PHOSPHORYLATION	In KB epidermoid cells, we previously showed that interleukin-1 alpha (IL-1) and various mitogens activate the mitogen-activated protein (MAP) kinases ERK1 and ERK2, which phosphorylate both myelin basic protein (MBP) and a peptide containing Thr(669) of the epidermal growth factor receptor. In cell-free extracts made from gingival fibroblasts treated with platelet-derived growth factor or HepG2 hepatoma cells stimulated with phorbol myristate acetate, MBP and Thr(669) kinase were both elevated 4-fold, and ERK1 and ERK2 were tyrosine-phosphorylated. In these cells IL-1 activated a kinase(s) that phosphorylated Thr(669) peptide but not MBP and failed to cause tyrosine phosphorylation of ERK1/ERK2. Ceramide has been proposed as an intracellular mediator of IL-1 action, but C-2-ceramide or sphingosine stimulated predominantly MBP-specific kinase activity in fibroblasts and had no effect in HepG2 cells, p54 MAP kinase (also called stress-activated protein kinase) is a c-Jun kinase first isolated from livers of cycloheximide-treated rats. After IL-1 stimulation, immunoprecipitates of lysates made from all three cell types with specific anti-p54 MAP kinase serum contained Thr(669) and c-Jun phosphorylating activity, whereas precipitates from unstimulated cells contained no detectable p54 kinase activity. The major peak of IL-1 stimulated HepG2 Thr(669) kinase activity co chromatographed on Mono Q and phenyl-Superose with immunodetectable p54 MAP kinase. IL-1 did not cause p21(ras) activation in any cell type. Induction of Thr(669) kinase activity was not abrogated by elevation of cAMP levels, which has been shown to interfere with the activation of Raf-1. We could not detect MAP kinase kinase phosphorylating activity in unfractionated lysates made from IL-1-stimulated fibroblasts or HepG2 cells. KB cells contained a small amount of this activity, but it was not precipitated with an anti-Raf-1 antibody. We conclude that most of the IL-1-activated Thr(669) kinase activity in fibroblasts and HepG2 cells, and a portion in KB cells, is due to p54 MAP kinase and that its activation is Ras-, Raf-, and MAP kinase kinase-independent.	IMMUNEX CORP,DEPT BIOCHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROT CHEM,SEATTLE,WA 98101; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,BOSTON,MA 02129	Immunex Corporation; Harvard University; Harvard Medical School; Massachusetts General Hospital								AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1992, CYTOKINE, V4, P429, DOI 10.1016/1043-4666(92)90003-A; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CONCA W, 1991, J BIOL CHEM, V266, P16265; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUY GR, 1991, J BIOL CHEM, V266, P14343; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KIM MY, 1991, J BIOL CHEM, V266, P484; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU J, 1994, J BIOL CHEM, V269, P3047; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	64	105	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31836	31844						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527398				2022-12-25	WOS:A1994PX30300078
J	KLINT, P; KANDA, S; CLAESSONWELSH, L				KLINT, P; KANDA, S; CLAESSONWELSH, L			SHC AND A NOVEL 89-KDA COMPONENT COUPLE TO THE GRB2-SOS COMPLEX IN FIBROBLAST GROWTH FACTOR-2-STIMULATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; POINT MUTATION; BETA-RECEPTOR; FACTOR FAMILY; PROTEIN; DOMAIN; CLONING; PHOSPHORYLATION; IDENTIFICATION	A major pathway for mitogenicity is gated via the small GTP-binding protein Ras. Receptor tyrosine kinases couple to Ras through the Src homology 2 (SH2) domain protein Grb2. The activated fibroblast growth factor receptor-1 (FGFR-1) expressed in L6 myoblasts did not bind Grb2 directly, but indirectly, through the small adaptor protein She, which was tyrosine-phosphorylated in response to fibroblast growth factor-2 (FCF-S) stimulation, A FGFR-1 mutant in which Tyr(766), a known autophosphorylation site, was changed to Phe, mediated less efficient tyrosine phosphorylation of Shc. FGF-S stimulation of mutant FGFR-1-expressing cells still allowed formation of complexes containing She, Grb2, and the nucleotide exchange factor Sos and mediation of a mitogenic signal, Another pool of Grb2 was found in complex with a tyrosine-phosphorylated 89-kDa component after FGF-2 stimulation. Stimulation with other growth factors did not lead to tyrosine phosphorylation of p89. As shown by ''far-Western'' analysis, p89 bound directly to the Grb2 SH2 domain, and this interaction was inhibited by a peptide containing the Y(P)-X-N motif. Tyrosine-phosphorylated p89 was found exclusively in the membrane fraction, indicating its role in bringing Grb2, as well as Sos, to the plasma membrane. These data support the concept of growth factor-specific coupling of Grb2 to the Ras pathway.			KLINT, P (corresponding author), LUDWIG INST CANC RES, CTR BIOMED, BOX 595, S-75124 UPPSALA, SWEDEN.			Claesson-Welsh, Lena/0000-0003-4275-2000				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HOU JZ, 1993, PROTEIN SCI, V2, P86; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LANDGREN E, 1995, ONCOGENE, V10, P2027; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SETH A, 1992, J BIOL CHEM, V267, P24796; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SOLER C, 1994, ONCOGENE, V9, P2207; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23337	23344		10.1074/jbc.270.40.23337	http://dx.doi.org/10.1074/jbc.270.40.23337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559490	hybrid			2022-12-25	WOS:A1995RY90900019
J	GONZALEZHABA, MG; GARCIAMAURINO, S; CALVO, JR; GOBERNA, R; GUERRERO, JM				GONZALEZHABA, MG; GARCIAMAURINO, S; CALVO, JR; GOBERNA, R; GUERRERO, JM			HIGH-AFFINITY BINDING OF MELATONIN BY HUMAN CIRCULATING T-LYMPHOCYTES (CD4(+))	FASEB JOURNAL			English	Article						PINEAL GLAND; CD4(+) CELLS	VASOACTIVE-INTESTINAL-PEPTIDE; PINEAL-GLAND; OPIATERGIC MECHANISM; GUANINE-NUCLEOTIDES; ANTIBODY-RESPONSE; RAT THYMUS; SITES; RECEPTORS; IMMUNITY; 2-<I-125>MELATONIN	This paper shows the presence of high-affinity binding sites for melatonin in human circulating T lymphocytes, but not in B lymphocytes. The binding of melatonin to T cells was dependent on time, stable, reversible, saturable, specific, and inversely correlated to the production of melatonin, expressed as the nocturnal 12 h production of its urinary metabolite 6-sulfatoxymelatonin. The affinity of these binding sites (K-d = 0.27 nM) suggests that they may recognize the physiological concentrations of melatonin in serum. Moreover, among the lymphocyte subpopulations, studied, binding of melatonin was mostly found in CD4(+) cells rather than in CD8(+) cells. Results suggest that CD4(+) cells may be the target of melatonin among the human circulating lymphocytes.	UNIV SEVILLE, SCH MED, DEPT MED BIOCHEM & MOLEC BIOL, E-41009 SEVILLE, SPAIN; VIRGEN MACARENA HOSP, E-41009 SEVILLE, SPAIN	University of Sevilla; Hospital Universitario Virgen Macarena	GUERRERO, JM (corresponding author), UNIV SEVILLE, SCH MED, DEPT MED BIOCHEM & MOLEC BIOL, E-41009 SEVILLE, SPAIN.		Guerrero, Josep M./D-5519-2014; Calvo, Juan R./A-7338-2017; Guerrero, Josep M./Y-2929-2019; García-Mauriño, Sofía/E-6707-2010; IBIS, NEUROINMUNO/O-9306-2015	Guerrero, Josep M./0000-0001-5236-4592; Calvo, Juan R./0000-0002-4854-2963; García-Mauriño, Sofía/0000-0002-7698-5112; Goberna Ortiz, Raimundo/0000-0003-1206-5058; Guerrero, Juan Miguel/0000-0001-7553-0119				Ader R., 1981, PSYCHONEUROIMMUNOLOG, V1st ed.; BLALOCK JE, 1985, FED PROC, V44, P108; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; DELGOBBO V, 1986, INT J IMMUNOPHARMACO, V5, P567; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; GUERRERO JM, 1981, MOL CELL ENDOCRINOL, V21, P151, DOI 10.1016/0303-7207(81)90052-6; GUERRERO JM, 1994, ADV PINEAL, V7, P109; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; LAITINEN JT, 1989, ENDOCRINOLOGY, V124, P1585, DOI 10.1210/endo-124-3-1585; LAITINEN JT, 1990, NEUROENDOCRINOLOGY, V51, P619, DOI 10.1159/000125401; LAITINEN JT, 1990, ENDOCRINOLOGY, V126, P2110, DOI 10.1210/endo-126-4-2110; Lopez-Gonzalez Miguel A., 1993, Biotechnology Therapeutics, V4, P253; LOPEZGONZALEZ MA, 1992, J PINEAL RES, V12, P97, DOI 10.1111/j.1600-079X.1992.tb00034.x; LOPEZGONZALEZ MA, 1993, J NEUROIMMUNOL, V45, P121, DOI 10.1016/0165-5728(93)90171-T; LOPEZGONZALEZ MA, 1992, J PINEAL RES, V12, P174, DOI 10.1111/j.1600-079X.1992.tb00045.x; MAESTRONI GJM, 1988, IMMUNOLOGY, V63, P465; MAESTRONI GJM, 1987, CLIN EXP IMMUNOL, V68, P384; MAESTRONI GJM, 1989, INT J IMMUNOPHARMACO, V11, P333, DOI 10.1016/0192-0561(89)90078-7; MAESTRONI GJM, 1990, J NEUROIMMUNOL, V28, P167, DOI 10.1016/0165-5728(90)90031-H; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; MARTINCACAO A, 1993, IMMUNOL LETT, V36, P59, DOI 10.1016/0165-2478(93)90069-E; MORREY KM, 1994, J IMMUNOL, V153, P2671; PANG CS, 1992, J PINEAL RES, V12, P167, DOI 10.1111/j.1600-079X.1992.tb00044.x; POON AMS, 1992, LIFE SCI, V50, P1719, DOI 10.1016/0024-3205(92)90427-Q; RAFIIELIDRISSI M, 1995, J NEUROIMMUNOL, V57, P171, DOI 10.1016/0165-5728(94)00182-N; REITER RJ, 1980, J EXP ZOOL, V212, P47, DOI 10.1002/jez.1402120107; REITER RJ, 1986, J NEURAL TRANSM, P35; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; VANECEK J, 1988, J NEUROCHEM, V51, P1436, DOI 10.1111/j.1471-4159.1988.tb01108.x; WEAVER DR, 1989, J NEUROSCI, V9, P2581; YU ZH, 1991, NEUROSCI LETT, V125, P175, DOI 10.1016/0304-3940(91)90021-K; YUAN H, 1991, J ENDOCRINOL, V128, P475, DOI 10.1677/joe.0.1280475	32	87	92	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1995	9	13					1331	1335		10.1096/fasebj.9.13.7557023	http://dx.doi.org/10.1096/fasebj.9.13.7557023			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557023				2022-12-25	WOS:A1995TA37000012
J	MCCLAIN, DE; KALINICH, JF; RAMAKRISHNAN, N				MCCLAIN, DE; KALINICH, JF; RAMAKRISHNAN, N			TROLOX INHIBITS APOPTOSIS IN IRRADIATED MOLT-4 LYMPHOCYTES	FASEB JOURNAL			English	Article						RADIATION; APOPTOSIS	LIPID-PEROXIDATION; CELL-DEATH; INTERPHASE DEATH; PARINARIC ACID; RADIATION; CA-2+; THYMOCYTES; MEMBRANES; KINETICS	MOLT-4 cells, a human lymphocytic leukemia line, undergo apoptosis in response to a variety of stimuli, including exposure to ionizing radiation. Very little is known of the molecular mechanisms by which radiation induces apoptosis, Morphology changes and chromatin cleavage at internucleosomal sites accompany apoptosis in these cells. We found that trolox, a water-soluble derivative of vitamin E that penetrates biomembranes and protects mammalian cells from oxidative damage, blocks DNA fragmentation in irradiated MOLT-4 cells. Levels of DNA fragmentation in cells not treated with trolox were directly related to both radiation dose and time postirradiation. Preincubation of cells with trolox or incubation with trolox only during irradiation did not protect cells. A 4 h postirradiation incubation with trolox was sufficient to completely block fragmentation measured at 24 h, indicating the processes triggered by radiation to induce DNA fragmentation occur early after irradiation. Removal of cells from trolox earlier than 4 h resulted in progressively less inhibition, Trolox preserves the integrity of irradiated cells as judged by increased viability and thymidine incorporation. Radiation induces an uptake of extracellular Ca2+ into MOLT-4 cells that was blocked by a postirradiation incubation with trolox. These results suggest that membrane-associated oxidations triggered by radiation are responsible for radiation-induced apoptosis in MOLT-4 cells.			MCCLAIN, DE (corresponding author), ARMED FORCES RADIOBIOL RES INST,DEPT APPL CELLULAR RADIOBIOL,8901 WISCONSIN AVE,BETHESDA,MD 20889, USA.							ASHWELL JD, 1987, J IMMUNOL, V136, P3649; Bacq Z.M., 1961, FUNDAMENTALS RADIOBI, V2nd; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; CASTLE L, 1986, J AM CHEM SOC, V108, P6381, DOI 10.1021/ja00280a041; FORSTER TH, 1992, INT J RADIAT BIOL, V61, P365, DOI 10.1080/09553009214551051; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; KUYPERS FA, 1987, BIOCHIM BIOPHYS ACTA, V921, P266, DOI 10.1016/0005-2760(87)90027-0; MCCLAIN DE, 1984, AGENTS ACTIONS, V15, P279, DOI 10.1007/BF01972363; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MICKLE DAG, 1989, ANN THORAC SURG, V47, P553, DOI 10.1016/0003-4975(89)90431-1; MINOWADA J, 1972, J NATL CANCER I, V49, P891; NAKANO H, 1994, RADIAT RES, V140, P1, DOI 10.2307/3578561; NAKAZAWA T, 1980, INT J RADIAT BIOL, V38, P537, DOI 10.1080/09553008014551351; OJEDA F, 1991, INT J RADIAT BIOL, V59, P53, DOI 10.1080/09553009114550051; PASCOE GA, 1989, FREE RADICAL BIO MED, V6, P209, DOI 10.1016/0891-5849(89)90118-4; POTTEN CS, 1982, CELL TISSUE KINET, V15, P351, DOI 10.1111/j.1365-2184.1982.tb01053.x; PUROHIT SC, 1980, INT J RADIAT BIOL, V38, P147, DOI 10.1080/09553008014551041; RAMAKRISHNAN N, 1993, INT J RADIAT BIOL, V63, P693, DOI 10.1080/09553009314552091; SHINOHARA K, 1993, RADIAT RES, V135, P197, DOI 10.2307/3578295; SOLARY E, 1992, EXP CELL RES, V203, P495, DOI 10.1016/0014-4827(92)90027-6; STEPHENS LC, 1989, RADIAT RES, V120, P140, DOI 10.2307/3577641; SZEKELEY JG, 1982, SCAN ELECTRON MICROS, V82, P335; SZEKELY JG, 1985, INT J RADIAT BIOL, V47, P681, DOI 10.1080/09553008514550921; WU TW, 1990, BIOCHEM CELL BIOL, V68, P1189, DOI 10.1139/o90-176; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMADA T, 1988, INT J RADIAT BIOL, V53, P65, DOI 10.1080/09553008814550431; ZHIVOTOVSKY B, 1993, EXP CELL RES, V207, P163, DOI 10.1006/excr.1993.1176	28	85	88	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1995	9	13					1345	1354		10.1096/fasebj.9.13.7557025	http://dx.doi.org/10.1096/fasebj.9.13.7557025			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557025				2022-12-25	WOS:A1995TA37000014
J	VANFLETEREN, JR; DEVREESE, A				VANFLETEREN, JR; DEVREESE, A			THE GERONTOGENES AGE-1 AND DAF-2 DETERMINE METABOLIC-RATE POTENTIAL IN AGING CAENORHABDITIS-ELEGANS	FASEB JOURNAL			English	Article						METABOLIC RATE POTENTIAL; AGING; LONGEVITY	GLYOXYLATE CYCLE; INTERMEDIARY METABOLISM; DAUER LARVA; NEMATODE; LIFE	Mutations in the genes age-1 and daf-2 extend life span of Caenorhabditis elegans by 100 and 200%, respectively, in axenic culture. Adult worms that are mutant in either of these genes have higher metabolic capacities, called metabolic rate potentials, at all ages and the extension of their life expectancies are positively correlated with the increases of metabolic rate potential. The activities of catalase, superoxide dismutase, isocitrate dehydrogenase, isocitrate lyase, and malate synthase are all higher relative to those in worms that are wild type for these genes, but acid phosphatase is down-regulated and alkaline phosphatase activity is lowered to 10% of the activity measured in age-1(+) and daf-2(+) worms. These results suggest that genes that regulate metabolic activity may play central roles in longevity and senescence.			VANFLETEREN, JR (corresponding author), STATE UNIV GHENT, DEPT MORPHOL SYSTEMAT & ECOL, LEDEGANCKST 35, B-9000 GHENT, BELGIUM.							AEBI H, 1984, METHOD ENZYMOL, V105, P121; ANDERSON GL, 1982, CAN J ZOOL, V60, P288, DOI 10.1139/z82-038; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; BARRETT J, 1970, COMP BIOCHEM PHYSIOL, V35, P577, DOI 10.1016/0010-406X(70)90974-6; BEH CT, 1991, DEV BIOL, V147, P133, DOI 10.1016/S0012-1606(05)80013-2; BRENNER S, 1974, GENETICS, V77, P71; Crapo J D, 1978, Methods Enzymol, V53, P382; DIXON GH, 1959, BIOCHEM J, V72, pP3; FRIEDMAN DB, 1988, GENETICS, V118, P75; HARMAN D, 1968, J GERONTOL, V23, P476, DOI 10.1093/geronj/23.4.476; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HARMAN D, 1962, RADIAT RES, V16, P753, DOI 10.2307/3571274; HODGKIN J, 1991, P ROY SOC B-BIOL SCI, V246, P19, DOI 10.1098/rspb.1991.0119; ISHII N, 1994, J GERONTOL, V49, pB117, DOI 10.1093/geronj/49.3.B117; JOHNSON TE, 1992, J AM GERIATR SOC, V40, P936, DOI 10.1111/j.1532-5415.1992.tb01993.x; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KHAN FR, 1980, FEBS LETT, V115, P312, DOI 10.1016/0014-5793(80)81195-1; KHAN FR, 1982, EXP PARASITOL, V54, P47, DOI 10.1016/0014-4894(82)90109-6; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; MISHRA A, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P239; ORIORDAN VB, 1989, COMP BIOCHEM PHYS B, V92, P233, DOI 10.1016/0305-0491(89)90271-X; ORIORDAN VB, 1990, COMP BIOCHEM PHYS B, V95, P125, DOI 10.1016/0305-0491(90)90258-U; PATEL TR, 1978, NEMATOLOGICA, V24, P51, DOI 10.1163/187529278X00065; REISS U, 1974, BIOCHEMISTRY-US, V13, P1796, DOI 10.1021/bi00706a003; Rose M.R., 1991, EVOLUTIONARY BIOL AG; ROTHSTEIN M, 1966, COMP BIOCHEM PHYSIOL, V17, P1181, DOI 10.1016/0010-406X(66)90293-3; ROTHSTEIN M, 1964, ARCH BIOCHEM BIOPHYS, V108, P134, DOI 10.1016/0003-9861(64)90364-9; SCHMIDT J, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P321; Sulston J., 1988, NEMATODE CAENORHABDI, P587; VANFLETEREN JR, 1994, ELECTROPHORESIS, V15, P289, DOI 10.1002/elps.1150150149; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VANFLETEREN JR, 1990, BIOCHEM J, V265, P739, DOI 10.1042/bj2650739; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WARD CW, 1967, COMP BIOCHEM PHYSIOL, V23, P335, DOI 10.1016/0010-406X(67)90391-X; WONG A, 1995, GENETICS, V139, P1247; WOOD WB, 1994, CURR BIOL, V4, P151, DOI 10.1016/S0960-9822(94)00036-9	40	137	146	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1995	9	13					1355	1361		10.1096/fasebj.9.13.7557026	http://dx.doi.org/10.1096/fasebj.9.13.7557026			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557026				2022-12-25	WOS:A1995TA37000015
J	YU, WH; WOLFGANG, W; FORTE, M				YU, WH; WOLFGANG, W; FORTE, M			SUBCELLULAR-LOCALIZATION OF HUMAN VOLTAGE-DEPENDENT ANION CHANNEL ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER MITOCHONDRIAL-MEMBRANE; PORIN 31 HL; CELL-LINE; EXPRESSION; CLONING; HEXOKINASE; VDAC; RECEPTOR; PROTEIN; BRAIN	The voltage dependent anion channel of the outer mitochondrial membrane, VDAC (also known as mitochondrial porin), is a small abundant protein which forms a voltage-gated pore when incorporated into planar lipid bilayers. This protein forms the primary pathway for movement of major metabolites through the outer membrane. Recently, it has been demonstrated that two human VDAC genes, INDAC1 and HVDAC2, produce three proteins that differ most significantly at their amino termini. These results suggest that the distinct amino termini lead to the targeting of individual VDAC isoforms to different cellular compartments. Consistent with this hypothesis, recent reports suggest that HV-DAC1 is found in the plasma membrane of mammalian cells. To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes recognized by either of two monoclonal antibodies. Introduction of these epitope tags had no effect on the function of modified VDAC proteins. Epitope-tagged proteins were then individually expressed in COS7 cells or rat astrocytes and the intracellular location of each isoform subsequently identified by subcellular fractionation, light level immunofluorescence, and immunoelectron microscopy. Our results demonstrate that each HVDAC protein is exclusively located in fractions or subcellular regions containing mitochondrial marker proteins. In addition, immunofluorescence and immunoelectron microscopy show that an individual mitochondrion can contain both HVDAC1 and HVDAC2. Our results call into question previous reports demonstrating VDAC molecules in the plasma membrane and suggest that functional differences between individual VDAC isoforms may result in distinct regulatory processes within a single mitochondrion.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University				Wolfgang, William/0000-0003-1769-0215	NIGMS NIH HHS [GM35759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1994, GENOMICS, V20, P62, DOI 10.1006/geno.1994.1127; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRDICZKA D, 1990, EXPERIENTIA, V46, P161, DOI 10.1007/BF02027312; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COLE T, 1992, BIOL CHEM H-S, V373, P891, DOI 10.1515/bchm3.1992.373.2.891; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; Craigen W. J., 1994, American Journal of Human Genetics, V55, pA130; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAINS L, 1994, J BIOL CHEM, V269, P26402; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; Horwich A L, 1991, Curr Top Microbiol Immunol, V170, P1; JALONEN T, 1989, ACTA PHYSIOL SCAND, V136, P611, DOI 10.1111/j.1748-1716.1989.tb08709.x; KABIR F, 1991, BIOCHIM BIOPHYS ACTA, V1057, P147, DOI 10.1016/S0005-2728(05)80095-7; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KONIG U, 1991, BIOL CHEM H-S, V372, P565, DOI 10.1515/bchm3.1991.372.2.565; KONSTANTINOVA SA, 1995, IN PRESS J BIOENERGE; KOTTKE M, 1988, BIOCHIM BIOPHYS ACTA, V935, P87, DOI 10.1016/0005-2728(88)90111-9; LINDEN M, 1984, BIOCHIM BIOPHYS ACTA, V770, P93, DOI 10.1016/0005-2736(84)90077-4; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MCCABE ERB, 1994, J BIOENERG BIOMEMBR, V26, P307; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MULLER G, 1994, ARCH BIOCHEM BIOPHYS, V308, P8, DOI 10.1006/abbi.1994.1002; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; PRREHN S, 1990, EUR J BIOCHEM, V1188, P439; SCHMID A, 1992, BIOCHIM BIOPHYS ACTA, V1112, P174, DOI 10.1016/0005-2736(92)90389-4; SIMPSON IA, 1982, ANAL BIOCHEM, V119, P424, DOI 10.1016/0003-2697(82)90608-X; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; WEINER GJ, 1990, J IMMUNOL, V144, P2436	43	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13998	14006		10.1074/jbc.270.23.13998	http://dx.doi.org/10.1074/jbc.270.23.13998			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539795	hybrid			2022-12-25	WOS:A1995RC44800061
J	SOLTOFF, SP; TOKER, A				SOLTOFF, SP; TOKER, A			CARBACHOL, SUBSTANCE-P, AND PHORBOL ESTER PROMOTE THE TYROSINE PHOSPHORYLATION OF PROTEIN-KINASE C-DELTA IN SALIVARY-GLAND EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; INTRACELLULAR CALCIUM; AMYLASE SECRETION; RAT FIBROBLASTS; EXPRESSION; ACTIVATION; CA2+; ZETA; DESENSITIZATION	The initiation of saliva formation by parotid acinar cells, which comprise the majority of cells in this salivary gland, is initiated by the release of neurotransmitters (acetylcholine, substance P) from parasympathetic nerves. In response to substance P and the muscarinic agonist carbachol, two ligands that activate phospholipase C-linked receptors, which stimulate fluid secretion, PKC delta was phosphorylated on tyrosine residues. The maximal agonist dependent tyrosine phosphorylation occurred within seconds of the addition of either agonist and then returned rapidly to a smaller increased level. Phorbol ester also caused a rapid increase in tyrosine phosphorylation, which reached a maximal level 5 min after the addition of phorbol 12-myristate 13-acetate. The increase in tyrosine phosphorylation of PKC delta was blocked by tyrosine kinase inhibitors genistein and staurosporine. Ionophore-mediated elevation of [Ca2+](i) or activation of the beta-adrenergic receptor, epidermal growth factor receptor, or insulin receptor did not promote the tyrosine phosphorylation of PKC delta. These results indicate that tyrosine phosphorylation plays a role in early signal transduction events promoted by the activation of muscarinic and substance P receptors and suggests that the tyrosine phosphorylation of PKC delta has a role in the activation of fluid secretion by neurotransmitters binding to phospholipase C-Linked receptors.	BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center					NIDCR NIH HHS [DE10877] Funding Source: Medline; NIGMS NIH HHS [GM41890] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUM BJ, 1993, BIOL SALIVARY GLANDS, P153; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DUNNE MJ, 1994, AM J PHYSIOL, V267, pC501, DOI 10.1152/ajpcell.1994.267.2.C501; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HAYASHI Y, 1987, CANCER, V60, P1000, DOI 10.1002/1097-0142(19870901)60:5<1000::AID-CNCR2820600514>3.0.CO;2-4; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUGHES AR, 1991, MOL PHARMACOL, V40, P254; KOMABAYASHI T, 1992, EUR J PHARM-MOLEC PH, V225, P209, DOI 10.1016/0922-4106(92)90022-N; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MCGLYNN E, 1992, J CELL BIOCHEM, V49, P239, DOI 10.1002/jcb.240490306; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V148, P1017, DOI 10.1016/S0006-291X(87)80233-4; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MORAN A, 1993, AM J PHYSIOL, V265, pC1405, DOI 10.1152/ajpcell.1993.265.5.C1405; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PADEL U, 1985, EUR J BIOCHEM, V151, P1, DOI 10.1111/j.1432-1033.1985.tb09061.x; QUISSELL DO, 1993, BIOL SALIVARY GLANDS, P181; SHIMOMURA H, 1988, BIOCHEM BIOPH RES CO, V150, P1309, DOI 10.1016/0006-291X(88)90772-3; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKUMA T, 1986, FEBS LETT, V199, P53, DOI 10.1016/0014-5793(86)81222-4; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TERZIAN AR, 1993, ARCH ORAL BIOL, V38, P1051, DOI 10.1016/0003-9969(93)90166-J; TOJYO Y, 1993, JPN J PHARMACOL, V63, P439, DOI 10.1254/jjp.63.439; TOJYO Y, 1992, CELL STRUCT FUNCT, V17, P223, DOI 10.1247/csf.17.223; TORCHIA J, 1994, J BIOL CHEM, V269, P29778; Turner R. J., 1993, BIOL SALIVARY GLANDS, P105; WATSON EL, 1993, CELL SIGNAL, V5, P583, DOI 10.1016/0898-6568(93)90053-O; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; WOON PY, 1993, ARCH ORAL BIOL, V38, P1021, DOI 10.1016/0003-9969(93)90117-5; YEH CK, 1992, AM J PHYSIOL, V263, pG934, DOI 10.1152/ajpgi.1992.263.6.G934	43	90	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13490	13495		10.1074/jbc.270.22.13490	http://dx.doi.org/10.1074/jbc.270.22.13490			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539427	hybrid			2022-12-25	WOS:A1995RB43900079
J	SIEGALL, CB; BACUS, SS; COHEN, BD; PLOWMAN, GD; MIXAN, B; CHACE, D; CHIN, DM; GOETZE, A; GREEN, JM; HELLSTROM, I; HELLSTROM, KE; FELL, HP				SIEGALL, CB; BACUS, SS; COHEN, BD; PLOWMAN, GD; MIXAN, B; CHACE, D; CHIN, DM; GOETZE, A; GREEN, JM; HELLSTROM, I; HELLSTROM, KE; FELL, HP			HER4 EXPRESSION CORRELATES WITH CYTOTOXICITY DIRECTED BY A HEREGULIN-TOXIN FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; RECEPTOR; DIFFERENTIATION; LIGAND; P185ERBB2; ANTIGEN	We have constructed, expressed, and purified a fusion protein, HAR-TX beta 2, consisting of heregulin-beta 2 fused to a binding defective form of Pseudomonas exotoxin A, PE40. The fusion protein was found to induce receptor tyrosine phosphorylation in CEM cells transfected with HER4 alone or in combination with HER2 but not in cells transfected with HER2 or HER1 alone. The phosphorylation of receptor tyrosines was both dose-dependent and saturable in amounts similar to those shown to be active for native heregulin. HAR-TX beta 2 was specifically cytotoxic toward a variety of carcinoma cell lines in the ng/ml range, However, some tumor cell lines were found to be insensitive to the cytotoxic action of the fusion protein even at >2 mu g/ml. Relative amounts of HER4, HER3, and HER2 were determined on seven cell lines sensitive and four cell lines insensitive to HAR-TX beta 2, All lines that express HER4 were killed by HAR-TX beta 2, while none lacking HER4 were affected, HAR-TX beta 2 was able to bind to and signal via tyrosine phosphorylation in cell lines that co-express HER2 and HER3 in the absence of HER4 without inducing cytotoxicity, Thus HAR-TX beta 2 may prove to be a useful reagent for the targeting and elimination of HER4-positive tumor cells.	BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,BIOPROC RES DEPT,SEATTLE,WA 98121; ADV CELLULAR DIAGNOST INC,ELMHURST,IL 60126	Bristol-Myers Squibb	SIEGALL, CB (corresponding author), BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT MOLEC IMMUNOL,3005 1ST AVE,SEATTLE,WA 98121, USA.		PLOWMAN, Greg D/E-2012-2011					BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CANCER RES, V52, P2580; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FELL HP, 1992, J BIOL CHEM, V267, P15552; FRIEDMAN PN, 1993, CANCER RES, V53, P334; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KONDO T, 1988, J BIOL CHEM, V263, P9470; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SIEGALL CB, 1994, J IMMUNOL, V152, P2377; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	22	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7625	7630		10.1074/jbc.270.13.7625	http://dx.doi.org/10.1074/jbc.270.13.7625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535774	hybrid			2022-12-25	WOS:A1995QQ43100088
J	MARTIN, SJ; OBRIEN, GA; NISHIOKA, WK; MCGAHON, AJ; MAHBOUBI, A; SAIDO, TC; GREEN, DR				MARTIN, SJ; OBRIEN, GA; NISHIOKA, WK; MCGAHON, AJ; MAHBOUBI, A; SAIDO, TC; GREEN, DR			PROTEOLYSIS OF FODRIN (NONERYTHROID SPECTRIN) DURING APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROGRAMMED CELL-DEATH; MONOCLONAL-ANTIBODY; GENE CED-3; ACTIVATION; PROTEASE; HYBRIDOMAS; CALMODULIN; INDUCTION; RECEPTOR; CLEAVAGE	Several recent studies have implicated proteases as important triggers of apoptosis. Thus far, substrates that are cleaved during apoptosis have been elusive. In this report we demonstrate that cleavage of alpha-fodrin (non erythroid spectrin) accompanies apoptosis, induced by activation via the CD3/T cell receptor complex in a murine T cell hybridoma, ligation of the Fas (CD95) molecule on a human T cell lymphoma line and other Fas-expressing cells, or treatment of cells with staurosporine, dexamethasone, or synthetic ceramide. Furthermore, inhibition of activation-induced apoptosis by pretreatment of T hybridoma cells with antisense oligonucleotides directed against c-myc also inhibited fodrin proteolysis, confirming that this cleavage process is tightly coupled to apoptosis. Fodrin cleavage during ap optosis may have implications for the membrane blebbing seen during this process.	TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science	MARTIN, SJ (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,11149 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Green, Douglas R/N-8083-2018	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Green, Douglas R/0000-0002-7332-1417; Martin, Seamus/0000-0002-8539-3143	NIGMS NIH HHS [GM52735] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CIFONE MG, 1994, J EXP MED, V177, P1547; McGahon A J, 1994, Cell Death Differ, V1, P77; COTTER TG, 1992, CANCER RES, V52, P997; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; FOX JEB, 1987, BLOOD, V69, P537; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; IIDA N, 1994, J BIOL CHEM, V269, P28576; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1994, CURR BIOL, V4, P337, DOI 10.1016/S0960-9822(00)00073-7; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MARTIN SJ, 1994, J IMMUNOL, V152, P330; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UCKER DS, 1992, J IMMUNOL, V149, P1583; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABE T, J BIOL CHEM, V269, P17656; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	39	461	465	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6425	6428		10.1074/jbc.270.12.6425	http://dx.doi.org/10.1074/jbc.270.12.6425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7534762	hybrid			2022-12-25	WOS:A1995QQ85500002
J	JOSEPH, SK; RYAN, SV; PIERSON, S; RENARDROONEY, D; THOMAS, AP				JOSEPH, SK; RYAN, SV; PIERSON, S; RENARDROONEY, D; THOMAS, AP			THE EFFECT OF MERSALYL OIL INOSITOL TRISPHOSPHATE RECEPTOR-BINDING AND ION-CHANNEL FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; CA2+ RELEASE; PERMEABILIZED HEPATOCYTES; THIOL REAGENTS; HAMSTER EGGS; RAT-LIVER; THIMEROSAL; CEREBELLUM; MEMBRANES	A number of thiol-reactive agents induce repetitive Ca2+ spiking in cells by a mechanism thought to involve sensitization of the inositol 1,4,5-trisphosphate receptor (IP(3)R). To further define the basis of this interaction, we have studied the effect of several thiol-reactive agents on [H-3]IP3 binding, IP3-gated channel activity, and conformation of the IP(3)R in membranes from hepatocytes, cultured WR rat liver epithelial cells, and cerebellum microsomes, At 4 degrees C, the organomercurial thiol-reactive agent mersalyl markedly stimulates (3-4-fold) [H-3]IP3 binding to permeabilized hepatocytes. The closely related molecule, thimerosal, has only a small stimulatory effect under these conditions, and GSSG or N-ethylmaleimide are without effect. The stimulatory effect of mersalyl was associated with a decrease in K-d of the IP(3)R with no change in B-max. Mersalyl was without effect on detergent-solubilized hepatocyte binding sites or on the [H-3]IP3 binding activity of cerebellum microsomes. In contrast to thimerosal, which potentiates IP3-mediated Ca2+ release, mersalyl blocked IP3-gated Ca2+ channels. Mersalyl pretreatment of WB membranes altered the pattern of immunoreactive receptor fragments generated upon subsequent cleavage of the receptor with proteinase K. This effect was not reproduced py thimerosal and was also not observed in experiments on cerebellum microsomes. We conclude that the WB cell and brain IP3 receptors are differently regulated by modification of thiol groups. Reaction of the WB cell IP3 receptor with mersalyl alters its conformation and modifies the accessibility of sites on the protein that are cleaved by proteinase K. In the presence of mersalyl, the receptor has high affinity for IP3 but is inactive as a Ca2+ channel, This contrasts with the high affinity receptor/active Ca2+ channel induced by thimerosal, suggesting that even closely related thiol agents may interact at different thiol groups.			JOSEPH, SK (corresponding author), THOMAS JEFFERSON UNIV,SCH MED,DEPT PATHOL & CELL BIOL,RM 230A JAH,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.		Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA-07186] Funding Source: Medline; NIDDK NIH HHS [DK-38422, DK-34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422, R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FONYO A, 1978, J BIOENERG BIOMEMBR, V10, P171, DOI 10.1007/BF00743106; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HILLY M, 1993, J BIOL CHEM, V268, P16488; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PIETRI F, 1990, J BIOL CHEM, V265, P17478; POITRAS M, 1993, J BIOL CHEM, V268, P24078; PRUIJN FB, 1990, BIOCHEM PHARMACOL, V40, P1947, DOI 10.1016/0006-2952(90)90223-8; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKETERA K, 1993, ANAL CHEM, V65, P3644; TANAKA Y, 1994, J BIOL CHEM, V269, P11247; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B	46	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3588	3593		10.1074/jbc.270.8.3588	http://dx.doi.org/10.1074/jbc.270.8.3588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533153	hybrid			2022-12-25	WOS:A1995QH68800022
J	TEWARI, M; DIXIT, VM				TEWARI, M; DIXIT, VM			FAS-INDUCED AND TUMOR NECROSIS FACTOR-INDUCED APOPTOSIS IS INHIBITED BY THE POXVIRUS CRMA GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; PROGRAMMED CELL-DEATH; MONOCLONAL-ANTIBODY; CYTO-TOXICITY; C-ELEGANS; PROTEASE; ANTIGEN; PROTECTION; INDUCTION; RECEPTOR	crmA is a cowpox virus gene that encodes a protease inhibitor of the serpin family, The only reported target for the CrmA protein is the cysteine protease interleukin-1 beta converting enzyme (ICE). ICE, by virtue of its homology to the Caenorhabditis elegans cell death protein Ced-3, has been suggested to play a fundamentally important role in mammalian apoptosis. We hypothe sized that a function of crmA may be to inhibit cell death, since a major mechanism of viral clearance is the immune system-mediated induction of apoptosis of infected cells. The tumor necrosis factor receptor and the Fas antigen are two cytokine receptors which, by engaging and activating the death pathway, can eliminate virus-infected cells. Remarkably, crmA was found to be an exceptionally potent inhibitor of apoptosis induced by both these receptors, capable of blocking the cell death program even at pharmacological doses of the death stimulus. Therefore, an important new function for crmA is the inhibition of cytokine-induced apoptosis. Further, the data suggest that a protease, either ICE or a related crmA-inhibitable protein, is a component of the Fas- and tumor necrosis factor-induced cell death pathways.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,GRAD PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL CANCER INSTITUTE [R01CA061348] Funding Source: NIH RePORTER; NCI NIH HHS [CA61348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DUKE RC, 1991, APOPTOSIS MOL BASIS, P209; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GOODING LR, 1992, CELL, V71, P5; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1991, J BIOL CHEM, V266, P20960; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; STALDER T, 1994, J IMMUNOL, V152, P1127; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG GHW, 1992, TUMOR NECROSIS FACTO, P371; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	597	631	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3255	3260		10.1074/jbc.270.7.3255	http://dx.doi.org/10.1074/jbc.270.7.3255			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531702	hybrid			2022-12-25	WOS:A1995QG47100056
J	JACKSON, A; TARANTINI, F; GAMBLE, S; FRIEDMAN, S; MACIAG, T				JACKSON, A; TARANTINI, F; GAMBLE, S; FRIEDMAN, S; MACIAG, T			THE RELEASE OF FIBROBLAST GROWTH-FACTOR-I FROM NIH 3T3 CELLS IN RESPONSE TO TEMPERATURE INVOLVES THE FUNCTION OF CYSTEINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-I; GOLGI-COMPLEX; PROTEINS; SEQUENCE	Fibroblast growth factor (FGF)-1 is released from NIH 3T3 cells in response to heat shock as a biologically inactive protein that is unable to bind heparin and requires activation by (NH4)(2)SO4 to generate a biologically active extracellular heparin-binding growth factor (Jackson, A., Friedman, S., Zhan, X., Engleka, K. A., Forough, R., and Maciag, T. (1992) Proc. Natl. Acad. Sci. USA 89, 10691-10695). To further study the mechanism of FGF-1 release in response to heat shock (42 degrees C), we examined the kinetics of FGF-1 release from FGF-1-transfected NIH 3T3 cells and observed that the cells require at least 1 h of exposure to heat shock conditions for the release of FGF-1, Interestingly, agents that interfere with the function of the endoplasmic reticulum-Golgi apparatus, exocytosis, and the multidrug resistance pathway (brefelden A, methylamine, and verapamil, respectively) do not inhibit the release of FGF-1 in response to temperature; rather, they exaggerate the release of FGF-1. Because immunoblot analysis of FGF-1 in the conditioned medium of heat-shocked NM 3T3 cells revealed the presence of a minor band with an apparent molecular weight of a FGF-1 homodimer and because we have previously shown that FGF-1, but not FGF-2, is able to form a homodimer in response to chemical oxidation by CuCl2 (Engleka, K. A., and Maciag, T. (1992) J. Biol. Chem. 267, 11307-11315), we examined whether reducing agents would substitute for (NH4)(2)SO4 and activate extracellular FGF-1. Indeed, dithiothreitol and reduced glutathione are able to individually generate a FGF-1 monomer as a heparin-binding protein from the conditioned medium of heat-shocked NM 3T3 cell transfectants. To confirm that cysteine residues are involved in the release of FGF-1 in response to temperature, we used mutagenesis to prepare a human FGF-1 Cys-free mutant in which Cys(30), Cys(97), and Cys(131) were converted to serine. Analysis of the release of the FGF-1 Cys-free mutant in NM 3T3 cells transfected with the FGF-1 Cys-free mutant demonstrated that the FGF-1 Cys-free mutant is not released into the conditioned medium in response to temperature. Interestingly, exposure of the NM 3T3 cell FGF-1 Cys-free transfectants to brefelden A followed by heat shock also demonstrated the absence of the extracellular FGF-1 Cys-free mutant, Finally, ion-exchange and reverse-phase chromatographies of heat-shocked conditioned medium analyzed by FGF-1 immunoblot analysis were able to resolve FGF-1 as a homodimer under nonreducing conditions and as a monomer under reducing conditions. These data demonstrate that FGF-1 utilizes cysteine residues as an important component of its release from NM 3T3 cells in vitro in response to temperature and exits the cell as a biologically inactive homodimer with reduced heparin affinity that requires activation by reducing agents to generate heparin binding and biological activities.	AMER RED CROSS,HOLLAND LAB,DEPT BIOL MOLEC,ROCKVILLE,MD 20855	American Red Cross			Tarantini, Francesca/I-6332-2012	TARANTINI, FRANCESCA/0000-0002-1390-2965	NHLBI NIH HHS [HL44336, T32-HL07698, HL32348] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, T32HL007698, P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DORVAL G, 1975, J IMMUNOL METHODS, V7, P237, DOI 10.1016/0022-1759(75)90021-6; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; LIPPINCOTTSCHWARTZ, 1989, CELL, V56, P801; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425	14	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					33	36		10.1074/jbc.270.1.33	http://dx.doi.org/10.1074/jbc.270.1.33			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529229	Green Submitted, hybrid			2022-12-25	WOS:A1995QA28700009
J	WEI, Y; WALTZ, DA; RAO, N; DRUMMOND, RJ; ROSENBERG, S; CHAPMAN, HA				WEI, Y; WALTZ, DA; RAO, N; DRUMMOND, RJ; ROSENBERG, S; CHAPMAN, HA			IDENTIFICATION OF THE UROKINASE RECEPTOR AS ALL ADHESION RECEPTOR FOR VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CELL-ADHESION; GROWTH-FACTOR; HUMAN-BREAST; LIGAND-BINDING; EXPRESSION; MEMBRANE; LOCALIZATION; INTEGRIN; SURFACE	Urokinase receptors, expressed on surfaces of many cell types, focus to the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. We now report that the urokinase receptor (uPAR) is also a high affinity (K-d < 30 nar) receptor for vitronectin. Recombinant uPAR binds vitronectin in the absence of urokinase, but vitronectin binding is promoted by concurrent receptor binding of either urokinase or fragments thereof containing its uPAR binding domain. Stable epithelial cell transfectants expressing membrane-anchored uPAR, but not cells expressing soluble uPAR,become strongly adhesive with altered morphology in the absence of urokinase. These observations identify a new class of vitronectin receptor and imply a duality in function for the receptor that intrinsically links matrix adhesion to regulation of protease activity. Increases in urokinase receptor expression known to be associated with cellular activation and malignant transformation could modulate cellular trafficking and function by promoting attachment to vitronectin.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV RESP, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DIV BIOL SCI, PHYSIOL PROGRAM, BOSTON, MA 02115 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Novartis					NHLBI NIH HHS [HL44712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; CHAPMAN HA, 1990, AM J PHYSIOL, V259, pL432, DOI 10.1152/ajplung.1990.259.6.L432; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JANKUN J, 1993, J CELL BIOCHEM, V53, P135, DOI 10.1002/jcb.240530206; KAUFMAN SE, 1993, ANAL BIOCHEM, V211, P261, DOI 10.1006/abio.1993.1267; KORETZ K, 1993, EUR J CANCER, V29A, P1184; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LORIDONROSA B, 1988, AM J CLIN PATHOL, V90, P7, DOI 10.1093/ajcp/90.1.7; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; PARANJPE M, 1980, LIFE SCI, V26, P1223, DOI 10.1016/0024-3205(80)90067-3; PEDERSEN H, 1994, CANCER RES, V54, P120; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PLOUG M, 1992, EUR J BIOCHEM, V208, P397, DOI 10.1111/j.1432-1033.1992.tb17200.x; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; PYKE C, 1991, AM J PATHOL, V138, P1059; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; REICH E, 1978, BIOL MARKERS NEOPLAS, P491; REILLY JT, 1988, J CLIN PATHOL, V41, P1269, DOI 10.1136/jcp.41.12.1269; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHI GP, 1992, J BIOL CHEM, V267, P7258; SIER CFM, 1992, CANCER RES, V33, pA386; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUMIYOSHI K, 1991, THROMB RES, V63, P59, DOI 10.1016/0049-3848(91)90270-7; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	60	548	565	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32380	32388						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528215				2022-12-25	WOS:A1994PX30400056
J	CHIGNOLA, R; ANSELMI, C; SERRA, MD; FRANCESCHI, A; FRACASSO, G; PASTI, M; CHIESA, E; LORD, JM; TRIDENTE, G; COLOMBATTI, M				CHIGNOLA, R; ANSELMI, C; SERRA, MD; FRANCESCHI, A; FRACASSO, G; PASTI, M; CHIESA, E; LORD, JM; TRIDENTE, G; COLOMBATTI, M			SELF-POTENTIATION OF LIGAND-TOXIN CONJUGATES CONTAINING RICIN-A CHAIN FUSED WITH VIRAL STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOMATITIS-VIRUS GLYCOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; POSITIVELY CHARGED RESIDUES; SMALL UNILAMELLAR VESICLES; DIPHTHERIA-TOXIN; A-CHAIN; PH; PROTEIN; IMMUNOTOXINS; FUSION	A chimeric protein was obtained by fusing together the ricin toxin A chain (RTA) gene and a DNA fragment encoding the N terminus of protein G of the vesicular stomatitis virus. Chimeric RTA (cRTA) retained full enzymic activity in a cell-free assay, but was 10-fold less toxic against human leukemic cells than either native RTA (nRTA) or unmodified recombinant RTA (rRTA). However, conjugates made with cRTA and human transferrin (Tfn) showed 10-20 fold greater cell killing efficacy than Tfn-nRTA or Tfn-rRTA conjugates despite equivalent binding of the three conjugates to target tumor cells. As a consequence, by fusion of the KFT25 peptide to the RTA sequence, the specificity factor (i.e. the ratio between nonspecific and specific cytotoxicity) of Tfn-cRTA was increased 90-240 times with respect to those of Tfn-nRTA and Tfn-rRTA. cRTA interacted with phospholipid vesicles with 15-fold faster kinetics than nRTA at acidic pH. Taken together, our results suggest that the ability of vesicular stomatitis virus protein G to interact with cell membranes can be transferred to RTA to facilitate its translocation to the cell cytosol. Our strategy may serve as a general approach for potentiating the cytotoxic efficacy of antitumor immunotoxins.	UNIV VERONA,POLICLIN BORGO ROMA,IST IMMUNOL & MALATTIE INFETTIVE,I-37134 VERONA,ITALY; CNR,CTR FIS STATI AGGREGATI,I-38050 TRENT,ITALY; UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Consiglio Nazionale delle Ricerche (CNR); University of Warwick			Fracasso, Giulio/O-3955-2019; Serra, Mauro Dalla/AAK-9299-2021; Fracasso, Giulio/E-1271-2013; Serra, Mauro Dalla/A-6218-2010	Fracasso, Giulio/0000-0003-3024-0307; Serra, Mauro Dalla/0000-0003-1048-2739; Fracasso, Giulio/0000-0003-3024-0307; Serra, Mauro Dalla/0000-0003-1048-2739; CHIGNOLA, Roberto/0000-0001-6981-6890				BRINKMANN U, 1994, BBA-REV CANCER, V1198, P27, DOI 10.1016/0304-419X(94)90004-3; CABIAUX V, 1984, BIOCHIM BIOPHYS ACTA, V775, P31, DOI 10.1016/0005-2736(84)90231-1; CANDIANI C, 1992, CANCER RES, V52, P623; CHIGNOLA R, 1994, INT J CANCER, V57, P268, DOI 10.1002/ijc.2910570223; CHIGNOLA R, 1990, INT J CANCER, V46, P1117, DOI 10.1002/ijc.2910460628; CHIGNOLA R, 1994, J IMMUNOL, V152, P2333; COBB PW, 1992, SEMIN HEMATOL, V29, P6; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DALLASERRA M, 1993, LIFE SCI ADV BIOPHYS, V12, P109; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; EIDELMAN O, 1984, J BIOL CHEM, V259, P4622; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; ESWORTHY RS, 1984, J BIOL CHEM, V259, P1496; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FRANCESCHI A, 1994, EUR J BIOCHEM, V219, P469, DOI 10.1111/j.1432-1033.1994.tb19961.x; FULTON RJ, 1986, J BIOL CHEM, V261, P5314; ITTELSON TR, 1973, NATURE, V242, P330, DOI 10.1038/242330b0; JANSEN FK, 1992, J BIOL CHEM, V267, P12577; JANSEN FK, 1982, IMMUNOL REV, V62, P185, DOI 10.1111/j.1600-065X.1982.tb00394.x; JOHNSON VG, 1989, J NEUROSURG, V70, P240, DOI 10.3171/jns.1989.70.2.0240; KLAPPE K, 1986, BIOCHEMISTRY-US, V25, P8252, DOI 10.1021/bi00373a019; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKE DW, 1992, 3RD INT S IMM ORL, P124; MARSH JW, 1988, J IMMUNOL, V140, P3674; MASSARI S, 1986, CHEM PHYS LIPIDS, V39, P203, DOI 10.1016/0009-3084(86)90011-3; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; PAPINI E, 1987, EUR J BIOCHEM, V169, P629, DOI 10.1111/j.1432-1033.1987.tb13654.x; PATTUS F, 1983, BIOCHEMISTRY-US, V22, P5698, DOI 10.1021/bi00294a003; SCHILD HO, 1957, PHARMACOL REV, V9, P242; SCHLEGEL R, 1984, J BIOL CHEM, V259, P4691; SCHLEGEL R, 1985, J VIROL, V53, P319, DOI 10.1128/JVI.53.1.319-323.1985; STEUBER D, 1984, EMBO J, V3, P3143; SUEMAGA M, 1989, BIOCHIM BIOPHYS ACTA, V981, P143; UTSUMI T, 1989, FEBS LETT, V242, P255, DOI 10.1016/0014-5793(89)80480-6; UTSUMI T, 1984, BIOCHIM BIOPHYS ACTA, V772, P202, DOI 10.1016/0005-2736(84)90045-2; VITETTA ES, 1993, IMMUNOL TODAY, V14, P252, DOI 10.1016/0167-5699(93)90041-I; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WALES R, 1993, J BIOL CHEM, V268, P23986; YOULE RJ, 1987, IMMUNOCONJUGATES ANT, P153	42	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23345	23351		10.1074/jbc.270.40.23345	http://dx.doi.org/10.1074/jbc.270.40.23345			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559491	hybrid			2022-12-25	WOS:A1995RY90900020
J	KEYVANIAMINEH, H; DIOURI, M; GUILLEMETTE, JG; WEBER, JM				KEYVANIAMINEH, H; DIOURI, M; GUILLEMETTE, JG; WEBER, JM			ELECTROPHORETIC AND SPECTRAL CHARACTERIZATION OF WILD-TYPE AND MUTANT ADENOVIRUS PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SECONDARY STRUCTURE; GLOBULAR-PROTEINS; CATHEPSIN-B; PREDICTION; ACTINIDIN; PROFILES; PAPAIN	The P137L mutation in the adenovirus type 2 protease results in a temperature sensitive protein-trafficking phenotype expressed during infection but not in vitro. Homology-derived secondary structure prediction placed the mutation within an externally disposed loop. Circular dichroism and urea gradient gel electrophoresis suggested that, unlike other thiol proteases, the Ad2 protease is comprised of a single conformational domain. The -0.32-kcal difference in the free energy of folding and the temperature-independent CD spectra of the mutant and wild type enzymes point to a very subtle structural change as the cause of the in vivo phenotype.	UNIV SHERBROOKE, FAC MED, DEPT MICROBIOL, SHERBROOKE, PQ J1H 5N4, CANADA	University of Sherbrooke				Keyvani, Hossein/0000-0002-6528-7861				ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Creighton T E, 1986, Methods Enzymol, V131, P156; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; DUFOUR E, 1988, BIOCHIMIE, V70, P1335, DOI 10.1016/0300-9084(88)90004-1; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; HANNAN C, 1983, INTERVIROLOGY, V19, P213, DOI 10.1159/000149363; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LIANG YK, 1983, J MOL BIOL, V167, P217, DOI 10.1016/S0022-2836(83)80044-8; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; PALUKA AA, 1989, ANNU REV GENET, V23, P289; PETTY KJ, 1994, CURRENT PROTOCOLS MO, V2; RANCOURT C, 1995, VIROLOGY, V209, P167, DOI 10.1006/viro.1995.1240; RANCOURT C, 1994, P NATL ACAD SCI USA, V91, P844, DOI 10.1073/pnas.91.3.844; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; TIHANYI K, 1993, J BIOL CHEM, V268, P1780; WEBER JM, 1994, METHOD ENZYMOL, V244, P595; WEBER JM, 1995, CURR TOP MICROBIOL I, V199, P277; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	29	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23250	23253		10.1074/jbc.270.40.23250	http://dx.doi.org/10.1074/jbc.270.40.23250			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559476	hybrid			2022-12-25	WOS:A1995RY90900005
J	XU, HX; GREENGARD, P; GANDY, S				XU, HX; GREENGARD, P; GANDY, S			REGULATED FORMATION OF GOLGI SECRETORY VESICLES CONTAINING ALZHEIMER BETA-AMYLOID PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-C; PHOSPHORYLATION; CLEAVAGE; RECEPTOR; ABSENCE; NETWORK	Phorbol esters, activators of protein kinase C (PKC), regulate the relative utilization of alternative processing pathways for the Alzheimer beta-amyloid precursor protein (beta-APP) in intact cells, increasing the production of nonamyloidogenic soluble beta-APP (s beta-APP) and decreasing that of neurotoxic beta-amyloid (A beta) peptide. The molecular and cellular bases of PKC-regulated beta-APP cleavage are poorly understood. Here we demonstrate in a reconstituted cell-free system that activation of endogenous PKC increases formation from the trans-Golgi network of secretory vesicles containing beta-APP and that this effect can be mimicked by purified PKC. The results demonstrate directly that PKC is involved in regulation of secretory vesicle formation and provide a mechanism by which PKC may reduce the formation of the A beta peptide characteristic of Alzheimer disease.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,ALZHEIMERS RES LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Cornell University; Rockefeller University			Xu, Huaxi/AAV-7177-2021		NIA NIH HHS [AG09464, AG11508, AG10491] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R55AG011508, P01AG009464, R01AG011508, P01AG010491] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; FELSENSTEIN KM, 1994, NEUROSCI LETT, V174, P173, DOI 10.1016/0304-3940(94)90014-0; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P885; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUNG AY, 1993, J BIOL CHEM, V268, P22959; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; OHASHI M, 1994, J BIOL CHEM, V269, P24897; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169	22	151	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23243	23245		10.1074/jbc.270.40.23243	http://dx.doi.org/10.1074/jbc.270.40.23243			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559474	hybrid			2022-12-25	WOS:A1995RY90900003
J	HAYRY, P; MYLLARNIEMI, M; AAVIK, E; ALATALO, S; AHO, P; YILMAZ, S; RAISANENSOKOLOWSKI, A; COZZONE, G; JAMESON, BA; BASERGA, R				HAYRY, P; MYLLARNIEMI, M; AAVIK, E; ALATALO, S; AHO, P; YILMAZ, S; RAISANENSOKOLOWSKI, A; COZZONE, G; JAMESON, BA; BASERGA, R			STABILE D-PEPTIDE ANALOG OF INSULIN-LIKE GROWTH-FACTOR-I INHIBITS SMOOTH-MUSCLE CELL-PROLIFERATION AFTER CAROTID BALLOONING INJURY IN THE RAT	FASEB JOURNAL			English	Article						RESTENOSIS; IGF-I ANALOG; RNA EXTRACTION; ENDOTHELIAL DENUDATION; TRIATED THYMIDINE; CAROTID DENUDATION	I MESSENGER-RNA; ARTERIAL INJURY; VASCULAR INJURY; ANGIOPLASTY; DENUDATION; CULTURES; ANTIBODY; GENE	Restenosis after angioplasty is believed to result from stimulation of smooth muscle cells (SMC) by various growth-promoting factors as a consequence of endothelial injury. In this study we have tested the hypothesis that insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) interaction is a rate-limiting step for SMC replication by blocking this interaction with a synthetic D-amino acid peptide structurally resembling the D-domain of IGF-1. After rat carotid artery denudation, semiquantitative PCR analysis demonstrated a significant elevation of IGF-1, platelet-derived growth factor B, transforming growth factor pi, and epidermal growth factor mRNAs 10 days after endothelial injury, concomitantly with the induction of intimal SMC proliferation and intimal thickening. Administration of 10-30 mu g . kg-1 . day-1 of D-analog of IGF-1, devoid of proteolytic degradation in body fluids, reduced intimal SMC replication by 60-70%, The peptide also inhibited [H-3]TdR incorporation and [H-3]glycine incorporation in cultured SMCs by 60-80%, whereas a ''scrambled'' control peptide consisting of the same amino acids had no effect. The results suggest that IGF-1/IGF-1R interaction is a rate-limiting step for SMC replication. Blocking of this interaction with stabile D-peptide analog of IGF-1 at the level of IGF-1R may offer an entirely new approach for the prophylaxis and treatment of restenosis after cardiac revascularization procedures.	HELSINKI UNIV HOSP,HELSINKI,FINLAND; RAGGIO ITALGENE,ROME,ITALY; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	University of Helsinki; Helsinki University Central Hospital; Jefferson University	HAYRY, P (corresponding author), HELSINKI UNIV,TRANSPLANTAT LAB,POB 21,HAARTMANINKATU 3,SF-00014 HELSINKI,FINLAND.		Räisänen-Sokolowski, Anne/AAD-7005-2021	Räisänen-Sokolowski, Anne/0000-0002-2154-7377; Myllarniemi, L Marjukka/0000-0001-9343-0867	NIGMS NIH HHS [GM 33694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BRADY L, 1994, NATURE, V368, P692, DOI 10.1038/368692a0; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CERCEK B, 1991, AM J CARDIOL, V63, pC24; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; CLEMMONS DR, 1984, J CLIN ENDOCR METAB, V58, P850, DOI 10.1210/jcem-58-5-850; CLOWES AW, 1983, LAB INVEST, V49, P327; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; DIGLIO CA, 1988, TISSUE CELL, V20, P477, DOI 10.1016/0040-8166(88)90051-1; EMANUELSSON H, 1995, CIRCULATION, V91, P1689, DOI 10.1161/01.CIR.91.6.1689; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; HAYRY P, 1993, FASEB J, V7, P1055, DOI 10.1096/fasebj.7.11.8370476; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; HOWELL MH, 1993, CLIN SCI, V85, P183, DOI 10.1042/cs0850183; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; KHORSANDI M, 1992, ATHEROSCLEROSIS, V93, P115, DOI 10.1016/0021-9150(92)90205-U; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MACLEOD DC, 1994, J AM COLL CARDIOL, V23, P59, DOI 10.1016/0735-1097(94)90502-9; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MIURA M, 1994, CANCER RES, V54, P2472; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; ROSS R, 1991, TRENDS CARDIOVAS MED, V1, P277, DOI 10.1016/1050-1738(91)90043-E; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; THYBERG J, 1983, DIFFERENTIATION, V25, P156; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966	31	87	97	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1995	9	13					1336	1344						9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557024				2022-12-25	WOS:A1995TA37000013
J	DOBASHI, Y; KUDOH, T; MATSUMINE, A; TOYOSHIMA, K; AKIYAMA, T				DOBASHI, Y; KUDOH, T; MATSUMINE, A; TOYOSHIMA, K; AKIYAMA, T			CONSTITUTIVE OVEREXPRESSION OF CDK2 INHIBITS NEURONAL DIFFERENTIATION OF RAT PHEOCHROMOCYTOMA PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; D-TYPE CYCLINS; NERVE GROWTH-FACTOR; G1 CYCLIN; DEPENDENT KINASES; PROTEIN-KINASE; E1A PROTEINS; FIBROBLASTS; PHOSPHORYLATION; G(1)	Changes in the levels of cyclins A, D, and E, p21, and cyclin-dependent kinase 2 (CDK2) were examined in rat pheochromocytoma PC12 cells during neuronal differentiation induced by nerve growth factor (NGF), Expression of cyclin A decreased to an undetectable level after 5 days of exposure to NGF, while expression of CDK2 decreased gradually after day 3. In contrast, the levels of cyclins D1 and E increased gradually through day 10, yet the amount of cyclin E associated with CDK2 decreased concomitant with a decrease in the CDK2 protein level, p21 expression increased gradually after day 7, while the level of CDK2-associated p21 remained unchanged. When human cDNAs encoding cyclins and CDK2 were introduced into PC12 cells, only CDK2 overexpression inhibited NGF-induced differentiation. The cell lines overexpressing CDK2 showed stable and high levels of CDK2 kinase activity during differentiation, whereas parental and vector-transfected cell lines displayed a marked decline in CDK2 kinase activity 1 day after NGF treatment. In cell lines overexpressing cyclins A, D, and E, this reduction of the kinase activity was not apparent until day 3. These results suggest that downregulation of CDK2 activity is a crucial event for the neuronal differentiation of PC12 cells.	OSAKA UNIV, MICROBIAL DIS RES INST, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN; CTR ADULT DIS, OSAKA 537, JAPAN	Osaka University				Dobashi, Yoh/0000-0003-0507-3332				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURGER C, 1994, J CELL SCI, V107, P2047; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMJANOV I, 1994, BIOCHEM BIOPH RES CO, V201, P994, DOI 10.1006/bbrc.1994.1800; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIESS M, 1995, ONCOGENE, V10, P159; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARUYAMA K, 1987, ONCOGENE, V1, P361; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAMARU T, 1993, NEUROSCI LETT, V153, P169, DOI 10.1016/0304-3940(93)90314-B; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	56	93	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23031	23037		10.1074/jbc.270.39.23031	http://dx.doi.org/10.1074/jbc.270.39.23031			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559442	hybrid			2022-12-25	WOS:A1995RY05400062
J	HOULE, MG; KAHN, RA; NACCACHE, PH; BOURGOIN, S				HOULE, MG; KAHN, RA; NACCACHE, PH; BOURGOIN, S			ADP-RIBOSYLATION FACTOR TRANSLOCATION CORRELATES WITH POTENTIATION OF GTP-GAMMA-S-STIMULATED PHOSPHOLIPASE-D ACTIVITY IN MEMBRANE-FRACTIONS OF HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; HUMAN NEUTROPHILS; BINDING-PROTEIN; PHORBOL ESTERS; MECHANISMS; CALCIUM; ARF; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROL; GRANULOCYTES	Phospholipase D (PLD) activation by guanine nucleotides requires protein cofactors from both the membrane and the cytosol. The small GTP-binding protein ADP-ribosylation factor (ARF) has been established as one important component of PLD activation. By stimulating HL-60 cells with various agonists and then isolating the membrane fraction and assaying PLD activity in the presence and absence of GTP gamma S, we observed that fMet-Leu-Phe (fMLP) and phorbol esters induced a potentiation of GTP gamma S-stimulated PLD activity in the membrane fractions of these cells. Inactive phorbol esters induced no such potentiation. Both fMLP and active phorbol esters induced a 2-3-fold increase in GTP gamma S-stimulated PLD in HL-60 membranes, Membranes derived from stimulated HL-60 cells contained 60-70% more ARF as compared with membranes derived from control cells. Membrane contents of ARF were assessed by Western blotting with the anti-ARF monoclonal antibody 1D9 followed by densitometric evaluation. Therefore, ARF translocation correlates with the potentiation of the GTP gamma S-stimulated PLD activity. The effect on PLD activity and ARF membrane content achieved through fMLP stimulation was greatly enhanced by prior treatment of the cells with cytochalasin B. Membranes derived from control and fMLP-stimulated cells were assayed for PLD activity in the presence of exogenous ARF and a 50-kDa fraction known to contain elements implicated in PLD activation. The ability of ARF and the 50-kDa fraction to enhance GTP gamma S-sensitive PLD activity was significantly reduced when the membranes were derived from fMLP-stimulated cells. The data indicate that, in addition to ARF, elements of the 50-kDa PLD-inducing factors were likely already translocated to the membranes upon stimulation. We propose that ARF, upon stimulation with agonists such as fMLP or phorbol esters, is translocated to the membrane and in concert with other protein components of the 50-kDa fraction enhances PLD activity.	CHU LAVAL,CTR RECH,CTR RECH RHUMATOL & IMMUNOL,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT PHYSIOL,ST FOY,PQ G1V 4G2,CANADA; NCI,MED CHEM LAB,BETHESDA,MD 20892	Laval University; Laval University; Laval University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601; Bourgoin, Sylvain/0000-0001-9779-0368				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOURGOIN S, 1992, CELL SIGNAL, V4, P487; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; HA KS, 1993, J BIOL CHEM, V268, P10534; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KUSNER DJ, 1994, BIOCHEM J, V304, P485, DOI 10.1042/bj3040485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1993, J LEUKOCYTE BIOL, V53, P630, DOI 10.1002/jlb.53.6.630; NACCACHE PH, 1993, LAB INVEST, V69, P19; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, J BIOL CHEM, V263, P12472; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; TERUI T, 1994, J BIOL CHEM, V269, P28130; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WHATMORE J, 1994, FEBS LETT, V352, P113, DOI 10.1016/0014-5793(94)00930-9; ZHANG J, 1993, J BIOL CHEM, V268, P22251	46	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22795	22800		10.1074/jbc.270.39.22795	http://dx.doi.org/10.1074/jbc.270.39.22795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559408	hybrid			2022-12-25	WOS:A1995RY05400028
J	ROSE, PM; FERNANDES, P; LYNCH, JS; FRAZIER, ST; FISHER, SM; KODUKULA, K; KIENZLE, B; SEETHALA, R				ROSE, PM; FERNANDES, P; LYNCH, JS; FRAZIER, ST; FISHER, SM; KODUKULA, K; KIENZLE, B; SEETHALA, R			CLONING AND FUNCTIONAL EXPRESSION OF A CDNA-ENCODING A HUMAN TYPE-2 NEUROPEPTIDE-Y RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; SUBTYPES; PROTEIN; GENE	Neuropeptide Y (NPY) is a 36-amino acid polypeptide that is widely distributed in the central nervous system and periphery. Pharmacological studies have suggested that there are at least three receptor subtypes, Y1, Y2, and Y3. Cloning of the Y1 subtype has been reported previously. Here we report the isolation by expression cloning of a cDNA encoding a human NPY receptor displaying a pharmacology typical of a Y2 receptor. COS-7 cells transfected with the cDNA express high affinity binding sites for NPY, peptide TY, and NPY13-36, whereas [Leu(31),pro(34)]NPY binds with lower affinity. The receptor is 381 amino acids in length and has seven putative transmembrane regions typical of G-protein-coupled receptors. Comparison of the amino acid sequence of this Y2 receptor to that of the human Y1 receptor indicates that the two receptors are 31% identical at the amino acid level. Northern blot analyses reveal a single 4-kilobase mRNA species and indicate that the messenger RNA is present in many areas of the central nervous system. NPY induced calcium mobilization and inhibited forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells that stably express the Y2 receptor cDNA, indicating that the recombinant Y2 receptor is functionally coupled to second messenger systems.	BRISTOL MYERS SQUIBB CO, DEPT METAB DIS, PRINCETON, NJ 08543 USA; BRISTOL MYERS SQUIBB CO, DEPT BIOMOLEC SCREENING, WALLINGFORD, CT 06492 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	ROSE, PM (corresponding author), BRISTOL MYERS SQUIBB CO, DEPT MICROBIAL MOLEC BIOL, BOX 4000, PRINCETON, NJ 08543 USA.							BALASUBRAMANIAM A, 1994, J MED CHEM, V37, P811, DOI 10.1021/jm00032a015; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Colmers W. F., 1993, BIOL NEUROPEPTIDE Y; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT Y, 1993, J NEUROSCI, V13, P73; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HAZLEWOOD RL, 1993, P SOC EXP BIOL MED, V202, P44; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10953; LYNCH JW, 1994, J BIOL CHEM, V269, P8226; MANSSON E, 1994, BIOCHEM BIOPH RES CO, V202, P1431, DOI 10.1006/bbrc.1994.2091; McCormack J.G., 1991, CELLULAR CALCIUM PRA; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHIGERI Y, 1992, BIOCHEM BIOPH RES CO, V187, P1565, DOI 10.1016/0006-291X(92)90481-Y; SHIGERI Y, 1994, J BIOL CHEM, V269, P8842; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; XIE GX, 1992, P NATL ACAD SCI USA, V89, P4124, DOI 10.1073/pnas.89.9.4124	27	237	245	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22661	22664		10.1074/jbc.270.39.22661	http://dx.doi.org/10.1074/jbc.270.39.22661			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559383	hybrid			2022-12-25	WOS:A1995RY05400003
J	HASE, CC; LEDAIN, AC; MARTINAC, B				HASE, CC; LEDAIN, AC; MARTINAC, B			PURIFICATION AND FUNCTIONAL RECONSTITUTION OF THE RECOMBINANT LARGE MECHANOSENSITIVE ION-CHANNEL (MSCL) OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; MEMBRANE PATCHES; CELLS; CLAMP	The large mechanosensitive ion channel (MscL) of Escherichia coli was expressed on a plasmid encoding MscL as a fusion protein with glutathione S-transferase in an Escherichia coli strain containing a disruption in the chromosomal mscL gene. After purification of the fusion protein using glutathione-coated beads, thrombin cleavage allowed recovery of the MscL protein. The purified protein was reconstituted into artificial liposomes and found to be fully functional when examined with the patch-clamp technique. The reconstituted recombinant MscL protein formed ion channels that exhibited characteristic conductance and pressure sensitivity and were blocked by the mechanosensitive ion channel inhibitor gadolinium. The recombinant MscL protein was also used to raise specific anti-MscL polyclonal antibodies which abolished channel activity when preincubated with the MscL protein.	UNIV WESTERN AUSTRALIA,DEPT PHARMACOL,NEDLANDS,WA 6907,AUSTRALIA	University of Western Australia			Martinac, Boris/A-7178-2018	Martinac, Boris/0000-0001-8422-7082				BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BUECHNER MJ, 1990, THESIS U WISCONSIN M; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; ERXLEBEN C, 1989, J GEN PHYSIOL, V94, P1071, DOI 10.1085/jgp.94.6.1071; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILL OP, 1994, NEWS PHYSIOL SCI, V9, P53; HAMILL OP, 1994, TRENDS NEUROSCI, V17, P439, DOI 10.1016/0166-2236(94)90125-2; HARLOW E, 1988, ANTIBODIES LABORATOR; Hase Claudia C., 1995, Biophysical Journal, V68, pA393; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MARTINAC B, 1992, ADV COMP ENV PHYSL, V10, P3; MARTINAC B, 1993, CRC THERMODYNAMICS M, P327; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; SACHS F, 1989, CRC CRIT R BIOMED EN, V16, P141; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sukharev Sergei I., 1994, Methods (Orlando), V6, P51, DOI 10.1006/meth.1994.1007; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; ZHOU XL, 1991, SCIENCE, V253, P1415, DOI 10.1126/science.1716786	22	161	170	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18329	18334		10.1074/jbc.270.31.18329	http://dx.doi.org/10.1074/jbc.270.31.18329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7543101	hybrid			2022-12-25	WOS:A1995RM64200030
J	KIRCHHOFF, S; KOROMILAS, AE; SCHAPER, F; GRASHOFF, M; SONENBERG, N; HAUSER, H				KIRCHHOFF, S; KOROMILAS, AE; SCHAPER, F; GRASHOFF, M; SONENBERG, N; HAUSER, H			IRF-1 INDUCED CELL-GROWTH INHIBITION AND INTERFERON INDUCTION REQUIRES THE ACTIVITY OF THE PROTEIN-KINASE PKR	ONCOGENE			English	Article						IRF-1; INTERFERON-BETA; PROLIFERATION; PROTEIN KINASE PKR; TUMOR SUPPRESSOR	REGULATORY FACTOR-I; IFN-INDUCIBLE GENES; CONSTITUTIVE EXPRESSION; TRANSCRIPTION FACTOR; BETA PROMOTERS; P68 KINASE; RESISTANCE; ELEMENTS; ACTIVATION; VIRUS	Expression of the tumor suppressor IRF-1 results in the inhibition of cell growth and transcriptional activation of the IFN-beta gene. IFN production is not responsible for the IRF-1 mediated cell growth inhibition. It is shown here that activation of IRF-1 causes induction of PKR expression, PKR is a serine/threonine kinase with tumor suppressor activity. IRF-1 mediated cell growth inhibition and IFN induction correlates with PKR expression. A catalytically inactive dominant negative PKR mutant abolishes both activities of IRF-1. These data demonstrate that the tumor suppressor activity of IRF-1 is mediated, at least in part, by PKR.	GESELL BIOTECHNOL FORSCH MBH,GENET EUKARYOTES,D-38124 BRAUNSCHWEIG,GERMANY; MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST MED RES,DEPT ONCOL & EXPTL MED,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	Gesellschaft fur Biotechnologische Forschung mbH; Lady Davis Institute; McGill University; McGill University; McGill University			Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOULTWOOD J, 1993, BLOOD, V82, P2611; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DAIGNEAULT L, 1992, NUCLEIC ACIDS RES, V20, P2749, DOI 10.1093/nar/20.11.2749; DINTER H, 1987, EMBO J, V6, P599, DOI 10.1002/j.1460-2075.1987.tb04796.x; DIRKS W, 1989, J INTERFERON RES, V9, P125, DOI 10.1089/jir.1989.9.125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HISCOTT J, 1989, J VIROL, V63, P2504; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; ICELY PL, 1991, J BIOL CHEM, V266, P16073; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LACOSTE J, 1990, J VIROL, V64, P4726, DOI 10.1128/JVI.64.10.4726-4734.1990; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; Sambrook J, 1989, MOL CLONING LABORATO; SEN GC, 1992, J BIOL CHEM, V267, P5017; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	44	107	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					439	445						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543195				2022-12-25	WOS:A1995RN53000003
J	POLLOCK, AS; SANTIESTEBAN, HL				POLLOCK, AS; SANTIESTEBAN, HL			CALBINDIN EXPRESSION IN RENAL TUBULAR EPITHELIAL-CELLS - ALTERED SODIUM-PHOSPHATE COTRANSPORT IN ASSOCIATION WITH CYTOSKELETAL REARRANGEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE INHIBITION; SIGNAL TRANSDUCTION; BINDING PROTEIN; ACTIN CYTOSKELETON; CALCIUM-TRANSPORT; KIDNEY-CELLS; OK CELLS; LINE; PHOSPHORYLATION; COTRANSPORT	Sodium-phosphate transport in the opossum kidney (OK) cell line was studied in an OK clonal cell line that was transfected with an episomal vector expressing high levels of rat calbindin (28 kDa). High level expression of calbindin buffered the influx of calcium induced by ionomycin by 53% and raised the basal intracellular calcium from 100 +/- 6 to 150 +/- 8 nM. The decrement in sodium phosphate uptake induced by parathyroid hormone or forskolin was identical in the two cell lines, However, phorbol esters (10(-10)-10(-7) M), which decreased sodium phosphate uptake in the parental OK line, increased it in the calbindin-expressing line. Similarly, the parental clone did not respond to phosphate deprivation, while the calbindin expressing clone did increase phosphate uptake in response to phosphate deprivation, In the calbindin-expressing cells, phorbol 12-myristate 13-acetate or low phosphate medium, which increased phosphate transport, produced actin filament aggregation, dissociation of the myristoylated alanine-rich C kinase substrate protein from sub-apical actin, and membrane-associated tyrosine phosphate staining, Agonists that reduced sodium phosphate uptake (cAMP, parathyroid hormone) did not affect these cellular features, The cytoskeletal rearrangement, redistribution of the myristoylated alanine-rich C kinase substrate protein, and membrane tyrosine phosphorylation are suggested to be involved in the events by which phosphate transport is increased in this cell line.	UNIV CALIF SAN FRANCISCO, DEPT MED, DIV NEPHROL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	POLLOCK, AS (corresponding author), VET AFFAIRS MED CTR, 111J, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007219, R01DK031398, R01DK037423] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37423, R01DK31398, 5T32 DK07219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; AHARONI D, 1993, ENDOCRINOLOGY, V133, P1426, DOI 10.1210/en.133.3.1426; BATINI C, 1993, NEUROREPORT, V4, P927, DOI 10.1097/00001756-199307000-00022; BIBER J, 1993, RENAL PHYSIOL BIOCH, V16, P37; BIBER J, 1988, AM J PHYSIOL, V256, pC155; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CAVERZASIO J, 1992, ENDOCRINOLOGY, V130, P373, DOI 10.1210/en.130.1.373; CHARD PS, 1993, J PHYSIOL-LONDON, V472, P341, DOI 10.1113/jphysiol.1993.sp019950; CHRISTAKOS S, 1992, J NUTR, V122, P678, DOI 10.1093/jn/122.suppl_3.678; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; CLUSTER M, 1994, AM J PHYSIOL, V266, pF767; COLLINS CA, 1991, METHOD ENZYMOL, V196, P246; DENNIS WW, 1992, HDB PHYSL 3; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; GOLIGORSKY MS, 1986, J MEMBRANE BIOL, V92, P151, DOI 10.1007/BF01870704; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANSCH E, 1993, PFLUG ARCH EUR J PHY, V422, P516, DOI 10.1007/BF00375080; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; LLEDO PM, 1992, NEURON, V9, P943, DOI 10.1016/0896-6273(92)90246-A; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MARJA JAH, 1990, CELL REGUL, V1, P921; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MATSUMOTO PS, 1993, AM J PHYSIOL, V264, pC246, DOI 10.1152/ajpcell.1993.264.1.C246; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MUFF R, 1992, ANNU REV PHYSIOL, V54, P67, DOI 10.1146/annurev.physiol.54.1.67; MUIR EM, 1993, CELL CALCIUM, V14, P349, DOI 10.1016/0143-4160(93)90055-B; Nelson W J, 1991, Semin Cell Biol, V2, P375; NEMERE I, 1992, MOL CELL ENDOCRINOL, V86, P83, DOI 10.1016/0303-7207(92)90178-9; NEMERE I, 1991, ENDOCRINOLOGY, V129, P2972, DOI 10.1210/endo-129-6-2972; NEMERE I, 1990, MINER ELECTROL METAB, V16, P109; OJAKIAN GK, 1992, J CELL SCI, V103, P677; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; QUAMME G, 1989, BIOCHIM BIOPHYS ACTA, V1013, P166, DOI 10.1016/0167-4889(89)90045-1; QUAMME G, 1994, BBA-MOL CELL RES, V1223, P107, DOI 10.1016/0167-4889(94)90079-5; QUAMME G, 1989, BIOCHEM BIOPH RES CO, V58, P951; RAYMOND JR, 1991, J BIOL CHEM, V266, P372; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; RESINER PD, 1992, FEBS LETT, V297, P127; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SEGAL JH, 1990, J CLIN INVEST, V86, P1442, DOI 10.1172/JCI114860; SONNENBERG J, 1984, ENDOCRINOLOGY, V115, P640, DOI 10.1210/endo-115-2-640; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; STEIN WD, 1992, J NUTR, V122, P651, DOI 10.1093/jn/122.suppl_3.651; SUZUKI M, 1993, J MEMBRANE BIOL, V134, P31; TREMBLAY L, 1992, BIOCHIM BIOPHYS ACTA, V1108, P183, DOI 10.1016/0005-2736(92)90024-G; VINAY P, 1981, AM J PHYSIOL, V241, pF403, DOI 10.1152/ajprenal.1981.241.4.F403; YAMAMOTO K, 1992, EXP CELL RES, V201, P55, DOI 10.1016/0014-4827(92)90347-B	56	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16291	16301		10.1074/jbc.270.27.16291	http://dx.doi.org/10.1074/jbc.270.27.16291			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7541797	hybrid			2022-12-25	WOS:A1995RH22600063
J	HEYWARD, SA; DUBOISSTRINGFELLOW, N; RAPOPORT, R; BAUTCH, VL				HEYWARD, SA; DUBOISSTRINGFELLOW, N; RAPOPORT, R; BAUTCH, VL			EXPRESSION AND INDUCIBILITY OF VASCULAR ADHESION RECEPTORS IN DEVELOPMENT	FASEB JOURNAL			English	Article						ENDOTHELIAL CELLS; CYSTIC EMBRYOID BODIES; MURINE DEVELOPMENT; BLOOD ISLANDS	TUMOR-NECROSIS-FACTOR; INTEGRIN VLA-4; LYMPHO-HEMATOPOIESIS; GENE-EXPRESSION; EMBRYOID BODIES; BINDING-PROTEIN; CELL-LINE; MOLECULE-1; INVITRO; MODEL	ICAM-1 and VCAM are cell adhesion receptors expressed on vascular endothelial cells, and their expression is up-regulated as part of the inflammatory response. Tumor-derived Py-4-1 cells were a source of murine endothelial cells, and they showed increased lymphocyte binding when incubated with TNF alpha. Py-4-1 cells stimulated with TNF alpha or LPS also had elevated levels of ICAM-1 and VCAM RNAs, with maximum levels at 2 h, Developmental expression of adhesion receptors was assayed in murine yolk sacs and in cystic embryoid bodies (CEBs) that differentiate in vitro from murine embryonic: stem cells, ICAM-1 and VCAM RNAs were expressed in unstimulated yolk sacs and CEB's. Expression was inducible in CEBs by exposure to LPS at ah developmental stages, beginning at day 6. The time course of RNA induction in CEBs was similar to that of the Py-4-1 endothelial cell line, ICAM-1 protein expression was localized to vascular and hematopoietic blood islands in the CEBs, These results show that embryonic cells respond to inflammatory mediators by up-regulating expression of vascular adhesion receptors, and they imply an early ontogeny for the endothelial cell signal transduction pathway necessary for leukocyte recruitment.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL47314] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARKIN S, 1991, BLOOD, V77, P948; BOYD AW, 1989, BLOOD, V73, P1896; BUTCHER EC, 1990, CELL, V67, P1033; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; FRIES JWU, 1993, AM J PATHOL, V143, P725; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; IZON DJ, 1989, CELL IMMUNOL, V124, P264, DOI 10.1016/0008-8749(89)90130-5; JAATTELA M, 1988, LAB INVEST, V58, P48; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MUNRO JM, 1993, EUR HEART J, V14, P72; OBESO J, 1990, LAB INVEST, V63, P259; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RISAU W, 1988, DEVELOPMENT, V102, P471; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; WANG R, 1992, DEVELOPMENT, V114, P303; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WILES MV, 1991, DEVELOPMENT, V111, P259; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YANAI N, 1994, BLOOD, V83, P2844, DOI 10.1182/blood.V83.10.2844.2844	34	21	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					956	962		10.1096/fasebj.9.10.7542216	http://dx.doi.org/10.1096/fasebj.9.10.7542216			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7542216	Green Submitted			2022-12-25	WOS:A1995RK89900018
J	ZWEIFACH, A; LEWIS, RS				ZWEIFACH, A; LEWIS, RS			SLOW CALCIUM-DEPENDENT INACTIVATION OF DEPLETION-ACTIVATED CALCIUM CURRENT - STORE-DEPENDENT AND STORE-INDEPENDENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; CYCLOSPORINE-A; LYMPHOCYTES-T; OKADAIC ACID; MAST-CELLS; ENTRY; INFLUX; PROTEIN; OSCILLATIONS; PHOSPHATASE	Feedback regulation of Ca2+ release-activated Ca2+ (CRAC) channels was studied in Jurkat leukemic T lymphocytes using whole cell recording: and [Ca2+](i) measurement techniques. CRAC channels were activated by passively depleting intracellular Ca2+ stores in the absence of extracellular Ca2+. Under conditions of moderate intracellular Ca2+ buffering, elevating [Ca2+](o) to 22 mM initiated an inward current through CRAC channels that declined slowly with a half-time of similar to 30 s. This slow inactivation was evoked by a rise in [Ca2+]i, as it was effectively suppressed by an elevated level of EGTA in the recording pipette that prevented increases in [Ca2+](i). Blockade of Ca2+ uptake into stores by thapsigargin with or without intracellular inositol 1,4,5-trisphosphate reduced the extent of slow inactivation by similar to 50%, indicating that store refilling normally contributes significantly to this process. The store-independent (thapsigargin-insensitive) portion of slow inactivation was largely prevented by the protein phosphatase inhibitor, okadaic acid, land by a structurally related compound, 1-norokadaone, but not by calyculin A nor by cyclosporin A and FK506 at concentrations that fully inhibit calcineurin (protein phosphatase 2B) in T cells. These results argue against the involvement of protein phosphatases 1, 2A, 2B, or 3 in store-independent inactivation, We conclude that calcium acts through at least two slow negative feedback pathways to inhibit CRAC channels. Slow feedback inhibition of CRAC current is likely to play important roles in controlling the duration and dynamic behavior of receptor-generated Ca2+ signals.			ZWEIFACH, A (corresponding author), STANFORD UNIV,SCH MED,BECKMAN CTR B003,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.			Lewis, Richard/0000-0002-6010-7403	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045374] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08568] Funding Source: Medline; NIGMS NIH HHS [GM47354, R01 GM045374] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS SD, 1993, J IMMUNOL, V150, P2620; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; XU X, 1994, J BIOL CHEM, V269, P12645; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1994, BIOPHYS J, V66, pA153; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	34	212	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14445	14451		10.1074/jbc.270.24.14445	http://dx.doi.org/10.1074/jbc.270.24.14445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540169	hybrid			2022-12-25	WOS:A1995RD45500034
J	BLUMEJENSEN, P; WERNSTEDT, C; HELDIN, CH; RONNSTRAND, L				BLUMEJENSEN, P; WERNSTEDT, C; HELDIN, CH; RONNSTRAND, L			IDENTIFICATION OF THE MAJOR PHOSPHORYLATION SITES FOR PROTEIN-KINASE-C IN KIT/STEM CELL FACTOR-RECEPTOR IN-VITRO AND IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TYROSINE KINASE; GROWTH-FACTOR; KIT-LIGAND; MAST-CELLS; W-LOCUS; V-KIT; ACTIVATION; ONCOGENE; EXPRESSION	The c-kit-encoded tyrosine kinase receptor for stem cell factor (Kit/SCFR) is crucial for the development of hematopoietic cells, melanoblasts, and germ cells. Ligand stimulation of Kit/SCFR leads to receptor dimerization and autophosphorylation on tyrosine residues. We recently showed, that protein kinase C (PKC) acts in an SCF-stimulated negative feedback loop, which controls Kit/SCFR tyrosine kinase activity and modulates the cellular responses to SCF (Blume Jensen, P., Siegbahn, A., Stabel, S., Heldin, C.-H., and Ronnstrand, L. (1993) EMBO J. 12, 4199-4209). We present here the identification of the major phosphorylation sites for PKC in Kit/SCFR. Two serine residues in the kinase insert, Ser-741 and Ser-746, are PKC-dependent phosphorylation sites in vivo and account for all phosphorylation by PKC in vitro. Together they comprise more than 60% of the total SCF-stimulated receptor phosphorylation in living cells and 85-90% of its phosphorylation in resting cells. Two additional serine residues, Ser-821 close to the major tyrosine autophosphorylation site in the kinase domain and Ser-959 in the carboxyl terminus are SCF-stimulated PKC-dependent phosphorylation sites. However, they are not phosphorylated directly by PKC-alpha in vitro. Both specific receptor tyrosine autophosphorylation and specific receptor-associated phosphatidylinositide 3'-kinase activity was increased approximately 2-fold in response to SCF in PAE cells stably expressing Kit/SCFR(S741A/S746A). Furthermore, the kinase activity of Kit/SCFR(S741A/S746A) toward an exogenous substrate was increased, which was reflected as a decreased K-m and an increased V-max, in accordance with the negative regulatory role of PKC on Kit/SCFR signaling.			BLUMEJENSEN, P (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,UPPSALA BRANCH,S-75124 UPPSALA,SWEDEN.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21798; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRIZZI MF, 1994, ONCOGENE, V9, P1583; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; GANDINO L, 1990, ONCOGENE, V5, P721; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; HERBST R, 1991, J BIOL CHEM, V266, P19908; HU ZB, 1994, BLOOD, V83, P2133; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IWASHITA S, 1992, CELL SIGNAL, V4, P123, DOI 10.1016/0898-6568(92)90076-K; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOIKE T, 1993, J IMMUNOL, V151, P359; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIU L, 1994, J BIOL CHEM, V269, P16774; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SERVE H, 1994, J BIOL CHEM, V269, P6026; SOZERI O, 1992, ONCOGENE, V7, P2259; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991; YEO EJ, 1994, J BIOL CHEM, V269, P27823	40	78	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14192	14200		10.1074/jbc.270.23.14192	http://dx.doi.org/10.1074/jbc.270.23.14192			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539802	hybrid			2022-12-25	WOS:A1995RC44800087
J	SCHWEMMLE, M; RICHTER, MF; HERRMANN, C; NASSAR, N; STAEHELI, P				SCHWEMMLE, M; RICHTER, MF; HERRMANN, C; NASSAR, N; STAEHELI, P			UNEXPECTED STRUCTURAL REQUIREMENTS FOR GTPASE ACTIVITY OF THE INTERFERON-INDUCED MXA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIVIRAL ACTIVITY; ESCHERICHIA-COLI; INFLUENZA-VIRUS; BINDING; LOCALIZATION; INHIBITION; MECHANISM	MxA is an interferon-induced 76-kDa GTPase that inhibits the multiplication of several RNA viruses. Deleting seven amino acids from the COOH terminus reduced the GTPase activity of purified MxA to 1.4%. MxA mutants with COOH-terminal deletions of 63 or more amino acids lost all ability to hydrolyze GTP and failed to bind guanine nucleotides. By contrast, an MxA deletion mutant consisting of 301 amino acids from the NH2 terminus and 87 amino acids from the COOH terminus retained about 9% of wild-type GTPase activity, underscoring the pivotal role of COOH-terminal sequences. Limited proteolysis of wild-type MxA with proteinase K resulted in two resistant polypeptides of 60 and 10 kDa, respectively, which copurified as a stable complex. The p60-p10 complex exhibited high GTPase activity, suggesting that it included all MxA domains required for this biochemical activity. Sequencing revealed that the NH2 terminus of the 60-kDa polypeptide mapped to leucine 41 and the NH2 terminus of the 10-kDa polypeptide to glutamine 564 of the MxA sequence. Based on these results we propose a model that suggests that the GTP-binding consensus element located in the NH2-terminal half of MxA is held in an active conformation by strong physical interactions with amino acids from the COOH-terminal region.	UNIV FREIBURG,INST MED MIKROBIOL & HYG,DEPT VIROL,VIROL ABT,D-79008 FREIBURG,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,STRUKT BIOL ABT,D-44139 DORTMUND,GERMANY	University of Freiburg; Max Planck Society				Richter, Marc Francois/0000-0002-0868-9127				BERNASCONI D, 1994, J INTERFERON CYTOKIN, V15, P47; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; GARBER EA, 1993, VIROLOGY, V194, P715, DOI 10.1006/viro.1993.1312; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; KRUNAK F, 1985, SCIENCE, V230, P32; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS H, 1995, IN PRESS VIROLOGY; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1991, J INTERFERON RES, V11, P215, DOI 10.1089/jir.1991.11.215; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCHNEIDERSCHAUL.S, 1994, J VIROL, V68, P6910; SCHNORR JJ, 1993, J VIROL, V67, P4760, DOI 10.1128/JVI.67.8.4760-4768.1993; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P246; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; ZURCHER T, 1992, EMBO J, V11, P1657, DOI 10.1002/j.1460-2075.1992.tb05212.x; ZURCHER T, 1992, J VIROL, V66, P5059	28	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13518	13523		10.1074/jbc.270.22.13518	http://dx.doi.org/10.1074/jbc.270.22.13518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539430	hybrid			2022-12-25	WOS:A1995RB43900083
J	PASYK, EA; FOSKETT, JK				PASYK, EA; FOSKETT, JK			MUTANT (DELTA-F508) CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CL- CHANNEL IS FUNCTIONAL WHEN RETAINED IN ENDOPLASMIC-RETICULUM OF MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHLORIDE CHANNELS; MOLECULAR-BASIS; CFTR; MUTATION; IDENTIFICATION; TRANSPORT; GENE; LOCALIZATION; MEMBRANE	Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a plasma membrane-localized chloride channel, Some mutations in CFTR, including one which affects most patients (Delta F508-CFTR), prevent CFTR from exiting the endoplasmic reticulum (ER) where it is synthesized. To examine whether normal and mutant CFTRs function as chloride channels when they reside in the ER, the patch clamp technique was used to measure currents in the outer membrane of nuclei isolated from mammalian cells expressing CFTR. Both Delta F508-CFTR as well as CFTR were revealed to function as cAMP-regulated chloride channels in native ER membrane. These results represent the first demonstrations of functional activity of CFTR in the biosynthetic pathway and suggest that conformational changes in the mutant protein, although recognized by ER-retention mechanisms, do not necessarily affect CFTR chloride channel properties, which may have implications for pathophysiology and therapeutic interventions in cystic fibrosis.	HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT PHYSIOL, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				[Anonymous], [No title captured]; BARASCH J, 1993, J CELL SCI, P229; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1992, EXP CELL RES, V201, P235, DOI 10.1016/0014-4827(92)90368-I; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FISCHER H, 1994, J GEN PHYSIOL, V104, P541, DOI 10.1085/jgp.104.3.541; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; PIND S, 1994, J BIOL CHEM, V269, P12784; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; Tsui L C, 1991, Adv Hum Genet, V20, P153; WARD CL, 1994, J BIOL CHEM, V269, P25710; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	39	122	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12347	12350		10.1074/jbc.270.21.12347	http://dx.doi.org/10.1074/jbc.270.21.12347			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7539001	hybrid			2022-12-25	WOS:A1995QZ71100006
J	SCHULTZ, JF; ARMANT, DR				SCHULTZ, JF; ARMANT, DR			BETA(1)-CLASS AND BETA(3)-CLASS INTEGRINS MEDIATE FIBRONECTIN-BINDING ACTIVITY AT THE SURFACE OF DEVELOPING MOUSE PERIIMPLANTATION BLASTOCYSTS - REGULATION BY LIGAND-INDUCED MOBILIZATION OF STORED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; PROTEOLYTIC FRAGMENTS; CELL-ADHESION; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; SYNTHETIC PEPTIDES; EMBRYO ATTACHMENT; OUTGROWTH INVITRO; GLYCOPROTEIN-IIIA; ENDOTHELIAL-CELLS	Implanting mouse blastocysts adhere through their abembryonic surfaces to the endometrial extracellular matrix. Because blastocysts cultured on fibronectin in vitro dissociate to form trophoblast outgrowths, it is unclear whether this adhesion is initially mediated by fibronectin receptors on the apical or basolateral surface of the trophectoderm. Intact blastocysts were examined in a ligand binding assay utilizing the fibronectin cell binding domain attached to fluorescent microspheres. Fibronectin binding activity on the apical surface of the trophectoderm was confined to the abembryonic pole of the blastocyst, where trophoblast differentiation initiates, and was regulated temporally in accordance with blastocyst outgrowth. Soluble fibronectin (IC50 = 0.2 mu M) or Gly-Arg-Gly-Asp- Ser-Pro, but not laminin, competitively inhibited fibronectin binding activity. Addition of antibodies against the alpha(v), alpha(5), beta(1), or beta(3) integrin subunits also inhibited binding activity. Blastocysts cultured in the absence of an adhesive substratum exhibited fibronectin binding activity only after exposure to immobilized or soluble ligand. Potentiation of binding activity by Ligand was unaffected by cycloheximide but was sensitive to brefeldin A inhibition of protein trafficking. These findings suggest that the interaction of fibronectin with the trophectoderm induces a translocation event that up-regulates fibronectin binding beta(1)- and beta(3)-class integrins on the apical surface.	WAYNE STATE UNIV, SCH MED, DEPT OBSTET & GYNECOL, CS MOTT CTR HUMAN GROWTH & DEV, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, DETROIT, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University				Armant, D. Randall/0000-0001-5904-9325	NICHD NIH HHS [HD25795] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025795] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Akiyama SK, 1992, TRENDS GLYCOSCI GLYC, V4, P346; ARMANT DR, 1986, DEV BIOL, V116, P519, DOI 10.1016/0012-1606(86)90152-1; ARMANT DR, 1991, BIOL REPROD, V45, P664, DOI 10.1095/biolreprod45.5.664; ARMANT DR, 1986, P NATL ACAD SCI USA, V83, P6751, DOI 10.1073/pnas.83.18.6751; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Bangs L B, 1990, Am Clin Lab, V9, P16; CARDARELLI PM, 1987, J CELL BIOL, V105, P499, DOI 10.1083/jcb.105.1.499; CARSON DD, 1988, DEV BIOL, V127, P368, DOI 10.1016/0012-1606(88)90323-5; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CHAVEZ DJ, 1984, ULTRASTRUCTURE REPRO, P247; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DESOUSA PA, 1993, DEVELOPMENT, V117, P1355; DICKSON AD, 1963, J REPROD FERTIL, V6, P465, DOI 10.1530/jrf.0.0060465; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUCIBELLA T, 1975, DEV BIOL, V45, P231, DOI 10.1016/0012-1606(75)90063-9; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ENDERS AC, 1981, CELLULAR MOL ASPECTS, P365; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FERREIRA OC, 1991, EXP CELL RES, V193, P20, DOI 10.1016/0014-4827(91)90533-Z; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GLASS RH, 1979, J EXP ZOOL, V208, P327, DOI 10.1002/jez.1402080309; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; GULINO D, 1990, J BIOL CHEM, V265, P9575; GWATKIN RBL, 1966, ANN NY ACAD SCI, V139, P79, DOI 10.1111/j.1749-6632.1966.tb41186.x; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIRBY DRS, 1967, J EMBRYOL EXP MORPH, V17, P527; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; Latimer Jean J, 1993, Mod Cell Biol, V12, P131; NADIJCKA M, 1974, J EMBRYOL EXP MORPH, V32, P675; NIEDER GL, 1990, BIOL REPROD, V43, P251, DOI 10.1095/biolreprod43.2.251; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RICHA J, 1985, DEV BIOL, V108, P513, DOI 10.1016/0012-1606(85)90054-5; RIDER V, 1992, DEV DYNAM, V195, P1, DOI 10.1002/aja.1001950102; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHINDLER J, 1981, DEV BIOL, V84, P332, DOI 10.1016/0012-1606(81)90401-2; SCHLAFKE S, 1975, BIOL REPROD, V12, P41, DOI 10.1095/biolreprod12.1.41; SHERMAN MI, 1975, CELL, V5, P343, DOI 10.1016/0092-8674(75)90052-5; SHERMAN MI, 1978, HUMAN FERTILIZATION, P179; SHU MA, 1994, BIOL REPROD, V50, P187; SUTHERLAND AE, 1988, J CELL BIOL, V106, P1331, DOI 10.1083/jcb.106.4.1331; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; SUZUKI H, 1992, HISTOCHEMISTRY, V97, P381, DOI 10.1007/BF00270384; TARONE G, 1993, DEVELOPMENT, V117, P1369; THORSTEINSDOTTIR S, 1992, ANAT RECORD, V232, P141, DOI 10.1002/ar.1092320116; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WEWER UM, 1986, DIFFERENTIATION, V32, P49, DOI 10.1111/j.1432-0436.1986.tb00555.x; WILEY LM, 1990, BIOESSAYS, V12, P67, DOI 10.1002/bies.950120204; YELIAN FD, 1993, J CELL BIOL, V121, P923, DOI 10.1083/jcb.121.4.923; YELIAN FD, 1995, IN PRESS MOL REPROD; ZHANG ZY, 1993, J BIOL CHEM, V268, P5557	61	93	96	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11522	11531		10.1074/jbc.270.19.11522	http://dx.doi.org/10.1074/jbc.270.19.11522			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7538116	hybrid			2022-12-25	WOS:A1995QX86500071
J	CHUI, G; LINN, S				CHUI, G; LINN, S			FURTHER CHARACTERIZATION OF HELA DNA-POLYMERASE-EPSILON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER EMBRYOS; CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; GENE-EXPRESSION; ALPHA; REPLICATION; DELTA; IDENTIFICATION; PROTEIN	DNA polymerase epsilon (pol epsilon) from HeLa cells was purified to near homogeneity, utilizing Mono S fast protein liquid chromatography for complete separation from pol alpha. The purified pol epsilon preparation showed two polypeptides of >200 and 55 kDa and a small amount of active 122-kDa proteolysis product on denaturing polyacrylamide gels. Pol epsilon (as well as pols alpha and delta) is optimally active in 100-150 mM potassium glutamate and 15 mM MgCl2. Replication factors RF-A and RF-C, proliferating cell nuclear antigen, and Escherichia coli single-stranded DNA binding protein showed no significant effect on this preparation's pol epsilon activity, processivity, or substrate specificity. The size of the pol epsilon transcript for the catalytic subunit (>200 kDa) was investigated in both normal human fibroblasts and HeLa cells. A 7.7-kilobase transcript was detected which was 5-16-fold more prevalent in proliferating than in quiescent HeLa cells. No significant difference in the level of pol epsilon transcript in HeLa cells or fibroblasts was seen after ultraviolet irradiation. Mouse polyclonal antiserum was produced to a 144-amino acid fragment of pol epsilon fused to staphylococcal protein A. This non-neutralizing polyclonal antiserum specifically recognized the catalytic subunit of pol epsilon by immunoblotting, but not that of pol alpha, beta, or delta. In addition, mouse polyclonal antiserum raised against column-purified pol epsilon was able to recognize and to neutralize pol epsilon, and a mouse monoclonal antibody was raised which was able to recognize specifically the catalytic subunit of pol epsilon.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIEHS NIH HHS [P30ES011896] Funding Source: Medline; NIGMS NIH HHS [GM30415] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R43ES011896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030415] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker T. A., 1992, DNA REPLICATION; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; CAMPBELL J, 1986, ANN REV BIOCH, V5, P733; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P4585, DOI 10.1073/pnas.79.15.4585; COTTERILL S, 1987, J BIOL CHEM, V262, P16100; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; JOHNSTON B, 1986, J HIST BEHAV SCI, V22, P107, DOI 10.1002/1520-6696(198604)22:2<107::AID-JHBS2300220203>3.0.CO;2-A; KAGUNI LS, 1983, J BIOL CHEM, V258, P9037; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KESTI T, 1993, J BIOL CHEM, V268, P10238; KESTI T, 1991, J BIOL CHEM, V266, P6336; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NISHIDA C, 1988, J BIOL CHEM, V263, P501; NISHIDA C, 1988, CANCER CELL, V6, P411; OVERMAN LB, 1978, Q REV BIOPHYS, V11, P103; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	33	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7799	7808		10.1074/jbc.270.14.7799	http://dx.doi.org/10.1074/jbc.270.14.7799			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7536191	hybrid			2022-12-25	WOS:A1995QR52600005
J	HARRISONFINDIK, D; SUSA, M; VARTICOVSKI, L				HARRISONFINDIK, D; SUSA, M; VARTICOVSKI, L			ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH SHC IN CHRONIC MYELOGENEOUS LEUKEMIA-CELLS	ONCOGENE			English	Article						BCR/ABL; SHC; SH2; SH3; PI 3-KINASE; TYROSINE PHOSPHORYLATION	SIGNAL TRANSDUCTION; TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; PHILADELPHIA-CHROMOSOME; MITOGENIC SIGNAL; ADAPTER PROTEIN; PI 3-KINASE; RAS; DOMAIN; TRANSFORMATION	Expression of p210 BCR/abl oncoprotein transforms hematopoietic cells. P210 BCR/abl tyrosine kinase induces tyrosine phosphorylation of Shc, and activation of p21(ras) and PI 3-Kinase. Here we show that PI 3-Kinase associates with She in cells transformed by BCR/abl oncoprotein. Immunoprecipitation of Shc from cells expressing p210 BCR/abl had 7.5-fold increase in PI 3-Kinase activity compared to parental cells. Tyrosine phosphorylated She specifically bound to the C-SH2 domain of the p85 subunit of PI 3-Kinase. The p85 SH3 domain also interacted with She in cell lysates from parental and transformed cells. The binding of p85 SH3 domain to She was substantially higher in BCR/abl transformed than in parental cells. Phenylphosphate blocked p85 SH2 mediated association with She but enhanced the binding of the p85 SH3 domain to She. The N-terminal proline-rich region of She between A263 and N273 specifically blocked the interaction of p85 SH3 domain with She. Our results indicate that PI 3-Kinase interacts with She directly in hematopoietic cells which express p210 BCR/abl oncoprotein.	TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED, BOSTON, MA 02135 USA; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University				Varticovski, Lyuba/0000-0002-5105-9008	NCI NIH HHS [R29CA530094] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P737; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANDANAS RA, 1993, BLOOD, V82, P1838; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MINAMI Y, 1991, J BIOL CHEM, V266, P9222; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RREN R, 1993, SCIENCE, V259, P1157; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUSA M, 1992, J BIOL CHEM, V267, P22951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	53	68	68	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1385	1391						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7537361				2022-12-25	WOS:A1995QR65100016
J	VOURETCRAVIARI, V; AUBERGER, P; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E				VOURETCRAVIARI, V; AUBERGER, P; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E			DISTINCT MECHANISMS REGULATE 5-HT2 AND THROMBIN RECEPTOR DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALPHA-THROMBIN; SIGNALING PATHWAYS; HOMOLOGOUS DESENSITIZATION; MOLECULAR-CLONING; ACTIVATION; FIBROBLASTS; INTERNALIZATION; EXPRESSION; AGONIST	We have compared the desensitization of two receptors, the thrombin receptor which displays dual coupling to both pertussis toxin-sensitive (G(i)) and -insensitive (G(q)) proteins and the serotonin type 2 (5-HT2) receptor which selectively couples to G(q). In the case of the thrombin receptor, cleavage induces activation and irreversible receptor modification followed by rapid (T 1/2 = 3 min) and extensive desensitization of the receptor's ability to modulate phospholipase C (G(q)). 5-HT-induced desensitization of its receptor is markedly slower (T 1/2 = 10 min) and by 60 min only 50% of the phospholipase C response is lost. This effect occurs with a parcel disappearance of 5-HT receptors from the cell surface. Whole cell phosphorylation studies showed that the thrombin receptor is rapidly phosphorylated upon activation, In contrast, the 5-HT2 receptor displays a low basal level of phosphorylation which is not increased upon agonist treatment. The cytoplasmic tail of the 5-HT2 receptor which contains several protein kinase consensus sequences was found not to be involved in receptor activation or desensitization. However, a chimeric receptor having the core of the 5-HT2 receptor and the cytoplasmic tail of the thrombin receptor was able to undergo 5-HT-induced desensitization and phosphorylation. These results indicate that (i) both 5-HT2 and thrombin receptors have unique shut-off mechanisms, and (ii) that sequences in the carboxyl terminus of the thrombin receptor are sufficient to trigger rapid uncoupling of the receptor from its G protein(s) and downstream effector(s).	FAC MED NICE, INSERM, U364, F-06107 NICE 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	VOURETCRAVIARI, V (corresponding author), CTR BIOCHIM, CNRS, UMR 134, PARC VALROSE, F-06108 NICE 2, FRANCE.		AUBERGER, Patrick/G-1491-2013; Van Obberghen-Schilling, Ellen/Q-4372-2019; Van Obberghen-Schilling, Ellen/O-1581-2016	AUBERGER, Patrick/0000-0002-2481-8275; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059				BARAK LS, 1994, J BIOL CHEM, V269, P2790; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CHAMBARD JC, 1990, NUCLEIC ACIDS RES, V18, P5282, DOI 10.1093/nar/18.17.5282; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1993, J BIOL CHEM, V268, P7825; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUIZEN FV, 1993, NEUROREPORT, V4, P1327; HUNG DT, 1992, J BIOL CHEM, V267, P20831; ISHII K, 1994, J BIOL CHEM, V269, P1125; IVINS KJ, 1991, J PHARMACOL EXP THER, V259, P423; KAGAYA A, 1990, J PHARMACOL EXP THER, V255, P305; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PARIS S, 1988, J BIOL CHEM, V263, P11250; POUYSSEGUR J, 1990, BIOL COUN S, P119; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; POUYSSEGUR J, 1991, ORIGINS OF HUMAN CANCER, P285; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANOBBERGHENSCH.E, 1994, ACTUAL CHIM THER, V21, P35; VANOBBERGHENSCHILLING E, 1991, MOL ENDOCRINOL, V5, P881, DOI 10.1210/mend-5-7-881; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YU SS, 1993, J BIOL CHEM, V268, P337	44	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4813	4821		10.1074/jbc.270.9.4813	http://dx.doi.org/10.1074/jbc.270.9.4813			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533166	hybrid			2022-12-25	WOS:A1995QK08400091
J	FALCONE, DJ; BORTH, W; MCCAFFREY, TA; MATHEW, J; MCADAM, K				FALCONE, DJ; BORTH, W; MCCAFFREY, TA; MATHEW, J; MCADAM, K			REGULATION OF MACROPHAGE RECEPTOR-BOUND PLASMIN BY AUTOPROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PHORBOL-MYRISTATE ACETATE; HUMAN-ENDOTHELIAL-CELLS; UROKINASE RECEPTOR; EXTRACELLULAR-MATRIX; CATALYTIC EFFICIENCY; LYS-PLASMINOGEN; HUMAN-MONOCYTES; U937 CELLS; ACTIVATOR	The activation of plasminogen by macrophage is regulated by their expression of receptors for urokinase and plasmin(ogen). In these studies we have examined plasmin(ogen) binding to adherent human THP-1 macrophage. Plasmin bound to the THP-1 cells in a time- and dose-dependent manner (K-d 15.8 +/- 6.2 nM; B-max 1.4 +/- 0.3 x 10(6)/cell). The lysine analog epsilon-aminocaproic acid competitively inhibited plasmin binding. The fraction of membrane-bound plasmin, however, became increasingly resistant to displacement with E-aminocaproic acid. Over a 24-h period, membrane-bound plasmin activity fell 80% despite the presence of catalytically active plasmin in the incubation media. The loss of receptor-bound plasmin activity was not due to proteolytic alterations of its receptor since I-125-Lys-plasminogen bound to THP-1 cells pretreated with plasmin with similar affinity as to untreated cells. Following a 24-h incubation of I-125-Lys-plasminogen or I-125-plasmin with THP-1 cells, several degradative fragments were apparent in their conditioned media. The smaller degradative fragments (28 and 36 kDa) lacked cell binding activity and were demonstrated to be active by casein-zymography. A 48-kDa fragment bound to cells in a lysine-dependent manner but was not active. In contrast, phenylmethylsulfonyl fluoride-inactivated I-125-plasmin retained its binding activity over 24 h, and degradative fragments were not present in the conditioned media. The binding of I-125-Lys-plasmin(ogen) to THP-1 cells was also examined in the presence of excess alpha 2 plasmin inhibitor. Despite the absence of fluid-phase plasmin activity, membrane-bound I-125-Lys-plasmin(ogen) decreased over 24 h. At 24 h a radiolabeled 48-kDa fragment was observed in the conditioned media and together with I-125-Lys-plasmin(ogen) was bound to cells. Unlike I-125-Lys-plasmin, the 48-kDa fragment did not form a complex with alpha 2 plasmin inhibitor. Thus, autoproteolysis of receptor-bound plasmin results in fragments with truncated physiologic properties that possess either cell binding or catalytic activities. We propose that autoproteolysis is a mechanism for regulating membrane-bound plasmin activity.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DIV HEMATOL,NEW YORK,NY 10021	Cornell University; Cornell University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	FALCONE, DJ (corresponding author), CORNELL UNIV,COLL MED,DEPT PATHOL,1300 YORK AVE,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [P01 HL46403, R29 HL42606, R01-HL40819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL040819, R29HL042606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BURGE SM, 1992, BRIT J DERMATOL, V126, P35, DOI 10.1111/j.1365-2133.1992.tb08400.x; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FELEZ J, 1990, J CELL BIOL, V111, P1673, DOI 10.1083/jcb.111.4.1673; GONZALEZGRONOW M, 1991, ARCH BIOCHEM BIOPHYS, V286, P625, DOI 10.1016/0003-9861(91)90090-6; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HALL SW, 1991, J BIOL CHEM, V266, P12329; HUARTE J, 1993, DEV BIOL, V157, P539, DOI 10.1006/dbio.1993.1156; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KONNO H, 1993, EUR SURG RES, V25, P239, DOI 10.1159/000129283; LUND LR, 1991, J BIOL CHEM, V266, P5177; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MOHANAM S, 1993, CANCER RES, V53, P4143; MOSER TL, 1993, J BIOL CHEM, V268, P18917; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; RICHARDSON M, 1988, CLIN INVEST MED, V11, P139; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SCHLECHTE W, 1990, CANCER COMMUN, V2, P173; SILVERSTEIN RL, 1988, J CLIN INVEST, V82, P1948, DOI 10.1172/JCI113814; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WANG L, 1994, J BIOL CHEM, V269, P4332; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1990, J BIOL CHEM, V265, P19658; WU LH, 1987, P NATL ACAD SCI USA, V84, P8292	42	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32660	32666						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528219				2022-12-25	WOS:A1994PX30400095
J	ABRAMS, CS; ZHAO, W; BELMONTE, E; BRASS, LF				ABRAMS, CS; ZHAO, W; BELMONTE, E; BRASS, LF			PROTEIN-KINASE-C REGULATES PLECKSTRIN BY PHOSPHORYLATION OF SITES ADJACENT TO THE N-TERMINAL PLECKSTRIN HOMOLOGY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELETS; SIGNALING PROTEINS; PHORBOL ESTER; FEEDBACK-REGULATION; RECEPTOR; THROMBIN; HYDROLYSIS; BETA	Pleckstrin is a substrate for protein kinase C in activated platelets that contains at its N and C termini two of the pleckstrin homology (PH) domains that have been proposed to mediate protein-protein and protein-lipid interactions. We have recently shown that pleckstrin can inhibit agonist-induced phosphoinositide hydrolysis and that this inhibition requires an intact N-terminal PH domain (residues 6 to 99). In the present studies, we have identified the sites of phosphorylation in pleckstrin and examined their contribution to pleckstrin function. In human platelets activated with thrombin or phorbol esters, and in COS-1 cells expressing pleckstrin, a combination of phosphopeptide analysis and site directed mutagenesis shows that three residues in the intervening sequence between the two pleckstrin PH domains become phosphorylated: Ser(113), Thr(114), and Ser(117). Replacing all three of these sites with glycine decreased phosphorylation by >90% and reduced pleckstrin's ability to inhibit phosphoinositide hydrolysis by as much as 80%. Replacing the phosphorylation sites with alanine residues had a similar effect, while substitution with aspartate, glutamate, or lysine residues produced pleckstrin variants that were fully active even in the absence of phosphorylation, These results suggest that phosphorylation enhances pleckstrin's activity by introducing a cluster of charges into a region adjacent to, but not within, the N-terminal PH domain. This may have an allosteric effect on the N-terminal PH domain, regulating its interaction with other molecules necessary for the inhibition of phosphoinositide hydrolysis.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; VET ADM MED CTR,PHILADELPHIA,PA 19104	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ABRAMS, CS (corresponding author), UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,422 CURIE BLVD,CRB 1005,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R29HL053545] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387, R29 HL53545] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; BRASS LF, 1992, J BIOL CHEM, V267, P13795; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LONGO C, 1992, INT J BIOCHEM, V24, P133, DOI 10.1016/0020-711X(92)90239-W; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MORRIS JF, 1991, ONCOGENE, V6, P2339; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; RYU SH, 1990, J BIOL CHEM, V265, P17941; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	32	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23317	23321		10.1074/jbc.270.40.23317	http://dx.doi.org/10.1074/jbc.270.40.23317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559487	hybrid			2022-12-25	WOS:A1995RY90900016
J	GOTO, S; SALOMON, DR; IKEDA, Y; RUGGERI, ZM				GOTO, S; SALOMON, DR; IKEDA, Y; RUGGERI, ZM			CHARACTERIZATION OF THE UNIQUE MECHANISM MEDIATING THE SHEAR-DEPENDENT BINDING OF SOLUBLE VON-WILLEBRAND-FACTOR TO PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; GLYCOPROTEIN-IIB-IIIA; AMINO-ACID RESIDUES; FLUORESCEIN ISOTHIOCYANATE; STIMULATED PLATELETS; THROMBUS FORMATION; RELEASE REACTION; VWF MULTIMERS; ALPHA-CHAIN; IB	We have studied the mechanism of interaction between soluble von Willebrand factor (vWF), labeled with fluorescein isothiocyanate (FITC), and platelets exposed 60 shear in a cone-and-plate viscometer. A flow cytometer calibrated with fluorescent bead standards was used 60 calculate the number of molecules associated with each platelet in suspension. To validate the methods and reagents used, binding of the same labeled vWF was assessed in the presence of ristocetin or alpha-thrombin and found to be saturable, with a narrow and symmetric distribution on >90% of the platelets. As expected, essentially all bound ligand interacted exclusively with platelet membrane glycoprotein (GP) Ib alpha in the presence of ristocetin and with GP IIb-IIIa after stimulation with alpha-thrombin. In contrast, only a minor proportion (<20%) of the platelets exposed to shear were found to bind vWF, with no evidence for saturation and markedly decreased interaction when the platelet count was below 100,000 mu l. Moreover, shear-induced vWF binding was blocked equally effectively by selected monoclonal antibodies against either GP Ib alpha or GP IIb-IIIa or against the respective binding sites in VWF. Thus, both receptors are involved in the process, possibly through initial transient interactions mediated by GP Ib alpha that lead to platelet activation and subsequent irreversible binding supported by GP IIb-IIIa. While the levels of shear stress theoretically applied to platelets in these experiments are above those thought to occur in the normal circulation, our findings demonstrate a unique vWF binding mechanism that is not mimicked by other known modulators and correlates with platelet aggregation, Similar processes may occur in response to lower shear stress when platelets are exposed to thrombogenic surfaces and agonists generated at sites of vascular injury during thrombus formation.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Salomon, Daniel/E-9380-2012		NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-42846, HL-48728] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042846, R01HL042846, P01HL048728] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEVRIADOU BR, 1993, BLOOD, V81, P1263; Batchelor G., 1967, INTRO FLUID DYNAMICS; BERLINER S, 1988, J BIOL CHEM, V263, P7500; CHOW TW, 1992, BLOOD, V80, P113; CORASH L, 1990, BLOOD CELLS, V160, P97; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; EDGECOMBE M, 1993, PLATELETS, V4, P141, DOI 10.3109/09537109309013210; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FUJIMURA Y, 1991, BLOOD, V77, P113; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; GOTO S, 1992, CIRCULATION, V86, P1859, DOI 10.1161/01.CIR.86.6.1859; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MASSINI P, 1971, THROMB DIATH HAEMOST, V25, P13, DOI 10.1055/s-0038-1654275; MOAKE JL, 1988, BLOOD, V71, P1366; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; MUSTARD JF, 1975, AM J PHYSIOL, V228, P1757, DOI 10.1152/ajplegacy.1975.228.6.1757; NIIYA K, 1987, BLOOD, V70, P475; PACKHAM MA, 1987, BLOOD, V70, P647; PETERSON DM, 1987, BLOOD, V69, P625; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; READ MS, 1989, BLOOD, V74, P1031; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; THE TH, 1970, IMMUNOLOGY, V18, P875; THE TH, 1970, IMMUNOLOGY, V18, P865; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; Whitmore R.L., 1968, RHEOLOGY CIRCULATION; [No title captured]	43	241	253	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23352	23361		10.1074/jbc.270.40.23352	http://dx.doi.org/10.1074/jbc.270.40.23352			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559492	hybrid			2022-12-25	WOS:A1995RY90900021
J	WROBEL, S				WROBEL, S			SERENDIPITY, SCIENCE, AND A NEW HANTAVIRUS	FASEB JOURNAL			English	Article								This essay follows a team of scientific investigators step by intriguing step as it pursues the cause of the mysterious 1993 deaths of healthy young adults in the southwestern United States. Using the science of the day, the team unravels the elusive origin of a potentially widespread killer-tracking a new hantavirus to its home, tracing its lineage, and differentiating its DNA from the large hantavirus family. This is the first in the ''Breakthroughs'' series.			WROBEL, S (corresponding author), EMORY UNIV,ATLANTA,GA 30322, USA.							CHAPMAN LE, 1993, INFECTIOUS AGENTS DI, V3, P234; Garrett L., 1994, COMING PLAGUE; HENIG RM, 1993, DANCING MATRIX VOYAG; STONE R, 1993, SCIENCE, V262, P832	4	8	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1995	9	13					1247	1254		10.1096/fasebj.9.13.7557014	http://dx.doi.org/10.1096/fasebj.9.13.7557014			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557014				2022-12-25	WOS:A1995TA37000003
J	MAO, JR; SHIMADA, M; INOUYE, S; INOUYE, M				MAO, JR; SHIMADA, M; INOUYE, S; INOUYE, M			GENE-REGULATION BY ANTISENSE DNA PRODUCED IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-STRANDED-DNA; RNA-LINKED MSDNA; ESCHERICHIA-COLI; BRANCHED RNA; REVERSE-TRANSCRIPTASE; RETRON; RETROELEMENT; EXPRESSION; CDNA	Antisense technology has been widely used for regulating gene expression, Single-stranded RNA or DNA complementary to a target mRNA can inhibit the translation of the mRNA. Antisense RNA is produced in vivo, while antisense DNA is chemically synthesized as an oligonucleotide, which is extracellularly added to the cells, To maintain the effect of antisense DNA, a synthetic oligonucleotide has to be constantly added to the system, An advantage of antisense DNA over antisense RNA is that the target mRNA hybridized with the antisense DNA can be specifically digested by ribonuclease H. Here, we attempted to produce in vivo short single-stranded DNAs complementary to a specific mRNA. We demonstrate that such antisense oligodeoxyribonucleotide of a desired sequence can be produced in Escherichia coli using a retron, a bacterial retroelement, as a vector and that the antisense DNA thus produced in vivo can effectively inhibit the expression of a specific E, coli gene, such as the gene for the major outer membrane lipoprotein.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center			Inouye, Sharon/R-7216-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLEMAN J, 1984, CELL, V37, P429, DOI 10.1016/0092-8674(84)90373-8; DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; FURUICHI T, 1987, CELL, V48, P55, DOI 10.1016/0092-8674(87)90355-2; GREENE PJ, 1981, J BIOL CHEM, V256, P2143; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; HSU MY, 1992, J BIOL CHEM, V267, P13823; INOUYE S, 1993, CURR OPIN GENET DEV, V3, P713, DOI 10.1016/S0959-437X(05)80088-7; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; MAHER LJ, 1992, BIOESSAYS, V14, P807, DOI 10.1002/bies.950141204; MIROCHNITCHENKO O, 1994, J BIOL CHEM, V269, P2380; MIYATA S, 1992, P NATL ACAD SCI USA, V89, P5735, DOI 10.1073/pnas.89.13.5735; RICE SA, 1993, J BACTERIOL, V175, P4250, DOI 10.1128/JB.175.13.4250-4254.1993; SHIMADA M, 1994, J BIOL CHEM, V269, P14553; SHIMAMOTO T, 1995, J BIOL CHEM, V270, P581, DOI 10.1074/jbc.270.2.581; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; YANISCHPERRON C, 1982, GENE, V19, P259	20	17	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19684	19687		10.1074/jbc.270.34.19684	http://dx.doi.org/10.1074/jbc.270.34.19684			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544343	hybrid			2022-12-25	WOS:A1995RQ99100005
J	SATO, C; KITAJIMA, K; INOUE, S; SEKI, T; TROY, FA; INOUE, Y				SATO, C; KITAJIMA, K; INOUE, S; SEKI, T; TROY, FA; INOUE, Y			CHARACTERIZATION OF THE ANTIGENIC SPECIFICITY OF 4 DIFFERENT ANTI-(ALPHA-2-]8-LINKED POLYSIALIC ACID) ANTIBODIES USING LIPID-CONJUGATED OLIGO POLYSIALIC ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; ESCHERICHIA-COLI K1; GROUP-B-MENINGOCOCCI; LONG OLIGOSACCHARIDE SEGMENT; MONOCLONAL-ANTIBODY; POLY(SIALIC ACID); NEURAMINIC ACID; RAINBOW-TROUT; RICH GLYCOPROTEIN; ADULT-RAT	A rapid, sensitive, and facile method for screening and characterizing anti-polysialic acid (polySia) antibodies using lipid-conjugated oligo/polysialic acids (oligo/polySia) was developed, which is based on an enzyme linked immunosorbent assay, Homooligo/polymers of alpha 2-->8-linked N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid, and 2-keto-3-deoxy-D-galacto-nononic acid (KDN) were conjugated with phosphatidylethanolamine dipalmitoyl (PE) by reductive amination to prepare neo-oligo/polysialoglycolipids (oligo/polySia-PE), Using this method, the anti-polySia equine antibody, H.46, bound to (-->8Neu5Ac alpha 2-->)(n)-PE, where n = 9 or more residues, a result in confirmation of previous binding studies using radiolabeled oligo/polyNeu5Ac. The antigenic specificity and sensitivity of two monoclonal anti-poly/oligoNeu5Ac antibodies (mAb.12E3 and mAb.5A5) and one anti-oligoKDN antibody (mAb.kdn8kdn), were also determined, mAb.12E3 could detect as little as 25 pg/well of oligo/polyNeu5Ac-PE, while mAb.5A5 and polyclonal antibody H.46 required at least 0.4 ng/well of oligo/polyNeu5Ac-PE to be detected, mAb.kdn8kdn detected as little as 12 ng/well of oligoKDN-PE, Using a series of oligo/polySia-PE with defined degrees of polymerization (DP), the minimum chain length for immunoreactivity of the anti-polySia antibodies was determined to be: DP 5 for mAb.12E3; DP 3 for mAb.5A5; DP 2 for mAb.kdn8kdn; and DP 8 for H.46, Thus, mAb.12E3 and mAb.5A5 recognize shorter oligomers of Neu5Ac than H.46, a finding that is of practical value for identifying shorter oligoSia chains in glycoconjugates, Because mAb.12E3 and mAb.5A5 also recognize extended polySia chains, these antibodies cannot be used, however, to differentiate between short and long chains of polySia when both are expressed on the same molecule.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOCHEM & BIOPHYS,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN; JUNTENDO UNIV,SCH MED,DEPT ANAT,TOKYO 113,JAPAN; UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of Tokyo; Showa University; Juntendo University; University of California System; University of California Davis			SATO, Chihiro/B-7396-2014					ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; ALLEN PZ, 1982, J CLIN MICROBIOL, V15, P324, DOI 10.1128/JCM.15.2.324-329.1982; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; DEVI SJN, 1991, P NATL ACAD SCI USA, V88, P7175, DOI 10.1073/pnas.88.16.7175; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; FINNE J, 1985, J BIOL CHEM, V260, P1265; FINNE J, 1982, J BIOL CHEM, V257, P1966; FINNE J, 1987, J IMMUNOL, V138, P4402; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Gandour-Edwards R., 1995, Modern Pathology, V8, p101A; GROGAN T, 1994, LAB INVEST, V70, pA110; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; INOUE Y, 1993, POLYSIALIC ACID MICR, P171; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; JENNINGS HJ, 1981, J IMMUNOL, V127, P1011; KABAT EA, 1986, J EXP MED, V164, P642, DOI 10.1084/jem.164.2.642; KANAMORI A, 1994, HISTOCHEMISTRY, V101, P333, DOI 10.1007/BF00268994; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANDRELL RE, 1982, J IMMUNOL, V129, P2172; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; ROTH J, 1993, POLYSIALIC ACID MICR, P335; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SARFF LD, 1975, LANCET, V1, P1099; SATO C, 1993, J BIOL CHEM, V268, P23675; SCOTT AA, 1994, LAB INVEST, V70, pA120; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; SHIMODA Y, 1994, BIOCHEMISTRY-US, V33, P1202, DOI 10.1021/bi00171a020; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WYLE FA, 1972, J INFECT DIS, V126, P514, DOI 10.1093/infdis/126.5.514; YANG PF, 1994, J BIOL CHEM, V269, P23039; ZUBER C, 1992, J BIOL CHEM, V267, P9965	50	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18923	18928		10.1074/jbc.270.32.18923	http://dx.doi.org/10.1074/jbc.270.32.18923			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7543897	hybrid			2022-12-25	WOS:A1995RN95400037
J	RIGOTTI, A; ACTON, SL; KRIEGER, M				RIGOTTI, A; ACTON, SL; KRIEGER, M			THE CLASS-B SCAVENGER RECEPTORS SR-BI AND CD36 ARE RECEPTORS FOR ANIONIC PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; GLYCOPROTEIN-IV CD36; MEDIATED ENDOCYTOSIS; HUMAN-ERYTHROCYTES; CELL MUTANTS; RECOGNITION; MACROPHAGES; SURFACE; LIPOSOMES; BINDING	The specific recognition of anionic phospholipids in the outer leaflets of cell membranes and lipoproteins by cell surface receptors may play an important role in a variety of physiologic and pathophysiologic processes (e.g. recognition of damaged or senescent cells by the reticuloendothelial system or lipoprotein homeostasis). Several investigators have described anionic phospholipid binding to cells, and phosphatidylserine (PS) binding to a partially purified similar to 95-kDa membrane protein has recently been reported (Sambrano, G. R., and Steinberg, D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1396-1400). Using both direct binding and ligand competition assays in transfected cells, we have found that two class B scavenger receptors, SR-BI and CD36, can tightly bind PS and phosphatidylinositol (PI)-containing liposomes (K-d for PS liposome binding to SR-BI is similar to 15 mu g phospholipid/ml or 0.18 nM (mol PS liposomes/l)), but not phosphatidylcholine, phosphatidylethanolamine, or sphingomyelin liposomes. PS and PI liposomes, but not the others, could effectively compete with PS liposomes and modified or native lipoproteins for binding to these receptors. Phosphatidic acid, another anionic phospholipid, could also compete, but was not as effective as PS or PI. Class B scavenger receptors are the first molecularly well-defined, specific cell surface receptors for anionic phospholipids to be described.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Krieger, Marco/AAE-8611-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212, F32HL009047, P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484, HL52212, HL09047-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON S, 1993, J BIOL CHEM, V268, P3530; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL MD, 1994, J NEUROCYTOL, V23, P605, DOI 10.1007/BF01191555; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; DERIJKE YB, 1994, J BIOL CHEM, V269, P824; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FUKASAWA M, 1995, J BIOL CHEM, V270, P1921, DOI 10.1074/jbc.270.4.1921; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREENWALT DE, 1992, BLOOD, V80, P1105; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JOSHI P, 1988, BRIT J HAEMATOL, V68, P255, DOI 10.1111/j.1365-2141.1988.tb06198.x; KINGSLEY DM, 1986, MOL CELL BIOL, V6, P2734, DOI 10.1128/MCB.6.7.2734; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kuypers Frans A., 1994, P139; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1103, P185, DOI 10.1016/0005-2736(92)90086-2; LEVINE YK, 1971, NATURE-NEW BIOL, V230, P69, DOI 10.1038/newbio230069a0; NAITO M, 1991, AM J PATHOL, V139, P1411; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; RATNER S, 1986, P SOC EXP BIOL MED, V182, P272; Roelofsen Ben, 1994, V40, P7; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHROIT AJ, 1982, CANCER RES, V42, P161; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; SHUKLA SD, 1982, ARCH BIOCHEM BIOPHYS, V214, P335, DOI 10.1016/0003-9861(82)90038-8; SZOKA F, 1980, BIOCHIM BIOPHYS ACTA, V601, P559, DOI 10.1016/0005-2736(80)90558-1; TANDON NN, 1989, J BIOL CHEM, V264, P7576	43	472	490	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16221	16224		10.1074/jbc.270.27.16221	http://dx.doi.org/10.1074/jbc.270.27.16221			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7541795	hybrid			2022-12-25	WOS:A1995RH22600052
J	BISBAL, C; MARTINAND, C; SILHOL, M; LEBLEU, B; SALEHZADA, T				BISBAL, C; MARTINAND, C; SILHOL, M; LEBLEU, B; SALEHZADA, T			CLONING AND CHARACTERIZATION OF A RNASE-L INHIBITOR - A NEW COMPONENT OF THE INTERFERON-REGULATED 2-5A PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CONSTITUTIVE EXPRESSION; 2-5A-DEPENDENT RNASE; MESSENGER-RNA; 2',5'-OLIGOADENYLATE SYNTHETASE; RIBONUCLEASE INHIBITOR; ANTIVIRAL ACTIVITY; TREATED CELLS; INTACT-CELLS; DEGRADATION	The 2-5A/RNase L system is considered as a central pathway of interferon (IFN) action and could possibly play a more general physiological role as for instance in the regulation of RNA stability in mammalian cells. We describe here the expression cloning and initial characterization of RLI (for RNase L inhibitor), a new type of endoribonuclease inhibitor. RLI cDNA codes for a 68-kDa polypeptide whose expression is not regulated by IFN. Its expression in reticulocyte extracts antagonizes the 2-5A binding ability and the nuclease activity of endogenous RNase L or the cloned 2DR polypeptide. The inhibition requires the association of RLI with the nuclease and is dependent on the ratio between the two proteins. Likewise RLI is coimmunoprecipitated with the RNase L complex by a nuclease specific antibody. RLI does not lead to 2-5A degradation or to irreversible modification of RNase L. The overexpression of RLI in stably transfected HeLa cells inhibits the antiviral activity of IFN on encephalomyocarditis virus but not on vesicular stomatitis virus. RLI therefore appears as the first described and potentially important mediator of the 2-5A/RNase L pathway.	UNIV MONTPELLIER 1,INST MOLEC GENET,CNRS,UMR 9942,F-34033 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier			Bisbal, Catherine/I-6984-2016	Bisbal, Catherine/0000-0003-1086-020X				BAYARD B, 1986, BIOCHEMISTRY-US, V25, P3730, DOI 10.1021/bi00360a038; BAYARD B, 1984, EUR J BIOCHEM, V142, P291, DOI 10.1111/j.1432-1033.1984.tb08284.x; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; CATHALA G, 1983, DNA CELL BIOL, V4, P327; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; CONTENT J, 1987, MOL BASIS VIRAL REPL, P163; DONG BH, 1994, J BIOL CHEM, V269, P14153; FIELD AK, 1967, P NATL ACAD SCI USA, V58, P1004, DOI 10.1073/pnas.58.3.1004; FLOYDSMITH G, 1982, J BIOL CHEM, V257, P8584; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HO M, 1984, INTERFERON, V1, P79; JOHNSTON MI, 1987, J BIOL CHEM, V262, P8377; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; MARIE I, 1992, J BIOL CHEM, V267, P9933; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MIELE MB, 1991, J INTERFERON RES, V11, P33, DOI 10.1089/jir.1991.11.33; MILHAUD PG, 1983, ANN INST PASTEUR VIR, V134, P405, DOI 10.1016/S0769-2617(83)80012-4; NILSEN TW, 1981, J BIOL CHEM, V256, P7806; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PRINCE RC, 1993, TRENDS BIOCHEM SCI, V18, P153; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SALEHZADA T, 1993, J BIOL CHEM, V268, P7733; SALEHZADA T, 1991, ANAL BIOCHEM, V196, P410, DOI 10.1016/0003-2697(91)90486-D; SALEHZADA T, 1991, J BIOL CHEM, V266, P5808; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1981, EUR J BIOCHEM, V115, P79; SILVERMAN RH, 1984, J VIROL, V46, P1051; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATLING D, 1985, EMBO J, V4, P431, DOI 10.1002/j.1460-2075.1985.tb03647.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; [No title captured]	50	203	216	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13308	13317		10.1074/jbc.270.22.13308	http://dx.doi.org/10.1074/jbc.270.22.13308			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539425	hybrid, Green Submitted			2022-12-25	WOS:A1995RB43900056
J	MELCHIOR, R; QUIGLEY, JP; ARMSTRONG, PB				MELCHIOR, R; QUIGLEY, JP; ARMSTRONG, PB			ALPHA(2)-MACROGLOBULIN-MEDIATED CLEARANCE OF PROTEASES FROM THE PLASMA OF THE AMERICAN HORSESHOE-CRAB, LIMULUS-POLYPHEMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-MACROGLOBULIN COMPLEXES; BAIT REGION; FAST FORMS; BINDING; TRYPSIN; BLOOD; HEPATOCYTES; HEMOLYMPH	Because proteases free in the body are damaging to the tissues, animals have evolved various agents for their inactivation and clearance. Mammals, for instance, have a diverse array of active site protease inhibitors in the plasma, in addition, mammals have alpha(2)-macroglobulin (alpha(2)M), which binds active proteases, and the alpha(2)M-protease complex is then cleared from the plasma by a receptor-mediated endocytotic process. (alpha(2)M is also present in the plasma of many invertebrates, and in the American horseshoe crab, Limulus polyphemus, it is the only protease inhibitor in the plasma. To search for a clearance process for proteases in Limulus, fluerescein isothiocyanate (FITC)-labeled proteins were injected into the blood, and the fluorescence in the plasma and associated with the blood cells was determined. FITC-labeled trypsin was cleared with an initial mixing period (0-10 min) and a rapid clearance period (10-30 min), followed by the reappearance of FITC in the plasma (45-90 min). Before and during the clearance process, the labeled trypsin was associated with a complex having a molecular mass identical to that of Limubus alpha(2)M, and that was precipitated by antibodies directed against Limubus alpha(2)M. The fluoresceinated material that reappeared in the plasma after 45 min was of low molecular mass (<10 kDa) and thus appears to have experienced degradation. The clearance of trypsin requires its protease activity, since phenylmethylsulfonyl fluoride-inactivated, FITC-labeled trypsin was cleared only very slowly if at all (t1/2 > 180 min). FITC-labeled, trypsin-reacted Limubus alpha(2)M was cleared rapidly from the plasma of Limubus, whereas FITC-labeled, native Limubus alpha(2)M persisted undiminished in excess of 400 min. The blood cells of Limubus bound FITC-labeled trypsin-reacted Limubus alpha(2)M, and the peak of recovery from the blood cells coincided with the minimum concentration of FITC-labeled protein in the plasma, suggesting that the blood cells participate in the clearance of alpha(2)M-protease complex from the plasma. Thus, we have demonstrated the existence of a clearance pathway in Limubus that operates selectively on enzymatically active proteases and have shown that Limulus alpha(2)M is the probable agent for protease clearance. This is the first documentation of a protease clearance pathway in invertebrates and represents the first identified physiological function for alpha(2)M in invertebrates.	LAWRENCE LIVERMORE NATL LAB,DEPT MOLEC & CELL BIOL,DAVIS,CA 95616; MARINE BIOL LAB,WOODS HOLE,MA 02543; SUNY STONY BROOK,HLTH SCI CTR,DEPT PATHOL,STONY BROOK,NY 11794	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Marine Biological Laboratory - Woods Hole; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Armstrong, Peter/0000-0001-5197-1999				Armstrong P.B., 1979, Progress in Clinical and Biological Research, V29, P73; ARMSTRONG PB, 1982, EXP CELL RES, V140, P15, DOI 10.1016/0014-4827(82)90150-1; ARMSTRONG PB, 1985, BIOCHIM BIOPHYS ACTA, V827, P453, DOI 10.1016/0167-4838(85)90232-8; ARMSTRONG PB, 1985, J EXP ZOOL, V236, P1, DOI 10.1002/jez.1402360102; ARMSTRONG PB, 1980, J CELL SCI, V44, P243; ARMSTRONG PB, 1991, J BIOL CHEM, V266, P2526; ARMSTRONG PB, 1987, BIOCHEM J, V248, P703, DOI 10.1042/bj2480703; ARMSTRONG PB, 1991, IMMUNOLOGY INSECTS O, P1; ARMSTRONG PB, 1985, BLOOD CELLS MARINE I, P77; ARMSTRONG PB, 1995, IN PRESS PROG MOL SU; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P734; BEATTY K, 1982, BIOCHIM BIOPHYS ACTA, V704, P221, DOI 10.1016/0167-4838(82)90149-2; BERTHILLIER G, 1968, BIOCHIM BIOPHYS ACTA, V170, P140, DOI 10.1016/0304-4165(68)90168-2; BESTERMAN JM, 1983, BIOCHEM J, V210, P1; BIETH J, 1978, FEBS LETT, V8, P319; BRETON CB, 1992, P NATL ACAD SCI USA, V89, P9647, DOI 10.1073/pnas.89.20.9647; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CUMMINGS HS, 1984, BIOPHYS J, V45, P721, DOI 10.1016/S0006-3495(84)84214-9; DAVIDSEN O, 1985, BIOCHIM BIOPHYS ACTA, V846, P85, DOI 10.1016/0167-4889(85)90113-2; DEBANNE MT, 1976, BIOCHIM BIOPHYS ACTA, V428, P466; DEBANNE MT, 1973, BRIT J EXP PATHOL, V54, P571; DESNUELLE P, 1960, ENZYMES, P119; FELDMAN SR, 1985, BIOCHEM BIOPH RES CO, V128, P795, DOI 10.1016/0006-291X(85)90117-2; FREADMAN MA, 1989, BIOL BULL, V177, P386, DOI 10.2307/1541598; GLIEMANN J, 1983, BIOCHIM BIOPHYS ACTA, V756, P230, DOI 10.1016/0304-4165(83)90096-X; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPEL PC, 1973, J EXP MED, V138, P508, DOI 10.1084/jem.138.3.508; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIXSON HF, 1973, ARCH BIOCHEM BIOPHYS, V154, P501, DOI 10.1016/0003-9861(73)90002-7; HOLTET TL, 1994, FEBS LETT, V344, P242, DOI 10.1016/0014-5793(94)00349-1; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; HOWELL JB, 1983, ARCH BIOCHEM BIOPHYS, V221, P261, DOI 10.1016/0003-9861(83)90143-1; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KAPLAN J, 1981, J BIOL CHEM, V256, P7705; KAPLAN J, 1979, J BIOL CHEM, V254, P7329; KATAYAMA K, 1974, BIOCHIM BIOPHYS ACTA, V336, P165, DOI 10.1016/0005-2795(74)90394-8; KATAYAMA K, 1974, BIOCHIM BIOPHYS ACTA, V336, P178, DOI 10.1016/0005-2795(74)90395-X; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LANCHANTIN GF, 1966, P SOC EXP BIOL MED, V121, P444; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MARYNEN P, 1981, J IMMUNOL, V127, P1782; MARYNEN P, 1982, FEBS LETT, V137, P241, DOI 10.1016/0014-5793(82)80358-X; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; NELLES LP, 1980, BIOCHIM BIOPHYS ACTA, V623, P46, DOI 10.1016/0005-2795(80)90006-9; NEY KA, 1984, BIOCHEMISTRY-US, V23, P3395, DOI 10.1021/bi00310a003; OHLSSON K, 1971, ACTA PHYSIOL SCAND, V81, P269, DOI 10.1111/j.1748-1716.1971.tb04900.x; OHLSSON K, 1971, BIOCHIM BIOPHYS ACTA, V236, P84, DOI 10.1016/0005-2795(71)90153-X; PASTAN I, 1977, CELL, V12, P609, DOI 10.1016/0092-8674(77)90261-6; PASTAN IH, 1981, ANNU REV PHYSIOL, V43, P239, DOI 10.1146/annurev.ph.43.030181.001323; QUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; QUIGLEY JP, 1985, J BIOL CHEM, V260, P2715; QUIGLEY JP, 1991, J BIOL CHEM, V266, P19426; REBECK GW, 1993, NEURON, V11, P75; Redmond JR, 1982, PHYSL BIOL HORSESHOE, P133; Shuster C. N, 1978, CIRCULATORY SYSTEM B; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1981, FEBS LETT, V127, P167, DOI 10.1016/0014-5793(81)80197-4; SOTTRUPJENSEN L, 1990, COMP BIOCH PHYSL, V96, P261; SPYCHER SE, 1987, J BIOL CHEM, V262, P14606; STARKEY PM, 1973, BIOCHEM J, V131, P823, DOI 10.1042/bj1310823; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANHOLDE KE, 1982, Q REV BIOPHYS, V15, P1, DOI 10.1017/S0033583500002705; VANLEUVEN F, 1984, MOL CELL BIOCHEM, V58, P121, DOI 10.1007/BF00240611; VANLEUVEN F, 1983, ANN NY ACAD SCI, V421, P434; Volbeda A., 1988, Progress in Clinical and Biological Research, V274, P291; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	79	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13496	13502		10.1074/jbc.270.22.13496	http://dx.doi.org/10.1074/jbc.270.22.13496			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539428	hybrid			2022-12-25	WOS:A1995RB43900080
J	STAUFFER, TP; GUERINI, D; CARAFOLI, E				STAUFFER, TP; GUERINI, D; CARAFOLI, E			TISSUE DISTRIBUTION OF THE 4 GENE-PRODUCTS OF THE PLASMA-MEMBRANE CA2+ PUMP - A STUDY USING SPECIFIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; MOLECULAR CHARACTERIZATION; MESSENGER-RNAS; CA-2+-TRANSPORTING ATPASE; RAT-KIDNEY; CA-2+ PUMP; CLONING; LOCALIZATION; PURIFICATION; PROTEINS	Antibodies against the four isoforms of the human plasma membrane Ca2+-ATPase (PMCA) were raised using an N-terminal sequence of the pump as epitope. The antibodies against PMCA isoforms 1, 2, and 3 were not species-specific, e,g. they also recognized the corresponding proteins in rat, whereas that against the human PMCA isoform 4 failed to do so. The tissue distribution of the four isoforms was estimated by Western blot analysis. Two, PMCA1 and PMCA4, were expressed in all tissues tested (with the exception of the choroid plexus, where the former was not detected). In most tissues the signal from the PMCA1 protein exceeded that of PMCA4, the exception being the erythrocyte. The PMCA2 and PMCA3 proteins were only found in neuronal tissues; the PMCA2 protein was present in high concentrations in the cerebellum and in the cerebral cortex, At variance with previous results on mRNA (e.g. the kidney) no other tissues contained the PMCA2 protein. PMCA3 was the other tissue-specific isoform; in agreement with results in the rat, the protein was found in human neuronal tissues, particularly in the choroid plexus, but was practically absent in all other tissues tested.	ETH ZURICH,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				BENHAM CD, 1992, J PHYSIOL-LONDON, V455, P567, DOI 10.1113/jphysiol.1992.sp019316; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BLEAKMAN D, 1993, BRAIN RES, V600, P257, DOI 10.1016/0006-8993(93)91381-2; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BORKE JL, 1989, BRAIN RES, V489, P355, DOI 10.1016/0006-8993(89)90870-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT P, 1992, GENOMICS, V14, P484, DOI 10.1016/S0888-7543(05)80246-0; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CARONI P, 1981, J BIOL CHEM, V256, P9371; ENYEDI A, 1994, J BIOL CHEM, V269, P41; GREEB J, 1989, J BIOL CHEM, V264, P18569; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOWARD A, 1993, AM J PHYSIOL, V264, pF91; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KNAUF PA, 1974, J GEN PHYSIOL, V63, P324, DOI 10.1085/jgp.63.3.324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATIF F, 1993, CANCER RES, V53, P861; Llinas R., 1992, CEREBELLUM REVISITED, P167; MAGOCSI M, 1992, AM J PHYSIOL, V263, pF7, DOI 10.1152/ajprenal.1992.263.1.F7; NIGGLI V, 1987, METHOD ENZYMOL, V139, P791; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; OLSON S, 1991, GENOMICS, V9, P629, DOI 10.1016/0888-7543(91)90356-J; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STUEBER D, 1990, European Journal of Immunology, V20, P819; TALAMONI ND, 1993, P NATL ACAD SCI USA, V90, P11949; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG MG, 1994, CYTOGENET CELL GENET, V67, P41, DOI 10.1159/000133794; ZACHARIAS DA, 1995, MOL BRAIN RES, V28, P263, DOI 10.1016/0169-328X(94)00215-Z	42	226	227	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12184	12190		10.1074/jbc.270.20.12184	http://dx.doi.org/10.1074/jbc.270.20.12184			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538133	hybrid			2022-12-25	WOS:A1995QY73600072
J	CANALIS, E; GABBITAS, B				CANALIS, E; GABBITAS, B			SKELETAL GROWTH-FACTORS REGULATE THE SYNTHESIS OF INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-5 IN BONE CELL-CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-ENRICHED CULTURES; FETAL-RAT CALVARIAE; FACTOR-I; COLLAGEN-SYNTHESIS; MOLECULAR-CLONING; IGF-I; GENE; TRANSCRIPTION; STIMULATION; EXPRESSION	Skeletal cells secrete insulin-like growth factors (IGFs) I and II and six known IGF binding proteins (IGFBPs). IGFBP-5 stimulates bone formation, and its synthesis correlates with changes in osteoblast cell growth. We tested the effects of basic fibroblast growth factor (bFGF), transforming growth factor beta 1 (TGF beta 1), and platelet derived growth factor (PDGF) BB on IGFBP-5 expression in cultures of osteoblast-enriched cells from 22 day-old fetal rat calvariae (Ob cells). Treatment of Ob cells with bFGF, TGF beta 1, and PDGF BB caused a time- and dose dependent decrease in IGFBP-5 mRNA levels and inhibited IGFBP-5 polypeptide levels in the extracellular matrix. The effects of bFGF, TGF beta 1, and PDGF BB on IGFBP-5 transcripts were independent of cell division and were observed in the presence and absence of hydroxyurea. bFGF, TGF beta 1, and PDGF BB did not modify the decay of IGFBP-5 mRNA in transcriptionally arrested Ob cells, and they inhibited IGFBP-5 heterogeneous nuclear RNA and the rate of IGFBP-5 transcription. In conclusion, bFGF, TGF beta 1, and PDGF BB inhibit IGFBP-5 expression in Ob cells independently of their mitogenic activity and through mechanisms that involve decreased transcription.	ST FRANCIS HOSP & MED CTR,DEPT MED,HARTFORD,CT 06105; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06030	Saint Francis Hospital & Medical Center; University of Connecticut	CANALIS, E (corresponding author), ST FRANCIS HOSP & MED CTR,DEPT RES,114 WOODLAND ST,HARTFORD,CT 06105, USA.				NIAMS NIH HHS [AR21707, R37 AR021707] Funding Source: Medline; NIDDK NIH HHS [R01 DK042424, DK42424] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042424] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BIRNBAUM RS, 1994, ENDOCRINOLOGY, V135, P223, DOI 10.1210/en.135.1.223; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1993, ENDOCRINOLOGY, V133, P33, DOI 10.1210/en.133.1.33; Canalis Ernesto, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P155; CENTRELLA M, 1991, J CELL PHYSIOL, V147, P420, DOI 10.1002/jcp.1041470306; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CHEN TL, 1993, ENDOCRINOLOGY, V133, P1382, DOI 10.1210/en.133.3.1382; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; FROLIK CA, 1988, BIOCHEM BIOPH RES CO, V151, P1011, DOI 10.1016/S0006-291X(88)80466-2; GABBITAS B, 1994, ENDOCRINOLOGY, V135, P284, DOI 10.1210/en.135.1.284; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HASSAGER C, 1992, J CLIN ENDOCR METAB, V75, P228, DOI 10.1210/jc.75.1.228; HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KACHRA Z, 1994, ENDOCRINOLOGY, V135, P1722, DOI 10.1210/en.135.5.1722; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; KNUDSEN BS, 1988, J CLIN INVEST, V80, P1082; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; LOWE WL, 1994, ENDOCRINOLOGY, V135, P1719, DOI 10.1210/en.135.5.1719; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCUSKER RH, 1994, ENDOCRINOLOGY, V134, P2095, DOI 10.1210/en.134.5.2095; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; OKAZAKI R, 1994, ENDOCRINOLOGY, V134, P126, DOI 10.1210/en.134.1.126; PHILLIPS ID, 1994, ENDOCRINOLOGY, V134, P1238, DOI 10.1210/en.134.3.1238; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; THRAIKILL K, 1994, 76TH ANN M END SOC A, P438; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9	46	45	46	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10771	10776		10.1074/jbc.270.18.10771	http://dx.doi.org/10.1074/jbc.270.18.10771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537737	hybrid			2022-12-25	WOS:A1995QW60100060
J	ALNEMRI, ES; FERNANDESALNEMRI, T; POMERENKE, K; ROBERTSON, NM; DUDLEY, K; DUBOIS, GC; LITWACK, G				ALNEMRI, ES; FERNANDESALNEMRI, T; POMERENKE, K; ROBERTSON, NM; DUDLEY, K; DUBOIS, GC; LITWACK, G			FKBP46, A NOVEL SF9 INSECT-CELL NUCLEAR IMMUNOPHILIN THAT FORMS A PROTEIN-KINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; HUMAN FK506-BINDING PROTEIN; CYCLOSPORINE-A; SIGNAL TRANSDUCTION; BINDING-PROTEIN; CYCLOPHILIN; RAPAMYCIN; SEQUENCE; FK-506; OVEREXPRESSION	Recently, we identified a 59-kDa nuclear phosphoprotein that is associated with a recombinant mouse FKBP-52 (Alnemri, E. S., Fernandes-Alnemri, T., Nelki, D. S., Dudley, K., DuBois, G. C., and Litwack, G. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 6839-6843). Here we describe the cloning, overexpression, and characterization of this protein from Spodoptera frugiperda insect cells (Sf9 cells). The cloned cDNA codes for an acidic protein of 412 amino acids with distinct structural domains. Starting with the N terminus, the first 218 amino acids contain two highly acidic domains separated by a short basic domain. Following the second large acidic domain is another basic domain of 87 amino acids with significant sequence and structural homology to HMG1 and HMG2 DNA binding proteins. The two basic domains contain several nuclear targeting signals. The last 108 C-terminal amino acids contain a binding domain for immunosuppressive drugs FK506 and rapamycin, which makes this protein a new member of the immunophilin family. We provide evidence that the new immunophilin (FKBP46) is a DNA binding protein that can bind immunosuppressive drug FK506 and possesses peptidylprolyl isomerase activity. FKBP46 is localized in the nucleus and is associated with a nuclear kinase that specifically phosphorylates it in the presence of Mg2+ and ATP. Upon subsequent sequence analysis of the mouse FKBP52 cDNA used in our previous study, it was observed that a spermatid nuclear transition protein 2 (TP2) sequence is fused in frame with the C terminus of the recombinant FKBP52 probably as a result of a cloning artifact. We demonstrate that the FKBP46 does not form a complex with the FKBP52 but rather with the highly basic nuclear protein TP2. Our data suggest that interaction of FKBP46 with TP2 is mediated by the N-terminal acidic domains of FKBP46. This implies that the acidic domains of FKBP46 are involved in protein-protein interaction between nuclear FKBP46 and other basic chromatin proteins.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; UNIV LONDON KINGS COLL,DIV BIOMOLEC SCI,LONDON WC2B 5RL,ENGLAND	Jefferson University; Jefferson University; University of London; King's College London					NIAID NIH HHS [AI 35035-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALNEMRI ES, 1993, P NATL ACAD SCI USA, V90, P6839, DOI 10.1073/pnas.90.14.6839; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; BASKARAN R, 1991, BIOCHEM BIOPH RES CO, V179, P1491, DOI 10.1016/0006-291X(91)91741-T; COLE KD, 1987, BIOCHEM BIOPH RES CO, V147, P437, DOI 10.1016/S0006-291X(87)80140-7; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARK ST, 1992, J BIOL CHEM, V267, P3316; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4419, DOI 10.1021/bi00470a022; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	34	41	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30828	30834						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527037				2022-12-25	WOS:A1994PV51000018
J	BUDDE, P; BEWARDER, N; WEINRICH, V; SCHULZECK, O; FREY, J				BUDDE, P; BEWARDER, N; WEINRICH, V; SCHULZECK, O; FREY, J			TYROSINE-CONTAINING SEQUENCE MOTIFS OF THE HUMAN-IMMUNOGLOBULIN-G RECEPTORS FCRIIB1 AND FCRIIB2 ESSENTIAL FOR ENDOCYTOSIS AND REGULATION OF CALCIUM FLUX IN B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA RECEPTOR; CROSS-LINKING; LYMPHOCYTES-B; HUMAN-IGG; PHOSPHORYLATION; ANTIGEN; ACTIVATION; EXPRESSION; PROLIFERATION; HETEROGENEITY	Human B cells express two closely related immunoglobulin G receptors, FcRIIb1 and FcRIIb2, which differ by a 19 amino acid insertion in the cytoplasmic tail of FcRIIb1. The cytoplasmic tails of both isoforms contain a conserved sequence motif (AENTITYSLL) essential for mediating endocytosis via FcRIIb2. Truncation of this motif abolished endocytosis, while replacement of tyrosine (Tyr-(273)) in FcRIIba by phenylalanine had no effect on the amount and kinetics of ligand uptake. Co-crosslinking of FcRIIb1 or FcRIIb2 with the antigen receptor on B cells led to an abortive calcium signal. Neither isoform interfered with the early intracellular calcium mobilization, but both prevented the opening of a plasma membrane calcium channel essential for a sustained elevated intracellular calcium level. Modulation of calcium channel activity is mediated by the same sequence motif essential for endocytosis but requires the pres- ence of Tyr(292) in FcRIIb1 and Tyr(273) in, FcRIIb2. Co-crosslinking of FcRIIb1 with surface IgG is associated with tyrosine phosphorylation of Tyr(292), whereas Tyr(272) in FcRIIb2 was not phosphorylated. Thus, FcRIIb phosphorylation is probably not directly involved in the modulation of the calcium signal but may be essential for further diversification of signals transduced via the coexpressed isoforms FcRIIb1 and FcRIIb2.	UNIV BIELEFELD,FAK CHEM,D-33615 BIELEFELD,GERMANY	University of Bielefeld								AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BUDDE P, 1994, EUR J CELL BIOL, V64, P45; CAMBIER JC, 1994, CURR OPIN GENET DEV, V4, P55, DOI 10.1016/0959-437X(94)90091-4; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASSEL DL, 1993, MOL IMMUNOL, V30, P451, DOI 10.1016/0161-5890(93)90113-P; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; ENENKEL B, 1991, EUR J IMMUNOL, V21, P659, DOI 10.1002/eji.1830210318; ENGELHARDT W, 1991, EUR J IMMUNOL, V21, P2227, DOI 10.1002/eji.1830210934; ENGELHARDT W, 1990, EUR J IMMUNOL, V20, P1367, DOI 10.1002/eji.1830200624; FRIDMAN WH, 1992, IMMUNOL REV, V125, P49, DOI 10.1111/j.1600-065X.1992.tb00625.x; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GREENMAN J, 1991, MOL IMMUNOL, V28, P1243, DOI 10.1016/0161-5890(91)90011-8; HONING S, 1991, EUR J CELL BIOL, V55, P48; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; JENKINS MK, 1990, J IMMUNOL, V144, P1585; JONES B, 1986, J IMMUNOL, V136, P348; KEIJ JF, 1989, CYTOMETRY, V10, P814, DOI 10.1002/cyto.990100623; KLAUS GGB, 1985, IMMUNOLOGY, V56, P321; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIU Y, 1992, P NATL ACAD SCI USA, V89, P3845, DOI 10.1073/pnas.89.9.3845; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PULFORD K, 1986, IMMUNOLOGY, V57, P71; RIJKERS GT, 1990, CYTOMETRY, V11, P923, DOI 10.1002/cyto.990110813; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARMAY G, 1990, INT IMMUNOL, V2, P1235, DOI 10.1093/intimm/2.12.1235; SARMAY G, 1994, P NATL ACAD SCI USA, V91, P4140, DOI 10.1073/pnas.91.10.4140; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; VANDENHERIKOUDIJK IE, 1994, J IMMUNOL, V152, P574; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VARIN N, 1989, EUR J IMMUNOL, V19, P2263, DOI 10.1002/eji.1830191213; WARMERDAM PAM, 1991, J IMMUNOL, V147, P13338	40	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30636	30644						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527034				2022-12-25	WOS:A1994PU52500091
J	TREANOR, JJS; SCHMELZER, C; KNUSEL, B; WINSLOW, JW; SHELTON, DL; HEFTI, F; NIKOLICS, K; BURTON, LE				TREANOR, JJS; SCHMELZER, C; KNUSEL, B; WINSLOW, JW; SHELTON, DL; HEFTI, F; NIKOLICS, K; BURTON, LE			HETERODIMERIC NEUROTROPHINS INDUCE PHOSPHORYLATION OF TRK RECEPTORS AND PROMOTE NEURONAL DIFFERENTIATION IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTOONCOGENE PRODUCT; RECOMBINANT HUMAN; KINASE; NGF; BDNF; BINDING; ENCODES; EXPRESSION; PROTEINS	Neurotrophins are a family of highly conserved proteins that affect the development and maintenance of distinct neuronal populations. Neurotrophins exist in vivo as homodimers, but we show that neurotrophins can exist as heterodimers in vitro and are pluripotent, being able to bind and to activate different Trk tyrosine kinase receptors as well as promote neuronal differentiation in PC12 cells as effectively as wild type homodimers. These asymmetric neurotrophin dimers allow unique characterization of neurotrophin structure-function relationships with Trk receptors. The chimeric Trk activities of these heterodimers suggest an alternative model of neurotrophin-Trk receptor activation in which the critical Trk-interacting elements may be attributed to a single protomer.	GENENTECH INC,DEPT RECOVERY PROC RES & DEV,S SAN FRANCISCO,CA 94080; UNIV SO CALIF,ANDRUS GERONTOL CTR,LOS ANGELES,CA 94080	Roche Holding; Genentech; University of Southern California	TREANOR, JJS (corresponding author), GENENTECH INC,DEPT NEUROSCI,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.				NATIONAL INSTITUTE ON AGING [P01AG010480] Funding Source: NIH RePORTER; NIA NIH HHS [AG10480-04] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGELETT.RH, 1971, BIOCHEMISTRY-US, V10, P463; [Anonymous], [No title captured]; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; BURTON LE, 1992, J NEUROCHEM, V59, P1937, DOI 10.1111/j.1471-4159.1992.tb11030.x; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; ESCANDON E, 1993, J NEUROSCI RES, V34, P601, DOI 10.1002/jnr.490340602; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; HAMEL W, 1993, J NEUROSCI RES, V34, P147, DOI 10.1002/jnr.490340202; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JUNGBLUTH S, 1994, EUR J BIOCHEM, V221, P677, DOI 10.1111/j.1432-1033.1994.tb18780.x; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KNUSEL B, 1990, J NEUROSCI, V10, P558; KNUSEL B, 1994, J NEUROSCI, V14, P1542, DOI 10.1523/JNEUROSCI.14-03-01542.1994; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LUO Y, 1992, J BIOL CHEM, V267, P12275; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOORE JB, 1975, NEUROBIOLOGY, V5, P369; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NARHI LO, 1993, J BIOL CHEM, V268, P13309; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RADZIEWJEWSKI C, 1993, BIOCHEMISTRY-US, V32, P13350, DOI 10.1021/bi00211a049; SCHMELZER CH, 1992, J NEUROCHEM, V59, P1675, DOI 10.1111/j.1471-4159.1992.tb10998.x; SHIH A, 1994, J BIOL CHEM, V269, P27679; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUTER U, 1992, J NEUROSCI, V12, P306; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALE RD, 1985, METHOD ENZYMOL, V109, P21	40	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23104	23110		10.1074/jbc.270.39.23104	http://dx.doi.org/10.1074/jbc.270.39.23104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559453	hybrid			2022-12-25	WOS:A1995RY05400073
J	PAVETO, C; PEREIRA, C; ESPINOSA, J; MONTAGNA, AE; FARBER, M; ESTEVA, M; FLAWIA, MM; TORRES, HN				PAVETO, C; PEREIRA, C; ESPINOSA, J; MONTAGNA, AE; FARBER, M; ESTEVA, M; FLAWIA, MM; TORRES, HN			THE NITRIC-OXIDE TRANSDUCTION PATHWAY IN TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN MEMBRANES; BINDING-SITES; RELAXING FACTOR; RECEPTORS; GLUTAMATE; ANTAGONIST; SYNTHASE; AFFINITY; LIVER; ACID	A nitric oxide synthase was partially purified from soluble extracts of Trypanosoma cruzi epimastigote forms. The conversion of L-arginine to citrulline by this enzyme activity required NADPH and was blocked by EGTA. The reaction was activated by Ca2+, calmodulin, tetrahydrobiopterin, and FAD, and inhibited by N-omega-methyl-L-arginine. L-Glutamate and N-methyl-D-aspartate stimulated in vivo conversion of L-arginine to citrulline by epimastigote cells. These stimulations could be blocked by EGTA, MK-801, and ketamine and enhanced by glycine. A sodium nitroprusside-activated guanylyl cyclase activity was detected in cell-free, soluble preparations of T. cruzi epimastigotes. L-Glutamate, N-methyl-D-aspartate, and sodium nitroprusside increased epimastigote cyclic GMP levels. MK-801 bound specifically to T. cruzi epimastigote cells. This binding was competed by ketamine and enhanced by glycine or L-serine. Evidence thus indicates that in T. cruzi epimastigotes, L-glutamate controls cyclic GMP levels through a pathway mediated by nitric oxide.	CONSEJO NACL INVEST CIENT & TECN,INST INVEST INGN GENET & BIOL MOLEC,RA-1428 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,RA-1428 BUENOS AIRES,DF,ARGENTINA; INST NACL DIAGNOST & INVEST ENFERMED CHAGAS MARIO,RA-1063 BUENOS AIRES,DF,ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires			Torres, Héctor/GXG-1780-2022; Pereira, Claudio A/F-5382-2012	Pereira, Claudio A/0000-0001-7874-1894				BIRNBAUMER L, 1978, ANAL BIOCHEM, V93, P124; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; FOSTER AC, 1984, BRAIN RES REV, V7, P103, DOI 10.1016/0165-0173(84)90020-1; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KIMURA H, 1975, J BIOL CHEM, V250, P8016; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; MARTIN W, 1988, BRIT J PHARMACOL, V93, P229, DOI 10.1111/j.1476-5381.1988.tb11426.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MURPHY DE, 1987, J PHARMACOL EXP THER, V240, P778; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994; VINCENDEAU P, 1992, EXP PARASITOL, V75, P353, DOI 10.1016/0014-4894(92)90220-5; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; [No title captured]	25	73	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16576	16579		10.1074/jbc.270.28.16576	http://dx.doi.org/10.1074/jbc.270.28.16576			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542649	hybrid			2022-12-25	WOS:A1995RJ34700020
J	ZHANG, R; MIN, W; SESSA, WC				ZHANG, R; MIN, W; SESSA, WC			FUNCTIONAL-ANALYSIS OF THE HUMAN ENDOTHELIAL NITRIC-OXIDE SYNTHASE PROMOTER - SP1 AND GATA FACTORS ARE NECESSARY FOR BASAL TRANSCRIPTION IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CLONING; PRODUCT; PROTEIN	To gain insights into the mechanisms of endothelial nitric oxide synthase (eNOS) gene expression, we have cloned the eNOS promoter and fused it to a luciferase reporter gene to map regions of the promoter important for basal transcription in bovine aortic endothelial cells (BAEC), Transfection of BAEC with F1 luciferase (LUC) (-1600 to +22 nucleotides) yielded a 35-fold increase in promoter. Progressive deletion from -1600 to -1033 (F2 and F3 LUG) did not significantly influence eNOS promoter activity, Further deletion from -1033 to -779 (F4 LUG) resulted in an approximate 40% reduction in basal promoter activity, and still further deletion from -779 to -494 (F5 LUG) did not markedly influence activity. Deletion from -494 to -166 (F6 LUG) reduced eNOS promoter activity by 40-50%. Specific mutation of the consensus GATA site (-230) in the F3 LUC construct reduced luciferase activity (by 25-30%). Gel shift analysis and antibody depletion using BAEC nuclear extracts demonstrated in vitro binding of GATA-2 to the oligonucleotide sequence containing the -250 GATA site, Next, we mutated the Sp1 site (-103) in the F3 and F6 LUC constructs and in the F3 GATA mutant construct. Expression of these Sp1 mutants in BAEC resulted in a 85-90% reduction in normalized luciferase activity. Gel shift and antibody supershift analysis using a BAEC nuclear extracts demonstrated four specific, DNA-protein complexes binding to the eNOS Sp-1 site, with the slowest migrating form composed of Sp1 and another nuclear protein, These data demonstrate that the Sp1 site is an important cis-element in the core eNOS promoter.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,MOLEC CARDIOBIOL PROGRAM,NEW HAVEN,CT 06536	Yale University; Yale University			Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051948] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29-HL51948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAL JF, 1994, AM J PHYSIOL-CELL PH, V267, pC1381, DOI 10.1152/ajpcell.1994.267.5.C1381; ASSOULINE Z, 1988, BIOCHEM BIOPH RES CO, V156, P389; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LIU JW, 1994, J BIOL CHEM, V269, P11691; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PAN JL, 1993, J BIOL CHEM, V268, P22600; REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; SESSA WC, 1993, HYPERTENSION, V21, P934, DOI 10.1161/01.HYP.21.6.934; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; SESSA WC, 1992, J BIOL CHEM, V267, P15524; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; TRACEY WR, 1994, AM J PHYSIOL, V266, pC22, DOI 10.1152/ajpcell.1994.266.1.C22; VENEMA RC, 1994, BBA-GENE STRUCT EXPR, V1218, P413, DOI 10.1016/0167-4781(94)90195-3; XIE J, 1995, IN PRESS P NATL ACAD, V92; XIE QW, 1994, J BIOL CHEM, V269, P4705	36	196	209	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15320	15326		10.1074/jbc.270.25.15320	http://dx.doi.org/10.1074/jbc.270.25.15320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541039	hybrid			2022-12-25	WOS:A1995RE66600071
J	KOGAN, TP; REVELLE, BM; TAPP, S; SCOTT, D; BECK, PJ				KOGAN, TP; REVELLE, BM; TAPP, S; SCOTT, D; BECK, PJ			A SINGLE AMINO-ACID RESIDUE CAN DETERMINE THE LIGAND SPECIFICITY OF E-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; MANNOSE-BINDING PROTEIN; CARBOHYDRATE-RECOGNITION DOMAINS; VASCULAR ENDOTHELIAL-CELLS; T-CELLS; ELAM-1; OLIGOSACCHARIDE; IDENTIFICATION; NEUTROPHILS; EXPRESSION	E-selectin (ELAM-1) is a member of the selectin family of cellular adhesion molecules. This family of proteins possesses an amino-terminal Ca2+-dependent lectin or carbohydrate recognition domain that is essential for Ligand binding. A known E-selectin ligand is the carbohydrate antigen, sialyl Lewis(x) (sLe(x)) (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha-1-3)GlcNAc). We have developed a model of E-selectin binding to the sLe(x) tetrasaccharide, (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc), using the NMR-determined, E-selectin-bound solution conformation of sLe(x) (Cooke, R. M., Hale, R. S., Lister, S. G., Shah, G., and Weir, M. P. (1994) Biochemistry 33, 10591-10596) together with the x-ray crystallographic structures of E-selectin (Graves, B. J., Crowther, R. L., Chandran, C., Rumberger, J. B., Li, s., Huang, K.-S., Presky, D. H., Familletti, P. C., Wolitzky, B. A., and Burns, D. K. (1994) Nature 367, 532-538) (ligand unbound) and a related C-type animal lectin, the mannose-binding protein (Weis, W. I., Drickamer, K., and Hendrickson, A. (1992) Nature 360, 127-134) (ligand bound). Analysis of this model indicated that the alteration of one E-selectin amino acid, alanine 77, to a lysine residue might shift binding specificity from sLe(x) to mannose. The results presented here show that an E-selectin mutant protein possessing this change displays preferential binding to mannose containing oligosaccharides and that further mutagenesis of this mannose-binding selectin confers galactose recognition in a predictable manner. These mutagenesis data support the presented model of the detailed interactions between E-selectin and the sLe(x) oligosaccharide.	TEXAS BIOTECHNOL CORP,DEPT BIOL MOLEC,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT INTERNAL MED,HOUSTON,TX 77030	University of Texas System	KOGAN, TP (corresponding author), TEXAS BIOTECHNOL CORP,DEPT MED CHEM,HOUSTON,TX 77030, USA.							ABOLA EE, 1987, PROTEIN DATA BANK CR; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BERNSTEIN FC, 1977, J MOL BIOL, V115, P535; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BJERCKE RJ, 1986, J IMMUNOL METHODS, V90, P203, DOI 10.1016/0022-1759(86)90077-3; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BURKERT U, 1982, MOL MECHANICS; CARLOS T, 1991, BLOOD, V77, P2266; COOKE RM, 1994, BIOCHEMISTRY-US, V33, P10591, DOI 10.1021/bi00201a004; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GRABER N, 1990, J IMMUNOL, V145, P819; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; ICHIKAWA Y, 1992, J AM CHEM SOC, V114, P9283, DOI 10.1021/ja00050a007; MILLS A, 1993, FEBS LETT, V319, P5, DOI 10.1016/0014-5793(93)80026-Q; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POBER JS, 1986, J IMMUNOL, V136, P1680; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; TIERMEYER M, 1991, P NATL ACAD SCI USA, V88, P10372; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1994, STRUCTURE, V2, P147, DOI 10.1016/S0969-2126(00)00016-2; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430	34	88	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14047	14055		10.1074/jbc.270.23.14047	http://dx.doi.org/10.1074/jbc.270.23.14047			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539797	hybrid			2022-12-25	WOS:A1995RC44800067
J	MATSUSHITA, T; SADLER, JE				MATSUSHITA, T; SADLER, JE			IDENTIFICATION OF AMINO-ACID-RESIDUES ESSENTIAL FOR VON-WILLEBRAND-FACTOR BINDING TO PLATELET GLYCOPROTEIN IB - CHARGED-TO-ALANINE SCANNING MUTAGENESIS OF THE A1 DOMAIN OF HUMAN VON-WILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; BOTHROPS-JARARACA; MONOCLONAL-ANTIBODIES; HEMOPHILIA-A; ALPHA-CHAIN; IX COMPLEX; BOTROCETIN; RISTOCETIN; MUTATION; RECEPTOR	At sites of vascular injury, von Willebrand factor (VWF) mediates platelet adhesion through binding to platelet glycoprotein Ib (GPIb). The VWF-GPIb interaction was investigated by clustered charged-to-alanine scanning mutagenesis of VWF domain A1 between His-473 and Gly-716. Recombinant variants of VWF were assayed for binding to conformation-dependent monoclonal antibody NMC-4, for ristocetin-induced and botrocetin-induced binding to platelets, and for direct binding to botrocetin. Substitutions at 32 amino acids had no effect on VWF function. The epitope of NMC-4 depended on charged residues between Asp-514 and Arg-632 and not on segments previously implicated by peptide inhibition studies, Cys-474-Pro-488 and Leu-694-Pro-708. Substitutions at Glu-626 and in the segment Asp-520-Lys-534 abolished ristocetin-induced binding of VWF to GPIb but did not affect botrocetin-induced binding, suggesting that these regions are required for modulation by ristocetin but not for binding of VWF to GPIb. Mutations at Glu-596 and Lys-599 decreased binding of VWF to GPIb without affecting its binding to botrocetin, suggesting that this segment interacts directly with GPIb. Alanine substitutions at Arg-545 and in the segments Glu-497-Arg-511 and Arg-687-Glu-689 caused increased binding of VWF to GPIb. These results, and the locations of von Willebrand disease type 2B mutations, suggest that two acidic regions containing the Cys-509-Cys-695 disulfide (Glu-497-Arg-511, Arg-687-Val-698) and one predominantly basic region (Met-540-Arg-578) cooperate to inhibit a distinct GPIb binding site in the VWF A1 domain. This inhibition is relieved by specific mutations, by the modulators ristocetin and botrocetin, or by binding to subendothelial connective tissue.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Matsushita, Tadadshi/I-7349-2014; Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X				ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; AZUMA H, 1993, THROMB HAEMOSTASIS, V69, P192; BERNDT MC, 1992, BIOCHEMISTRY-US, V31, P11144, DOI 10.1021/bi00160a027; BURKE RL, 1986, J BIOL CHEM, V261, P2574; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLER BS, 1983, BLOOD, V61, P99; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DONG ZG, 1994, J BIOL CHEM, V269, P6753; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FUJIMURA Y, 1992, THROMB HAEMOSTASIS, V68, P464; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; GINSBURG D, 1993, THROMB HAEMOSTASIS, V69, P177; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOLMBERG L, 1993, J CLIN INVEST, V91, P2169, DOI 10.1172/JCI116443; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MAZURIER C, 1990, BRIT J HAEMATOL, V76, P372, DOI 10.1111/j.1365-2141.1990.tb06371.x; MIURA S, 1994, BLOOD, V84, P1553; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; MURATA M, 1991, J BIOL CHEM, V266, P15474; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; RANDI AM, 1992, J BIOL CHEM, V267, P21187; RIBBA AS, 1994, BLOOD, V83, P833; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SHIMA M, 1985, J NARA MED ASS, V36, P662; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; USAMI Y, 1993, P NATL ACAD SCI USA, V90, P928, DOI 10.1073/pnas.90.3.928; VICENTE V, 1990, J BIOL CHEM, V265, P274; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	42	129	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13406	13414		10.1074/jbc.270.22.13406	http://dx.doi.org/10.1074/jbc.270.22.13406			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539426	hybrid			2022-12-25	WOS:A1995RB43900068
J	DROLL, A; DOUGHERTY, ST; CHIU, RK; DIRKS, JF; MCBRIDE, WH; COOPER, DL; DOUGHERTY, GJ				DROLL, A; DOUGHERTY, ST; CHIU, RK; DIRKS, JF; MCBRIDE, WH; COOPER, DL; DOUGHERTY, GJ			ADHESIVE INTERACTIONS BETWEEN ALTERNATIVELY SPLICED CD44 ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; MONOCLONAL-ANTIBODIES; HYALURONATE RECEPTOR; EXTRACELLULAR DOMAIN; HEMATOPOIETIC-CELLS; GENE-TRANSFER; DISTINCT; VARIANT; BINDING; EXONS	Alternative splicing of a series of 10 contiguous exons present within the CD44 gene can generate a large number of differentially expressed CD44 isoforms that contain additional peptide sequences of varying length inserted into a single site within the extracellular domain of the molecule proximal to the membrane spanning domain. Although distinct functions have been ascribed to certain of these isoforms, the effect of particular inserted domains on the ligand-binding specificity of the CD44 molecule remains unclear. In the present study, we demonstrate that while CD44H, the major CD44 isoform expressed on resting hemopoietic cells, and CD44R1, an alternatively spliced isoform present on transformed epithelial cells and certain activated and/or malignant hemopoietic cell types, can both bind avidly to hyaluronan, only CD44R1 can promote homotypic cellular aggregation when expressed in the CD44-negative murine lymphoma cell line TIL1. Experiments in which TIL1 cells transduced with different CD44 isoforms were tested for their ability to adhere to one another or to COS7 cells transfected with CD44R1, indicated that CD44R1 can recognize and bind a common determinant present on both CD44H and CD44R1. Monoclonal antibody blocking studies suggest further, that the determinant recognized by CD44R1 is located in a region of the CD44 molecule distinct from that involved in hyaluronan binding.	BRITISH COLUMBIA CANC AGCY, DEPT RADIAT ONCOL, VANCOUVER, BC V5Z 1L3, CANADA; UNIV CALIF LOS ANGELES, MED CTR, DEPT RADIAT ONCOL, LOS ANGELES, CA 90024 USA; UNIV PITTSBURGH, SCH MED, DEPT PATHOL, PITTSBURGH, PA 15261 USA	British Columbia Cancer Agency; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DROLL, A (corresponding author), BRITISH COLUMBIA CANC AGCY, TERRY FOX LAB, TUMOUR IMMUNOL GRP, 601 W 10TH AVE, VANCOUVER, BC V5Z 1L3, CANADA.							ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARD JBL, 1983, J CELL SCI, V62, P371; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hakomori S., 1986, HDB EXPT IMMUNOLOGY; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; HUGHES PFD, 1992, J CLIN INVEST, V89, P1817, DOI 10.1172/JCI115786; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANSDORP PM, 1980, J IMMUNOL METHODS, V39, P393, DOI 10.1016/0022-1759(80)90240-9; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MCBRIDE WH, 1979, J EXP MED, V149, P507, DOI 10.1084/jem.149.2.507; MCBRIDE WH, 1992, CANCER RES, V52, P3931; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; St John T, 1989, Reg Immunol, V2, P300; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; SUGIMOTO K, 1994, EXP HEMATOL, V22, P488; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; TOYAMASORIMACHI N, 1994, INT IMMUNOL, V6, P655, DOI 10.1093/intimm/6.4.655	38	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11567	11573		10.1074/jbc.270.19.11567	http://dx.doi.org/10.1074/jbc.270.19.11567			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7538117	hybrid			2022-12-25	WOS:A1995QX86500076
J	HE, TC; JIANG, N; ZHUANG, HM; WOJCHOWSKI, DM				HE, TC; JIANG, N; ZHUANG, HM; WOJCHOWSKI, DM			ERYTHROPOIETIN-INDUCED RECRUITMENT OF SHC VIA A RECEPTOR PHOSPHOTYROSINE-INDEPENDENT, JAK2-ASSOCIATED PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; PROTEIN; GRB2; ASSOCIATION; RAS; ACTIVATION	Based on the recently implicated role of Shc as a signaling effector for type I cytokine receptors, factors which mediate the recruitment and phosphorylation of Shc in the erythropoietin receptor (EPOR) system have been studied. FDC-P1 cells stably expressing the wild type murine EPOR supported the EPO-induced association of Shc with Jak2 and its rapid tyrosine phosphorylation. However, this did not depend upon the presence of phosphotyrosine sites within the EPOR and was mediated by a mitogenically deficient receptor form (EPOR329) lacking cytoplasmic tyrosine residues. This was shown both by Western blotting of Shc and Jak2 co-immunoprecipitates and through the development of an in vitro assay for cytokine-induced Shc phosphorylation. The direct association of Shc with Jak2 also was observed and was shown to depend upon EPO-exposure and the SH2 subdomain of Shc. Together, these studies indicate that Jak2, in part, may mediate the EPO-induced phosphorylation of Shc.	PENN STATE UNIV,DEPT PATHOBIOL & VET SCI,UNIVERSITY PK,PA 16802; PENN STATE UNIV,INTERCOLL GRAD PROGRAM GENET,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	HE, TC (corresponding author), PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040242, R01DK040242] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03042, HL44491] Funding Source: Medline; NIDDK NIH HHS [DDK40242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HANAZONO Y, 1993, BLOOD, V81, P3193; HE TC, 1993, BLOOD, V82, P3530; HE TC, 1994, J BIOL CHEM, V269, P18291; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V268, P18674; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMIT L, 1994, J BIOL CHEM, V269, P20209; SONYANG Z, 1994, MOL CELL BIOL, V14, P2777; TORTI M, 1992, J BIOL CHEM, V267, P8293; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	48	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11055	11061		10.1074/jbc.270.19.11055	http://dx.doi.org/10.1074/jbc.270.19.11055			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7538110	hybrid			2022-12-25	WOS:A1995QX86500009
J	HUH, HY; LO, SK; YESNER, LM; SILVERSTEIN, RL				HUH, HY; LO, SK; YESNER, LM; SILVERSTEIN, RL			CD36 INDUCTION ON HUMAN MONOCYTES UPON ADHESION TO TUMOR NECROSIS FACTOR-ACTIVATED ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GLYCOPROTEIN-IV; MELANOMA-CELLS; GROWTH-FACTOR; RECEPTOR; IDENTIFICATION; SPECIFICITY; RECOGNITION; NEUTROPHILS; BINDING	Cell adhesion between circulating monocytes and the endothelium is a critical component of vascular thromboregulation and atherogenesis. The biochemical and genetic consequences of adhesion are poorly understood, We have found that monocyte surface expression of CD36, an integral membrane receptor for thrombospondin, collagen, and oxidized low density lipoprotein, increased dramatically upon adhesion to tumor necrosis factor-activated human umbilical vein endothelial cells (HUVEC), Expression was assessed by indirect immunofluorescence microscopy and immunoblotting using monoclonal antibodies to CD36, Steady-state CD36 mRNA levels, detected by RNase protection assay, also showed a similar pattern of up-regulation, To verify the adhesion dependence of the observed phenomenon, monocytes were co-cultured with tumor necrosis factor-activated HUVEC in a transwell apparatus that physically separated monocytes from the endothelial cells, Under these conditions, no increase in CD36 expression was detected, demonstrating that the enhanced monocyte CD36 expression observed is not due to soluble factors released by HUVEC, To characterize the specific adhesion molecules involved in the process, co culture assays were performed on murine L cells transfected with either human E-selectin or intercellular adhesion molecule-1 cDNAs, A dramatic increase in CD36 mRNA was seen upon monocyte adhesion to E-selectin-transfected L cells compared with adhesion to intercellular adhesion molecule-1 or control transfectants, Furthermore, monoclonal antibodies to E-selectin inhibited the adhesion-dependent up-regulation of CD36 mRNA induced by transfected L cells or cytokine-activated endothelial cells, These findings demonstrate adhesion-dependent gene regulation of monocyte CD36 and suggest the possible involvement of E-selectin in initiating this process.	CORNELL UNIV,COLL MED,DEPT MED,DIV HEMATOL & ONCOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,NATL INST HLTH,SPECIALIZED CTR RES THROMBOSIS,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; National Institutes of Health (NIH) - USA					NHLBI NIH HHS [HL 46403, HL 18828, HL 42540] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, P50HL018828, R01HL042540] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LO SK, 1995, IN PRESS J IMMUNOL; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; NICHOLSON AC, 1995, IN PRESS ARTERIOSCLE; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TANDON NN, 1989, J BIOL CHEM, V264, P7576; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YESNER LM, 1993, MOL BIOL CELL, V4, P1035	22	51	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6267	6271		10.1074/jbc.270.11.6267	http://dx.doi.org/10.1074/jbc.270.11.6267			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7534309	hybrid			2022-12-25	WOS:A1995QM94500083
J	PEARCE, SFA; WU, J; SILVERSTEIN, RL				PEARCE, SFA; WU, J; SILVERSTEIN, RL			RECOMBINANT GST/CD36 FUSION PROTEINS DEFINE A THROMBOSPONDIN BINDING DOMAIN - EVIDENCE FOR A SINGLE CALCIUM-DEPENDENT BINDING-SITE ON CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; MEMBRANE-PROTEIN; GLYCOPROTEIN-IV; PLATELET THROMBOSPONDIN; SECRETE THROMBOSPONDIN; COMPLEX-FORMATION; TISSUE ACTIVATOR; EPITHELIAL-CELLS; RECEPTOR; ADHESION	CD36 is a multifunctional cell surface glycoprotein that acts as a surface receptor for thrombospondin (TSP), and thereby may mediate adhesive interactions between cells and substrata, platelets and other cells, and macrophages and apoptotic neutrophils. The identity of the TSP binding site on CD36 is controversial and may involve more than one structural domain. We have constructed a series of recombinant bacterial GST/CD36 fusion proteins that span nearly all of the CD36 molecule and have demonstrated that fusion proteins containing the region extending from amino acid 93 to 120 formed specific, saturable, and reversible complexes with TSP. As with intact CD36, binding was calcium-dependent, was independent of which ligand was immobilized, and was blocked by monoclonal antibodies to both CD36 and TSP. Stoichiometry and affinity of the fusion proteins for TSP were consistent with that of the intact protein. We also demonstrated that these fusion proteins competitively inhibited binding of TSP to puri fied platelet CD36 and to cell surface CD36 on peripheral blood monocytes and CD36 cDNA-transfected melanoma cells. These data demonstrate that the region between amino acids 93 and 120 has all of the characteristics required of the TSP binding domain.	CORNELL UNIV,COLL MED,DEPT MED HEMATOL ONCOL,NEW YORK,NY 10021	Cornell University					NHLBI NIH HHS [T32 HL-07029, R01-HL42540, P5O-HL46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007029, P01HL046403, R01HL042540] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CATIMEL B, 1992, BIOCHEM J, V284, P21; CLEMETSON KJ, 1977, BIOCHIM BIOPHYS ACTA, V464, P493, DOI 10.1016/0005-2736(77)90025-6; CLEMETSON KJ, 1985, PLATELET MEMBRANE GL, P51; DAVIES J, 1987, SEMIN THROMB HEMOST, V13, P378; EDELMAN P, 1986, BLOOD, V67, P56; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; HANDUNNETTI SM, 1992, BLOOD, V80, P2097; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OSHEA KS, 1990, J CELL BIOL, V111, P2713, DOI 10.1083/jcb.111.6.2713; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; PEARCE SFA, 1994, BLOOD, V84, P384; RISER BL, 1989, CANCER RES, V49, P6123; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; RYEOM SW, 1994, CLIN RES, V42, pA113; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SILVERSTEIN RL, 1986, J CLIN INVEST, V79, P867; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	46	73	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2981	2986		10.1074/jbc.270.7.2981	http://dx.doi.org/10.1074/jbc.270.7.2981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531696	hybrid			2022-12-25	WOS:A1995QG47100017
J	BENJAMIN, CW; LINSEMAN, DA; JONES, DA				BENJAMIN, CW; LINSEMAN, DA; JONES, DA			PLATELET-DERIVED GROWTH-FACTOR STIMULATES PHOSPHORYLATION OF GROWTH-FACTOR RECEPTOR-BINDING PROTEIN-2 IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; TYROSINE KINASES; PHOSPHOAMINO ACIDS; GRB2; RAS; SH2; ASSOCIATION; SEVENLESS; DOMAIN	Growth factor receptor binding protein-2 (GRB2) couples growth factor receptor activation to the p21(ras) nucleotide exchange factor son-of-sevenless (SOS). Son-of-sevenless can serve as a substrate for mitogen-activated protein kinases and may be subject to feed back regulation in mitogen-stimulated cells. Herein, we demonstrate phosphorylation on GRB2 in rat A10 Vascular smooth muscle cells exposed to platelet-derived growth factor (PDGF). Lysates from smooth cells stimulated with PDGF revealed a shift in the electrophoretic mobility of GRB2. Further investigation confirmed that phosphorylation on GRB2 accompanied this mobility shift. Phosphorylation on GRB2 was time dependent and correlated with PDGF receptor activation. The time-course for phosphorylation of GRB2 and subsequent decay corresponded with other events characteristic of platelet-derived growth factor signaling. GRB2 was not phosphorylated in cells treated with phorbol 12-myristate 13-acetate, and down-regulation of protein kinase C failed to attenuate phosphorylation on GRB2 in response to growth factor. Analysis of GRB2 immune complexes revealed a kinase activity capable of phosphorylating GRB2 in vitro and demonstrated that the kinase activated in response to PDGF may physically associate with GRB2 signaling complexes.	UPJOHN CO,UPJOHN LABS,KALAMAZOO,MI 49001	Pfizer			Linseman, Daniel/L-3846-2019					BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BOBIK A, 1993, PHARMACOL REV, V45, P1; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCROSKEY MC, 1988, J CHROMATOGR, V442, P307, DOI 10.1016/S0021-9673(00)94478-9; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMPSON KE, 1993, J CELL BIOCHEM, V52, P384, DOI 10.1002/jcb.240520403; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	22	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31346	31349						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527385				2022-12-25	WOS:A1994PX30300007
J	LEMMON, MA; LADBURY, JE; MANDIYAN, V; ZHOU, M; SCHLESSINGER, J				LEMMON, MA; LADBURY, JE; MANDIYAN, V; ZHOU, M; SCHLESSINGER, J			INDEPENDENT BINDING OF PEPTIDE LIGANDS TO THE SH2 AND SH3 DOMAINS OF GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; GUANINE-NUCLEOTIDE EXCHANGE; SURFACE-PLASMON RESONANCE; SIGNALING GENE SEM-5; ADAPTER PROTEIN; VIRAL ONCOGENE; RAS; RECEPTOR; ASSOCIATION; KINASES	Grb2, composed entirely of SH2 and SH3 domains, serves as an adaptor protein in signaling from growth factor-activated tyrosine kinase receptors. It interacts via its SH2 domain with the autophosphorylated carboxyl-terminal tail of activated epidermal growth factor (EGF) receptor and via its SH3 domains with proline-rich sequences in the Ras guanine nucleotide releasing factor, Son of sevenless (Sos). Recruitment of the Grb2.Sos complex to the receptor upon its stimulation leads to Ras activation. A major question remains as to whether SH2-mediated binding of Grb2 to the activated receptor results in conformational changes that influence its SH3-mediated association with Sos, thereby affecting Sos activity, This question is addressed through studies of the binding to intact Grb2 of an EGF receptor-derived phosphotyrosine-containing peptide and a Sos-derived proline-rich peptide using isothermal titration calorimetry and surface plasmon resonance measurements. The phosphopeptide binds to Grb2 in a 1:1 complex, with a K-D of 0.4 mu M. The Sos proline-rich peptide binds to Grb2 in a 2:1 complex, with a K-D of 22 mu M. Saturation of the SH2 domain of Grb2 with the EGFR phosphopeptide was found not to affect its subsequent binding to the Sos peptide. Thus we detected no influence of SH2 binding upon SH3-mediated interactions, suggesting that the domains do not communicate, and that recruitment itself of Sos to the cell surface is sufficient for Ras signaling.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University				Lemmon, Mark/0000-0002-3379-5319; Ladbury, John/0000-0002-6328-7200	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM004725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM04725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31653	31658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527391				2022-12-25	WOS:A1994PX30300052
J	WANG, DR; BAUMANN, A; SZEBENI, A; OLSON, MOJ				WANG, DR; BAUMANN, A; SZEBENI, A; OLSON, MOJ			THE NUCLEIC-ACID BINDING-ACTIVITY OF NUCLEOLAR PROTEIN B23.1 RESIDES IN ITS CARBOXYL-TERMINAL END	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOPROTEIN B23; 2 FORMS; GENE; LOCALIZATION; C23	Protein B23 is a major nucleolar phosphoprotein proposed to be a ribosome assembly factor. Protein B23 exists as two isoforms, B23.1 and B23.2, differing only in their carboxyl-terminal sequences. The interaction of recombinantly produced B23 isoforms with double-stranded DNA was studied using gel retardation and nitrocellulose filter disk assays. Protein B23.1 bound saturably to radiolabeled plasmid DNA. By competition assays protein B23.1 was also capable of binding RNA and single-stranded DNA. On the other hand, protein B23.2, the shorter of the two isoforms, was not capable of binding double-stranded DNA. The latter result suggested that the carboxyl-terminal end of B23.1 is essential for DNA binding activity. This was confirmed by partial digestion experiments using staphylococcal V8 protease which showed that a 5-kDa fragment, containing the carboxyl-terminal end of protein B23.1 retained DNA binding activity similar to that of the parent molecule. In contrast, a 19-kDa fragment from the aminoterminal half of B23.1 did not bind DNA. The sequence of the carboxyl-terminal 68 amino acids comprising the 5-kDa fragment showed little, if any, similarity to other proteins, suggesting that this segment contains a previously undiscovered nucleic acid binding motif.	UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Mississippi; University of Mississippi Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028349] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 RO1 GM28349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGIOGERA M, 1989, J HISTOCHEM CYTOCHEM, V37, P1371, DOI 10.1177/37.9.2768807; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHANG JH, 1989, J BIOL CHEM, V264, P11732; CHANG JH, 1990, J BIOL CHEM, V265, P18227; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FLORES C, 1990, NUCLEIC ACIDS RES, V18, P901, DOI 10.1093/nar/18.4.901; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; MARKS GL, 1993, GENE, V123, P121, DOI 10.1016/0378-1119(93)90550-M; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; OLSON MOJ, 1990, EUKARYOTIC NUCLEUS M, V2, P541; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; Raska I., 1993, CHROMOSOME TODAY, V11, P101, DOI [DOI 10.1007/978-94-011-1510-0_8, 10.1007/978-94-011-1510-0_8]; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P461; UMEKAWA H, 1993, CELL MOL BIOL RES, V39, P635; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	30	102	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30994	30998						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527039				2022-12-25	WOS:A1994PV51000042
J	WEBB, DJ; ATKINS, TL; CROOKSTON, KP; BURMESTER, JK; QIAN, SW; GONIAS, SL				WEBB, DJ; ATKINS, TL; CROOKSTON, KP; BURMESTER, JK; QIAN, SW; GONIAS, SL			TRANSFORMING GROWTH-FACTOR-BETA ISOFORM 2-SPECIFIC HIGH-AFFINITY BINDING TO NATIVE ALPHA(2)-MACROGLOBULIN - CHIMERAS IDENTIFY A SEQUENCE THAT DETERMINES AFFINITY FOR NATIVE BUT NOT ACTIVATED ALPHA(2)-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-MACROGLOBULIN; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; PRIMARY AMINES; FAST FORMS; FACTOR-BETA-1; METHYLAMINE; COMPLEX; GROWTH-FACTOR-BETA-2	Transforming growth factor beta 2 (TGF-beta 2) is less potent than TGF-beta 1 in some endothelial cell proliferation as says due to the greater tendency of TGF-beta 2 to bind alpha(2)-macroglobulin (alpha(2)M). Substitution of TGF-beta 1 residues 40-47 into the TGF-beta 2 sequence yields a chimeric molecule that, like TGF-beta 1, expresses activity that is not substantially affected by serum alpha(2)M (Burmester, J. K., Qian, S. W., Roberts, A. B., Huang, A., Amatayakul-Chantler, S., Suardet, L., Odartchenko, N., Madri, J. A., and Sporn, M. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8628-8632). In this investigation, we studied the binding of TGF-beta chimeras, which contain TGF-beta 1 residues 40-47, to both major conformations of human alpha(2)M under apparent equilibrium conditions. Native alpha(2)M, the primary form of this protein in serum, bound TGF-beta(2)/beta(1)(40-82) and TGF-beta(2)/beta(1)(40-47) with low affinity. The apparent K-D values for the two chimeras and native alpha(2)M were 310 and 330 nM, respectively. These values were much higher than the K-D determined for TGF-beta 2 and native alpha(2)M (11 nM) and equivalent to the K-D determined for TGF-beta 1 and native alpha(2)M. By contrast, both TGF-beta chimeras bound alpha(2)M-methylamine, an altered conformation of alpha(2)M, with high affinity (16 and 19 nM), which is characteristic of TGF-beta 2 and not TGF-beta 1. Fetal bovine heart endothelial cell DNA synthesis was inhibited to a similar degree by TGF-beta 1, TGF-beta 2, TGF-beta(2)/beta(1)(40-82), and TGF-beta(2)/beta(1)(40-47) in the presence of dilute (0.2%) fetal bovine serum. When 0.07 mu M alpha 2M-methylamine was added, the activities of TGF-beta 2, TGF-beta(2)/beta(1)(40-82), and TGF-beta(2)/beta(1)(40-47) were significantly counteracted while the activity of TGF-beta 1 was unchanged, as would be predicted by the equilibrium binding analyses. These studies indicate that the TGF-beta structural elements, which mediate binding to native alpha(2)M and conformationally transformed alpha(2)M, are not equivalent. Residues 40-47 are critical in determining affinity for native alpha(2)M but are less important in determining affinity for alpha(2)MM methylamine.	UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI 54449; NIH,CHEMOPREVENT LAB,BETHESDA,MD 20892	University of Virginia; University of Virginia; Marshfield Clinic; National Institutes of Health (NIH) - USA					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline; NHLBI NIH HHS [HL-02272] Funding Source: Medline; NIGMS NIH HHS [GM 07267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BJORK I, 1982, BIOCHEM J, V207, P347; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, BIOCHEM BIOPH RES CO, V200, P1578, DOI 10.1006/bbrc.1994.1631; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; GANROT PO, 1967, CLIN CHIM ACTA, V16, P328, DOI 10.1016/0009-8981(67)90201-X; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; LAMARRE J, 1990, LAB INVEST, V62, P545; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; MERWIN JR, 1991, AM J PATHOL, V138, P37; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PIZZO SV, 1984, RECEPTORS, V1, P177; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024	34	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30402	30406						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527030				2022-12-25	WOS:A1994PU52500057
J	JOSEPH, SK; LIN, C; PIERSON, S; THOMAS, AP; MARANTO, AR				JOSEPH, SK; LIN, C; PIERSON, S; THOMAS, AP; MARANTO, AR			HETEROLIGOMERS OF TYPE-I AND TYPE-III INOSITOL TRISPHOSPHATE RECEPTORS IN WB RAT-LIVER EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; FUNCTIONAL-CHARACTERIZATION; INTRACELLULAR STORES; CA2+ MOBILIZATION; INSP3 RECEPTOR; PHOSPHORYLATION; HEPATOCYTES; EXPRESSION	We have previously shown that a 222-kDa polypeptide co-immunoprecipitates together with the type-I myoinositol 1,4,5-trisphosphate receptor (IP(3)R) in WB rat liver epithelial cell extracts, when the immunoprecipitation is carried out with a type-I isoform specific antibody (Joseph, S. K. (1994) J. Biol. Chem. 269, 5673-5679), Utilizing isoform specific antibodies raised to unique sequences within the COOH-terminal region of IP3 receptors, we now report that the co immunoprecipitating 222-kDa polypeptide is the type-III IP(3)R isoform and that type-III IP(3)R antibodies (Abs) can co-immunoprecipitate the type-I IP(3)R isoform. Co-immunoprecipitation of IP(3)R isoforms was not due to cross-reactivity of the antibodies for the following reasons: (a) on immunoblots the type-III antibodies did not cross-react with type-I IP(3)R and vice versa; (b) inclusion of the COOH-terminal type-III peptide had no effect on the ability of type-I IP(3)R Ab to co-immunoprecipitate the type III IP(3)R but blocked the ability of type-III IP(3)R Ab to coimmunoprecipitate the type-I isoform; and (c) crude hepatocyte lysates contain undetectable amounts of type III IP(3)R, and immunoprecipitation with type-III IP(3)R Ab does not co-immunoprecipitate any other isoforms, However, type-I and type-II IP(3)R isoforms were co-immunoprecipitated by their respective antibodies in hepatocyte lysates. Sucrose density gradient analysis of WB cell lysates indicated that the co-immunoprecipitating fraction is exclusively located at the density expected for tetrameric receptors, suggesting that co immunoprecipitation was not a reflection of the nonspecific aggregation of IP(3)R isoforms. Phosphorylation of either type-I or type-III immunoprecipitates by protein kinase A indicated that only the type-I IP(3)R could be phosphorylated in vitro. Fractionation of WB cell membranes and immunofluorescence studies showed that the type-I and type-III isoforms have very similar sub-cellular localizations. We conclude that the WE cell contains both type-I and type III IP(3)R isoforms and that a proportion of these receptors exist as heterotetramers.	THOMAS JEFFERSON UNIV, DEPT PATHOL, PHILADELPHIA, PA 19107 USA; TUFTS UNIV, ST ELIZABETHS HOSP, SCH MED, DEPT MED, BOSTON, MA 02135 USA; TUFTS UNIV, ST ELIZABETHS HOSP, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135 USA	Jefferson University; Tufts University; Tufts University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044475, R01DK038422, R29DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38422, DK44475] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; ENYEDI P, 1994, ENDOCRINOLOGY, V134, P2354, DOI 10.1210/en.134.6.2354; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; TAKEI K, 1992, J NEUROSCI, V12, P489; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VANDELDEN C, 1992, BIOCHEM J, V281, P651, DOI 10.1042/bj2810651; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WATRAS J, 1994, BIOCHEMISTRY-US, V33, P14359, DOI 10.1021/bi00251a050; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	37	118	121	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23310	23316		10.1074/jbc.270.40.23310	http://dx.doi.org/10.1074/jbc.270.40.23310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559486	hybrid			2022-12-25	WOS:A1995RY90900015
J	FIELDS, TA; CASEY, PJ				FIELDS, TA; CASEY, PJ			PHOSPHORYLATION OF C-Z-ALPHA BY PROTEIN-KINASE-C BLOCKS INTERACTION WITH THE BETA-GAMMA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; PERTUSSIS TOXIN; ADENYLATE-CYCLASE; HUMAN-PLATELETS; REGULATORY COMPONENT; HORMONAL INHIBITION; GUANINE-NUCLEOTIDES; LIPID MODIFICATIONS; INTACT HEPATOCYTES; ADP-RIBOSYLATION	G(Z alpha) is a G protein alpha subunit with biochemical properties that distinguish it from other members of the G protein alpha subunit family. One such property is its ability to be stoichiometrically phosphorylated by protein kinase C (PRC), both in vitro and in intact cells. The site of this phosphorylation has been mapped to a region near the N terminus of G(Z alpha), but no functional significance of the modification has been established. To investigate this question, we have developed a baculovirus/Sf9 cell expression system to produce G(Z alpha). The protein purified from Sf9 cells is functional as assessed by its ability both to bind guanine nucleotide in a Mg2+-sensitive fashion and to serve as a substrate for phosphorylation by PKC. Furthermore, addition of the G protein beta gamma complex purified from bovine brain inhibits phosphorylation of G(Z alpha) in a dose-dependent manner. Conversely, phosphorylation of G(Z alpha) inhibits its ability to interact with beta gamma subunits. These results establish a functional consequence for PKC-catalyzed phosphorylation of G(Z alpha) and suggest a mechanism for regulation of signaling through G(Z) by preventing reassociation of its subunits.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University	FIELDS, TA (corresponding author), DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,BOX 3686,DURHAM,NC 27710, USA.			Casey, Patrick/0000-0002-7366-9309				BUSHFIELD M, 1991, BIOCHEM J, V274, P317, DOI 10.1042/bj2740317; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; BUSHFIELD M, 1990, EUR J BIOCHEM, V192, P537, DOI 10.1111/j.1432-1033.1990.tb19258.x; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HINTON DR, 1990, J NEUROSCI, V10, P2763; JAKOBS KH, 1985, EUR J BIOCHEM, V151, P425, DOI 10.1111/j.1432-1033.1985.tb09119.x; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OFFERMANNS S, 1994, MOL CELL ENDOCRINOL, V100, P71, DOI 10.1016/0303-7207(94)90281-X; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARKER EM, 1991, J BIOL CHEM, V266, P519; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; Summers M. D., 1987, TEX AGR EXP STA B, V1555; THISSEN JA, 1995, METHOD ENZYMOL, V250, P158; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	40	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23119	23125		10.1074/jbc.270.39.23119	http://dx.doi.org/10.1074/jbc.270.39.23119			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559455	hybrid			2022-12-25	WOS:A1995RY05400075
J	DEANS, JP; KALT, L; LEDBETTER, JA; SCHIEVEN, GL; BOLEN, JB; JOHNSON, P				DEANS, JP; KALT, L; LEDBETTER, JA; SCHIEVEN, GL; BOLEN, JB; JOHNSON, P			ASSOCIATION OF 75/80-KDA PHOSPHOPROTEINS AND THE TYROSINE KINASES LYN, FYN, AND LCK WITH THE B-CELL MOLECULE-CD20 - EVIDENCE AGAINST INVOLVEMENT OF THE CYTOPLASMIC REGIONS OF CD20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-B; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; SURFACE-ANTIGEN; PROTEIN; ACTIVATION; BP35; PHOSPHORYLATION; EXPRESSION; CDNA	CD20, a non-glycosylated cell-surface protein expressed exclusively on B lymphocytes, is one of a family of 4-pass transmembrane molecules that also includes the beta chain of the high affinity receptor for IgE. The precise function of CD20 is unknown, although in vitro effects of CD20-specific antibodies on resting B cells indicate that it is able to transduce an extracellular signal affecting the G(0)/G(1) cell cycle transition, Previous studies have demonstrated that CD20-initiated intracellular signals involve tyrosine kinase activation and that CD20 is tightly associated with both serine and tyrosine kinases, Here, analysis of CD20-associated molecules has revealed that CD20 is associated with the Src family tyrosine kinases p56/53(lyn), p56(lck), and p59(fyn) and with 75/80-kDa proteins phosphorylated in vivo on tyrosine residues. Mutagenesis of CD20 was performed to define regions of CD20 involved in intermolecular interactions. Mutants were analyzed in the human T lymphoblastoid cell line Molt-4, in which ectopically expressed wild-type CD20 associated with p59(fyn), p56(lck), and 75/80-kDa phosphoproteins. Deletion of major portions of the cytoplasmic regions of CD20 did not abolish its association with either p75/80 or tyrosine kinases, The interaction between CD20 and the Src-related kinases is therefore likely to be independent of CD20 cytoplasmic domains and may occur indirectly, The interaction may be mediated by the p75/80 phosphoproteins, which were found to be tightly associated with the Src family kinases isolated from the CD20 complex.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6P 1Z3, CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA	University of British Columbia; Bristol-Myers Squibb; Bristol-Myers Squibb			Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				ADRA CN, 1994, P NATL ACAD SCI USA, V91, P10178, DOI 10.1073/pnas.91.21.10178; ALBER G, 1991, J BIOL CHEM, V266, P22613; BOLEN JB, 1993, ONCOGENE, V8, P2025; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CLARK EA, 1987, J IMMUNOL, V138, P720; CLARK EA, 1989, ADV CANCER RES, V52, P81; CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766, DOI 10.1073/pnas.82.6.1766; CLARK EA, 1986, HUM IMMUNOL, V16, P100, DOI 10.1016/0198-8859(86)90039-X; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1989, J IMMUNOL, V143, P3873; DEANS JP, 1993, J IMMUNOL, V151, P4494; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; EISEMAN E, 1992, NATURE, V355, P78; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GOLAY JT, 1985, J IMMUNOL, V135, P3795; GOLD MR, 1994, ADV IMMUNOL, V55, P221; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LEDBETTER JA, 1986, HUM IMMUNOL, V15, P30, DOI 10.1016/0198-8859(86)90315-0; LEDBETTER JA, 1987, LEUKOCYTE TYPING, V3, P339; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; OETTGEN HC, 1983, HYBRIDOMA, V2, P17, DOI 10.1089/hyb.1983.2.17; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SMELAND EB, 1987, J IMMUNOL, V138, P3179; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; STASHENKO P, 1980, J IMMUNOL, V125, P1678; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; TEDDER TF, 1988, J BIOL CHEM, V263, P10009; TEDDER TF, 1988, MOL IMMUNOL, V25, P1321, DOI 10.1016/0161-5890(88)90047-8; TEDDER TF, 1989, LEUKOCYTE TYPING, V4, P48; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; VALENTINE MA, 1987, P NATL ACAD SCI USA, V84, P8085, DOI 10.1073/pnas.84.22.8085; WATTS JD, 1993, J BIOL CHEM, V268, P23275; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	45	93	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22632	22638		10.1074/jbc.270.38.22632	http://dx.doi.org/10.1074/jbc.270.38.22632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545683	hybrid			2022-12-25	WOS:A1995RW31400087
J	LINSLEY, PS; NADLER, SG; BAJORATH, J; PEACH, R; LEUNG, HT; ROGERS, J; BRADSHAW, J; STEBBINS, M; LEYTZE, G; BRADY, W; MALACKO, AR; MARQUARDT, H; SHAW, SY				LINSLEY, PS; NADLER, SG; BAJORATH, J; PEACH, R; LEUNG, HT; ROGERS, J; BRADSHAW, J; STEBBINS, M; LEYTZE, G; BRADY, W; MALACKO, AR; MARQUARDT, H; SHAW, SY			BINDING STOICHIOMETRY OF THE CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED MOLECULE-4 (CTLA-4) - A DISULFIDE-LINKED HOMODIMER BINDS 2 CD86 MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; CELL PROLIFERATION; CRYSTAL-STRUCTURE; SOLUBLE FORM; RECEPTOR; CD28; ANTIGEN; EXPRESSION; ACTIVATION; COSTIMULATION	CD28 and CTLA-4 are homologous T cell receptors of the immunoglobulin (Ig) superfamily, which bind B7 molecules (CD80 and CD86) on antigen-presenting cells and transmit important costimulatory signals during T cell activation. Here we have investigated the subunit structure of CTLA-4 and the stoichiometry of its binding to B7 molecules. We demonstrate CTLA-4 is a homodimer interconnected by one disulfide bond in the extracellular domain at cysteine residue 120. Each monomeric polypeptide chain of CTLA-4 contains a high affinity binding site for B7 molecules; soluble CTLA-4 and CD86 form complexes containing equimolar amounts of monomeric CTLA-4 and CD86 (i.e. a 2:2 molecular complex). Thus, CTLA-4 and probably CD28 have a receptor structure consisting of preexisting covalent homodimers with two binding sites. Dimerization of CTLA-4 and CD28 is not required for B7 binding, nor is it sufficient to trigger signaling.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb	LINSLEY, PS (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA.		Bajorath, Jürgen/F-7493-2014					AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BALZANO C, 1992, INT J CANCER, P28; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAMLE NK, 1994, J IMMUNOL, V152, P2686; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; GUINAN EC, 1994, BLOOD, V84, P3261; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HARPER K, 1991, J IMMUNOL, V147, P1037; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; IMLER JL, 1992, J BIOL CHEM, V267, P13185; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LINDSTEN T, 1993, J IMMUNOL, V151, P3489; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUSZBEK L, 1975, ARCH BIOCHEM BIOPHYS, V167, P99, DOI 10.1016/0003-9861(75)90445-2; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SYMINGTON FW, 1993, J IMMUNOL, V150, P1286; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOUNG JR, 1994, J IMMUNOL, V152, P3848; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	37	94	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15417	15424		10.1074/jbc.270.25.15417	http://dx.doi.org/10.1074/jbc.270.25.15417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541042	hybrid			2022-12-25	WOS:A1995RE66600085
J	OXVIG, C; HAANING, J; KRISTENSEN, L; WAGNER, JM; RUBIN, I; STIGBRAND, T; GLEICH, GJ; SOTTRUPJENSEN, L				OXVIG, C; HAANING, J; KRISTENSEN, L; WAGNER, JM; RUBIN, I; STIGBRAND, T; GLEICH, GJ; SOTTRUPJENSEN, L			IDENTIFICATION OF ANGIOTENSINOGEN AND COMPLEMENT C3DG AS NOVEL PROTEINS BINDING THE PROFORM OF EOSINOPHIL MAJOR BASIC-PROTEIN IN HUMAN-PREGNANCY SERUM AND PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT ANGIOTENSINOGEN; ALPHA-TRYPSIN INHIBITOR; AMINO-ACID SEQUENCE; A PAPP-A; MONOCLONAL-ANTIBODIES; AMNIOTIC-FLUID; GRANULE; PRECURSOR; COMPONENT; CDNA	In sera from pregnant women, pregnancy-associated plasma protein-A (PAPP-A) circulates as a disulfide-bound complex (approximately 474 kDa) with the proform of eosinophil major basic protein (proMBP) (Oxvig, C., Sand, O., Kristensen, T., Gleich, G. J., and Sottrup-Jensen, L. (1993) J. Biol. Chem. 268, 12243-12246). We have produced monoclonal antibodies (mAbs) against the PAPP-A proMBP complex and established a radioimmunoassay utilizing a mAb recognizing the PAPP-A subunit. Surprisingly, serum levels of proMBP exceed those of PAPP-A four to 10-fold on a molar basis throughout pregnancy. This result prompted an investigation of the status of proMBP in pregnancy. Using a proMBP-specific mAb two novel proMBP complexes have been isolated by chromatographic techniques. Based on sequence analysis, sodium dodecyl sulfate-polyacrylamide gel electro phoresis, and reaction with specific antibodies, one is shown to be a 2:2 disulfide-bound complex (approximately 200 kDa) between proMBP and angiotensinogen. The other is a 2:2:2 complex (approximately 300 kDa) between proMBP, angiotensinogen, and complement C3dg. Circulating proMBP in pregnancy is thus present in three types of complexes. These results suggest that specific interactions between the complexed proteins occur in pregnancy, and the possibility is raised that their interactions are important in the pathophysiology of pregnancies associated with hypertension.	AARHUS UNIV, DEPT MOLEC BIOL, DK-8000 AARHUS, DENMARK; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT MED, ROCHESTER, MN 55905 USA; UNIV COPENHAGEN, PANUM INST, DEPT MED BIOCHEM, DK-2200 COPENHAGEN N, DENMARK; UNIV COPENHAGEN, PANUM INST, DEPT GENET, DK-2200 COPENHAGEN N, DENMARK; UMEA UNIV, DEPT MED BIOCHEM & BIOPHYS, S-90187 UMEA, SWEDEN	Aarhus University; Mayo Clinic; Mayo Clinic; University of Copenhagen; University of Copenhagen; Umea University				Oxvig, Claus/0000-0002-4715-9719	NIAID NIH HHS [AI 15231, AI 09728] Funding Source: Medline; NICHD NIH HHS [HD 22924] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009728, R37AI009728, R01AI015231, R37AI015231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; AXELSON NH, 1973, QUANTITATIVE IMMUNOE; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BISCHOF P, 1982, BRIT J OBSTET GYNAEC, V89, P358, DOI 10.1111/j.1471-0528.1982.tb05078.x; BISCHOF P, 1979, CLIN CHIM ACTA, V95, P243, DOI 10.1016/0009-8981(79)90365-6; BONNO M, 1994, LAB INVEST, V70, P234; BONNO M, 1994, LAB INVEST, V71, P560; BRAMBATI B, 1993, BRIT J OBSTET GYNAEC, V100, P324, DOI 10.1111/j.1471-0528.1993.tb12973.x; CAMPBELL DJ, 1985, J CLIN INVEST, V75, P1880, DOI 10.1172/JCI111902; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DOLMER K, 1993, FEBS LETT, V315, P85, DOI 10.1016/0014-5793(93)81139-Q; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; FOLKERSEN J, 1981, AM J OBSTET GYNECOL, V139, P910, DOI 10.1016/0002-9378(81)90957-1; GEBHARD W, 1988, FEBS LETT, V229, P63, DOI 10.1016/0014-5793(88)80798-1; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1973, J EXP MED, V137, P1459, DOI 10.1084/jem.137.6.1459; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GORDON DB, 1976, P SOC EXP BIOL MED, V153, P314; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4471; KAGEYAMA R, 1984, BIOCHEMISTRY-US, V23, P3603, DOI 10.1021/bi00311a006; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ T, 1993, PLACENTA, V14, P695, DOI 10.1016/S0143-4004(05)80386-8; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428; RUBIN I, 1988, J IMMUNOASSAY, V9, P257, DOI 10.1080/01971528808053216; SUNDSTROM BE, 1989, J HISTOCHEM CYTOCHEM, V37, P1845, DOI 10.1177/37.12.2479674; TEISNER B, 1982, AM J REPROD IMMUNOL, V2, P309, DOI 10.1111/j.1600-0897.1982.tb00198.x; TETLOW HJ, 1986, J ENDOCRINOL, V109, P257, DOI 10.1677/joe.0.1090257; TEWKSBURY DA, 1986, CLIN CHIM ACTA, V158, P7, DOI 10.1016/0009-8981(86)90110-5; TEWKSBURY DA, 1989, AM J HYPERTENS, V2, P411, DOI 10.1093/ajh/2.5.411; UOTILA M, 1980, MOL IMMUNOL, V17, P791, DOI 10.1016/0161-5890(80)90150-9; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; WASMOEN TL, 1987, P NATL ACAD SCI USA, V84, P3029, DOI 10.1073/pnas.84.9.3029; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WESTERGAARD JG, 1983, ARCH GYNECOL, V233, P211, DOI 10.1007/BF02114602	49	64	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13645	13651		10.1074/jbc.270.23.13645	http://dx.doi.org/10.1074/jbc.270.23.13645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539791	hybrid			2022-12-25	WOS:A1995RC44800012
J	CARLSON, RW; REUHS, B; CHEN, TB; BHAT, UR; NOEL, KD				CARLSON, RW; REUHS, B; CHEN, TB; BHAT, UR; NOEL, KD			LIPOPOLYSACCHARIDE CORE STRUCTURES IN RHIZOBIUM-ETLI AND MUTANTS DEFICIENT IN O-ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCT-2-ULOSONIC ACID KDO; LEGUMINOSARUM BIOVAR PHASEOLI; BRADYRHIZOBIUM-JAPONICUM; ESCHERICHIA-COLI; OLIGOSACCHARIDES; COMPONENT; BACTERIA; STRAINS; REGIONS	Lipopolysaccharide (LPS) is a major component of the bacterial outer membrane, and for Rhizobium spp. has been shown to play a critical role in the establishment of an effective nitrogen-fixing symbiosis with a legume host. Many genes required for O-chain polysaccharide synthesis are in the lps alpha region of the CE3 genome; this region may also carry lps genes required for core oligosaccharide synthesis. The LPSs from several strains mutated in the alpha region were isolated, and their mild acid released oligosaccharides, purified by high performance anion-exchange chromatography, were characterized by electro- spray- and fast atom bombardment-mass spectrometry, NMR, and methylation analysis. The LPSs from several mutants contained truncated O-chains, and the core region consisted of a (3-deoxy-D-manno-2-octulosomic acid) (Kdo)-(2-->6)-alpha-Galp-(1-->6)-[alpha-GalpA-(1-->4)]-alpha-Manp-(1-->5)-Kdop (3-deoxy-D-manno-2-octulosomic acid) (Kdo)pentasaccharide and a alpha-GalpA-(1-->4)-[alpha-GalpA-(1-->5)]-Kdop trisaccharide. The pentasaccharide was altered in two mutants in that it was missing either the terminal Kdo or the GalA residue. These results indicate that the lps alpha region, in addition to having the genes for O-chain synthesis, contains genes required for the transfer of these 2 residues to the core region. Also, the results show that an LPS with a complete core but lacking an O-chain polysaccharide is not sufficient for an effective symbiosis.	MARQUETTE UNIV,DEPT BIOL,MILWAUKEE,WI 53233	Marquette University	CARLSON, RW (corresponding author), UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,220 RIVERBEND RD,ATHENS,GA 30607, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BRINK BA, 1990, J BACTERIOL, V172, P548, DOI 10.1128/jb.172.2.548-555.1990; Carlson R. W., 1992, Plant biotechnology and development., P33; CARLSON RW, 1984, J BACTERIOL, V158, P1012, DOI 10.1128/JB.158.3.1012-1017.1984; CARLSON RW, 1988, CARBOHYD RES, V176, P127, DOI 10.1016/0008-6215(88)84064-3; CARLSON RW, 1978, PLANT PHYSIOL, V62, P912, DOI 10.1104/pp.62.6.912; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CARLSON RW, 1992, CARBOHYD RES, V231, P205, DOI 10.1016/0008-6215(92)84020-S; CARLSON RW, 1990, CARBOHYD RES, V195, P101; CAVA JR, 1990, MOL GEN GENET, V221, P125, DOI 10.1007/BF00280377; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; DIEBOLD R, 1989, J BACTERIOL, V171, P4821, DOI 10.1128/jb.171.9.4821-4830.1989; HOLLINGSWORTH RI, 1990, J BIOL CHEM, V265, P12752; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9294; KRAUSS JH, 1988, INT J SYST BACTERIOL, V38, P157, DOI 10.1099/00207713-38-2-157; MCNICHOLAS PA, 1986, CARBOHYD RES, V146, P219, DOI 10.1016/0008-6215(86)85041-8; MCNICHOLAS PA, 1987, CARBOHYD RES, V165, P17, DOI 10.1016/0008-6215(87)80073-3; NOEL KD, 1984, J BACTERIOL, V158, P148, DOI 10.1128/JB.158.1.148-155.1984; Noel KD., 1992, MOL SIGNALS PLANT MI, P341; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PETERSON AA, 1985, J BACTERIOL, V162, P738, DOI 10.1128/JB.162.2.738-745.1985; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; REUHS BL, 1993, J BACTERIOL, V175, P3570, DOI 10.1128/jb.175.11.3570-3580.1993; RYAN JM, 1974, ARCH BIOCHEM BIOPHYS, V162, P530, DOI 10.1016/0003-9861(74)90213-6; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; STACEY G, 1991, MOL PLANT MICROBE IN, V4, P332, DOI 10.1094/MPMI-4-332; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; ZHANG Y, 1992, CARBOHYD RES, V231, P261, DOI 10.1016/0008-6215(92)84024-M	34	57	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11783	11788		10.1074/jbc.270.20.11783	http://dx.doi.org/10.1074/jbc.270.20.11783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538123	Green Submitted, hybrid			2022-12-25	WOS:A1995QY73600020
J	FENG, W; MATZUK, MM; MOUNTJOY, K; BEDOWS, E; RUDDON, RW; BOIME, I				FENG, W; MATZUK, MM; MOUNTJOY, K; BEDOWS, E; RUDDON, RW; BOIME, I			THE ASPARGINE-LINKED OLIGOSACCHARIDES OF THE HUMAN CHORIONIC-GONADOTROPIN BETA-SUBUNIT FACILITATE CORRECT DISULFIDE BOND PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; PROTEIN; PREGNANCY; FORM; FRAGMENT; HORMONE; DIMER; UNITS; CHORIOGONADOTROPIN	The role of asparagine (N)-linked oligosaccharide chains in intracellular folding of the human chorionic gonadotropin (hCG)-beta subunit was determined by examining the kinetics of folding in Chinese hamster ovary (CHO) cells transfected with wild-type or mutant hCG-beta genes lacking one or both of the asparagine glycosylation sites, The half time for folding of p beta 1 into p beta 2, the rate-determining step in beta folding, was 7 min for wildtype beta but 33 min for beta lacking both N-linked glycans, The p beta 1 --> p beta 2 half-time was 7.5 min in CHO cells expressing the beta subunit missing the Asn(13)-linked glycan and 10 min for the beta subunit missing the Asn(30)-linked glycan. The inefficient folding of hCG-beta lacking both N linked glycans correlated with the slow formation of the last three disulfide bonds (i,e, disulfides 23-72, 93-100, and 26-110) to form in the hCG-beta-folding pathway. Unglycosylated hCG-beta was slowly secreted from CHO cells, and beta subunit-folding intermediates retained in cells for more than 5 h were degraded into a hCG-beta core fragment-like protein, However, coexpression of the hCG-alpha gene enhanced folding and formation of disulfide bonds 23-72, 93-100, and 26-110 of hCG-beta lacking N-linked glycans, In addition, the molecular chaperones BiP, ERp72, and ERp94, but not calnexin, were found in a complex with unglycosylated, unfolded hCG-beta and may be involved in the folding of this beta form, These data indicate that N-linked oligosaccharides assist hCG-beta subunit folding by facilitating disulfide bond formation.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Washington University (WUSTL); Washington University (WUSTL)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023398] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032949, P30CA036727] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727, CA32949] Funding Source: Medline; NICHD NIH HHS [HD23398] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1994, J BIOL CHEM, V269, P10574; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BIRKEN S, 1988, ENDOCRINOLOGY, V123, P572, DOI 10.1210/endo-123-1-572; BIRKEN S, 1977, J BIOL CHEM, V252, P5386; COLE LA, 1983, ENDOCRINOLOGY, V113, P1176, DOI 10.1210/endo-113-3-1176; FENG WJ, 1995, ENDOCRINOLOGY, V136, P52, DOI 10.1210/en.136.1.52; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOVERMAN JM, 1982, J BIOL CHEM, V257, P5059; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOE MH, 1992, J BIOL CHEM, V267, P4916; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1993, J BIOL CHEM, V268, P16472; KATO Y, 1988, J CLIN ENDOCR METAB, V66, P1197, DOI 10.1210/jcem-66-6-1197; KESSLER MJ, 1979, J BIOL CHEM, V254, P7901; KEUTMANN HT, 1977, J BIOL CHEM, V252, P5393; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MISE T, 1981, J BIOL CHEM, V256, P6587; PETERS BP, 1984, J BIOL CHEM, V259, P5123; RUDDON RW, 1989, ENDOCRINOLOGY, V124, P862, DOI 10.1210/endo-124-2-862; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SCHROEDER HR, 1983, CLIN CHEM, V29, P667; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WEINTRAUB BD, 1983, ENDOCRINOLOGY, V112, P1331, DOI 10.1210/endo-112-4-1331; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	37	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11851	11859		10.1074/jbc.270.20.11851	http://dx.doi.org/10.1074/jbc.270.20.11851			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538125	hybrid			2022-12-25	WOS:A1995QY73600030
J	VANETTEN, RA; DEBNATH, J; ZHOU, H; CASASNOVAS, JM				VANETTEN, RA; DEBNATH, J; ZHOU, H; CASASNOVAS, JM			INTRODUCTION OF A LOSS-OF-FUNCTION POINT MUTATION FROM THE SH3 REGION OF THE CAENORHABDITIS-ELEGANS SEM-5 GENE ACTIVATES THE TRANSFORMING ABILITY OF C-ABL IN-VIVO AND ABOLISHES BINDING OF PROLINE-RICH LIGANDS IN-VITRO	ONCOGENE			English	Article						ONCOGENES; ABELSON MURINE LEUKEMIA VIRUS; TYROSINE KINASE; CELL TRANSFORMATION; SRC HOMOLOGY REGION	TYROSINE-PHOSPHORYLATED PEPTIDES; GUANINE-NUCLEOTIDE EXCHANGE; ONCOGENIC ACTIVATION; CRYSTAL-STRUCTURE; ADAPTER PROTEIN; KINASE-ACTIVITY; DOMAIN; GRB2; SRC; RAS	We have introduced two loss-of-function point mutations from highly conserved regions of the src homology 3 (SH3) domains of the Caenorhabditis elegans sem-5 gene into the SH3 domain of the murine type IV c-abl tyrosine kinase proto-oncogene. One of the mutations, P131L, activated abl to transform fibroblasts while tbe other, G128R, did not. When combined with independent activating mutations in the c-abl kinase domain or NH,terminus, the G128R mutation blocked transformation by the double mutant, suggesting that the G128R mutant was unable to transform cells for trivial reasons. The c-Abl G128R mutant, like wild type c-Abi protein, was localized to the nucleus and actin cytoskeleton and had normal tyrosine kinase activity in vitro, while the transforming c-Abl P131L protein was localized exclusively to the cytoplasm and exhibited decreased in vitro kinase activity. By real-time biospecific interaction analysis, the wild type Abl SH3 domain bound to two proteins containing proline-rich motifs with dissociation constants of 0.2 and 17 mu M; the G128R mutant bound with 50-fold lower affinity, and no binding was detected by the P131L mutant. Both mutations completely abolished binding of the Abl SH3 domain to proline-rich target proteins in a filter-binding assay, These results suggest that the transforming activity of Abl is regulated in vivo by an inhibitor protein which associates with the SH3 domain via a proline-rich sequence.	HARVARD UNIV, SCH MED, CTR BLOOD RES, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	VANETTEN, RA (corresponding author), HARVARD UNIV, SCH MED, CTR BLOOD RES, DEPT GENET, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.			Debnath, Jayanta/0000-0002-8745-4069	NIAID NIH HHS [AI 39121] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DRUKER BJ, 1992, NEW ENGL J MED, V321, P1383; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASISEKHARAN V, 1959, ACTA CRYSTALLOGR, V12, P897, DOI 10.1107/S0365110X59002535; SAWYERSMAKER L, 1986, J VIROL, V57, P1182; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	70	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1977	1988						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7539119				2022-12-25	WOS:A1995QZ92600012
J	ALIMANDI, M; ROMANO, A; CURIA, MC; MURARO, R; FEDI, P; AARONSON, SA; DIFIORE, PP; KRAUS, MH				ALIMANDI, M; ROMANO, A; CURIA, MC; MURARO, R; FEDI, P; AARONSON, SA; DIFIORE, PP; KRAUS, MH			COOPERATIVE SIGNALING OF ERBB3 AND ERBB2 IN NEOPLASTIC TRANSFORMATION AND HUMAN MAMMARY CARCINOMAS	ONCOGENE			English	Article						ERBB RECEPTOR FAMILY; ONCOGENES; TYROSINE PHOSPHORYLATION; HETERODIMERIZATION; PI3-KINASE	TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CARCINOMA; FACTOR RECEPTOR FAMILY; HER-2 NEU ONCOGENE; EGF RECEPTOR; PROTO-ONCOGENE; C-ERBB-2 ONCOGENE; POINT MUTATION; BETA-ACTIN; CELLS	In the present study we demonstrate that erbB-3 and erbB-2 cooperate in neoplastic transformation. Under conditions in which neither gene alone induced transformation, they readily transformed NIH3T3 cells if coexpressed. Furthermore, at high expression levels of ErbB2 which cause transformation, ErbB3 enhanced focus formation by one order of magnitude. Synergy required an intact ErbB2 extracellular domain and tyrosine kinase activity. Cooperation between ErbB3 and ErbB2 involved heterodimerization and increased tyrosine phosphorylation of ErbB3. Signaling by the heterodimer resulted in increased PI 3-kinase recruitment as web as quantitative and qualitative differences in substrate phosphorylation. Evidence for signaling by an active ErbB3-ErbB2 heterodimer in four mammary tumor cell lines indicated relevance of this mechanism for human neoplasia. Our detection of the NDF/heregulin transcript in NIH3T3 cells implicates an autocrine loop involving this ligand in signaling by the ErbB3-ErbB2 heterodimer in the model system, whereas heregalin-independent mechanisms likely exist for cooperative signaling by ErbB3 and ErhB2 chronically activated in some human mammary carcinomas.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, EXPTL CARCINOGENESIS LAB, BETHESDA, MD 20892 USA; UNIV G DANNUNZIO, IST PATOL UMANA & MED SOCIALE, I-66013 CHIETI, ITALY; MT SINAI MED CTR, DERALD H RUTTENBERG CANC CTR, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); G d'Annunzio University of Chieti-Pescara; Icahn School of Medicine at Mount Sinai			Di Fiore, Pier Paolo/K-2130-2012; Alimandi, Maurizio/AAG-9246-2019; curia, maria cristina/AAA-3118-2019; Mieszkowska, Magdalena/O-6753-2017	Di Fiore, Pier Paolo/0000-0002-2252-0950; Alimandi, Maurizio/0000-0002-1409-6803; 				BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BERGER MS, 1988, CANCER RES, V48, P1238; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALEY JD, 1989, ONCOGENE, V4, P273; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PATERSON MC, 1991, CANCER RES, V51, P556; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROMANO A, 1994, ONCOGENE, V9, P2923; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YOKOTA J, 1986, LANCET, V1, P765	51	499	543	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1813	1821						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7538656				2022-12-25	WOS:A1995QX46900014
J	HU, DD; HOYER, JR; SMITH, JW				HU, DD; HOYER, JR; SMITH, JW			CA2+ SUPPRESSES CELL-ADHESION TO OSTEOPONTIN BY ATTENUATING BINDING-AFFINITY FOR INTEGRIN ALPHA(V)BETA(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; PLATELET FIBRINOGEN RECEPTOR; SURFACE-PLASMON RESONANCE; ISOLATED RAT OSTEOCLASTS; GLYCOPROTEIN-IIB-IIIA; BONE-RESORPTION; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; MESSENGER-RNA; IN-VITRO	Osteopontin (OPN) is an extracellular matrix protein that supports osteoclast adhesion to the bone by binding to integrin alpha v beta(3). We measured the binding between OPN and integrin alpha(v) beta(3) with recombinant human OPN and the urinary form of human OPN, uropontin. Recombinant OPN was expressed in Escherichia coli as a fusion protein with glutathione S-transferase and cleaved from glutathione S-transferase with Factor Xa, The mass of this form of OPN (rOP27) is 27,046 Da. rOP27 is truncated at arginine residue 228, 69 amino acids short of the native carboxyl terminus. Uropontin and rOP27 support RGD-dependent cell adhesion and to bind purified integrin alpha(v) beta(3) with similar affinities. Further study showed that OPN is the only known naturally occurring RGD-containing protein with a much greater affinity for alpha(v) beta(3) than for the platelet integrin alpha(IIb)beta(3). Most importantly, we find that physiologic levels of Ca2+ block cell adhesion to OPN. Measurement of binding constants between rOPN and purified integrin alpha(v) beta(3) with surface plasmon resonance showed that the affinity between rOPN and alpha(v) beta(3) is 26-fold lower in Ca2+ (K-d = 1.1 X 10(-8) M) than in Mn2+ (K-d = 4.3 X 10(-10) M) and 9-fold lower than in Mg2+ (K-d = 1.3 x 10(-9) M). In bone, the resorbing osteoclast generates elevated levels of extracellular Ca2+, therefore the findings presented here suggest a previously unappreciated mechanism for the modulation of bone resorption by extracellular Ca2+.	CHILDRENS HOSP, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	HU, DD (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA 56483] Funding Source: Medline; NIAMS NIH HHS [AR 42750] Funding Source: Medline; NIDDK NIH HHS [DK 33501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033501] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; BARBAS CF, 1993, IN PRESS P NATL ACAD; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CARPENTER TO, 1992, AM J PHYSIOL, V263, pE107, DOI 10.1152/ajpendo.1992.263.1.E107; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1994, IN PRESS CELL; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HORTON MA, 1989, J BONE MINER RES, V4, P803; HWANG S, 1994, J BIOL CHEM, V269, P711; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; LAMPUGNANI MG, 1991, LAB INVEST, V65, P96; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MARK MP, 1988, DIFFERENTIATION, V37, P123, DOI 10.1111/j.1432-0436.1988.tb00804.x; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PARISE LV, 1985, J BIOL CHEM, V260, P698; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RECHLER MM, 1977, J BIOL CHEM, V252, P3898; REINHOLT FP, 1993, BONE MINER, V22, P147; SALTMAN PD, 1993, J AM COLL NUTR, V12, P384, DOI 10.1080/07315724.1993.10718327; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SEELIG MS, 1994, J AM COLL NUTR, V13, P429; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAUB R, 1989, J BIOL CHEM, V264, P259; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; WHANG R, 1987, AM J MED, V82, P24, DOI 10.1016/0002-9343(87)90129-X; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003; ZAIDI M, 1991, J CELL PHYSIOL, V149, P422, DOI 10.1002/jcp.1041490310; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZIMOLO Z, 1994, AM J PHYSIOL, V266, pC376, DOI 10.1152/ajpcell.1994.266.2.C376	61	104	106	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9917	9925		10.1074/jbc.270.17.9917	http://dx.doi.org/10.1074/jbc.270.17.9917			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537271	hybrid			2022-12-25	WOS:A1995QV41700035
J	NODA, K; SAAD, Y; KINOSHITA, A; BOYLE, TP; GRAHAM, RM; HUSAIN, A; KARNIK, SS				NODA, K; SAAD, Y; KINOSHITA, A; BOYLE, TP; GRAHAM, RM; HUSAIN, A; KARNIK, SS			TETRAZOLE AND CARBOXYLATE GROUPS OF ANGIOTENSIN RECEPTOR ANTAGONISTS BIND TO THE SAME SUBSITE BY DIFFERENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR; ANTIHYPERTENSIVES; DISCOVERY; POTENT	To identify specific interactions between either the tetrazole or carboxylate pharmacophores of non-peptide antagonists and the rat AT(1) receptor, 6 basic residues were examined by site-directed mutagenesis. Three of the mutants (H183Q, H256Q, and H272Q) appeared to be like wild type. Lys(102) and Arg(167) mutants displayed reduced binding of the non-peptide antagonist losartan. Examination of their properties employing group-specific angiotensin II analogues indicated that their effects on binding were indirect. Interestingly, the affinity of losartan was not altered by a K199Q mutation, but the same mutation reduced the affinity of angiotensin II, the antagonist [Sar(1),Ile(8)]angiotensin II, and several carboxylate analogues of losartan. An Ala(199) substitution reduced the affinity of peptide analogues to a larger extent as compared to the affinity of losartan, Thus, the crucial acidic pharmacophores of angiotensin and losartan appear to occupy the same space within the receptor pocket, but the protonated amino group of Lys(199) is not essential for binding the tetrazole anion. The binding of the tetrazole moiety with the AT(1) receptor involves multiple contacts with residues such as Lys(199) and His(256) that constitute the same subsite of the ligand binding pocket, However, this interaction does not involve a conventional salt bridge, but rather an unusual lysine-aromatic interaction.	CLEVELAND CLIN FDN,DEPT MOLEC CARDIOL,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019; Husain, Ahsan/J-6861-2012	Karnik, Sadashiva/0000-0003-0746-2753; Husain, Ahsan/0000-0003-3426-3469	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33713, R01 HL057470] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIHAREAU C, 1993, P NATL ACAD SCI USA, V90, P5133; BUMPUS FM, 1977, HYPERTENSION PHYSIOP, P183; CARINI DJ, 1991, J MED CHEM, V34, P2525, DOI 10.1021/jm00112a031; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; DUNCIA JV, 1990, J MED CHEM, V33, P1312, DOI 10.1021/jm00167a007; ERIKSSON AE, 1992, SCIENCE, V255, P179; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FONG TM, 1994, NATURE, V362, P350; Furakawa Y, 1982, U. S. Patent, Patent No. [4340 598, 4355 040, 4340598]; FURUKAWA Y, 1982, Patent No. 4355040; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HSIEH KH, 1986, J MED CHEM, V29, P1968, DOI 10.1021/jm00160a028; HUSAIN A, 1986, J PHARMACOL EXP THER, V2339, P71; JI H, 1994, J BIOL CHEM, V269, P16533; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NODA K, 1994, J BIOL CHEM, V269, P6743; PRENDERGAST K, 1994, J COMPUT AID MOL DES, V8, P491, DOI 10.1007/BF00123662; PUCELL AG, 1987, J BIOL CHEM, V262, P7076; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	29	168	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2284	2289		10.1074/jbc.270.5.2284	http://dx.doi.org/10.1074/jbc.270.5.2284			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7530721	hybrid			2022-12-25	WOS:A1995QE49300048
J	DENISOVA, G; ZWICKEL, J; GERSHONI, JM				DENISOVA, G; ZWICKEL, J; GERSHONI, JM			BINDING OF HIV-1 GP120 TO AN ANTI-V3 LOOP ANTIBODY REVEALS NOVEL ANTIGEN-INDUCED EPITOPES	FASEB JOURNAL			English	Article						AIDS; VACCINE; FAB; CONFORMATIONAL EPITOPE	PROTEIN-G; SEQUENCE; PEPTIDE; COMPLEX	Antigen association to its corresponding binding site in the immunoglobulin molecule can elicit conformational rearrangements, generating novel epitopes termed metatopes. Such metatopes were characterized for the immunocomplex between the AIDS virus envelope protein, gp120, and M77, a mAb directed against the V3 loop. Five novel mAbs were described (GV1, GV3, GV7, GV8, and GV12). These mAbs were found to bind epitopes harbored in the M77 Fab fragment. Binding to the epitopes was shown to require the complexation of Fab with its antigen. The degree of this antigen requirement was found to be variable for the different mAbs and also for the state of IgG fragmentation. Binding of GV12 to its antigen increased the affinity of M77 for gp120. Moreover, in the presence of GV12, M77 acquired extended cross-reactivity for a second gp120 variant, namely Bat. These results could indicate a novel approach towards improving the performance of anti-HIV antibodies.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								AKERSTROM B, 1986, J BIOL CHEM, V261, P240; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; CARSON DA, 1987, ANNU REV IMMUNOL, V5, P109, DOI 10.1146/annurev.iy.05.040187.000545; ELIASSON M, 1991, MOL IMMUNOL, V28, P1055, DOI 10.1016/0161-5890(91)90020-K; GERSHONI JM, 1993, FASEB J, V7, P1185, DOI 10.1096/fasebj.7.12.7690724; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PAL R, 1992, INTERVIROLOGY, V86, P86; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1; RODKEY LS, 1980, MICROBIOL REV, V44, P631, DOI 10.1128/MMBR.44.4.631-659.1980; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STURA EA, 1992, PROTEINS, V14, P499, DOI 10.1002/prot.340140410; VUKPAVLOVIC S, 1979, BIOCHEMISTRY-US, V18, P1125, DOI 10.1021/bi00574a001; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281	15	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					127	132		10.1096/fasebj.9.1.7529735	http://dx.doi.org/10.1096/fasebj.9.1.7529735			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7529735				2022-12-25	WOS:A1995QD20200020
J	FURUYA, S; IRIE, F; HASHIKAWA, T; NAKAZAWA, K; KOZAKAI, A; HASEGAWA, A; SUDO, K; HIRABAYASHI, Y				FURUYA, S; IRIE, F; HASHIKAWA, T; NAKAZAWA, K; KOZAKAI, A; HASEGAWA, A; SUDO, K; HIRABAYASHI, Y			GANGLIOSIDE GD1-ALPHA IN CEREBELLAR PURKINJE-CELLS - ITS SPECIFIC ABSENCE IN MOUSE MUTANTS WITH PURKINJE-CELL ABNORMALITY AND ALTERED IMMUNOREACTIVITY IN RESPONSE TO CONJUNCTIVE STIMULI CAUSING LONG-TERM DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING GLYCOSPHINGOLIPIDS; HANGANUTZIU-DEICHER ANTIGENS; RAT ASCITES HEPATOMA; ADULT BOVINE BRAINS; MONOCLONAL-ANTIBODY; IMMUNOHISTOCHEMICAL LOCALIZATION; STAGGERER MUTANT; MURINE MUTANTS; WEAVER MUTANT; MICE	The alpha-series ganglioside, IV(3)NeuAc,III(6)NeuAcGgOse(4)-Cer (G(D1 alpha)), was previously identified as a minor constituent in bovine brain gangliosides (Hirabayashi, Y., Hyogo, A., Nakao, T., Tsuchiya, K., Suzuki, Y., Matsumoto, M., Kon, K, and Ando, S. (1990) J. Biol. Chem. 265, 8144-8151). In the present study, we have generated a specific mouse monoclonal antibody against G(D1 alpha) and explored the distribution of G(D1 alpha) in murine central nervous system. In adult rat brain, G(D1 alpha) occurred as a minor constituent, and its expression was exclusively detected in the mouse cerebellum, the content of G(D1 alpha) was reduced significantly in the Purkinje cell-deficient mutants, lurcher (Lc/+), staggerer (sg/sg), and Purkinje cell degeneration (pcd/pcd), but were not reduced in the weaver (wv/wv) mutant, which loses mostly granule cells. The G(D1 alpha) synthase, assayed in cerebellar microsomes, was also reduced in Purkinje cell-deficient mutants. Immunohistochemistry showed that the staining for G(D1 alpha) in rat and mouse cerebella was mostly found in the proximal dendrites and cell bodies of Purkinje cells. Also, it appeared slightly in the processes of Bergmann glial cells. The immunoreactivity of G(D1 alpha) disappeared specifically from the Purkinje cell dendrites and the Bergmann glial processes after co-application of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 8-bromo-guanosine 3':5'-cyclic monophosphate, which induced long-term desensitization of the AMPA-selective glutamate receptors in Purkinje cells. The present data provide suggestive evidence that G(d1 alpha) ganglioside is enriched in Purkinje cells and may have a role in Purkinje cell functions in the cerebellum.	INST PHYS & CHEM RES,GLYCOCELL BIOL LAB,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,NEURAL SYST LAB,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,NEURAL NETWORKS LAB,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; GIFU UNIV,FAC AGR,DEPT APPL BIOORGAN CHEM,GIFU 50111,JAPAN; UNIV TOKYO,INST MED SCI,ANIM RES CTR,TOKYO 108,JAPAN; UNIV TOKYO,FAC MED,DEPT PHYSIOL CHEM & NUTR,TOKYO 113,JAPAN	RIKEN; RIKEN; RIKEN; Gifu University; University of Tokyo; University of Tokyo			Nakazawa, Kazutoshi/J-6195-2015	Nakazawa, Kazutoshi/0000-0001-5699-9093; Furuya, Shigeki/0000-0001-9020-3597; Hirabayashi, Yoshio/0000-0002-5774-7354				ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; ARIGA T, 1987, J LIPID RES, V28, P285; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CADDY KWT, 1976, BRAIN RES, V111, P396, DOI 10.1016/0006-8993(76)90783-6; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CONYERS SM, 1991, ANAL BIOCHEM, V192, P207, DOI 10.1016/0003-2697(91)90208-B; FOLCH J, 1957, J BIOL CHEM, V226, P497; FURUYA S, 1993, GLYCOCONJUGATE J, V10, P293, DOI 10.1007/BF01210029; HAKOMORI S, 1993, ADV LIPID RES, V25, P235; HIDARI KIPJ, 1994, EUR J BIOCHEM, V221, P603, DOI 10.1111/j.1432-1033.1994.tb18772.x; HIGASHI H, 1984, J BIOCHEM, V95, P785, DOI 10.1093/oxfordjournals.jbchem.a134670; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRABAYASHI Y, 1979, FEBS LETT, V100, P253, DOI 10.1016/0014-5793(79)80345-2; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; IRIE F, 1994, FEBS LETT, V351, P291, DOI 10.1016/0014-5793(94)00883-3; IRIE F, 1993, GLYCOCONJUGATE J, V10, P292, DOI 10.1007/BF01210027; Ito M, 1990, Neuroreport, V1, P129; Ito M, 1984, CEREBELLUM NEURAL CO; JOHNSTONE SR, 1988, J NEUROCHEM, V51, P1655, DOI 10.1111/j.1471-4159.1988.tb01138.x; KOTANI M, 1992, P JPN ACAD B-PHYS, V68, P109, DOI 10.2183/pjab.68.109; KUSUNOKI S, 1993, BRAIN RES, V623, P83, DOI 10.1016/0006-8993(93)90013-D; LANDIS DMD, 1978, J COMP NEUROL, V179, P831, DOI 10.1002/cne.901790408; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; LEDEEN RW, 1992, TRENDS GLYCOSCI GLYC, V4, P174; MALLET J, 1976, BRAIN RES, V103, P291, DOI 10.1016/0006-8993(76)90800-3; MATSUMOTO M, 1981, J BIOL CHEM, V256, P9737; MIYAZAWA A, 1992, J NEUROCHEM, V59, P1547, DOI 10.1111/j.1471-4159.1992.tb08472.x; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; NAGAI Y, 1989, GANGLIOSIDES CANCER, P33; NAKAZAWA K, 1993, NEUROREPORT, V4, P1275, DOI 10.1097/00001756-199309000-00017; OBROCKI J, 1988, EXP BRAIN RES, V72, P71, DOI 10.1007/BF00248502; OHASHI M, 1981, GLYCOCONJUGATES, P33; PRABHANJAN H, 1992, CARBOHYD RES, V233, P87, DOI 10.1016/S0008-6215(00)90922-4; PRASADARAO N, 1990, J HISTOCHEM CYTOCHEM, V38, P1193, DOI 10.1177/38.8.1694876; RAKIC P, 1973, P NATL ACAD SCI USA, V70, P240, DOI 10.1073/pnas.70.1.240; ROSNER H, 1993, POLYSIALIC ACID, P279; SEYFRIED TN, 1984, J NEUROCHEM, V43, P1152, DOI 10.1111/j.1471-4159.1984.tb12856.x; SEYFRIED TN, 1990, J NEUROSCI RES, V26, P105, DOI 10.1002/jnr.490260113; SEYFRIED TN, 1982, J NEUROCHEM, V38, P551, DOI 10.1111/j.1471-4159.1982.tb08662.x; SEYFRIED TN, 1983, J NEUROCHEM, V41, P491, DOI 10.1111/j.1471-4159.1983.tb04767.x; SEYFRIED TN, 1994, J LIPID RES, V35, P993; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SUZUKI Y, 1986, J BIOL CHEM, V261, P7057; SUZUKI Y, 1985, J BIOCHEM-TOKYO, V97, P1189, DOI 10.1093/oxfordjournals.jbchem.a135164; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKI T, 1986, J BIOL CHEM, V261, P3075; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; TODD AJ, 1991, NEUROSCIENCE, V44, P741, DOI 10.1016/0306-4522(91)90093-4; YAMAMOTO M, 1992, CELL SURFACE CARBOHY, P195	55	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32418	32425						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528216				2022-12-25	WOS:A1994PX30400061
J	SUEYOSHI, S; TSUBOI, S; SAWADAHIRAI, R; DANG, UN; LOWE, JB; FUKUDA, M				SUEYOSHI, S; TSUBOI, S; SAWADAHIRAI, R; DANG, UN; LOWE, JB; FUKUDA, M			EXPRESSION OF DISTINCT FUCOSYLATED OLIGOSACCHARIDES AND CARBOHYDRATE-MEDIATED ADHESION EFFICIENCY DIRECTED BY 2 DIFFERENT ALPHA-1,3-FUCOSYL-TRANSFERASES - COMPARISON OF E-SELECTIN-MEDIATED AND L-SELECTIN-MEDIATED ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ELAM-1-DEPENDENT CELL-ADHESION; MYELOGENOUS LEUKEMIA-CELLS; POLY-N-ACETYLLACTOSAMINE; SIALYL-LEWIS-X; LINKED OLIGOSACCHARIDES; DETERMINES EXPRESSION; ENDOTHELIAL LIGAND; EMBRYONIC ANTIGEN	Among five different human alpha 1-->3 fucosyltransferases cloned, fucosyltransferases III (Fuc-TIII) and IV (Fuc-TIV) differ significantly from each other. Fuc-TIII transfers a fucose to both sialylated and nonsialylated N-acetyllactosamine, but Fuc-TIV apparently transfers a fucose only to neutral N-acetyllactosamine, In this study, Chinese hamster ovary (CHO) cells were stably transfected with Fuc-TIII or Fuc-TIV, and the resultant cell lines, CHO-FTIII and CHO-FTIV, were compared for the carbohydrate structures and for their binding to E-selectin or L-selectin. CHO-FTIII and CHO-FTIV cells were labeled metabolically with [H-3]galactose, and glycopeptides obtained from these cells were fractionated by serial lectin affinity chromatography. The fractionated glycopeptides were then subjected to various combinations of exoglycosidase treatment or endo-beta-galactosidase digestion. The results obtained can be summarized as follows. CHO-FTIII cells express sialyl Lewis(x), Lewis(x), and VIM-2 structures, whereas CHO-FTIV cells express only an Le(x) structure with a small amount of VIM-2 structure. When CHO-FTIII and CHO-FTIV cells were tested for adhesion to E-selectin expressed by tumor necrosis factor-activated endothelial cells and to an E-selectin chimeric protein, only CHO-FTIII cells were found to adhere well to E-selectin. Moreover, both CHO-FTIII and CHO-FTIV cells failed to adhere to an L-selectin chimeric protein. T hese results clearly indicate that FT-III and FT-IV direct distinctly different fucosylated oligosaccharides. This difference in oligosaccharide structures results in an entirely different efficiency in adhesion to E-selectin. The results also demonstrate that expression of sialyl Le(x) itself is not sufficient for L-selectin binding.	LA JOLLA CANC RES FDN,GLYCOBIOL PROGRAM,LA JOLLA,CA 92037; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA033000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA33000] Funding Source: Medline; NIAID NIH HHS [AI33189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERG EL, 1991, J BIOL CHEM, V266, P14869; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FINNE J, 1982, J CELL BIOL, V92, P277, DOI 10.1083/jcb.92.2.277; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEE N, 1990, J BIOL CHEM, V265, P20476; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SANO M, 1992, J BIOL CHEM, V267, P1522; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SUEYOSHI S, 1992, GLYCOCONJUGATE J, V9, P99, DOI 10.1007/BF00731706; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TOYAMASORIMACHI N, 1993, EUR J IMMUNOL, V23, P439, DOI 10.1002/eji.1830230221; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YOSHIDA T, 1994, BIOCHEM BIOPH RES CO, V204, P969, DOI 10.1006/bbrc.1994.2555	56	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32342	32350						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528213				2022-12-25	WOS:A1994PX30400051
J	MATSUMOTO, K; MATSUMOTO, K; NAKAMURA, T; KRAMER, RH				MATSUMOTO, K; MATSUMOTO, K; NAKAMURA, T; KRAMER, RH			HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR INDUCES TYROSINE PHOSPHORYLATION OF FOCAL ADHESION KINASE (P125(FAK)) AND PROMOTES MIGRATION AND INVASION BY ORAL SQUAMOUS-CELL CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-BINDING INTEGRIN; SCATTER FACTOR; EXTRACELLULAR-MATRIX; FACTOR RECEPTOR; PROTEIN; EXPRESSION; IDENTIFICATION; PP125(FAK); FIBRONECTIN; INVITRO	Fibroblasts or their conditioned medium stimulated invasion by squamous cell carcinoma cells. The fibroblast-derived activity responsible for increased invasion is the hepatocyte growth factor/scatter factor (HGF/SF), a ligand for the c-Met receptor, HGF/SF stimulated migration of the cells on various extracellular matrix substrates but did not alter their adhesion efficiency nor integrin expression, HGF/SF stimulated motility in a two step process: initially cells spread rapidly and formed focal adhesions, and then they disassembled these condensations, which was followed by increased cell locomotion, The focal adhesions contained vinculin, p125(FAK), beta 1 integrin, and phosphotyrosine, Within minutes after exposure of cells to HGF/SF, proteins of 125 and 145 kDa showed elevated tyrosine phosphorylation and were identified as p125(FAK) and c-Met, respectively, Gradual loss of tyrosine phosphorylation coincided with disruption of focal adhesions and conversion to a motile phenotype, HGF/SF-mediated tyrosine phosphorylation of p125(FAK) was inhibited by the tyrosine kinase inhibitor, herbimycin A, which also blocked spreading and the migratory response, These results indicate that fibroblast-derived HGF/SF triggers migration through the initial recruiting of integrins, cytoskeletal proteins, and p125(FAK) into focal adhesions that is dependent on tyrosine kinase activity.	UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Osaka University					NCI NIH HHS [CA51884] Funding Source: Medline; NIDCR NIH HHS [DE10356, DE10306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AM, 1988, ONCOGENE, V2, P599; CHEN BMC, 1991, SCIENCE, V251, P1600; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; FIDLER IJ, 1987, CANCER B, V39, P129; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1991, CANCER METAST REV, V10, P49, DOI 10.1007/BF00046843; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MIZOGUCHI H, 1991, INT J CANCER, V49, P738, DOI 10.1002/ijc.2910490518; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OTEY CA, 1993, MOL BIOL CELL S, V4, P2011; PICARD O, 1986, CANCER RES, V46, P3290; RAMOS DM, 1991, INVAS METAST, V11, P125; RANKIN S, 1994, J BIOL CHEM, V269, P704; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RENZO MFD, 1991, ONCOGENE, V6, P1997; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STOKER M, 1987, NATURE, V327, P238; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; WARM RM, 1989, NATURE, V340, P186; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	47	336	336	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31807	31813						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527397				2022-12-25	WOS:A1994PX30300074
J	MITRA, S; BECHHOFER, DH				MITRA, S; BECHHOFER, DH			SUBSTRATE-SPECIFICITY OF AN RNASE III-LIKE ACTIVITY FROM BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; EARLY MESSENGER-RNA; PROCESSING SIGNALS; CLEAVAGE SITES; DNA; MECHANISM; SEQUENCE; LAMBDA; GENE	Bacillus subtilis bacteriophage SP82 codes for several early RNAs that were shown previously to be cleaved by an RNase III-like enzyme called ''Bs-RNase III.'' Cloning of DNA fragments that encode these RNA sequences downstream of a T7 RNA polymerase promoter allowed the synthesis of substrates that were used to test the cleavage specificity of Bs-RNase III, which was purified from a protease-deficient strain of B. subtilis. Single nucleotide changes at or near the cleavage site and deletions upstream and downstream of the cleavage site were constructed. The effects of these changes on the rate of Bs-RNase III cleavage were measured. The activity of Bs-RNase III and Escherichia coli RNase III on heterologous substrates was also tested. Although the local environment of the site of Bs-RNase III cleavage appears very similar to that of E. coli RNase III, there are important differences in their substrate specificity.	CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIGMS NIH HHS [GM-48804, GM-39516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048804, R29GM039516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; BECHHOFER DH, 1989, J BACTERIOL, V171, P5803, DOI 10.1128/jb.171.11.5803-5811.1989; CHELLADURAI B, 1993, BIOCHEMISTRY-US, V32, P7549, DOI 10.1021/bi00080a029; CHELLADURAI BS, 1991, NUCLEIC ACIDS RES, V19, P1759, DOI 10.1093/nar/19.8.1759; Court D. L., 1993, CONTROL MESSENGER RN, P71; DIMARI JF, 1993, MOL MICROBIOL, V7, P705; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI DS, 1993, NUCLEIC ACIDS RES, V21, P3977, DOI 10.1093/nar/21.17.3977; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; NICHOLSON AW, 1988, NUCLEIC ACIDS RES, V16, P1577, DOI 10.1093/nar/16.4.1577; PANGANIBAN AT, 1983, CELL, V33, P907, DOI 10.1016/0092-8674(83)90033-8; PANGANIBAN AT, 1983, J BIOL CHEM, V258, P2487; ROBERTSON HD, 1982, CELL, V30, P669, DOI 10.1016/0092-8674(82)90270-7; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	19	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31450	31456						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527387				2022-12-25	WOS:A1994PX30300022
J	LIU, ML; OLSON, AL; EDGINGTON, NP; MOYEROWLEY, WS; PESSIN, JE				LIU, ML; OLSON, AL; EDGINGTON, NP; MOYEROWLEY, WS; PESSIN, JE			MYOCYTE ENHANCER FACTOR-2 (MEF2) BINDING-SITE IS ESSENTIAL FOR C2C12 MYOTUBE-SPECIFIC EXPRESSION OF THE RAT GLUT4 MUSCLE-ADIPOSE FACILITATIVE GLUCOSE-TRANSPORTER GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; SKELETAL-MUSCLE; TRANSGENIC MICE; PRETRANSLATIONAL SUPPRESSION; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; DECREASED EXPRESSION; DIABETES-MELLITUS; MESSENGER-RNA; ELEMENT	We have cloned and characterized the rat GLUT4 gene in order to identify the cis-DNA elements responsible for tissue-specific GLUT4 expression. In this study, a variety of luciferase reporter gene constructs were transiently transfected into C2C12 myoblasts and myotubes as a model for skeletal muscle differentiation. These data identified a 103-base pair fragment, located from -522 to -420 relative to the transcription initiation site, that was sufficient to account for GLUT4 C2C12 myotube-specific expression. This fragment was operationally defined as an enhancer since it conferred myotube-specific expression in the context of both the minimal native GLUT4 or the heterologous thymidine kinase promoters in an orientation-independent manner. Further, mutagenesis of this fragment demonstrated that a sequence analogous to the muscle creatine kinase myocyte enhancer factor 2 (MEF2) binding site (-466 and -457) was required for transcriptional activation. Electrophoretic mobility gel shift assays demonstrated specific binding activity to the GLUT4 MEF2 sequences which directly correlated with functional expression. Although this element was capable of directing myotube-specific expression when cloned as multiple copies into luciferase reporter gene constructs, the MEF2 sequence alone was insufficient to enhance GLUT4 expression. These data demonstrated that GLUT4 muscle-specific expression is conferred by a 103-base pair DNA sequence located between -522 and -420 of rat GLUT4 gene, This region encompasses a MEF2 binding site which was necessary, but not sufficient, for transcriptional activation.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIDDK NIH HHS [DK44612, DK42452, DK25925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042452, R01DK044612] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL CV, 1983, J MOL APPL GENET, V2, P401; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; REN JM, 1993, J BIOL CHEM, V268, P16113; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RICHARDSON JM, 1993, J BIOL CHEM, V268, P21021; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	52	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28514	28521						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7545962				2022-12-25	WOS:A1994PV77200108
J	ANDRES, V; CERVERA, M; MAHDAVI, V				ANDRES, V; CERVERA, M; MAHDAVI, V			DETERMINATION OF THE CONSENSUS BINDING-SITE FOR MEF2 EXPRESSED IN MUSCLE AND BRAIN REVEALS TISSUE-SPECIFIC SEQUENCE CONSTRAINTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HELIX-LOOP-HELIX; TRANSCRIPTION FACTORS; CYCLIC AMPLIFICATION; FACTOR-II; ENHANCER; PROTEINS; TARGETS; SELECTION; COMPLEXES; ELEMENT	The myocyte-specific enhancer factor-2 (MEF2) proteins are expressed in the three major types of muscle (skeletal, cardiac, and smooth) and function as transcriptional activators of muscle-specific and growth factor-regulated genes through binding to a canonical A/T-rich cis-element. Although MEF2 proteins are also expressed in brain, MEF2-regulated muscle-specific gene products are not detected in this tissue. To gain insight into the regulation of MEF2 function in vivo, we have selected its optimal DNA targets from a library of degenerate oligonucleotides using anti-MEF2A antibodies and cell extracts from skeletal muscle, heart, and brain. The consensus binding site in these three tissues contains an indistinguishable core motif, 5'-CT(A/t)(a/ t)AAATAG-3'. However, the optimal target for MEF2 expressed in the brain shows additional sequence constraints (5'-TGTTACT(A/t)(a/t)AAATAGA(A/t)-3') that are not observed in the sequences selected with skeletal and cardiac muscle extracts. Thus, differences in DNA binding preferences of MEF2 proteins in muscle and brain may contribute to tissue-specific gene expression during myogenesis and neurogenesis.	CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Andres, Vicente/I-6440-2014	Andres, Vicente/0000-0002-0125-7209	NHLBI NIH HHS [R0IHL45425, R0IHL35576] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035576, R01HL045425] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES V, 1995, MOL CELL BIOL, V15, P4272; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1994, MOL CELL BIOL, V13, P2564; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	29	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23246	23249		10.1074/jbc.270.40.23246	http://dx.doi.org/10.1074/jbc.270.40.23246			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559475	hybrid			2022-12-25	WOS:A1995RY90900004
J	COPPOLINO, M; LEUNGHAGESTEIJN, C; DEDHAR, S; WILKINS, J				COPPOLINO, M; LEUNGHAGESTEIJN, C; DEDHAR, S; WILKINS, J			INDUCIBLE INTERACTION OF INTEGRIN ALPHA(2)BETA(1) WITH CALRETICULIN - DEPENDENCE ON THE ACTIVATION STATE OF THE INTEGRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EXOCRINE PANCREATIC-CELLS; CALCIUM-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; ADHESION; ALPHA-2-BETA-1; MODULATION; INVITRO; COMPLEX	We have previously demonstrated an interaction between the highly conserved KXGFFKR sequence of the integrin alpha-subunit cytoplasmic domains and calreticulin. Since this highly conserved sequence motif has been implicated in the regulation of the integrin affinity state, we wanted to determine whether the calreticulin-integrin interaction also depended on the integrin affinity state, and whether calreticulin occupation of integrin via the KXGFFKR motif was involved in the regulation of the ligand affinity state; We now demonstrate that anti-integrin antibody- or phorbol la-myristate 13-acetate (PMA)-induced activation of the alpha(2) beta(1) integrin on Jurkat cells, as determined by stimulation of adhesion to collagen type I, resulted in an increased amount of calreticulin bound to this integrin. alpha(2) beta(1) activation with either anti-beta(1) or anti-alpha(2) monoclonal antibodies resulted in a greater amount of calreticulin coimmunoprecipitating with this integrin. Inactivation by neutralizing anti-integrin antibodies abrogated the calreticulin-integrin interaction. A correlation was also found between PMA-induced alpha(2) beta(1) activation and the amount of calreticulin bound to this integrin. Furthermore, pretreatment of streptolysin O-permeablized Jurkat cells with an anti-calreticulin antibody resulted in a significant and specific inhibition of the adhesion to collagen type I that could be induced by antibodies to alpha(2) beta(1) or by PMA. These data suggest that the active, high affinity form of alpha(2) beta(1) binds calreticulin and that calreticulin binding to the alpha(2) cytoplasmic domain may be required for stabilizing the high affinity state of this integrin. The data presented here also demonstrate, for the first time, an inducible interaction of an integrin with an intracellular protein that occurs via the alpha subunit of the integrin.	SUNNYBROOK HLTH SCI CTR,DIV CANC BIOL RES,TORONTO,ON M4N 3M5,CANADA; RDU,MED RES LAB,WINNIPEG,MB K3A 1M4,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center				Dedhar, Shoukat/0000-0003-4355-1657				BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DEDHAR S, 1990, BIOESSAYS, V12, P583, DOI 10.1002/bies.950121205; GUAN SH, 1991, BIOCHEMISTRY-US, V30, P9892, DOI 10.1021/bi00105a012; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V1020, P577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; MACLENNAN DH, 1972, P NATL ACAD SCI USA, V68, P1231; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PACIFICI R, 1994, J IMMUNOL, V153, P2222; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STUPACK DG, 1994, CELL IMMUNOL, V155, P237, DOI 10.1006/cimm.1994.1116; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKEMOTO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P129, DOI 10.1016/0003-9861(92)90554-A; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	30	125	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23132	23138		10.1074/jbc.270.39.23132	http://dx.doi.org/10.1074/jbc.270.39.23132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559457	hybrid			2022-12-25	WOS:A1995RY05400077
J	DUSETTI, NJ; ORTIZ, EM; MALLO, GV; DAGORN, JC; IOVANNA, JL				DUSETTI, NJ; ORTIZ, EM; MALLO, GV; DAGORN, JC; IOVANNA, JL			PANCREATITIS-ASSOCIATED PROTEIN-I (PAP-I), AN ACUTE-PHASE PROTEIN-INDUCED BY CYTOKINES - IDENTIFICATION OF 2 FUNCTIONAL INTERLEUKIN-6 RESPONSE ELEMENTS IN THE RAT PAP-I PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; INTERFERON-GAMMA; GENE-EXPRESSION; HUMAN-FIBROBLASTS; FACTOR-ALPHA; INDUCTION; RECEPTOR; GLUCOCORTICOIDS; TRANSCRIPTION	Expression of the pancreatitis-associated protein I (PAP I), an exocrine pancreatic protein, increases rapidly and strongly in acinar cells during the acute phase of pancreatitis, This is reminiscent of the response to stress of acute phase proteins, We have previously demonstrated that serum factors from rats with acute pancreatitis, but not from healthy rats, could induce endogenous PAP I gene expression in the acinar cell Line AR-42J (Dusetti, N., Mallo, G., Dagorn, J.-C., Iovanna, J. L. (1994) Biochem, Biophys, Res, Commun, 204, 238-243), In the present work, we have evaluated the influence of several mediators of inflammation on rat PAP I gene transcription in these cells, Tumor necrosis factor alpha induced an increase in PAP I mRNA expression, and interferon gamma caused an even greater increase in PAP I mRNA level, These stimulations were antagonized by dexamethasone. Interleukin (IL)-1, IL-6, or dexamethasane alone were ineffective, Combinations of IL-1 with n-6 or dexamethasone were also ineffective, IL-6 and dexamethasone together induced a marked stimulation of PAP I gene transcription, and this effect was slightly attenuated by IL-1, To analyze the cis-regulatory elements responsible for the induction of transcription, we fused a 1,2-kilobase segment of the rat PAP I promoter to the chloramphenicol acetyltransferase (CAT) gene as reporter, The resultant chimeric DNA was transfected into AR-42J cells. Addition of IL-6 or dexamethasone was ineffective, whereas their mixture increased the CAT activity 12 times. Progressive deletions of the PAP I promoter were then fused to the CAT gene, and the constructs were transfected to AR-42J cells, A la-fold increase in CAT activity was seen upon IL-6/dexamethasane treatment with constructs containing more than 274 base pairs upstream from the cap site, In that region, two sequences are similar to the canonical IL-6 response element, Site-directed mutagenesis of these regions strongly decreased induction, showing that they were functional, PAP I should therefore be classified among acute phase proteins of class 2, whose expression is increased by IL-6 acting in combination with glucocorticoids.	INSERM,U315,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Dusetti, Nelson/O-7919-2017; Iovanna, Juan/M-9805-2017	Dusetti, Nelson/0000-0002-6161-8483; Iovanna, Juan/0000-0003-1822-2237				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; AMEZAGA MA, 1992, BLOOD, V79, P735; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BAUER J, 1989, FEBS LETT, V249, P27, DOI 10.1016/0014-5793(89)80008-0; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1897, J IMMUNOL, V139, P4122; BERESINI MH, 1988, J IMMUNOL, V140, P485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUSETTI NJ, 1995, BIOCHEM J, V307, P9, DOI 10.1042/bj3070009; DUSETTI NJ, 1994, BIOCHEM BIOPH RES CO, V204, P238, DOI 10.1006/bbrc.1994.2450; DUSETTI NJ, 1993, J BIOL CHEM, V268, P14470; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FRIGERIO JM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P329, DOI 10.1016/0167-4781(93)90167-C; FRIGERIO JM, 1993, BIOCHEMISTRY-US, V32, P9236, DOI 10.1021/bi00086a032; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HEATH DI, 1989, GUT, V30, pA1456; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; IOVANNA JL, 1991, AM J PHYSIOL, V261, P485; IOVANNA JL, 1993, AM J PHYSIOL, V265, P611; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; MAGIELSKAZERO D, 1988, BIOCHEM INT, V17, P17; MASCIOTRA L, 1995, DIGEST DIS SCI, V40, P519, DOI 10.1007/BF02064359; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; POLITIS AD, 1992, J IMMUNOL, V148, P801; RUBIN BY, 1988, J IMMUNOL, V141, P1180; SCIAVOLINO PJ, 1994, J BIOL CHEM, V269, P21627; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STEPHANOVA E, 1995, IN PRESS CYTOGENET C	40	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22417	22421		10.1074/jbc.270.38.22417	http://dx.doi.org/10.1074/jbc.270.38.22417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545677	hybrid			2022-12-25	WOS:A1995RW31400056
J	LYSIAK, JJ; HUSSAINI, IM; WEBB, DJ; GLASS, WF; ALLIETTA, M; GONIAS, SL				LYSIAK, JJ; HUSSAINI, IM; WEBB, DJ; GLASS, WF; ALLIETTA, M; GONIAS, SL			ALPHA(2)-MACROGLOBULIN FUNCTIONS AS A CYTOKINE CARRIER TO INDUCE NITRIC-OXIDE SYNTHESIS AND CAUSE NITRIC OXIDE-DEPENDENT CYTOTOXICITY IN THE RAW-264.7 MACROPHAGE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; MURINE PERITONEAL-MACROPHAGES; FACTOR-BETA; ALPHA-2-MACROGLOBULIN RECEPTOR; MOUSE MACROPHAGES; L-ARGININE; ACTIVATED MACROPHAGES; DNA FRAGMENTATION; INTERFERON-GAMMA	Nitric oxide (NO) is an important mediator of macrophage activities. We studied the regulation of macrophage NO synthesis by alpha(2)-macroglobulin (alpha(2)M), a proteinase inhibitor and carrier of certain growth factors, including transforming growth factor-beta (TGF-beta). Native alpha(2)M and the alpha(2)M receptor-recognized derivative, alpha(2)M-methylamine (alpha(2)M-MA), increased nitrite generation by the RAW 264.7 murine macrophage cell line. The level of nitrite accumulation, which is an index of NO synthesis, was comparable to that observed with interferon-gamma. Native alpha(2)M and alpha(2)M-MA also increased inducible nitric oxide synthase (iNOS) mRNA levels and substantially reduced the number of viable cells, as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium/succinyl dehydrogenase assay or trypan blue exclusion. At slightly higher alpha(2)M concentrations, [H-3]thymidine incorporation was inhibited. All of these activities were counteracted nearly completely when the iNOS competitive inhibitor N-G-monomethyl-L-arginine was included. By in situ nick translation, native alpha(2)M and alpha(2)M-MA increased the percentage of cells with detectable single strand chromatin nicks from 4 to 12 and 17%, respectively. This change suggested apoptosis; however, electron microscopy studies demonstrated variability in the morphology of injured cells. To determine the mechanism by which alpha(2)M increases macrophage NO synthesis, we studied proteolytic alpha(2)M derivatives that retain partial activity. A 600-kDa derivative that retains growth factor binding activity increased RAW 264.7 cell NO synthesis and iNOS mRNA levels comparable to native alpha(2)M and alpha(2)M-MA. The purified 18-kDa alpha(2)M receptor-binding fragment had no effect on NO synthesis or iNOS expression. Thus, the growth factor-carrier activity of alpha(2)M and not its receptor-binding activity is essential for NO synthesis regulation. A TGF-beta-neutralizing antibody mimicked the activity of alpha(2)M, increasing RAW 264.7 cell NO synthesis and decreasing cellular viability. These studies demonstrate that alpha(2)M can regulate macrophage NO synthesis and profoundly affect cellular function without gaining entry into the cell and without binding specific plasma membrane receptors.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA-53462] Funding Source: Medline; NIDDK NIH HHS [DK-46735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BJORK I, 1982, BIOCHEM J, V207, P347; BORTH W, 1994, ANN NY ACAD SCI, V737, P267, DOI 10.1111/j.1749-6632.1994.tb44317.x; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHU CT, 1994, LAB INVEST, V71, P792; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DING A, 1990, J IMMUNOL, V145, P940; FUKUO K, 1995, J CLIN INVEST, V95, P669, DOI 10.1172/JCI117712; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; GOLD R, 1994, LAB INVEST, V71, P219; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HAUSMANN EHS, 1994, INFECT IMMUNOL, V362, P3625; HECK DE, 1992, J BIOL CHEM, V267, P21277; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOFFMAN M, 1988, AGENTS ACTIONS, V25, P360, DOI 10.1007/BF01965043; HOFFMAN M, 1983, BIOCHIM BIOPHYS ACTA, V760, P421, DOI 10.1016/0304-4165(83)90384-7; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; HUANG SS, 1988, J BIOL CHEM, V263, P1535; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JUNQUERO DC, 1992, J PHYSIOL-LONDON, V454, P451, DOI 10.1113/jphysiol.1992.sp019273; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; MAJNO G, 1995, AM J PATHOL, V146, P3; MALORANTA U, 1994, FEBS LETT, V337, P179, DOI 10.1016/0014-5793(94)80269-6; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MEBMER UK, 1994, FEBS LETT, V355, P23; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PIETRAFORTE D, 1994, J LEUKOCYTE BIOL, V55, P175, DOI 10.1002/jlb.55.2.175; ROBERTS AB, 1992, MOL ENDOCRINOL, V5, P1921; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; Sottrup-Jensen L, 1987, PLASMA PROTEINS STRU, V5, P192; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WEBB DJ, 1994, J BIOL CHEM, V269, P30402; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WOLF BB, 1992, AM J PATHOL, V141, P37; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YATES MT, 1992, FEBS LETT, V309, P135, DOI 10.1016/0014-5793(92)81081-V; ZEMBALA M, 1994, EUR J IMMUNOL, V24, P435, DOI 10.1002/eji.1830240225	75	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21919	21927		10.1074/jbc.270.37.21919	http://dx.doi.org/10.1074/jbc.270.37.21919			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545171	hybrid			2022-12-25	WOS:A1995RU75700076
J	ZHANG, SH; ECKBERG, WR; YANG, Q; SAMATAR, AA; TONKS, NK				ZHANG, SH; ECKBERG, WR; YANG, Q; SAMATAR, AA; TONKS, NK			BIOCHEMICAL-CHARACTERIZATION OF A HUMAN BAND 4.1-RELATED PROTEIN-TYROSINE-PHOSPHATASE, PTPH1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; IDENTIFICATION; EZRIN; EXPRESSION; HOMOLOGY; CLONING; KINASES; GENE	PTPH1 is a human protein-tyrosine phosphatase with homology to the band 4.1 superfamily of cytoskeleton-associated proteins, Here, we report the purification and biochemical characterization of this enzyme from baculovirus-infected insect cells. The purified protein exhibited an apparent M(r) of 120,000 on SDS gels. The native enzyme dephosphorylated both myelin basic protein (MBP) and reduced, carboxamidomethylated, and maleylated lysozyme (RCML) but was over 5-fold more active on MBP. The K-m values for the two substrates were similar (1.45 mu M for MBP and 1.6 mu M for RCML). Phosphorylation of PTPH1 by protein kinase C in vitro resulted in a decrease in K-m but had no effect on V-max. Removal of the NH2-terminal band 4.1 homology domain of PTPH1 by limited trypsin cleavage stimulated dephosphorylation of RCML but inhibited its activity toward MBP, The dephosphorylation of RCML by full-length PTPH1 was enhanced up to B-fold by unphosphorylated MBP and increasing ionic strength up to 0.2 M Nacl, whereas trypsinized preparations of PTPH1 containing the isolated catalytic domain were unaffected. These results suggest that in addition to a potential role in controlling subcellular localization, the NH2-terminal band 4.1 homology domain of PTPH1 may exert a direct effect on catalytic function.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DELVECCHIO RL, 1994, J BIOL CHEM, V269, P19639; FAZIOLI F, 1992, ONCOGENE, V8, P1335; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; KELLIE S, 1991, J CELL SCI, V99, P207; LABBE D, 1994, FEBS LETT, V356, P351, DOI 10.1016/0014-5793(94)01305-5; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SARAS J, 1994, J BIOL CHEM, V26, P24082; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5945; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZHANG SH, 1994, J BIOL CHEM, V269, P17593; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	34	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20067	20072		10.1074/jbc.270.34.20067	http://dx.doi.org/10.1074/jbc.270.34.20067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544351	hybrid			2022-12-25	WOS:A1995RQ99100059
J	RODRIGUEZRODRIGUEZ, L; TSUCHIHASHI, Z; FUENTES, GM; BAMBARA, RA; FAY, PJ				RODRIGUEZRODRIGUEZ, L; TSUCHIHASHI, Z; FUENTES, GM; BAMBARA, RA; FAY, PJ			INFLUENCE OF HUMAN-IMMUNODEFICIENCY-VIRUS NUCLEOCAPSID PROTEIN ON SYNTHESIS AND STRAND TRANSFER BY THE REVERSE-TRANSCRIPTASE IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA ANNEALING ACTIVITIES; ZINC FINGER DOMAIN; ESCHERICHIA-COLI; HIV-1; TYPE-1; RECOMBINATION; SEQUENCES; DNA; GENOMES; BINDING	Human immunodeficiency virus (HIV) nucleocapsid protein (NC) influences HIV reverse transcriptase (RT) catalyzed strand transfer synthesis from internal regions of natural sequence RNA. In the strand transfer assay reaction in vitro, primer synthesis initiated on a donor template can transfer and be completed on an acceptor template. NC was added at concentrations up to twice that needed for 100% template coating. As the concentration of NC was increased, primer extension was stimulated until NC coated approximately 50% of the template. Stimulation was caused in part by an increase in the number of primers that sustained synthesis. Subsequent increments of NC decreased synthesis. The presence of NC also increased the efficiency of the strand transfer reaction, allowing a greater proportion of extended primers to transfer from donor to acceptor templates. Processivity of the RT on the donor template was measured using both challenged and enzyme dilution assays. NC did not alter the proportion of synthesis products that reached the end of the template, indicating little effect on processivity. This result suggests that the increase in full-length product synthesis, observed in reactions where the RT repeatedly bound the primer-template, resulted from promotion of RT reassociation by NC. Consequently, since the RT could not reassociate with the template in the processivity assay, NC could not stimulate the amount of full-length synthesis. No strand transfer was observed in dilution processivity assays, suggesting that the RT must dissociate and rebind during the transfer reaction. Stimulation of synthesis, e.g. by increased dNTP concentration, normally inhibits strand transfer. Stimulation of both synthesis and transfer by NC indicates that properties of NC that improve the transfer event prevail over the negative effects of rapid synthesis on transfer efficiency.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	University of Rochester; University of Rochester; University of Rochester; Howard Hughes Medical Institute; Stanford University					NCI NIH HHS [CA11198] Funding Source: Medline; NIAID NIH HHS [AI 01146] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DELAHUNTY MD, 1992, BIOCHEMISTRY-US, V31, P6461, DOI 10.1021/bi00143a015; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1994, J MOL BIOL, V243, P558, DOI 10.1016/0022-2836(94)90030-2; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; DUPRAZ P, 1993, J VIROL, V64, P4978; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Kornberg A., 1991, DNA REPLICATION; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sambrook J, 1989, MOL CLONING LABORATO; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WEISS S, 1992, GENE, V121, P203, DOI 10.1016/0378-1119(92)90123-7; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491	39	138	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15005	15011		10.1074/jbc.270.25.15005	http://dx.doi.org/10.1074/jbc.270.25.15005			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541033	hybrid			2022-12-25	WOS:A1995RE66600027
J	IVANENKOV, VV; JAMIESON, GA; GRUENSTEIN, E; DIMLICH, RVW				IVANENKOV, VV; JAMIESON, GA; GRUENSTEIN, E; DIMLICH, RVW			CHARACTERIZATION OF S-100B BINDING EPITOPES - IDENTIFICATION OF A NOVEL TARGET, THE ACTIN CAPPING PROTEIN, CAPZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-MODULATED PROTEINS; LIGHT-CHAIN KINASE; ALPHA-ALPHA PROTEIN; BOVINE BRAIN; SKELETAL-MUSCLE; MICROTUBULE PROTEINS; S100B PROTEIN; IONS BINDING; Z-LINE; CALMODULIN	Short amino acid sequences that interact with the Ca2+ binding protein S-100b were identified by screening a bacteriophage random peptide display library. S-100b binding bacteriophages were selected by Ca2+-dependent affinity chromatography, and the sequence of the random peptide insert contained in 51 clones was determined. Alignment of the sequence of 44 unique S-100b binding peptides identified a common motif of eight amino acids. A subgroup of peptides that contained sequences with the highest degree of similarity had the consensus motif (K/R)(L/I)XWXXIL, in which predominantly P, S, and N were found in position 3, and S and D were found in position 5. Analysis of sequence databanks identified a similar sequence in the COOH-terminal region of the alpha-subunit of actin capping proteins. The peptide TRTKIDWNKILS (TRTK-12), corresponding to the region of greatest homology within this region of the subunit of actin capping proteins (e.g. amino acids 265-276 in CapZ alpha 1 and CapZ alpha 2), was synthesized and shown by fluorescence spectrophotometry to bind S-100b in a Ca2+-dependent manner. Gel overlay and cross-linking experiments demonstrated the interaction of S-100b with CapZ to be Ca2+ dependent. Moreover, this interaction was blocked by addition of TRTK-12 peptide. These results identify Ca2+-dependent S-100b target sequence epitopes and designate the carboxyl terminus of the alpha-subunit of actin capping proteins, like CapZ, to be a target of S-100b activity. The high level of conservation within this region of actin capping proteins and the apparent high affinity of this interaction strongly suggest that the interaction between S-100b and the alpha-subunit of actin capping proteins is biologically significant.	UNIV CINCINNATI,COLL MED,DEPT EMERGENCY MED,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NINDS NIH HHS [NS-27814, NS-25635] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025635, R01NS027814] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; ANKENBAUER T, 1989, NATURE, V342, P822, DOI 10.1038/342822a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BAUDIER J, 1983, BIOCHEMISTRY-US, V22, P3360, DOI 10.1021/bi00283a009; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1989, BIOCHEM J, V264, P79, DOI 10.1042/bj2640079; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BLUMENTHAL DK, 1988, BIOCHEM BIOPH RES CO, V156, P860, DOI 10.1016/S0006-291X(88)80923-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1984, J CELL BIOL, V99, P550, DOI 10.1083/jcb.99.2.550; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CASELLA JF, 1989, P NATL ACAD SCI USA, V86, P5800, DOI 10.1073/pnas.86.15.5800; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CHAFOULEAS JG, 1979, J BIOL CHEM, V254, P262; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; COOPER JA, 1991, CELL MOTIL CYTOSKEL, V18, P204, DOI 10.1002/cm.970180306; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DEDMAN JR, 1984, ROLE CALCIUM HLTH DI, P135; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DONATO R, 1989, J NEUROCHEM, V53, P566, DOI 10.1111/j.1471-4159.1989.tb07371.x; DONATO R, 1984, BIOCHEM BIOPH RES CO, V122, P983, DOI 10.1016/0006-291X(84)91188-4; DONATO R, 1987, CELL CALCIUM, V8, P283, DOI 10.1016/0143-4160(87)90004-2; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; DYCK RH, 1993, DEV BRAIN RES, V72, P181, DOI 10.1016/0165-3806(93)90183-B; HAIMOTO H, 1988, EUR J BIOCHEM, V171, P409, DOI 10.1111/j.1432-1033.1988.tb13805.x; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HERTZBERG EL, 1987, METHOD ENZYMOL, V139, P445; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; ISOBE T, 1981, EUR J BIOCHEM, V115, P469; ISOBE T, 1983, BIOCHEM INT, V6, P419; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; JAMIESON GA, 1979, BIOCHEM BIOPH RES CO, V90, P1048, DOI 10.1016/0006-291X(79)91932-6; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MASURE HR, 1984, BIOCHEM J, V218, P691, DOI 10.1042/bj2180691; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MOORE BW, 1988, NEUROCHEM RES, V13, P539, DOI 10.1007/BF00973294; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; SKRIPNIKOVA EV, 1989, FEBS LETT, V257, P380, DOI 10.1016/0014-5793(89)81577-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANELDIK LJ, 1985, BIOCHEM BIOPH RES CO, V126, P825, DOI 10.1016/0006-291X(85)90259-1; VANELDIK LJ, 1988, CALCIUM CALCIUM BIND, P114; ZIMMER DB, 1993, CELL CALCIUM, V14, P323, DOI 10.1016/0143-4160(93)90053-9; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424; ZIMMER DB, 1988, J NEUROCHEM, V50, P572, DOI 10.1111/j.1471-4159.1988.tb02949.x	63	113	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14651	14658		10.1074/jbc.270.24.14651	http://dx.doi.org/10.1074/jbc.270.24.14651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540176	hybrid			2022-12-25	WOS:A1995RD45500063
J	EDWARDS, CP; CHAMPE, M; GONZALEZ, T; WESSINGER, ME; SPENCER, SA; PRESTA, LG; BERMAN, PW; BODARY, SC				EDWARDS, CP; CHAMPE, M; GONZALEZ, T; WESSINGER, ME; SPENCER, SA; PRESTA, LG; BERMAN, PW; BODARY, SC			IDENTIFICATION OF AMINO-ACIDS IN THE CD11A I-DOMAIN IMPORTANT FOR BINDING OF THE LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 (LFA-1) TO INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD11B/CD18; SITE; CLONING; LIGAND; MAC-1	Leukocyte function-associated antigen-1 (LFA-1) is a cell surface adhesion receptor for intercellular adhesion molecule-1, -2, and -3 (ICAM-1, -2, -3). Using human/murine chimeras of the I domain of the LFA-1 alpha subunit (CD11a), we recently identified the epitopes recognized by eight monoclonal antibodies against CD11a that inhibit LFA-1 binding to ICAM-1. In this report, we determined that replacement of the entire human I domain with the entire murine I-domain in CD11a completely abrogated LFA-1 binding to human ICAM-1 without affecting the gross conformation or heterodimer formation of LFA-1, as assayed by antibody binding, In order to assess which residues of the I-domain are responsible for binding to ICAM-1, we tested the ability of a panel of human/murine I-domain chimeras to bind to human ICAM-1. When complexed with CD18, all CD11a chimeras bound ICAM-1 at levels comparable to wild-type CD11a/CD18, indicating that the residues in these chimeras which differ in human and murine I domains may not play a critical role in LFA-1 binding to ICAM-1. A series of point mutations of residues that are conserved between murine and human CD11a I-domains, as well as between CD11b and CD11c, were also generated, Substitution of alanine for proline at position 192 in the human CD11a I-domain abrogated adhesion of LFA-1 to ICAM-1. Antibody binding data suggested that this was due to conformational changes within the I domain. Mutation of the aspartic acids at positions 137 and 239 to either alanine or lysine completely destroyed ICAM-1 binding. The conformation of LFA-1 alanine mutants was not significantly altered. This suggests that these aspartic acids are required for binding of human LFA-1 to human ICAM-1.	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	EDWARDS, CP (corresponding author), GENENTECH INC, DEPT IMMUNOL, MS 34, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.							ARNAOUT MA, 1990, BLOOD, V75, P1037; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KERN A, 1994, J BIOL CHEM, V269, P22811; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; RANDI AM, 1994, J BIOL CHEM, V269, P12395; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	26	67	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12635	12640		10.1074/jbc.270.21.12635	http://dx.doi.org/10.1074/jbc.270.21.12635			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7539005	hybrid			2022-12-25	WOS:A1995QZ71100048
J	ROWLEY, RB; BURKHARDT, AL; CHAO, HG; MATSUEDA, GR; BOLEN, JB				ROWLEY, RB; BURKHARDT, AL; CHAO, HG; MATSUEDA, GR; BOLEN, JB			SYK PROTEIN-TYROSINE KINASE IS REGULATED BY TYROSINE-PHOSPHORYLATED IG-ALPHA IG-BETA IMMUNORECEPTOR TYROSINE ACTIVATION MOTIF BINDING AND AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; X-LINKED AGAMMAGLOBULINEMIA; SRC FAMILY; COMPLEX; ASSOCIATION; GENES; COMPONENTS	Syk is a cytoplasmic protein-tyrosine kinase containing two amino-terminal Src homology 2 domains that is activated following ligation of the B cell antigen receptor. Syk activation in B cells correlates with Syk tyrosine phosphorylation as well, as with Syk SH2-mediated association with the tyrosine-phosphorylated Ig alpha and Ig beta B cell antigen receptor subunits. Tyrosine-phosphorylated peptide 20-mers representing Ig alpha and Ig beta immunoreceptor tyrosine activation motifs were synthesized and found to stimulate the specific activity of Syk by as much as 10-fold in vitro. Maximal phosphopeptide-induced Syk activation required both Syk SH2 domains and phosphorylation of both tyrosine residues present in the immunoreceptor tyrosine activation motif, The biochemical mechanism responsible for the phosphopeptide-induced Syk enzyme activation appears to be a function of Syk autophosphorylation. Our observations suggest the association of Syk tandem SH2 domains with the tyrosine-phosphorylated Ig alpha and/or Ig beta immunoreceptor tyrosine activation motifs in B cells stimulates Syk autophosphorylation leading to Syk enzyme activation.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MACROMOLEC STRUCT,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb								ADAM D, 1993, J BIOL CHEM, V268, P19882; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1992, NATURE, V338, P383; ROWLEY RB, 1995, IN PRESS J BIOL CHEM, V270; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	25	233	238	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11590	11594		10.1074/jbc.270.19.11590	http://dx.doi.org/10.1074/jbc.270.19.11590			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7538118	hybrid			2022-12-25	WOS:A1995QX86500079
J	AOUBALA, M; DELAFOURNIERE, L; DOUCHET, I; ABOUSALHAM, A; DANIEL, C; HIRN, M; GARGOURI, Y; VERGER, R; DECARO, A				AOUBALA, M; DELAFOURNIERE, L; DOUCHET, I; ABOUSALHAM, A; DANIEL, C; HIRN, M; GARGOURI, Y; VERGER, R; DECARO, A			HUMAN PANCREATIC LIPASE - IMPORTANCE OF THE HINGE REGION BETWEEN THE 2 DOMAINS, AS REVEALED BY MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GASTRIC LIPASE; LINKED IMMUNOSORBENT-ASSAY; LIMITED PROTEOLYSIS; PROCOLIPASE COMPLEX; COLIPASE; SPECIFICITY; ENZYME; LIPOLYSIS; PROTEINS; GEL	Several monoclonal antibodies (mAbs) were prepared against human pancreatic lipase (HPL). Two enzyme-linked immunosorbent assay (ELISA) procedures were set up for screening hybridomas producing specific antibodies. Four mAbs (81-23, 146-40, 315-25, and 320-24) of the IgG1 isotype were found to react with HPL in both simple sandwich and double sandwich ELISAs, while mAb 248-31, of the IgG2b isotype, reacted only with HPL in a double sandwich ELISA. The results of Western blot analysis carried out with native and SDS-denatured HPLs indicated that mAb 248 31 recognized only native HPL, while all the other mAbs recognized both forms of HPL. Since mAb 248-31 did not recognize SDS-denatured HPL, it was not possible to localize its epitope. To carry out epitope mapping along the primary sequence of HPL, four fragments (14, 26, 30, and 36 kDa) resulting hom a Limited chymotryptic cleavage of HPL were characterized by Western blotting as well as N-terminal amino acid sequence analysis. Of the above five anti-HPL mAbs, four (81-23, 248-31, 315-25, and 320-24) were found to inhibit the lipolytic activity of HPL (in both the presence and absence of bile salts and colipase), while mAb 146-40 had no inhibitory effects. The epitope recognized by mAb 146-40 was found to be located in the N-terminal domain (Lys(1)-Phe(335)). Combined immunoinactivation and epitope mapping studies showed that three inhibitory mAbs (81-23, 315-25, and 320-24) recognize overlapping epitopes from the hinge region between the N- and C-terminal domains of HPL, belonging to the 26-kDa fragment. In the presence of Lipids, a significant decrease has been observed in the bending angle between the N- and C-terminal domains of the HPL tertiary structure (van Tilbeurgh, H., Egloff, M. P., Martinet, C., Rugani, N., Verger, R. and Cambillau, C. (1993) Nature 362, 814-820). From the present immunochemical data, we further propose that locking the hinge movement with mAbs may induce lipase immunoinactivation.	CNRS,LIPOLYSE ENZYMAT LAB,GROUPEMENT RECH 1000,UNITE PROPRE RECH 9025,F-13402 MARSEILLE 20,FRANCE; IMMUNOTECH SA,F-13009 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			ABOUSALHAM, Abdelkarim/Q-4487-2019; abousalham, abdelkarim/A-4363-2018	abousalham, abdelkarim/0000-0002-8020-4294				ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; AOUBALA M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P183, DOI 10.1016/0005-2760(93)90204-M; AOUBALA M, 1993, EUR J BIOCHEM, V211, P99, DOI 10.1111/j.1432-1033.1993.tb19874.x; BOSCBIERNE I, 1987, BIOCHIM BIOPHYS ACTA, V911, P326; BOUSSETRISSO M, 1985, FEBS LETT, V182, P323, DOI 10.1016/0014-5793(85)80325-2; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; DECARO A, 1977, BIOCHIM BIOPHYS ACTA, V490, P411, DOI 10.1016/0005-2795(77)90016-2; DELAFOURNIERE L, 1989, BIOCHIM BIOPHYS ACTA, V998, P158, DOI 10.1016/0167-4838(89)90268-9; ERLANSONALBERTS.C, 1992, BIOCHIM BIOPHYS ACTA, V1125, P1; FOURNET B, 1987, EUR J BIOCHEM, V170, P369, DOI 10.1111/j.1432-1033.1987.tb13709.x; FRIGUET B, 1983, J IMMUNOL METHODS, V60, P351, DOI 10.1016/0022-1759(83)90292-2; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GARGOURI Y, 1983, J LIPID RES, V24, P1336; GARGOURI Y, 1989, BIOCHIM BIOPHYS ACTA, V1006, P255, DOI 10.1016/0005-2760(89)90012-X; GERSHONI JM, 1982, ANAL BIOCHEM, V124, P396, DOI 10.1016/0003-2697(82)90056-2; Hamosh M., 1990, LINGUAL GASTRIC LIPA, P179; IVANOVA MG, 1993, COLLOID SURFACE B, V1, P17, DOI 10.1016/0927-7765(93)80013-O; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PARHAM P, 1983, J IMMUNOL, V131, P2895; RATHELOT J, 1975, BIOCHIMIE, V57, P1117; RUGANI N, 1991, BIOCHEM BIOPH RES CO, V177, P726, DOI 10.1016/0006-291X(91)91848-7; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R, 1980, Methods Enzymol, V64, P340; WILSON JE, 1985, J BIOL CHEM, V260, P2838; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	28	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3932	3937		10.1074/jbc.270.8.3932	http://dx.doi.org/10.1074/jbc.270.8.3932			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533157	hybrid			2022-12-25	WOS:A1995QH68800071
J	ARMSTRONG, SK; MCINTOSH, MA				ARMSTRONG, SK; MCINTOSH, MA			EPITOPE INSERTIONS DEFINE FUNCTIONAL AND TOPOLOGICAL FEATURES OF THE ESCHERICHIA-COLI FERRIC ENTEROBACTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; NUCLEOTIDE-SEQUENCE; CYTOPLASMIC MEMBRANE; RESISTANT MUTANTS; PROTEIN; TRANSPORT; TONB; GENE; BACTERIA; K-12	The outer membrane protein FepA of Escherichia coli is the receptor for the ferric enterobactin siderophore complex and colicins B and D. A foreign antigenic determinant inserted into selected FepA sites allowed mutational analysis of receptor function and in situ immunological tracking of specific protein domain's with respect to the bacterial cell compartment, Immunoblot analysis of bacterial proteins using an epitope-specific antibody detected the peptide determinant in the receptor fusions. The impact of the insertions on FepA function was examined by ferric enterobactin-mediated iron uptake experiments and colicin sensitivity tests. In all cases, FepA retained biological activity despite introduction of the foreign sequence. To further develop the topological model of FepA, the peptide-specific antibody was used to localize epitope-carrying FepA domains in intact bacterial cells and their isolated membranes. One epitope resided in a region on the exterior of the cell, at the surface of the FepA protein, while other epitopes appeared to be localized to the periplasm or within the outer membrane.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858; UNIV MISSOURI,SCH MED,DEPT MOLEC MICROBIOL & IMMUNOL,COLUMBIA,MO 65212	University of North Carolina; East Carolina University; University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI007610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040565] Funding Source: NIH RePORTER; NIAID NIH HHS [1 F32 AI 07610] Funding Source: Medline; NIGMS NIH HHS [1 R01 GM40565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGTERBERG M, 1990, VACCINE, V8, P85, DOI 10.1016/0264-410X(90)90184-N; ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; ARMSTRONG SK, 1989, MOL MICROBIOL, V3, P757, DOI 10.1111/j.1365-2958.1989.tb00224.x; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; CHARBIT A, 1987, J IMMUNOL, V139, P1658; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; LANGMAN L, 1972, J BACTERIOL, V112, P1142, DOI 10.1128/JB.112.3.1142-1149.1972; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; Miller J. H., 1972, EXPT MOL GENETICS, P433; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; PIERCE JR, 1986, J BACTERIOL, V166, P930, DOI 10.1128/jb.166.3.930-936.1986; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; PUGSLEY AP, 1976, J BACTERIOL, V127, P218, DOI 10.1128/JB.127.1.218-228.1976; PUGSLEY AP, 1976, J BACTERIOL, V126, P1052, DOI 10.1128/JB.126.3.1052-1062.1976; PUGSLEY AP, 1977, J BACTERIOL, V130, P26, DOI 10.1128/JB.130.1.26-36.1977; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; RUTZ JM, 1991, J BACTERIOL, V173, P5964, DOI 10.1128/jb.173.19.5964-5974.1991; Sambrook J, 1989, MOL CLONING LABORATO; SAUER M, 1990, MOL MICROBIOL, V4, P427, DOI 10.1111/j.1365-2958.1990.tb00609.x; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SHEA CM, 1991, MOL MICROBIOL, V5, P1415, DOI 10.1111/j.1365-2958.1991.tb00788.x; SKARE JT, 1993, J BIOL CHEM, V268, P16302; VANDIE I, 1990, MOL GEN GENET, V222, P297, DOI 10.1007/BF00633832	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2483	2488		10.1074/jbc.270.6.2483	http://dx.doi.org/10.1074/jbc.270.6.2483			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531690	hybrid			2022-12-25	WOS:A1995QF53500016
J	NAGY, E; RIGBY, WFC				NAGY, E; RIGBY, WFC			GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE SELECTIVELY BINDS AU-RICH RNA IN THE NAD(+)-BINDING REGION (ROSSMANN FOLD)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MYC MESSENGER-RNA; C-MYC; GROWTH-FACTOR; PROTEIN; SEQUENCE; IDENTIFICATION; ASSOCIATION; INVITRO; CELLS	A 36-kDa protein that binds AU-rich RNA was purified from human spleen and identified as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). CARER has been previously demonstrated to bind tRNA with high affinity. Competition studies suggested that cytoplasmic GAPDH binds the AU-rich elements (AREs) of lymphokine mRNA 3'-untranslated regions with higher affinity than tRNA. The AUUUA-specific RNA binding activity of GAPDH was inhibited by NAD(+), NADH, and ATP in a concentration-dependent manner, suggesting that RNA binding of GAPDH might involve the NAD(+)-binding region, or dinucleotide-binding (Rossmann) fold. This hypothesis was supported by experiments that localized RNA binding to the predicted N-terminal 6.8-kDa peptide, known to be involved in the formation of the NAD(+)-binding domain. The direct demonstration of ARE-specific binding protein activity localized to the NAD(+)-binding region of GAPDH supports the general concept that enzymes containing this domain may exhibit specific RNA binding activity and play additional roles in nucleic acid metabolism. Finally, cytoplasmic GAPER was found in the polysomal fraction of T lymphocytes. Thus, the RNA binding specificity of GAPDH as well as its localization within the cell merit its strong consideration as a protein important in the regulation of ARE-dependent mRNA turnover and translation in addition to its well described role in glycolysis.	DARTMOUTH COLL SCH MED,DEPT MED,LEBANON,NH 03756; DARTMOUTH COLL SCH MED,DEPT MICROBIOL,LEBANON,NH 03756; VET ADM MED CTR,WHITE RIVER JCT,VT 05009	Dartmouth College; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000910] Funding Source: NIH RePORTER; NIAID NIH HHS [KO4 AI00910, R01 AI2434] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BICKEL M, 1990, J IMMUNOL, V145, P840; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Brawerman G., 1993, CONTROL MESSENGER RN, P149; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CLERCH LB, 1993, FASEB J, V7, pA1233; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; FUKAMIKOBAYASHI K, 1993, FEBS LETT, V335, P289, DOI 10.1016/0014-5793(93)80749-K; FURFINE CS, 1965, J BIOL CHEM, V240, P844; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARRIS JI, 1976, ENZYMES, V13, P1; HENICS T, 1994, J BIOL CHEM, V269, P5377; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HUANG LY, 1993, J BIOL CHEM, V268, P25769; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KARPEL RL, 1981, BIOCHIM BIOPHYS ACTA, V654, P256, DOI 10.1016/0005-2787(81)90180-5; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P5460; MISETA A, 1991, J BIOL CHEM, V266, P19158; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; PERUCHO M, 1977, EUR J BIOCHEM, V81, P557, DOI 10.1111/j.1432-1033.1977.tb11982.x; PINOLROMA S, 1992, NATURE, V335, P730; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PREISS T, 1993, J BIOL CHEM, V268, P24523; ROSSMANN RG, 1975, ENZYMES, P62; RYAZANOV AG, 1985, FEBS LETT, V192, P131, DOI 10.1016/0014-5793(85)80058-2; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEAL G, 1988, P NATL ACAD SCI USA, V85, P2339, DOI 10.1073/pnas.85.7.2339; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1988, J IMMUNOL, V140, P2243; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SULLIVAN NF, 1992, BIOESSAYS, V14, P333, DOI 10.1002/bies.950140508; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YANG ST, 1969, BIOCHEMISTRY-US, V8, P2806, DOI 10.1021/bi00835a017; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	69	299	327	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2755	2763		10.1074/jbc.270.6.2755	http://dx.doi.org/10.1074/jbc.270.6.2755			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531693	hybrid			2022-12-25	WOS:A1995QF53500056
J	TEDESCHI, G; CHEN, S; MASSEY, V				TEDESCHI, G; CHEN, S; MASSEY, V			ACTIVE-SITE STUDIES OF DT-DIAPHORASE EMPLOYING ARTIFICIAL FLAVINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER NAD(P)H-QUINONE OXIDOREDUCTASE; AMINO-ACID SEQUENCE; RAT-LIVER; NAD(P)H DEHYDROGENASE; 6-SUBSTITUTED FLAVINS; DIRECTED MUTAGENESIS; BINDING-SITE; ONE-ELECTRON; MECHANISM; REDUCTASE	NAD(P)H:quinone oxidoreductase (EC 1.6.99.2) (DT-diaphorase) is an FAD-containing enzyme that catalyzes the 2-electron reduction of quinones to hydroquinones using either NADH or NADPH as the electron donor. In this study, FAD was removed by dialyzing the holoprotein against 2 M KBr, and synthetic analogs of FAD were substituted in the flavin binding site as structural probes. Spectral analysis indicates that the benzoquinoid forms of 8-mercapto-FAD and 6-mercapto-FAD are stabilized on binding to the enzyme. This is consistent with the fact that the native flavoprotein forms the anion flavin radical upon photoreduction and suggests the presence of a positive charge near the N(1)C(2)O position of the isoalloxazine ring. Reactivity studies using 8-chloro- and 8-mercapto-flavins suggest that the 8 position of the FAD is accessible to the solvent. However, the rates of the reactions were dramatically decreased in the presence of the competitive inhibitor, dicumarol. 6-Mercapto-, 6-thiocyanato-, 6-azido-, and 6-amino-flavins were also used as structural probes. The results indicate that the 6 position is accessible to solvent. Dicumarol binding increases the pK(a) of the enzyme-bound 6-mercapto-flavin from below pH 5.0 to higher than pH 9.0. The results suggest that DT-diaphorase shows the same properties as the C-C transhydrogenases, and the binding of dicumarol elicits a conformational change or an adjustment in the polarity of the FAD pocket. The enzyme reconstituted with oxidized 5-deaza-FAD has significant catalytic activity, confirming that DT-diaphorase is an obligatory 2-electron transfer enzyme and plays a role in the detoxification of quinones and quinoid compounds by reducing them to the relatively stable hydroquinones.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; BECKMAN RES INST CITY HOPE,DIV IMMUNOL,DUARTE,CA 91010	University of Michigan System; University of Michigan; City of Hope; Beckman Research Institute of City of Hope			Tedeschi, Gabriella/I-6247-2017	Tedeschi, Gabriella/0000-0003-2082-6443	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1992, J BIOL CHEM, V267, P3832; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BLANKENHORN G, 1976, EUR J BIOCHEM, V67, P67, DOI 10.1111/j.1432-1033.1976.tb10634.x; CHEN HH, 1992, BIOCHEM J, V284, P855, DOI 10.1042/bj2840855; Clark W.M., 1960, OXIDATION REDUCTION, P184; DEFLORA S, 1985, CANCER RES, V45, P3188; DENG PSK, 1991, BIOCHEMISTRY-US, V30, P6942, DOI 10.1021/bi00242a019; ERNSTER L, 1962, BIOCHIM BIOPHYS ACTA, V58, P171, DOI 10.1016/0006-3002(62)90997-6; FITZPATRICK PF, 1983, J BIOL CHEM, V258, P9700; FORREST GL, 1990, BIOCHEM BIOPH RES CO, V169, P1087, DOI 10.1016/0006-291X(90)92006-L; GHISLA S, 1986, BIOCHEMISTRY-US, V25, P3282, DOI 10.1021/bi00359a030; GHISLA S, 1980, BIOCHEMISTRY-US, V19, P2537, DOI 10.1021/bi00553a001; GHISLA S, 1986, BIOCHEM J, V239, P1; HANIU M, 1988, BIOCHEMISTRY-US, V27, P6877, DOI 10.1021/bi00418a033; HOSODA S, 1974, J BIOL CHEM, V249, P6416; HUANG MT, 1979, J BIOL CHEM, V254, P1223; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; LAURELL C, 1970, TETRAHEDRON LETT, V26, P2235; LIN AJ, 1972, J MED CHEM, V15, P1247, DOI 10.1021/jm00282a011; LIU XF, 1989, MOL PHARMACOL, V35, P818; MA Q, 1992, J BIOL CHEM, V267, P22298; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1985, BIOCHEMISTRY-US, V25, P8103; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MOORE EG, 1979, J BIOL CHEM, V254, P8173; MOORE EG, 1978, J BIOL CHEM, V253, P6413; MYSZKA DG, 1991, J BIOL CHEM, V266, P4789; NAGAO M, 1966, ADV CANCER RES, V23, P131; PROCHASKA HJ, 1991, OXIDATIVE STRESS OXI, P195; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; SHOPFER L, 1990, STUDY ENZYMES, V2, P247; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3594, DOI 10.1021/bi00635a015; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3586, DOI 10.1021/bi00635a014; TEDESCHI G, 1995, J BIOL CHEM, V270, P1198, DOI 10.1074/jbc.270.3.1198; TSUDA H, 1984, CARCINOGENESIS, V5, P331, DOI 10.1093/carcin/5.3.331; WALLIN R, 1978, BIOCHEM J, V169, P95, DOI 10.1042/bj1690095; WALSH C, 1978, BIOCHEMISTRY-US, V17, P1942, DOI 10.1021/bi00603a022; Williams C H Jr, 1979, Methods Enzymol, V62, P185	39	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2512	2516		10.1074/jbc.270.6.2512	http://dx.doi.org/10.1074/jbc.270.6.2512			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531691	hybrid			2022-12-25	WOS:A1995QF53500020
J	MAYER, B; KLATT, P; WERNER, ER; SCHMIDT, K				MAYER, B; KLATT, P; WERNER, ER; SCHMIDT, K			KINETICS AND MECHANISM OF TETRAHYDROBIOPTERIN-INDUCED OXIDATION OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; SYNTHASE; BRAIN; SUPEROXIDE; PEROXYNITRITE; PURIFICATION; INHIBITION; COFACTOR; CELLS; HEMOPROTEIN	A Clark-type nitric oxide-sensitive electrode was used for electrochemical determination of NO oxidation kinetics. Reaction with molecular oxygen followed second-order rate law with respect to NO with an overall rate constant of 9.2 +/- 0.33 x 10(6) M(-2) s(-1). Tetrahydrobiopterin, an essential cofactor of NO syntheses, was found to induce rapid oxidation of NO in a 1:1 stoichiometry. The reaction required the presence of oxygen, was zero order with respect to NO and first order with respect to tetrahydrobiopterin, completely blocked by 5,000 units/ml superoxide dismutase, and mimicked by a superoxide-generating system, Purified brain NO synthase produced no detectable NO unless high amounts of superoxide dismutase were present. NO synthase catalyzed citrulline formation was inhibited by superoxide dismutase (5,000 units/ml) in an oxyhemoglobin-sensitive manner, indicating that NO induces feedback inhibition of NO synthase, NO-stimulated soluble guanylyl cyclase was inhibited by tetrahydrobiopterin at half-maximally active concentrations of 2 mu m. The present data suggest that NO is inactivated to peroxynitrite by superoxide generated in the course of tetrahydrobiopterin autoxidation.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	MAYER, B (corresponding author), KARL FRANZENS UNIV GRAZ, INST PHARMAKOL & TOXIKOL, UNIV PL 2, A-8010 GRAZ, AUSTRIA.		Mayer, Bernd/B-9391-2008	Werner, Ernst R./0000-0003-1948-3391; Mayer, Bernd/0000-0002-2921-3494				ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BLAIR JA, 1974, J CHEM SOC PERK T 2, P80, DOI 10.1039/p29740000080; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; FUKUTO JM, 1993, J MED CHEM, V36, P2666, DOI 10.1021/jm00070a010; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KUKOVETZ WR, 1989, J CARDIOVASC PHARM, V14, pS40, DOI 10.1097/00005344-198914110-00008; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MAYER B, 1992, J CARDIOVASC PHARM, V20, pS54, DOI 10.1097/00005344-199204002-00016; MAYER B, 1994, IN PRESS BIOL NITRIC; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; POU S, 1992, J BIOL CHEM, V267, P24173; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; Schultz G., 1984, METHOD ENZYMAT AN, P379; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016	45	145	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					655	659		10.1074/jbc.270.2.655	http://dx.doi.org/10.1074/jbc.270.2.655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529763	hybrid			2022-12-25	WOS:A1995QB81600025
J	PIRNER, MA; LINCK, RW				PIRNER, MA; LINCK, RW			TEKTINS ARE HETERODIMERIC POLYMERS IN FLAGELLAR MICROTUBULES WITH AXIAL PERIODICITIES MATCHING THE TUBULIN LATTICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEINS; URCHIN SPERM FLAGELLA; DOUBLET MICROTUBULES; CHLAMYDOMONAS FLAGELLA; SURFACE LATTICE; COILED-COIL; COMPONENTS; SUBUNITS; CILIARY; PROTOFILAMENTS	Tektins are proteins that copartition with tubulin in a stable ribbon of three protofilaments from ciliary and flagellar microtubules. After purification, tektins A, B, and C from sea urchin sperm flagellar microtubules appear as extended relatively insoluble filaments, <5 nm in diameter. We used cross-linking reagents to investigate the associations and structural organization of subunits within tektin polymers isolated from stable protofilament ribbons of Strongylocentrotus purpuratus. We show by SDS-polyacrylamide gel electrophoresis, immunoblots, and transmission electron microscopy that tektins are continuous heteropolymers in the stable protofilament ribbons, and thus flagellar microtubules. Our results also provide evidence for the arrangement of different tektin polypeptides within ''core'' filaments containing equimolar tektins A and B, Treatment of these core filaments with bis(sulfosuccinimidyl)suberate and with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide yielded a predominant cross-linked similar to 106-kDa heterodimer of tektins A and B; similar results were obtained by glutaraldehyde cross-linking of tektins solubilized under mild conditions. Finally, cross-linking with 3,3'-dithiobis(sulfosuccinimidylpropionate revealed a 16 nn periodicity in isolated tektin AB filaments that can be related to the 8 nm tubulin dimer lattice and to periodically associated microtubule components.			PIRNER, MA (corresponding author), UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035648] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1974, J CELL SCI, V14, P523; AMOS LA, 1976, CELL MOTILITY, P847; AMOS WB, 1986, J CELL SCI, P55; CHANG XJ, 1987, J CELL BIOL, V104, P1563, DOI 10.1083/jcb.104.6.1563; CHEN R, 1993, J CELL SCI, V106, P909; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; ERICKSON HP, 1974, J CELL BIOL, V60, P153, DOI 10.1083/jcb.60.1.153; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GIBBONS IR, 1972, J CELL BIOL, V54, P365, DOI 10.1083/jcb.54.2.365; GIBBONS IR, 1960, J BIOPHYS BIOCHEM CY, V7, P697, DOI 10.1083/jcb.7.4.697; GOODENOUGH UW, 1985, J CELL BIOL, V100, P2008, DOI 10.1083/jcb.100.6.2008; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; JOHNSON KA, 1994, J CELL SCI, V107, P1551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINCK RW, 1981, J CELL BIOL, V89, P309, DOI 10.1083/jcb.89.2.309; LINCK RW, 1985, J CELL BIOL, V100, P126, DOI 10.1083/jcb.100.1.126; LINCK RW, 1982, J CELL SCI, V58, P1; LINCK RW, 1987, J CELL BIOL, V104, P1069, DOI 10.1083/jcb.104.4.1069; LINCK RW, 1976, J CELL SCI, V20, P405; LINCK RW, 1987, J CELL SCI, V88, P453; LINCK RW, 1990, ADV CELL BIOL, V3, P35; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEZA I, 1972, EXP CELL RES, V74, P535, DOI 10.1016/0014-4827(72)90413-2; MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9; NORRANDER JM, 1992, P NATL ACAD SCI USA, V89, P8567, DOI 10.1073/pnas.89.18.8567; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEFFEN W, 1988, P NATL ACAD SCI USA, V85, P2643, DOI 10.1073/pnas.85.8.2643; STEFFEN W, 1992, J CELL SCI, V101, P809; STEFFEN W, 1989, CELL MOTIL CYTOSKEL, V14, P359, DOI 10.1002/cm.970140306; STEFFEN W, 1994, J CELL SCI, V107, P2095; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEPHENS RE, 1989, J CELL SCI, V92, P391; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAISSTEIDER C, 1987, J MOL BIOL, V197, P205, DOI 10.1016/0022-2836(87)90119-7; WITMAN GB, 1972, J CELL BIOL, V54, P540, DOI 10.1083/jcb.54.3.540; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; [No title captured]; [No title captured]	40	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31800	31806						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527396				2022-12-25	WOS:A1994PX30300073
J	HE, WM; ONEILL, TJ; GUSTAFSON, TA				HE, WM; ONEILL, TJ; GUSTAFSON, TA			DISTINCT MODES OF INTERACTION OF SHC AND INSULIN-RECEPTOR SUBSTRATE-1 WITH THE INSULIN-RECEPTOR NPEY REGION VIA NON-SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; PROTEIN; PHOSPHORYLATION; IRS-1; YEAST; BINDING; KINASE; SITES	Insulin receptor substrate 1 (IRS-1) and src homology and collagen protein (SHC) are signaling proteins which are rapidly phosphorylated on tyrosines after insulin receptor (IR) activation. We have recently shown that both SHC and IRS-1 interact with the tyrosine-phosphorylated NPEY motif of the PR and insulin-like growth factor I receptor via non-SH2 domains (Gustafson, T. A., He, W., Craparo, A., Schaub, C. D., and O'Neill, T. J. (1995) Mel. Cell. Biol. 15, 2500-2508; O'Neill, T. J., Craparo, A., and Gustafson, T. A. (1994) Mel. Cell. Biol. 14, 6433-6442; Craparo, A., O'Neill, T. J., and Gustafson, T. A. (1995) J. Biol. Chem. 270, 15639-15643). In this study we characterize these interactions by examining the effects of 18 amino acid substitutions within and around the IR NPEY motif upon interaction with SHC and IRS 1. We confirm that Tyr-960 within the NPEY motif of the IR is essential for both IRS-1 and SHC interaction and that Asn 957 and Pro-958 are essential for IRS-1 interaction and important but not critical for SHC interaction. Additional mutations surrounding the NPEY motif revealed completely distinct patterns of interaction for SHC and IRS-1. Specifically, mutation of Leu-952 or Tyr-953 (at positions -7 and -8 from Tyr-960) markedly reduced IRS-1 interaction but had no effect upon SHC interaction. Likewise, mutation of Ala-963 (+3) reduced IRS-1 but not SHC interaction. Conversely, substitution of Leu-961 (+1) with either Ala or Arg reduced SHC interaction by 70 and 90%, respectively, yet had no effect upon interaction with IRS-1. Our data show that the sequences within and surrounding the NPEY contribute differentially to either SHC or IRS-1 recognition. Our findings suggest mechanisms by which the differential interaction of known receptors with IRS-1 and SHC may be mediated.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, PROGRAM MOLEC & CELLULAR BIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [DK44093] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Miller J.H., 1972, EXPT MOL GENETICS; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P2262; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	44	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23258	23262		10.1074/jbc.270.40.23258	http://dx.doi.org/10.1074/jbc.270.40.23258			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559478	hybrid			2022-12-25	WOS:A1995RY90900007
J	CLARKE, AS; LOTZ, MM; CHAO, C; MERCURIO, AM				CLARKE, AS; LOTZ, MM; CHAO, C; MERCURIO, AM			ACTIVATION OF THE P21 PATHWAY OF GROWTH ARREST AND APOPTOSIS BY THE BETA(4) INTEGRIN CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARCINOMA-CELLS; ALPHA-6-BETA-4; HEMIDESMOSOMES; SUPPRESSION; EXPRESSION; RECEPTOR; ADHESION; LAMININ	The integrin alpha(6) beta(4), a receptor for members of the laminin family of basement membrane components, contributes to the function of epithelial cells and their oncogenically transformed derivatives, In our efforts to study alpha(6) beta(4)-mediated functions in more detail and to assess the contribution of the beta(4) cytoplasmic domain in such functions, we identified a rectal carcinoma cell line that lacks expression of the beta(4) integrin subunit, This cell line, termed RKO, expresses alpha(6) beta(4), but not alpha(6) beta(4), and it interacts with laminin-1 less avidly than similar cell lines that express alpha(6) beta(4). We expressed a full-length beta(4) cDNA, as well as a mutant cDNA that lacks the beta(4) cytoplasmic domain, in RKO cells and isolated stable subclones of these transfectants. In this study, we report that subclones that expressed the full-length beta(4) cDNA in association with endogenous alpha 6 exhibited partial G(1) arrest and apoptosis, properties that were not evident in RKO cells transfected with either the cytoplasmic domain mutant or the expression vector alone, In an effort to define a mechanism for these observed changes in growth, we observed that expression of the alpha(6) beta(4) integrin induced expression of the p21 (WAF1; CiP1) protein, an inhibitor of cyclin-dependent kinases. These data suggest that the beta(4) integrin cytoplasmic domain is linked to a signaling pathway involved in cell cycle regulation in the beta(4) transfected RKO cells.	HARVARD UNIV,DEACONESS HOSP,SCH MED,CANC BIOL LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOYD D, 1988, CANCER RES, V48, P3112; BREEN E, 1995, IN PRESS ANN SURG ON; CLARKE AS, 1994, CELL ADHES COMMUN, V2, P1, DOI 10.3109/15419069409014197; CLARKE AS, 1994, MOL BIOL CELL, V5, pA424; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HALL PA, 1994, J CELL SCI, V107, P3569; HARPER JW, 1993, CELL, V75, P805; KIMMEL KA, 1986, CANCER RES, V46, P3614; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MARX J, 1995, SCIENCE, V267, P963, DOI 10.1126/science.7863339; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NIESSEN CM, 1994, EXP CELL RES, V2111, P360; Quaranta V, 1991, Trends Cell Biol, V1, P2, DOI 10.1016/0962-8924(91)90046-C; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; TOZEREN A, 1994, J CELL SCI, V107, P3153	30	112	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22673	22676		10.1074/jbc.270.39.22673	http://dx.doi.org/10.1074/jbc.270.39.22673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559386	hybrid			2022-12-25	WOS:A1995RY05400006
J	HAUDENSCHILD, DR; TONDRAVI, MM; HOFER, U; CHEN, Q; GOETINCK, PF				HAUDENSCHILD, DR; TONDRAVI, MM; HOFER, U; CHEN, Q; GOETINCK, PF			THE ROLE OF COILED-COIL ALPHA-HELICES AND DISULFIDE BONDS IN THE ASSEMBLY AND STABILIZATION OF CARTILAGE MATRIX PROTEIN SUBUNITS - A MUTATIONAL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; COLLAGEN; SITES; ORGANIZATION; DOMAINS; BINDING; HEPARIN; CHAIN	Cartilage matrix protein (CMP) exists as a disulfide-bonded homotrimer in the matrix of cartilage, Each monomer consists of two CMP-A domains that are separated by an epidermal growth factor-like domain. A heptad repeat-containing tail makes up the carboxyl-terminal domain of the protein. The secreted form of CMP contains 12 cysteine residues numbered C1 through C12. Two of these are in each of the CMP-A domains, six are in the epidermal growth factor-like domain, and two are in the heptad repeat-containing tail. Two major categories of mutant CMPs were generated to analyze the oligomerization process of CMP: a mini-CMP and a heptad-less full-length CMP. The mini CMP consists of the CMP-A2 domain and the heptad repeat-containing tail. In addition, a number of mutations affecting C9 through C12 were generated within the full-length, the mini-, and the heptad-less CMPs, The mutational analysis indicates that the heptad repeats are necessary for the initiation of CMP trimerization and that the two cysteines in the heptad repeat-containing tail are both necessary and sufficient to form intermolecular disulfide bonds in either full-length or mini-CMP. The two cysteines within a CMP-A domain form an intradomain disulfide bond.	MASSACHUSETTS GEN HOSP, CUTANEOUS BIOL RES CTR, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Chen, Qian/C-4354-2011; Haudenschild, Dominik/B-2381-2008	Chen, Qian/0000-0003-4406-5618; Haudenschild, Dominik/0000-0001-9947-9864	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-22016] Funding Source: Medline; NIGMS NIH HHS [P20 GM104937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; Engel J, 1991, CURR OPIN CELL BIOL, V3, P779, DOI 10.1016/0955-0674(91)90050-9; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOETINCK PF, 1990, ANN NY ACAD SCI, V599, P29, DOI 10.1111/j.1749-6632.1990.tb42361.x; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KISS I, 1989, J BIOL CHEM, V264, P8126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MOHRI H, 1989, J BIOL CHEM, V264, P17361; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TONDRAVI MM, 1993, PROG CLIN BIOL RES, V383, P515; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307	26	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23150	23154		10.1074/jbc.270.39.23150	http://dx.doi.org/10.1074/jbc.270.39.23150			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559460	hybrid			2022-12-25	WOS:A1995RY05400080
J	WILKINS, PP; MOORE, KL; MCEVER, RP; CUMMINGS, RD				WILKINS, PP; MOORE, KL; MCEVER, RP; CUMMINGS, RD			TYROSINE SULFATION OF P-SELECTIN GLYCOPROTEIN LIGAND-1 IS REQUIRED FOR HIGH-AFFINITY BINDING TO P-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							O-LINKED OLIGOSACCHARIDES; ENDOTHELIAL LIGAND; MYELOID CELLS; IDENTIFICATION; GMP-140; RECOGNIZE; RECEPTOR; PROTEINS; CD62	P-selectin glycoprotein ligand-1 (PSGL-1) is a mucin-like glycoprotein on leukocytes that is a high affinity ligand for P-selectin. Previous studies have shown that sialylation and fucosylation of PSGL-1 are required for its binding to P-selectin, but other post-translational modifications of PSGL-1 may also be important. We demonstrate that PSGL-1 synthesized in human HL-60 cells can be metabolically labeled with [S-35]sulfate that is incorporated primarily into tyrosine sulfate. Treatment of PSGL-1 with a bacterial arylsulfatase releases sulfate from tyrosine, resulting in a concordant decrease in binding to P-selectin. These studies demonstrate that tyrosine sulfate on PSGL-1 functions in conjunction with sialylated and fucosylated glycans to mediate high affinity binding to P-selectin.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NCI NIH HHS [CA37626] Funding Source: Medline; NHLBI NIH HHS [HL45510] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045510] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; CECCONI O, 1994, J BIOL CHEM, V269, P15060; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DODGSON KS, 1959, BIOCHEM J, V71, P10, DOI 10.1042/bj0710010; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; FIETE D, 1991, CELL, V65, P1103; FOWLER LR, 1964, BIOCHEMISTRY-US, V3, P230, DOI 10.1021/bi00890a015; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HORTIN G, 1986, J BIOL CHEM, V261, P5827; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; IMAI Y, 1993, NATURE, V361, P555; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P852; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NELSON RM, 1993, BLOOD, V82, P3253; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SHILATIFARD A, 1993, J VIROL, V67, P943, DOI 10.1128/JVI.67.2.943-952.1993; SHILATIFARD A, 1995, GLYCOBIOLOGY, V5, P291, DOI 10.1093/glycob/5.3.291; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	36	258	273	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22677	22680		10.1074/jbc.270.39.22677	http://dx.doi.org/10.1074/jbc.270.39.22677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559387	hybrid			2022-12-25	WOS:A1995RY05400007
J	LARSON, RC; OSADA, H; LARSON, TA; LAVENIR, I; RABBITTS, TH				LARSON, RC; OSADA, H; LARSON, TA; LAVENIR, I; RABBITTS, TH			THE ONCOGENIC LIM-PROTEIN RBTN2 CAUSES THYMIC DEVELOPMENTAL ABERRATIONS THAT PRECEDE MALIGNANCY IN TRANSGENIC MICE	ONCOGENE			English	Article						RBTN2; LEUKEMIA; THYMUS; HEMATOPOIESIS; TRANSLOCATION	T-CELL ONCOGENE; HUMAN CD2 GENE; THY-1 GENE; BURKITT-LYMPHOMA; EXPRESSION; TRANSLOCATION; LEUKEMIA; TTG-1; RECEPTOR; ANTIGEN	RBTN2 is activated by the chromosomal translocation t(11;14) (P13;p11) in some T cell leukaemias. Histologically similar T cell. tumours develop with long latency in transgenic mice when either CD2 or thy1.1 promoters control rbtn2 expression, During the asymptomatic period, perturbation of T cell differentiation occurs in the thymus. The major anomalies present during this phase are an increase in the percentage of large thymocytes lacking CD4 and CD8 markers and also of small thymocytes express both the T cell marker CD3 and the B cell-specific form of CD45. These abnormal T cell populations can be clonal and thus a primary result of aberrant expression of the LIM-protein Rbtn2 is alteration of T cell differentiation preceding overt malignancy, These data provide a biological explanation for the role of Rbtn2 in tumorigenesis and presumably RBTN2 expression in T cells after the translocation t(11;14) in children has the same effect.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	MRC Laboratory Molecular Biology; Aichi Cancer Center			Osada, Hiroyuki/AAY-6254-2020; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN SH, 1987, CELL, V51, P7, DOI 10.1016/0092-8674(87)90005-5; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; Coffman R L, 1982, Immunol Rev, V69, P5; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; FEINBERG AP, 1993, ANAL BIOCHEM, V132, P6; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GORDON JW, 1987, CELL, V50, P445, DOI 10.1016/0092-8674(87)90498-3; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; KAMOUN M, 1991, J EXP MED, V1553, P207; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOLLIAS G, 1987, P NATL ACAD SCI USA, V84, P1492, DOI 10.1073/pnas.84.6.1492; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LARSON RC, 1994, ONCOGENE, V9, P3675; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; NISHIMURA H, 1992, CELL IMMUNOL, V140, P423; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Sperling A I, 1989, Int Immunol, V1, P434, DOI 10.1093/intimm/1.4.434; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yagita H, 1989, INT IMMUNOL, V1, P94, DOI 10.1093/intimm/1.1.94	39	80	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					853	862						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545805				2022-12-25	WOS:A1995RU79800005
J	YONE, K; BAJARD, S; TSUNEKAWA, N; SUZUKI, J				YONE, K; BAJARD, S; TSUNEKAWA, N; SUZUKI, J			EPITOPIC REGIONS FOR ANTIBODIES AGAINST TUMOR-NECROSIS-FACTOR-ALPHA - ANALYSIS BY SYNTHETIC PEPTIDE-MAPPING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; RECEPTOR-BINDING; HUMAN INTERFERON; FACTOR-BETA; EXPRESSION; RESOLUTION; CLONING; PURIFICATION	The location of biologically relevant epitopes on hu man tumor necrosis factor alpha (hTNF-alpha) was evaluated by testing the immunoreactivity of anti-TNF-alpha antibodies against 149 sequential, overlapping octamer peptides. A goat polyclonal antibody raised against recombinant hTNF-alpha, which neutralizes hTNF-alpha biological activities, reacted with oligopeptides corresponding to hTNF-alpha residues 7-11, 17-23, 30-39, 42-49, 106-112, and 135-142. A possible assembled epitopic region (residues 25, 27, and 144) for neutralizing murine monoclonal antibodies designated 11D7G4 and 9C4G5 was deduced from the fact that they bound to tripeptides, mimicking a discontinuous epitope. These antigenic regions were found to include or adjoin poorly conserved amino acids and they were located in the turns between beta-sheets on the surface of the molecule. Three of the sequential epitopic regions and an assembled region were closely related to the receptor binding sites proposed in several other studies. These antibodies appear to neutralize TNF-alpha activities by directly masking receptor binding sites.			YONE, K (corresponding author), TEIJIN LTD,BIOTECHNOL RES LABS,4-3-2 ASAHIGAOKA,HINO,TOKYO 191,JAPAN.		CHARLES, Sandrine/B-3907-2016	CHARLES, Sandrine/0000-0003-4604-0166				AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P1; BRINGMAN TS, 1987, HYBRIDOMA, V6, P489, DOI 10.1089/hyb.1987.6.489; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FENDLY BM, 1987, HYBRIDOMA, V6, P359, DOI 10.1089/hyb.1987.6.359; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GREEN S, 1977, J NATL CANCER I, V59, P1519, DOI 10.1093/jnci/59.5.1519; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES EY, 1992, TUMOR NECROSIS FACTO, P93; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Moller A, 1990, Cytokine, V2, P162, DOI 10.1016/1043-4666(90)90011-H; NAKAMURA S, 1990, AGR BIOL CHEM TOKYO, V54, P3241, DOI 10.1080/00021369.1990.10870471; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; RATHJEN DA, 1991, MOL IMMUNOL, V28, P79, DOI 10.1016/0161-5890(91)90089-3; REDLICH PN, 1991, P NATL ACAD SCI USA, V88, P4040, DOI 10.1073/pnas.88.9.4040; RUFF MR, 1980, J IMMUNOL, V125, P1671; SHIRAI T, 1985, NATURE, V313, P803, DOI 10.1038/313803a0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRANG SR, 1992, TUMOR NECROSIS FACTO, P11; TWOBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; VANOSTADE X, 1993, NATURE, V361, P266; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	34	8	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19509	19515		10.1074/jbc.270.33.19509	http://dx.doi.org/10.1074/jbc.270.33.19509			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7543899				2022-12-25	WOS:A1995RP70300050
J	BHATTACHARYA, S; FU, CZ; BHATTACHARYA, J; GREENBERG, S				BHATTACHARYA, S; FU, CZ; BHATTACHARYA, J; GREENBERG, S			SOLUBLE LIGANDS OF THE ALPHA(V)BETA(3) INTEGRIN MEDIATE ENHANCED TYROSINE PHOSPHORYLATION OF MULTIPLE PROTEINS IN ADHERENT BOVINE PULMONARY-ARTERY ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL COMPLEMENT COMPLEX; SIGNAL TRANSDUCTION; EXTRACELLULAR-MATRIX; VITRONECTIN RECEPTOR; MULTIMERIC VITRONECTIN; ADHESION; BINDING; PAXILLIN; MEMBRANE; IDENTIFICATION	Binding of substrate-bound extracellular matrix proteins to cell surface integrins results in a variety of cellular responses including adhesion, cytoskeletal reorganization, and gene expression. We have previously shown that addition of soluble SC5b-9, the complement-vitronectin complex, resulted in an RGD-dependent increase in lung venular hydraulic conductivity (Ishikawa, S., Tsukada, H., and Bhattacharya, J. (1993) J. Clin. Invest. 91, 103-109). To identify specific integrin(s) and signal transduction pathways that are responsive to soluble vitronectin-containing ligands, we exposed confluent bovine pulmonary artery cells to purified soluble human mono- or multimeric vitronectin, or SC5b-9, and determined the extent of endothelial cell protein tyrosine phosphorylation. Monomeric vitronectin (Vn) did not induce enhanced protein tyrosine phosphorylation. However, multimeric Vn and SC5b-9 elicited time and concentration-dependent increases in tyrosine phosphorylation of numerous proteins. Antiserum against vitronectin, RGD peptides, and monoclonal and polyclonal antibodies against the alpha(v) beta(3) integrin blocked the vitronectin- or SC5b-9-induced enhanced accumulation of tyrosine phosphoproteins, while antibodies against beta(1) integrins and the alpha(v) beta(5) integrin did not. Clustering of the alpha(v) beta(3) integrin using monoclonal antibody LM609 caused a pattern of enhanced tyrosine phosphorylation similar to that caused by multimeric Vn and SC5b-9, suggesting that aggregation of alpha(v) beta(3), was critical for signaling. Among the proteins that underwent enhanced tyrosine phosphorylation in response to vitronectin were the cytoskeletal proteins paxillin, cortactin, and ezrin, as well as the SH2 domain containing protein She, and p125(FAK). We conclude that ligation of the alpha(v) beta(3) integrin by soluble ligands promotes enhanced phosphorylation of several proteins implicated in tyrosine kinase signaling and suggest that this pathway may be important in inflammatory states which are accompanied by accumulation of SC5b-9.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University	BHATTACHARYA, S (corresponding author), ST LUKES ROOSEVELT HOSP,428 W 59TH ST,NEW YORK,NY 10019, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002483, R37HL036024, R01HL036024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36024, HL 02641, HL02483] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BHAKDI S, 1990, BLUT, V60, P309, DOI 10.1007/BF01737843; BIESECKER G, 1990, J IMMUNOL, V145, P209; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHHATWAL GS, 1987, INFECT IMMUN, V55, P1878, DOI 10.1128/IAI.55.8.1878-1883.1987; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CONFORTI G, 1992, BLOOD, V80, P437; CUAN JL, 1992, NATURE, V358, P690; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GAWRYL MS, 1986, J IMMUNOL METHODS, V95, P217, DOI 10.1016/0022-1759(86)90409-6; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Greenberg Steven, 1993, P941; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIKAWA S, 1993, J CLIN INVEST, V91, P103, DOI 10.1172/JCI116157; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIM JP, 1994, J BIOL CHEM, V269, P26926; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KOLB WP, 1975, J EXP MED, V141, P724; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LANGLOIS PF, 1988, AM REV RESPIR DIS, V138, P368, DOI 10.1164/ajrccm/138.2.368; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PREISSNER KP, 1989, EUR J IMMUNOL, V19, P69, DOI 10.1002/eji.1830190112; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARTZ MA, 1994, J BIOL CHEM, V269, P11133; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SIFLINGERBIRNBO.A, 1987, J CELL PHYSL, V32, P111; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMYTH SS, 1993, BLOOD, V81, P2827; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Taylor AE, 1984, HDB PHYSL 2, V4, P467; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VOLKER W, 1993, J HISTOCHEM CYTOCHEM, V41, P1823, DOI 10.1177/41.12.7504009; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; VUORI K, 1993, J BIOL CHEM, V28, P21459; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116; ZIMOLO Z, 1994, AM J PHYSIOL, V266, pC376, DOI 10.1152/ajpcell.1994.266.2.C376	67	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16781	16787		10.1074/jbc.270.28.16781	http://dx.doi.org/10.1074/jbc.270.28.16781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542653	hybrid			2022-12-25	WOS:A1995RJ34700051
J	NOJIMA, Y; MORINO, N; MIMURA, T; HAMASAKI, K; FURUYA, H; SAKAI, R; SATO, T; TACHIBANA, K; MORIMOTO, C; YAZAKI, Y; HIRAI, H				NOJIMA, Y; MORINO, N; MIMURA, T; HAMASAKI, K; FURUYA, H; SAKAI, R; SATO, T; TACHIBANA, K; MORIMOTO, C; YAZAKI, Y; HIRAI, H			INTEGRIN-MEDIATED CELL-ADHESION PROMOTES TYROSINE PHOSPHORYLATION OF P130(CAS), A SRC HOMOLOGY 3-CONTAINING MOLECULE HAVING MULTIPLE SRC HOMOLOGY 2-BINDING MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; PROTEIN; KINASE; FIBRONECTIN	p130(Cas) (Cas) has been recently identified as a 130-kDa protein that is highly phosphorylated on tyrosine residues and is stably associated with p47(v-crk) (v-Crk) and p60(v-src) (v-Src) oncogene products in cells transformed by the respective genes. Cas is a novel signaling molecule having a single Src homology (SH) 3 domain and a cluster of multiple SH2-binding motifs. While the tight association of Cas with v-Crk and v-Src is strongly suggestive of a significant role in regulating cellular transformation, the function of Cas in normal untransformed cells is totally unknown. We report here that cell adhesion to fibronectin rapidly promotes tyrosine phosphorylation of Cas in human and rat fibroblast cell lines. The response was equally induced by cell adhesion to plates coated with vitronectin, laminin, and collagen but not by cell attachment to nonspecific substrate poly-L-lysine. The kinetic profile of Cas phosphorylation was almost identical with that of tyrosine phosphorylation of focal adhesion kinase pp125(FAK) (Fak), which is well known to be activated subsequent to integrin-mediated cell adhesion. Adhesion-dependent Cas phosphorylation was completely inhibited by treating cells with cytochalasin D, an agent that disrupts polymerization of actin stress fibers. These results suggest that tyrosine phosphorylation of Cas is stimulated by normal cell adhesion in close association with Fak phosphorylation and the formation of actin stress fibers. In v-Src- or v-Crk-transformed cells, however, the tyrosine phosphorylation of Cas is markedly increased in an adhesion-independent manner that is insensitive to treatment with cytochalasin D. Thus, Cas plays a role in signaling pathways mediated by cell adhesion as well as by transformation. We propose that Cas may amplify and propagate integrin-mediated signals by interacting with SH2-containing molecule(s).	JICHI MED SCH,DIV MOLEC BIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115	Jichi Medical University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	NOJIMA, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.			Sakai, Ryuichi/0000-0001-6833-1103				BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1987, ANN REV CELL BIOL, V4, P487; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DOBB BS, 1994, MOL CELL BIOL, V14, P147; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325	26	293	295	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15398	15402		10.1074/jbc.270.25.15398	http://dx.doi.org/10.1074/jbc.270.25.15398			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541040	hybrid			2022-12-25	WOS:A1995RE66600082
J	OZAKI, Y; SATOH, K; KURODA, K; QI, RM; YATOMI, Y; YANAGI, S; SADA, K; YAMAMURA, H; YANABU, M; NOMURA, S; KUME, S				OZAKI, Y; SATOH, K; KURODA, K; QI, RM; YATOMI, Y; YANAGI, S; SADA, K; YAMAMURA, H; YANABU, M; NOMURA, S; KUME, S			ANTI-CD9 MONOCLONAL-ANTIBODY ACTIVATES P72(SYK) IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; THROMBIN-STIMULATED PLATELETS; CELL-ANTIGEN RECEPTOR; CD9 ANTIGEN; MEMBRANE GLYCOPROTEIN; PHOSPHORYLATION; ASSOCIATION; KINASE-P72(SYK); MOBILIZATION; PP60C-SRC	NNKY 1-19, anti-CD9 monoclonal antibody (MoAb), induced protein tyrosine phosphorylation of 125-, 97-, 75-, 64-, and 40-kDa proteins in human platelets, whereas F(ab')(2) fragments of NNKY 1-19 did not, suggesting that the stimulation of Fc gamma II receptors is required for the induction of protein tyrosine phosphorylation. Tyrosine-phosphorylated proteins of 97 and 125 kDa were associated with aggregation, while NNKY 1-19-induced protein tyrosine phosphorylation was completely inhibited by prostaglandin I-2 (PGI(2)). The activity of p72(syk) was assessed in immunoprecipitation kinase assays to determine at which step the signal transduction pathway leading to protein tyrosine phosphorylation was suspended. NNKY 1-19 induced a rapid and transient increase in the p72(syk)-associated tyrosine kinase activity that peaked at 10 s and subsided to the original level a min after stimulation. Coinciding with this time course, p60(c-src) transiently associated with p72(syk). In platelets preexposed to GRGDS peptides or PGI(2), NNKY 1-19 also increased the p72(syk)-associated tyrosine kinase activity and led to the association of p60(c-src) with p72(syk), However, in contrast to the control without any inhibitor, the elevated tyrosine kinase activity and the associated state of the two tyrosine kinases persisted as long as 5 min after stimulation, F(ab')(2) fragments of NNKY 1-19 induced changes similar to those observed with the effects of GRGDS peptides or PGI(2) treatment on intact IgG NNKY 1-19 stimulation. F(ab')(2) fragments of another CD9 MoAb, PMA2, had effects on p72(syk) essentially similar to those of NNKY 1-19. These findings suggest that the binding of anti-CDS MoAb to CD9 on the platelet membrane per se induces an increase in the p72(syk)-associated tyrosine kinase activity but that Fc gamma II receptor-mediated signal(s) is required for the full activation of platelets and the appearance of tyrosine-phosphorylated proteins. The elevated intracellular cAMP level induced by PGI(2) acts at a step distal to the activation of p72(syk) and inhibited the signal transduction pathway leading to protein tyrosine phosphorylation and aggregation. p72(syk) activation occurs in the absence of aggregation, but aggregation appears to reduce the elevated p72(syk) activity induced by anti-CDS MoAb.	KANSAI MED UNIV,DEPT INTERNAL MED 1,MORIGUCHI,OSAKA 570,JAPAN; FUKUI MED SCH,DEPT BIOCHEM 2,YOSHIDA,FUKUI,JAPAN	Kansai Medical University; University of Fukui	OZAKI, Y (corresponding author), YAMANASHI MED COLL,DEPT CLIN LAB & MED,SHIMOKATO 1110,TAMAHO,YAMANASHI 40938,JAPAN.		Sada, Kiyonao/H-7373-2015; qi, rui/HGU-2541-2022; Qi, Ruomei/AAA-2835-2021	Sada, Kiyonao/0000-0001-6124-3100; Yatomi, Yutaka/0000-0003-1719-4297				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSON GP, 1990, BLOOD, V76, P1165; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CARROLL RC, 1990, BIOCHEM J, V266, P527, DOI 10.1042/bj2660527; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GRIFFITH L, 1991, BLOOD, V178, P1753; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATAKEYAMA M, 1991, SCIENCE, V241, P42; HATO T, 1990, BLOOD, V75, P1087; HENSON PM, 1973, J CLIN INVEST, V52, P1282, DOI 10.1172/JCI107296; HIGASHIHARA M, 1985, BLOOD, V65, P382; HORSEWOOD P, 1991, BLOOD, V78, P1019; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KANG JH, 1993, BLOOD, V81, P1505; LAMOYI E, 1983, J IMMUNOL METHODS, V56, P235, DOI 10.1016/0022-1759(83)90415-5; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAEDA H, 1993, BIOCHEM BIOPH RES CO, V197, P62, DOI 10.1006/bbrc.1993.2441; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; NAGATA H, 1990, ACTA HAEMATOL JAPON, V53, P1156; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; OZAKI Y, 1991, EUR J BIOCHEM, V199, P347, DOI 10.1111/j.1432-1033.1991.tb16130.x; POWLING MJ, 1989, LEUCOCYTE TYPING, V4, P1012; PUMIGLIA KM, 1990, BIOCHEM BIOPH RES CO, V171, P738, DOI 10.1016/0006-291X(90)91208-A; RENDU F, 1987, BIOCHEM BIOPH RES CO, V146, P1397, DOI 10.1016/0006-291X(87)90805-9; RENDU F, 1989, BLOOD, V73, P1545; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHUIE L, 1995, MOL CELL BIOL, V15, P272; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; WONG S, 1992, ONCOGENE, V7, P2407; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YATOMI Y, 1993, FEBS LETT, V322, P285, DOI 10.1016/0014-5793(93)81587-P	43	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15119	15124		10.1074/jbc.270.25.15119	http://dx.doi.org/10.1074/jbc.270.25.15119			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541034	hybrid			2022-12-25	WOS:A1995RE66600042
J	CHOW, YH; PUMIGLIA, K; JUN, TH; DENT, P; STURGILL, TW; JOVE, R				CHOW, YH; PUMIGLIA, K; JUN, TH; DENT, P; STURGILL, TW; JOVE, R			FUNCTIONAL MAPPING OF THE N-TERMINAL REGULATORY DOMAIN IN THE HUMAN RAF-1 PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE CODING SEQUENCE; PHORBOL ESTER BINDING; SIGNAL-TRANSDUCTION; MAP KINASE; TRANSFORMING ACTIVITY; RAS; PHOSPHORYLATION; IDENTIFICATION; ONCOGENE; ACTIVATION	Raf-1 is a serine/threonine kinase poised at a key relay point in mitogenic signal transduction pathways hom the cell surface to the nucleus. Activation of the transforming potential of Raf-1 has been associated with N-terminal truncation and/or fusion to other proteins, suggesting that the Raf-1 N-terminal half harbors a negative regulatory domain, Seven internal deletion mutants that together scan the entire N-terminal half of human Raf-1 protein were generated to map functional regions in this regulatory domain. Effects of the deletion mutations on kinase activity of Raf-1 were evaluated using a baculovirus/insect cell overexpression system and an in vitro kinase assay with the known physiological substrate of Raf-1, mitogen-activated protein kinase kinase. Deletion of amino acids 276-323 in the unique sequence between conserved regions 2 and 3 leads to modest elevation of Raf-1 basal kinase activity, whereas deletion of amino acids 133-180 in conserved region 1 results in diminished kinase activity. Surprisingly, none of the Raf-1 N-terminal deletion mutants, including a truncated version that is transforming in rodent fibroblasts, exhibits greatly increased levels of basal kinase activity. In addition, while activation of Raf-1 kinase by Ras requires sequences in conserved region 1, only the C-terminal half containing the kinase domain of Raf-1 is required for activation by Src, These findings demonstrate that N-terminal deletions in Raf-1 do not necessarily result in constitutively elevated basal kinase activity and that the N-terminal regulatory domain is completely dispensable for Raf-1 activation by Src.	UNIV MICHIGAN, SCH MED, DEPT IMMUNOL & MICROBIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, CTR COMPREHENS CANC, ANN ARBOR, MI 48109 USA; UNIV VIRGINIA, HLTH SCI CTR, HOWARD HUGHES MED INST, CHARLOTTESVILLE, VA 22908 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Virginia				Pumiglia, Kevin/0000-0003-4655-0334	NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ISHIKAWA F, 1988, ONCOGENE, V3, P653; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARK S, 1992, J BIOL CHEM, V267, P11612; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; STORM SM, 1990, ONCOGENE, V5, P345; STROKOE D, 1994, SCIENCE, V264, P1463; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	52	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14100	14106		10.1074/jbc.270.23.14100	http://dx.doi.org/10.1074/jbc.270.23.14100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539798	hybrid			2022-12-25	WOS:A1995RC44800075
J	GETTINS, PGW; HAHN, KH; CREW, BC				GETTINS, PGW; HAHN, KH; CREW, BC			ALPHA(2)-MACROGLOBULIN BAIT REGION VARIANTS - A ROLE FOR THE BAIT REGION IN TETRAMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; PREGNANCY ZONE PROTEIN; HUMAN ALPHA-2-MACROGLOBULIN; THIOL-ESTER; BOVINE ALPHA-2-MACROGLOBULIN; NUCLEOPHILIC MODIFICATION; ALPHA-MACROGLOBULIN; HALF-MOLECULES; CROSS-LINKING; CLEAVAGE	To test the hypothesis that a large portion of the bait region of human alpha(2)-macroglobulin (alpha(2)M) can be removed without adversely affecting the protein's structural and functional properties, we expressed two human alpha(2)M variants with truncated bait regions and examined whether these variants folded normally and functioned as proteinase inhibitors, Each variant contains sites that are normal bait region cleavage sites in wild-type alpha(2)M, including the primary trypsin cleavage site, The truncated bait regions are shorter by 23 and 27 residues, respectively, and lack the C-terminal portion as well as different parts of the N-terminal section of the bait region, We found that such bait region truncation permitted normal folding of the monomers as well as formation of the thiol ester and dimerization by disulfide cross-linking, although the resulting species bound 6-(p-toluidino)-2-naphthalenesulfonic acid in a manner more like thiol ester-cleaved alpha(2)M than native alpha(2)M. The variants' thiol esters reacted with nucleophiles at rates identical to wild-type alpha(2)M. Surprisingly, however, the truncations prevented the noncovalent association of the covalent 360-kDa dimers that normally gives tetrameric alpha(2)M, decoupled bait region cleavage from thiol ester activation, and resulted in the inability of the two variants to ''trap'' proteinase, This was despite apparent cleavage of the bait region by proteinase, albeit at very much reduced rates relative to wild-type tetrameric alpha(2)M. The kinetics of thiol ester cleavage-dependent protein conformational changes also changed from sigmoidal to exponential, These findings indicate that residues in the bait region appear to be necessary for noncovalent association of 360-kDa disulfide-linked dimers to give tetrameric alpha(2)M and suggest a role for the bait region in normal alpha(2)M in coupling bait region cleavage to the sequence of conformational changes that result in thiol ester activation and ultimately proteinase trapping.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University	GETTINS, PGW (corresponding author), UNIV ILLINOIS,DEPT BIOCHEM,1819-1853 W POLK ST,CHICAGO,IL 60612, USA.				NICHD NIH HHS [HD28187] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028187] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARAKAWA H, 1986, BIOCHEMISTRY-US, V25, P6785, DOI 10.1021/bi00370a009; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1984, BIOCHEM J, V217, P303; BJORK I, 1985, BIOCHEMISTRY-US, V24, P2653; BOEL E, 1990, BIOCHEMISTRY-US, V29, P4081, DOI 10.1021/bi00469a009; BOISSET N, 1994, ANN NY ACAD SCI, V737, P229, DOI 10.1111/j.1749-6632.1994.tb44315.x; BOISSET N, 1992, J STRUCT BIOL, V108, P221, DOI 10.1016/1047-8477(92)90022-3; DANGOTT LJ, 1982, BIOCHEM BIOPH RES CO, V107, P1243, DOI 10.1016/S0006-291X(82)80131-9; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P1232; GETTINS P, 1986, BIOCHEMISTRY-US, V25, P5011, DOI 10.1021/bi00366a007; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GETTINS P, 1990, BIOCHEMISTRY-US, V29, P7747, DOI 10.1021/bi00485a025; GETTINS PGW, 1994, FEBS LETT, V339, P276, DOI 10.1016/0014-5793(94)80430-3; GETTINS PGW, 1993, FEBS LETT, V332, P211, DOI 10.1016/0014-5793(93)80633-6; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HARPEL PC, 1979, J BIOL CHEM, V254, P8669; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4459; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; JENSEN PEH, 1992, EUR J BIOCHEM, V210, P1071, DOI 10.1111/j.1432-1033.1992.tb17513.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LJ, 1984, BIOCHEMISTRY-US, V23, P2802, DOI 10.1021/bi00307a041; LARSSON LJ, 1988, BIOCHEMISTRY-US, V27, P983, DOI 10.1021/bi00403a022; MARYNEN P, 1990, FEBS LETT, V262, P349, DOI 10.1016/0014-5793(90)80226-9; MOOS M, 1988, J BIOL CHEM, V263, P6005; PANGBURN MK, 1992, J BIOL CHEM, V267, P8584; POCHON F, 1987, BIOCHEM BIOPH RES CO, V149, P488, DOI 10.1016/0006-291X(87)90394-9; POCHON F, 1989, BIOCHIM BIOPHYS ACTA, V996, P132, DOI 10.1016/0167-4838(89)90105-2; ROCHE PA, 1989, BIOCHEMISTRY-US, V28, P7629, DOI 10.1021/bi00445a019; ROCHE PA, 1988, BIOCHEMISTRY-US, V27, P759, DOI 10.1021/bi00402a040; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; STOOPS JK, 1994, ANN NY ACAD SCI, V737, P212, DOI 10.1111/j.1749-6632.1994.tb44314.x; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P6679, DOI 10.1021/bi00321a061; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P3115, DOI 10.1021/bi00309a002; STRICKLAND DK, 1991, BIOCHEMISTRY-US, V30, P2797, DOI 10.1021/bi00225a009; THOMSEN NK, 1992, EUR J BIOCHEM, V209, P409, DOI 10.1111/j.1432-1033.1992.tb17303.x; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9023; ZHAO BL, 1988, BIOCHEMISTRY-US, V27, P5304, DOI 10.1021/bi00414a053	42	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14160	14167		10.1074/jbc.270.23.14160	http://dx.doi.org/10.1074/jbc.270.23.14160			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539801	hybrid			2022-12-25	WOS:A1995RC44800083
J	HONDA, S; TOMIYAMA, Y; PELLETIER, AJ; ANNIS, D; HONDA, Y; ORCHEKOWSKI, R; RUGGERI, Z; KUNICKI, TJ				HONDA, S; TOMIYAMA, Y; PELLETIER, AJ; ANNIS, D; HONDA, Y; ORCHEKOWSKI, R; RUGGERI, Z; KUNICKI, TJ			TOPOGRAPHY OF LIGAND-INDUCED BINDING-SITES, INCLUDING A NOVEL CATION SENSITIVE EPITOPE (AP5) AT THE AMINO-TERMINUS, OF THE HUMAN INTEGRIN BETA(3) SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; VON-WILLEBRAND FACTOR; MONOCLONAL-ANTIBODY; FIBRINOGEN BINDING; PLATELET-AGGREGATION; RECOGNITION SITE; GPIIB-IIIA; RECEPTOR; MEMBRANE; ADHESION	Changes in ligand binding ability of the integrin alpha(IIb)beta(3) can be monitored by the concomitant expression of ligand-inducible binding sites (LIES). A new LIES, the hexapeptide sequence GPNICT (residues 1-6) at the amino terminus of beta(3) recognized by the murine monoclonal antibody (mAb) AP5, is sensitive both to the binding of ligand and to micromolar differences in divalent cation levels. Calcium or magnesium can completely inhibit the binding of AP5 to alpha(IIb)beta(3), on platelets, with ID50 values of 80 and 1500 mu M, respectively. The inhibitory effect of calcium plus magnesium is cumulative. In the presence of 1 mM calcium plus 1 mat magnesium, the peptide RGDW overcomes this inhibition and induces maximal binding of AP5. Maximal AP5 binding is also induced by a molar excess of EDTA. The unique location of the AP5 LIES was determined by comparing the binding of LIBS specific mAb to recombinant human Xenopus beta(3) chimeras produced in a baculovirus expression system. AP5 defines one region at the amino terminus beta(3)1-6. A second region, defined by mAb D3GP3, is probably located within beta(3)422-490, confirming the finding of Kouns ct al. (Kouns, W. C., Newman, P. J., Puckett, H. J., Miller, A. A., Wall, C, D., Fox, C. F., Seyer, J. M., and Jennings, L. K. (1991) Blood 78, 3215-3223). The third region, encompassing at most residues 490-690, and perhaps more precisely located within 602-690 (Du X., Gu, M., Weise, J. W., Nagaswami, C., Bennett, J. S., Bowditch, R., and Ginsberg, M. H. (1993) J. Biol. Chem. 268, 23087-23092), is recognized by the four mAb, anti-LIBS2, anti LIBSS, ant-LIBS6, and P41. Since its exposure is uniquely regulated by both divalent cations and ligand, the amino terminus of beta(3), may be involved in control of ligand binding by divalent cation mobilization.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; OSAKA UNIV, SCH MED, DEPT INTERNAL MED 2, OSAKA 565, JAPAN	Scripps Research Institute; Scripps Research Institute; Versiti Blood Center of Wisconsin; Osaka University				Tomiyama, Yoshiaki/0000-0001-7645-0989	NHLBI NIH HHS [HL-46979, HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046979, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BAJT ML, 1992, J BIOL CHEM, V267, P3789; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DU XP, 1993, J BIOL CHEM, V268, P23087; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG MH, 1981, J SUPRAMOL STR CELL, V17, P91, DOI 10.1002/jsscb.380170111; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GINSBERG MH, 1990, BLOOD, V76, P2017; HAVERSTICK DM, 1985, BLOOD, V66, P946; HONDA S, 1990, BRIT J HAEMATOL, V75, P245, DOI 10.1111/j.1365-2141.1990.tb02657.x; HONDA S, 1995, IN PRESS LEUCOCYTE T, V5; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KEKOMAKI R, 1991, J CLIN INVEST, V88, P847, DOI 10.1172/JCI115386; KOUNS WC, 1991, BLOOD, V78, P3215; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; KUNICKI TJ, 1991, J AUTOIMMUN, V4, P415, DOI 10.1016/0896-8411(91)90156-7; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NEWMAN PJ, 1987, BLOOD, V69, P668; NEWMAN PJ, 1985, BLOOD, V65, P227; OLLIER P, 1985, EMBO J, V4, P3681, DOI 10.1002/j.1460-2075.1985.tb04135.x; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; SACHS DH, 1972, P NATL ACAD SCI USA, V69, P3790, DOI 10.1073/pnas.69.12.3790; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; TOMIYAMA Y, 1992, BLOOD, V80, P2261; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEBB N R, 1990, Technique (Philadelphia), V2, P173; XI X, 1992, NOUV REV FR HEMATOL, V34, P239	50	148	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11947	11954		10.1074/jbc.270.20.11947	http://dx.doi.org/10.1074/jbc.270.20.11947			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538128	hybrid			2022-12-25	WOS:A1995QY73600043
J	HORN, IR; MOESTRUP, SK; VANDENBERG, BMM; PANNEKOEK, H; NIELSEN, MS; VANZONNEVELD, AJ				HORN, IR; MOESTRUP, SK; VANDENBERG, BMM; PANNEKOEK, H; NIELSEN, MS; VANZONNEVELD, AJ			ANALYSIS OF THE BINDING OF PROUROKINASE AND UROKINASE-PLASMINOGEN ACTIVATOR INHIBITOR-1 COMPLEX TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN USING A FAB FRAGMENT SELECTED FROM A PHAGE-DISPLAYED FAB LIBRARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; LIGAND RECOGNITION; HIGH-AFFINITY; TYPE-1; DEGRADATION; CLEARANCE; SURFACES; ANTIGEN; LIPASE; CELLS	The low density lipoprotein receptor-related protein/ alpha(2)-macroglobulin receptor (LRP) mediates endocytosis of a number of structurally unrelated ligands, including complexes of plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) or urokinase plasminogen activator (u-PA), free t-PA, single-chain urokinase (pro-u-PA), alpha(2)-macroglobulin-protease complexes, and lipoprotein lipase. So far, all ligands have in common the fact that they bind to the receptor in a Ca2+-dependent way and the fact that binding to the receptor can be inhibited by a 39-40-kDa protein, termed the receptor-associated protein. To obtain inhibitory antibodies for the analysis of the structure and function of the receptor we applied the combinatorial immunoglobulin repertoire cloning technique in order to specifically select monoclonal Fab fragments directed against Ca2+-dependent epitopes. In this report we describe the isolation of a Fab fragment (Fab A8) showing a high relative affinity for the receptor (0.5 nM). The binding of this Fab fragment to purified LRP is inhibited in the presence of 5 mM EDTA, receptor-associated protein, and lipoprotein lipase (IC50 values of 1.4 and 31 nM, respectively). By immunoblotting of CNBr-digested LRP it is shown that Fab A8 binds to a fragment that harbors the second cluster of cysteine-rich complement-type repeats flanked by epidermal growth factor repeats. Binding studies using I-125-labeled ligands and immobilized receptor show that Fab A8 partially inhibits the binding of [I-125]u-PA PAI-1 complexes (IC50 = 1.1 nM) and completely inhibits the binding of [I-125]pro-u-PA to the receptor (IC50 = 2.2 nM). No inhibition was observed for the binding of I-125-labeled methylamine-activated alpha(2)- macroglobulin or [I-125]t-PA . PAI-1 to LRP. Degradation of [I-125]u-PAPAI-1 complexes by COS-1 cells was also partially (43%) inhibited by Fab A8. Our results provide evidence for the presence of an interaction site for pro-u-PA localized in the second cluster of cysteine-rich repeats that is unrelated to the t-PA . PAI-1 or methylamine-activated alpha(2)-macroglobulin interaction sites.	UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM K1-161,1105 AZ AMSTERDAM,NETHERLANDS; AARHUS UNIV,INST MED BIOCHEM,DK-8000 AARHUS C,DENMARK	University of Amsterdam; Academic Medical Center Amsterdam; Aarhus University			Moestrup, Søren Kragh/A-1403-2014; van Zonneveld, Anton Jan/D-8060-2018; Moestrup, Søren Kragh/AAD-1735-2019; Nielsen, Morten Schallburg/G-9498-2016	Moestrup, Søren Kragh/0000-0003-3862-2107; van Zonneveld, Anton Jan/0000-0002-1676-7738; Nielsen, Morten Schallburg/0000-0001-9863-9694; Horn, Ivo/0000-0003-1162-6052				ANDERSSON B, 1970, J EXP MED, V132, P77, DOI 10.1084/jem.132.1.77; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; CAMANI C, 1994, J BIOL CHEM, V269, P5770; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONESE M, 1994, J BIOL CHEM, V269, P17886; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HORN IR, 1995, IN PRESS LEUKOCYTE T, V5; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KANG A S, 1991, Methods (Orlando), V2, P111, DOI 10.1016/S1046-2023(05)80211-7; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RATH S, 1988, J IMMUNOL METHODS, V106, P245, DOI 10.1016/0022-1759(88)90204-9; SOTTRUPJENSEN L, 1980, FEBS LETT, V221, P55; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	40	25	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11770	11775		10.1074/jbc.270.20.11770	http://dx.doi.org/10.1074/jbc.270.20.11770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538122	hybrid			2022-12-25	WOS:A1995QY73600018
J	BLOM, A; PERTOFT, H; FRIES, E				BLOM, A; PERTOFT, H; FRIES, E			INTER-ALPHA-INHIBITOR IS REQUIRED FOR THE FORMATION OF THE HYALURONAN-CONTAINING COAT ON FIBROBLASTS AND MESOTHELIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRYPSIN-INHIBITOR; EXTRACELLULAR-MATRIX; PERICELLULAR MATRIX; INTERSTITIAL FLUID; CULTURED-CELLS; OOCYTE COMPLEX; SERUM; ACID; DERIVATIVES; INVITRO	Cultured cells of various origins have been shown to be surrounded by a hyaluronan-containing coat, a structure that can be visualized by its ability to exclude large particles such as erythrocytes. When cultured in medium with no Or low concentrations of serum, the cells lose their coats, although they still produce hyaluronan; upon the addition of serum, the coats are formed again. Here, we show that the serum protein inter-alpha-inhibitor can replace whole serum as an inducer of the formation of the coats on fibroblasts and mesothelial cells. The physiological role of inter alpha-inhibitor has so far been unclear; our findings, together with those obtained with cumulus cell-oocyte complexes (Chen, L., Mao, S. J., and Larsen, W. J. (1992) J. Biol. Chen. 267, 12380-12386), suggest that inter-alpha inhibitor and related proteins have a general function as stabilizers of hyaluronan-containing pericellular coats.			BLOM, A (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,BOX 575,S-75123 UPPSALA,SWEDEN.		Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734				CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1992, J BIOL CHEM, V267, P12380; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; CLERC C, 1990, CLIN CHIM ACTA, V189, P181, DOI 10.1016/0009-8981(90)90090-F; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; EPPIG JJ, 1980, BIOL REPROD, V22, P629, DOI 10.1093/biolreprod/22.3.629; FRASER JRE, 1970, CLIN EXP IMMUNOL, V6, P211; GOLDBERG RL, 1984, J CELL BIOL, V99, P2114, DOI 10.1083/jcb.99.6.2114; HEIDE K, 1965, CLIN CHIM ACTA, V11, P82, DOI 10.1016/0009-8981(65)90093-8; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; HUANG L, 1993, J BIOL CHEM, V268, P26725; KNUDSON CB, 1985, DEV BIOL, V112, P308, DOI 10.1016/0012-1606(85)90401-4; KNUDSON W, 1991, J CELL SCI, V99, P227; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; LIONY C, 1991, PRESSE MED, V20, P203; MCBRIDE WH, 1979, J EXP MED, V149, P507, DOI 10.1084/jem.149.2.507; MCGUIRE PG, 1987, J CELL PHYSIOL, V133, P267, DOI 10.1002/jcp.1041330210; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; ODUM L, 1990, BIOL CHEM H-S, V371, P1153, DOI 10.1515/bchm3.1990.371.2.1153; PATTERSON RL, 1975, P SOC EXP BIOL MED, V149, P594, DOI 10.3181/00379727-149-38859; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; ROSSING N, 1981, CLIN PHYSIOL, V1, P275, DOI 10.1111/j.1475-097X.1981.tb00896.x; SALIER JP, 1980, ANAL BIOCHEM, V109, P273, DOI 10.1016/0003-2697(80)90649-1; SALIER JP, 1983, ANAL BIOCHEM, V133, P336, DOI 10.1016/0003-2697(83)90093-3; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SALUSTRI A, 1990, J BIOL CHEM, V265, P19517; SCHWICK HG, 1984, PLASMA PROTEINS, P187; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; SLOTA A, 1994, BIOL CHEM H-S, V375, P127; UNDERHILL CB, 1982, J CELL PHYSIOL, V110, P123, DOI 10.1002/jcp.1041100204; VERSNEL MA, 1989, INT J CANCER, V44, P256, DOI 10.1002/ijc.2910440212	33	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9698	9701		10.1074/jbc.270.17.9698	http://dx.doi.org/10.1074/jbc.270.17.9698			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537268	hybrid			2022-12-25	WOS:A1995QV41700003
J	JUSTICE, JM; BLIZIOTES, MM; STEVENS, LA; MOSS, J; VAUGHAN, M				JUSTICE, JM; BLIZIOTES, MM; STEVENS, LA; MOSS, J; VAUGHAN, M			INVOLVEMENT OF N-MYRISTOYLATION IN MONOCLONAL-ANTIBODY RECOGNITION SITES ON CHIMERIC G-PROTEIN ALPHA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; ADP-RIBOSYLATION FACTOR; ROD OUTER SEGMENTS; BETA-GAMMA; ESCHERICHIA-COLI; PLASMA-MEMBRANE; AMINO TERMINUS; TRANSDUCIN; RHODOPSIN; RECONSTITUTION	Monoclonal antibody, LAS-2, directed against the alpha subunit of transducin (G(t alpha)), inhibited G(t beta gamma-)dependent, pertussis toxin-catalyzed ADP ribosylation of G(t alpha) and was specific for G(t alpha). Immunoblotting studies on proteolytic fragments of G(t alpha) were consistent with an aminoterminal epitope. To define the antibody recognition site, recombinant G(t alpha) was synthesized in Escherichia coli cotransfected with or without yeast N-myristoyltransferase. Amino-terminal fatty acylation of G(t alpha), verified by use of radiolabeled fatty acid, was required for immunoreactivity. LAS-2 did not react with a chimeric protein consisting of residues 1-9 of G(t alpha) and the remainder G(o alpha), regardless of its myristoylation. Immunoreactivity was observed when amino acids 1-17 of G(t alpha) were present in a G(o alpha) chimera and the protein was amino-terminally myristoylated; there was no reactivity without myristoylation. It appears that the LAS-S epitope requires both G(t alpha)-specific sequence in amino acids 10-17 and a fatty acyl group in proximity to these residues. These results are consistent with the hypothesis that the myristoyl group is essential for protein structure; conceivably it ''folds back'' on and stabilizes the amino-terminal structure of G(t alpha), as opposed to protruding from an amino-terminal alpha-helix and serving as an amino terminal membrane anchor.			JUSTICE, JM (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,BLDG 10,RM 5N-307,10 CTR DR,MSC 1434,BETHESDA,MD 20892, USA.							BORSTEIN P, 1977, METHOD ENZYMOL, V47, P132; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; DENKAR BM, 1991, J BIOL CHEM, V266, P6272; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GRAF R, 1992, J BIOL CHEM, V267, P24307; HALPERN JL, 1986, MOL PHARMACOL, V29, P515; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HONG JX, 1994, J BIOL CHEM, V269, P9743; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KRUEGER JG, 1983, CURR TOP MICROBIOL I, V107, P52; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SHENKEIN I, 1977, ARCH BIOCHEM BIOPHYS, V182, P64; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNWEIS PC, 1984, J BIOL CHEM, V254, P13806; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SC, 1987, BIOCHEMISTRY-US, V26, P4728, DOI 10.1021/bi00389a020; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	38	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6436	6439		10.1074/jbc.270.12.6436	http://dx.doi.org/10.1074/jbc.270.12.6436			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7534763	hybrid			2022-12-25	WOS:A1995QQ85500005
J	OKUTANI, T; OKABAYASHI, Y; KIDO, Y; SUGIMOTO, Y; SAKAGUCHI, K; MATUOKA, K; TAKENAWA, T; KASUGA, M				OKUTANI, T; OKABAYASHI, Y; KIDO, Y; SUGIMOTO, Y; SAKAGUCHI, K; MATUOKA, K; TAKENAWA, T; KASUGA, M			GRB2/ASH BINDS DIRECTLY TO TYROSINE-1068 AND TYROSINE-1086 AND INDIRECTLY TO TYROSINE-1148 OF ACTIVATED HUMAN EPIDERMAL GROWTH-FACTOR RECEPTORS IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GUANINE-NUCLEOTIDE EXCHANGE; SH3 DOMAINS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; AUTOPHOSPHORYLATION SITES; PHOSPHORYLATION SITES; MITOGENIC SIGNAL; ADAPTER PROTEIN; 85-KDA SUBUNIT	The activation of receptor tyrosine kinases generates tyrosine-phosphorylated recognition motifs for the binding of signaling proteins containing Src homology 2 domains. We determined the binding sites of Grb2/Ash, an Src homology 2 domain-containing adaptor protein, within epidermal growth factor (EGF) receptors, using Chinese hamster ovary cells overexpressing human EGF receptor mutants in which one of the autophosphorylation sites was retained. In intact cells, the amount of Grb2/Ash coimmunoprecipitated with mutant receptors retaining tyrosines 992, 1068, 1086, 1148, or 1173 was approximately 10, 85, 55, 50, or 20% of wild-type levels, respectively The association of Grb2/Ash with in vitro autophosphorylated EGF receptor mutants was detectable in those retaining either tyrosines 1068 or 1086 but not in other mutants including those retaining tyrosine 1148. In peptide inhibition assay phosphorylated peptides representing tyrosines 1068 and 1086 inhibited the binding of Grb2/Ash to in vitro autophosphorylated wild-type EGF receptors, whereas the other peptides representing tyrosines 992, 1148, and 1173 failed to inhibit the binding. Given that tyrosine 1148 of the activated EGF receptor is a major binding site of Shc (Okabayashi, Y., Kido, Y., Okutani, T., Sugimoto, Y., Sakaguchi, K., and Kasuga, M. (1994) J. Biol. Chem. 269, 18674-18678), these results indicate that tyrosines 1068 and 1086 of activated human EGF receptors are direct high affinity binding sites of Grb2/Ash and that tyrosine 1148 is an indirect binding site through Shc in intact cells.	KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, KOBE 650, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL, DEPT BIOSIGNAL RES, TOKYO 173, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC ONCOL, TOKYO 108, JAPAN	Kobe University; University of Tokyo								ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MIKI H, 1994, J BIOL CHEM, V269, P5489; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALTON GM, 1990, J BIOL CHEM, V265, P1750; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31310	31314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527043				2022-12-25	WOS:A1994PV51000086
J	DALY, TJ; LAROSA, GJ; DOLICH, S; MAIONE, TE; COOPER, S; BROXMEYER, HE				DALY, TJ; LAROSA, GJ; DOLICH, S; MAIONE, TE; COOPER, S; BROXMEYER, HE			HIGH-ACTIVITY SUPPRESSION OF MYELOID PROGENITOR PROLIFERATION BY CHIMERIC MUTANTS OF INTERLEUKIN-8 AND PLATELET FACTOR-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MEGAKARYOCYTOPOIESIS INVITRO; RECEPTOR-BINDING; FACTOR-IV; ACTIVATING FACTOR; CYTOKINE FAMILY; PROTEIN; INHIBITION; CELLS; PURIFICATION; EXPRESSION	The proliferation of human myeloid progenitor cells is negatively regulated in the presence of certain members of the chemokine family of molecules. This includes interleukin 8 (IL 8) and platelet factor 4 (PF4), which in combination are able to synergize, resulting in cell suppression at very low concentrations of these molecules. A series of PF4 and IL-8 mutant proteins were analyzed in an in. vitro colony formation assay for myeloid progenitor cells to assess domains of these proteins that are required for activity. Mutation of either of the two DLQ motifs within PF4 resulted in an inactive protein. Perturbations within the IL-8 dimer interface region also resulted in mutants that were incapable of suppressing colony formation, A class of chimeric mutants consisting of domains of either PF4 and IL-8, Gro-alpha and PF4, or Gro-beta and PF4 were observed to inhibit myeloid cell proliferation at concentrations which were between 500 and 5000-fold lower than either the IL 8 or PF4 wild-type proteins alone. These chimeric mutants possessed activities that were comparable to or better than the activity observed when IL-8 and PF4 were added together in vitro. One of these highly active chimeric proteins was observed to be 1000-fold more active than either IL-8 or PF4 alone in suppressing not only the proliferation but also the cell cycling of myeloid progenitor cells following intravenous injection of the mutant into mice. Examination of additional IL-8-based mutants in the colony formation assay, which centered on the perturbation of the amino-terminal ''ELR'' motif, resulted in the observation that the highly active IL-8 mutant required both aspartic acid at amino acid residue 4 and either glutamine or asparagine at residue 6, Single mutations at either of these positions resulted in mutants with myelosuppressive activity equivalent to wild-type IL-8. Mutants such as IL-8M1 and IL-8M10 were observed to be significantly reduced in their ability to activate isolated human neutrophils, suggesting that separate mechanisms may exist by which myeloid progenitor cells and neutrophils are affected by chemokines.	INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	DALY, TJ (corresponding author), REPLIGEN CORP,1 KENDALL SQ,BLDG 700,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [R37 CA36464] Funding Source: Medline; NHLBI NIH HHS [R01 HL46549, R01 HL49202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046549, R01HL049202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARONE AD, 1988, J BIOL CHEM, V263, P8710; BROXMEYER HE, 1990, BLOOD, V76, P1110; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; BROXMEYER HE, 1993, J IMMUNOL, V150, P3448; BROXMEYER HE, 1995, HUMAN CYTOKINES THEI; BROXMEYER HE, 1993, CLIN APPLICATIONS CY, P201; BROXMEYER HE, 1992, CONCISE REV CLIN EXP, P119; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CAEN JP, 1993, BLOOD, V82, pA162; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; COOPER S, 1994, EXP HEMATOL, V22, P186; DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; DUNLOP DJ, 1992, BLOOD, V79, P2221; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GEWIRTZ AM, 1989, J CLIN INVEST, V83, P1477, DOI 10.1172/JCI114041; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HAN ZC, 1990, BLOOD, V75, P1234; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORTON JE, 1980, BIOCHIM BIOPHYS ACTA, V630, P459, DOI 10.1016/0304-4165(80)90295-0; HORUK R, 1994, J BIOL CHEM, V269, P17730; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONARD EJ, 1991, J LEUKOCYTE BIOL, V49, P258, DOI 10.1002/jlb.49.3.258; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LORD BI, 1992, BLOOD, V79, P2605; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MAZE R, 1992, J IMMUNOL, V149, P1004; MOORE S, 1975, BIOCHIM BIOPHYS ACTA, V379, P370, DOI 10.1016/0005-2795(75)90144-0; MOSER B, 1993, J BIOL CHEM, V268, P7125; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; RUCINSKI B, 1979, BLOOD, V53, P47; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; TAUB DD, 1993, CYTOKINE, V5, P175, DOI 10.1016/1043-4666(93)90001-L; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	46	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23282	23292		10.1074/jbc.270.40.23282	http://dx.doi.org/10.1074/jbc.270.40.23282			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559482	hybrid			2022-12-25	WOS:A1995RY90900011
J	KUNICKI, TJ; ELY, KR; KUNICKI, TC; TOMIYAMA, Y; ANNIS, DS				KUNICKI, TJ; ELY, KR; KUNICKI, TC; TOMIYAMA, Y; ANNIS, DS			THE EXCHANGE OF ARG-GLY-ASP (RGD) AND ARG-TYR-ASP (RYD) BINDING SEQUENCES IN A RECOMBINANT MURINE FAB FRAGMENT SPECIFIC FOR THE INTEGRIN ALPHA(IIB)BETA(3) DOES NOT ALTER INTEGRIN RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION INHIBITOR; VON-WILLEBRAND FACTOR; NONACTIVATED PLATELETS; ADHESION RECEPTORS; FIBRONECTIN; FIBRINOGEN; MEMBRANE; ANTAGONIST; PEPTIDE	The murine monoclonal antibody OPG2 is an excellent paradigm of natural RGD ligands and binds specifically to alpha(IIb)beta(3) integrin. A reactive Arg(103)-Tyr(104)-Asp(105) (RYD) tripeptide is located in an extended loop, the third complementarity-determining region of the heavy chain (H3). When compared to other RGD ligands, the RYD tripeptide of OPG2 is unique, in that the side chains are fixed in a stable orientation that we have defined by x-ray crystallography. In this study, we express OPG2 H chain segments (Fd) and kappa chains as components of active, Fab heterodimers by coinfection of Spodoptera frugiperda cell lines with recombinant baculoviruses containing cDNA specific for each protein. Recombinant AP7 Fd segments are generated from the parent OPG2 Fd segments by replacement of Tyr(104) with Gly, while recombinant AP7E Fd segments are produced Rom AP7 Fd segments, by exchange of Asp(105) with Glu. Neither the free Fd segments nor the free kappa chains of OPG2 or AP7 can bind to alpha(IIb)beta(3). The AP7 Fab fragment, like the parent OPG2 Fab, binds strongly to purified alpha(IIb)beta(3), but weakly, if at all, to purified alpha(v) beta(3). The affinity of OPG2 and AP7 Fab fragments for gel-filtered platelets, whether nonstimulated or activated by 0.2 mu M phorbol 12-myristate 13-acetate, is identical. As with other natural RGD ligands, the binding of recombinant OPG2 Fab or AP7 Fab fragments to purified alpha(IIb)beta(3) or to gel-filtered platelets is completely inhibited by the peptide RGDW or by addition of EDTA. AP7E Fab fragments do not bind at all to either purified alpha(IIb)beta(3) or platelets. Our results demonstrate, for the first time within a natural protein ligand, that the tripeptides RGD and RYD exhibit equivalent binding capacity and specificity for the integrin alpha(IIb)beta(3).	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; OSAKA UNIV, SCH MED, DEPT INTERNAL MED 2, OSAKA 565, JAPAN	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; Osaka University	KUNICKI, TJ (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA.			Tomiyama, Yoshiaki/0000-0001-7645-0989	NHLBI NIH HHS [R01 HL-46979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CHENG S, 1994, J MED CHEM, V37, P1, DOI 10.1021/jm00027a001; COOK JJ, 1989, AM J PHYSIOL, V256, pH1038, DOI 10.1152/ajpheart.1989.256.4.H1038; DALVIT C, 1991, EUR J BIOCHEM, V202, P315, DOI 10.1111/j.1432-1033.1991.tb16378.x; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FURIHATA K, 1987, J CLIN INVEST, V80, P1624, DOI 10.1172/JCI113250; GAN ZR, 1988, J BIOL CHEM, V263, P19827; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HAVERSTICK DM, 1985, BLOOD, V66, P946; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; KUNICKI TJ, 1993, BLOOD, V82, P2693; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; NISHIMURA SL, 1993, MOL BIOL CELL S, V4, P285; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SHEN JR, 1992, THROMB RES, V66, P679; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; TAUB R, 1992, BIOCHEMISTRY-US, V31, P7431, DOI 10.1021/bi00148a001; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P161; TOMIYAMA Y, 1992, BLOOD, V79, P2303; WENCELDRAKE JD, 1986, AM J PATHOL, V124, P324	42	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16660	16665		10.1074/jbc.270.28.16660	http://dx.doi.org/10.1074/jbc.270.28.16660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542651	hybrid			2022-12-25	WOS:A1995RJ34700033
J	HERWALD, H; HASAN, AAK; GODOVAC-ZIMMERMANN, J; SCHMAIER, AH; MULLERESTERL, W				HERWALD, H; HASAN, AAK; GODOVAC-ZIMMERMANN, J; SCHMAIER, AH; MULLERESTERL, W			IDENTIFICATION OF AN ENDOTHELIAL-CELL BINDING-SITE ON KININOGEN DOMAIN D3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; LOW-MR KININOGEN; HEAVY-CHAIN; ANTIIDIOTYPIC ANTIBODIES; MONOCLONAL-ANTIBODIES; CYSTEINE PROTEINASES; LIGHT-CHAINS; EXPRESSION; BRADYKININ; PLATELETS	High and low molecular mass kininogen, two multidomain plasma proteins, bind to endothelial cells, platelets, and neutrophils in the intravascular compartment. The specific cell attachment site on their common heavy chain is mediated by domain-3, a cystatin-like structure with inhibitory capacity for papain-like proteinases (Jiang, Y., Muller-Esterl, W., and Schmaier, A. H. (1992) J. Biol. Chem, 267, 3712-3717). In this report, the domain-3 cell binding site is determined by an antibody-directed strategy. The epitope of monoclonal antibody HKH15, which binds to domain-3 and blocks the binding of kininogens to platelets and endothelial cells, was mapped using seven synthetic peptides, which span the entire domain-3 sequence. One peptide, LDC27, specifically bound to HKH15. Fine mapping of the epitope of HKH15 revealed that a minimal 13-residue segment in LDC27, named CNA13, is the antibody binding site. LDC27 and CNA13 inhibited biotinylated high molecular mass kininogen binding to endothelial cells with apparent IC50 values of 60.3 +/- 12 and 113.3 +/- 63.7 mu M, respectively. Carboxymethylated papain and affinity purified anti-LDC27 polyclonal antibodies also inhibited the binding of biotinylated high molecular mass kininogen to endothelial cells with an apparent IC50 of 1.04 mu M and 59 nM, respectively. Biotinylated LDC27 itself directly bound to endothelial cells, and domain-3 inhibited biotinylated LDC27 binding to human umbilical vein endothelial cells with an IC50 of 41 nM. Using the crystalline structure of cystatin to computer model domain-3, LDC27 and CNA13 were located in the second hairpin loop of the reactive site of cystatin-like proteins (Bode, W., Engh, R., Musil, D., Thiele, U. Huber, R., Karshikov, A., Brzin, J., Kos, J., and Turk, V. (1988) EMBO J. 7, 2593-2599). These results indicate that the major endothelial cell attachment site on kininogen domain-3 is located on its carboxyl-terminal portion and that it overlaps its cysteine protease inhibitory region.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-55099 MAINZ, GERMANY; UNIV MICHIGAN, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, ANN ARBOR, MI 48109 USA	Johannes Gutenberg University of Mainz; University of Michigan System; University of Michigan			Herwald, Heiko/AAN-3708-2021; Schmaier, Alvin/AAM-1063-2020; Zimmermann, Jasminka Godovac/E-6863-2010	Herwald, Heiko/0000-0002-8111-2842; Schmaier, Alvin/0000-0002-3884-6234; 	NHLBI NIH HHS [HL35553] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035553] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERSWALD EA, 1993, FEBS LETT, V321, P93, DOI 10.1016/0014-5793(93)80628-8; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERRY PD, 1982, P NATL ACAD SCI-BIOL, V79, P2106, DOI 10.1073/pnas.79.6.2106; DELACADENA RA, 1993, THROMB HEMOSTASIS, V69, P854; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, IN PRESS BLOOD; HERWALD H, 1993, J BIOL CHEM, V268, P14527; HIGASHIYAMA S, 1987, BIOCHEMISTRY-US, V26, P7450, DOI 10.1021/bi00397a038; HOCK J, 1990, J BIOL CHEM, V265, P12005; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JOHNSON DA, 1987, THROMB RES, V48, P187, DOI 10.1016/0049-3848(87)90415-4; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; KELLERMANN J, 1987, BIOCHEM J, V247, P15, DOI 10.1042/bj2470015; KELLERMANN J, 1986, EUR J BIOCHEM, V154, P471, DOI 10.1111/j.1432-1033.1986.tb09421.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; MELONI FJ, 1992, BLOOD, V79, P1233; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; NISHIKAWA K, 1992, BLOOD, V80, P1980; REDDIGARI SR, 1993, BLOOD, V81, P1306; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMAIER AH, 1989, METHOD ENZYMOL, V169, P276; SCHMAIER AH, 1984, THROMB RES, V33, P51, DOI 10.1016/0049-3848(84)90154-3; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; VOGEL R, 1988, J BIOL CHEM, V263, P12661; VOGEL R, 1990, J BIOL CHEM, V265, P12494; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; ZINI JM, 1993, BLOOD, V81, P2936	43	94	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14634	14642						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540175				2022-12-25	WOS:A1995RD45500061
J	KIM, S; MCKAY, RR; MILLER, K; SHORTRIDGE, RD				KIM, S; MCKAY, RR; MILLER, K; SHORTRIDGE, RD			MULTIPLE SUBTYPES OF PHOSPHOLIPASE-C ARE ENCODED BY THE NORPA GENE OF DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION METHOD; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; NERVOUS-SYSTEM; CLONING; ACTIVATION; EXPRESSION; MUTANTS; PHOTOTRANSDUCTION; PURIFICATION	The norpA gene of Drosophila melanogaster encodes a phosphatidylinositol-specific phospholipase C that is essential for phototransduction. Besides being found abundantly in retina, norpA gene products are expressed in a variety of tissues that do not contain phototransduction machinery, implying that norpA is involved in signaling pathways in addition to phototransduction. We have identified a second subtype of norpA protein that is generated by alternative splicing of norpA RNA The alternative splicing occurs at a single exon that is excluded from mature norpA transcripts when a substitute exon of equal size is retained. The net difference between the two subtypes of norpA protein is 14 amino acid substitutions occurring between amino acid positions 130 and 155 of the enzyme. Results from Northern analyses suggest that norpA subtype I transcripts are most abundantly expressed in adult retina, while subtype II transcripts are most abundant in adult body. Moreover, norpA subtype I RNA can be detected by the reverse transcription-polymerase chain reaction in extracts of adult head tissue but not adult body nor at earlier stages of Drosophila development. Conversely, norpA subtype II RNA can be detected by reverse transcription-polymerase chain reaction throughout development as well as in heads and bodies of adults. Furthermore, norpA subtype I RNA is easily detected in retina using tissue in situ hybridization analysis, while subtype II RNA is not detectable in retina but is found in brain. Since only norpA subtype I RNA is found in retina, we conclude that subtype I protein is utilized in phototransduction. Since norpA subtype IE RNA is not found in retina but is expressed in a variety of tissues not known to contain phototransduction machinery, subtype II protein is likely to be utilized in signaling pathways other than phototransduction, The amino acid differences between the two subtypes of norpA protein may reflect the need for each subtype to interact with signaling components of different signal-generating pathways.	SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BAHK YY, 1994, J BIOL CHEM, V269, P8240; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FUQUA SAW, 1990, BIOTECHNIQUES, V9, P206; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HAFEN E, 1983, EMBO J, V2, P617, DOI 10.1002/j.1460-2075.1983.tb01472.x; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; HU KG, 1978, J COMP PHYSIOL, V126, P15, DOI 10.1007/BF01342646; INNIS MA, 1990, PCR PROTOCOLS; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jones Gwenith, 1992, Progress in Growth Factor Research, V4, P97, DOI 10.1016/0955-2235(92)90025-D; KAUFMAN DL, 1990, BIOTECHNIQUES, V9, P304; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE SB, 1993, J BIOL CHEM, V268, P25952; LEW PD, 1990, AM REV RESPIR DIS, V141, pS127, DOI 10.1164/ajrccm/141.3_Pt_2.S127; MARKOW TA, 1980, BEHAV NEURAL BIOL, V29, P276, DOI 10.1016/S0163-1047(80)90612-3; MASAI I, 1991, J BIOCHEM-TOKYO, V109, P867, DOI 10.1093/oxfordjournals.jbchem.a123472; MCKAY RR, 1995, IN PRESS J BIOL CHEM; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MICHELL RH, 1989, BIOCHEM SOC T, V17, P1; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PARK D, 1992, J BIOL CHEM, V267, P16048; PUTNEY JW, 1988, J EXP BIOL, V139, P135; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIESGOESCOVAR J, 1995, P NATL ACAD SCI USA, V92, P2864, DOI 10.1073/pnas.92.7.2864; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; Sambrook J, 1989, MOL CLONING LABORATO; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMPKINS L, 1982, BEHAV GENET, V12, P295, DOI 10.1007/BF01067849; VOLPE P, 1986, FEBS LETT, V197, P1, DOI 10.1016/0014-5793(86)80285-X; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; ZHU LQ, 1993, J BIOL CHEM, V268, P15994	46	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14376	14382		10.1074/jbc.270.24.14376	http://dx.doi.org/10.1074/jbc.270.24.14376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540168	hybrid			2022-12-25	WOS:A1995RD45500024
J	HUANG, JT; MOHAMMADI, M; RODRIGUES, GA; SCHLESSINGER, J				HUANG, JT; MOHAMMADI, M; RODRIGUES, GA; SCHLESSINGER, J			REDUCED-ACTIVATION OF RAF-1 AND MAP KINASE BY A FIBROBLAST GROWTH-FACTOR RECEPTOR MUTANT DEFICIENT IN STIMULATION OF PHOSPHATIDYLINOSITOL HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PROTEIN-KINASE; PHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; TYROSINE KINASES; RAS; IDENTIFICATION; DOWNSTREAM; PATHWAYS; BINDING	Signaling via the fibroblast growth factor receptor 1 (FGFR1, flg) was analyzed in Ba/F3 hematopoietic cells expressing either wild-type or a mutant FGF receptor (Y766F) unable to activate phospholipase C-gamma (PLC ?I) and stimulate phosphatidylinositol (PI) hydrolysis. Stimulation of cells expressing wild-type or mutant FGFR with acidic FGF (aFGF) caused similar activation of Ras. However, an approximately S-fold reduced activation of Raf-1 and MAP kinase was observed in aFGF-stimulated cells expressing mutant receptors as compared to cells expressing wild-type FGF receptors. Comparison of phosphopeptide maps of Raf-1 immunoprecipitated from the two cell types activated by either aFGF or the phorbol ester (12-O-tetradecanoylphorbol-13-acetate) suggests that Raf-1 is phosphorylated by both Ras-dependent and PLC-gamma-dependent mechanisms. In spite of the differential effect on Raf-1 and MAP kinase activation, aFGF stimulated similar proliferation of cells expressing wild-type or mutant receptors indicating that Ras-dependent activation of Raf-1 and MAP kinase is sufficient for transduction of FGFR mitogenic signals. Ras may also activate signal transduction pathways that are complementary or parallel to the MAP kinase pathway to stimulate cell proliferation.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University			kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437				BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RAPP UR, 1991, ONCOGENE, V6, P495; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SATOH T, 1903, MOL CELL BIOL, V13, P3706; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SOZERI O, 1992, ONCOGENE, V7, P2259; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P1419; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	43	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5065	5072		10.1074/jbc.270.10.5065	http://dx.doi.org/10.1074/jbc.270.10.5065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534287	hybrid			2022-12-25	WOS:A1995QL58000020
J	TAUCHI, T; FENG, GS; SHEN, R; HOATLIN, M; BAGBY, GC; KABAT, D; LU, L; BROXMEYER, HE				TAUCHI, T; FENG, GS; SHEN, R; HOATLIN, M; BAGBY, GC; KABAT, D; LU, L; BROXMEYER, HE			INVOLVEMENT OF SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP IN ERYTHROPOIETIN RECEPTOR SIGNAL-TRANSDUCTION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEIN; HEMATOPOIETIC-CELL PHOSPHATASE; PHOSPHATIDYLINOSITOL 3-KINASE; ASSOCIATION; ACTIVATION; EXPRESSION; SUBUNIT; MITOGENESIS; STIMULATION; HOMOLOGY	Erythropoietin (Epo) regulates the proliferation and differentiation of erythroid precursors. The phosphorylation of proteins at tyrosine residues is critical in the growth signaling induced by Epo. This mechanism is regulated by the activities of both protein tyrosine kinases and protein tyrosine phosphatases. The discovery of phosphotyrosine phosphatases that contain SH2 domains suggests roles for these molecules in growth factor signaling pathways. We found that Syp, a phosphotyrosine phosphatase, widely expressed in all tissues in mammals became phosphorylated on tyrosine after stimulation with Epo in M07ER cells engineered to express high levels of human EpoR. Syp was complexed with Grb2 in Epo-stimulated M07ER cells. Direct binding between Syp and Grba was also observed in vitro. Furthermore, Syp appeared to bind directly to tyrosine-phosphorylated EpoR in M07ER cells. Both NH2-terminal and COOH-terminal SH2 domains of Syp, made as glutathione S-trnsferase fusion proteins, were able to bind to the tyrosine-phosphorylated EpoR in vitro. These results suggest that Syp may be an important signaling component downstream of the EpoR and may regulate the proliferation and differentiation of hematopoietic cells.	INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Oregon Health & Science University; Oregon Health & Science University					NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049202, R01HL046549] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA36464] Funding Source: Medline; NHLBI NIH HHS [R01 HL46549, R01 HL49202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CASE RD, 1994, J BIOL CHEM, V269, P10467; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HE TC, 1993, BLOOD, V82, P3530; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOZAK SL, 1990, J VIROL, V64, P3500, DOI 10.1128/JVI.64.7.3500-3508.1990; KRANTZ SB, 1991, BLOOD, V77, P419; KUKNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SPANGLER R, 1992, BLOOD, V79, P52; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TORTI M, 1992, J BIOL CHEM, V267, P8293; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	125	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5631	5635		10.1074/jbc.270.10.5631	http://dx.doi.org/10.1074/jbc.270.10.5631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534299	hybrid			2022-12-25	WOS:A1995QL58000102
J	DAVIS, SJ; DAVIES, EA; BARCLAY, AN; DAENKE, S; BODIAN, DL; JONES, EY; STUART, DI; BUTTERS, TD; DWEK, RA; VANDERMERWE, PA				DAVIS, SJ; DAVIES, EA; BARCLAY, AN; DAENKE, S; BODIAN, DL; JONES, EY; STUART, DI; BUTTERS, TD; DWEK, RA; VANDERMERWE, PA			LIGAND-BINDING BY THE IMMUNOGLOBULIN SUPERFAMILY RECOGNITION MOLECULE CD2 IS GLYCOSYLATION-INDEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I HISTOCOMPATIBILITY ANTIGEN; CELL ERYTHROCYTE RECEPTOR; CRYSTAL-STRUCTURE; N-GLYCOSYLATION; 3-DIMENSIONAL STRUCTURE; GLYCOPROTEIN CD2; ADHESION DOMAIN; RIBONUCLEASE-B; SOLUBLE FORM; RAT CD2	The evolutionary success of the immunoglobulin superfamily (IgSF) is thought to reflect the ability of IgSF protein domains to form stable structural units. The role of glycosylation in stabilizing these domains is controversial, however. In this study a systematic analysis of the effect of glycosylation on the ligand-binding properties of the cell cell recognition molecule CD2, which consists of two IgSF domains, was undertaken. A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H. The ligand and antibody binding properties of this form of hsCD2 were indistinguishable from those of fully glycosylated hsCD2 as determined by surface plasmon resonance analyses. The protein also formed diffraction quality crystals and analysis of the 2.5-Angstrom resolution crystal structure indicated that the single N-acetylglucosamine residue present on domain 1 is unlikely to stabilize the ligand binding face of hsCD2. A second, fully deglycosylated form of hsCD2 also bound the ligand and antibodies although this form of the protein tended to aggregate. In contrast to the results of previous studies, the current data indicate that the structural integrity and ligand binding function of human CD2 are glycosylation-independent.	JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, DIV MOLEC SCI, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, INST GLYCOBIOL, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	University of Oxford; University of Oxford; University of Oxford	DAVIS, SJ (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, S PARKS RD, OXFORD OX1 3RE, ENGLAND.		Jones, Yvonne/J-2293-2016; van der Merwe, P. Anton/F-8539-2011; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Daenke, Susan/0000-0003-3290-6627				ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARVIEUX J, 1988, ANTIBODIES PRACTICAL, P113; BARCLAY AN, 1992, LEUCOCYTE ANTIGEN FA, P13; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BERMAN E, 1981, J BIOL CHEM, V256, P3853; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BROCKBANK RL, 1990, BIOCHEMISTRY-US, V29, P5574, DOI 10.1021/bi00475a023; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN MH, 1994, PROTEIN ENG, V7, P515, DOI 10.1093/protein/7.4.515; CICCARELLI E, 1993, EUR J BIOCHEM, V213, P271, DOI 10.1111/j.1432-1033.1993.tb17759.x; CYSTER JG, 1992, THESIS OXFORD U; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; DAVIS SJ, 1993, BIOCHEM SOC T, V21, P952, DOI 10.1042/bst0210952; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; JOAO HC, 1992, FEBS LETT, V307, P343, DOI 10.1016/0014-5793(92)80709-P; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LOCH N, 1992, EUR J BIOCHEM, V210, P161, DOI 10.1111/j.1432-1033.1992.tb17404.x; MATHEW PA, 1993, J IMMUNOL, V151, P5328; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; RECNY MA, 1992, J BIOL CHEM, V267, P22428; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANDRIN MS, 1992, J IMMUNOL, V149, P1636; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; WILLIAMS RL, 1987, J BIOL CHEM, V262, P16020; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WOLFF HL, 1990, J IMMUNOL, V144, P1215; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WOODS RJ, 1994, NAT STRUCT BIOL, V1, P499, DOI 10.1038/nsb0894-499; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; WYSS DF, 1993, BIOCHEMISTRY-US, V32, P10995, DOI 10.1021/bi00092a008; YANG B, 1993, J BIOL CHEM, V268, P7435	52	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					369	375		10.1074/jbc.270.1.369	http://dx.doi.org/10.1074/jbc.270.1.369			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529232	hybrid			2022-12-25	WOS:A1995QA28700058
J	SENFTEN, M; SCHENKER, G; SOWADSKI, JM; BALLMERHOFER, K				SENFTEN, M; SCHENKER, G; SOWADSKI, JM; BALLMERHOFER, K			CATALYTIC ACTIVITY AND TRANSFORMATION POTENTIAL OF V-SRC REQUIRE ARGININE-385 IN THE SUBSTRATE-BINDING POCKET	ONCOGENE			English	Note						SRC; TYROSINE KINASE; ONCOGENE; CATALYSIS; PHOSPHORYLATION; RSV	ROUS-SARCOMA VIRUS; DEPENDENT PROTEIN-KINASE; MIDDLE-T-ANTIGEN; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; MONOCLONAL-ANTIBODIES; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; PP60C-SRC KINASE; TUMOR-ANTIGEN	Tyrosine kinases are important mediators of signal transduction in eukaryotic cells. In order to better understand the mechanism of catalysis we studied a set of mutants of the prototype tyrosine kinase, the c-Src protein, a homologue of the Rous Sarcoma virus oncogene. Based on an X-ray structure of cAMP-dependent protein kinase (cAPK) we mutated an arginine residue conserved in subdomain VI of all known kinases to a non-charged residue. This residue coordinates phosphate of the autophosphorylation site located in subdomain VII of cAPK and this interaction has been proposed to be crucial for substrate binding. The mutant R385A of c-Src had low kinase activity towards exogenous substrates yet was able to autophosphorylate at tyrosine 416. When introduced into an activated v-src gene the R385A, mutation totally blocked cell transformation. Our data suggest that the function of the conserved arginine 385 is to coordinate the phosphate of the autophosphorylation site and to provide in this way a stable template for substrate binding.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Friedrich Miescher Institute for Biomedical Research; University of California System; University of California San Diego				Ballmer-Hofer, Kurt/0000-0002-3800-9129				BALLMERHOFER K, 1987, VIRUS RES, V6, P345, DOI 10.1016/0168-1702(87)90066-9; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; ERIKSON RL, 1984, ADV CYCLIC NUCL PROT, V17, P457; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUJITA DJ, 1981, VIROLOGY, V111, P223, DOI 10.1016/0042-6822(81)90667-X; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KELLIE S, 1987, BIOCHEM SOC T, V15, P791, DOI 10.1042/bst0150791; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MANESS PF, 1983, MOL CELL BIOL, V3, P102, DOI 10.1128/MCB.3.1.102; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSER J, 1989, ONCOGENE, V4, P1433; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZ L, 1993, P NATL ACAD SCI USA, V90, P8113, DOI 10.1073/pnas.90.17.8113; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	48	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					199	203						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529917				2022-12-25	WOS:A1995QA98000023
J	VITALE, N; DELOULME, JC; THIERSE, D; AUNIS, D; BADER, MF				VITALE, N; DELOULME, JC; THIERSE, D; AUNIS, D; BADER, MF			GAP-43 CONTROLS THE AVAILABILITY OF SECRETORY CHROMAFFIN GRANULES FOR REGULATED EXOCYTOSIS BY STIMULATING A GRANULE-ASSOCIATED G(O)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEINS; HETEROTRIMERIC G-PROTEIN; DYNAMIC FATTY ACYLATION; SUBSTRATE B-50 GAP-43; GROWTH CONE PROTEIN; SENSITIVE G-PROTEIN; GUANINE-NUCLEOTIDES; NORADRENALINE RELEASE; GOLGI MEMBRANES	Besides having a role in signal transduction, heterotrimeric G proteins may also be involved in membrane trafficking events as suggested by their presence in specific intracellular compartments. In chromaffin cells, G(alpha o) is associated with secretory organelles, and its activation inhibits exocytosis. Although plasma membrane-bound G proteins are activated by cell surface receptors, the intracellular proteins controlling organelle-associated G proteins are currently unknown. GAP-43, a neuronal protein enriched in axonal growth cones and presynaptic terminals, is one possible candidate since it can directly stimulate purified G(o). We have investigated the interaction of adrenal medullary GAP-43 with chromaffin granule-associated G(o) and its effect on catecholamine secretion. Cytosolic and depalmitoylated membrane-extracted GAP-43 were found to stimulate guanine nucleotide binding and exchange activity in chromaffin granule membranes. In permeabilized chromaffin cells, both forms of GAP-43 blocked calcium dependent exocytosis, and this effect was inhibited by specific antibodies against G(alpha o). A synthetic peptide corresponding to the GAP-43 domain that interacts with G(o) inhibited catecholamine secretion. This effect could be selectively reversed by the COOH-terminal peptide of G(alpha o). These results indicate that GAP-43 may be an endogenous pseudoreceptor for the secretory granule-bound form of G(o) and can thereby control calcium-regulated exocytosis in chromaffin cells.	INSERM,U338,F-67084 STRASBOURG,FRANCE; CNRS,UPR 417,NEUROBIOL ONTOGEN LAB,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Deloulme, Jean Christophe/P-6858-2017; Bader, Marie-France/O-2098-2016; Dominique, Aunis/W-1419-2019; Vitale, Nicolas/G-5967-2014	Deloulme, Jean Christophe/0000-0002-2234-5865; Vitale, Nicolas/0000-0002-4752-4907				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; BADER MF, 1986, J BIOL CHEM, V261, P5777; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BON S, 1990, EUR J BIOCHEM, V190, P221, DOI 10.1111/j.1432-1033.1990.tb15567.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; FLODGAARD H, 1974, J BIOL CHEM, V249, P3465; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GRANT NJ, 1992, EUR J NEUROSCI, V8, P1789; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HENS JJH, 1993, J NEUROCHEM, V61, P602; HENS JJH, 1993, J NEUROCHEM, V60, P1264, DOI 10.1111/j.1471-4159.1993.tb03286.x; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; IRVINS KJ, 1993, J NEUROCHEM, V60, P626; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; MUKAI H, 1992, J BIOL CHEM, V267, P16237; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; ROUOT B, 1989, BIOCHEM J, V260, P307, DOI 10.1042/bj2600307; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SILLEN LG, 1971, STABILITY CONSTANTS, V1; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; VITALE N, 1993, J BIOL CHEM, V268, P14715; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	65	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30293	30298						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527027				2022-12-25	WOS:A1994PU52500041
J	SWIETER, M; BERENSTEIN, EH; SWAIM, WD; SIRAGANIAN, RP				SWIETER, M; BERENSTEIN, EH; SWAIM, WD; SIRAGANIAN, RP			AGGREGATION OF IGE RECEPTORS IN RAT BASOPHILIC LEUKEMIA 2H3 CELLS INDUCES TYROSINE PHOSPHORYLATION OF THE CYTOSOLIC PROTEIN-TYROSINE-PHOSPHATASE HEPTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; HISTAMINE-RELEASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHOLIPASE C-GAMMA-1; CALCIUM SIGNAL; ACTIVATION; CLONING; KINASE; IDENTIFICATION; STIMULATION	The cDNA encoding the rat equivalent of the human hematopoietic tyrosine phosphatase, also known as leukocyte phosphatase, was isolated from a rat basophilic leukemia mast cell cDNA library. By two-dimensional electrophoresis, the protein expressed in the mast cells was of a size (40 kDa) and pI (6.9) predicted from the deduced amino acid sequence. Thus, although previously shown to be preferentially expressed in T cells and B cells, the phosphatase is also Pound in mast cells. By immunofluorescence microscopy, rat hematopoietic tyrosine phosphatase localized to discrete, globular compartments within the cytoplasm and was not found either in the nucleus or associated with the cell surface membrane. Aggregation of high affinity IgE receptors in the mast cells induced tyrosine phosphorylation of the phosphatase. The tyrosine phosphorylation was mimicked by stimulation with calcium ionophore A23187 but not by direct activation of protein kinase C. Since phosphorylation of the phosphatase was dramatically reduced when the cells were activated in Ca2+ free media, it is dependent on a rise in intracellular Ca2+. These data strongly suggest that hematopoietic tyrosine phosphatase may be involved in the IgE receptor-mediated signaling cascade.			SWIETER, M (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM 1N1-6,BETHESDA,MD 20892, USA.							ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; EISEMAN E, 1992, NATURE, V355, P78; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1995, IN PRESS CELL SIGNAL; HOOK WA, 1991, J IMMUNOL, V147, P2670; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P4108; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIN PY, 1991, J IMMUNOL, V146, P1609; MANRO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; NISHIKATA H, 1992, J IMMUNOL, V149, P862; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Siraganian RP, 1986, MANUAL CLIN LABORATO, P675; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE KN, 1988, J IMMUNOL, V141, P942; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	46	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21902	21906		10.1074/jbc.270.37.21902	http://dx.doi.org/10.1074/jbc.270.37.21902			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545170	hybrid			2022-12-25	WOS:A1995RU75700074
J	BEBENEK, K; BEARD, WA; CASASFINET, JR; KIM, HR; DARDEN, TA; WILSON, SH; KUNKEL, TA				BEBENEK, K; BEARD, WA; CASASFINET, JR; KIM, HR; DARDEN, TA; WILSON, SH; KUNKEL, TA			REDUCED FRAMESHIFT FIDELITY AND PROCESSIVITY OF HIV-1 REVERSE-TRANSCRIPTASE MUTANTS CONTAINING ALANINE SUBSTITUTIONS IN HELIX-H OF THE THUMB SUBDOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; DNA; MISALIGNMENT; TERMINATION; POLYMERASE; MECHANISM; TEMPLATE	We have analyzed two human immunodeficiency virus (HIV-1) reverse transcriptase mutants of helix H in the thumb subdomain suggested by x-ray crystallography to interact with the primer strand of the template-primer. These enzymes, G262A and W266A, were previously shown to have greatly elevated dissociation rate constants for template-primer and to be much less sensitive to inhibition by 3'-azidodeoxythymidine 5'-triphosphate. Here we describe their processivity and error specificity. The results reveal that: (i) both enzymes have reduced processivity and lower fidelity for template-primer slippage errors, (ii) they differ from each other in sequence dependent termination of processive synthesis and in error specificity, and (iii) the magnitude of the mutator effect relative to wild-type enzyme for deletions in homopolymeric sequences decreases as the length of the run increases. Thus amino acid substitutions in a subdomain thought to interact with the duplex template-primer confer a strand slippage mutator phenotype to a replicative DNA polymerase. This suggests that interactions between specific amino acids and the primer stem at positions well removed from the active site are critical determinants of processivity and fidelity. These effects, obtained in aqueous solution during catalytic cycling, are consistent with and support the existing crystallographic structural model.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709; NIEHS,QUANTITAT & COMP BIOL LAB,RES TRIANGLE PK,NC 27709; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,STRUCT BIOCHEM PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BEENEK K, 1993, REVERSE TRNSCRIPTASE, P85; BONNER G, 1994, J BIOL CHEM, V269, P25129; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; CASASFINET JR, 1992, FASEB J, V6, pA486; DARDEN T, 1991, J MOL GRAPHICS, V9, P18, DOI 10.1016/0263-7855(91)80028-X; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LOEB LA, 1994, CANCER RES, V54, P5059; MEHTA CR, 1980, COMMUN STAT B-SIMUL, V9, P649, DOI 10.1080/03610918008812182; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	25	112	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19516	19523		10.1074/jbc.270.33.19516	http://dx.doi.org/10.1074/jbc.270.33.19516			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7543900				2022-12-25	WOS:A1995RP70300051
J	MAMAJIWALLA, SN; BURGESS, DR				MAMAJIWALLA, SN; BURGESS, DR			DIFFERENTIAL REGULATION OF THE ACTIVITY OF THE 42 KD MITOGEN-ACTIVATED PROTEIN-KINASE (P42(MAPK)) DURING ENTEROCYTE DIFFERENTIATION IN-VIVO	ONCOGENE			English	Article						MAP KINASE; INTESTINAL EPITHELIUM; DIFFERENTIATION	HUMAN-COLON-CARCINOMA; SERINE THREONINE KINASES; MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; GROWTH; CELLS; INSULIN; IDENTIFICATION; PHOSPHATASE	The family of mitogen activated protein (MAP) kinases appear to play a central role in relaying signals generated by receptor protein tyrosine kinases (RPTK) from the cell surface to the nucleus, We previously demonstrated that undifferentiated and mitotically active crypt cells have high levels of tyrosine phosphorylated proteins (DR Burgess, W Jiang, S Mamajiwalla and W Kinsey. 1989, J. Cell Biol., 109: 2139) possibly due to the activation of RPTKs and also have high pp60(mapk) protein tyrosine kinase activity (CA Cartwright, SN Mamajiwalla, SA Skolnik, W Eckhart and DR Burgess, 1993. Oncogene. 8: 1033) when compared to differentiated, non-mitotic villus cells. Since activation of RPTKs leading to cell proliferation or differentiation involves activation of the Ras-MAP kinase pathway, we chose to determine in this study if the activity of the MAP kinases were also regulated during differentiation of normal adult enterocytes. Our data show that although the 42 kD MAP kinase (p42(mapk)) was expressed in both crypt and villus cells, it was phosphorylated on tyrosine and active only in the crypt cells, Our data further suggest that p42(mapk) is inactivated during differentiation, possibly by a protein tyrosine phosphatase, Immunofluorescence studies revealed that p42(mapk) localized to the nuclei in both undifferentiated and differentiated enterocytes and colocalized with phosphotyrosine containing proteins at the region of the junctional complex, These results suggest that p42(mapk) and its regulators are tightly controlled during enterocyte differentiation in vivo and implicate p42(mapk) as a key regulatory molecule in the normal development of the epithelium.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031643] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CARRASCO D, 1993, CELL GROWTH DIFFER, V4, P849; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FATH KR, 1990, DEVELOPMENT, V109, P449; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Le Blond CP, 1976, STEM CELLS RENEWING, P7; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAMAJIWALLA SN, 1992, CURR TOP DEV BIOL, V26, P123, DOI 10.1016/S0070-2153(08)60443-3; MARIAN B, 1989, CANCER RES, V49, P4231; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARK JS, 1993, ONCOGENE, V8, P2627; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; POTTEN CS, 1982, CYTOTOXIC INSULT TIS, P105; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SMITH MW, 1991, CURR TOP MEMBR, V39, P153; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STIDWILL RP, 1986, DEV BIOL, V114, P381, DOI 10.1016/0012-1606(86)90202-2; STURGILL TW, 1991, METHOD ENZYMOL, V200, P342; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Wilson Clive, 1994, Trends in Cell Biology, V4, P409, DOI 10.1016/0962-8924(94)90094-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRIGHT N, 1973, GUT, V14, P701, DOI 10.1136/gut.14.9.701; WRIGHT NA, 1975, CELL TISSUE KINET, V8, P361, DOI 10.1111/j.1365-2184.1975.tb01500.x; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	65	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					377	386						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542764				2022-12-25	WOS:A1995RK95700018
J	STRAND, D; UNGER, S; CORVI, R; HARTENSTEIN, K; SCHENKEL, H; KALMES, A; MERDES, G; NEUMANN, B; KRIEGSCHNEIDER, F; COY, JF; POUSTKA, A; SCHWAB, M; MECHLER, BM				STRAND, D; UNGER, S; CORVI, R; HARTENSTEIN, K; SCHENKEL, H; KALMES, A; MERDES, G; NEUMANN, B; KRIEGSCHNEIDER, F; COY, JF; POUSTKA, A; SCHWAB, M; MECHLER, BM			A HUMAN HOMOLOG OF THE DROSOPHILA TUMOR-SUPPRESSOR GENE L(2)GL MAPS TO 17P11.2-12 AND CODES FOR A CYTOSKELETAL PROTEIN THAT ASSOCIATES WITH NONMUSCLE MYOSIN-II HEAVY-CHAIN	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; DROSOPHILA L(2)GL GENE; HUMAN CHROMOSOME 17; CYTOSKELETON; NONMUSCLE MYOSIN II	BREAST-CANCER; RECESSIVE ONCOGENE; OVARIAN-CARCINOMA; CHROMOSOME 17P; ALLELE LOSSES; P53 MUTATIONS; MELANOGASTER; EXPRESSION; EZRIN; DELETIONS	Inactivation of the tumour suppressor gene lethal(2) giant larvae (D-lgl) of Drosophila leads to malignant transformation of the presumptive adult optic centers in the larval brain and tumours of the imaginal discs. These from the disorganization of a in which the D-LGL protein participates. Here we describe the isolation of a cDNA encoding the human homologue to the D-lgl gene designated as hugl. The hugl cDNA detects a locus spanning at least 25 kilobases (kb) in human chromosome band 17p11.2-12, which is centromeric to the p53 gene and recognizes a 4.5 kb RNA transcript. The hugl gene is expressed in brain, kidney and muscle but is barely seen in heart and placenta. Sequence analysis of the hugl cDNA demonstrates a long open reading frame, which has the potential to encode a protein of 1057 amino acids with a predicted molecular weight of 115 kDaltons (kD). To further substantiate and identify the HUGL protein, we have prepared polyclonal rabbit antibodies against synthetic peptides corresponding to the amino and carboxyl termini of the conceptual translation product of the hugl gene. The affinity-purified anti-HUGL antibodies recognize a single protein with an apparent molecular weight of similar to 115 kD, Similar to the Drosophila protein, HUGL is part of a cytoskeletal network and, is associated with nonmuscle myosin II heavy chain and a kinase that specifically phosphorylates HUGL at serine residues.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT CYTOGENET, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT MOLEC GENOME ANAL, D-69120 HEIDELBERG, GERMANY; UNIV WURZBURG, INST MED RADIAT & CELL RES, D-97078 WURZBURG, GERMANY; MED CLIN 3, D-68305 MANNHEIM, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg	STRAND, D (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT DEV GENET, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							ADAMSON R, 1994, ONCOGENE, V9, P2077; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARDI G, 1993, INT J CANCER, V55, P422, DOI 10.1002/ijc.2910550317; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; BRIDGES CB, 1944, CARNEGIE I WASHINGTO, V522; Bryant Peter J., 1993, Trends in Cell Biology, V3, P31, DOI 10.1016/0962-8924(93)90147-S; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; ECCLES DM, 1990, ONCOGENE, V5, P1599; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GATEFF E, 1994, INT J DEV BIOL, V38, P565; GATEFF E, 1969, NATL CANCER I MONOGR, P365; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GOLUBOVSKY MD, 1980, GENETICA, V52-3, P139; Golubovsky MD, 1978, DROSOPH INF SERV, V53, P179; GREEN MM, 1979, GENETICS, V92, P823; GRIFFIN CA, 1988, CANCER RES, V48, P175; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; JOHANSSON M, 1994, INT J ONCOL, V5, P17; JONES E, 1994, GENE CHROMOSOME CANC, V11, P163, DOI 10.1002/gcc.2870110305; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LUTZELSCHWAB R, 1986, MOL GEN GENET, V204, P58, DOI 10.1007/BF00330187; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MECHLER B, 1990, CANCER SURV, V9, P505; MECHLER BM, 1994, J BIOSCIENCES, V19, P537; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MECHLER BM, 1990, TUMOR SUPPRESSOR GEN, P123; MERTENS F, 1994, GENE CHROMOSOME CANC, V10, P221, DOI 10.1002/gcc.2870100402; OPPER M, 1987, ONCOGENE, V1, P91; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RADFORD DM, 1993, CANCER RES, V53, P2947; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SATO N, 1992, J CELL SCI, V103, P131; SATO T, 1990, CANCER RES, V50, P7184; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STAND D, 1994, J CELL BIOL, V127, P1361; STRAND D, 1991, ADV ENZYME REGUL, V31, P339, DOI 10.1016/0065-2571(91)90022-E; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; TOROK I, 1993, ONCOGENE, V8, P1537; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSAO SW, 1991, ANTICANCER RES, V11, P1975; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	60	94	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					291	301						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542763				2022-12-25	WOS:A1995RK95700010
J	BUCK, V; ALLEN, KE; SORENSEN, T; BYBEE, A; HIJMANS, EM; VOORHOEVE, PM; BERNARDS, R; LATHANGUE, NB				BUCK, V; ALLEN, KE; SORENSEN, T; BYBEE, A; HIJMANS, EM; VOORHOEVE, PM; BERNARDS, R; LATHANGUE, NB			MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF E2F-5, A NEW MEMBER OF THE E2F FAMILY	ONCOGENE			English	Article						E2F; DP; TRANSCRIPTION FACTOR; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CYCLIN-A; BINDING PROTEIN; CLONING; COMPLEX; CDNA; P107; IDENTIFICATION; EXPRESSION	The transcription factor DRTF1/E2F is implicated in the control of cellular proliferation due to its interaction with key regulators of cell cycle progression, such as the retinoblastoma tumour suppressor gene product and related pocket proteins, cyclins and cyclin-dependent kinases. DRTF1/E2F DNA binding activity arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers. Here, we report the isolation and characterisation of a new member of the E2F family of proteins, called E2F-5. E2F-5 was isolated through a yeast two hybrid assay in which a 14.5 d.p.c. mouse embryo library was screened for molecules capable of binding to murine DP-1, but also interacts with all known members of the DP family of proteins. E2F-5 exists as a physiological heterodimer with DP-1 in the generic DRTF1/E2F DNA binding activity present in mammalian cell extracts, an interaction which results in co-operative DNA binding activity and transcriptional activation through the E2F site. A potent transcriptional activation domain, which functions in both yeast and mammalian cells and resides in the C-terminal region of E2F-5, is specifically inactivated upon pocket protein binding. Comparison of the sequence with other members of the family indicates that E2F-5 shows a greater level of similarity with E2F-4 than to E2F-1, -2 and -3. The structural and functional similarity of E2F-5 and E2F-4 defines a subfamily of E2F proteins.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; NETHERLANDS CANC INST,DIV MOLEC CARCINOGENESIS,1066 CX AMSTERDAM,NETHERLANDS	MRC National Institute for Medical Research; Netherlands Cancer Institute				Allen, Liz/0000-0001-8579-7730				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEIBERT SW, 1992, GENE DEV, V6, P177; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIJMANS EM, 1995, IN PRESS MOL CELL BI; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; NEVINS JR, 1992, SCIENCE, V258, P424; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	36	44	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					31	38						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7542760				2022-12-25	WOS:A1995RJ29500005
J	KAWAMURA, A; SU, MSS				KAWAMURA, A; SU, MSS			INTERACTION OF FKBP12-FK506 WITH CALCINEURIN-A AT THE B-SUBUNIT-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLOSPORINE-A; PROTEIN PHOSPHATASE; IMMUNOSUPPRESSIVE AGENT; CDNA CLONE; IDENTIFICATION; ACTIVATION; FK-506; RAPAMYCIN; COMPLEX; TARGET	Calcineurin is a calcium-dependent protein phosphatase that plays a pivotal role in antigen stimulated T cell activation, The complexes formed between the immunosuppressants cyclosporin A and FH506 and their respective intracellular binding proteins (immunophilins) block T cell activation by binding to calcineurin, Recent studies have shown that the immunophilin-immunosuppressant complexes interact with the latch region of the calcineurin B subunit (Milan, D,, Griffith, J,, Su, M., Price, E, R,, and McKeon, F, (1994) Cell 79, 437-447), Mutations in the B subunit-binding domain of the calcineurin A subunit result in a reduction of calcineurin activity that correlates with B binding affinity, Calcineurin A subunit mutants D348A, F350A, W352A, S353A, and E359A lost greater than 90% of their activity to activate the transcription factor NF kappa B in Jurkat T cells, Furthermore, calcineurin A subunit mutants of residues Thr(351), Leu(354) and Lys(360) showed NF kappa B transactivation activity and phosphatase activity with increased resistance to FKBP12-FK506 but displayed no or minimal increase in resistance for cyclosporin A inhibition, Together, these results strongly suggest that the E subunit-binding domain is required for calcineurin activity intracellularly and interacts with the FKBP12-FK506 complex.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COHEN DJ, 1984, ANN INTERN MED, V101, P667, DOI 10.7326/0003-4819-101-5-667; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HUSI H, 1994, J BIOL CHEM, V269, P14199; JAIN J, 1993, NATURE, V356, P801; KAHAN BD, 1991, TRANSPLANTATION, V52, P185, DOI 10.1097/00007890-199108000-00001; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1988, MOL ASPECTS CELL REG, V5, P225; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MURAMATSU T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P117, DOI 10.1016/0167-4889(93)90117-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; WATANABE UY, 1995, J BIOL CHEM, V270, P456; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8517	32	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15463	15466		10.1074/jbc.270.26.15463	http://dx.doi.org/10.1074/jbc.270.26.15463			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541044	hybrid			2022-12-25	WOS:A1995RG53800006
J	HEALEY, JF; LUBIN, IM; NAKAI, H; SAENKO, EL; HOYER, LW; SCANDELLA, D; LOLLAR, P				HEALEY, JF; LUBIN, IM; NAKAI, H; SAENKO, EL; HOYER, LW; SCANDELLA, D; LOLLAR, P			RESIDUES 484-508 CONTAIN A MAJOR DETERMINANT OF THE INHIBITORY EPITOPE IN THE A2 DOMAIN OF HUMAN FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBODY; POLYPEPTIDE; LOCALIZATION; MUTAGENESIS; FRAGMENTS; COMPLEXES; PROTEINS; BINDING	The A2 domain (residues 373-740) of human blood coagulation factor VIII (fVIII) contains a major epitope for inhibitory alloantibodies and autoantibodies. We took advantage of the differential reactivity of inhibitory antibodies with human and porcine fVIII and mapped a major determinant of the A2 epitope by using a series; of active recombinant hybrid human/porcine fVIII molecules. Hybrids containing a substitution of porcine sequence at segment 410-508, 445-508, or 484-508 of the human A2 domain were not inhibited by a murine monoclonal antibody A2 inhibitor, mAb 413, whereas hybrids containing substitutions at 387-403, 387-444, and 387-468 were inhibited by mAb 413, This indicates that the segment bounded by Arg(484) and Ile(508) contains a major determinant of the A2 epitope. mAb 413 did not inhibit two more hybrids that contained porcine substitutions at residues 484-488 and 489-508, indicating that amino acid side chains on both sides of the Ser(488)-Arg(489) band within the Arg(484)-Ile(508) segment contribute to the A2 epitope. The 484-508, 484-488, and 489-508 porcine substitution hybrids displayed decreased inhibition by A2 inhibitors from four patient plasmas, suggesting that there is little variation in the structure of the A2 epitope in the inhibitor population.	EMORY UNIV,ATLANTA,GA 30322; AMER RED CROSS,HOLLAND LAB,ROCKVILLE,MD 20855	Emory University; American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215, P50HL044336] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36094, R01-HL46215, P50-HL44336] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BOWIE EJW, 1984, DISORDERS HEMOSTASIS, P43; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; FULCHER CA, 1985, P NATL ACAD SCI USA, V82, P7728, DOI 10.1073/pnas.82.22.7728; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; NAKAI H, 1994, BLOOD, V84, P59; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCANDELLA D, 1989, BLOOD, V74, P1618; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1993, BLOOD, V82, P1767; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; WARE J, 1992, BLOOD COAGUL FIBRIN, V3, P703, DOI 10.1097/00001721-199212000-00002; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	30	120	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14505	14509		10.1074/jbc.270.24.14505	http://dx.doi.org/10.1074/jbc.270.24.14505			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540171	hybrid			2022-12-25	WOS:A1995RD45500043
J	MULDERS, SM; PRESTON, GM; DEEN, PMT; GUGGINO, WB; VANOS, CH; AGRE, P				MULDERS, SM; PRESTON, GM; DEEN, PMT; GUGGINO, WB; VANOS, CH; AGRE, P			WATER CHANNEL PROPERTIES OF MAJOR INTRINSIC PROTEIN OF LENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; XENOPUS-OOCYTES; BOVINE LENS; CELL; EXPRESSION; GENE; MOUSE; MIP; RECONSTITUTION; LIPOSOMES	The functions of major intrinsic protein (MIP) of lens are still unresolved; however the sequence homology with channel-forming integral membrane protein (CHIP) and other Aquaporins suggests that MIP is a water channel. Immunolocalizations confirmed that Xenopus oocytes injected with bovine MIP cRNA express the protein and target it to the plasma membrane. Control oocytes or oocytes expressing MIP or CHIP exhibited small, equivalent membrane currents that could be reversibly increased by osmotic swelling. When compared with water-injected control oocytes, the coefficient of osmotic water permeability (P-f) of MIP oocytes was increased 4-5-fold with a low Arrhenius activation energy, while the P-f of CHIP oocytes increased > 30-fold. To identify structures responsible for these differences in P-f recombinant MIP proteins were expressed. Analysis ysis of MIP CHIP chimeric proteins revealed that the 4-kDa cytoplasmic domain of MIP did not behave as a negative regulator. Individual residues in MIP were replaced by residues conserved among the Aquaporins, and introduction of a proline in the 5th transmembrane domain of MIP raised the P-f by 50%. Thus oocytes expressing MIP failed to exhibit ion channel activity and consistently exhibited water transport by a facilitated pathway that was qualitatively similar to the Aquaporins but of lesser magnitude. We conclude that MIP functions as an Aquaporin in lens, but the protein may also have other essential functions.	UNIV NIJMEGEN, DEPT CELL PHYSIOL, 6500 HB NIJMEGEN, NETHERLANDS; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Radboud University Nijmegen; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Deen, P.M.T./H-8023-2014; Deen, Peter MT/B-9854-2013	Deen, P.M.T./0000-0002-7868-4655; Deen, Peter MT/0000-0002-7868-4655	NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048268, R01HL048268, R01HL033991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARIK S, 1991, BIOTECHNIQUES, V10, P489; CHANDY G, 1995, BIOPHYS J, V68, P353; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; Finkelstein A., 1987, WATER MOVEMENT LIPID; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GIRSCH SJ, 1985, J MEMBRANE BIOL, V83, P217, DOI 10.1007/BF01868696; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GRIFFIN CS, 1992, CYTOGENET CELL GENET, V59, P300, DOI 10.1159/000133274; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, J BIOL CHEM, V269, P14648; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KUSHMERICK C, 1994, BIOPHYS J, V66, pA215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1990, EUR J BIOCHEM, V194, P541, DOI 10.1111/j.1432-1033.1990.tb15650.x; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MA TH, 1994, J BIOL CHEM, V269, P21845; MATHIAS RT, 1979, BIOPHYS J, V25, P181, DOI 10.1016/S0006-3495(79)85284-4; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MICHEA LF, 1994, BIOCHEMISTRY-US, V33, P7663, DOI 10.1021/bi00190a021; MUGGLETONHARRIS AL, 1987, GENET RES, V49, P235, DOI 10.1017/S0016672300027129; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1931, J CELL BIOL, V120, P120; NIKAIDO H, 1985, J MEMBRANE BIOL, V85, P87, DOI 10.1007/BF01872008; Peracchia C, 1989, Lens Eye Toxic Res, V6, P613; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Sambrook J, 1989, MOL CLONING LABORATO; SHEN L, 1991, J MEMBRANE BIOL, V124, P21, DOI 10.1007/BF01871361; SHIELS A, 1993, CURR EYE RES, V12, P913, DOI 10.3109/02713689309020398; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; VERBAVATZ JM, 1994, J CELL SCI, V107, P1083; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; WEAVER CD, 1994, J BIOL CHEM, V269, P17858; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZHANG R, 1990, J BIOL CHEM, V265, P15375	50	194	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					9010	9016		10.1074/jbc.270.15.9010	http://dx.doi.org/10.1074/jbc.270.15.9010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7536742	Green Published, hybrid			2022-12-25	WOS:A1995QT44800092
J	TOYAMASORIMACHI, N; SORIMACHI, H; TOBITA, Y; KITAMURA, F; YAGITA, H; SUZUKI, K; MIYASAKA, M				TOYAMASORIMACHI, N; SORIMACHI, H; TOBITA, Y; KITAMURA, F; YAGITA, H; SUZUKI, K; MIYASAKA, M			A NOVEL LIGAND FOR CD44 IS SERGLYCIN, A HEMATOPOIETIC-CELL LINEAGE-SPECIFIC PROTEOGLYCAN - POSSIBLE INVOLVEMENT IN LYMPHOID-CELL ADHERENCE AND ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MOUSE MAST-CELL; SECRETORY GRANULE PROTEOGLYCAN; HYALURONIC-ACID BINDING; INVARIANT-CHAIN; CORE PROTEIN; MOLECULAR-CLONING; HOMING RECEPTOR; LYMPHOCYTES-T; PEPTIDE CORE	The lymphocyte adhesion molecule CD44 recognizes a non-hyaluronate proteoglycan, gp600, secreted by mouse T cell line CTLL2. We now demonstrate that gp600 is identical to serglycin, a member of the small proteoglycan family stored in intracellular secretory granules of lymphoid, myeloid, and some tumor cells. Purified gp600 has the ability to bind specifically to CD44, and the binding is dependent on activation of CD44. The CD44-binding elements on gp600 or serglycin are glycosaminoglycans consisting of chondroitin 4-sulfate. Serglycin is readily exocytosed, and its interaction with active form CD44 augments the CDS dependent degranulation of CD44 positive CTL clones. We conclude that the serglycin secreted from secretory granules of hematopoietic cells is a novel ligand for CD44, and could regulate lymphoid cell adherence and activation.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,DEPT BIOL MOLEC,MOLEC STRUCT & FUNCT LAB,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT BIOREGULAT,OSAKA 565,JAPAN; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,OSAKA 565,JAPAN	University of Tokyo; Osaka University; Juntendo University	TOYAMASORIMACHI, N (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT IMMUNOL,BUNKYO KU,3-18-22 HON KOMAGOME,TOKYO 113,JAPAN.		Sorimachi, Hiroyuki/C-6448-2009; Miyasaka, Masayuki/AAM-6343-2020	Sorimachi, Hiroyuki/0000-0001-9509-6727; 				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DENNING SM, 1990, J IMMUNOL, V144, P7; GALANDRINI R, 1993, J IMMUNOL, V150, P4225; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; HYMAN R, 1991, IMMUNOGENETICS, V33, P392, DOI 10.1007/BF00216699; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; KARASUYAMA H, 1989, J EXP MED, V169, P13, DOI 10.1084/jem.169.1.13; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LEVITT D, 1986, CELL IMMUNOL, V98, P78, DOI 10.1016/0008-8749(86)90269-8; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; MASSON D, 1990, BIOCHEMISTRY-US, V29, P11229, DOI 10.1021/bi00503a011; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; RAZIN E, 1984, J IMMUNOL, V132, P1479; RAZIN E, 1982, J BIOL CHEM, V257, P7229; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANT AJ, 1985, J IMMUNOL, V135, P416; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SETH A, 1991, P NATL ACAD SCI USA, V88, P7877, DOI 10.1073/pnas.88.17.7877; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STEVENS RL, 1985, J BIOL CHEM, V260, P4194; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; STEVENS RL, 1988, CURR TOP MICROBIOL I, V140, P93; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; TOYAMASORIMACHI N, 1993, EUR J IMMUNOL, V23, P439, DOI 10.1002/eji.1830230221; TOYAMASORIMACHI N, 1994, INT IMMUNOL, V6, P655, DOI 10.1093/intimm/6.4.655; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	50	165	171	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7437	7444		10.1074/jbc.270.13.7437	http://dx.doi.org/10.1074/jbc.270.13.7437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535771	hybrid			2022-12-25	WOS:A1995QQ43100064
J	SHEPPARD, AM; MCQUILLAN, JJ; IADEMARCO, MF; DEAN, DC				SHEPPARD, AM; MCQUILLAN, JJ; IADEMARCO, MF; DEAN, DC			CONTROL OF VASCULAR CELL-ADHESION MOLECULE-1 GENE PROMOTER ACTIVITY DURING NEURAL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTEGRIN VLA-4; TRANSCRIPTION FACTORS; EMBRYONIC-CELLS; VCAM-1; PROTEIN; SUBUNIT; DNA; LYMPHOCYTES; ACTIVATION	Here we demonstrate that vascular cell adhesion molecule-1 (VCAM-1) is expressed in the developing central nervous system on neuroepithelial cells, which are the precursors of neurons and glia. As these cells differentiate, VCAM-1 is restricted to a subset of the glial population. An understanding of mechanisms responsible for this restricted pattern could provide insights into how lineage-specific gene expression is maintained during neural differentiation. As a model of neural differentiation, we turned to the P19 embryonic carcinoma cell line, which in response to retinoic acid will differentiate along a neural pathway. We show that VCAM-1 expression on the differentiating P19 cells resembles that in the central nervous system. Transfection of VCAM-1 gene promoter constructs into P19 cells revealed that the VCAM-1 gene is controlled sequentially by negative and positive elements during differentiation. We present evidence that early during differentiation, POU proteins block VCAM-1 gene activity; however, later in differentiation coincident with the appearance of VCAM-1 the pattern of POU proteins changes and the VCAM-1 gene promoter is activated. This activation is mediated through the NF kappa B/rel complex p50/p65, which forms during P19 cell differentiation.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317, R01HL043418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43418, HL07317] Funding Source: Medline; NIAMS NIH HHS [AR41908] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EASTER SS, 1993, J NEUROSCI, V13, P285; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FREEDMAN AS, 1991, SCIENCE, V249, P1030; GILBERT SF, 1988, DEV BIOL, P156; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HIRANO M, 1988, J NEUROSCI RES, V21, P155, DOI 10.1002/jnr.490210208; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; MISSON JP, 1987, DEV BRAIN RES, V38, P183; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1991, SCIENCE, V253, P144, DOI 10.1126/science.1853199; ROSNER MH, 1990, NATURE, V344, P686; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEEREN RA, 1991, EUR J IMMUNOL, V21, P1101, DOI 10.1002/eji.1830210503; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SHEPPARD AM, 1994, CELL ADHES COMMUN, V1, P27; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WASSERMAN SA, 1993, MOL BIOL CELL, V8, P767; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I	47	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3710	3719		10.1074/jbc.270.8.3710	http://dx.doi.org/10.1074/jbc.270.8.3710			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533155	hybrid			2022-12-25	WOS:A1995QH68800040
J	CHANTRY, A				CHANTRY, A			THE KINASE DOMAIN AND MEMBRANE LOCALIZATION DETERMINE INTRACELLULAR INTERACTIONS BETWEEN EPIDERMAL GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; TYROSINE KINASES; TRANSMEMBRANE DOMAIN; INSULIN-RECEPTORS; EGF RECEPTOR; SH2 DOMAINS; PROTEIN; TRANSPHOSPHORYLATION; PHOSPHORYLATION; OLIGOMERIZATION	Receptor tyrosine kinases play a central role in cellular growth, differentiation, and oncogenesis. Ah of these responses are triggered by growth factors interacting with the extracellular domain of transmembrane-spanning receptors, leading to dimerization and activation of an intrinsic tyrosine specific kinase activity by an allosteric mechanism. Precise mechanisms of receptor dimerization remain poorly understood, and current models suggest that the ligand binding domain plays a major determining role. To examine the role of the in tracellular domain in the association of juxtaposing receptor molecules, the full-length epidermal growth factor receptor was transiently co-expressed in human 293 fibroblasts with a truncated receptor that lacks the extracellular domain. After metabolic labeling with [S-35]methionine, the association of these receptor constructs was monitored by co-immunoprecipitation with an extracellular domain-specific antibody. Specific interactions found between these receptors were independent of ligand binding or an intact ATP-binding site. Truncated receptors that had sequences necessary for membrane localization, and that were capable of interacting with full-length receptor tyrosine kinase, also displayed constitutive kinase activity as well as the capacity to transphosphorylate kinase-negative receptors. Receptor co-immunoprecipitation occurred between constructs that comprise the intracellular domains of the epidermal growth factor and beta-platelet-derived growth factor receptors, and HER-2. Subsequent deletion analysis has identified the major region of epidermal growth factor receptor intracellular interaction to be within the kinase domain.	CHARING CROSS & WESTMINSTER MED SCH,DEPT MED ONCOL,LONDON W6 8RP,ENGLAND	Imperial College London	CHANTRY, A (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,FULHAM PALACE RD,LONDON W6 8RP,ENGLAND.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENDLY BM, 1990, CANCER RES, V50, P1550; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; KWATRA MM, 1992, BIOCHIM BIOPHYS ACTA, V1134, P178, DOI 10.1016/0167-4889(92)90042-A; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P13828; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; TARTARE S, 1991, J BIOL CHEM, V266, P13828; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	33	74	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3068	3073						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531698				2022-12-25	WOS:A1995QG47100029
J	DIBRINO, M; PARKER, KC; MARGULIES, DH; SHILOACH, J; TURNER, RV; BIDDISON, WE; COLIGAN, JE				DIBRINO, M; PARKER, KC; MARGULIES, DH; SHILOACH, J; TURNER, RV; BIDDISON, WE; COLIGAN, JE			THE HLA-B14 PEPTIDE BINDING-SITE CAN ACCOMMODATE PEPTIDES WITH DIFFERENT COMBINATIONS OF ANCHOR RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LYMPHOCYTE-T RECOGNITION; INFLUENZA-VIRUS PROTEINS; ENDOGENOUS PEPTIDES; MATRIX PEPTIDE; VIRAL PEPTIDES; CELL EPITOPES; MHC; MOLECULES; ANTIGEN	Most peptides that bind to a particular major histocompatibility complex class I molecule share amino acid residues important for binding at one or two positions. Sequence analyses of peptides bound to HLA-B14 revealed at least four candidates for these so-called anchor residues: Arg at P2, Tyr at P3, Arg at P5, and Leu at P9. Combinations of any three of these amino acids sufficed for binding to HLA-B14 in vitro. Using this information, we identified an antigenic peptide critical for cytotoxic T lymphocyte recognition of virus-infected cells. Molecular models of HLA-B14 peptide complexes were constructed to investigate how the potential anchor residues might function. By using binding data to calculate the contribution to binding of each amino acid at anchor positions and predicting the stability of all possible nonapeptide complexes that could be formed from antigenic proteins, we estimate that three known antigenic nonapeptides are in the highest affinity cohort of peptides, Thus, even when multiple combinations of anchor residues contribute to binding, antigenic peptides are routinely identifiable.	NIAID, MOLEC STRUCT LAB, BETHESDA, MD 20892 USA; NIAID, IMMUNOL LAB, MOLEC BIOL SECT, BETHESDA, MD 20892 USA; NIDDK, CELLULAR & DEV BIOL LAB, BETHESDA, MD 20892 USA; NINCDS, NEUROIMMUNOL BRANCH, MOLEC IMMUNOL SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Margulies, David/0000-0001-8530-7375; Parker, Kenneth/0000-0002-6282-2478				BENNINK JR, 1988, J EXP MED, V168, P1935, DOI 10.1084/jem.168.5.1935; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOVIER M, 1994, SCIENCE, V265, P398; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1993, J IMMUNOL, V151, P5930; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906; FALK K, 1993, P NATL ACAD SCI USA, V90, P12005, DOI 10.1073/pnas.90.24.12005; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOGAN KT, 1988, J EXP MED, V168, P725, DOI 10.1084/jem.168.2.725; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOHNSON RP, 1992, J EXP MED, V175, P961, DOI 10.1084/jem.175.4.961; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KOENIG S, 1993, J IMMUNOL, V151, P3874; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PARHAM P, 1979, J IMMUNOL, V123, P342; PARKER KC, 1992, J BIOL CHEM, V267, P5451; PARKER KC, 1992, J IMMUNOL, V149, P1896; PARKER KC, 1994, J IMMUNOL, V152, P163; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WINTER CC, 1991, J IMMUNOL, V146, P3508; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; ZEMMOUR J, 1991, HUM IMMUNOL, V31, P195, DOI 10.1016/0198-8859(91)90026-6; ZHANG QJ, 1993, P NATL ACAD SCI USA, V90, P2217, DOI 10.1073/pnas.90.6.2217	46	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32426	32434						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528217				2022-12-25	WOS:A1994PX30400062
J	REICHSLOTKY, R; BONNEHBARKAY, D; SHAOUL, E; BLUMA, B; SVAHN, CM; RON, D				REICHSLOTKY, R; BONNEHBARKAY, D; SHAOUL, E; BLUMA, B; SVAHN, CM; RON, D			DIFFERENTIAL EFFECT OF CELL-ASSOCIATED HEPARAN SULFATES ON THE BINDING OF KERATINOCYTE GROWTH-FACTOR (KGF) AND ACIDIC FIBROBLAST GROWTH-FACTOR TO THE KGF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; EXTRACELLULAR-MATRIX; MESSENGER-RNA; FACTOR FAMILY; FGF RECEPTOR; BASIC-FGF; SPECIFICITY; LIGAND; EXPRESSION; PROTEINS	The fibroblast growth factors (FGFs) act through high affinity tyrosine kinase receptors and, in addition, interact with lower affinity receptors that represent cellor matrix-associated heparan sulfate proteoglycans. These lower affinity receptors modulate the biological activities of FGFs, but the mechanism by which they exert these effects is rather controversial. We have previously shown (Ron, D., Bottaro, D. P., Finch, P. W., Morris, D., Rubin, J. S., and Aaronson, S. A. (1993) J. Biol. Chem, 268, 2984-2988) that heparin potentiates the mitogenic activity of acidic FGF (aFGF) but inhibits that of the keratinocyte growth factor (HGF) in cells that express the KGF receptor (KGFR). Both growth factors bind the KGFR with high affinity, To gain an insight into the mechanism by which heparin modulates the biological activity of aFGF and KGF, we studied the effect of heparin and cell-associated heparan sulfates on the binding of these two growth factors to the KGFR, To work in a well defined system, we expressed functional KGFR in L6E9 myoblasts that lack detectable high affinity binding sites for FGFs, Low concentrations of heparin inhibited the binding of KGF to the KGFR. By contrast, similar concentrations of heparin enhanced the binding of aFGF to this receptor, The effect of heparin was not unique to L6E9 cells expressing the KGFR; it was also observed in Balb/MK cells that naturally express KGFR. Treatment of cells with sodium chlorate, which blocks sulfation of proteoglycans, reduced the binding of aFGF to its low and high affinity binding sites by 95 and 80%, respectively. In contrast, the binding of KGF to its high affinity binding sites was enhanced about S-fold, Similar results were obtained after degradation of cell-associated heparan sulfates by heparinase and heparitinase. Heparin restored the high affinity binding of aFGF to chlorate-treated cells and completely abolished the high affinity binding of KGF, Binding competition experiments suggest that aFGF and KGF bind to the same population of cell-associated heparan sulfates, In addition, KGF is apparently interacting with an as yet unidentified type of low affinity binding site that is not affected by chlorate or heparan sulfate-degrading enzymes. An important property of the FGF high affinity receptors is their ability to bind more than one ligand with high affinity, Based on the differential effect of cell-associated heparan sulfates on the binding of KGF and aFGF to the KGFR, we propose a regulatory role for cell-associated heparan sulfates as coordinators of the interaction of aFGF and KGF with the KGFR, Such a regulatory mechanism may be important for the coordination of cellular responses to KGF and aFGF.	TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL; KABI PHARM, S-11287 STOCKHOLM, SWEDEN	Technion Israel Institute of Technology								ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CORDONCARDO C, 1990, LAB INVEST, V63, P832; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPADAROWICZ D, 1990, J CLIN ORTHOPED RELA, V58, P231; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, P NATL ACAD SCI USA, V89, P3315, DOI 10.1073/pnas.89.8.3315; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1994, IN PRESS J ENDOCRINO; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YUEN S, 1991, METHOD ENZYMOL, V198, P91	58	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32279	32285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528211				2022-12-25	WOS:A1994PX30400042
J	YEE, NS; HSIAU, CWM; SERVE, H; VOSSELLER, K; BESMER, P				YEE, NS; HSIAU, CWM; SERVE, H; VOSSELLER, K; BESMER, P			MECHANISM OF DOWN-REGULATION OF C-KIT RECEPTOR - ROLES OF RECEPTOR TYROSINE KINASE, PHOSPHATIDYLINOSITOL 3'-KINASE, AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; LIGAND-INDUCED INTERNALIZATION; FACTOR BETA-RECEPTOR; FACTOR-I RECEPTOR; STEM-CELL FACTOR; MAST-CELLS; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; EGF RECEPTOR; W-LOCUS	The receptor tyrosine kinase Kit and Hit ligand (KL), encoded at the murine white spotting (W) and steel (SI) loci, respectively, function in hematopoiesis, melanogenesis, and gametogenesis. To understand the mechanism of turnover of Bit in mast cells, mutant receptors generated in vitro were heterologously expressed in W-sh/W-sh mast cells lacking endogenous c-kit expression, and the effects of mutations on KL-induced internalization and ubiquitination/degradation of Kit were studied. Upon binding of KL, KL-Kit receptor complexes were rapidly internalized, and the turnover was accelerated by ubiquitin-mediated degradation. Inactivation of the Kit kinase resulted in a reduced rate of internalization of KL-Kit complexes, degradation of kinase-inactive receptor complexes was relatively slow, and receptor ubiquitination was absent. But abolishment of Kt induced receptor association and activation of phosphatidylinositol 3'-kinase and of tyrosine 821 autophosphorylation did not affect KL-induced internalization and ubiquitination/degradation of Kit. Furthermore, Kit receptors can be down-regulated by proteolytic cleavage induced by either activation of protein kinase C or by isopropyl alcohol. In summary, KL-induced internalization of ICL Kit complexes and ubiquitination/degradation require an active kinase. By contrast, proteolytic cleavage of Kit mediated by protein kinase C activation is independent of kinase activity.	SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [R37 CA 32926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA032926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DASTYCH J, 1994, J IMMUNOL, V152, P213; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P354; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOIKE T, 1993, J IMMUNOL, V151, P359; KONG SK, 1992, J BIOL CHEM, V267, P14189; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; MORI S, 1994, J BIOL CHEM, V269, P4917; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SERVE H, 1994, J BIOL CHEM, V269, P6026; SHIEH JH, 1991, J IMMUNOL, V146, P2648; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TONO T, 1992, BLOOD, V80, P1448; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	48	134	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31991	31998						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527401				2022-12-25	WOS:A1994PX30300100
J	FORD, CE; FURLONG, MT; GEAHLEN, RL; HARRISON, ML				FORD, CE; FURLONG, MT; GEAHLEN, RL; HARRISON, ML			SIGNALING-INDUCED ASSOCIATION OF A TYROSINE-PHOSPHORYLATED 36-KDA PROTEIN WITH P50(CSK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SRC FAMILY KINASES; PHOSPHATASE INHIBITOR; LYMPHOCYTES-T; ACTIVATION; CSK; TRANSDUCTION; PERVANADATE; EXPRESSION; PLATELETS	The protein-tyrosine kinase, p50(csk), is thought to participate in the regulation of signal transduction pathways by catalyzing the phosphorylation of the Src-related protein-tyrosine kinases on a negative regulatory tyrosine residue located near the COOH terminus. To study possible mechanisms by which the activity of p50(csk) might be regulated, we searched for p50(csk)-interacting proteins in human erythroleukemia cells. We found that in response to the treatment of cells with pervanadate, a potent inhibitor of protein tyrosine phosphatases, or to the cross-linking of Fc gamma RIIA receptors, p50(csk) becomes tightly associated with a 36-kDa protein (p36). This association is dependent on the tyrosine phosphorylation of p36 and involves its interaction with the SH2 domain of p50(csk). p36 can be phosphorylated in vitro by p50(csk) or by a full-length GST-Csk fusion protein expressed in Escherichia coli. Tyrosine-phosphorylated p36 is found exclusively in the particulate membrane fraction of the cell. Conditions that induce the formation of the p50(csk) p36 complex promote the appearance of p50(csk) in the particulate fraction. These data suggest that the association between p50(csk) and p36 serves to translocate the normally cytosolic p50(csk) to the membrane, where it presumably interacts with its physiologically relevant substrates.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NIDCD NIH HHS [1F31DC00152] Funding Source: Medline; NIGMS NIH HHS [GM48099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F31DC000152] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOUGERET C, 1993, ONCOGENE, V8, P1241; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EISEMAN E, 1992, NATURE, V355, P78; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KING M, 1992, EXP HEMATOL, V20, P576; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OETKEN C, 1994, ONCOGENE, V9, P1625; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1991, ONCOGENE, V6, P683; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	50	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30378	30385						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527029				2022-12-25	WOS:A1994PU52500054
J	BISCHOF, O; URLAUB, H; KRUFT, V; WITTMANNLIEBOLD, B				BISCHOF, O; URLAUB, H; KRUFT, V; WITTMANNLIEBOLD, B			PEPTIDE ENVIRONMENT OF THE PEPTIDYL TRANSFERASE CENTER FROM ESCHERICHIA-COLI 70-S RIBOSOMES AS DETERMINED BY THERMOAFFINITY LABELING WITH DIHYDROSPIRAMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-RIBOSOMES; BINDING-SITE; SUBUNIT; RNA; ERYTHROMYCIN; COMPONENTS; ANTIBIOTICS; PROTEINS; MODEL	In an attempt to gain information about the peptidyl transferase center at the peptide level we cross-linked the spiramycin derivative dihydrospiramycin to its functional binding site in the 70 S ribosome of Escherichia coli, In this manner ribosomal proteins S12, S14, L17, L18, L27 and L35 were found specifically affinity-labeled, Proteolytic fragmentation of these proteins, separation by C-18 reversed-phase high performance liquid chromatography of the peptide mixtures, and subsequent sequence analysis of labeled peptides revealed peptide regions at positions Ala(1)-Lys(9) and Tyr(116)-Lys(119) of S12, Leu(47)-Asp(53) of protein S14, Ser(6)-Lys(35) of protein L17, Ala(57)-Lys(63) of protein L18, Ala(5)-Lys(18) and Val(66)- Lys(71) of protein L27, and Thr(5)-Lys(11) of protein L35. This approach is a valuable tool to characterize the binding site of spiramycin as well as the peptidyl transferase center at the molecular level.	MAX DELBRUCK CENTRUM MOLEK MED,PROT CHEM ABT,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Bischof, Oliver/K-1548-2019					ALEXANDER RW, 1994, BIOCHEMISTRY-US, V33, P12109, DOI 10.1021/bi00206a014; AREVALO MA, 1988, J BIOL CHEM, V263, P58; BISCHOF O, 1994, J BIOL CHEM, V269, P18315; BRIMACOMBE R, 1990, RIBOSOME, P93; BROCKMOLLER J, 1986, BIOL CHEM H-S, V367, P925, DOI 10.1515/bchm3.1986.367.2.925; BROSIUS J, 1975, FEBS LETT, V56, P359, DOI 10.1016/0014-5793(75)81127-6; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CHEN R, 1975, FEBS LETT, V59, P96, DOI 10.1016/0014-5793(75)80349-8; CONTRERAS A, 1977, EUR J BIOCHEM, V74, P539, DOI 10.1111/j.1432-1033.1977.tb11422.x; COOPERMAN BS, 1990, RIBOSOME STRUCTURE F, P123; CUNDLIFFE E, 1990, RIBOSOME, P479; DINOS G, 1993, BIOCHEMISTRY-US, V32, P10638, DOI 10.1021/bi00091a014; FUNATSU G, 1977, FEBS LETT, V73, P12, DOI 10.1016/0014-5793(77)80004-5; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HOGENAUER G, 1981, BIOCHEMISTRY-US, V20, P546; KAMP RM, 1986, ADV METHODS PROTEIN, P8; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MONRO RE, 1969, COLD SPRING HARB SYM, V34, P357, DOI 10.1101/SQB.1969.034.01.042; OAKES MI, 1990, RIBOSOME, P180; ROMBAUTS W, 1982, FEBS LETT, V149, P320, DOI 10.1016/0014-5793(82)81124-1; SACERDOT C, 1982, EMBO J, V1, P311, DOI 10.1002/j.1460-2075.1982.tb01166.x; SALTZMAN L, 1976, MOL GEN GENET, V143, P301, DOI 10.1007/BF00269407; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STOFFLERMEILICK.M, 1990, RIBOSOME STRUCTURE F, P123; TEJEDOR F, 1986, BIOCHEMISTRY-US, V25, P7725, DOI 10.1021/bi00371a066; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; URLAUB H, 1995, EMBO J, V14, P101; VAZQUEZ D, 1979, INHIBITORS PROTEIN S, P120; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; WOWER J, 1993, TRANSLATIONAL APPARATUS, P455; YAGUCHI M, 1975, FEBS LETT, V59, P217, DOI 10.1016/0014-5793(75)80378-4	31	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23060	23064		10.1074/jbc.270.39.23060	http://dx.doi.org/10.1074/jbc.270.39.23060			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559446	hybrid			2022-12-25	WOS:A1995RY05400066
J	SCHEIDEGGER, EP; STERNBERG, LR; ROTH, J; LOWE, JB				SCHEIDEGGER, EP; STERNBERG, LR; ROTH, J; LOWE, JB			A HUMAN STX CDNA CONFERS POLYSIALIC ACID EXPRESSION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADHESION MOLECULES; GENE FAMILY; NCAM; CLONING; UNITS; BRAIN; RAT; SIALYLTRANSFERASE; GLYCOPROTEINS; BIOSYNTHESIS	Polysialic acid, or PSA, is a term used to refer to linear homopolymers of alpha(2,8)-sialic acid residues displayed at the surface of some mammalian cells. PSA is typically linked to the neural cell adhesion molecule N-CAM, where it can modulate the homotypic adhesive properties of this polypeptide. PSA expression is developmentally regulated, presumably through mechanisms involving regulated expression of sialyltransferases involved in PSA biosynthesis. Several different sialyltransferase sequences have been implicated in PSA expression, although the precise roles of these enzymes in this context remain unclear. One such sequence, termed STX, maintains approximately 59% amino acid sequence identity with another sialyltransferase (PST-1, from hamster; PST, human) that is known to participate in PSA expression. While a murine STX fusion protein can catalyze the synthesis of a single alpha(2,8)-sialic acid linkage in vitro, the ability of STX to participate in PSA expression in vivo has not been demonstrated. We show here that STX transcripts are present in a PSA-positive, N-CAM-positive human small cell carcinoma line (NCI H69/F3), but are absent in a variant of this line (NCI-H69/E2) selected to be PSA-negative and N-CAM-positive. To functionally confirm this correlation, we have cloned a human cDNA encoding the human STX sequence,and show, transfection studies, that human STX can restore PSA expression when expressed in the PSA-negative, NCAM-positive small cell carcinoma variant. We furthermore show that STX can confer PSA expression when expressed in a PSA-negative, N-CAM-positive murine cell line (NIH-3T3 cells), or when expressed in PSA-negative, N-CAM-negative COS-7 cells. These observations imply that STX, like PST-1/PST, can determine PSA expression in vivo. When considered together with the correlation between STX expression and PSA expression in vivo in the brain, these results suggest a regulatory role for STX in PSA expression in the developing central nervous system and small cell lung carcinoma.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV ZURICH HOSP,DEPT PATHOL,DIV CELL & MOLEC PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Michigan System; University of Michigan; University of Zurich; University Zurich Hospital	SCHEIDEGGER, EP (corresponding author), UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,MSRBI,RM 3510,1150 W MED CTR DR,ANN ARBOR,MI 48109, USA.							ACHESON A, 1988, J CELL BIOL, V106, P479, DOI 10.1083/jcb.106.2.479; ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREEN KC, 1985, DEVELOPMENT, V104, P147; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DECHASEVAL R, 1991, NUCLEIC ACIDS RES, V20, P245; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FINNE J, 1982, J BIOL CHEM, V257, P1966; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P898; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; LACKIE PM, 1994, DIFFERENTIATION, V57, P119, DOI 10.1046/j.1432-0436.1994.5720119.x; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NYBROE O, 1988, NEUROCHEM INT, V12, P251, DOI 10.1016/0197-0186(88)90162-3; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI K, 1994, J BIOL CHEM, V22, P15950; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; ZUBER C, 1992, J BIOL CHEM, V267, P9965	36	144	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22685	22688		10.1074/jbc.270.39.22685	http://dx.doi.org/10.1074/jbc.270.39.22685			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559389	hybrid			2022-12-25	WOS:A1995RY05400009
J	SCHNAPP, LM; HATCH, N; RAMOS, DM; KLIMANSKAYA, IV; SHEPPARD, D; PYTELA, R				SCHNAPP, LM; HATCH, N; RAMOS, DM; KLIMANSKAYA, IV; SHEPPARD, D; PYTELA, R			THE HUMAN INTEGRIN ALPHA-8-BETA-1 FUNCTIONS AS A RECEPTOR FOR TENASCIN, FIBRONECTIN, AND VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX RECEPTORS; CELL-ADHESION; COLLAGEN; SUBUNIT; BINDING; PROTEIN; CYTOTACTIN; AFFINITY; FORM	The integrin family of adhesion receptors consists of at least 21 heterodimeric transmembrane proteins that differ in their tissue distribution and ligand specificity. The recently identified alpha 8 integrin subunit associates with beta 1 and is predominantly expressed in smooth muscle and other contractile cells in adult tissues, and in mesenchymal and neural cells during development, We now show that alpha 8 beta 1 specifically localizes to focal contacts in cells plated on the extracellular matrix proteins fibronectin or vitronectin, In addition we show that human embryonic kidney cells (293), transfected with alpha 8 cDNA, express alpha 8 beta 1 on their surface and use this recep tor for adhesion to fibronectin and vitronectin. Furthermore, alpha 8 beta 1 binds to both fibronectin- and vitronectin-Sepharose and can be specifically eluted from either matrix protein by the arginine-glycine-aspartic acid (RGD)-containing peptide, GRGDSP. Because fibronectin and vitronectin adhesion appeared to be mediated by RGD, we examined additional RGD-containing proteins, including tenascin, fibrinogen, thrombospondin, osteopontin, and denatured collagen type I. We found that only tenascin was able to mediate adhesion of alpha 8-transfected 293 cells, By using recombinant fragments of tenascin in adhesion assays, we were able to localize the alpha 8 beta 1 binding domain of tenascin to the RGD-containing, third fibronectin type III repeat. These data strongly suggest that tenascin, fibronectin, and vitronectin are Ligands for alpha 8 beta 1 and that this integrin binds to the RGD site in each of these ligands through mechanisms that are distinct and separate from alpha 5-and alpha v-containing integrins.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SCHNAPP, LM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,INST CARDIOVASC RES,CTR LUNG BIOL,UCSF BOX 0854,SAN FRANCISCO,CA 94143, USA.		Hatch, Nan/ABC-9177-2020; Hatch, Nan/AAQ-8465-2020	Hatch, Nan/0000-0002-2632-0841	NCI NIH HHS [CA53259] Funding Source: Medline; NHLBI NIH HHS [HL191551, HL/A133259] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BUSK M, 1992, J BIOL CHEM, V267, P5790; CLYMAN RI, 1990, CIRC RES, V67, P175, DOI 10.1161/01.RES.67.1.175; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; DITTEL BN, 1993, BLOOD, V81, P2272; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FATH KR, 1989, J CELL SCI, V92, P67; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; MULLER U, 1995, MOL BIOL CELL, V6, P433; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SINGER II, 1988, J CELL BIOL, V106, P2171, DOI 10.1083/jcb.106.6.2171; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691	25	178	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23196	23202		10.1074/jbc.270.39.23196	http://dx.doi.org/10.1074/jbc.270.39.23196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559467	hybrid			2022-12-25	WOS:A1995RY05400087
J	ZHANG, MJ; YUAN, T; ARAMINI, JM; VOGEL, HJ				ZHANG, MJ; YUAN, T; ARAMINI, JM; VOGEL, HJ			INTERACTION OF CALMODULIN WITH ITS BINDING DOMAIN OF RAT CEREBELLAR NITRIC-OXIDE SYNTHASE - A MULTINUCLEAR NMR-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SEQUENCE-INDEPENDENT RECOGNITION; PROTEOLYTIC FRAGMENTS; MULTIDIMENSIONAL NMR; SECONDARY STRUCTURE; TERMINAL DOMAINS; PEPTIDE COMPLEX; SPECTROSCOPY; CD-113; PURIFICATION	The intercellular messenger nitric oxide is produced through the action of nitric oxide synthases, a class of enzymes that is regulated by calcium-calmodulin (CaM). In this work, the interaction of CaM with a 23-amino-acid residue synthetic peptide, encompassing the CaM-binding domain of constitutive rat cerebellar nitric oxide synthase (cNOS), was investigated by various NMR methods, Cadmium-113 NMR studies showed that binding of the cNOS peptide increased the affinity of CaM for metal ions and induced interdomain cooperativity in metal ion binding as earlier observed for complexes of CaM with myosin light chain kinase (MLCK) peptides. By using specific isotopically labeled [C-13]methyl-Met and selenomethionine-substituted CaM in two dimensional proton-detected C-13 and Se-77 NMR studies, we obtained evidence for the involvement of the Met residues of CaM in the binding of the cNOS peptide. These residues form two hydrophobia: surface areas on CaM, and they are also involved in the binding of other target proteins. A nitroxide spin-labeled version of the cNOS peptide caused broadening only for NMR resonances in the N-terminal. half of CaM, showing that the peptide binds with a C to N orientation to the N- and C-terminal domains of CaM, pH titration experiments of CaM dimethylated with [C-13]formaldehyde show that Lys-75 (and Lys-148) experience a large increase in pK(a) upon peptide binding; this indicates an unraveling of part of the helical linker region of CaM upon cNOS peptide binding. Taken together, our data show that the cNOS and MLCK peptides bind in a closely analogous fashion to CaM.	UNIV CALGARY, DEPT BIOL SCI, CALGARY, AB T2N 1N4, CANADA	University of Calgary				Zhang, Mingjie/0000-0001-9404-0190				ANDERSSON A, 1983, BIOCHEMISTRY-US, V22, P2309, DOI 10.1021/bi00279a001; ARAMINI JM, 1995, J BIOCHEM, V117, P623, DOI 10.1093/oxfordjournals.jbchem.a124754; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; CRAESCU CT, 1995, J BIOL CHEM, V270, P7088, DOI 10.1074/jbc.270.13.7088; DEJONG EAM, 1988, J MAGN RESON, V80, P197, DOI 10.1016/0022-2364(88)90291-0; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FOLKERS PJM, 1993, BIOCHEMISTRY-US, V32, P9407, DOI 10.1021/bi00087a020; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; HIRAOKI T, 1987, J CARDIOVASC PHARM, V10, pS14, DOI 10.1097/00005344-198710001-00004; HUQUE ME, 1993, J PROTEIN CHEM, V12, P693; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; IKURA M, 1989, BIOCHEM BIOPH RES CO, V161, P1233, DOI 10.1016/0006-291X(89)91374-0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KORDEL J, 1992, J MAGN RESON, V100, P581, DOI 10.1016/0022-2364(92)90063-D; KOSEN PA, 1986, BIOCHEMISTRY-US, V25, P2356, DOI 10.1021/bi00357a009; LINSE S, 1986, FEBS LETT, V199, P28, DOI 10.1016/0014-5793(86)81217-0; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P99; Luthra N. P., 1986, CHEM ORGANIC SELENIU, V1, P189; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MUSCI G, 1988, BIOCHEMISTRY-US, V27, P1260, DOI 10.1021/bi00404a028; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OHKI S, 1993, J BIOL CHEM, V268, P12388; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PENINGTON CJ, 1992, BIOCHEMISTRY-US, V31, P2912, DOI 10.1021/bi00126a010; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SIIVARI K, 1995, FEBS LETT, V366, P104, DOI 10.1016/0014-5793(95)00504-3; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; VOGEL HJ, 1990, ADV SEC MESS PHOSPH, V24, P254; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; VOGEL HJ, 1987, BIOL MAGN RESON, V7, P245; VOGEL HJ, 1995, MOL CELL BIOCHEM, P3; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P10883, DOI 10.1021/bi00202a006; ZHANG MJ, 1994, J MOL BIOL, V239, P545, DOI 10.1006/jmbi.1994.1393; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114	56	49	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20901	20907		10.1074/jbc.270.36.20901	http://dx.doi.org/10.1074/jbc.270.36.20901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7545663	hybrid			2022-12-25	WOS:A1995RU05400009
J	WHITNEY, GS; STARLING, GC; BOWEN, MA; MODRELL, B; SIADAK, AW; ARUFFO, A				WHITNEY, GS; STARLING, GC; BOWEN, MA; MODRELL, B; SIADAK, AW; ARUFFO, A			THE MEMBRANE-PROXIMAL SCAVENGER RECEPTOR CYSTEINE-RICH DOMAIN OF CD6 CONTAINS THE ACTIVATED LEUKOCYTE CELL-ADHESION MOLECULE-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SURFACE PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; CLONING; LIGAND; GLYCOPROTEIN; PHOSPHORYLATION	Binding studies with a CD6 immunoglobulin fusion protein (CD6 Rg) resulted in the identification and cloning of a CD6 ligand, This ligand was found to be a member of the immunoglobulin supergene family and was named ALCAM (activated leukocyte cell adhesion molecule), Cell adhesion assays showed that CD6-ALCAM interactions mediate thymocyte-thymic epithelium cell binding, ALCAM is also expressed by activated leukocytes and neurons and may be involved in interactions between T cells and activated leukocytes and between cells of the immune and nervous systems, respectively. Herein we describe the preparation of domain-specific murine CD6 Rg fusion proteins and show that the membrane-proximal SRCR (scavenger receptor cysteine-rich) domain of CD6 contains the ALCAM binding site, We also show that mAbs which bind to this domain preferentially block CD6-ALCAM binding. These results demonstrate that the membrane-proximal SRCR do main of CD6 is necessary for CD6 binding to ALCAM and provide the first direct evidence for the interaction of an SRCR domain with a ligand.			WHITNEY, GS (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.			Starling, Gary/0000-0001-9879-4336				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; BOTT CM, 1993, INT IMMUNOL, V7, P783; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CARDENAS L, 1990, J IMMUNOL, V145, P1450; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; GANGEMI RMR, 1989, J IMMUNOL, V143, P2439; GOLDBERGER G, 1987, J BIOL CHEM, V262, P10065; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOTHS K, 1993, J BIOL CHEM, V268, P14245; LEDBETTER JA, 1989, MOL IMMUNOL, V26, P137, DOI 10.1016/0161-5890(89)90095-3; LUO W, 1992, J IMMUNOL, V148, P1630; MORIMOTO C, 1988, J IMMUNOL, V140, P2165; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; PEDUZZI JD, 1994, BRAIN RES, V640, P296, DOI 10.1016/0006-8993(94)91885-6; PESANDO JM, 1986, J IMMUNOL, V137, P3689; POURQUIE O, 1992, P NATL ACAD SCI USA, V89, P5261, DOI 10.1073/pnas.89.12.5261; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; SWACK JA, 1989, MOL IMMUNOL, V26, P1037, DOI 10.1016/0161-5890(89)90068-0; SWACK JA, 1991, J BIOL CHEM, V266, P7137; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; VAN DE VELDE H, 1991, NATURE, V351, P662; WEE SF, 1993, J EXP MED, V177, P219, DOI 10.1084/jem.177.1.219; WEE SF, 1994, CELL IMMUNOL, V158, P353, DOI 10.1006/cimm.1994.1282; WHITNEY G, 1994, MOL IMMUNOL, V32, P89	30	85	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18187	18190		10.1074/jbc.270.31.18187	http://dx.doi.org/10.1074/jbc.270.31.18187			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7543097	hybrid			2022-12-25	WOS:A1995RM64200004
J	STEINERT, PM; MAREKOV, LN				STEINERT, PM; MAREKOV, LN			THE PROTEINS ELAFIN, FILAGGRIN, KERATIN INTERMEDIATE FILAMENTS, LORICRIN, AND SMALL PROLINE-RICH PROTEIN-1 AND PROTEIN-2 ARE ISODIPEPTIDE CROSS-LINKED COMPONENTS OF THE HUMAN EPIDERMAL CORNIFIED CELL-ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN EPIDERMIS; ELASTASE INHIBITOR; TRANSGLUTAMINASE; SEQUENCE; LINKING; GENE; PRECURSOR; SKIN; DIFFERENTIATION; PURIFICATION	The cornified cell envelope (CE) is a 15-nm thick layer of insoluble protein deposited on the intracellular side of the cell membrane of terminally differentiated stratified squamous epithelia. The CE is thought to consist of a complex amalgam of proteins cross-linked by isodipeptide bonds formed by the action of transglutaminases, but little is known about how or in which order the several putative proteins are cross-linked together. In this paper, CEs purified from human foreskin epidermis were digested in two steps by proteinase K, which released as soluble peptides about 30% and then another 35% of CE protein mass, corresponding to approximately the outer third (cytoplasmic surface) and middle third, respectively. Following fractionation, 145 unique peptides containing two or more sequences cross-linked by isodipeptide bond(s) were sequenced. Based on these data, most (94% molar mass) of the outer third of CE structure consists of intra- and interchain cross-linked loricrin, admired with SPR1 and SPR2 proteins as bridging cross-links between loricrin. Likewise, the middle third of CE structure consists largely of crosslinked loricrin and SPR proteins, but is mixed with the novel protein elafin which also forms cross-bridges between loricrin. In addition, cross-links involving loricrin and keratins 1, 2e, and 10 or filaggrin were recovered in both levels. The data establish for the first time that these several proteins are indeed cross-linked protein components of the CE structure. In addition, the data support a model for the intermediate to final stages of CE assembly: the proteins elafin, SPR1 and SPR2, and loricrin bean to be deposited on a preformed scaffold; later, elafin deposition decreases as loricrin and SPR accumulation continues to effect final assembly. The recovery of cross-links involving keratins further suggests that the subjacent cytoplasmic keratin intermediate filament-filaggrin network is anchored to the developing CE during these events.			STEINERT, PM (corresponding author), NIAMSD,SKIN BIOL BRANCH,BETHESDA,MD 20892, USA.							ABERNETHY JL, 1977, J BIOL CHEM, V252, P1837; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; BADEN HP, 1987, BIOCHIM BIOPHYS ACTA, V925, P63, DOI 10.1016/0304-4165(87)90148-6; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; DALE BA, 1983, J CELL BIOL, V101, P1257; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNING DT, 1992, J LIPID RES, V33, P301; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V19, P1531; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM SY, 1994, J BIOL CHEM, V269, P27979; KIMONIS V, 1994, J INVEST DERMATOL, V103, P713; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE SC, 1993, J BIOL CHEM, V268, P12164; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; MING ME, 1993, J INVEST DERMATOL, V100, P578; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NONOMURA K, 1994, J INVEST DERMATOL, V103, P88, DOI 10.1111/1523-1747.ep12391802; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; PHILLIPS SB, 1990, COMP BIOCHEM PHYS B, V95, P781, DOI 10.1016/0305-0491(90)90317-M; Reichert Uwe, 1993, P107; RICE RH, 1979, CELL, V11, P417; RICHARDS S, 1988, BIOCHEM J, V253, P153, DOI 10.1042/bj2530153; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; STEVEN AC, 1994, J CELL SCI, V107, P693; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; TAKAHASHI M, 1992, FEBS LETT, V308, P79, DOI 10.1016/0014-5793(92)81055-Q; TARCSA E, 1992, J BIOL CHEM, V267, P25648; TEZUKA T, 1987, J INVEST DERMATOL, V88, P47, DOI 10.1111/1523-1747.ep12464862; WALSH F, 1963, NATURE, V198, P188; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; YUSPA SH, 1982, J BIOL CHEM, V257, P9906; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	60	438	442	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17702	17711		10.1074/jbc.270.30.17702	http://dx.doi.org/10.1074/jbc.270.30.17702			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543090	hybrid			2022-12-25	WOS:A1995RM26600014
J	GAO, JL; MURPHY, PM				GAO, JL; MURPHY, PM			CLONING AND DIFFERENTIAL TISSUE-SPECIFIC EXPRESSION OF 3 MOUSE BETA-CHEMOKINE RECEPTOR-LIKE GENES, INCLUDING THE GENE FOR A FUNCTIONAL MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; MOLECULAR-CLONING; RANTES; IDENTIFICATION; MIP-1-BETA; CYTOKINE; CELLS; MIP-1-ALPHA; BINDING; INVIVO	Macrophage inflammatory protein-1 alpha (MIP-1 alpha) and RANTES, members of the beta chemokine family of leukocyte chemoattractants, bind to a common seven-transmembrane domain human receptor. We have now cloned three related mouse genes: one for a selective MIP-1 alpha receptor (MIP-1 alpha R) and two for orphan receptors provisionally designated MIP-1 alpha receptor-like 1 and 2 (MIP 1 alpha RL1 and 2). Their deduced sequences are 80, 62, and 63% identical to the human. MIP-1 alpha/RANTES receptor, respectively. K562 cells stably transfected with MIP-1 alpha R specifically bound I-125-human MLP-1 alpha and I-125-human RANTES with high affinity. The rank order of beta chemokine competition for I-125-human MIP-1 alpha binding was human MIP-1 alpha > mouse MLP-1 alpha similar to RANTES similar to MIP-1 beta > MCP-1. However, human RANTES was similar to 100-fold less potent as a calcium-mobilizing agonist for MIP-1 alpha R than either human or mouse MIP-1 alpha, which matched the selectivity of mouse leukocytes for calcium mobilization by MIP-1 alpha and RANTES. No other beta or a chemokines tested were agonists for MIP-1 alpha R. RNA for all three genes was detected in mouse leukocytes, but unique patterns of expression were identified in solid organs: MIP-1 alpha R, heart, spleen, and lung; MIP-1 alpha RL1, skeletal muscle; and MIP-1(alpha RL2, spleen and liver. These data identify potentially important new targets for beta chemokine action in the mouse.			GAO, JL (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N113,BETHESDA,MD 20892, USA.		Gao, Ji-Liang/Y-4397-2019					AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; AHUJA SK, 1994, J BIOL CHEM, V269, P26381; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BOZIC CR, 1994, J BIOL CHEM, V269, P29355; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; COMBADIERE C, 1995, IN PRESS DNA CELL BI; COOPER S, 1994, EXP HEMATOL, V22, P186; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P389; DUNLOP DJ, 1992, BLOOD, V79, P2221; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAO JL, 1994, J BIOL CHEM, V269, P28539; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; HEINRICH JN, 1993, MOL CELL BIOL, V13, P2020, DOI 10.1128/MCB.13.4.2020; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; MAZE R, 1992, J IMMUNOL, V149, P1004; MICHIEL D, 1993, BIO-TECHNOL, V11, P739, DOI 10.1038/nbt0693-739; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OH KO, 1991, J IMMUNOL, V147, P2978; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WANG JM, 1993, J IMMUNOL, V150, P3022	36	69	74	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17494	17501		10.1074/jbc.270.29.17494	http://dx.doi.org/10.1074/jbc.270.29.17494			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542241	hybrid			2022-12-25	WOS:A1995RK68900069
J	WU, YN; SAXENA, SK; ARDELT, W; GADINA, M; MIKULSKI, SM; DELORENZO, C; DALESSIO, G; YOULE, RJ				WU, YN; SAXENA, SK; ARDELT, W; GADINA, M; MIKULSKI, SM; DELORENZO, C; DALESSIO, G; YOULE, RJ			A STUDY OF THE INTRACELLULAR ROUTING OF CYTOTOXIC RIBONUCLEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-30 PROTEIN; BREFELDIN-A; SEMINAL RIBONUCLEASE; GOLGI PROTEINS; INVITRO; CELLS; RNASE; SUPERFAMILY; ANGIOGENIN; MECHANISM	Several ribonucleases serve as cytotoxic agents in host defense and in physiological cell death pathways. Although certain members of the pancreatic ribonuclease A superfamily can be toxic when applied to the outside of cells, they become thousands of times more toxic when artificially introduced into the cytosol, indicating that internalization is the rate-limiting step for cytotoxicity. We have used three agents that disrupt the Golgi apparatus by distinct mechanisms, retinoic acid, brefeldin A, and monensin, to probe the intracellular pathways ribonucleases take to reach the cytosol. Retinoic acid and monensin potentiate the cytotoxicity of bovine seminal RNase, Onconase, angiogenin, and human ribonuclease A 100 times or more. Retinoic acid-mediated potentiation of ribonucleases is completely blocked by brefeldin A. Ribonucleases appear to route more efficiently into the cytosol through the Golgi apparatus disrupted by monensin or retinoic acid. Intracellular RNA degradation by BS-RNase increased more than 100 times in the presence of retinoic acid confirming that the RNase reaches the cytosol and indicating that degradation of RNA is the intracellular lesion causing toxicity. As retinoic acid alone and Onconase are in clinical trials for cancer therapy, combinations of RNases and retinoic acid in vivo may offer new clinical utility.	ALFACELL CORP, BLOOMFIELD, NJ 07003 USA; UNIV NAPLES, DIPARTIMENTO CHIM ORGAN & BIOL, I-80134 NAPLES, ITALY	University of Naples Federico II	WU, YN (corresponding author), NINCDS, SURG NEUROL BRANCH, BIOCHEM SECT, BLDG 36, RM 4D04, BETHESDA, MD 20892 USA.		Saxena, Shailendra K/X-4252-2019; Saxena, Shailendra K/ABK-6489-2022; Gadina, Massimo/R-4195-2019	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185; 				ARDELT W, 1991, J BIOL CHEM, V266, P245; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1975, BIOCHEMISTRY-US, V14, P1116, DOI 10.1021/bi00677a004; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; GANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; LACCETTI P, 1992, CANCER RES, V52, P4582; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MIKULSKI SM, 1990, CELL TISSUE KINET, V23, P237, DOI 10.1111/j.1365-2184.1990.tb01119.x; MISUMI Y, 1986, J BIOL CHEM, V261, P11399; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; RYBAK SM, 1992, P NATL ACAD SCI USA, V89, P3165, DOI 10.1073/pnas.89.8.3165; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCHULTZ DA, 1992, PROTEIN SCI, V1, P910, DOI 10.1002/pro.5560010709; TAMBURRINI M, 1986, ITAL J BIOCHEM, V35, P22; VESCIA S, 1980, CANCER RES, V40, P3740; WU YN, 1993, J BIOL CHEM, V268, P10686; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1	32	101	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17476	17481		10.1074/jbc.270.29.17476	http://dx.doi.org/10.1074/jbc.270.29.17476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542240	hybrid			2022-12-25	WOS:A1995RK68900066
J	STANLEY, S; DIAS, JA; DARCANGELIS, D; MANNELLA, CA				STANLEY, S; DIAS, JA; DARCANGELIS, D; MANNELLA, CA			PEPTIDE-SPECIFIC ANTIBODIES AS PROBES OF THE TOPOGRAPHY OF THE VOLTAGE-GATED CHANNEL IN THE MITOCHONDRIAL OUTER-MEMBRANE OF NEUROSPORA-CRASSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VDAC ION CHANNEL; PORIN; CLONING; PROTEIN; YEAST; RESOLUTION; EXPRESSION; DOMAINS; IMPORT; ARRAYS	The voltage-dependent anion-selective channel (VDAC) in mitochondrial outer membranes is formed by a polypeptide (M(r) 31,000) coded by a nuclear gene whose cDNA sequence is known for several organisms. Antibodies have been raised against synthetic peptides corresponding to four different regions in the predicted sequence of the VDAC polypeptide of the fungus Neurospora crassa (residues 1-20, amino terminus; 195-210, 251-268, and 272-283, carboxyl terminus). Specificity of the antibodies has been characterized in terms of binding to peptides or fungal mitochondria on microtiter plates and binding to mitochondrial proteins of several species in Western blots. Reactivity of three of the four antibodies with fungal mitochondria in suspension increases with lysis of outer membranes, indicating that the respective epitopes (including those near the amino and carboxyl termini) are exposed on the surface of the outer membrane that faces inside the mitochondrion. Preincubation of mitochondria with a polyanion that modulates VDAC voltage dependence strongly inhibits binding of the antibody against residues 251-268, whose epitopes are on the outer mitochondrial surface.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR,DIV MOLEC MED,ALBANY,NY 12201; NEW YORK STATE DEPT HLTH,WADSWORTH CTR,DIV GENET,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Dias, James A/0000-0002-9792-5469				BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BOWMAN CL, 1984, BIOCHIM BIOPHYS ACTA, V731, P261; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; Colombini Marco, 1994, V42, P73; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DILL ET, 1987, J MEMBRANE BIOL, V99, P187, DOI 10.1007/BF01995699; DOUCE R, 1973, BIOCHIM BIOPHYS ACTA, V292, P105, DOI 10.1016/0005-2728(73)90255-7; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; HOLZENBURG A, 1989, BIOCHEMISTRY-US, V28, P4187, DOI 10.1021/bi00436a010; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KOPPEL D, 1995, BIOPHYS J, V68, P145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGAN PS, 1987, P NATL ACAD SCI USA, V84, P4896, DOI 10.1073/pnas.84.14.4896; MANNELLA CA, 1990, EXPERIENTIA, V46, P137, DOI 10.1007/BF02027309; MANNELLA CA, 1987, BIOPHYS J, V51, P221, DOI 10.1016/S0006-3495(87)83327-1; MANNELLA CA, 1975, BIOCHIM BIOPHYS ACTA, V413, P213, DOI 10.1016/0005-2736(75)90105-4; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MANNELLA CA, 1995, BIOPHYS J, V68, P145; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MUNN EA, 1968, J ULTRA MOL STRUCT R, V25, P362, DOI 10.1016/S0022-5320(68)80092-9; PAUPTIT RA, 1991, J STRUCT BIOL, V107, P136, DOI 10.1016/1047-8477(91)90017-Q; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; REID J, 1988, J BIOL CHEM, V263, P7753; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SHAO L, 1994, THESIS SUNY U ALBANY; SHAO L, 1994, BIOPHYS J, V66, P21; STANLEY S, 1994, THESIS SUNY U ALBANY; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; WEINER RS, 1990, ENDOCRINOLOGY, V127, P573, DOI 10.1210/endo-127-2-573; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WOOD JN, 1984, METHODS MOL BIOL PRO, V1, P264; WUNDER UR, 1991, J MEMBRANE BIOL, V123, P83, DOI 10.1007/BF01993966; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZIZI M, 1994, J BIOL CHEM, V269, P1614	45	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16694	16700		10.1074/jbc.270.28.16694	http://dx.doi.org/10.1074/jbc.270.28.16694			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542652	hybrid			2022-12-25	WOS:A1995RJ34700039
J	WADDELL, TK; FIALKOW, L; CHAN, CK; KISHIMOTO, TK; DOWNEY, GP				WADDELL, TK; FIALKOW, L; CHAN, CK; KISHIMOTO, TK; DOWNEY, GP			SIGNALING FUNCTIONS OF L-SELECTIN - ENHANCEMENT OF TYROSINE PHOSPHORYLATION AND ACTIVATION OF MAP KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; NODE HOMING RECEPTOR; HUMAN-NEUTROPHILS; P-SELECTIN; PROTEIN-PHOSPHORYLATION; ENDOTHELIAL LIGAND; CROSS-LINKING; INFLAMMATION; INVOLVEMENT; BINDING	L-selectin is a leukocyte cell surface glycoprotein involved in carbohydrate-specific ligand binding which mediates rolling of leukocytes along endothelial surfaces. In addition to its role in adhesion, an intracellular signaling role for L-selectin has recently been recognized. In particular, cross-linking L-selectin leads to increased cytosolic Ca2+ levels and potentiation of the oxidative burst. As several cell surface glycoproteins have been shown to be linked to tyrosine kinases, we examined the hypothesis that L-selectin may be linked to pathways involving tyrosine phosphorylation in human neutrophils. Ligation of L-selectin by three different antibodies recognizing separate epitopes led to increased tyrosine phosphorylation of several cellular proteins as judged by anti-phosphotyrosine immunoblots of whole cell lysates with prominent bands at 40-42, 55-60, 70-72, and 105-120 kDa. The 42-kDa band co-migrated with mitogen- activated protein (MAP) kinase as determined by immunoblotting with anti-MAP kinase antibody. This effect was specific for L-selectin, because antibodies against CD18, CD45, and CD10 did not increase tyrosine phosphorylation. Phosphorylation was not due to Fc binding, since F(ab')(2) fragments of the anti-L-selectin antibodies were similarly effective, and the response was unaffected by Fc receptor blockade. Cross-linking of L-selectin was not required for enhanced tyrosine phosphorylation, because monovalent Fab fragments also increased tyrosine phosphorylation. The response to L-selectin antibodies was not inhibited by cytochalasin, suggesting that reorganization of the actin cytoskeleton was not required for this response, Sulfatides, sulfated glycolipids which may be natural ligands for L-selectin, also induced a rapid, dose-dependent increase in tyrosine phosphorylation. In addition, sulfatides, but not control glycolipids, resulted in enhanced tyrosine phosphorylation of MAP kinase. Both sulfatides and anti-L-selectin antibodies increased kinase activity of MAP kinase as determined by gel renaturation assay. The tyrosine kinase inhibitor, genistein, blocked the transient increase in intracellular Ca2+ and the oxidative burst induced by sulfatides, suggesting that this tyrosine phosphorylation is functionally important. We conclude that L-selectin is able to transmit intracellular signals, including increased tyrosine phosphorylation and activation of MAP kinase in neutrophils. We speculate that these events may contribute to the activation of neutrophils during adhesion.	UNIV TORONTO,DEPT MED,DIV CLIN SCI,TORONTO,ON M5S 1A8,CANADA; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877	University of Toronto; Boehringer Ingelheim				Downey, Gregory P/0000-0003-3253-5862				BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERKOW RL, 1990, BLOOD, V75, P2445; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CROCKETTTORABI E, 1995, J IMMUNOL, V154, P2291; DOWNEY GP, 1995, IN PRESS TXB PEDIATR; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; DUSI S, 1994, BIOCHEM BIOPH RES CO, V201, P1100, DOI 10.1006/bbrc.1994.1819; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GAUDRY M, 1992, J LEUKOCYTE BIOL, V51, P103, DOI 10.1002/jlb.51.2.103; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HASLETT C, 1985, AM J PATHOL, V119, P101; HUANG K, 1994, J NEUROIMMUNOL, V53, P133, DOI 10.1016/0165-5728(94)90023-X; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; IMAI Y, 1993, NATURE, V361, P555; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; LEY K, 1991, BLOOD, V77, P2553; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; MODDERMAN PW, 1994, BIOCHEM J, V299, P613, DOI 10.1042/bj2990613; MURAKAWA Y, 1992, J IMMUNOL, V148, P1771; NASMITH PE, 1987, J BIOL CHEM, V262, P13558; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; RICHARD S, 1994, BIOCHEM BIOPH RES CO, V199, P653, DOI 10.1006/bbrc.1994.1278; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401	46	176	179	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15403	15411		10.1074/jbc.270.25.15403	http://dx.doi.org/10.1074/jbc.270.25.15403			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541041	hybrid			2022-12-25	WOS:A1995RE66600083
J	PANAYOTATOS, N; RADZIEJEWSKA, E; ACHESON, A; SOMOGYI, R; THADANI, A; HENDRICKSON, WA; MCDONALD, NQ				PANAYOTATOS, N; RADZIEJEWSKA, E; ACHESON, A; SOMOGYI, R; THADANI, A; HENDRICKSON, WA; MCDONALD, NQ			LOCALIZATION OF FUNCTIONAL RECEPTOR EPITOPES ON THE STRUCTURE OF CILIARY NEUROTROPHIC FACTOR INDICATES A CONSERVED, FUNCTION-RELATED EPITOPE TOPOGRAPHY AMONG HELICAL CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CNTF RECEPTOR; ALPHA COMPONENT; TERMINUS; PROTEIN	By rational mutagenesis, receptor-specific functional analysis, and visualization of complex formation in solution, we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor (CNTF) with CNTFR alpha and not with the beta-components, gp130 and LIFR. In the crystal structure, the side chains of these residues, which are located in helix A, the AB loop, helix B, and helix D, are surface accessible and are clustered in space, thus constituting an epitope for CNTFR alpha. By the same analysis, a partial epitope for gp130 was also identified on the surface of helix A that faces away from the alpha-epitope. Superposition of the CNTF and growth hormone structures showed that the location of these epitopes on CNTF is analogous to the location of the first and second receptor epitopes on the surface of growth hormone. Further comparison with proposed binding sites for alpha- and beta-receptors on interleukin-6 and leukemia inhibitory factor indicated that this epitope topology is conserved among helical cytokines. In each case, epitope I is utilized by the specificity-conferring component, whereas epitopes II and III are used by accessory components. Thus, in addition to a common fold, helical cytokines share a conserved order of receptor epitopes that is function related.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute	PANAYOTATOS, N (corresponding author), REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591, USA.							ACHESON A, 1994, SEMIN NEUROSCI, V6, P507; BAZAN JF, 1991, NEURON, V2, P197; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DAVIS S, 1994, CURR OPIN NEUROBIOL, V3, P20; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MCDONALD NW, 1995, EEMBO J, V14; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PANAYOTATOS N, 1993, J BIOL CHEM, V268, P19000; PANAYOTATOS N, 1994, BIOCHEMISTRY-US, V33, P5813, DOI 10.1021/bi00185a020; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873	27	55	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14007	14014		10.1074/jbc.270.23.14007	http://dx.doi.org/10.1074/jbc.270.23.14007			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539796	hybrid			2022-12-25	WOS:A1995RC44800062
J	KANZAKI, M; SHIBATA, H; MOGAMI, H; KOJIMA, I				KANZAKI, M; SHIBATA, H; MOGAMI, H; KOJIMA, I			EXPRESSION OF CALCIUM-PERMEABLE CATION CHANNEL CD20 ACCELERATES PROGRESSION THROUGH THE G(1) PHASE IN BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; HUMAN LYMPHOCYTES-B; CYCLE; ACTIVATION; PHOSPHORYLATION; CALMODULIN; MOLECULE; PROTEIN; ANTIGEN; INVOLVEMENT	CD20 is a transmembrane protein that functions as a Ca2+-permeable cation channel (Bubien, J. K., Zhou, L. J., Bell, P. D., Frizzel, R. A., and Tedder, T. F. (1993) J. Cell Biol. 121, 1121-1132) and is involved in growth regulation of B lymphocytes. In order to further investigate the role of calcium entry in cell cycle progression, we introduced the cDNA encoding a Ca2+-permeable cation channel, CD20, into Balb/c 3T3 cells. Balb/c 3T3 cells transfected with a vector containing cDNA encoding CD20 expressed the CD20 protein, which was detected by assaying the binding of a monoclonal antibody against CD20. Calcium-permeable cation channel activity was detected in CDaO-expressing cells by whole cell patch clamp recording and microfluorometric determination of the cytoplasmic Ca2+ concentration using fura-2. The expression of CD20 induced significant alterations in the responses of the cells to insulin-like growth factor-I (IGF-I). IGF-I induced DNA synthesis by control cells only when they had been pretreated with both platelet-derived growth factor (PDGF) and epidermal growth factor (EGF). In contrast, DNA synthesis by 30% of the quiescent CD20 expressing cells was initiated in response to IGF-I in the absence of priming with PDGF and EGF. When control quiescent cells were primed with PDGF and EGF, the addition of IGF-I led to the initiation of DNA synthesis after 14 h or more, whereas it induced DNA synthesis by CD20 expressing cells primed with PDGF and EGF 4 h earlier. The IGF-induced DNA synthesis was dependent on extracellular Ca2+, and expression of CD20 reduced the concentration of extracellular Ca2+ required for it. Furthermore, DNA synthesis by approximately 25% of the CD20-expressing cells was initiated after priming with PDGF and EGF, even in the absence of the progression factor IGF-I. These results indicate that CD20 expressed in Balb/c 3T3 cells functions as a constitutively active Ca2+-permeable cation channel and that expression of CD20 accelerates G(1) progression in a Ca2+-dependent manner.	GUNMA UNIV,INST MOLEC & CELLULAR REGULAT,DEPT CELL BIOL,MAEBASHI,GUMMA 371,JAPAN	Gunma University			Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955				BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; COLOMER J, 1994, BIOCHEM BIOPH RES CO, V200, P306, DOI 10.1006/bbrc.1994.1449; GENOT EM, 1993, J IMMUNOL, V151, P71; GOLAY JT, 1985, J IMMUNOL, V135, P3795; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KATO M, 1992, J PHYSIOL-LONDON, V447, P171, DOI 10.1113/jphysiol.1992.sp018997; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KOJIMA I, 1990, J CELL PHYSIOL, V143, P529, DOI 10.1002/jcp.1041430318; KOJIMA I, 1993, J BIOL CHEM, V268, P10003; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MATSUNAGA H, 1988, AM J PHYSIOL, V255, pC442, DOI 10.1152/ajpcell.1988.255.4.C442; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1981, P NATL ACAD SCI-BIOL, V78, P4358, DOI 10.1073/pnas.78.7.4358; RUSSELL WE, 1984, P NATL ACAD SCI-BIOL, V81, P2389, DOI 10.1073/pnas.81.8.2389; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STASHENKO P, 1980, J IMMUNOL, V125, P1678; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAKUWA N, 1992, FEBS LETT, V306, P173, DOI 10.1016/0014-5793(92)80993-Q; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; TEDDER TF, 1988, J BIOL CHEM, V263, P10009; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2	29	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13099	13104		10.1074/jbc.270.22.13099	http://dx.doi.org/10.1074/jbc.270.22.13099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539422	hybrid			2022-12-25	WOS:A1995RB43900026
J	LEGRES, LG; POCHON, F; BARRAY, M; GAY, F; CHOUAIB, S; DELAIN, E				LEGRES, LG; POCHON, F; BARRAY, M; GAY, F; CHOUAIB, S; DELAIN, E			EVIDENCE FOR THE BINDING OF A BIOLOGICALLY-ACTIVE INTERLEUKIN-2 TO HUMAN ALPHA(2)-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR BINDING; HUMAN ALPHA-2-MACROGLOBULIN; ELECTROPHORETICALLY SLOW; HALF-MOLECULES; KILLER CELLS; FAST FORMS; PROTEIN; MECHANISM; CLEARANCE; COMPLEXES	Human alpha(2)-macroglobulin (alpha(2)M), which irreversibly entraps proteinases through a drastic conformational change, has also been reported to bind various cytokines. The meaning of cytokine binding to native and/or transformed alpha(2)M molecules is, however, not understood. In an attempt to elucidate this question, we have studied the interaction of radioiodinated recombinant human interleukin-2 (I-125-rhIL-2) with native and chymotrypsin (alpha(2)M-C)- or methylamine-transformed (alpha(2)M-MA) alpha(2)M. Our results show that native and alpha(2)M-MA are able to bind I-125-rhIL-2, with binding occurring only with the latter in a covalent manner, whereas the labeled cytokine is proteolyzed when incubated with alpha(2)M-entrapped chymotrypsin. The degradation of uncomplexed I-125-rhIL-2 has also been observed in the presence of trypsin, whereas I-125-rhIL-2 bound to alpha(2)M-MA is protected. Moreover, the proliferative activity of this cytokine on responsive cells is still maintained either with native alpha(2)M- or alpha(2)M-MA-complexed rhIL-2 in comparison with that observed with the cytokine alone. Our results, which lead us to consider alpha(2)M molecules as IL-2-binding proteins, emphasize the possible role of these molecules as immune response regulators.	UNIV PARIS 11,INST CURIE BIOL,INSERM,U350,F-91400 ORSAY,FRANCE; INST GUSTAVE ROUSSY,INSERM,CJF 9411,CYTOKINES & IMMUN ANTITUMORALE GRP,F-94805 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	LEGRES, LG (corresponding author), INST GUSTAVE ROUSSY,MICROSCOPIE CELLULAIRE & MOLEC LAB,CNRS,URA 147,RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.		Luc, LEGRES/R-4956-2019; LEGRES, Luc/A-7650-2012; Chouaib, Salem/F-7939-2016					ARMSTRONG PB, 1987, BIOCHEM J, V248, P703, DOI 10.1042/bj2480703; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BONNER JC, 1992, J BIOL CHEM, V267, P12837; BORTH W, 1986, IMMUNOLOGY, V57, P367; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; CHU CT, 1994, J IMMUNOL, V152, P1538; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; DILLMAN RO, 1993, CANCER, V71, P2358, DOI 10.1002/1097-0142(19930401)71:7<2358::AID-CNCR2820710730>3.0.CO;2-M; FELDMAN SR, 1985, BIOCHEM BIOPH RES CO, V128, P795, DOI 10.1016/0006-291X(85)90117-2; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P7916, DOI 10.1021/bi00082a012; GILLIS S, 1978, J IMMUNOL, V120, P2027; HEUMANN D, 1988, EUR J IMMUNOL, V18, P755, DOI 10.1002/eji.1830180515; HUBBARD WJ, 1981, J IMMUNOL, V126, P292; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JAMES K, 1994, J IMMUNOL METHODS, V168, P33, DOI 10.1016/0022-1759(94)90206-2; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LAMARRE J, 1991, LAB INVEST, V65, P3; LARGMAN C, 1977, NATURE, V269, P168, DOI 10.1038/269168a0; LIANG SM, 1986, J BIOL CHEM, V261, P334; LIANG SM, 1985, BIOCHEM J, V229, P429, DOI 10.1042/bj2290429; MANNHALTER JW, 1986, J IMMUNOL, V136, P2792; MATSUDA T, 1989, J IMMUNOL, V142, P148; POCHON F, 1987, BIOCHEM BIOPH RES CO, V149, P488, DOI 10.1016/0006-291X(87)90394-9; POCHON F, 1989, BIOCHIM BIOPHYS ACTA, V996, P132, DOI 10.1016/0167-4838(89)90105-2; ROBB RJ, 1984, P NATL ACAD SCI-BIOL, V81, P6486, DOI 10.1073/pnas.81.20.6486; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SOKER S, 1993, J BIOL CHEM, V268, P7685; STARKEY PM, 1982, BIOCHEM J, V205, P91, DOI 10.1042/bj2050091; STARKEY PM, 1977, RES MONOGRAPHS CELL, V2, P663; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WEBB DJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P487, DOI 10.1016/0003-9861(92)90020-W	38	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8381	8384		10.1074/jbc.270.15.8381	http://dx.doi.org/10.1074/jbc.270.15.8381			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7536736	hybrid			2022-12-25	WOS:A1995QT44800003
J	MITCHELL, FM; HEASLEY, LE; QIAN, NX; ZAMARRIPA, J; JOHNSON, GL				MITCHELL, FM; HEASLEY, LE; QIAN, NX; ZAMARRIPA, J; JOHNSON, GL			DIFFERENTIAL MODULATION OF BOMBESIN-STIMULATED PHOSPHOLIPASE C-BETA AND MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVITY BY [D-ARG(1),D-PHE(5),D-TRP(7,9),LEU(11)] SUBSTANCE-P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; MAP KINASE; LUNG-CANCER; ALPHA-SUBUNITS; GROWTH; RECEPTOR; INHIBITION; BINDING; RAF-1; CAMP	Mitogenic stimulation of Swiss 3T3 fibroblasts with bombesin results in receptor-mediated activation of a complex array of effecters, including phospholipase C beta and mitogen-activated protein (MAP) kinase. Incubation of Swiss 3T3 fibroblasts with the 11-amino acid [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P peptide inhibited bombesin-stimulated cell proliferation and phospholipase C beta activation even at high bombesin concentrations. The peptide did not inhibit the activation of phospholipase C beta by a GTPase-deficient form of the G(q)-like protein, G(16), indicating that the peptide does ndt inhibit phospholipase C beta and is acting at a point upstream of the activated form of the G protein alpha subunit. The peptide inhibited MAP kinase activation at low bombesin concentrations, but unlike phospholipase C beta, this inhibition could be overcome with 30 nM bombesin, In control Swiss 3T3 cells, bombesin did not measurably activate has or Raf-1 above basal levels. Following incubation of the cells with the [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P peptide, 50 nM bombesin activated Raf-1 4-6-fold over basal levels. Platelet-derived growth factor stimulated activities of PLC, Ras, Raf-1, and MAP kinase were unaltered after incubation of Swiss 3T3 cells with the [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P peptide, as was platelet-derived growth factor-stimulated growth of the Swiss 3T3 cells. Thus, the peptide behaves as an antagonist that differentially inhibited phospholipase C beta and MAP kinase signal transduction pathways. The growth arrest observed with the peptide indicates that the bombesin-stimulated activation of MAP kinase is not sufficient to support mitogenesis in Swiss 3T3 cells.	UNIV COLORADO,SCH MED,DIV RENAL MED,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MITCHELL, FM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.				NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NCI NIH HHS [CA58187] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUKAI H, 1992, J BIOL CHEM, V267, P16237; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; QIAN NX, 1994, J BIOL CHEM, V269, P81747; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; WOLL PJ, 1990, CANCER RES, V50, P3968; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	39	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8623	8628		10.1074/jbc.270.15.8623	http://dx.doi.org/10.1074/jbc.270.15.8623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7536738	hybrid			2022-12-25	WOS:A1995QT44800040
J	HAMAGUCHI, M; YAMAGATA, S; THANT, AA; XIAO, HY; IWATA, H; MAZAKI, T; HANAFUSA, H				HAMAGUCHI, M; YAMAGATA, S; THANT, AA; XIAO, HY; IWATA, H; MAZAKI, T; HANAFUSA, H			AUGMENTATION OF METALLOPROTEINASE (GELATINASE) ACTIVITY SECRETED FROM ROUS-SARCOMA VIRUS-INFECTED CELLS CORRELATES WITH TRANSFORMING ACTIVITY OF SRC	ONCOGENE			English	Article						SRC; TRANSFORMATION; ROUS SARCOMA VIRUS; METALLOPROTEINASE; GELATINASE	CHICKEN-EMBRYO FIBROBLASTS; BASEMENT-MEMBRANE COLLAGEN; PROTEIN-KINASE ACTIVITY; GENE-PRODUCT; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; TISSUE INHIBITOR; C-SRC; ASSOCIATION; MATRIX	To search for the biochemical properties of cells relevant to transformation by p60(v-src), we examined the activities and amounts of metalloproteinase (gelatinase) released from chicken embryonic fibroblasts infected with various mutants of Rous sarcoma virus by zymography and immunoblotting, While nontransforming Src proteins, including cellular p60(c-src) and its nonmyristylated form, had no stimulatory effect, wild-type p60(v-src) and the transforming mutant of cellular p60(c-src) stimulated the secretion and proteolytic activation of metalloproteinases, Moreover, the activation of metalloproteinase secretion strongly correlated with the invasiveness of cells assayed by the modified Boyden Chamber method, Chimeric mutants between v-src and c-src, which are transforming but produce less distinct morphological changes in infected cells, also stimulated the secretion of metalloproteinases as well as wild-type p60(v-src). Deletion mutants of v-Src in which varying portions of the NH2-terminal half of p60(v-src) are deleted stimulated secretion to a level similar to that of wild-type regardless of the degree of morphological change they induce, Together with Src protein, other oncogene products including Yes, Fps, ErbB and Crk were also found to stimulate the secretion of metalloproteinases, Thus, these results suggest that transformation of cells with src and other oncogenes is closely secretion of metalloproteinases associated with the enhanced that may play an important role in tumor invasion and metastasis.	AICHI CANC CTR,RES INST,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; ROCKEFELLER UNIV,NEW YORK,NY 10021	Aichi Cancer Center; Rockefeller University	HAMAGUCHI, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT MOLEC PATHOGENESIS,SHOWA KU,TSURUMAI CHO 65,NAGOYA,AICHI 466,JAPAN.							ALBINI A, 1987, CANCER RES, V47, P3239; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CHEN JM, 1991, J BIOL CHEM, V266, P5113; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FELDMAN RA, 1983, J VIROL, V45, P782, DOI 10.1128/JVI.45.2.782-791.1983; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V77, P1311; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P1353; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMADA KM, 1978, NATURE, V275, P179, DOI 10.1038/275179a0; YAMAGATA S, 1991, CANCER LETT, V59, P51, DOI 10.1016/0304-3835(91)90135-5	38	61	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1037	1043						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535415				2022-12-25	WOS:A1995QN35300002
J	WHITEHURST, CE; OWAKI, H; BRUDER, JT; RAPP, UR; GEPPERT, TD				WHITEHURST, CE; OWAKI, H; BRUDER, JT; RAPP, UR; GEPPERT, TD			THE MEK KINASE-ACTIVITY OF THE CATALYTIC DOMAIN OF RAF-1 IS REGULATED INDEPENDENTLY OF RAS BINDING IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; SIGNAL TRANSDUCTION; THREONINE KINASE; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; BIOLOGICAL-ACTIVITY; RECEPTOR; INHIBITION	Deletion of the amino-terminal domain of Raf-1, which contains the Ras-binding region, results in the constitutive activation of the liberated Raf-1 catalytic domain in fibroblast cell lines. We demonstrate that the MEK kinase activity of the isolated Raf-1 catalytic domain, Raf-BXB, is not constitutively active, but is regulated in Jurkat T cells. Raf-BXB is activated by engaging the antigen receptor-CD3 complex, or treating cells with phorbol myristate acetate or okadaic acid. Increasing intracellular cAMP inhibits Raf-1 activation stimulated by phorbol myristate acetate, but not the activation of Raf-BXB. Serine 621, but not serine 499, is essential for Raf-BXB MEK kinase activity. Because Raf-BXB does not bind Ras, the data establishes a Ras-independent signal in directly regulating the activity of the Raf-1 catalytic domain.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GRAD PROGRAM IMMUNOL,DALLAS,TX 75235; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SEGER R, 1992, J BIOL CHEM, V267, P25628; SETH A, 1991, J BIOL CHEM, V266, P23521; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WASYLYK C, 1993, MOL CELL BIOL, V9, P2247; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	65	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5594	5599		10.1074/jbc.270.10.5594	http://dx.doi.org/10.1074/jbc.270.10.5594			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534298	hybrid			2022-12-25	WOS:A1995QL58000096
J	FALKENBERG, C; ALLHORN, M; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; SALVESEN, G; AKERSTROM, B; ENGHILD, JJ				FALKENBERG, C; ALLHORN, M; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; SALVESEN, G; AKERSTROM, B; ENGHILD, JJ			ALPHA(1)-MICROGLOBULIN DESTROYS THE PROTEINASE INHIBITORY ACTIVITY OF ALPHA(1)-INHIBITOR-3 BY COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; IMMUNE-RESPONSE; FAST FORMS; RAT; ALPHA-1-MICROGLOBULIN; ALPHA-2-MACROGLOBULIN; BINDING; RECEPTOR; ALPHA2-MACROGLOBULIN; ALPHA-1-INHIBITOR-3	The immunoregulatory plasma protein alpha(1)-microglobulin (alpha(1)-m) and the proteinase inhibitor alpha(1)-inhibitor-3 (alpha(1)I(3)) form a complex in rat plasma. In the present work, it was demonstrated that the alpha(1)I(3).alpha(1)-m complex has no inhibitory activity, the bait region was not cleaved by low amounts of proteinases, and it was unable to covalently incorporate proteinases. The results also indicated that the thiolester bond of the alpha(1)I(3).alpha(1)-m complex was broken. The alpha(1)I(3).alpha(1)-m complex was cleared from the circulation much faster than native alpha(1)I(3), with a half-life of approximately 7 min. Structurally, however, the alpha(1)I(3).alpha(1)-m complex was similar to native alpha(1)I(3) rather than alpha(1)I(3) cleaved by proteinases. It is speculated that the role of alpha(1)-m is to destroy the function of alpha(1)I(3) by blocking the bait region and breaking the thiolester and causing its physical elimination by rapid clearing from the blood circulation. It is also possible that the formation of complexes between alpha(1)-m and alpha(1)I(3) may serve as a mean to regulate the function of alpha(1)-m since its complex with alpha(1)I(3) is taken up rapidly by cellular receptors for alpha-macroglobulins.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	FALKENBERG, C (corresponding author), LUND UNIV, DEPT MED & PHYSIOL CHEM, POB 94, S-22100 LUND, SWEDEN.			Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL049542, R01HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24066, HL49542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; AKERSTROM B, 1992, FOLIA HISTOCHEM CYTO, V30, P183; BABIKERMOHAMED H, 1991, SCAND J IMMUNOL, V34, P655, DOI 10.1111/j.1365-3083.1991.tb01589.x; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BRATT T, 1993, BIOCHIM BIOPHYS ACTA, V1157, P147, DOI 10.1016/0304-4165(93)90058-G; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CALERO M, 1994, J BIOL CHEM, V269, P384; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1994, J IMMUNOL, V152, P1538; DAVID GS, 1974, BIOCHEMISTRY-US, V13, P1014, DOI 10.1021/bi00702a028; DEBANNE MT, 1976, BIOCHIM BIOPHYS ACTA, V428, P466; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; FALKENBERG C, 1994, BIOCHEM J, V301, P745, DOI 10.1042/bj3010745; FALKENBERG C, 1990, J BIOL CHEM, V265, P16150; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GAUTHIER F, 1979, BIOCHIM BIOPHYS ACTA, V566, P200, DOI 10.1016/0005-2744(79)90262-6; GLIEMANN J, 1987, FEBS LETT, V221, P55, DOI 10.1016/0014-5793(87)80351-4; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GRUBB A, 1986, J BIOL CHEM, V261, P14313; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; NILSON B, 1986, J IMMUNOL METHODS, V91, P275, DOI 10.1016/0022-1759(86)90490-4; PIERZCHALSKI P, 1992, FEBS LETT, V298, P165, DOI 10.1016/0014-5793(92)80047-K; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155	33	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4478	4483		10.1074/jbc.270.9.4478	http://dx.doi.org/10.1074/jbc.270.9.4478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533162	hybrid			2022-12-25	WOS:A1995QK08400047
J	JUAN, TSC; KELLEY, MJ; JOHNSON, DA; BUSSE, LA; HAILMAN, E; WRIGHT, SD; LICHENSTEIN, HS				JUAN, TSC; KELLEY, MJ; JOHNSON, DA; BUSSE, LA; HAILMAN, E; WRIGHT, SD; LICHENSTEIN, HS			SOLUBLE CD14 TRUNCATED AT AMINO-ACID-152 BINDS LIPOPOLYSACCHARIDE (LPS) AND ENABLES CELLULAR-RESPONSE TO LPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ENDOTOXIN; PROTEIN; ACTIVATION; MEMBRANE; LEUCINE; ANTIGEN; CELLS; RECEPTOR; CAPACITY	CD14 is a 55-kDa glycoprotein which binds lipopolysaccharide (LPS) and enables LPS-dependent responses in a variety of cells. In order to identify the domains in CD14 required for function, we deleted increasing amounts of CD14 from the C terminus. Truncated CD14 cDNA sequences were transfected into COS-7 cells and serum-free conditioned medium was analyzed for mutant CD14 expression and bioactivity, Mutant CD14s containing as few as 152 amino acids were found to have activity equivalent to full-length sCD14, To further characterize the mutant CD14, we constructed a stable Chinese hamster ovary cell line expressing sCD14(1-152) and purified the protein to homogeneity. sCD14(1-152) bound radioactive LPS, enabled U373 cells to synthesize interleukin 6 in response to LPS, and enabled human neutrophils to respond to smooth LPS. In all of these assays, the behavior of sCD14(1-152) was quantitatively similar to full-length sCD14. We also found that two neutralizing anti-CD14 antibodies (3C10 and MEM-18) bound and neutralized sCD14(1-152). We conclude from these experiments that the N-terminal 152 amino acids of CD14 are sufficient to bind LPS and confer essentially wild-type bioactivity in vitro.	AMGEN INC,THOUSAND OAKS,CA 91320; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Amgen; Rockefeller University								ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; BAZIL V, 1989, MOL IMMUNOL, V26, P657, DOI 10.1016/0161-5890(89)90048-5; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DETMERS PA, 1994, J IMMUNOL, V152, P2137; FERRERO E, 1990, J IMMUNOL, V145, P331; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GRUNWALD U, 1993, CIRC SHOCK, V39, P220; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1988, J IMMUNOL, V141, P547; HAZIOT A, 1993, J IMMUNOL, V150, P5556; HAZIOT A, 1993, J IMMUNOL, V151, P1500; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; KRANTZ DD, 1991, J BIOL CHEM, V266, P16801; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; MATA T, 1991, J BIOL CHEM, V266, P6554; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; SIMMONS DL, 1989, BLOOD, V73, P284; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TAN FL, 1990, J BIOL CHEM, V265, P13; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	29	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1382	1387		10.1074/jbc.270.3.1382	http://dx.doi.org/10.1074/jbc.270.3.1382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7530712	hybrid			2022-12-25	WOS:A1995QB15600061
J	WANG, XJ; GREENHALGH, DA; LU, XR; BICKENBACH, JR; ROOP, DR				WANG, XJ; GREENHALGH, DA; LU, XR; BICKENBACH, JR; ROOP, DR			TGF-ALPHA AND V-FOS COOPERATION IN TRANSGENIC MOUSE EPIDERMIS INDUCES ABERRANT KERATINOCYTE DIFFERENTIATION AND STABLE, AUTONOMOUS PAPILLOMAS	ONCOGENE			English	Article						CARCINOGENESIS; DIFFERENTIATION; ONCOGENE; GROWTH FACTOR	GROWTH-FACTOR-ALPHA; GRB2 ADAPTER PROTEIN; C-FOS; SKIN CARCINOGENESIS; HA-RAS; GENE-EXPRESSION; NUCLEOTIDE EXCHANGE; ALTERED REGULATION; PHORBOL ESTERS; MICE	To assess the synergistic effect of growth and transcription factor deregulation on carcinogenesis in vivo, mating experiments were performed between transgenic mice expressing human TGF alpha or v-fos exclusively in the epidermis by means of a human keratin K1-based targeting vector (HK1.fos, HK1.TGF alpha and HK1.fos/alpha). While HK1.TGF alpha mice exhibited mild epidermal hyperplasia resulting in a wrinkled appearance, this hyperplasia was significantly increased in HK1,fos/alpha mice which also exhibited a novel opalescent and peeling skin phenotype, HK1.fos/alpha keratinocyte differentiation was considerably deregulated with cornified cells appearing in the granular layer, granular cells in the spinous layer and a sixfold increase in BrdU labeling over normal. In addition, hyperplastic HK1.fos/alpha epidermis exhibited aberrant loricrin, filagrin and novel K13 expression associated with v-fos expression, Unlike adult HK1.TGF alpha controls, hyperplasia persisted in HK1,fos/alpha adults which also rapidly developed autonomous squamous cell papillomas, These results demonstrate that v-fos and TGF alpha over-expression can cooperate to reprogram keratinocyte differentiation and elicit the early stages of neoplasia. Moreover, TGF alpha over-expression appeared to play an early, initiating role in HK1.fos/alpha papilloma etiology, and a promotion role in the accelerated appearance of v-fos wound-associated preneoplastic phenotypes, However, the stable persistence of HK1.fos/alpha papillomas for up to 12 months, suggests that additional events are required for malignant conversion.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER; NCI NIH HHS [CA52607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHANG EH, 1982, NATURE, V297, P478; CHARDIN P, 1993, SCIENCE, V260, P1358; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUTRY AF, 1988, BIOCHEM BIOPH RES CO, V152, P216, DOI 10.1016/S0006-291X(88)80702-2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINZI E, 1988, MOL CARCINOGEN, V1, P7, DOI 10.1002/mc.2940010105; FISHER C, 1991, DEVELOPMENT, V111, P253; FRIEDBERG T, 1990, ARCH BIOCHEM BIOPHYS, V279, P167, DOI 10.1016/0003-9861(90)90477-G; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; GREENHALGH DA, 1994, ADV CANCER RES, V64, P247, DOI 10.1016/S0065-230X(08)60840-4; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAYAT MA, 1972, BASIC ELECTRON MICRO; HOGAN B, 1982, MANIPULATING MOUSE E; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; KIM SH, 1993, J CELL BIOL, V123, P87; LAND H, 1983, NATURE, V304, P546; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LU B, 1994, J BIOL CHEM, V269, P7443; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROSEJOHN S, 1988, CARCINOGENESIS, V9, P831, DOI 10.1093/carcin/9.5.831; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER SM, 1991, NEUROSCI RES, V29, P549; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHAUI K, 1993, SCIENCE, V261, P1744; SINN E, 1987, CELL, V49, P415; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TOFTGARD R, 1985, CARCINOGENESIS, V6, P655, DOI 10.1093/carcin/6.4.655; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VAUGHAN TJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P322, DOI 10.1016/0167-4781(92)90170-5; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; YUSPA SH, 1980, TRANSPLANT P, V12, P114	68	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					279	289						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530825				2022-12-25	WOS:A1995QC62400007
J	LIAO, J; LOWTHERT, LA; GHORI, N; OMARY, MB				LIAO, J; LOWTHERT, LA; GHORI, N; OMARY, MB			THE 70-KDA HEAT-SHOCK PROTEINS ASSOCIATE WITH GLANDULAR INTERMEDIATE FILAMENTS IN AN ATP-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR LAMIN-B; COGNATE PROTEIN; UNCOATING ATPASE; EPITHELIAL-CELLS; KINASE-C; BETA-INTERNEXIN; COATED VESICLES; VIMENTIN; CLATHRIN; BINDING	Keratin polypeptides 8 and 18 (K8/18) are intermediate filament proteins expressed preferentially in glandular epithelia. We describe the identification, by coimmunoprecipitation from normal human colonic tissues and cultured cell lines, of the 70-kDa heat shock protein (hsp) and its related heat shock cognate protein as K8/18-associated proteins (hsp/c). The association is significant but sub-stoichiometric and occurs preferentially with the soluble rather than the cytoskeletal K8/18 fractions. Heat stress increases the level of soluble K8/18 in association with an increase in hsp70 levels and an increase in the stoichiometry of K8/18-hsp70 association. Identity of the associated proteins was confirmed by microsequencing of a tryptic digest of the purified associated protein and by using anti-hsp/c70-specific antibodies. The K8/18-hsp/c70 complex can be dissociated in a Mg-ATP-dependent manner that requires ATP hydrolysis. finding of hsp to K8/18 can be reconstituted using purified bovine hsp70 and human K8/18 immunoprecipitates that have been depleted of bound hsp/c70 and increases slightly in the presence of ATP. The reconstituted H8/18-hsp70 complex can be again released in the presence of Mg-ATP. In addition, hsp70 binds to K8/18 without having a significant effect on in vitro filament assembly when added during or after assembly. Using an overlay assay, hsp70 binds exclusively to K8 in the presence of ATP. Our results show direct association of the hsp/c70 proteins with K8/18, This interaction may serve, at least in part, to regulate the function of these two abundant protein groups.	VET AFFAIRS MED CTR, PALO ALTO, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	LIAO, J (corresponding author), STANFORD UNIV, SCH MED, CTR DIGEST DIS, LAB SURGE BLDG, RM P304, STANFORD, CA 94305 USA.			Omary, Bishr/0000-0002-8624-2347	NIAAA NIH HHS [AA0947A-01] Funding Source: Medline; NIDDK NIH HHS [DK380707] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHTSTAETTER T, 1986, METHOD ENZYMOL, V134, P355; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BROWN KD, 1992, J CELL SCI, V102, P19; CARTAUD A, 1990, J CELL BIOL, V111, P581, DOI 10.1083/jcb.111.2.581; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHOU CF, 1994, BIOCHEM J, V298, P457, DOI 10.1042/bj2980457; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU CF, 1993, J CELL SCI, V105, P433; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; CHOU CF, 1994, J CELL SCI, V107, P1833; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; CLARK BD, 1986, BIOCHEM BIOPH RES CO, V139, P974, DOI 10.1016/S0006-291X(86)80273-X; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CYR DM, 1992, J BIOL CHEM, V267, P20927; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GAO Y, 1983, MOL CELL BIOL, V13, P2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1989, J CELL BIOL, V109, P257; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN LAD, 1989, J BIOL CHEM, V264, P15210; GUPTA RS, 1990, TRENDS BIOCHEM SCI, V15, P415, DOI 10.1016/0968-0004(90)90276-H; HAUS U, 1993, EMBO J, V12, P3763, DOI 10.1002/j.1460-2075.1993.tb06054.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WC, 1993, J CELL BIOCHEM, V52, P253, DOI 10.1002/jcb.240520302; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NAPOLITANO EW, 1985, J CELL BIOL, V101, P1323, DOI 10.1083/jcb.101.4.1323; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OHTSUKA K, 1986, RADIAT RES, V108, P34, DOI 10.2307/3576967; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; OMARY MB, 1992, J CELL BIOCHEM, V48, P316, DOI 10.1002/jcb.240480312; OMARY MB, 1992, MOL IMMUNOL, V29, P9, DOI 10.1016/0161-5890(92)90151-M; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUN TT, 1979, P NATL ACAD SCI USA, V76, P2813, DOI 10.1073/pnas.76.6.2813; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WALTON PA, 1994, J CELL BIOL, V125, P1037, DOI 10.1083/jcb.125.5.1037; WYATT TA, 1991, J BIOL CHEM, V266, P21274	64	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					915	922		10.1074/jbc.270.2.915	http://dx.doi.org/10.1074/jbc.270.2.915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529764	hybrid			2022-12-25	WOS:A1995QB81600065
J	ABRAMS, CS; ZHAO, W				ABRAMS, CS; ZHAO, W			SH3 DOMAINS SPECIFICALLY REGULATE KINASE-ACTIVITY OF EXPRESSED SRC FAMILY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; SITE-DIRECTED MUTAGENESIS; ROUS-SARCOMA VIRUS; C-SRC; TYROSINE KINASE; V-SRC; SIGNAL TRANSDUCTION; BINDING SITE; GENE-PRODUCT; 3T3 CELLS	The Src homology 2 (SH2) and Src homology 3 (SH3) domain are approximately 50% conserved in various Src family kinase members. Several lines of evidence suggest that in Src these domains are sequence motifs that direct substrate recognition, regulate kinase activity, or control subcellular localization, We sought to investigate the function of the homology domains in human Lyn, and to determine whether the differences between various SH3 domains affect function. To do this, we generated variant forms of Lyn lacking SH2 and SH3 domains, and created chimeras in which the SH3 domains in human c-Src and Lyn were replaced with SH3 domains from other family members. In contrast to similar deletions in Src, forms of Lyn lacking SH2 or SH3 had decreased kinase activity. The SH3 chimeras all had individual characteristics. Insertion of the Blk SH3 domain into Lyn restored kinase activity, while insertion of the Fyn or Src SH3 into Lyn enhanced the kinase activity 2-3-fold. Insertion of the Lyn SH3 into Src also doubled kinase activity, Expression of the Lyn-Src SH3 chimera in mammalian cells induced cell transformation, This study 1) demonstrates that the regulation of Lyn is different than Src, and 2) provides new evidence that despite their homology, there are important functional differences between the SH3 domains of the various Src family members.			ABRAMS, CS (corresponding author), UNIV PENN, SCH MED,DEPT MED,DIV HEMATOL ONCOL,415 CURIE BLVD, RM 678, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002464] Funding Source: NIH RePORTER; NHLBI NIH HHS [5-K11-HL02464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BRUGGE JS, 1984, J BIOL CHEM, V259, P4550; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRANDORI C, 1989, NATURE, V338, P467, DOI 10.1038/338467a0; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVINSON AD, 1991, P NATL ACAD SCI USA, V78, P1624; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MORRIS JF, 1991, ONCOGENE, V6, P2339; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1993, J BIOL CHEM, V268, P18070; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUDOL M, 1993, ONCOGENE, V8, P823; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; VEILLETTE A, 1992, ONCOGENE, V7, P971; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	54	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					333	339		10.1074/jbc.270.1.333	http://dx.doi.org/10.1074/jbc.270.1.333			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529230	hybrid			2022-12-25	WOS:A1995QA28700053
J	HAQUE, NS; BUCHBERG, AM; KHALILI, K				HAQUE, NS; BUCHBERG, AM; KHALILI, K			ISOLATION AND CHARACTERIZATION OF MRF-1, A BRAIN-DERIVED DNA-BINDING PROTEIN WITH A CAPACITY TO REGULATE EXPRESSION OF MYELIN BASIC-PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR SC35; MOUSE-BRAIN; MOLECULAR-BIOLOGY; MUTANT MICE; TRANSCRIPTION; ELEMENTS; CELLS; PROMOTER; IDENTIFICATION; CLONING	The 5'-flanking region of the myelin basic protein (MBP) contains several regulatory elements that differentially contribute to the cell type specific transcription of MBP in cells derived from the central nervous system. The distal regulatory element, termed MB3, had previously been shown to have characteristics of a cell type-specific enhancer element and bind to multiple brain-derived nuclear proteins in vitro. We now report the isolation of a recombinant cDNA clone, named myelin regulatory factor-1 (MRF-1) from a mouse brain expression library that encodes a novel protein which interacts with the MB3 domain. Computer-assisted analysis of MRF-1 revealed substantial sequence homology in the central and the COOH-terminal regions of this protein with the previously identified splicing factor SC35. Co transfection studies indicated that MRF-1 increases transcription of the MBP promoter in glial cells and that this activation requires an intact MRF-1-binding site within the MB3 region. MRF-1 cDNA hybridized to three RNA species 1.8, 2.5, and 3.0 kilobases which are expressed in all tissues analyzed. The gene encoding MRF-1 is located on the distal half of mouse chromosome 11 in a region where the human homolog would be predicted to reside on human chromosome 17.	THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, MOLEC NEUROVIROL SECT, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University				Buchberg, Arthur/0000-0002-0543-5631				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARBARESE E, 1978, J NEUROCHEM, V31, P779, DOI 10.1111/j.1471-4159.1978.tb00110.x; BERNDT JA, 1992, J BIOL CHEM, V267, P14730; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; BUCHBERG AM, 1989, GENETICS, V122, P153; BUCHBERG AM, 1993, MAMM GENOME, V4, pS164, DOI 10.1007/BF00360837; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CAMPAGNONI CW, 1978, ARCH BIOCHEM BIOPHYS, V190, P118, DOI 10.1016/0003-9861(78)90258-8; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; DEVINEBEACH K, 1992, NUCLEIC ACIDS RES, V20, P545, DOI 10.1093/nar/20.3.545; Dickie M.M., 1967, MOUSE NEWS LETT, V36, P39; DIETRICH W, 1992, GENETICS, V131, P423; DUBOISDALCQ M, 1986, J CELL BIOL, V102, P384, DOI 10.1083/jcb.102.2.384; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GONG QH, 1988, NUCLEIC ACIDS RES, V16, P1203, DOI 10.1093/nar/16.3.1203; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green MC., 1989, GENETIC VARIANTS STR, P12; HAAS S, 1993, MOL CELL BIOL, V13, P3103, DOI 10.1128/MCB.13.5.3103; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON I, 1990, MOUSE GENOME, V86, P226; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRONQUIST KE, 1987, J NEUROSCI RES, V18, P395, DOI 10.1002/jnr.490180303; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASHGARI MS, 1990, J CLIN INVEST, V86, P1671, DOI 10.1172/JCI114890; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACKLIN WB, 1991, J NEUROCHEM, V56, P163, DOI 10.1111/j.1471-4159.1991.tb02576.x; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARINI JC, 1993, GENOMICS, V15, P200, DOI 10.1006/geno.1993.1034; MEIER H, 1967, ARCH NEUROL-CHICAGO, V16, P59, DOI 10.1001/archneur.1967.00470190063008; MIURA M, 1989, GENE, V75, P31; MORGAN WC, 1950, J HERED, V41, P208, DOI 10.1093/oxfordjournals.jhered.a106131; SHIOTA C, 1991, J NEUROCHEM, V56, P818, DOI 10.1111/j.1471-4159.1991.tb01997.x; SIDMAN RL, 1980, MOUSE NEWS LETT, V63, P13; STRUM R, 1987, GENE DEV, V1, P1147; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WIKTOROWICZ M, 1991, DEV NEUROSCI-BASEL, V13, P143, DOI 10.1159/000112152; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZELLER NK, 1984, P NATL ACAD SCI-BIOL, V81, P18, DOI 10.1073/pnas.81.1.18	52	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31149	31156						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7527040				2022-12-25	WOS:A1994PV51000064
J	WANG, BC; DICKINSON, LA; KOIVUNEN, E; RUOSLAHTI, E; KOHWISHIGEMATSU, T				WANG, BC; DICKINSON, LA; KOIVUNEN, E; RUOSLAHTI, E; KOHWISHIGEMATSU, T			A NOVEL MATRIX ATTACHMENT REGION DNA-BINDING MOTIF IDENTIFIED USING A RANDOM PHAGE PEPTIDE LIBRARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHROMOSOMAL LOOP ANCHORAGE; NUCLEAR SCAFFOLD; DISPLAY LIBRARY; CHROMATIN; ENHANCER; AFFINITY; SITES; PROTEINS; TRANSCRIPTION; ORGANIZATION	SATB1 is a nuclear matrix attachment DNA (MAR)-binding protein which is predominantly expressed in thymocytes. This protein binds to the minor groove specifically recognizing an unusual DNA context exhibited by a specific MAR region with strong base-unpairing propensity. A phage library displaying nonamer random peptides without any built-in structure was used to identify a MAR binding motif of SATB1. One predominant cyclic peptide C1 of CRQNWGLEGC selected by a MAR-affinity column showed 50% identity with a segment in SATB1 (amino acids 355-363). Replacement of the C1 similarity segment in SATB1 by a random amino acid sequence or its truncation resulted in more than 80% reduction in MAR binding. In contrast, replacement of the same SATB1 segment with the C1 peptide restored full MAR binding activity and specificity as the wild-type protein. Single amino acid mutation of the conserved Arg or Glu residue to Ala greatly reduced MAR binding. Taken together our data show that a nine amino acid sequence in SATB1 represents a key MAR binding motif. Phage display may provide a general tool for rapid identification of DNA binding peptide motifs.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Koivunen, Erkki/0000-0002-6443-9595	NCI NIH HHS [CA 28896, CA 30199, CA 39681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039681, P30CA030199, P01CA028896, R37CA039681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIJKWEL DA, 1990, MOL CELL BIOL, V8, P5398; FAY E, 1988, P NATL ACAD SCI USA, V85, P121; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; LEVIWILSON B, 1990, J BIOL CHEM, V264, P21196; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; NIKOLOV D, 1992, NATURE, V360, P10; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z	38	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23239	23242		10.1074/jbc.270.40.23239	http://dx.doi.org/10.1074/jbc.270.40.23239			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559473	hybrid			2022-12-25	WOS:A1995RY90900002
J	TODD, R; MCBRIDE, J; TSUJI, T; DONOFF, RB; NAGAI, M; CHOU, MY; CHIANG, T; WONG, DTW				TODD, R; MCBRIDE, J; TSUJI, T; DONOFF, RB; NAGAI, M; CHOU, MY; CHIANG, T; WONG, DTW			DELETED IN ORAL CANCER-1 (DOC-1), A NOVEL ORAL TUMOR-SUPPRESSOR GENE	FASEB JOURNAL			English	Article						CHEMICAL CARCINOGENS; SUBTRACTIVE HYBRIDIZATION	HUMAN CHORIONIC-GONADOTROPIN; POUCH KERATINOCYTES; DOWN-REGULATION; HA-RAS; CELLS; EXPRESSION; ONCOGENES; CARCINOGENESIS; ANGIOGENESIS; CARCINOMA	We have identified, isolated, and partially characterized doc-1, a novel cDNA sequence whose activity is consistent with a suppressor of hamster oral carcinogenesis. Doc-1 is an evolutionarily conserved gene exhibiting loss of heterozygosity and marked reduction in expression in malignant hamster oral keratinocytes. The full-length doc-1 cDNA encodes an 87 amino acid product that shows a significant homology to one of the seven novel genes induced in mouse fibroblasts by TNF-alpha. Transfection of the full-length doc-1 cDNA into malignant hamster oral keratinocytes alters the behavior of the recipients in terms of morphology, growth rate, and anchorage-independent growth, suggesting reversion of transformation phenotypes. We propose that doc-1 is a novel tumor suppressor gene in oral cancer development.	HARVARD UNIV, SCH DENT MED, DEPT ORAL MED & DIAGNOST SCI, DIV ORAL PATHOL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ORAL & MAXILLOFACIAL SURG, BOSTON, MA 02114 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Massachusetts General Hospital			Wilson, Matthew H/K-3193-2013		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008680, R29DE008680, R03DE010208] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-10208, DE-08680, DE-00275] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUSTRUY E, 1993, CANCER RES, V53, P2888; BOUCK N, 1986, CANCER RES, V46, P5101; BOUCK NP, 1989, RECESSIVE ONCOGENE T; BOYD NM, 1988, J ORAL PATHOL MED, V17, P193, DOI 10.1111/j.1600-0714.1988.tb01524.x; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHIANG T, 1991, CARCINOGENESIS, V12, P529; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD JK, 1994, ORAL ONCOL, V288, P67; Freshney RI, 1994, CULTURE ANIMAL CELLS; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIMENEZCONTI IB, 1992, ADV EXP MED BIOL, V320, P63; GIMENEZCONTI IB, 1903, J CELL BIOCHEM, P83; HARLOW E, 1988, ANTIBODIES LABORATOR; HSU LC, 1993, CANCER RES, V53, P5766; HUSAIN Z, 1989, P NATL ACAD SCI USA, V86, P1264, DOI 10.1073/pnas.86.4.1264; ISSING WJ, 1993, ANTICANCER RES, V13, P2541; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JIN YS, 1993, ORAL ONCOL, V29B, P257, DOI 10.1016/0964-1955(93)90045-G; KLICKSTEIN LB, 1987, CURRENT PROTOCOLS MO; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LIN MH, 1994, ORAL ONCOL, V30B, P252, DOI 10.1016/0964-1955(94)90007-8; MOROCO JR, 1990, LAB INVEST, V63, P298; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; ODUKOYA O, 1983, J NATL CANCER I, V71, P1253; ONO M, 1985, J VIROL, V55, P387, DOI 10.1128/JVI.55.2.387-394.1985; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PARTRIDGE M, 1994, ORAL ONCOL, V30B, P248, DOI 10.1016/0964-1955(94)90006-X; POLVERINI PJ, 1986, LAB INVEST, V54, P432; POLVERINI PJ, 1988, CARCINOGENESIS, V9, P117, DOI 10.1093/carcin/9.1.117; POLVERINI PJ, 1988, J ORAL PATHOL MED, V17, P522, DOI 10.1111/j.1600-0714.1988.tb01328.x; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SAGER R, 1992, Current Opinion in Cell Biology, V4, P155, DOI 10.1016/0955-0674(92)90026-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCULLY C, 1993, J ORAL PATHOL MED, V22, P337, DOI 10.1111/j.1600-0714.1993.tb01086.x; Shklar G, 1984, ORAL CANCER, P41; SILVERMAN S, 1990, J AM DENT ASSOC, V120, P495, DOI 10.14219/jada.archive.1990.0082; SLAGA TJ, 1992, NATL CANCER I MONOGR, V13, P55; SOBEL ME, 1990, JNCI-J NATL CANCER I, V82, P267, DOI 10.1093/jnci/82.4.267; TADOKORO K, 1989, ONCOGENE, V4, P499; TAM JP, 1989, J IMMUNOL METHODS, V124, P53, DOI 10.1016/0022-1759(89)90185-3; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WONG DTW, 1985, J CELL BIOL, V101, P2245, DOI 10.1083/jcb.101.6.2245; WONG DTW, 1984, J BIOL CHEM, V259, P738; WONG DTW, 1993, ORAL ONCOL, V29B, P3, DOI 10.1016/0964-1955(93)90003-W; YASWEN P, 1990, P NATL ACAD SCI USA, V87, P7360, DOI 10.1073/pnas.87.19.7360	53	76	86	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1995	9	13					1362	1370		10.1096/fasebj.9.13.7557027	http://dx.doi.org/10.1096/fasebj.9.13.7557027			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557027				2022-12-25	WOS:A1995TA37000016
J	FISHER, SL; JIANG, WH; WANNER, BL; WALSH, CT				FISHER, SL; JIANG, WH; WANNER, BL; WALSH, CT			CROSS-TALK BETWEEN THE HISTIDINE PROTEIN-KINASE VANS AND THE RESPONSE REGULATOR PHOB - CHARACTERIZATION AND IDENTIFICATION OF A VANS DOMAIN THAT INHIBITS ACTIVATION OF PHOB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCOCCUS-FAECIUM BM4147; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; VANCOMYCIN RESISTANCE; PHOSPHATE REGULON; PEPTIDOGLYCAN PRECURSORS; D-ALANINE; 2-COMPONENT; PHOSPHORYLATION; PHOSPHOTRANSFER	VanS is a two-component transmembrane sensory kinase that, together with its response regulator VanR, activates the expression of genes responsible for vancomycin resistance in Enterococcus faecium BM4147, In this report, we demonstrate that the cytoplasmic domain of VanS (including residues Met(95) to Ser(384)) is ca pable of high level activation (>500 fold) of the Escherichia coli response regulator PhoB in vivo in the absence of its signaling kinases PhoR, CreC (PhoM), or acetyl phosphate synthesis, In vitro experiments carried out on the purified proteins confirmed that the activation is due to efficient cross-talk between VanS and PhoB, since phospho-VanS catalyzed transfer of its phosphoryl group to PhoB with approximate to 90% transfer in 5 min at a 1:4 VanS/PhoB stoichiometry. However, the rate of transfer was at least 100-fold slower than that observed between phospho-VanS and VanR. The in vivo activation of PhoB was used as a reporter system to identify peptide fragments of VanS capable of interfering with activation by VanS(Met(95)-Ser(384)), in order to identify an interaction domain, A library of plasmids encoding fragments of VanS(Met(95)-Ser(384)) was constructed using transposon mutagenesis, and a subpopulation of these plasmids encoded peptides that interfered with activation of PhoB by VanS(Met(95)-Ser(384)), A minimal size fragment (Met(95)-Ile(174)) was shown to be both necessary and sufficient for potent inhibition (85%) of this activation.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; PURDUE UNIV, DEPT SCI BIOL, W LAFAYETTE, IN 47907 USA	Harvard University; Harvard Medical School; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016259, R01GM035392] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16259, GM35392, GM49338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEMURA M, 1990, J BACTERIOL, V172, P6300, DOI 10.1128/jb.172.11.6300-6307.1990; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; ARTHUR M, 1991, GENE, V103, P133, DOI 10.1016/0378-1119(91)90405-Z; ARTHUR M, 1992, ANTIMICROB AGENTS CH, V36, P867, DOI 10.1128/AAC.36.4.867; ARTHUR M, 1992, J BACTERIOL, V174, P2582, DOI 10.1128/jb.174.8.2582-2591.1992; BERG CM, 1992, GENE, V113, P9, DOI 10.1016/0378-1119(92)90664-B; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; CHENG C, 1993, SCIENCE, V262, P539; COMESS KM, 1994, BIOCHEMISTRY-US, V33, P4175, DOI 10.1021/bi00180a010; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAKENBECK R, 1994, N COMP BIOC, V27, P535; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; JIN T, 1994, J MOL BIOL, V244, P477, DOI 10.1006/jmbi.1994.1746; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; METCALF WW, 1994, GENE, V138, P1, DOI 10.1016/0378-1119(94)90776-5; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5485, DOI 10.1073/pnas.91.12.5485; NAGARAJAN R, 1991, ANTIMICROB AGENTS CH, V35, P605, DOI 10.1128/AAC.35.4.605; NAGASAWA S, 1993, J BIOCHEM-TOKYO, V114, P350, DOI 10.1093/oxfordjournals.jbchem.a124180; NAGAYA M, 1993, GENE, V131, P119; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P76; REYNOLDS PE, 1994, BIOCHEM J, V301, P5, DOI 10.1042/bj3010005; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; TOKISHITA S, 1992, J BIOCHEM-TOKYO, V111, P707, DOI 10.1093/oxfordjournals.jbchem.a123823; UTSUMI R, 1994, GENE, V140, P73, DOI 10.1016/0378-1119(94)90733-1; WANDERSMAN C, 1993, MOL MICROBIOL, V7, P141, DOI 10.1111/j.1365-2958.1993.tb01105.x; Wanner B.L., 1994, METH MOL G, V3, P291; WANNER BL, 1993, J CELL BIOCHEM, V51, P47, DOI 10.1002/jcb.240510110; WANNER BL, 1992, J BACTERIOL, V174, P2124, DOI 10.1128/JB.174.7.2124-2130.1992; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WILHELM MP, 1991, MAYO CLIN PROC, V66, P1165, DOI 10.1016/S0025-6196(12)65799-1; WRIGHT GD, 1993, BIOCHEMISTRY-US, V32, P5057, DOI 10.1021/bi00070a013; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006; WU Z, 1995, BIOCHEMISTRY-US, V34, P2455, DOI 10.1021/bi00008a008; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	44	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23143	23149		10.1074/jbc.270.39.23143	http://dx.doi.org/10.1074/jbc.270.39.23143			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559459	hybrid			2022-12-25	WOS:A1995RY05400079
J	DANEN, EHJ; AOTA, SI; VANKRAATS, AA; YAMADA, KM; RUITER, DJ; VANMUIJEN, GNP				DANEN, EHJ; AOTA, SI; VANKRAATS, AA; YAMADA, KM; RUITER, DJ; VANMUIJEN, GNP			REQUIREMENT FOR THE SYNERGY SITE FOR CELL-ADHESION TO FIBRONECTIN DEPENDS ON THE ACTIVATION STATE OF INTEGRIN ALPHA-5-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GPIIB-IIIA; BINDING DOMAIN; MONOCLONAL-ANTIBODY; PLASMA FIBRONECTIN; SURFACE GLYCOPROTEIN; DIRECTED MUTAGENESIS; AFFINITY MODULATION; ENDOTHELIAL-CELLS; RECEPTOR; SUBUNIT	We investigated the influence of the activation state of integrin alpha 5 beta 1 on its dependence on the PHSRN synergy site for binding to RGD in fibronectin. K562 and MV3 cells lacked alpha v beta 3 expression and adhered to fibronectin through alpha 5 beta 1. Mel57 cells adhered through alpha v beta 3 and alpha 5 beta 1. A recombinant fibronectin polypeptide, containing five type III repeats from the central cell binding domain 3Fn6-10, and a mutated polypeptide lacking the synergy site were equally effective in promoting Mel57 adhesion. For K562 and MV3, the mutated polypeptide was not or poorly active compared to the control polypeptide. Expression of alpha v beta 3 in MV3 induced strong adhesion to the mutated polypeptide. TS2/16 stimulatory beta 1-integrin antibodies or Mn2+ induced alpha 5 beta 1-mediated adhesion of K562 and MV3 to GRGDSP. In the presence of TS2/16 or Mn2+, alpha 5 beta 1-mediated MV3 adhesion to the mutated polypeptide was equally strong as adhesion to the control polypeptide. Mn2+ or TS2/16 induced weak K562 binding to the mutated polypeptide, and in the presence of a combination of phorbol 12-myristate 13-acetate. Mn2+, and TS2/16, alpha 5 beta 1-mediated K562 adhesion to the mutated and control polypeptide was equally strong. Our findings demonstrate that requirement for the PHSRN synergy site for alpha 5 beta 1-mediated adhesion to RGD in fibronectin depends on the activation state of the integrin.	UNIV NIJMEGEN HOSP,DEPT PATHOL,6500 HB NIJMEGEN,NETHERLANDS; NIDR,DEV BIOL LAB,BETHESDA,MD 20892	Radboud University Nijmegen; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Ruiter, D.J./L-4617-2015	Yamada, Kenneth/0000-0003-1512-6805; danen, erik/0000-0002-0491-6345				AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BRUGGEN J, 1978, CANCER IMMUNOL IMMUN, V5, P53; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DANEN EHJ, 1993, INT J CANCER, V54, P315, DOI 10.1002/ijc.2910540225; DANEN EHJ, 1995, INT J CANCER, V61, P491, DOI 10.1002/ijc.2910610411; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; KANTOR RRS, 1987, J BIOL CHEM, V262, P15158; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MATSUMOTO A, 1993, J BIOL CHEM, V268, P228; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; Mosher DF, 1989, FIBRONECTIN; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OBARA M, 1995, EXP CELL RES, V216, P273, DOI 10.1006/excr.1995.1033; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAKADA Y, 1992, J BIOL CHEM, V268, P17597; TETTEROO PAT, 1983, BRIT J HAEMATOL, V55, P509, DOI 10.1111/j.1365-2141.1983.tb02166.x; VANDEWIELVANKEM.E, 1992, J CELL BIOL, V117, P461; VANKUPPEVELT THM, 1993, P NATL ACAD SCI USA, V86, P5415; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	64	142	147	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21612	21618		10.1074/jbc.270.37.21612	http://dx.doi.org/10.1074/jbc.270.37.21612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545166	Green Published, hybrid, Green Submitted			2022-12-25	WOS:A1995RU75700031
J	KIMURA, T; IMAI, Y; IRIMURA, T				KIMURA, T; IMAI, Y; IRIMURA, T			CALCIUM-DEPENDENT CONFORMATION OF A MOUSE MACROPHAGE CALCIUM-TYPE LECTIN - CARBOHYDRATE BINDING ACTIVITY IS STABILIZED BY AN ANTIBODY SPECIFIC FOR A CALCIUM-DEPENDENT EPITOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; INTEGRAL MEMBRANE-PROTEINS; MOLECULAR-CLONING; N-ACETYLGALACTOSAMINE; RECOGNITION DOMAINS; SEQUENCE-ANALYSIS; TUMOR-CELLS; SIALYL-LEX; CDNA; ADHESION	We established monoclonal antibodies (mAbs) against the mouse macrophage galactose/N-acetylgalactosamine-specific lectin (MMGL) that is a 42-kDa calcium-dependent lectin, using a solid phase carbohydrate binding assay as a novel strategy for screening mAbs. The specificity of six mAbs were investigated by antibody binding to native or recombinant forms (rML) of MMGL, flow cytometry, and immunoprecipitation using a macrophage cell line RAW264.7. Four of these mAbs strongly inhibited the binding of fluorescein 5-isothiocyanate-labeled galactosylated polylysine to immobilized rML, one inhibited moderately, and one did not inhibit binding, The competitive binding study revealed that the binding sites of these four blocking mAbs were closely related to each other but were different from the rest of these mAbs, A non-blocking mAb having a unique binding specificity (LOM-11) exhibited calcium-dependent binding to rML, suggesting that calcium-dependent epitope was not situated in the vicinity of the ligand binding site. Furthermore, pretreatment of rML with the mAb LOM-11 preserved ligand binding activity, especially in a low calcium environment, The four blocking mAbs mentioned above facilitated the binding of the mAb LOM-11 to rML. These results indicate that there is a positive cooperativity between the lectin's ligand binding site and its physically distinct calcium-dependent epitope.	UNIV TOKYO, FAC PHARMACEUT SCI, DEPT CANC BIOL & MOLEC IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Imai, Yasuyuki/E-8701-2010	Imai, Yasuyuki/0000-0002-8937-0221				BAUES RJ, 1977, J BIOL CHEM, V252, P57; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HARLOW E, 1988, ANTIBODIES LABORATOR; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; II M, 1990, J BIOL CHEM, V265, P11295; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1994, J IMMUNOL METHODS, V171, P23, DOI 10.1016/0022-1759(94)90224-0; IMAM SH, 1992, CURR MICROBIOL, V25, P1, DOI 10.1007/BF01570075; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KAWAKAMI K, 1994, JPN J CANCER RES, V85, P744, DOI 10.1111/j.1349-7006.1994.tb02423.x; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MATSUMOTO I, 1979, J BIOCHEM-TOKYO, V85, P1091, DOI 10.1093/oxfordjournals.jbchem.a132417; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; NAKAMORI S, 1993, CANCER RES, V53, P3632; ODA S, 1989, J BIOCHEM-TOKYO, V105, P1040, DOI 10.1093/oxfordjournals.jbchem.a122763; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROSEN SD, 1992, TRENDS GLYCOSCI GLYC, V4, P1; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SPRINGER GF, 1989, MOL IMMUNOL, V26, P1, DOI 10.1016/0161-5890(89)90013-8; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379	33	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16056	16062		10.1074/jbc.270.27.16056	http://dx.doi.org/10.1074/jbc.270.27.16056			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7541793	hybrid			2022-12-25	WOS:A1995RH22600029
J	JENSEN, TH; LEFFERS, H; KJEMS, J				JENSEN, TH; LEFFERS, H; KJEMS, J			INTERMOLECULAR BINDING-SITES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REV PROTEIN DETERMINED BY PROTEIN FOOTPRINTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENV MESSENGER-RNA; GENE-EXPRESSION REQUIRES; HIV-1 REV; RESPONSE ELEMENT; TRANS-ACTIVATOR; STRUCTURED REGION; CARBOXY-TERMINUS; ESCHERICHIA-COLI; TARGET SEQUENCE; AMINO-ACIDS	Human immunodeficiency virus encodes the regulatory protein Rev, which is required far expression of viral structural proteins, It binds to an RNA element (RRE) in the viral transcript and up-regulates the cyto plasmic appearance of unspliced and singly spliced viral mRNA We have studied the structure of Rev alone and complexed with the RRE and two monoclonal antibodies, using a protein footprinting approach, The method involves radioactive labeling at the C-terminal end of Rev fusion protein followed by limited proteolysis under native conditions, using 10 different proteinases. Rev protein was mainly cleaved within the basic domain and in the C-terminal part, The periodicity of the proteolytic cleavages within the basic domain strongly suggests that it forms an alpha-helical structure with one side facing the solvent, In the presence of RRE, these cleavages became significantly reduced. In addition, strong protection was observed at position 66 outside the basic domain, As a control for the specificity of the footprinting reaction, we confirmed the position of the epitopes for two monoclonal antibodies, This protein footprinting methodology is generally applicable to other proteins for which terminal modifications are acceptable, and provides a useful tool for mapping structure, substrate binding, and conformational changes.	AARHUS UNIV, DEPT MOLEC BIOL, DK-8000 AARHUS C, DENMARK; AARHUS UNIV, DEPT MED BIOCHEM, DK-8000 AARHUS C, DENMARK	Aarhus University; Aarhus University			Kjems, Jorgen/I-3490-2016; Jensen, Torben H/G-2954-2017	Kjems, Jorgen/0000-0003-4128-9317; 				ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; AUER M, 1994, BIOCHEMISTRY-US, V33, P2988, DOI 10.1021/bi00176a031; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; BOHNLEIN E, 1991, J VIROL, V65, P7051; BOND JS, 1989, PROTEOLYTIC ENZYMES; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAEFLER S, 1990, P NATL ACAD SCI USA, V87, P4571, DOI 10.1073/pnas.87.12.4571; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P8945, DOI 10.1021/bi00085a028; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG HV, 1983, METHOD ENZYMOL, V91, P318; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; JUE RA, 1985, BIOCHEMISTRY-US, V24, P162, DOI 10.1021/bi00322a023; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAWRENCE JB, 1991, NEW BIOL, V3, P1220; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MATSUDAIRA P, 1985, P NATL ACAD SCI USA, V82, P6788, DOI 10.1073/pnas.82.20.6788; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	54	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13777	13784		10.1074/jbc.270.23.13777	http://dx.doi.org/10.1074/jbc.270.23.13777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539792	hybrid			2022-12-25	WOS:A1995RC44800031
J	KATO, M; ISHIZAKI, A; HELLMAN, U; WERNSTEDT, C; KYOGOKU, M; MIYAZONO, K; HELDIN, CH; FUNA, K				KATO, M; ISHIZAKI, A; HELLMAN, U; WERNSTEDT, C; KYOGOKU, M; MIYAZONO, K; HELDIN, CH; FUNA, K			A HUMAN KERATINOCYTE CELL-LINE PRODUCES 2 AUTOCRINE GROWTH-INHIBITORS, TRANSFORMING GROWTH-FACTOR-BETA AND INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-6, IN A CALCIUM-DEPENDENT AND CELL DENSITY-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HUMAN SERUM; MOLECULAR-CLONING; HUMAN-FETUS; CULTURED KERATINOCYTES; EPIDERMAL-CELLS; RETINOIC ACID; PURIFICATION; DIFFERENTIATION; IDENTIFICATION; RECEPTOR	Two growth inhibitors were identified in culture medium conditioned by a human keratinocyte cell line, HaCat. TGF-beta was detected in media conditioned by growing or confluent HaCat cells, as well as in media conditioned at physiological (1 mM) or low (0.03 mM) Ca2+ concentrations. However, a considerable part of transforming growth factor beta (TGF-beta) in media conditioned at a physiological Ca2+ concentration was in active form, whereas most TGF-beta in media conditioned at a low Ca2+ concentration was latent. The other growth-inhibitory activity, which was detected only in media conditioned by confluent cells at a physiological Ca2+ concentration, was purified to homogeneity by a four-step procedure. The N-terminal amino acid sequence of the 33-kDa protein was identical with that of insulin-like growth factor binding protein-6 (IGFBP-6). Purified IGFBP-6 inhibited the growth of HaCat and Balb/MK keratinocyte cell lines, as well as Mv1Lu cells. The growth activity was also demonstrated by human recombinant IGFBP-6. In summary, HaCat cells secrete at least two possible autocrine growth inhibitors: TGF-beta which is secreted constitutively, but activated in a Ca2+-dependent manner, and IGFBP-6 which is secreted in a cell density- and Ca2+-dependent manner.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; TOHOKU UNIV,SCH MED,DEPT PATHOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Ludwig Institute for Cancer Research; Tohoku University				Ishisaki, Akira/0000-0001-6704-4436				ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; GRAY A, 1987, DNA-J MOLEC CELL BIO, V6, P283, DOI 10.1089/dna.1987.6.283; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; HAN VKM, 1987, PEDIATR RES, V22, P245, DOI 10.1203/00006450-198709000-00001; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOLLEY RW, 1980, P NATL ACAD SCI-BIOL, V77, P5989, DOI 10.1073/pnas.77.10.5989; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; Lamson G, 1991, Growth Factors, V5, P19, DOI 10.3109/08977199109000268; LILLIE JH, 1980, EXP CELL RES, V125, P153, DOI 10.1016/0014-4827(80)90199-8; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MARTIN JL, 1994, J BIOL CHEM, V269, P11470; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NICKOLOFF BJ, 1988, DERMATOLOGICA, V177, P265, DOI 10.1159/000248577; Nielsen Finn Cilius, 1992, Progress in Growth Factor Research, V4, P257, DOI 10.1016/0955-2235(92)90023-B; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OH YM, 1993, J BIOL CHEM, V268, P14964; PEEHL DM, 1980, IN VITRO CELL DEV B, V16, P516; Rechler M. M., 1990, PEPTIDE GROWTH FACTO, P263; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROGHANI M, 1989, FEBS LETT, V255, P253, DOI 10.1016/0014-5793(89)81101-9; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Wataya-Kaneda Mari, 1994, Journal of Dermatological Science, V8, P38, DOI 10.1016/0923-1811(94)90319-0; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; ZAPF J, 1990, J BIOL CHEM, V265, P14892	47	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12373	12379		10.1074/jbc.270.21.12373	http://dx.doi.org/10.1074/jbc.270.21.12373			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7539002	hybrid			2022-12-25	WOS:A1995QZ71100010
J	MANGROO, D; RAJBHANDARY, UL				MANGROO, D; RAJBHANDARY, UL			MUTANTS OF ESCHERICHIA-COLI INITIATOR TRANSFER-RNA DEFECTIVE IN INITIATION - EFFECTS OF OVERPRODUCTION OF METHIONYL-TRANSFER-RNA TRANSFORMYLASE AND THE INITIATION-FACTORS IF2 AND IF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONINE TRANSFER-RNA; ELONGATION-FACTOR-TU; PROTEIN-SYNTHESIS; ANTICODON STEM; ACCEPTOR STEM; FACTOR-II; FORMYLTRANSFERASE; SEQUENCE; RECOGNITION; EXPRESSION	We describe the effects of overproduction of methionyl-tRNA transformylase and initiation factors IF2 and IF3 on the activity, in vivo, of initiator tRNA mutants defective at specific steps of the initiation process in protein synthesis. The activity of the U35A36/G72 and U35A36/G72G73 mutants, which are defective in formylation, was increased by overproduction of methionyl-tRNA transformylase. In contrast, the activity of the C30:G40/U35A36 mutant, which is formylated normally but is defective in binding to the ribosomal P site, was not increased. Overproduction of IF2 had a strong stimulatory effect on the activity of virtually all the mutants carrying the U35A36 anticodon sequence change, including the U35A36, U35A36/G72, U35A36/G72G73, and the C30:G40/U35A36 mutants. In cells overproducing IF2, the amount of protein made by translation of a mutant mRNA, which uses the U35A36 mutant initiator tRNA, is severalfold higher than that made by translation of a wild type mRNA. We discuss the possible implications of this result on overproduction of proteins and on the order of assembly of the 30 S ribosome . mRNA . fMet-tRNA initiation complex in Escherichia coli. Overproduction of IF3 did not affect the initiator activity of any of the tRNA mutants studied.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM17151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017151, R37GM017151, R01GM017151, R56GM017151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERLY AG, 1972, NATURE-NEW BIOL, V240, P245, DOI 10.1038/newbio240245a0; BROMBACH M, 1987, MOL GEN GENET, V208, P94, DOI 10.1007/BF00330428; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; DONDON J, 1985, BIOCHIMIE, V67, P643, DOI 10.1016/S0300-9084(85)80206-6; DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025; GIEGE R, 1973, FEBS LETT, V30, P291, DOI 10.1016/0014-5793(73)80672-6; GOLD L, 1984, P NATL ACAD SCI-BIOL, V81, P7061, DOI 10.1073/pnas.81.22.7061; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; HOWE JG, 1978, ARCH BIOCHEM BIOPHYS, V191, P813, DOI 10.1016/0003-9861(78)90424-1; KNOWLTON RG, 1980, J MOL BIOL, V139, P721, DOI 10.1016/0022-2836(80)90057-1; KOZAK M, 1983, MICROBIOL REV, V47, P1; LATEANA A, 1993, P NATL ACAD SCI USA, V90, P4161, DOI 10.1073/pnas.90.9.4161; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MASSON JM, 1986, GENE, V47, P179, DOI 10.1016/0378-1119(86)90061-2; MEINNEL T, 1993, J BACTERIOL, V175, P993, DOI 10.1128/JB.175.4.993-1000.1993; MEINNEL T, 1993, J BACTERIOL, V175, P7737, DOI 10.1128/JB.175.23.7737-7740.1993; PINGOUD A, 1980, BIOCHEMISTRY-US, V19, P2108, DOI 10.1021/bi00551a017; PRAMANIK A, 1986, J BACTERIOL, V168, P746, DOI 10.1128/jb.168.2.746-751.1986; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SMITH JD, 1973, NATURE-NEW BIOL, V243, P66; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1992, J BACTERIOL, V174, P7819, DOI 10.1128/JB.174.23.7819-7826.1992; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; WAGNER T, 1980, EUR J BIOCHEM, V108, P213, DOI 10.1111/j.1432-1033.1980.tb04714.x; WAGNER T, 1984, J BIOL CHEM, V259, P4706; WAKAO H, 1989, J BIOL CHEM, V264, P20363	41	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					12203	12209		10.1074/jbc.270.20.12203	http://dx.doi.org/10.1074/jbc.270.20.12203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538134	hybrid			2022-12-25	WOS:A1995QY73600075
J	TOBIAS, PS; SOLDAU, K; GEGNER, JA; MINTZ, D; ULEVITCH, RJ				TOBIAS, PS; SOLDAU, K; GEGNER, JA; MINTZ, D; ULEVITCH, RJ			LIPOPOLYSACCHARIDE-BINDING PROTEIN-MEDIATED COMPLEXATION OF LIPOPOLYSACCHARIDE WITH SOLUBLE CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PHASE REACTANT; LIPID-A; ACTIVATION; RESPONSES; COMPONENT; ENDOTOXIN; MEMBRANE; CELLS; LPS	Endotoxin (lipopolysaccharide; LPS) activates a wide variety of host defense mechanisms. In mammals LPS binding protein (LBP) and CD14 interact with LPS to mediate cellular activation, Using sucrose density gradients and a fluorescent endotoxin derivative we have investigated the mechanism of LPS binding to LBP and the soluble form of CD14 (sCD14). LPS binds to LBP to form two types of complex; at low ratios of LPS to LBP complexes with one molecule of LBP and 1-2 molecules of LPS predominate, while at high ratios of LPS to LBP a large aggregate of LBP and LPS predominates, Complexes of LPS with sCD14 do not form large aggregates, consisting of only 1-2 LPS bound to a single sCD14 even at high multiples of LPS to sCD14. LBP catalyzes LPS binding to sCD14, Catalysis by LBP apparently occurs because LBP provides a pathway for LPS to bind to sCD14 which avoids the necessity for LPS monomers in aqueous solution, The dissociation constants for LPS . LBP and LPS . sCD14 complexes were determined to be 3.5 x 10(-9) and 29 x 10(-9) M, respectively. These numbers suggest that when LBP and sCD14 are present at roughly equal concentrations as they are in normal human plasma and compete for limited LPS, the LPS will predominantly associate with LBP.			TOBIAS, PS (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM-12, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ulevitch, Richard J/Q-3393-2017		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136, R01AI032021] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23584] Funding Source: Medline; NIAID NIH HHS [AI15136, AI32021] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DIN ZZ, 1993, BIOCHEMISTRY-US, V32, P4579, DOI 10.1021/bi00068a014; FEARNS C, 1995, J EXP MED, V181, P857, DOI 10.1084/jem.181.3.857; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALANOS C, 1986, EUR J BIOCHEM, V160, P55, DOI 10.1111/j.1432-1033.1986.tb09939.x; GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1988, J IMMUNOL, V141, P547; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LOPPNOW H, 1995, INFECT IMMUN, V63, P1020, DOI 10.1128/IAI.63.3.1020-1026.1995; MATHISON JC, 1992, J IMMUNOL, V149, P200; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; PUGIN J, 1993, J EXP MED, V178, P2193, DOI 10.1084/jem.178.6.2193; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SKELLY RR, 1979, INFECT IMMUN, V23, P287, DOI 10.1128/IAI.23.2.287-293.1979; TAKAYAMA K, 1994, J BIOL CHEM, V269, P2241; TANFORD C, 1980, HYDROPHOBIC EFFECT; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; WAINWRIGHT NR, 1990, INT CONGR SER, V923, P315; WEINGARTEN R, 1993, J LEUKOCYTE BIOL, V53, P518, DOI 10.1002/jlb.53.5.518; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	26	260	270	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10482	10488		10.1074/jbc.270.18.10482	http://dx.doi.org/10.1074/jbc.270.18.10482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537731	hybrid			2022-12-25	WOS:A1995QW60100021
J	SIRI, A; KNAUPER, V; VEIRANA, N; CAOCCI, F; MURPHY, G; ZARDI, L				SIRI, A; KNAUPER, V; VEIRANA, N; CAOCCI, F; MURPHY, G; ZARDI, L			DIFFERENT SUSCEPTIBILITY OF SMALL AND LARGE HUMAN TENASCIN-C ISOFORMS TO DEGRADATION BY MATRIX METALLOPROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CELL-LINES; EXPRESSION; TISSUES; CYTOTACTIN; ADHESION; LOCALIZATION; FIBRONECTIN	Two major tenascin-C (TN-C) isoforms are generated by the alternative splicing of the pre-mRNA. The large isoform contains seven extra type three repeats that, by contrast, are omitted in the small TN-C isoform, The large TN-C isoform is mainly expressed at the onset of cellular processes that entail active cell migration, proliferation, or tissue remodeling such as occur in neoplasia, wound healing, and during development. Thus, the large TN-C isoform seems to be a specific component of the provisional extracellular matrix. Here we have studied the degradation of the large and small TN-C isoforms by matrix metalloproteinases (MMPs) 2, 3, 7, and 9. Among these proteolytic enzymes only MMP-7 can degrade the small TN-C isoform removing the NH2-terminal knob. The large TN-C isoform shows the same MMP-7-sensitive site adjacent to the NH2-terminal sequence, but is further degraded in the splicing area where three fibronectin-like type III repeats are completely digested. Moreover, the large TN-C isoform is degraded by MMP-2 and MMP-3 which completely digest a single type III repeat inside the splicing area. By contrast, the large TN-C isoform is resistant to MMP-9 digestion. The results show that the presence of the spliced sequence introduces new protease-sensitive sites in the large TN-C isoform.	IST NAZL RIC CANC, CELL BIOL LAB, I-16132 GENOA, ITALY; STRANGEWAYS RES LAB, CAMBRIDGE CB1 4RN, ENGLAND	University of Genoa; IRCCS AOU San Martino IST				Knauper, Vera/0000-0002-3965-9924	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BALZA E, 1993, FEBS LETT, V332, P39, DOI 10.1016/0014-5793(93)80479-E; BORSI L, 1994, CELL ADHES COMMUN, V1, P307, DOI 10.3109/15419069409097262; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; CARNEMOLLA B, 1992, EUR J BIOCHEM, V205, P561, DOI 10.1111/j.1432-1033.1992.tb16813.x; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CHIQUET M, 1991, EUR J BIOCHEM, V199, P379, DOI 10.1111/j.1432-1033.1991.tb16134.x; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1993, SEMIN CANCER BIOL, V4, P301; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; CHUONG CM, 1991, AM J PATHOL, V138, P427; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; CROSSIN KL, 1994, PERSPECT DEV NEUROBI, V2, P21; EDELMAN GM, 1992, TRENDS BIOCHEM SCI, V17, P228, DOI 10.1016/0968-0004(92)90383-K; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JULIAN JA, 1994, DEVELOPMENT, V120, P661; KAPLONY A, 1991, DEVELOPMENT, V112, P605; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LEPRINI A, 1994, PERSPECT DEV NEUROBI, V2, P117; MACKIE EJ, 1994, PERSPECT DEV NEUROBI, V2, P125; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NATALI PG, 1989, INT J CANCER, P66; OYAMA F, 1991, CANCER RES, V51, P4876; PRIETO AL, 1990, J CELL BIOL, V111, P685, DOI 10.1083/jcb.111.2.685; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SAKAKURA T, 1994, PERSPECT DEV NEUROBI, V2, P111; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TAYLOR HC, 1989, J CELL BIOCHEM, V41, P71, DOI 10.1002/jcb.240410204; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; TUCKER RP, 1994, PERSPECT DEV NEUROBI, V2, P89; TUCKER RP, 1993, J CELL SCI, V104, P69; TUCKER RP, 1994, FUNCTION TENASCIN HY, V2; VAUGHAN L, 1994, PERSPECT DEV NEUROBI, V2, P43; VENTIMIGLIA JB, 1992, J NEUROIMMUNOL, V36, P41, DOI 10.1016/0165-5728(92)90029-K; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	49	152	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8650	8654		10.1074/jbc.270.15.8650	http://dx.doi.org/10.1074/jbc.270.15.8650			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7536739	hybrid			2022-12-25	WOS:A1995QT44800044
J	SAMET, JM; FASANO, MB; FONTEH, AN; CHILTON, FH				SAMET, JM; FASANO, MB; FONTEH, AN; CHILTON, FH			SELECTIVE INDUCTION OF PROSTAGLANDIN G/H SYNTHASE-I BY STEM-CELL FACTOR AND DEXAMETHASONE IN MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; SWISS 3T3 CELLS; C-KIT LIGAND; H-SYNTHASE; MESSENGER-RNA; PHORBOL ESTER; INDUCIBLE CYCLOOXYGENASE; ALVEOLAR MACROPHAGES; SYNOVIAL-FLUID; EXPRESSION	This study examines the regulatory effects of two cytokines, stem cell factor (SCF) and interleukin-3, and a glucocorticoid, dexamethasone, on Lipid mediator generation in mouse bone marrow-derived mast cells (BMMC). Treatment of BMMC with SCF induced a modest, dose-dependent increase in three eicosanoids, thromboxane B-2, prostaglandin D-2, and leukotriene B-4. These increases were accompanied by a marked elevation in cytosolic PLA(2) (cPLA(2)). Dexamethasone blocked the induction of cPLA(2) levels and the elevation in leukotriene B-4 induced by SCF. By contrast, the combination of SCF and dexamethasone dramatically increased (5-8-fold) the capacity by BMMC to produce prostanoid products. This increase in prostanoid products was mirrored by an increase in prostaglandin G/H synthase I (PGHS-I) levels. Dexamethasone, alone, had no effect on PGHS-I, cPLA(2), or prostanoid levels. Moreover, neither SCF or dexamethasone, alone or in combination, influenced prostaglandin G/H synthase II (PGHS-II) levels. In contrast to SCF, interleukin-3 alone or in combination with dexamethasone had no effect on prostanoid synthesis or PGHS-I or II levels. To better understand the SCF and dexamethasone effect, PGHS-I and PGHS-II mRNA expression were examined by Northern analysis. PGHS-I mRNA was markedly induced (maximal levels at 5 h) by the combination of SCF and dexamethasone. PGHS-II mRNA was undetectable in either control or SCF/dexamethasone-treated BMMC. Neither SCF or dexamethasone, alone, altered mRNA for either PGHS isotype. Taken together, these studies reveal that PGHS-I may be critical to prostanoid formation in mast cells exposed to cytokines and glucocorticoids. Moreover, they suggest that synergistic induction of PGHS-I could represent a novel mechanism for the anti-inflammatory action of glucocorticoids.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, PULM & CRIT CARE MED SECT, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, INFECT DIS SECT, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT INTERNAL MED, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center				Fasano, Mary/0000-0001-8468-1605; Chilton, Floyd/0000-0002-3686-0198	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024985, R29AI024985] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 07122-0352] Funding Source: Medline; NHLBI NIH HHS [HL-50395] Funding Source: Medline; NIAID NIH HHS [AI 24985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHEN J, 1994, J BIOL CHEM, V269, P2365; CHILTON FH, 1990, CHEM IMMUNOL, V49, P173; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COLEMAN JW, 1993, J IMMUNOL, V150, P556; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DIEZ E, 1990, J BIOL CHEM, V265, P14654; ELING TE, 1991, J BIOL CHEM, V266, P12348; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FONTEH AN, 1992, J IMMUNOL, V148, P1784; FONTEH AN, 1994, J IMMUNOL, V152, P5438; GALLI SJ, 1990, LAB INVEST, V62, P5; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HOLGATE ST, 1980, J IMMUNOL, V125, P1367; HUBBARD WC, 1987, PROSTAGLANDIN LIPID, P365; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; INASE N, 1994, J LEUKOCYTE BIOL, V55, P192; JACKSON BA, 1993, BIOCHEM BIOPH RES CO, V197, P1465, DOI 10.1006/bbrc.1993.2642; KIRSHENBAUM AS, 1989, J IMMUNOL, V142, P2424; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; LEE SH, 1992, J BIOL CHEM, V267, P25934; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RILEY SC, 1992, GYNECOL OBSTET INVES, V33, P85, DOI 10.1159/000294854; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SCHLEIMER RP, 1983, CLIN REV ALLERG, V1, P327; SEIBERT K, 1991, ADV PROSTAG THROMB L, V21, P45; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SMIEJA Z, 1993, AM J OBSTET GYNECOL, V169, P653, DOI 10.1016/0002-9378(93)90639-Z; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; SMITH JB, 1974, THROMB RES, V5, P291; TAKAISHI T, 1992, INT ARCH ALLERGY IMM, V98, P205, DOI 10.1159/000236186; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; VANDENBOSCH H, 1992, ADV EXP MED BIOL, V318, P1; VISHWANATH BS, 1993, J CLIN INVEST, V92, P1974, DOI 10.1172/JCI116791; WAITE M, 1990, BIOCH MOL BIOL PHYSL; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; ZYGLEWSKA T, 1993, J LAB CLIN MED, V122, P542	64	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8044	8049		10.1074/jbc.270.14.8044	http://dx.doi.org/10.1074/jbc.270.14.8044			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7536192	hybrid			2022-12-25	WOS:A1995QR52600042
J	WANG, YD; WONG, K; WOOD, WI				WANG, YD; WONG, K; WOOD, WI			INTRACELLULAR TYROSINE RESIDUES OF THE HUMAN GROWTH-HORMONE RECEPTOR ARE NOT REQUIRED FOR THE SIGNALING OF PROLIFERATION OR JAK-STAT ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; EXTRACELLULAR DOMAIN; TRANSDUCTION PATHWAY; CYTOKINE RECEPTORS; KINASE; PHOSPHORYLATION; PROTEIN; CELLS; IDENTIFICATION	Ligand binding and dimerization of the growth hormone (GH) receptor leads to the rapid tyrosine phosphorylation of the intracellular kinase, Jak2, to the tyrosine phosphorylation and activation of STAT protein(s) and to the tyrosine phosphorylation of the receptor itself. Expression of the human GH receptor in the mouse promyeloid, interleukin-3-dependent cell line, FDC-P1, shows that this receptor can signal ligand-dependent proliferation in these cells as well as induce the tyrosine phosphorylation of Jak2 and the activation of transcription factors. We now examine the requirement for tyrosine phosphorylation of the GH receptor for these three events by expression of a receptor without tyrosine residues in the intracellular domain, Six of the seven intracellular tyrosine residues were removed by a carboxyl-terminal truncation, and the remaining tyrosine was changed to phenylalanine to yield the GH receptor D351Stop/Y314F. When expressed in FDC-P1 cells, this receptor retained its ability to induce the tyrosine phosphorylation of Jak2, to induce the activation of transcription factors, and to signal ligand dependent cell proliferation. Thus, tyrosine phosphorylation of the GH receptor is not essential for the signaling of these three events at least in this system. This finding contrasts with that for the interferon-gamma receptor system where data indicate that the specific tyrosine phosphorylation of the interferon-gamma receptor leads to an association with the STAT protein, p91, that is the mechanism by which ligand couples the receptor to the signal transduction system.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KILGOUR E, 1994, FEBS LETT, V343, P205, DOI 10.1016/0014-5793(94)80556-3; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; RAZ R, 1994, J BIOL CHEM, V269, P24391; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG YD, 1995, IN PRESS MOL ENDOCRI; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0	34	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7021	7024		10.1074/jbc.270.13.7021	http://dx.doi.org/10.1074/jbc.270.13.7021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535764	hybrid			2022-12-25	WOS:A1995QQ43100003
J	GIASSON, E; MELOCHE, S				GIASSON, E; MELOCHE, S			ROLE OF P70 S6 PROTEIN-KINASE IN ANGIOTENSIN-II-INDUCED PROTEIN-SYNTHESIS IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR SUBTYPES; IMMUNOSUPPRESSANT RAPAMYCIN; RIBOSOMAL PROTEIN-S6; GROWTH-FACTOR; C ACTIVATION; MAP2 KINASE; LATE PHASE; EXPRESSION; RAT	Angiotensin II (AII) is a growth factor which induces cellular hypertrophy in cultured vascular smooth muscle cells (SMC). To understand the molecular basis of this action, we have examined the role of the 70-kDa Se kinases (p70(S6K)) in the hypertrophic response to AII in aortic SMC. AII potently stimulated the phosphotransferase activity of p70(S6K), which reached a maximal value at 15 min and persisted for at least 4 h. This response was completely abolished when the cells were incubated in the presence of the AT(1)-selective receptor antagonist losartan. The enzymatic activation of p70(S6K) was associated with increased phosphorylation of the enzyme on serine and threonine residues. The immunosuppressant drug rapamycin was found to selectively inhibit the activation of p70(S6K) by AII, but not the activation of mitogen-activated protein kinase or the induction of c-fos mRNA expression. Treatment of aortic SMC with rapamycin also potently inhibited AII-stimulated protein synthesis with a half-maximal concentration similar to that required for inhibition of p70(S6K). These results provide strong evidence that p70(S6K) plays a critical role in the signaling pathways by which AII induces hypertrophy of vascular SMC.	HOTEL DIEU MONTREAL, CTR RECH, MONTREAL, PQ H2W 1T8, CANADA; UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H2W 1T8, CANADA	Universite de Montreal; Universite de Montreal								ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1993, J CELL PHYSIOL, V154, P368, DOI 10.1002/jcp.1041540221; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHANG RSL, 1991, LIFE SCI, V49, P1485, DOI 10.1016/0024-3205(91)90048-G; Chiu A T, 1991, Receptor, V1, P133; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FORCE T, 1991, J BIOL CHEM, V266, P6650; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HADRAVA V, 1989, HYPERTENSION, V13, P589, DOI 10.1161/01.HYP.13.6.589; HARRIS RC, 1992, AM J PHYSIOL, V263, pF127, DOI 10.1152/ajprenal.1992.263.1.F127; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1995, IN PRESS J CELL PHYS; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAUL M, 1992, TRENDS CARDIOVAS MED, V2, P94, DOI 10.1016/1050-1738(92)90013-I; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHELLING P, 1991, J HYPERTENS, V9, P3; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCOTTBURDEN T, 1988, BIOCHEM BIOPH RES CO, V151, P583, DOI 10.1016/0006-291X(88)90634-1; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TERADA N, 1993, J BIOL CHEM, V268, P12062; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VISWANATHAN M, 1991, BIOCHEM BIOPH RES CO, V179, P1361, DOI 10.1016/0006-291X(91)91723-P; WOLF G, 1991, BIOCHEM BIOPH RES CO, V176, P902, DOI 10.1016/S0006-291X(05)80271-2; WONG PC, 1992, TRENDS ENDOCRIN MET, V3, P211, DOI 10.1016/1043-2760(92)90030-5	68	98	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5225	5231		10.1074/jbc.270.10.5225	http://dx.doi.org/10.1074/jbc.270.10.5225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534292	hybrid			2022-12-25	WOS:A1995QL58000043
J	THOMPSON, TC; PARK, SH; TIMME, TL; REN, C; EASTHAM, JA; DONEHOWER, LA; BRADLEY, A; KADMON, D; YANG, G				THOMPSON, TC; PARK, SH; TIMME, TL; REN, C; EASTHAM, JA; DONEHOWER, LA; BRADLEY, A; KADMON, D; YANG, G			LOSS OF P53 FUNCTION LEADS TO METASTASIS IN RAS+MYC-INITIATED MOUSE PROSTATE-CANCER	ONCOGENE			English	Article						P53; METASTASES; PROSTATE CANCER	MESSENGER-RNA LEVELS; WILD-TYPE P53; MOUSE PROSTATE; SV40-TRANSFORMED CELLS; CARCINOMA-CELLS; GENE MUTATION; GROWTH; CANCER; ONCOGENES; MYC	To study the interactions between dominantly acting oncogenes and tumor suppressor genes we used p53 'knockout' mouse urogenital sinus tissue for retroviral transduction of ras and myc in the mouse prostate reconstitution (MPR) model system. Epithelial hyperplasia was observed in all wild-type p53 MPRs with one small focal cancer and no evidence of metastasis. Prostatic cancer was found in 100% of the heterozygous and homozygous p53 mutant MPRs with metastatic deposits in 95% of the mice. The pattern of metastasis was remarkably similar to that in human prostate cancer with gross metastatic deposits in the lung, lymph nodes, bone and liver of many animals. Progression of carcinomas in the ras+myc-initiated heterozygous p53 mutant MPRs was invariably associated with either complete loss, partial deletion or loss of expression of the wild-type p53 allele. Southern blotting analysis of proviral-cellular DNA junction fragments in primary carcinomas and cell lines derived from metastatic deposits revealed that metastases do not necessarily seed out from the most abundant clone in the primary carcinoma.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT RADIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	THOMPSON, TC (corresponding author), BAYLOR COLL MED,DEPT UROL,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839	NCI NIH HHS [P50-CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BODNER SM, 1992, ONCOGENE, V7, P743; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EGAWA S, 1992, MOL CARCINOGEN, V5, P52, DOI 10.1002/mc.2940050110; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREENE DR, 1994, J UROLOGY, V151, P1301, DOI 10.1016/S0022-5347(17)35236-9; GREENE DR, 1991, CANCER RES, V51, P4084; Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERBEL RS, 1988, CANCER SURV, V7, P597; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T, 1989, DECONTAMINATION DILU; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERZ VW, 1991, MOL ENDOCRINOL, V5, P503, DOI 10.1210/mend-5-4-503; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; PURDIE CA, 1994, ONCOGENE, V9, P603; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAWIN K, 1993, CANCER RES, V53, P4461; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Steeg P S, 1991, Semin Cancer Biol, V2, P105; TAYLOR WR, 1992, ONCOGENE, V7, P1383; THOMPSON TC, 1990, CANCER CELL-MON REV, V2, P345; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TIMME TL, 1994, BIOTECHNIQUES, V17, P460; VAN MEIR EG, 1994, CANCER RES, V54, P649; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	58	116	122	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					869	879						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7534899				2022-12-25	WOS:A1995QL03800008
J	SAWASDIKOSOL, S; RAVICHANDRAN, KS; LEE, KK; CHANG, JH; BURAKOFF, SJ				SAWASDIKOSOL, S; RAVICHANDRAN, KS; LEE, KK; CHANG, JH; BURAKOFF, SJ			CRK INTERACTS WITH TYROSINE-PHOSPHORYLATED P116 UPON T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; SH3 DOMAINS; PROTEIN; ONCOGENE; RECEPTOR; FIBROBLASTS; KINASES	Products of the crk oncogene are expressed in all tissues. Crk proteins are composed exclusively of Src homology 2 (SH2) and Src homology 3 (SH3) domains, and they have been implicated in intracellular signaling. For example, they participate as mediators of Ras activation during nerve growth factor stimulation of PC12 pheochromocytoma cells. We examined the role of Crk proteins during T cell receptor-mediated signaling and observed that Crk proteins specifically interact, via their SH2 domains, with a tyrosine-phosphorylated 116-kDa protein upon T cell activation. p116 may be related to the recently cloned fibroblast p130(cus) and/or p120-Cbl. In addition, we observed that GST-Crk fusion proteins and Crk-L bind, most likely via their SH3 domain, to C3G, a has guanine nucleotide exchange factor. Thus, the interaction of Crk with p116 and C3G strongly implicates Crk as a mediator of T cell receptor signaling, possibly involved in Ras activation.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	SAWASDIKOSOL, S (corresponding author), HARVARD UNIV, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA.		Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Hoeve J.T., 1993, ONCOGENE, V8, P2469; HOEVE JT, 1994, BLOOD, V84, P1731; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1994, MOL CELL BIOL, V11, P1697; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TSUCHIE H, 1989, ONCOGENE, V4, P1281; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2893	2896		10.1074/jbc.270.7.2893	http://dx.doi.org/10.1074/jbc.270.7.2893			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531694	hybrid			2022-12-25	WOS:A1995QG47100004
J	LAI, CF; RIPPERGER, J; MORELLA, KK; WANG, YP; GEARING, DP; HORSEMAN, ND; CAMPOS, SP; FEY, GH; BAUMANN, H				LAI, CF; RIPPERGER, J; MORELLA, KK; WANG, YP; GEARING, DP; HORSEMAN, ND; CAMPOS, SP; FEY, GH; BAUMANN, H			STAT3 AND STAT5B ARE TARGETS OF 2 DIFFERENT SIGNAL PATHWAYS ACTIVATED BY HEMATOPOIETIN RECEPTORS AND CONTROL TRANSCRIPTION VIA SEPARATE CYTOKINE RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT ALPHA-2-MACROGLOBULIN GENE; MOLECULAR-CLONING; GM-CSF; INTERLEUKIN-6; EXPRESSION; BINDING; SUBUNIT; LEVEL; FORMS; DNA	Transient transfection of expression vectors for various members of the hematopoietin receptor family and STAT proteins into COS-1 cells indicated that each receptor was capable of stimulating the DNA binding activity of STAT1, STAT3, and STAT5B. However, gp130 preferentially activated STAT1 and STAT3. Activation of STAT5B differed from that of the other two in that the box 3 sequence motif in the cytoplasmic domain of gp130 was not required. Moreover, STAT5B and STAT3 enhanced gene transcription via separate regulatory elements. This study has identified two potential signal transduction pathways by which hematopoietin receptors, including the interleukin-6 receptor, control transcription of acute phase plasma protein genes in hepatic cells.	UNIV ERLANGEN NURNBERG,CHAIR GENET,D-91058 ERLANGEN,GERMANY; CHILDRENS HOSP,DIV ENDOCRINOL,BUFFALO,NY 14222; SYSTEMIX INC,PALO ALTO,CA 94304; UNIV CINCINNATI,DEPT MOLEC & CELLULAR PHYSIOL,CINCINNATI,OH 45267	University of Erlangen Nuremberg; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Novartis; University System of Ohio; University of Cincinnati	LAI, CF (corresponding author), ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,ELM & CARLTON ST,BUFFALO,NY 14263, USA.				NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BRECHNER T, 1991, MOL BIOL MED, V8, P267; CHEN XJ, 1994, ENDOCRINOLOGY, V135, P269, DOI 10.1210/en.135.1.269; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MORELLA KK, 1995, BLOOD, V86, P567; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUI ALF, 1995, EMBO J, V14, P1186; RIPPERGER J, 1995, IN PRESS ANN NY ACAD; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOWSKI HB, 1993, SCIENCE, V26, P1739; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG Y, 1995, IN PRESS BLOOD; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; ZHONG Z, 1994, SCIENCE, V264, P96; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; ZIEGLER SF, 1995, EUR J IMMUNOL, V25, P399, DOI 10.1002/eji.1830250214	34	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23254	23257		10.1074/jbc.270.40.23254	http://dx.doi.org/10.1074/jbc.270.40.23254			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559477	hybrid			2022-12-25	WOS:A1995RY90900006
J	YANG, MT; SCOTT, HB; GARDNER, JF				YANG, MT; SCOTT, HB; GARDNER, JF			TRANSCRIPTION TERMINATION AT THE THR-ATTENUATOR - EVIDENCE THAT THE ADENINE RESIDUES UPSTREAM OF THE STEM AND LOOP STRUCTURE ARE NOT REQUIRED FOR TERMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; PHENOTYPIC SELECTION; NUCLEOTIDE-SEQUENCE; REGULATORY REGION; OPERON ATTENUATOR; RNA-POLYMERASE; DNA; INITIATION; TEMPLATES	The Escherichia coli thr operon attenuator has a structure similar to other Rho-independent terminators. The DNA sequence immediately 5' to the termination site is dG+dC-rich and contains a region of dyad symmetry that, when transcribed into RNA, encodes a hairpin structure in the transcript. It also contains a stretch of 9 consecutive dA-dT residues immediately distal to the region of dyad symmetry which encode uridine residues at the 3' end of the terminated transcript. In addition, the thr attenuator has a stretch of 6 dA-dT residues immediately upstream of the region of dyad symmetry which encode 6 adenines. These adenines could potentially pair with the distal uridines to form a hairpin structure extended by as much as 6 A-U base pairs. In this report we have examined the role of the upstream adenines in transcription termination. We used templates that specify mismatches or create new base pairs in the potential A-U secondary structure of the transcript as well as templates that delete segments of the A residues upstream of the hairpin, We conclude that A-U pairing is not required for efficient transcription termination at the thr attenuator. This conclusion is likely to apply to other Rho-independent terminators that contain hairpin-proximal dA-dT residues.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign			Yang, Ming-Te/B-5626-2017	Yang, Ming-Te/0000-0002-7644-0964				BAUER CE, 1985, GENE, V37, P73, DOI 10.1016/0378-1119(85)90259-8; BAUER CE, 1983, GENE FUNCTION PROKAR, P73; BRENDEL V, 1986, J BIOMOL STRUCT DYN, V3, P705, DOI 10.1080/07391102.1986.10508457; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; FRIDEN P, 1982, P NATL ACAD SCI-BIOL, V79, P6156, DOI 10.1073/pnas.79.20.6156; GARDNER JF, 1982, J BIOL CHEM, V257, P3896; KELLER EB, 1979, P NATL ACAD SCI USA, V76, P6189; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYNN SP, 1988, J BIOL CHEM, V263, P472; LYNN SP, 1985, J MOL BIOL, V183, P529, DOI 10.1016/0022-2836(85)90169-X; MANIATIS T, 1982, MOL CLONING LABORATO, P249; Miller JH., 1972, EXPT MOL GENETICS; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; POSTLE K, 1985, CELL, V41, P577, DOI 10.1016/S0092-8674(85)80030-1; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Silhavy T.J., 1984, EXPT GENE FUSIONS; SLY WS, 1969, J MOL BIOL, V42, P385, DOI 10.1016/0022-2836(69)90231-9; WRIGHT JJ, 1992, EMBO J, V11, P1957, DOI 10.1002/j.1460-2075.1992.tb05249.x; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YANG MT, 1989, J BIOL CHEM, V264, P2634; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; ZURAWSKI G, 1978, P NATL ACAD SCI USA, V75, P4271, DOI 10.1073/pnas.75.9.4271	27	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23330	23336		10.1074/jbc.270.40.23330	http://dx.doi.org/10.1074/jbc.270.40.23330			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559489	hybrid			2022-12-25	WOS:A1995RY90900018
J	HWA, J; GRAHAM, RM; PEREZ, DM				HWA, J; GRAHAM, RM; PEREZ, DM			IDENTIFICATION OF CRITICAL DETERMINANTS OF ALPHA(1)-ADRENERGIC RECEPTOR SUBTYPE-SELECTIVE AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; CDNA; EXPRESSION; ACTIVATION	alpha(1)-Adrenergic receptor (AR) subtypes mediate many effects of the sympathetic nervous system. The three cloned subtypes (alpha(1a)-AR, alpha(1b)-AR, alpha(1d)-AR), although structurally similar, bind a series of ligands with different relative potencies. This is particularly true for the alpha(1a)-AR, which recognizes a number of agonists and antagonists with 5-50-fold higher affinity than the alpha(1b)- or alpha(1d)-subtypes. Since ligands bind to receptor-residues that are located in the transmembrane spanning domains, we hypothesize that subtype differences in ligand recognition are due to differences in the binding properties of nonconserved transmembrane residues, Using site-directed mutagenesis, selected putative ligand-binding residues in the alpha(1b)-AR were converted, either individually or in combination, to the corresponding residues in the alpha(1b)-AR. Mutation of two such residues (of approximately 172 amino acids in the transmembrane domains) converted the agonist binding profile entirely to that of the alpha(1a)-AR. Over 80% of this conversion was due to an Ala(204) --> Val substitution; the remainder was due to the additional substitution of Leu(314) --> Met. To confirm that Ala(204) and Leu(314) are indeed critical for agonist subtype-selectivity, the equivalent residues in the alpha(1a)-AR (Val(185) and Met(293)) were reversed of that of the alpha(1b)-AR. Correspondingly, the agonist-binding profile of this double alpha(1a)-AR mutant reverted to that of the alpha(1b)-AR. From these data, in conjunction with macromolecular modeling of the ligand-binding pocket, a model has been developed, which indicates that the determinants of these two residues for agonist subtype-selectivity are due not only to interactions between their side chains and specific ligand moieties but also to a critical interaction between these two amino acids.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; ST VINCENTS HOSP & MED CTR,VICTOR CHANG CARDIAC RES INST,DARLINGHURST,NSW 2010,AUSTRALIA	Cleveland Clinic Foundation; Case Western Reserve University; St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute					NINDS NIH HHS [NS19853] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANYUKHOVSKY EP, 1991, CIRCULATION, V83, P2076, DOI 10.1161/01.CIR.83.6.2076; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DIXON RAF, 1989, PROTEINS, V6, P267, DOI 10.1002/prot.340060309; FORRAY C, 1994, MOL PHARMACOL, V45, P703; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; HWA J, 1994, AUTONOMIC NERVOUS SY, V8; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; RIEK RP, 1995, J THEOR BIOL, V172, P245; Sambrook J, 1989, MOL CLONING LABORATO; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; STRADER CD, 1989, J BIOL CHEM, V264, P13572; SUNG SS, 1991, FASEB J, V5, P804; WANG CD, 1991, MOL PHARMACOL, V40, P168	18	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23189	23195		10.1074/jbc.270.39.23189	http://dx.doi.org/10.1074/jbc.270.39.23189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559466	hybrid			2022-12-25	WOS:A1995RY05400086
J	RACHMILEWITZ, J; ELKIN, M; ROSENSAFT, J; GELMANKOHAN, Z; ARIEL, I; LUSTIG, O; SCHNEIDER, T; GOSHEN, R; BIRAN, H; DEGROOT, N; HOCHBERG, A				RACHMILEWITZ, J; ELKIN, M; ROSENSAFT, J; GELMANKOHAN, Z; ARIEL, I; LUSTIG, O; SCHNEIDER, T; GOSHEN, R; BIRAN, H; DEGROOT, N; HOCHBERG, A			H19 EXPRESSION AND TUMORIGENICITY OF CHORIOCARCINOMA DERIVED CELL-LINES	ONCOGENE			English	Article						H19; CHORIOCARCINOMA CELL LINES; TUMOR SUPPRESSOR GENE; ONCOGENE	GROWTH FACTOR-II; IMPRINTED GENES; WILMS-TUMORS; CANCER; CHROMOSOME-11; DIFFERENTIATION; RELAXATION; MUTATION; INVITRO; INVIVO	Certain embryonal tumors demonstrate a loss of heterozygosity at the parentally imprinted region of chromosome 11p15.5. It has been hypothesized that this implicates a tumor suppressor gene at this locus. The human H19 gene maps to 11p15.5, is expressed in fetal tissues including the placenta and is paternally imprinted, Here we show that the abundance of H19 transcripts in cells of two choriocarcinoma derived cell lines (JAr and JEG-3) differs greatly. While JAr cells express high levels of H19 RNA, the expression of H19 in JEG-3 cells is much lower than that of normal trophoblasts, Cells of these two cell lines were subcutaneously injected into nude mice with subsequent tumor formation, A fivefold increase in the H19 RNA level was measured in tumors derived from JEG-3 cell lines as compared to these cells before injection, However this increase in H19 RNA did not alter the clonogenicity in soft agar nor the growth rate of the cells derived from these tumors as compared to the original JEG-3 cells, Nevertheless, the cells retaining the elevated level of H19 transcripts were more tumorigenic than the original cells, We propose that there is a selection of cells expressing high levels of H19 from the total JEG-3 cell population during the microevolution of tumor formation. These observations, together with our previous publications on H19 expression in human cancers, do not support the notion of a tumor suppressor role for the H19 gene.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; KAPLAN HOSP,CLIN GENET UNIT,REHOVOT,ISRAEL; HADASSAH UNIV HOSP,DEPT PATHOL,IL-91120 JERUSALEM,ISRAEL; KAPLAN HOSP,DEPT ONCOL,REHOVOT,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Kaplan Medical Center								ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1; BIRANNAN C, 1994, MOL CELL BIOL, V15, P123; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FRESHNEY RI, 1990, CULTURE ANIMAL CELLS, P142; GILEADI O, 1988, PLACENTAL PROTEIN HO, P251; GLASER A, 1992, MOL REPROD DEV, V33, P7, DOI 10.1002/mrd.1080330103; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; GLEN AE, 1993, CURR OPIN GENE DEV, V3, P418; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; HOCHBERG A, 1992, CANCER RES, V52, P3713; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LU X, 1988, EXP CELL RES, V174, P199, DOI 10.1016/0014-4827(88)90155-3; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; Mazur M. T., 1987, GESTATIONAL TROPHOBL, P45; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P221; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RACHMILEWITZ J, 1993, CELL GROWTH DIFFER, V4, P395; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTHMAN PA, 1992, MOL REPROD DEV, V33, P1, DOI 10.1002/mrd.1080330102; Sambrook J, 1989, MOL CLONING LABORATO; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEKIYA S, 1987, ARCH GYNECOL OBSTET, V241, P111, DOI 10.1007/BF00931231; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	38	37	41	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					863	870						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545806				2022-12-25	WOS:A1995RU79800006
J	OPALENIK, SR; SHIN, JT; WEHBY, JN; MAHESH, VK; THOMPSON, JA				OPALENIK, SR; SHIN, JT; WEHBY, JN; MAHESH, VK; THOMPSON, JA			THE HIV-1 TAT PROTEIN INDUCES THE EXPRESSION AND EXTRACELLULAR APPEARANCE OF ACIDIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; METAL-LINKED DIMER; FACTOR-I; KAPOSIS-SARCOMA; HEPARIN-BINDING; CELL-GROWTH; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; TYROSINE PHOSPHORYLATION; DIFFERENTIAL EXPRESSION	Mounting experimental evidence suggests that the TAT protein, released from human immunodeficiency virus-1 (HIV-1)-infected inflammatory cells, may genetically reprogram targeted cells within a localized environment to develop highly vascularized tumors of mesenchymal origin. The fibroblast growth factor (FGF) family of polypeptides has gained general acceptance as initiators of angiogenesis and functions as potent mito gens for mesoderm-derived cells. To evaluate a potential biological relationship between TAT and acidic FGF (FGF-1), primary murine embryonic fibroblasts either were transfected with the viral transactivator or were transduced (retrovirally mediated) with a secreted, chimeric form of the human polypeptide growth factor, human stomach tumor/Kaposi's sarcoma (hst/KS)FGF-1. Reverse transcriptase-polymerase chain reaction, Western blotting, in situ immunohistochemical, heparin affinity, DNA synthesis, and transient transfection techniques were used to confirm expression, localization, and functionality of the transgenes, Both transfected and transduced cells constitutively expressing either TAT or (hst/KS)FGF-1 adopted a transformed phenotype, maintained aggressive growth behavior, and demonstrated both induction of EGF-specific phosphotyrosyl proteins and nuclear association of FGF-1 and FGF-1 receptor. Increased levels of endogenous, murine FGF 1 mRNA (reverse transcriptase-polymerase chain reaction) and protein (immunoblot analysis) were apparent in both (hst/KS)FGF-1- and TAT-transformed cells, Medium conditioned by (hst/KS)FGF-1-transduced cells contained steady-state levels of biologically active FGF-1 which exhibited a representative molecular weight. Limited sodium dodecyl sulfate-polyacrylamide gel electrophoretic analysis of the conditioned medium from TAT-transformed cells demonstrated the appearance of FGF-1 as latent, high molecular weight complexes requiring reducing agents to activate full biological activity. Collectively, these results suggest that TAT induces the expression and secretion of FGF-1, which may be potentially relevant to the pathophysiological development of AIDS-Kaposi's sarcoma.	UNIV ALABAMA, SCH MED, DEPT SURG, DIV TRANSPLANTAT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA13148] Funding Source: Medline; NHLBI NIH HHS [HL48491, HL45990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045990, R01HL048491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KD, 1989, SOMAT CELL MOLEC GEN, V15, P215, DOI 10.1007/BF01534872; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BAJPAI R, 1987, ANN NY ACAD SCI, V506, P446, DOI 10.1111/j.1749-6632.1987.tb23840.x; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BLAM SB, 1988, ONCOGENE, V129, P136; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1986, CANCER RES, V46, P6333; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CRAWFORD D, 1988, ONCOGENE, V3, P27; CUPP C, 1993, ONCOGENE, V8, P2231; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1991, ADV EXP MED BIOL, V303, P27; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FALKNER FG, 1988, VIROLOGY, V164, P450, DOI 10.1016/0042-6822(88)90559-4; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GALLOWAY AC, 1984, SURGERY, V96, P435; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; HALL JA, 1993, J CELL BIOCHEM, V51, P116, DOI 10.1002/jcb.240510118; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; Jerome V, 1991, GROWTH FACTORS, V4, P317, DOI 10.3109/08977199109043917; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KIM CM, 1992, ONCOGENE, V7, P1525; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; LAWRENCE CB, 1982, J MOL BIOL, V162, P317, DOI 10.1016/0022-2836(82)90529-0; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; POCSIK E, 1992, LYMPHOKINE CYTOK RES, V11, P317; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; PURI RK, 1992, CANCER RES, V52, P3787; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; STEFFY K, 1991, MICROBIOL REV, V55, P193, DOI 10.1128/MMBR.55.2.193-205.1991; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; ZAULI G, 1993, MICROBIOLOGICA, V16, P115; ZAULI G, 1992, BLOOD, V80, P3036; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221	84	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17457	17467		10.1074/jbc.270.29.17457	http://dx.doi.org/10.1074/jbc.270.29.17457			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542239	hybrid			2022-12-25	WOS:A1995RK68900064
J	MUSTAEV, AA; GODSON, GN				MUSTAEV, AA; GODSON, GN			STUDIES OF THE FUNCTIONAL TOPOGRAPHY OF THE CATALYTIC CENTER OF ESCHERICHIA-COLI PRIMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; DNA-REPLICATION; ACTIVE-SITE; PROTEIN; HELICASE; REGION; RECOGNITION; EXPRESSION; STRAND; GENE	The catalytic center E. coli primase (581 amino acids) was identified by using, in the G4ori(c) single strand binding protein (SSB) primer RNA (pRNA) synthesis system, ATP and AMP derivatives, which were modified on the 5' side with reactive groups that can be crosslinked to the ATP binding site plus [alpha-P-32]GTP. The position of the covalently attached P-32-labeled dinucleotide was mapped by chemical and enzymatic cleavage of labeled wild type and deletion mutants of primase. The catalytic center involves one of the Lys residues Lys-211, Lys-229, and Lys-241. The ATP binding site is preformed in primase, and the cross-linked ATP residue can be elongated to a 5-nucleotide limit, which implies significant stretching of the catalytic center during pRNA synthesis, His-43 close to the N terminus in a proposed zinc finger and Lys-528 near the C terminus were also cross-linked to ATP residues in the primase ATP binding site, suggesting that these regions are topographically close to the catalytic center during pRNA synthesis, When cross-linking was performed on the preformed primase/SSB/G4ori(c) complex with long arm reagents (12-15 Angstrom), SSB was also labeled, indicating a close proximity to the site of pRNA synthesis.	NYU,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016; PUBL HLTH RES INST,NEW YORK,NY 10016	New York University					NIGMS NIH HHS [GM32898, GM 49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CHAMBERLIN MJ, 1994, HARVEY LECTURE, V88; CHATTERJI D, 1994, J BIOL CHEM, V259, P284; GODSON GN, 1991, GENE, V100, P59, DOI 10.1016/0378-1119(91)90350-K; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; MITINA RL, 1990, FEBS LETT, V272, P181, DOI 10.1016/0014-5793(90)80478-2; MOK M, 1987, J BIOL CHEM, V262, P16644; MOROZOVA OV, 1990, FEBS LETT, V277, P75, DOI 10.1016/0014-5793(90)80812-W; MUSTAEV A, 1991, J BIOL CHEM, V2626, P23927; MUSTAEV A, 1993, J BIOL CHEM, V266, P19185; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; RIVA M, 1987, J BIOL CHEM, V262, P14377; ROWEN L, 1978, J BIOL CHEM, V253, P758; ROWEN L, 1978, J BIOL CHEM, V253, P770; SAKAI H, 1987, GENE, V53, P265; SCHAFFNER AR, 1987, NUCLEIC ACIDS RES, V15, P8773, DOI 10.1093/nar/15.21.8773; SIMS J, 1980, P NATL ACAD SCI-BIOL, V77, P900, DOI 10.1073/pnas.77.2.900; SMILEY BL, 1982, P NATL ACAD SCI-BIOL, V79, P4550, DOI 10.1073/pnas.79.15.4550; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; SUN WL, 1994, P NATL ACAD SCI USA, V91, P11462, DOI 10.1073/pnas.91.24.11462; TONGU K, 1994, J BIOL CHEM, V269, P4675; VERLASALOVIC J, 1993, GENE, V136, P281; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698	33	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15711	15718		10.1074/jbc.270.26.15711	http://dx.doi.org/10.1074/jbc.270.26.15711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541046	hybrid			2022-12-25	WOS:A1995RG53800044
J	YANG, WM; INOUYE, CJ; SETO, E				YANG, WM; INOUYE, CJ; SETO, E			CYCLOPHILIN-A AND FKBP12 INTERACT WITH YY1 AND ALTER ITS TRANSCRIPTIONAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; ADENOVIRUS E1A PROTEIN; CYCLOSPORINE-A; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; FK506-BINDING PROTEIN; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; GLOBIN GENE; NF-E1 YY-1	YY1 is a zinc finger transcription factor with unusual structural and functional features. In a yeast two-hybrid screen, two cellular proteins, cyclophilin A (CyPA) and FK506-binding protein 12 (FKBP12), interacted with YY1. These interactions are specific and also occur in mammalian cells. Cyclosporin A and FK506 efficiently disrupt the YY1-CyPA and YY1-FKBP12 interactions. Overexpression of human CyPA and FKBP12 have different effects on YY1-regulated transcription with these effects being promoter-dependent. These results suggest that immunophilins may be mediators in the functional role of YY1.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio				Yang, Wen-Ming/0000-0002-5871-5979	NCI NIH HHS [CA61257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BASU A, 1993, J BIOL CHEM, V268, P4188; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BECKER KG, 1993, HUM MOL GENET, V2, P1697, DOI 10.1093/hmg/2.10.1697; BERGER R, 1982, IMMUNOPHARMACOLOGY, V5, P123, DOI 10.1016/0162-3109(82)90043-1; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GASTON K, 1994, FEBS LETT, V347, P289, DOI 10.1016/0014-5793(94)00567-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1991, PHARMACOTHERAPY, V11, pS142; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; HEITMAN J, 1992, NEW BIOL, V4, P448; HOHMAN R J, 1990, New Biologist, V2, P663; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; KINO T, 1993, ANN NY ACAD SCI, V685, P13, DOI 10.1111/j.1749-6632.1993.tb35846.x; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1994, ONCOGENE, V9, P1047; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU R, 1994, NUCLEIC ACIDS RES, V22, P2453, DOI 10.1093/nar/22.13.2453; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MOMOEDA M, 1994, J VIROL, V68, P7159, DOI 10.1128/JVI.68.11.7159-7168.1994; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NELSON PA, 1991, GENE, V109, P255, DOI 10.1016/0378-1119(91)90617-K; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARSONS WH, 1993, ANN NY ACAD SCI, V685, P22, DOI 10.1111/j.1749-6632.1993.tb35847.x; PETERS B, 1993, J BIOL CHEM, V268, P3430; QUESNIAUX VFJ, 1993, BIOESSAYS, V15, P731, DOI 10.1002/bies.950151106; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; REEM GH, 1992, J AUTOIMMUN, V5, P159, DOI 10.1016/0896-8411(92)90030-T; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; RYFFEL B, 1993, BIOCHEM PHARMACOL, V46, P1, DOI 10.1016/0006-2952(93)90341-S; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SATYAMOORTHY K, 1993, MOL CELL BIOL, V13, P6621, DOI 10.1128/MCB.13.11.6621; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SINGER MF, 1993, GENE, V135, P183, DOI 10.1016/0378-1119(93)90064-A; SMITH DF, 1993, J BIOL CHEM, V268, P18365; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YE JP, 1994, J BIOL CHEM, V269, P25728; YOST SE, 1993, MOL CELL BIOL, V13, P5439, DOI 10.1128/MCB.13.9.5439; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	74	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15187	15193		10.1074/jbc.270.25.15187	http://dx.doi.org/10.1074/jbc.270.25.15187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541038	hybrid			2022-12-25	WOS:A1995RE66600053
J	BALLIGAND, JL; KOBZIK, L; HAN, XQ; KAYE, DM; BELHASSEN, L; OHARA, DS; KELLY, RA; SMITH, TW; MICHEL, T				BALLIGAND, JL; KOBZIK, L; HAN, XQ; KAYE, DM; BELHASSEN, L; OHARA, DS; KELLY, RA; SMITH, TW; MICHEL, T			NITRIC OXIDE-DEPENDENT PARASYMPATHETIC SIGNALING IS DUE TO ACTIVATION OF CONSTITUTIVE ENDOTHELIAL (TYPE-III) NITRIC-OXIDE SYNTHASE IN CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; CLONING; MUSCLE; HEART; CELLS	Nitric oxide synthase (NOS) isoforms are discovered in an increasing variety of cell types with different roles in signaling. The inducible NOS (i.e. iNOS or NOS II) is expressed in cardiac myocytes in response to specific cytokines. Independent of iNOS induction, however, receptor-dependent signaling is modulated by a constitutive nitric oxide (NO) synthase isoform in these cells (Balligand, J. L., Kelly, R. A., Marsden, P. A., Smith, T. W., and Michel, T. (1993) Proc. Natl. Acad. Sci. U.S. A. 90, 347-351). We now show that cardiac myocytes constitutively express the endothelial isoform of NO synthase (ecNOS or NOS III). Transcripts for NOS III were detected by Northern blot in myocyte extracts using as a probe a polymerase chain reaction-generated cDNA amplified with isoform and species-specific primers. In subcellular fractionation experiments, a calcium-sensitive NO synthase activity was present primarily in the particulate fraction, coinciding with the distribution of NOS III analyzed by protein immunoblotting. The localization of NOS III within cardiac myocytes was further demonstrated by immunohistochemistry. The functional role of NOS III was explored by analyzing the effects of NOS inhibitors on single myocyte L-type calcium current and contractility. Inhibition of NOS blocked the attenuation by carbamylcholine of the increases in both parameters induced by beta-adrenergic stimulation, We conclude that NO-dependent parasympathetic signaling is mediated by NOS III in cardiac myocytes.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,PHYSIOL PROGRAM,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	BALLIGAND, JL (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Kaye, David/AAF-1202-2021; Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156; Kaye, David/0000-0003-4058-0372	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457, R01HL036141, R37HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36141, HL 46457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BRADY AJB, 1993, AM J PHYSIOL, V265, pH176, DOI 10.1152/ajpheart.1993.265.1.H176; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; DEBELDER AJ, 1993, LANCET, V341, pS4; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GROCOTTMASON R, 1994, AM J PHYSIOL-HEART C, V267, pH1804, DOI 10.1152/ajpheart.1994.267.5.H1804; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; HARE JM, 1995, J CLIN INVEST, V95, P360, DOI 10.1172/JCI117664; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LAMAS S, 1992, P NATL ACAD SCI USA, V88, P6348; LOFFELHOLZ K, 1985, PHARMACOL REV, V37, P1; LYONS CR, 1992, J BIOL CHEM, V267, P6370; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	30	341	351	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14582	14586		10.1074/jbc.270.24.14582	http://dx.doi.org/10.1074/jbc.270.24.14582			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540173	hybrid			2022-12-25	WOS:A1995RD45500054
J	WILSON, PT; BOURNE, HR				WILSON, PT; BOURNE, HR			FATTY ACYLATION OF ALPHA(Z) - EFFECTS OF PALMITOYLATION AND MYRISTOYLATION ALPHA(Z) SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; LIPID MODIFICATIONS; BETA-GAMMA; PROTEIN; SUBUNIT; ACTIVATION; PURIFICATION; EXPRESSION; INHIBITION; EFFICIENT	As the first step in an investigation of roles played by fatty acylation of G protein alpha chains in membrane targeting and signal transmission, we inserted monoclonal antibody epitopes, hemagglutinin (HA) or Glu-Glu (EE), at two internal sites in three alpha subunits, At site I, only HA-tagged alpha(q) and alpha(z) functioned normally, alpha(s), alpha(q), and alpha(z) subunits tagged at site II with the EE epitope showed normal expression, membrane localization, and signaling activity, Using epitope tagged alpha(z), we investigated effects of mutations in sites for fatty acylation, Mutational substitution of Ala for Gly(2) (G2A) prevented incorporation of myristate and decreased but did not abolish incorporation of palmitate. Substitution of Ala for Cys(3) (C3A) prevented incorporation of palmitate but had no effect on incorporation of myristate, Substitution of Ala for both Gly(2) and Cys(3) (G2AC3A) prevented incorporation of both myristate and palmitate. All three mutations substantially disrupted association of a, with the particulate fraction. G(z)-mediated inhibition of adenylyl cyclase, triggered by activation of the D2-dopamine receptor, was, respectively, abolished (G2AC3A), impaired (G2A), and enhanced (C3A). Constitutive inhi bition of adenylyl cyclase by a, was unchanged (G2AC3A), strongly diminished (G2A), or strongly enhanced (C3A), A nonacylated, mutationally activated alpha(z) mutant inhibited adenylyl cyclase, although less potently than normally acylated, mutationally activated alpha(z). From these findings we conclude: (a) fatty acylations of alpha(z) increase its association with membranes; (b) myristoylation is not required for palmitoylation of alpha(z) or for its productive interactions with adenylyl cyclase; (c) palmitoylation is not required for, but may instead inhibit, signaling by alpha(z).	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR BIOL & PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NIMH NIH HHS [MH00961] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000961] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; GRASSIE MA, 1994, BIOCHEM J, V303, P913; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HALLAK H, 1994, J BIOL CHEM, V269, P4571; JONES TL, 1990, P NATL ACAD SCI USA, V87, P5568; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABRIGHT DG, 1994, NATURE, V369, P621; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MANENTI S, 1984, J BIOL CHEM, V269, P8309; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	38	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9667	9675		10.1074/jbc.270.16.9667	http://dx.doi.org/10.1074/jbc.270.16.9667			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7536745	hybrid			2022-12-25	WOS:A1995QU08900090
J	TAKENAKA, I; MORIN, F; SEIZINGER, BR; KLEY, N				TAKENAKA, I; MORIN, F; SEIZINGER, BR; KLEY, N			REGULATION OF THE SEQUENCE-SPECIFIC DNA-BINDING FUNCTION OF P53 BY PROTEIN-KINASE-C AND PROTEIN PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; ACTIVATION DOMAIN; GROWTH ARREST; PHOSPHORYLATION; TRANSCRIPTION; REPRESSION; GENE; UV; INDUCTION; RADIATION	The p53 tumor suppressor protein is a transcription factor with sequence-specific DNA binding activity that is thought to be important for the growth-inhibitory function of p53. DNA binding appears to require activation of a cryptic form of p53 by allosteric mechanisms involving a negative regulatory domain at the carboxyl terminus of p53. The latent form of p53, reactive to the carboxyl-terminal antibody PAb421, is produced in a variety of eukaryotic cells, suggesting that activation of p53 is an important rate-limiting step in vivo. In this report we provide evidence that phosphorylation of serine 378 within the carboxyl-terminal negative regulatory domain of the human p53 protein by protein kinase C correlates with loss of PAb421 reactivity and a concomitant activation of sequence-specific DNA binding. These effects are reversed by subsequent dephosphorylation of the protein kinase C-reactive site by protein phosphatases 1 (PP1) and 2A (PP2A), which restore the reactivity of p53 to PAb421 and regenerate the latent form of p53 lacking significant DNA binding activity. Thus, p53 is subject to both positive and negative regulation by reversible enzymatic modifications affecting the latent or active state of the protein, suggesting a possible mechanism for the regulation of its tumor suppressor function.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC GENET & CELL BIOL, ONCOL DRUG DISCOVERY, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHUNG R, 1992, THESIS HARVARD U BOS; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1992, BIOCHEM J, V287, P1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROLLEY N, 1994, ONCOGENE, V9, P3067; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TRUANT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	48	223	227	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5405	5411		10.1074/jbc.270.10.5405	http://dx.doi.org/10.1074/jbc.270.10.5405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534296	hybrid			2022-12-25	WOS:A1995QL58000070
J	FUKASAWA, M; HIROTA, K; ADACHI, H; MIMURA, K; MURAKAMIMUROFUSHI, K; TSUJIMOTO, M; ARAI, H; INOUE, K				FUKASAWA, M; HIROTA, K; ADACHI, H; MIMURA, K; MURAKAMIMUROFUSHI, K; TSUJIMOTO, M; ARAI, H; INOUE, K			CHINESE-HAMSTER OVARY CELLS EXPRESSING A NOVEL TYPE OF ACETYLATED LOW-DENSITY-LIPOPROTEIN RECEPTOR - ISOLATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTORS; HUMAN MONOCYTE-MACROPHAGES; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; MEDIATED ENDOCYTOSIS; BINDING-PROPERTIES; LIGAND-BINDING; CULTURED-CELLS; DEGRADATION	Macrophage scavenger receptors mediate the recognition of a wide range of negatively charged macromolecules including acetylated low density lipoproteins (AcLDL). Chinese hamster ovary (CHO) cells were cultured in the presence of increasing concentrations of simvastatin, a cholesterol biosynthesis inhibitor, and AcLDL as the sole source of exogenous Lipoproteins. The cells surviving under these conditions specifically bound I-125-labeled AcLDL with high affinity and degraded them via an endocytic pathway, Unexpectedly, the association and degradation of I-125-labeled AcLDL by these CHO cells were not inhibited by dextran sulfate, fucoidan, and polyinosinic acid, competitors of macrophage scavenger receptors, but were completely inhibited by maleylated bovine serum albumin. Furthermore, these cells effectively took up negatively charged liposomes containing acidic phospholipids such as phosphatidylserine and phosphatidic acid, whereas CHO cells expressing macrophage scavenger receptors did not. AcLDL and negatively charged liposomes were cross-competed with each other. Northern blot analysis using the cDNA for the macrophage scavenger receptor revealed that these CHO cells did not express this receptor. From these observations, we conclude that the isolated CHO cells express a novel type of AcLDL receptor, which is distinct from macrophage scavenger receptors with respect to ligand specificity and competitor sensitivity.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN; SUNTORY INST BIOMED RES,MISHIMA 618,SHIZUOKA,JAPAN; OCHANOMIZU UNIV,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 112,JAPAN	University of Tokyo; Suntory Holdings Ltd; Ochanomizu University								ACTON SL, 1994, J BIOL CHEM, V269, P21003; ASHKENAS J, 1993, J LIPID RES, V34, P983; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHEN Z, 1993, BIOCHIM BIOPHYS ACTA, V1150, P79, DOI 10.1016/0005-2736(93)90124-I; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DEVRIES HE, 1993, J NEUROCHEM, V61, P1813; EMI M, 1993, J BIOL CHEM, V268, P2120; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1976, P NATL ACAD SCI USA, V76, P333; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; INABA T, 1992, J BIOL CHEM, V267, P13107; KATO Y, 1994, HEPATOLOGY, V20, P417; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAITO M, 1991, AM J PATHOL, V139, P1411; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SHECHTER I, 1981, J LIPID RES, V22, P63; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430	42	19	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1921	1927		10.1074/jbc.270.4.1921	http://dx.doi.org/10.1074/jbc.270.4.1921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530251				2022-12-25	WOS:A1995QD20400066
J	ROBINSON, LJ; BUSCONI, L; MICHEL, T				ROBINSON, LJ; BUSCONI, L; MICHEL, T			AGONIST-MODULATED PALMITOYLATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-C SUBSTRATE; PLASMA-MEMBRANE; PHOSPHORYLATION; TRANSLOCATION; ACYLATION; PROTEINS; RECEPTOR; MARCKS	The nitric oxide synthases (NOS) comprise a family of enzymes which differ in primary structure, biological roles, subcellular distribution, and post-translational modifications. The endothelial nitric oxide synthase (ecNOS) is unique among the NOS isoforms in being modified by N-terminal myristoylation, which is necessary for its targeting to the endothelial cell membrane. The subcellular localization of the ecNOS, but not enzyme myristoylation, is dynamically regulated by agonists such as bradykinin, which promote ecNOS translocation from membrane to cytosol, as well as enhancing enzyme phosphorylation. Using transiently transfected endothelial cells, we now show that a myristoylation-deficient mutant ecNOS undergoes phosphorylation despite restriction to the cytosol, suggesting that phosphorylation may be a consequence rather than a cause of ecNOS translocation. We therefore explored whether other post-translational modifications might regulate ecNOS targeting and now report that ecNOS is reversibly palmitoylated. Biosynthetic labeling of endothelial cells with [H-3]palmitic acid followed by immunoprecipitation of ecNOS revealed that the enzyme is palmitoylated; the label is released by hydroxylamine, consistent with formation of a fatty acyl thioester, and authentic palmitate can be recovered from labeled ecNOS following acid hydrolysis. Importantly, pulse-chase experiments in endothelial cells biosynthetically labeled with [H-3]palmitate show that bradykinin treatment promotes ecNOS depalmitoylation. We conclude that ecNOS palmitoylation is dynamically regulated by bradykinin and propose that depalmitoylation of the enzyme may result in its cytosolic translocation and subsequent phosphorylation.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, R01HL046457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LIU JW, 1994, J BIOL CHEM, V269, P11691; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	29	203	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					995	998		10.1074/jbc.270.3.995	http://dx.doi.org/10.1074/jbc.270.3.995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7530714	hybrid			2022-12-25	WOS:A1995QB15600003
J	BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM				BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM			ANGIOTENSIN-II STIMULATES SIS-INDUCING FACTOR-LIKE DNA-BINDING ACTIVITY - EVIDENCE THAT THE AT(1A) RECEPTOR ACTIVATES TRANSCRIPTION FACTOR-STAT91 AND/OR A RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CARDIAC FIBROBLASTS; INTERFERON-GAMMA; GENE-EXPRESSION; MESSENGER-RNA; KINASE; INDUCTION	Recent studies on cytokine and growth factor stimulated signal transduction have defined a direct pathway (Stat91) linking cell surface receptors to target genes in the nucleus. The Stat91 pathway regulated c-fos gene transcription involves activation by tyrosine phosphorylation of the DNA binding factor SIF (sis-inducing factor) in the cytoplasm, its nuclear translocation, and interaction with the regulatory element SIE (sis-inducing element). SIF is a complex of proteins containing members of the STAT family of transcription factors. We determined whether angiotensin II (ATI), which acts as a growth factor in many cell types, could activate the Stat91 pathway. We used neonatal rat cardiac fibroblasts expressing G-protein linked AII receptors and CHO-gl cells expressing stably transfected angiotensin type 1A (AT,) receptors to address this question. Angiotensin II induced SIF-like activity in both cell types, with initial induction at 15-30 min, maximal around 2-3 h, and undetectable at 6 h. Cytoplasmic and nuclear fractions from cells exposed to AII contained DNA binding activity to SIE. The SIF activity was insensitive to protein synthesis inhibitors and sensitive to the tyrosine kinase inhibitor genistein. Stat91 or a related protein was identified as a component of the AII-induced SIF complex and increased levels of this tyrosine phosphorylated protein were found in nuclear extracts of cells treated with AII. This is the first evidence that a seven transmembrane, G-protein-coupled receptor, namely AT(1A), activates the Stat91-nuclear signaling pathway.			BHAT, GJ (corresponding author), GEISINGER MED CLIN, WEIS CTR RES, 100 N ACAD AVE, DANVILLE, PA 17822 USA.		Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044379, R01HL044883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44379, HL44883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOCZ GW, 1994, AM J PHYTL, V267, pC1308; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IHLE JN, 1994, TRENDS ENDOCRIN MET, V5, P137, DOI 10.1016/1043-2760(94)90096-5; IHLE JN, 1994, TRENDS BIOCHEM SCI, V18, P338; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LINDPAINTNER K, 1994, CARDIAC RENIN ANGIOT; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MEEK DW, 1992, BIOCHEM J, V287, P1; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; PEACH MJ, 1980, RENIN ANGIOTENSIN SY; Raizada M.K., 1993, CELLULAR MOL BIOL RE; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SECHI LA, 1992, CIRC RES, V71, P1482, DOI 10.1161/01.RES.71.6.1482; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SHCORB W, 1994, J BIOL CHEM, V269, P19626; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SUZUKI J, 1993, CIRC RES, V73, P439, DOI 10.1161/01.RES.73.3.439; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THEKKUMKARA TJ, 1993, FASEB J, V7, pA491; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	168	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31443	31449						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527386				2022-12-25	WOS:A1994PX30300021
J	SONG, CZ; TIERNEY, CJ; LOEWENSTEIN, PM; PUSZTAI, R; SYMINGTON, JS; TANG, QQ; TOTH, K; NISHIKAWA, A; BAYLEY, ST; GREEN, M				SONG, CZ; TIERNEY, CJ; LOEWENSTEIN, PM; PUSZTAI, R; SYMINGTON, JS; TANG, QQ; TOTH, K; NISHIKAWA, A; BAYLEY, ST; GREEN, M			TRANSCRIPTIONAL REPRESSION BY HUMAN ADENOVIRUS E1A N-TERMINUS CONSERVED DOMAIN-1 POLYPEPTIDES IN-VIVO AND IN-VITRO IN THE ABSENCE OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; MUTATIONAL ANALYSIS; GENE-EXPRESSION; MESSENGER-RNA; PRODUCTS; TRANSFORMATION; ENHANCER; INVITRO; TYPE-5; IDENTIFICATION	The human adenovirus E1A 243R protein (243 residues) transcriptionally represses a set of cellular genes that regulate cellular growth and differentiation. We describe two lines of evidence that E1A repression does not require cellular protein synthesis but instead involves direct interaction with a cellular protein(s). First, E1A 243R protein represses an E1A repressible promotor in the presence of inhibitors of protein synthesis, as shown by cell microinjection-in situ hybridization. Second, E1A 243R protein strongly represses transcription in vitro from promoters of the E1A-repressible genes, human collagenase, and rat insulin type II. Repression in vitro is promoter-specific, and an E1A polypeptide containing only the N-terminal 80 residues is sufficient for strong repression both in vivo and in vitro. By use of a series of E1A 1-80 deletion proteins, the E1A repression function was found to require two E1A sequence elements, one within the nonconserved E1A N terminus, and the second within a portion of conserved region 1 (40-80). These domains have been reported to possess binding sites for several cellular transcription regulators, including p300, Dr1, YY1, and the TBP subunit of TFIID. The in vitro transcription-repression system described here provides a powerful tool for the fur ther analysis of molecular mechanism and the possible role of these cellular factors.	ST LOUIS UNIV, SCH MED, INST MOLEC VIROL, ST LOUIS, MO 63110 USA; MCMASTER UNIV, DEPT BIOL, HAMILTON, ON L8S 4K1, CANADA	Saint Louis University; McMaster University					NCI NIH HHS [CA-29561] Funding Source: Medline; NIAID NIH HHS [AI-04739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOULUKOS KE, 1993, ONCOGENE, V8, P237; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERY CV, 1987, ONCOGENE, V2, P15; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYSON N, 1992, TUMOR SUPPRESSOR GEN, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRISCH SM, 1990, ONCOGENE, V5, P75; GEDRICH RW, 1992, J VIROL, V66, P5849, DOI 10.1128/JVI.66.10.5849-5859.1992; GLENN GM, 1987, MOL CELL BIOL, V7, P1004, DOI 10.1128/MCB.7.3.1004; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; HANLY SM, 1985, MOL CELL BIOL, V5, P380, DOI 10.1128/MCB.5.2.380; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LOEWENSTEIN PM, 1989, J BIOL CHEM, V264, P21504; LUNBLAD JR, 1995, NATURE, V374, P85; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1993, SEMIN VIROL, V4, P25, DOI 10.1016/1044-5773(93)80005-9; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; SONG CZ, 1995, IN PRESS P NATL ACAD; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; VANORMONDT H, 1980, GENE, V12, P63, DOI 10.1016/0378-1119(80)90016-5; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VENTURA AM, 1990, P NATL ACAD SCI USA, V87, P1310, DOI 10.1073/pnas.87.4.1310; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZU YL, 1992, J BIOL CHEM, V267, P20181	52	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23263	23267		10.1074/jbc.270.40.23263	http://dx.doi.org/10.1074/jbc.270.40.23263			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559479	hybrid			2022-12-25	WOS:A1995RY90900008
J	TIMMONS, L; XU, J; HERSPERGER, G; DENG, XF; SHEARN, A				TIMMONS, L; XU, J; HERSPERGER, G; DENG, XF; SHEARN, A			POINT MUTATIONS IN AWD(KPN) WHICH REVERT THE PRUNE KILLER-OF-PRUNE LETHAL INTERACTION AFFECT CONSERVED RESIDUES THAT ARE INVOLVED IN NUCLEOSIDE DIPHOSPHATE KINASE SUBSTRATE-BINDING AND CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYXOCOCCUS-XANTHUS; SPINACH LEAVES; DROSOPHILA; GENE; EXPRESSION; NM23; HETEROGENEITY; METASTASIS; SEQUENCE; PROTEINS	The awd gene of Drosophila melanogaster encodes a nucleoside diphosphate kinase. Killer of prune (Kpn) is a mutation in the awd gene which substitutes Ser for Pro at position 97 and causes dominant lethality in individuals that do not have a functional prune gene. This lethality is not due to an inadequate amount of nucleoside diphosphate (NDP) kinase activity, In order to understand why the prune/Killer of prune combination is lethal, even in the presence of an adequate NDP kinase specific activity level, and to understand the biochemical basis for the conditional lethality of the awd(Kpn) mutation, we generated second site mutations which revert this lethal interaction. All of the 12 revertants we recovered are second site mutations of the awd(Kpn) gene. Three revertants have deletions of the awd(Kpn) protein coding region. Two revertants have substitutions of the initiator methionine and do not accumulate KPN protein. Seven revertants have amino acid substitutions of conserved residues that are likely to affect the active site: five of these have no enzymatic activity and two have a very low level of specific activity. These data suggest that an altered NDP kinase activity is involved in the mechanism underlying the conditional lethality of the awd(Kpn) mutation.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University					NIGMS NIH HHS [GM33959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; CHENG YC, 1971, BIOCHEMISTRY-US, V10, P2139; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; EDLUND B, 1969, EUR J BIOCHEM, V9, P451, DOI 10.1111/j.1432-1033.1969.tb00630.x; FROLOV MV, 1994, MOL GEN GENET, V242, P478, DOI 10.1007/BF00281800; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HACKSTEIN JHP, 1992, EUR J CELL BIOL, V58, P429; HADORN E, 1951, P NATL ACAD SCI USA, V37, P650, DOI 10.1073/pnas.37.10.650; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LASCU I, 1993, ANAL BIOCHEM, V209, P6, DOI 10.1006/abio.1993.1075; LASCU I, 1992, J BIOL CHEM, V267, P12775; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; NOMURA T, 1992, ARCH BIOCHEM BIOPHYS, V297, P42, DOI 10.1016/0003-9861(92)90638-D; PARKS RW, 1973, ENZYMES, P307; PEDERSEN PL, 1968, J BIOL CHEM, V243, P4305; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; RUGGIERI R, 1991, NATURE, V353, P390, DOI 10.1038/353390a0; SARASTE M, 1991, TRENDS BIOCHEM SCI, V15, P430; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURTEVANT AH, 1956, GENETICS, V41, P118; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TROLL H, 1993, J BIOL CHEM, V268, P25469; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; ZHANG J, 1993, BIOCHIM BIOPHYS ACTA, V1171, P304, DOI 10.1016/0167-4781(93)90070-T	40	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23021	23030		10.1074/jbc.270.39.23021	http://dx.doi.org/10.1074/jbc.270.39.23021			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559441	hybrid			2022-12-25	WOS:A1995RY05400061
J	MCGAHON, AJ; NISHIOKA, WK; MARTIN, SJ; MAHBOUBI, A; COTTER, TG; GREEN, DR				MCGAHON, AJ; NISHIOKA, WK; MARTIN, SJ; MAHBOUBI, A; COTTER, TG; GREEN, DR			REGULATION OF THE FAS APOPTOTIC CELL-DEATH PATHWAY BY ABL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-3 DEPENDENCE; MOLECULAR-CLONING; SURFACE ANTIGEN; EXPRESSION; MICE; RAS; ACTIVATION; VIRUS; LINE; DIFFERENTIATION	Relatively little is known about oncogene involvement in the regulation of Fas-mediated apoptosis. Inhibition of Pas-induced cell death by the bcl-2 oncogene has been demonstrated to be only partial. In light of a growing body of evidence for the Abl kinase as a negative regulator of cell death, we sought to determine whether Abl expression could protect against Pas-mediated cell death. To address this question, we utilized two separate strategies. In the first, we expressed human Fas in K562, a chronic myelogenous leukemia cell line, which constitutively expresses bcr-abl and examined the effects of Fas ligation in these cells. Fas-positive K562 transformants (K562.Fas) were found to be protected against Pas-mediated cell death. However, down-regulation of Bcr-Abl protein levels in K562,Fas cells using antisense oligonucleotides targeted to bcr-abl mRNA rendered these cells highly susceptible to Fas-induced death. In the second approach we utilized a Fas-positive HL-60 cell line, which we transfected with a temperature-sensitive mutant of v-Abl. HL-60.v-AbI(ts) transfectants were found to be protected from Fas-induced apoptosis at the permissive but not the restrictive temperature for the Abl kinase. Taken together, these observations identify the Abl kinase as a negative regulator of Pas-mediated cell death. Since Abl was also found to block apoptosis mediated by ceramide, a recently proposed downstream effector of the apoptotic pathway initiated by Fas, we propose that Abl exerts its protective effects downstream of the early Fas-initiated signaling events.	LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,LA JOLLA,CA 92037; NATL UNIV IRELAND UNIV COLL CORK,DEPT BIOCHEM,TUMOR BIOL LAB,CORK,IRELAND	La Jolla Institute for Immunology; University College Cork			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Cotter, Thomas/0000-0003-4626-5613; Martin, Seamus/0000-0002-8539-3143				ABELSON HT, 1970, CANCER RES, V30, P2213; BEDI A, 1994, BLOOD, V83, P2038; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CIFONE MG, 1994, J EXP MED, V177, P1547; DALEY GQ, 1988, P NATL ACAD SCI USA, V88, P506; ETTINGER R, 1994, J IMMUNOL, V152, P1557; EVANS CA, 1993, CANCER RES, V53, P1735; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAINOVITZFRIEDM.A, 1994, J EXP MED, V180, P525; Hariharan I K, 1988, Oncogene Res, V3, P387; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; MANDANAS RA, 1993, BLOOD, V82, P1838; MARTIAT P, 1993, BLOOD, V81, P502; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTIN SJ, 1994, J IMMUNOL, V145, P1859; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MCWHIRTER JR, 1993, EMBO J, V4, P1533; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NICHOLS GL, 1994, BLOOD, V84, P2912; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PENDERGAST AM, 1993, CELL, V75, P1275; PIERCE JH, 1986, CELL, V41, P685; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; ROVERA G, 1987, ONCOGENE, V1, P29; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STACEY DW, 1991, ONCOGENE, V6, P2297; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SZCYLIK C, 1991, SCIENCE, V253, P562; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TENHOEVE J, 1994, BLOOD, V84, P1731; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V1551, P324; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALSH CM, 1994, J IMMUNOL, V153, P2506; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1982, AM J PATHOL, V189, P78; YAMADA T, 1980, INT J RADIAT BIOL, V37, P695, DOI 10.1080/713857566	54	128	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22625	22631		10.1074/jbc.270.38.22625	http://dx.doi.org/10.1074/jbc.270.38.22625			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545682	hybrid			2022-12-25	WOS:A1995RW31400086
J	DEJONG, R; TENHOEVE, J; HEISTERKAMP, N; GROFFEN, J				DEJONG, R; TENHOEVE, J; HEISTERKAMP, N; GROFFEN, J			CRKL IS COMPLEXED WITH TYROSINE-PHOSPHORYLATED CBL IN PH-POSITIVE LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								The deregulated tyrosine kinase activity of the Bcr/Abl protein has been causally linked to the development of Philadelphia (Ph) chromosome-positive leukemia in mice and man. Abnormally tyrosine-phosphorylated substrates of the Bcr/Abl kinase in Ph-positive cells are likely to contribute to leukemogenesis by interfering with normal signal transduction pathways. We have previously shown that the adaptor molecule Crkl is a major in vivo substrate for the Bcr/Abl tyrosine kinase, and it is thought to connect Bcr/Abl with downstream effecters, In the current study, a tyrosine-phosphorylated protein with a molecular mass of approximately 120 kDa was identified which binds only to the Crkl Src homology 2 (SH2) domain in cells, including Ph-positive patient material, containing an active Bcr/Abl protein. We demonstrate here that this protein is Cbl, originally discovered as an oncogene which induces B-cell and myeloid leukemias in mice. The Crkl SH2 domain binds specifically to Cbl. The Src homology 3 (SH3) domains of Grid do not bind to Cbl, but do bind Bcr/Abl. These findings suggest the existence of a trimolecular complex involving Bcr/Abl, Crkl, and Cbl and are consistent with a model in which Crkl mediates the oncogenic signal of Bcr/Abl to Cbl.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC CARCINOGENESIS SECT,LOS ANGELES,CA 90027	Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRUKER B, 1992, BLOOD, V79, P2215; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FELLER SM, 1995, ONCOGENE, V10, P1465; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LU D, 1993, BLOOD, V82, P1257; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1993, LEUKEMIA ADV RES TRE	22	127	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21468	21471		10.1074/jbc.270.37.21468	http://dx.doi.org/10.1074/jbc.270.37.21468			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545163	hybrid			2022-12-25	WOS:A1995RU75700011
J	MANCHANDA, N; SCHWARTZ, BS				MANCHANDA, N; SCHWARTZ, BS			INTERACTION OF SINGLE-CHAIN UROKINASE AND PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PRO-UROKINASE; COMPLEX-FORMATION; BINDING-PROTEIN; HUMAN-PLASMA; VITRONECTIN; PURIFICATION; ZYMOGEN; INVITRO; FIBRIN	Urokinase (u-PA) is synthesized and secreted as a single-chain polypeptide (single-chain u-PA, scu-PA), which has such little enzymatic activity in solution that it has been considered essentially enzymatically inert. We found that plasminogen activator inhibitor type 1 (PAI-1), the major PAI in plasma, demonstrated concentration-dependent inhibition of this solution-phase scu-PA enzymatic activity. I-125-scu-PA formed complexes with PAI-1 in a concentration- and time-dependent manner, as detected by SDS-polyacrylamide gel electrophoresis under reducing conditions. Among a given population of scu-PA molecules, all measurable enzymatic activity was inhibited by a 10-fold molar excess of PAI-1. However, at this stoichiometry, only a minority of I-125-scu-PA molecules formed SDS-stable complexes with PAI-1 (i.e. complexes that formed a covalent bond upon denaturation), even though the uncomplexed PAI-1 molecules remained competent to inhibit u-PA enzymatic activity. Neither the extent nor the time course of complex formation was altered by using PAI-1 that had been pre-incubated with native human vitronectin, compared with native PAI-1 alone. I-251-scu-PA . PAI-1 complexes that would form a covalent bond if denatured were reversible and existed in equilibrium with either non-complexed or loosely complexed reactants. These data suggest that scu-PA has more enzyme-like properties than previously appreciated and raises the possibility that it resembles single-chain tissue type-plasminogen activator in lacking a complete zymogen conformation.	UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; WILLIAM A MIDDLETON VA HOSP, MED SERV, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL043506] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043506] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ERICKSON LA, 1985, P NATL ACAD SCI USA, V82, P8710, DOI 10.1073/pnas.82.24.8710; GEIGER M, 1989, BLOOD, V74, P722; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MUSSONI L, 1984, THROMB RES, V34, P241, DOI 10.1016/0049-3848(84)90008-2; NASKI MC, 1993, J BIOL CHEM, V268, P12367; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; POLLANEN J, 1991, ADV CANCER RES, V57, P273; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SCHLEEF RR, 1988, HAEMOSTASIS, V18, P328; SCHWARTZ BS, 1994, J BIOL CHEM, V269, P8319; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360	29	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20032	20035		10.1074/jbc.270.34.20032	http://dx.doi.org/10.1074/jbc.270.34.20032			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544349	hybrid			2022-12-25	WOS:A1995RQ99100054
J	WADA, N; MATSUMURA, M; OBA, Y; KOBAYASHI, N; TAKIZAWA, T; NAKANISHI, Y				WADA, N; MATSUMURA, M; OBA, Y; KOBAYASHI, N; TAKIZAWA, T; NAKANISHI, Y			TRANSCRIPTION STIMULATION OF THE FAS-ENCODING GENE BY NUCLEAR FACTOR FOR INTERLEUKIN-6 EXPRESSION UPON INFLUENZA-VIRUS INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SYNERGISTICALLY ACTIVATE TRANSCRIPTION; TUMOR-NECROSIS-FACTOR; DOUBLE-STRANDED-RNA; PROTEIN-KINASE; MONOCLONAL-ANTIBODY; T-CELLS; APOPTOSIS; ANTIGEN; NF-IL6	We previously found that the level of Fas, a cell surface receptor for an apoptosis signal, increases at the mRNA level in influenza virus-infected HeLa cells prior to their death by apoptosis. Here we investigated the mechanism of activation of the Fas-encoding gene expression upon influenza virus infection. Nucleotide sequences for the binding of nuclear factor for interleukin-6 expression (NF-IL6), also known as CCAAT/enhancer-binding protein beta, were repeated 8 times in the 5'-end region of the human FAS gene, spanning from -1360 to +320. This region directed the expression of a downstream marker gene when introduced into HeLa cells and the activity of the FAS gene promoter was stimulated about a fold upon influenza virus infection. Gene expression driven by the FAS promoter was activated when human NF-IL6 was overproduced in a DNA co-transfection study. Moreover, the DNA-binding activity of NF-IL6 increased after infection with the virus, whereas the amount of NF-IL6 seemed unchanged. The results suggest that NF-IL6 is activated upon influenza virus infection through post translational modification and that the modified factor stimulates the transcription of the human FAS gene.	KANAZAWA UNIV,FAC PHARMACEUT SCI,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,GRAD SCH NAT SCI & TECHNOL,KANAZAWA,ISHIKAWA 920,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT VIROL,UBE,YAMAGUCHI 755,JAPAN; AICHI HUMAN SERV CTR,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN	Kanazawa University; Kanazawa University; Yamaguchi University			Nakanishi, Yoshinobu/D-4602-2014	Nakanishi, Yoshinobu/0000-0002-8767-3587				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AMEISEN JC, 1992, IMMUNOL TODAY, V13, P388, DOI 10.1016/0167-5699(92)90086-M; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P287, DOI 10.1089/aid.1993.9.287; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GRIEBEL PJ, 1990, J GEN VIROL, V71, P369, DOI 10.1099/0022-1317-71-2-369; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HATADA E, 1992, J GEN VIROL, V73, P17, DOI 10.1099/0022-1317-73-1-17; HINSHAW VS, 1994, J VIROL, V68, P3667, DOI 10.1128/JVI.68.6.3667-3673.1994; HIROMATSU K, 1994, EUR J IMMUNOL, V24, P2446, DOI 10.1002/eji.1830241028; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JEURISSEN SHM, 1992, J VIROL, V66, P7383, DOI 10.1128/JVI.66.12.7383-7388.1992; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAWAMURA H, 1994, J VIROL, V68, P5056, DOI 10.1128/JVI.68.8.5056-5062.1994; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOBAYASHI N, 1990, P NATL ACAD SCI USA, V87, P9620, DOI 10.1073/pnas.87.24.9620; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LEE JC, 1993, J VIROL, V67, P6989, DOI 10.1128/JVI.67.12.6989-6994.1993; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; MARTIN SJ, 1994, J IMMUNOL, V152, P330; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA S, 1994, APOPTOSIS, V2, P313; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; RAZVI ES, 1993, J VIROL, V67, P5754, DOI 10.1128/JVI.67.10.5754-5765.1993; SAHA K, 1994, J VIROL, V68, P2735, DOI 10.1128/JVI.68.4.2735-2740.1994; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMIZU S, 1988, BLOOD, V71, P196; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; TAKIZAWA T, 1995, IN PRESS VIROLOGY; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TESMER VM, 1993, P NATL ACAD SCI USA, V90, P7298, DOI 10.1073/pnas.90.15.7298; TOMATSU S, 1989, GENE, V80, P353; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V6, P1553; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; [No title captured]	58	91	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18007	18012		10.1074/jbc.270.30.18007	http://dx.doi.org/10.1074/jbc.270.30.18007			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543095	hybrid			2022-12-25	WOS:A1995RM26600059
J	DERUSSO, PA; PHILPOTT, CC; IWAI, K; MOSTOWSKI, HS; KLAUSNER, RD; ROUAULT, TA				DERUSSO, PA; PHILPOTT, CC; IWAI, K; MOSTOWSKI, HS; KLAUSNER, RD; ROUAULT, TA			EXPRESSION OF A CONSTITUTIVE MUTANT OF IRON REGULATORY PROTEIN-1 ABOLISHES IRON HOMEOSTASIS IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELEMENT BINDING-PROTEIN; RESPONSIVE ELEMENT; MESSENGER-RNA	Iron regulatory proteins (IRPs) are iron-sensing proteins that bind to RNA stem-loop sequences known as iron-responsive elements (IREs) when cells are depleted of iron, Although IRPs have been shown to bind to IREs derived from ferritin and transferrin receptor (TfR) mRNAs in vitro, there has not been a direct demonstration of the impact of a recombinant IRP on the expression of endogenous IRE-containing transcripts, In this study, we evaluate the impact of expression of C437S, a mutant of IRP1 that binds IREs regardless of cellular iron status, on the regulation of biosynthesis of ferritin and TfR. Despite being made iron-replete, cells expressing C437S continue to synthesize and express high amounts of TfR, while the synthesis of ferritin is repressed, Thus, a single mutant IRP can prevent the usual homeostatic changes in ferritin and TfR biosynthesis, Cells expressing the mutant protein would therefore be predicted to be unable to defend against iron overload, Preliminary results show that cells treated with iron have diminished cell survival when C437S is expressed, and we have thus created a tissue culture model system for the study of iron toxicity.			DERUSSO, PA (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.		IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000850] Funding Source: NIH RePORTER; NICHD NIH HHS [K12-HD00850] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; GUO B, 1994, J BIOL CHEM, V268, P24252; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; TANG CK, 1992, J BIOL CHEM, V267, P24466	14	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15451	15454		10.1074/jbc.270.26.15451	http://dx.doi.org/10.1074/jbc.270.26.15451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541043	hybrid			2022-12-25	WOS:A1995RG53800003
J	VENEMA, RC; SAYEGH, HS; ARNAL, JF; HARRISON, DG				VENEMA, RC; SAYEGH, HS; ARNAL, JF; HARRISON, DG			ROLE OF THE ENZYME CALMODULIN-BINDING DOMAIN IN MEMBRANE ASSOCIATION AND PHOSPHOLIPID INHIBITION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PROTEIN-KINASE; MOLECULAR-CLONING; PURIFICATION; CELLS; BRAIN; SITE; PHOSPHORYLATION; PARTICULATE; SEQUENCE	Endothelial nitric oxide synthase (eNOS) is a calmodulin (CaM)-dependent, membrane-associated, myristoylated enzyme, which has an important role in regulation of vascular tone and platelet aggregation. In this study, wild-type and mutant forms of bovine eNOS were over-expressed in a baculovirus/Sf9 insect cell system and examined for interactions with membrane phospholipids. Purified wild-type eNOS binds to pure anionic phospholipid vesicles but not to neutral phospholipid vesicles, demonstrating that eNOS attachment to lipid bilayers requires electrostatic as well as hydrophobic interactions. Moreover, catalytic activity of the enzyme is potently inhibited by anionic phospholipids, notably phosphatidylserine (PS), but not by neutral phospholipids. eNOS activity is also significantly inhibited upon enzyme binding to biological membranes isolated from cultured cells. Binding of eNOS to PS vesicles prevents subsequent binding of the enzyme to CaM-Sepharose. Interactions of eNOS with PS are not affected by site-specific mutation of the myristic acid acceptor site in the enzyme. Deletional mutation of the eNOS CaM-binding domain, however, results in loss of binding capacity of the enzyme not only for CaM-Sepharose but also for PS vesicles. Furthermore, removal of the CaM-binding domain converts eNOS from a membrane to a cytosolic protein when the enzyme is expressed in Sf9 cells. These data demonstrate that electrostatic interactions between anionic membrane phospholipids and basic residues in the eNOS CaM-binding domain are important for enzyme membrane association. Membrane association can thus function to inhibit eNOS catalytic activity by interfering with the interaction of the enzyme with calmodulin.			VENEMA, RC (corresponding author), EMORY UNIV, SCH MED, DIV CARDIOL, PO DRAWER LL, ATLANTA, GA 30322 USA.			ARNAL, Jean Francois/0000-0003-2229-6300				ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BERTHIAUME F, 1994, BBA-BIOMEMBRANES, V1191, P209, DOI 10.1016/0005-2736(94)90251-8; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ESKO JD, 1983, ENZYMES, P207; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; HECKER M, 1994, J NEUROCHEM, V62, P1524; HIKI K, 1992, J BIOCHEM-TOKYO, V111, P556, DOI 10.1093/oxfordjournals.jbchem.a123795; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KIM JY, 1994, J BIOL CHEM, V269, P28214; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LIU JW, 1994, J BIOL CHEM, V269, P11691; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; POLITINO M, 1987, J BIOL CHEM, V262, P10109; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P1; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; WEY HE, 1986, BIOCHIM BIOPHYS ACTA, V878, P380, DOI 10.1016/0005-2760(86)90246-8	43	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14705	14711		10.1074/jbc.270.24.14705	http://dx.doi.org/10.1074/jbc.270.24.14705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540177	hybrid			2022-12-25	WOS:A1995RD45500071
J	OH, Y; MULLER, L; NG, L; ROSENFELD, RG				OH, Y; MULLER, L; NG, L; ROSENFELD, RG			TRANSFORMING GROWTH FACTOR-BETA-INDUCED CELL-GROWTH INHIBITION IN HUMAN BREAST-CANCER CELLS IS MEDIATED THROUGH INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-EXPRESSION; RECEPTOR; ESTROGEN; PROLIFERATION; FIBROBLASTS	Most estrogen receptor-negative breast cancer cells, including Hs578T cells, express mRNAs encoding insulin-like growth factor-binding protein (IGFBP)-3, as well as transforming growth factor (TGF)-beta receptors. Our previous studies (Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. (1993) J. Biol. Chem, 268, 14964-14971; Oh, Y., Muller, H. L., Pham, H. M., and Rosenfeld, R. G. (1993) J. Biol. Chem. 268, 26045-26048) have demonstrated a significant inhibitory effect of exogenous IGFBP-3- on Hs578T cell growth and existence of IGFBP-3-specific receptors that may mediate those direct inhibitory effect of IGFBP-3. TGF-beta is also a potent growth inhibitor in human breast cancer cells in vitro and regulates IGFBP-3 production in different cell systems, suggesting that IGFBP-3 is a major anti-proliferative factor and a key element for TGF-beta-induced growth inhibition in human breast cancer cells. In support of this hypothesis, we have demonstrated using Hs578T cells that: 1) TGF-beta stimulates IGFBP-3 gene expression and production prior to its inhibition of cell growth, 2) treatment with an IGFBP-3 antisense oligodeoxynucleotide selectively inhibits TGF-beta-induced IGFBP-3 synthesis and cell growth inhibition, and 3) treatment with IGF-II and IGF-II analogs diminish TGF-beta effects by blocking TGF-beta-induced binding of IGFBP-3 to the cell surface. These findings suggest that IGFBP-3 is a major anti-proliferative factor and a key element in TGF-beta-induced growth inhibition in human breast cancer cells.			OH, Y (corresponding author), OREGON HLTH SCI UNIV,SCH MED,DEPT PEDIAT,L343,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Muller, Hermann L./0000-0003-4929-9966	NCI NIH HHS [CA58110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, CANCER RES, V48, P3898; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; CULLEN KJ, 1991, CANCER RES, V51, P4978; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FONTANA JA, 1990, ENDOCRINOLOGY, V128, P1115; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAMSON G, 1991, J CLIN ENDOCR METAB, V72, P1391, DOI 10.1210/jcem-72-6-1391; MARTIN JL, 1992, ENDOCRINOLOGY, V181, P1703; OH Y, 1992, ENDOCRINOLOGY, V131, P3123, DOI 10.1210/en.131.6.3123; OH Y, 1993, J BIOL CHEM, V268, P25045; OH Y, 1994, ADV EXP MED BIOL, V343, P41; OH YM, 1993, J BIOL CHEM, V268, P14964; PRATT SE, 1993, CANCER RES, V53, P5193; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; ROCHEFORT H, 1991, AM J CLIN ONCOL-CANC, V14, pS1; Rosenfeld R G, 1990, Recent Prog Horm Res, V46, P99; SAMROMAN GA, 1992, J CLIN ENDOCR METAB, V75, P1010; SHEIKH MS, 1993, J CELL PHYSIOL, V155, P556, DOI 10.1002/jcp.1041550314; WOSIKOWSKI K, 1993, INT J CANCER, V53, P290, DOI 10.1002/ijc.2910530220; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	25	218	220	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13589	13592		10.1074/jbc.270.23.13589	http://dx.doi.org/10.1074/jbc.270.23.13589			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7539790	hybrid			2022-12-25	WOS:A1995RC44800003
J	ZALCMAN, G; CLOSSON, V; LINARESCRUZ, G; LEREBOURS, F; HONORE, N; TAVITIAN, A; OLOFSSON, B				ZALCMAN, G; CLOSSON, V; LINARESCRUZ, G; LEREBOURS, F; HONORE, N; TAVITIAN, A; OLOFSSON, B			REGULATION OF RAS-RELATED RHOB PROTEIN EXPRESSION DURING THE CELL-CYCLE	ONCOGENE			English	Article						GTP-BINDING PROTEIN; RHO; RNA EXPRESSION; PROTEIN EXPRESSION; CELL CYCLE	GTP-BINDING-PROTEIN; NERVE GROWTH-FACTOR; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GENE-PRODUCT; HUMAN HOMOLOG; SACCHAROMYCES-CEREVISIAE; CLOSTRIDIUM-BOTULINUM; MOLECULAR-CLONING; FAMILY	The immediate-early gene rhoB codes for a small GTP-binding protein highly homologous to the RhoA protein, While RhoA is known to regulate the assembly of focal adhesions and stress fibers in response to growth factors, the function of RhoB remains unknown. In a first attempt to elucidate its function, we examined the variation of the RhoB protein expression in response to induction of its mRNA. We report here that RhoB is an unstable protein rapidly and transiently induced by growth factors in PC12 and HeLa cells. Moreover, RhoB protein accumulation is periodic through the cell cycle. First detected at the G1/S phase transition, the level of the RhoB protein is maximal during the S phase and declines at the S/G2-M transition. This timing suggests that RhoB plays a role in the G1/S phase transition and/or in the S phase of the cell cycle. We also confirm here a vesicular and perinuclear localization of the endogenous RhoB protein induced by growth factors.	FAC MED LARIBOISIERE, INSERM, U248, F-75010 PARIS, FRANCE; INST GENET MOLEC, PHARMACOL EXPTL LAB, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			ZALCMAN, Gerard/P-4150-2015; ZALCMAN, Gerard/M-8113-2019; ZALCMAN, Gérard/L-7809-2015	ZALCMAN, Gérard/0000-0002-0343-9575				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DISBURY J, 1989, J BIOL CHEM, V264, P16378; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JUST I, 1994, J BIOL CHEM, V269, P10706; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; LANG P, 1992, J BIOL CHEM, V267, P11677; LINARESCRUZ G, 1994, J MICROSC-OXFORD, V173, P27, DOI 10.1111/j.1365-2818.1994.tb03425.x; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MORII N, 1992, J BIOL CHEM, V267, P20921; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OLOFSSON B, 1988, ONCOGENE, V3, P231; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	62	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1935	1945						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7539118				2022-12-25	WOS:A1995QZ92600007
J	TRACY, S; VANDERGEER, P; HUNTER, T				TRACY, S; VANDERGEER, P; HUNTER, T			THE RECEPTOR-LIKE PROTEIN-TYROSINE-PHOSPHATASE, RPTP-ALPHA, IS PHOSPHORYLATED BY PROTEIN-KINASE-C ON 2 SERINES CLOSE TO THE INNER FACE OF THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-I; T-CELLS; PHOSPHOTYROSINE PHOSPHATASE; CATALYTIC DOMAINS; ACTIVATION; FAMILY; CLONING; CD45; INTERNALIZATION; IDENTIFICATION	To determine whether the receptor-like protein-tyrosine phosphatase, RPTP alpha, which is widely expressed in both the developing and adult mouse, is regulated by phosphorylation, we raised antiserum against a C-terminal peptide. This antiserum precipitated a 140-kDa protein from metabolically S-35-labeled NIH3T3 cells. Using this antiserum, we showed that endogenous RPTP alpha is constitutively phosphorylated in NIH3T3 cells, predominantly on two serines, which we identified as Ser-180 and Ser-204, lying in the juxtamembrane domain. 12-O-tetradecanoylphorbol-13 acetate (TPA) stimulation of quiescent NIH3T3 cells rapidly increased phosphorylation of Ser-180 and Ser-204. Purified protein kinase C (PKC) phosphorylated bacterially expressed RPTP alpha at Ser-180 and Ser-204. When wild type and S180A/S204A double mutant RPTP alpha were transiently expressed in 293 human embryonic kidney cells. TPA stimulated phosphorylation of wild type but not of double mutant RPTP alpha. PKC down-regulation following prolonged exposure to TPA diminished TPA-stimulated RPTP alpha phosphorylation. Taken together, these results indicate that RPTP alpha is a direct substrate for (PKC). Examination of 293 cells expressing exogenous RPTP alpha using immunofluorescence confocal microscopy showed that RPTP alpha exists predominantly in two subcellular compartments: in dense intracellular granules or dispersed within the plasma membrane, TPA treatment caused redistribution of some intracellular RPTP alpha to the cell surface, but this did not require direct phosphorylation of RPTP alpha at Ser-180/Ser-204. Our results suggest that activation of PKC by cytokines modulates RPTP alpha function in several different ways.	SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA	Salk Institute				Tracy, Sharon/0000-0002-5731-5228	NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA14195, CA39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COCHET C, 1984, J BIOL CHEM, V259, P2553; DAUM G, 1994, J BIOL CHEM, V269, P10524; DAUM G, 1991, J BIOL CHEM, V266, P12211; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOXIE JA, 1986, J IMMUNOL, V137, P1194; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SU J, 1994, J BIOL CHEM, V269, P18731; TAN XH, 1993, J BIOL CHEM, V268, P6835; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WEINMASTER G, 1983, J VIROL, V46, P29, DOI 10.1128/JVI.46.1.29-41.1983; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	46	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10587	10594		10.1074/jbc.270.18.10587	http://dx.doi.org/10.1074/jbc.270.18.10587			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537734	hybrid			2022-12-25	WOS:A1995QW60100037
J	JHUN, BH; RIVNAY, B; PRICE, D; AVRAHAM, H				JHUN, BH; RIVNAY, B; PRICE, D; AVRAHAM, H			THE MATK TYROSINE KINASE INTERACTS IN A SPECIFIC AND SH2-DEPENDENT MANNER WITH C-KIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; SH2 DOMAINS; SI-LOCUS; LIGAND; PROLIFERATION; MEGAKARYOCYTOPOIESIS; PHOSPHORYLATION	We have cloned a protein tyrosine kinase, MATK, which is expressed abundantly in megakaryocytes and the brain. We investigated whether MATK participates in the c-Kit ligand/stem cell factor (KL/SCF) signaling pathway in the megakaryocytic cell line CMK. After KW SCF stimulation, five major proteins of molecular masses of 145, 113, 92, 76, and 63 kDa were rapidly and transiently tyrosine-phosphorylated in a time dependent manner, peaking within 5 min, and returning to basal levels within 60 min. To study the role of MATK in the KL/SCF signaling pathway, glutathione S-transferase (GST) fusion proteins containing SH2 and SH3 domains of MATK were cloned, expressed in Escherichia coli, and purified, MATK SH2, but not MATK-SH3, precipitated the tyrosine phosphorylated c-Kit (molecular mass of 145 kDa) in KL/SCF-stimulated CMK cells. Other GST fusion proteins containing the SH2 domain of p85 of phosphatidylinositol 3-kinase, phospholipase C gamma-1, and ras-GAP also precipitated c-Kit. The tyrosine-phosphorylated c-Kit was co-immunoprecipitated with anti-MATK and anti p85 antibodies in KL/SCF-stimulated CMX cells, but not in granulocyte-macrophage colony stimulating factor or interleukin-6-stimulated cells, suggesting receptor specificity. These results indicate that MATK associates with the c-Kit receptor following specific stimulation by KL/SCF via its SH2 domain and likely participates in transduction of growth signals induced by this cytokine in megakaryocytes.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02215	Harvard University; Harvard Medical School				Price, Daniel/0000-0002-4083-9113; Avraham, Hava/0000-0002-7545-3640	NHLBI NIH HHS [HL51456, HL46668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456, R01HL046668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM H, 1992, BLOOD, V79, P365; AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1993, STEM CELLS, V11, P499, DOI 10.1002/stem.5530110619; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BRIDDELL RA, 1991, BLOOD, V78, P2854; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HU ZB, 1994, BLOOD, V83, P2133; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KOMATSU N, 1989, BLOOD, V74, P42; KURIU A, 1991, BLOOD, V78, P2834; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PIETSCH T, 1992, BLOOD, V80, P1199; QUI F, 1988, EMBO J, V7, P1003; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUSSELL ES, 1970, REGULATION HEMATOPOI, P649; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKANO S, 1994, ONCOGENE, V19, P1155; SONGYAN Z, 1990, CELL, V72, P767; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TOHDA S, 1993, J CELL PHYSIOL, V154, P410, DOI 10.1002/jcp.1041540225; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	37	28	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9661	9666		10.1074/jbc.270.16.9661	http://dx.doi.org/10.1074/jbc.270.16.9661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7536744				2022-12-25	WOS:A1995QU08900089
J	BOLDIN, MP; VARFOLOMEEV, EE; PANCER, Z; METT, IL; CAMONIS, JH; WALLACH, D				BOLDIN, MP; VARFOLOMEEV, EE; PANCER, Z; METT, IL; CAMONIS, JH; WALLACH, D			A NOVEL PROTEIN THAT INTERACTS WITH THE DEATH DOMAIN OF FAS/APO1 CONTAINS A SEQUENCE MOTIF RELATED TO THE DEATH DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; FACTOR TNF RECEPTOR; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; MAMMALIAN-CELLS; NGF RECEPTOR; FAS ANTIGEN; APOPTOSIS; INDUCTION; HOMOLOGY	Signaling for cell death by Fas/APO1 occurs via a distinct region in its intracellular domain. This region contains a conserved sequence motif, the death domain motif, that is also found in the intracellular domains of p55 tumor necrosis factor receptor and the low affinity nerve growth factor receptor, as well as in the regulatory domain of the ankyrins. A novel protein that specifically binds to the death domain of Fas/APO1 but not to Fas/APO1 molecules with a loss of function point mutation occurring in lpr(cg) mice was cloned by a two-hybrid screen of a HeLa cells' cDNA library. The cloned protein itself contains a death domain motif, and this region binds to the death domain of Fas/APO1, while the region upstream to the death domain prompts self-association of the protein. Induced expression of the protein results in ligand-independent triggering of cytotoxicity, suggesting that it is involved in cell death induction by Fas/APO1.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; DENIS DIDEROT UNIV,INSERM,U248,F-75010 PARIS,FRANCE	Weizmann Institute of Science; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Boldin, Mark/0000-0003-4593-0669				BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ENGLEMANN H, 1990, J BIOL CHEM, V265, P1531; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANGER GA, 1968, NATURE, V218, P253; ITOH N, 1993, J BIOL CHEM, V268, P10932; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KUNKEL AT, 1994, CURRENT PROTOCOLS MO; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RUDDLE NH, 1968, J EXP MED, V128, P1267, DOI 10.1084/jem.128.6.1267; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALLACH D, 1994, CYTOKINE, V6, P556; WALLACH D, 1994, J IMMUNOL, V132, P2464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	27	916	969	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7795	7798		10.1074/jbc.270.14.7795	http://dx.doi.org/10.1074/jbc.270.14.7795			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7536190	hybrid			2022-12-25	WOS:A1995QR52600004
J	JUAN, TSC; HAILMAN, E; KELLEY, MJ; BUSSE, LA; DAVY, E; EMPIG, CJ; NARHI, LO; WRIGHT, SD; LICHENSTEIN, HS				JUAN, TSC; HAILMAN, E; KELLEY, MJ; BUSSE, LA; DAVY, E; EMPIG, CJ; NARHI, LO; WRIGHT, SD; LICHENSTEIN, HS			IDENTIFICATION OF A LIPOPOLYSACCHARIDE-BINDING DOMAIN IN CD14 BETWEEN AMINO-ACID-57 AND AMINO-ACID-64	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE CD14; HUMAN-MONOCYTES; ENDOTOXIN; ACTIVATION; PROTEIN; CELLS; MEMBRANE; CAPACITY; LPS	CD14 is a 55-kDa glycoprotein which binds lipopolysaccharide (LPS) and enables LPS-dependent responses in a variety of cells. Recent limited proteolysis studies have implicated a region in CD14 between amino acids 57 and 64 as being involved in LPS interaction, To specifically assess the importance of this region with respect to LPS binding, we constructed a mutant sCD14 (sCD14(Delta 57-64)) lacking amino acids 57-64. sCD14(Delta 57-64) was isolated from the serum-free conditioned medium of this cell line, and, in all assays, the purified protein failed to recognize LPS or enable LPS dependent responses in cells. We also demonstrated that the region between amino acids 57 and 64 is required for binding of a neutralizing CD14 mAb, MEM-18. Native polyacrylamide gel electrophoresis assays were used to demonstrate that MEM-18 and LPS compete for the same binding site on CD14. These data strongly suggest that the region spanning amino acids 57-64 binds LPS and that formation of sCD14 LPS complex is required in order for sCD14-mediated responses to occur.	AMGEN INC,THOUSAND OAKS,CA 91320; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; UNIV SO CALIF,DEPT BIOCHEM,LOS ANGELES,CA 90033	Amgen; Rockefeller University; University of Southern California					NIAID NIH HHS [AI-30556] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; BAZIL V, 1989, MOL IMMUNOL, V26, P657, DOI 10.1016/0161-5890(89)90048-5; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DETMERS PA, 1994, J IMMUNOL, V153, P2137; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GRUNWALD U, 1993, CIRC SHOCK, V39, P220; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1993, J IMMUNOL, V151, P1500; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; LETURCQ DJ, 1994, 3RD SAT M C INT END; MCGINLEY MD, 1995, J BIOL CHEM, V270, P5213, DOI 10.1074/jbc.270.10.5213; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SIMMONS DL, 1989, BLOOD, V78, P284; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TODD RF, 1982, HYBRIDOMA, V1, P329, DOI 10.1089/hyb.1.1982.1.329; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	23	114	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5219	5224		10.1074/jbc.270.10.5219	http://dx.doi.org/10.1074/jbc.270.10.5219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534291	hybrid			2022-12-25	WOS:A1995QL58000042
J	JOVOV, B; ISMAILOV, II; BENOS, DJ				JOVOV, B; ISMAILOV, II; BENOS, DJ			CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS REQUIRED FOR PROTEIN-KINASE-A ACTIVATION OF AN OUTWARDLY RECTIFIED ANION CHANNEL PURIFIED FROM BOVINE TRACHEAL EPITHELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING CHLORIDE CHANNELS; CL CHANNELS; FUNCTIONAL RECONSTITUTION; SECRETORY EPITHELIA; CFTR; AIRWAY; CELLS; CAMP; TEMPERATURE; MEMBRANES	Our laboratory has developed a protocol for the isolation of a 140-kDa protein that forms an anion-selective channel when reconstituted into planar lipid bilayers. Polyclonal antibodies have been raised against the 38-kDa component of this purified protein, This channel has a linear current-voltage relationship and is not activated by protein kinase A (PKA) plus ATP. Using the same antibody and a modified purification protocol (eliminating the ion exchange chromatography steps), we isolated and reconstituted two other anion channels from tracheal membrane vesicles. In vitro phosphorylation of these isolated proteins by PKA and ATP revealed four bands migrating at 52, 85, 120, and 174 kDa. Immunoprecipitation experiments with anti-CFTR antibodies indicate that the 174-kDa phosphoprotein was CFTR. Upon incorporation of these isolated proteins into planar bilayers, an anion channel that exhibited a marked outward rectification in symmetrical Cl- solutions with a slope conductance of 82 pS at depolarizing voltages was observed, PKA and ATP increased channel activity but only from one side of the bilayer. However, channel activity was unaffected by addition of ATP alone from either side of the membrane, DIDS (100 mu M) applied to the opposite side of the bilayer to which PKA and ATP act, blocked channel activity. A linear anion-selective channel with a conductance of 16 pS could be also resolved after inhibition of the outwardly rectified anion channel by DIDS in the presence of PKA and ATP. This small conductance channel was inhibited by 300 mu M diphenylamine 2-carboxylic acid. Immunodepletion of the 174-kDa phosphoprotein from the preparation prevented activation of the 82-pS outwardly rectified anion channel by PKA and ATP. However, the PKA-dependent in vitro phosphorylation of the 52-, 85-, and 120-kDa phosphoproteins was unaffected by the absence of CFTR. Our results suggest a direct regulatory relationship between an outwardly rectified anion channel and CFTR.			JOVOV, B (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,UAB STN,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; ANDERSON MP, 1991, SCIENCE, V251, P269; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DHO S, 1992, AM J PHYSIOL, V262, pC67, DOI 10.1152/ajpcell.1992.262.1.C67; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FRIZZELL RA, 1986, FASEB J, V45, P2727; FULLER CM, 1992, AM J PHYSIOL, V262, pC396, DOI 10.1152/ajpcell.1992.262.2.C396; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; FULLER CM, 1994, J BIOL CHEM, V269, P26642; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GUGGINO WB, 1993, J BIOENERG BIOMEMBR, V25, P27, DOI 10.1007/BF00768065; HALM DR, 1989, AM J PHYSIOL, V245, pC505; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MADERA JL, 1993, J CLIN INVEST, V91, P2320; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RAN S, 1992, J BIOL CHEM, V267, P20630; RAN S, 1991, J BIOL CHEM, V266, P4782; RAN S, 1992, J BIOL CHEM, V267, P3618; SCHUMACHER RA, 1987, NATURE, V330, P752; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1994, BIOPHYS J, V66, pA2; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TILLY BC, 1992, J BIOL CHEM, V267, P9470; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391	34	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1521	1528		10.1074/jbc.270.4.1521	http://dx.doi.org/10.1074/jbc.270.4.1521			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7530244	hybrid			2022-12-25	WOS:A1995QD20400009
J	WYLLIE, FS; HAUGHTON, MF; BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D				WYLLIE, FS; HAUGHTON, MF; BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D			EVASION OF P53-MEDIATED GROWTH-CONTROL OCCURS BY 3 ALTERNATIVE MECHANISMS IN TRANSFORMED THYROID EPITHELIAL-CELLS	ONCOGENE			English	Article						P53; CELL CYCLE; CHECK-POINT; TUMOR PROGRESSION; THYRO	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; LARGE-T-ANTIGEN; MONOCLONAL-ANTIBODIES; ATAXIA-TELANGIECTASIA; SIMIAN VIRUS-40; MDM-2 ONCOGENE; DNA DAMAGE; MUTANT P53; CARCINOMA	Using the thyroid as a model of multistep epithelial tumorigenesis, we have used representative cell lines to correlate the degree of malignant transformation with the functional status of p53 and the integrity of cell-cycle check-points. Three distinct phenotypes were observed: Type I lines, derived from poorly-differentiate human thyroid cancers, expressed high levels of mutant p53 protein; Type II, also poorly-differentiate but derived from rat, showed over-expression of wild-type (wt) p53 with marked cell-cell heterogeneity: Type III, from well-differentiated human cancers, contained uniformly low levels of wt p53, All cell lines containing wt p53 retained a near-normal induction of p53 by DNA damage. However, the ability to undergo growth arrest differed strikingly, Whereas Type I and II lines had lost both G2/M and G1/S check points, Type III cells retained both. In Type III cells, as in diploid human fibroblasts, mutant p53 expression specifically abrogated G1/S check-point function with no other change in phenotype, These data demonstrate 3 mechanisms for evasion of p53 growth control: (i) direct mutation (ii) indirect inactivation, or (iii) 'avoidance' of activation, most probably due to failure to reach a critical threshold of DNA damage.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Cardiff University; UNICANCER; Gustave Roussy			Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1993, J PATHOL S, V169, P231; BLAYDES JP, IN PRESS ONCOGENE; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P1885; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CHALLETON C, 1992, J ENDOCRINOL INVE S2, V15, P32; COOK PR, 1976, NATURE, V263, P679, DOI 10.1038/263679a0; CRAMER P, 1981, NATURE, V291, P671, DOI 10.1038/291671a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL LH, 1992, CELL, V71, P541; HSU TC, 1989, INT J CANCER, V43, P403, DOI 10.1002/ijc.2910430310; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOPEZLARRAZA D, 1990, MUTAT RES, V232, P57, DOI 10.1016/0027-5107(90)90110-P; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WRIGHT PA, 1993, J PATH S, V169, P230; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; WYLLIE FS, 1992, P ONCOGENES GROWTH C; WYNFORDTHOMAS D, 1990, MOL CELL BIOL, V10, P5365, DOI 10.1128/MCB.10.10.5365; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	54	41	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					49	59						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529918				2022-12-25	WOS:A1995QA98000007
J	MURAKAMI, M; AUSTEN, KF; BINGHAM, CO; FRIEND, DS; PENROSE, JF; ARM, JP				MURAKAMI, M; AUSTEN, KF; BINGHAM, CO; FRIEND, DS; PENROSE, JF; ARM, JP			INTERLEUKIN-3 REGULATES DEVELOPMENT OF THE 5-LIPOXYGENASE/LEUKOTRIENE C-4 SYNTHASE PATHWAY IN MOUSE MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							5-LIPOXYGENASE-ACTIVATING PROTEIN; LEUKOTRIENE SYNTHESIS; ARACHIDONIC-ACID; EXPRESSION; RELEASE; MICE; GENERATION; GENE	To study cytokine regulation of the 5-lipoxygenase (B-LO)/leukotriene (LT) synthase pathway we have developed mouse bone marrow-derived mast cells (BMMC) that minimally express each protein of the pathway by using a novel culture system, lacking interleukin (IL)-3. When mouse bone marrow cells were cultured for 5 weeks with 100 ng/ml c-kit ligand (KL) and 10 units/ml IL-10, a population of >95% mast cells was obtained, These cells generated 8.3 +/- 4.5 ng of LTC(4)/10(6) cells and 8.1 +/- 2.4 ng of prostaglandin (PG) D-2/10(6) cells after IgE-dependent activation, When these BMMC were cultured for 2-5 weeks more with 100 units/ml IL-3 in the continued presence of KL and IL-10, the IgE-dependent generation of LTC(4) and PGD(2) increased to 212 +/- 36 and 25.5 +/- 8.6 ng/10(6) cells, respectively. The dramatic increase in the IgE-dependent generation of LTC(4) in response to IL-3 was accompanied by a concomitant increase in expression of 5-LO and 5-LO-activating protein and preceded the increased expression of cytosolic phospholipase A, and LTC, synthase. The recognition that IL-3 up-regulates the expression of each protein of the 5-LO pathway for the generation of LTC(4) contrasts with our recent finding that KL up-regulates the expression of cytosolic phospholipase A(2), prostaglandin endoperoxide synthase-1, and hematopoietic PGD(2) synthase and increases the IgE-dependent generation of PGD(2) in BMMC developed from bone marrow with IL-3. Thus, developmentally segregated regulation of the prostanoid and cysteinyl leukotriene pathways in lineage-related com mitted mast cell progenitors reveals the pleiotropism of this effector cell of allergic inflammation, a cytokine/growth factor basis for preferential expression of pathways of eicosanoid biosynthesis, and the particular role of IL-3 in regulating the expression of the proteins of the 5-LO/LTC(4) synthase pathway.	BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, U19AI031599, R37AI022531, R01AI022531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI22531, AI31599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE T, 1993, IMMUNOLOGY, V80, P116; CHOMCZYNSKI P, 1983, BIOTECHNIQUES, V15, P532; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HAMASAKI Y, 1994, AM J RESP CELL MOL, V11, P49, DOI 10.1165/ajrcmb.11.1.8018338; HEAVEY DJ, 1988, J IMMUNOL, V140, P1953; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; KATZ HR, 1992, J IMMUNOL, V148, P868; KITAMURA Y, 1979, BLOOD, V53, P492; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7662; LIN LL, 1992, J BIOL CHEM, V267, P23451; MIYAJIMA A, 1993, BLOOD, V82, P1960; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; MURAKAMI M, 1994, ANN NY ACAD SCI, V744, P84, DOI 10.1111/j.1749-6632.1994.tb52726.x; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; REID GK, 1990, J BIOL CHEM, V265, P19818; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; STEINHILBER D, 1993, P NATL ACAD SCI USA, V90, P5984, DOI 10.1073/pnas.90.13.5984; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507	31	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22653	22656		10.1074/jbc.270.39.22653	http://dx.doi.org/10.1074/jbc.270.39.22653			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559381	hybrid			2022-12-25	WOS:A1995RY05400001
J	NORRIS, J; FAN, DJ; ALEMAN, C; MARKS, JR; FUTREAL, PA; WISEMAN, RW; IGLEHART, JD; DEININGER, PL; MCDONNELL, DP				NORRIS, J; FAN, DJ; ALEMAN, C; MARKS, JR; FUTREAL, PA; WISEMAN, RW; IGLEHART, JD; DEININGER, PL; MCDONNELL, DP			IDENTIFICATION OF A NEW SUBCLASS OF ALU DNA REPEATS WHICH CAN FUNCTION AS ESTROGEN RECEPTOR-DEPENDENT TRANSCRIPTIONAL ENHANCERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT; THYROID-HORMONE; SACCHAROMYCES-CEREVISIAE; BREAST-CANCER; BINDING-SITE; GENE; TAMOXIFEN; DELETION; YEAST	We have utilized a genetic selection system in yeast to identify novel estrogen-responsive genes within the hu man genome and to define the sequences in the BRCA-1 gene responsible for its estrogen responsiveness, This approach led to the identification of a new subclass within the Alu family of DNA repeats which have diverged from known Alu sequences and have acquired the ability to function as estrogen receptor-dependent enhancers, Importantly, these new elements confer receptor-dependent estrogen responsiveness to a heterologous promoter when assayed in mammalian cells, This transcriptional activity can be attenuated by the addition of either of three different classes of estrogen receptor antagonists, indicating that these elements function as classical estrogen receptor-dependent enhancers, Furthermore, this enhancer activity is restricted to a specific subset of DNA repeats because consensus Alu elements of four major subfamilies do not respond to the estrogen receptor. Previously, most Alu sequences have been considered to be functionally inert, However, this work provides strong evidence that a significant subset can confer estrogen responsiveness upon a promoter within which they are located, Clearly, Alu sequences must now be considered as important contributors to the regulation of gene transcription in estrogen receptor-containing cells.	DUKE UNIV, MED CTR, SCH MED, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, SCH MED, DEPT SURG, DURHAM, NC 27710 USA; NIEHS, MOLEC CARCINOGENESIS LAB, DURHAM, NC 27709 USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOL MOLEC, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, STANLEY S SCOTT CANC CTR, NEW ORLEANS, LA 70112 USA	Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Louisiana State University System; Louisiana State University System; Louisiana State University System			Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Deininger, Prescott/0000-0002-1067-3028; Norris, John/0000-0001-6553-8053	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048807, R01DK048807] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48807] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERKVENS TM, 1990, GENOMICS, V7, P486, DOI 10.1016/0888-7543(90)90190-6; CLARK JH, 1979, MONOGR ENDOCRINOL, V14, P4; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KETTEL LM, 1991, FERTIL STERIL, V56, P402; KLEINHITPASS L, 1988, J MOL BIOL, V201, P537; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLINGE CM, 1992, J STEROID BIOCHEM, V43, P249, DOI 10.1016/0960-0760(92)90159-G; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAKALOWSKI W, 1994, TRENDS GENET, V10, P188, DOI 10.1016/0168-9525(94)90254-2; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PEINADOONSURBE J, 1993, HORM RES, V40, P184, DOI 10.1159/000183792; QUENTIN Y, 1988, J MOL EVOL, V27, P194, DOI 10.1007/BF02100074; SHEN MR, 1991, J MOL EVOL, V33, P311; SHIMADA F, 1990, LANCET, V335, P1179, DOI 10.1016/0140-6736(90)92695-E; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vidaud Dominique, 1993, European Journal of Human Genetics, V1, P30; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	33	193	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22777	22782		10.1074/jbc.270.39.22777	http://dx.doi.org/10.1074/jbc.270.39.22777			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559405	hybrid			2022-12-25	WOS:A1995RY05400025
J	PATTERSON, C; PARRELLA, MA; HSIEH, CM; YOSHIZUMI, M; LEE, ME; HABER, E				PATTERSON, C; PARRELLA, MA; HSIEH, CM; YOSHIZUMI, M; LEE, ME; HABER, E			CLOTTING AND FUNCTIONAL-ANALYSIS OF THE PROMOTER FOR KDR/FLK-1, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; NF-KAPPA-B; TYROSINE KINASE; CELL GROWTH; DEVELOPMENTAL EXPRESSION; HEMATOPOIETIC-CELLS; ADHESION MOLECULE-1; MOUSE EMBRYOGENESIS; BINDING-SITES; GENE	KDR/flk-1 is one of two receptors for vascular endothelial growth factor, a potent angiogenic peptide, KDR/flk-1 is an early marker for endothelial cell progenitors, and its expression is restricted to endothelial cells in vivo, To investigate the molecular mechanisms regulating expression of KDR/flk-1, we cloned and characterized the promoter of the human KDR/flk-1 gene, The transcription start site was localized by primer extension and ribonuclease protection to a nucleotide 303 base pairs (bp) 5' of the initiation methionine codon, The 5'-flanking sequence is rich in G and C residues and contains five Spl elements but no TATA consensus sequence, By reporter gene transfection experiments, we found that similar to 4 kilobases of KDR/flk-1 5'-flanking sequence directed high level luciferase activity in bovine aortic endothelial cells; further deletion analysis revealed positive regulatory elements between bp -225 to -164, -95 to -77, -77 to -60, and +105 to +127. Mutation of an atypical GATA sequence between bp +105 and +127 did not affect promoter activity, suggesting that GATA elements are not essential for the high level promoter activity of this gene, Consistent with endothelial cell-restricted expression of KDR/flk-1 mRNA, we found that the 4-kilobase flanking sequence directed high level promoter activity in endothelial cells but not in other cell types, To our knowledge this is the first report characterizing the KDR/flk-1 promoter, Understanding the KDR/flk-1 promoter will allow us to investigate endothelial cell-specific gene regulation and to uncover methods for targeting gene delivery specifically to endothelial cells.	HARVARD UNIV, SCH PUBL HLTH, CARDIVASC BIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BREIER G, 1992, DEVELOPMENT, V114, P521; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; COLLINS T, 1991, J BIOL CHEM, V266, P2466; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ORKIN SH, 1992, BLOOD, V80, P575; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	48	142	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23111	23118		10.1074/jbc.270.39.23111	http://dx.doi.org/10.1074/jbc.270.39.23111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559454	hybrid			2022-12-25	WOS:A1995RY05400074
J	DASH, D; AEPFELBACHER, M; SIESS, W				DASH, D; AEPFELBACHER, M; SIESS, W			INTEGRIN ALPHA(IIB)BETA(3)-MEDIATED TRANSLOCATION OF CDC42HS TO THE CYTOSKELETON IN STIMULATED HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GLYCOPROTEIN-IIB-IIIA; TYROSINE PHOSPHORYLATION; MEMBRANE SKELETON; ACTIVATING PROTEIN; MOLECULAR-CLONING; RABBIT PLATELETS; PHOSPHOLIPASE-C; HUMAN HOMOLOG; THROMBIN	To investigate the function of the human Ras-related CDC42 GTP-binding protein (CDC42Hs) we studied its subcellular redistribution in platelets stimulated by thrombin-receptor activating peptide (TRAP) or ADP. In resting platelets CDC42Hs was detected exclusively in the membrane skeleton (9.6 +/- 1.5% of total) and the detergent soluble fraction (90 +/- 4%). When platelets were aggregated with TRAP or ADP, CDC42Hs (10% of total) appeared in the cytoskeleton and decreased in the membrane skeleton, whereas RhoGDI (guanine-nucleotide dissociation inhibitor) and CDC42HsGAP (GTPase-activating protein) remained exclusively in the detergent-soluble fraction. Upon prolonged platelet stimulation CDC42Hs disappeared from the cytoskeleton and reappeared in the membrane skeleton. Rac translocated to the cytoskeleton with a similar time course as CDC42Hs. When platelets were stimulated under conditions that precluded the activation of the alpha(IIb)beta(3) integrin and platelet aggregation, cytoskeletal association of CDC42Hs was abolished. Translocation of CDC42Hs to the cytoskeleton but not aggregation was also prevented by cytochalasins B or D or the protein tyrosine kinase inhibitor genistein. Platelet secretion and thromboxane formation were not required but facilitated the cytoskeletal association of CDC42Hs. The results indicate that in platelets stimulated by TRAP or ADP, a fraction of CDC42Hs translocates from the membrane skeleton to the cytoskeleton. This process is reversible and is mediated by activation of the alpha(IIb)beta(3) integrin and subsequent actin polymerization and protein-tyrosine kinase stimulation. CDC42Hs might be a new component of a signaling complex containing specific cytoskeletal proteins and protein-tyrosine kinases that forms after activation of the alpha(IIb)beta(3) integrin in platelets.	UNIV MUNICH,KREISLAUFKRANKHEITEN,INST PROPHYLAXE & EPIDEMIOL,D-81377 MUNICH,GERMANY	University of Munich			DASH, DEBABRATA/AAF-1837-2020; Siess, Wolfgang/A-6430-2009	Siess, Wolfgang/0000-0003-0698-6416				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; BACHELOT C, 1992, BIOCHEM J, V284, P923, DOI 10.1042/bj2840923; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARROLL RC, 1982, CELL, V30, P385, DOI 10.1016/0092-8674(82)90236-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COHEN I, 1989, BLOOD, V73, P1880; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DHAR A, 1990, MOL PHARMACOL, V37, P519; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISCHER TH, 1994, J BIOL CHEM, V265, P17257; FOX JEB, 1993, ADV EXP MED BIOL, V344, P175; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HART MJ, 1990, J BIOL CHEM, V265, P5990; HEPTINSTALL S, 1992, THROMB HAEMOSTASIS, V68, P727; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; JOHNSON DI, 1993, RAS SUPERFAMILY GTPA, P297; KOMETANI M, 1986, THROMB RES, V41, P801, DOI 10.1016/0049-3848(86)90378-6; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; MURPHY CT, 1993, EUR J BIOCHEM, V216, P639, DOI 10.1111/j.1432-1033.1993.tb18184.x; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; ODA A, 1992, J BIOL CHEM, V267, P20075; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHUKLA SD, 1990, LIPIDS, V26, P1028; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; UEDA T, 1990, J BIOL CHEM, V265, P9373; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307	63	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17321	17326		10.1074/jbc.270.29.17321	http://dx.doi.org/10.1074/jbc.270.29.17321			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542236	hybrid			2022-12-25	WOS:A1995RK68900044
J	FRANK, SJ; YI, WS; ZHAO, YM; GOLDSMITH, JF; GILLILAND, G; JIANG, J				FRANK, SJ; YI, WS; ZHAO, YM; GOLDSMITH, JF; GILLILAND, G; JIANG, J			REGIONS OF THE JAK2 TYROSINE KINASE REQUIRED FOR COUPLING TO THE GROWTH-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; EXPRESSION; CELLS; INDUCTION; STIMULATION; DOMAINS	Growth hormone (GH) treatment of cells promotes activation of JAK2, a GH receptor (GHR)-associated tyrosine kinase. We now explore JAK2 regions required for GHR induced signaling. Wild-type (WT) JAK2 and JAK2 molecules with deletions of the amino terminus (JAK2(ATD)), carboxyl terminus (JAK2(CTD)), or kinase like domain (JAK2(PKD)) were each transiently coexpressed in COS-7 cells with the rabbit GHR. The following responses were assayed: GH-induced transactivation of a luciferase reporter governed by a c-fos enhancer element; GH-induced shift in the molecular mass of a cotransfected epitope tagged extracellular signal-regulated kinase molecule; and GH-induced antiphosphotyrosine immunoprecipitability of the transfected JAK2 form. In each assay, WTJAK2 and JAK2(PKD) allowed GH-induced signaling, whereas JAK2(ATD) and JAK2(CTD) did not. Anti-GHR serum coimmunoprecipitated WTJAK2, JAK2(PKD), and JAK2(CTD), but not JAK2(ATD). Finally, a chimera in which the JAK2 kinase domain replaced the GHR cytoplasmic domain signaled GH-induced transactivation, We conclude: 1) kinase-like domain deletion eliminates neither physical nor functional interaction between JAK2 and the GHR; 2) kinase domain deletion eliminates functional but not physical coupling of JAK2 to the GHR; 3) interaction with the GHR appears dependent on the NH2-terminal one-fifth of JAK2; and 4) a GH-responsive signaling unit can include as little as the GHR external and transmembrane domains and the JAK2 kinase domain.	UNIV ALABAMA,DEPT MED,DIV HEMATOL & ONCOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	FRANK, SJ (corresponding author), UNIV ALABAMA,DEPT MED,DIV ENDOCRINOL & METAB,RM 756,DREB,UAB STN,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA13148] Funding Source: Medline; NIDDK NIH HHS [R01DK44741, R29DK46395] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046395, R01DK044741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Curran T, 1988, ONCOGENE HDB, P307; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14024; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUI H, 1994, J BIOL CHEM, V269, P5364; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SLOOTWEG MC, 1990, J MOL ENDOCRINOL, V6, P179; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUMANTRAN VN, 1992, ENDOCRINOLOGY, V130, P2016, DOI 10.1210/en.130.4.2016; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHINSTON LA, 1992, J BIOL CHEM, V267, P4747; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1994, MOL CELL BIOL, V370, P153; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	42	155	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14776	14785		10.1074/jbc.270.24.14776	http://dx.doi.org/10.1074/jbc.270.24.14776			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540178	hybrid			2022-12-25	WOS:A1995RD45500081
J	GULLBERG, U; LINDMARK, A; LINDGREN, G; PERSSON, AM; NILSSON, E; OLSSON, I				GULLBERG, U; LINDMARK, A; LINDGREN, G; PERSSON, AM; NILSSON, E; OLSSON, I			CARBOXYL-TERMINAL PRODOMAIN-DELETED HUMAN-LEUKOCYTE ELASTASE AND CATHEPSIN-G ARE EFFICIENTLY TARGETED TO GRANULES AND ENZYMATICALLY ACTIVATED IN THE RAT BASOPHILIC MAST-CELL LINE RBL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL ELASTASE; DIPEPTIDYL PEPTIDASE-I; HUMAN GRANULOCYTES; SERINE PROTEASE; MEMBRANE ASSOCIATION; LYSOSOMAL-ENZYMES; PROCATHEPSIN-L; MYELOID CELLS; HEPG2 CELLS; BIOSYNTHESIS	The hematopoietic neutral serine proteases leukocyte elastase and cathepsin G are synthesized as inactive precursors, but become activated by removal of an amino-terminal dipeptide and are stored in granules, Moreover, the pro forms of elastase and cathepsin G show carboxyl-terminal prodomains of 20 and 11 amino acids, respectively, which are not present in the mature enzymes. To investigate mechanisms for processing, activation, and granular targeting, we have utilized transgenic expression of myeloid serine proteases in the rat basophilic/mast cell line RBL-1 (Gullberg, U., Lindmark, A., Nilsson, E., Persson, A.-M.,, and Olsson, I. (1994) J. Biol. Chem. 269, 25219-25225). Leukocyte elastase was stably expressed in RBL-1 cells, and the translation products were characterized by biosynthetic labeling followed by immunoprecipitation, SDS-polyacrylamide gel electrophoresis, and fluorography. Processing of a main pro form of 34 kDa into mature 31- and 29-kDa forms was demonstrated. Translocation of mature forms to granule-containing fractions was shown by subcellular fractionation experiments. The processed forms were enzymatically active, judging by the occurrence of amino-terminal processing demonstrated by radiosequence analysis, the acquisition of affinity for the protease inhibitor aprotinin, and the appearance of elastase activity in transfected RBL cells. To investigate the function of the carboxyl-terminal prodomains, deletion mutants of leukocyte elastase and cathepsin G lacking the carboxyl-terminal extension were constructed and transfected into RBL cells. Our results show that as full-length proteins, the deletion mutants were converted to active enzymes and transferred to granules with kinetics similar to that of wild-type enzymes. me conclude that human leukocyte elastase and cathepsin G are converted into enzymatically active forms when expressed in RBL cells and targeted for storage in granules; the carboxyl-terminal prodomains are necessary neither for enzymatic activation nor for targeting to granules in RBL cells.	LUND UNIV,DEPT MED,DIV HEMATOL,S-22185 LUND,SWEDEN	Lund University								BAINTON DF, 1992, INFLAMMATION BASIC P, P303; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P581; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; BROWN GR, 1993, J IMMUNOL, V150, P4733; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; Elsbach P, 1992, INFLAMMATION BASIC P, P603; FARLEY D, 1988, BIOL CHEM H-S, V369, P3; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; KIDO H, 1986, J IMMUNOL, V136, P1061; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEHRER RI, 1990, BLOOD, V76, P2169; LINDMARK A, 1994, J LEUKOCYTE BIOL, V55, P50, DOI 10.1002/jlb.55.1.50; LINDMARK A, 1990, BLOOD, V76, P2374; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MORGAN JG, 1991, J IMMUNOL, V147, P3210; NAKAJIMA H, 1994, J IMMUNOL, V152, P1057; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; OHLSSON K, 1974, EUR J BIOCHEM, V42, P519, DOI 10.1111/j.1432-1033.1974.tb03367.x; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SINAH S, 1987, P NATL ACAD SCI USA, V84, P2228; Stack JH, 1993, CURR OPIN CELL BIOL, V5, P641, DOI 10.1016/0955-0674(93)90134-C; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; URATA H, 1993, J BIOL CHEM, V268, P24318; VALORE EV, 1992, BLOOD, V79, P1538; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; ZHU Y, 1994, J BIOL CHEM, V269, P3846	46	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12912	12918		10.1074/jbc.270.21.12912	http://dx.doi.org/10.1074/jbc.270.21.12912			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7539007	hybrid			2022-12-25	WOS:A1995QZ71100088
J	LOO, LWM; BERESTECKY, JM; KANEMITSU, MY; LAU, AF				LOO, LWM; BERESTECKY, JM; KANEMITSU, MY; LAU, AF			PP60(SRC)-MEDIATED PHOSPHORYLATION OF CONNEXIN-43, A GAP JUNCTION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-CELL COMMUNICATION; ROUS-SARCOMA VIRUS; GTPASE-ACTIVATING PROTEIN; C6 GLIOMA-CELLS; TYROSINE KINASE; INTERCELLULAR COMMUNICATION; FOCAL ADHESIONS; RAS ONCOGENE; GENE-PRODUCT; SRC GENE	Several laboratories have demonstrated a decrease in gap junctional communication in cells transformed by the src oncogene of the Rous sarcoma virus. The decrease in gap junctional communication was associated with tyrosine phosphorylation of the gap junction protein, connexin 43 (Cx43). This study was initiated to determine if the phosphorylation of Cx43 is the result of a direct kinase-substrate interaction between the highly active tyrosine kinase, pp60(v-src), and Cx43. Previous biochemical studies have been limited by the low levels of Cx43 protein in fibroblast cell lines. To obtain larger quantities of Cx43, we constructed a recombinant baculovirus expressing Cx43 in Spodoptera frugiperda (Sf-9) cells and subsequently purified the expressed Cx43 by immunoaffinity chromatography, We observed that this partially purified Cx43 was phosphorylated on tyrosine in vitro in the presence of kinase-active pp60(src). Phosphotryptic peptide mapping indicated that the in vitro phosphorylated Cx43 contained phosphopeptides which comigrated with a subset of tryptic peptides prepared from Cx43 phosphorylated in vivo. Furthermore, coinfection of Sf-9 cells with recombinant baculoviruses encoding pp60(v-src) and Cx43 resulted in the accumulation of phosphotyrosine in Cx43. Taken together, the evidence presented in this paper demonstrates that kinase active pp60(c-src) is capable of phosphorylating Cx43 in a direct manner. Since the presence of phosphotyrosine on Cx43 is correlated with the down-regulation of gap-junctional communication, these results suggest that pp60(v-src) regulates gap junctional gating activity via tyrosine phosphorylation of Cx43.	UNIV HAWAII MANOA, CANC RES CTR HAWAII, MOLEC CARCINOGENESIS PROGRAM, HONOLULU, HI 96813 USA; UNIV HAWAII MANOA, SCH MED, DEPT MOLEC BIOL & GENET, HONOLULU, HI 96813 USA; UNIV HAWAII MANOA, KAPIOLANI COMMUNITY COLL, DEPT MATH SCI, HONOLULU, HI 96813 USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa					NCI NIH HHS [CA 52098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; ATKINSON MM, 1988, AM J PHYSIOL, V255, pC674, DOI 10.1152/ajpcell.1988.255.5.C674; Atkinson MM, 1985, GAP JUNCTIONS, P205; AZARNIA R, 1987, MOL CELL BIOL, V7, P946, DOI 10.1128/MCB.7.2.946; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; Bennett M V, 1992, Semin Cell Biol, V3, P29; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELFOULY MH, 1989, MOL CARCINOGEN, V2, P131, DOI 10.1002/mc.2940020305; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GARFIELD RE, 1988, OXFORD REV REPROD B, V10, P436; Goding JW, 1983, MONOCLONAL ANTIBODIE; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HERTZBERG EL, 1988, J BIOL CHEM, V263, P19105; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KURATA WE, 1994, ONCOGENE, V9, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOEWENSTEIN WR, 1985, BIOCH SOC S, V50, P43; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MALDONADO PE, 1988, J MEMBRANE BIOL, V106, P203, DOI 10.1007/BF01872158; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEHTA PP, 1989, J CELL BIOL, V108, P1053, DOI 10.1083/jcb.108.3.1053; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MURRAY AW, 1979, BIOCHEM BIOPH RES CO, V91, P395, DOI 10.1016/0006-291X(79)91535-3; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NAUS CCG, 1992, CANCER RES, V52, P4208; PARK S, 1992, J BIOL CHEM, V267, P11612; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; QURESHI SA, 1991, ONCOGENE, V6, P995; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROSE B, 1975, NATURE, V254, P250, DOI 10.1038/254250a0; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; Summers MD, 1987, MANUAL METHODS BACUL; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TROSKO JE, 1990, PATHOBIOLOGY, V58, P265, DOI 10.1159/000163596; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994; ZHANG S, 1991, Cellular Physiology and Biochemistry, V1, P24, DOI 10.1159/000154590; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	75	125	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	1995	270	21					12751	12761		10.1074/jbc.270.21.12751	http://dx.doi.org/10.1074/jbc.270.21.12751			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QZ711	7539006	hybrid			2022-12-25	WOS:A1995QZ71100066
J	NESTEROV, A; KURTEN, RC; GILL, GN				NESTEROV, A; KURTEN, RC; GILL, GN			ASSOCIATION OF EPIDERMAL GROWTH-FACTOR RECEPTORS WITH COATED PIT ADAPTINS VIA A TYROSINE PHOSPHORYLATION-REGULATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; PLASMA-MEMBRANE; KINASE-ACTIVITY; INSULIN-RECEPTOR; DOWN-REGULATION; AUTOPHOSPHORYLATION SITES; MONOCLONAL-ANTIBODIES; JUXTAMEMBRANE REGION; VESICLE ADAPTERS; ENDOCYTIC SYSTEM	We investigated the mechanism by which ligand-activated epidermal growth factor receptors (EGFR) associate with coated pit adaptor protein (AP) complexes, In vivo association, assayed by coimmunoprecipitation of AP with mutant EGFR, required tyrosine kinase activity, intact autophosphorylation sites, and the regulatory carboxyl terminus of EGFR, The role of autophosphorylation of EGFR in interaction with AP was examined in vitro using a BIAcoreTM instrument. Purified active EGFR, immobilized on the biosensor surface, was reversibly autophosphorylated or dephosphorylated by treatment with ATP or phosphatase. Autophosphorylation of EGFR significantly increased AP binding, Once formed, EGFR . AP complexes were resistant to disassembly by dephosphorylation of EGFR or competition with phosphotyrosine, indicating that phosphorylated tyrosine residues do not directly participate in AP binding, Induction of conformational changes in EGFR by treatment with urea increased AP binding up to 10-fold in the absence of EGFR autophosphorylation, A recombinant EGFR carboxyl terminus specifically bound the AP complex and each of the isolated alpha- and beta-subunits of AP2. We conclude that tyrosine autophosphorylation of EGFR exposes structural motif(s) in the carboxyl terminus of EGFR that interact specifically with AP2.	UNIV CALIF SAN DIEGO,DEPT MED 0650,LA JOLLA,CA 92093	University of California System; University of California San Diego					NCI NIH HHS [P01 CA58689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CADENA DL, 1994, J BIOL CHEM, V269, P260; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1991, J BIOL CHEM, V266, P637; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; Jonsson U., 1992, ADV BIOSENSOR, P291; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LUND KA, 1990, J BIOL CHEM, V265, P15713; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; REDDY CC, 1995, IN PRESS BIOTECHNOL; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SBRACCIA P, 1990, J BIOL CHEM, V265, P4902; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SOROKIN A, 1991, J CELL BIOL, V112, P469; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THEIS RS, 1990, J BIOL CHEM, V265, P10132; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WEBER W, 1984, J BIOL CHEM, V259, P4631; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; WU RY, 1994, J BIOL CHEM, V269, P25085; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	58	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6320	6327		10.1074/jbc.270.11.6320	http://dx.doi.org/10.1074/jbc.270.11.6320			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7534311	hybrid			2022-12-25	WOS:A1995QM94500091
J	TOBE, K; TAMEMOTO, H; YAMAUCHI, T; AIZAWA, S; YAZAKI, Y; KADOWAKI, T				TOBE, K; TAMEMOTO, H; YAMAUCHI, T; AIZAWA, S; YAZAKI, Y; KADOWAKI, T			IDENTIFICATION OF A 190-KDA PROTEIN AS A NOVEL SUBSTRATE FOR THE INSULIN-RECEPTOR KINASE FUNCTIONALLY SIMILAR TO INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE-PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; RAT ADIPOCYTES; GROWTH-FACTOR; INTACT RAT; SH2 DOMAIN; IRS-1; ASSOCIATION	Recently, we generated mice with a targeted disruption of the insulin receptor substrate-1 (IRS-1) gene and demonstrated that they exhibited growth retardation and mild insulin resistance, suggesting the presence of IRS-1-independent pathway that partially substitutes for IRS-1 in IRS-1-deficient mice (Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., Sekihara, H., Yoshioka, S., Horikoshi, H., Furuta, Y., Ikawa, Y., Kasuga, M., Yazaki, Y., and Aizawa, S. (1994) Nature 372, 182-186). We have examined the insulin-stimulated tyrosine phosphorylated proteins in livers of wild type and IRS-1-deficient mice. Tyrosine phosphorylation of an 190-kDa protein (pp190) by insulin was significantly stimulated in livers of IRS-1-deficient mice, which was weakly observed in wild type mice in addition to IRS-1. We also demonstrated that pp190 was immunologically distinct from IRS-1 and was associated with both the 85-kDa subunit of phosphatidylinositol 3-kinase and the Grb2/Ash molecule as IRS-1. We identified pp190 as a novel substrate for insulin receptor kinase (IRS-2), which can bind both PI3-kinase and Ash/Grb2, and whose tyrosine phosphorylation is specifically induced in IRS-1-deficient mice. These data suggested that pp190 may play some physiological roles in insulin's signal transduction; furthermore, induction of tyrosine phosphorylation of pp190 may be one of the compensatory mechanisms that substitute for IRS-1 in IRS-1-deficient mice.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,IMEG,MORPHOGENESIS LAB,KUMAMOTO 860,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN	University of Tokyo; Kumamoto University; Asahi Life Foundation								ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; FOLLI F, 1992, J BIOL CHEM, V267, P22171; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FURUSAKA A, 1994, CANCER LETT, V84, P85, DOI 10.1016/0304-3835(94)90361-1; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; TOBE K, 1993, J BIOL CHEM, V268, P11167; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V268, P1; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	27	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5698	5701		10.1074/jbc.270.11.5698	http://dx.doi.org/10.1074/jbc.270.11.5698			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7534300	hybrid			2022-12-25	WOS:A1995QM94500004
J	RIIKONEN, T; KOIVISTO, L; VIHINEN, P; HEINO, J				RIIKONEN, T; KOIVISTO, L; VIHINEN, P; HEINO, J			TRANSFORMING GROWTH-FACTOR-BETA REGULATES COLLAGEN GEL CONTRACTION BY INCREASING ALPHA-2-BETA-1 INTEGRIN EXPRESSION IN OSTEOGENIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION RECEPTORS; SARCOMA CELLS; FIBRONECTIN; FIBROBLASTS; SUBUNIT; MATRIX; BONE; IDENTIFICATION; LAMININ; FAMILY	The contraction of floating collagen gels is suggested to mimic the reorganization of collagenous matrix during development and tissue healing. Here, we have studied two osteogenic cell lines, namely MG-63 and HOS, and a chemically transformed subclone of HOS cells, HOS-MNNG. Transforming growth factor-beta (TGF-beta), a putative regulator of bone fracture healing, increased collagen gel contraction by MG-63 and HOS-MNNG, but not by HOS cells. Our data show that TGF-beta-induced fibronectin synthesis is not sufficient for the process. Instead, anti-beta 1 integrin antibodies could prevent the contraction. There are three different integrin heterodimers that are known to mediate the cell collagen interaction, namely alpha 1 beta 1, alpha 2 beta 1, and alpha 3 beta 1. In MG-63 cells TGF-beta increased the expression of alpha 2 beta 1 integrin and decreased the expression of alpha 3 beta 1 integrin, whereas alpha 1 beta 1 integrin is not expressed. HOS cells had no alpha 2 beta 1 integrin, neither did TGF-beta induce its expression. However, HOS-MNNG cells expressed more alpha 2 beta 1 integrin when treated with TGF-beta. Thus, we suggest that the mechanism of the enhanced collagen gel contraction by TGF-beta is the increased expression of alpha 2 beta 1 integrin heterodimer. To further test this hypothesis, we expressed a full-length alpha 2 integrin cDNA in HOS cells and in MG-63 cells. We obtained HOS cell clones that expressed alpha 2 beta 1 heterodimer, and the ability of these cells to contract collagen gels was greatly enhanced. Furthermore, the contraction by MG-63 cells transfected with alpha 2 integrin cDNA was enhanced, and the contraction by cells transfected with antisense oriented alpha 2 integrin cDNA was decreased. Thus, both in MG-63 and HOS cells the increased alpha 2 integrin expression alone was sufficient for the enhanced contraction of collagen gels. Furthermore, the amount of alpha 2 integrin is critical for the process, and its decrease leads to diminished ability to contract gels.	UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU, FINLAND; UNIV TURKU, MEDICITY RES LAB, SF-20520 TURKU, FINLAND	University of Turku; University of Turku			Vihinen, Pia/AAQ-5574-2021	Vihinen, Pia/0000-0003-1763-5363				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ASAGA H, 1991, EXP CELL RES, V193, P167, DOI 10.1016/0014-4827(91)90552-6; BELLOWS CG, 1981, J ULTRASTRUCT RES, V78, P178; BRIGHTON CT, 1992, J ORTHOP RES, V10, P766, DOI 10.1002/jor.1100100604; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5291; CLARK RAF, 1989, J CLIN INVEST, V84, P1036, DOI 10.1172/JCI114227; CLOVER J, 1992, J CELL SCI, V103, P267; DANS MJ, 1994, J INVEST DERMATOL, V102, P118, DOI 10.1111/1523-1747.ep12371743; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1990, J BIOL CHEM, V265, P10181; HEINO J, 1989, J BIOL CHEM, V264, P380; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894; NIKKARI L, 1993, AM J PATHOL, V142, P1019; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; NUGENT MA, 1989, J BIOL CHEM, V264, P18060; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; RETTIG WJ, 1984, P NATL ACAD SCI-BIOL, V81, P6437, DOI 10.1073/pnas.81.20.6437; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROBEY PG, 1993, J BONE MINER RES, V8, P483; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311; SANTALA P, 1994, J BIOL CHEM, V269, P1276; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SHIRO JA, 1991, CELL, V67, P403; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1987, NATURE, V326, P607, DOI 10.1038/326607a0; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	43	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					376	382		10.1074/jbc.270.1.376	http://dx.doi.org/10.1074/jbc.270.1.376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529233	hybrid			2022-12-25	WOS:A1995QA28700059
J	PRUDOVSKY, I; SAVION, N; ZHAN, X; FRIESEL, R; XU, JM; HOU, JZ; MCKEEHAN, WL; MACIAG, T				PRUDOVSKY, I; SAVION, N; ZHAN, X; FRIESEL, R; XU, JM; HOU, JZ; MCKEEHAN, WL; MACIAG, T			INTACT AND FUNCTIONAL FIBROBLAST GROWTH-FACTOR (FGF) RECEPTOR-1 TRAFFICKS NEAR THE NUCLEUS IN RESPONSE TO FGF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; CELL-CYCLE; FACTOR-I; TRANSLOCATION; ASSOCIATION; EXPRESSION; PROTEINS; PHASE	Exogenous fibroblast growth factor-1 (FGF-1) associates with the nucleus in a receptor-dependent manner during the entire G(1) period of the BALB/c 3T3 cell cycle (Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol, Chem, 268, 9611-9620). To further study the role of the FGF receptor (FGFR) during this translocation, the intracellular fate of FGFR-1 protein and enzymatic activity was examined, Immunoprecipitation using multiple FGFR-1 antibodies followed by an in vitro tyrosine kinase activity assay enabled us to identify FGFR-1 as a 130-kDa phosphotyrosine-containing protein associated with the nuclear fraction of NIH 3T3 cells exposed to FGF-1. While FGFR-1 tyrosine kinase activity could be detected as a nuclear-associated protein after a 2-h exposure of the NIH 3T3 cells to FGF-1, this activity appeared to be maximal in the nuclear fraction between 4 and 12 h after FGF-1 treatment, In addition, analysis by confocal immunofluorescence microscopy of quiescent and FGF-1-stimulated NIH 3T3 cells reveal a prominent perinuclear FGFR-1 staining pattern in the cells exposed to FGF-1 but not in the quiescent population, We also observed FGFR-1 associated with the nuclear fraction in FGFR-1-transfected L6 rat myoblasts, which are known to be refractive to exogenous FGF-1 and express relatively low levels of endogenous FGFR-1, In addition, these cells also exhibited the presence of a 145-kDa phosphoprotein in the nuclear fraction that was recognized by FGFR-1 antibodies, These results suggest that the FGFR-1 may be translocated near the nucleus upon interaction with its ligand during the entire G(1) period of the NIH 3T3 cell cycle as a structurally intact and functional tyrosine kinase that may be accessible to perinuclear polypeptides as a regulatory enzyme.	AMER RED CROSS,DEPT MOLEC BIOL,HOLLAND LAB,ROCKVILLE,MD 20855; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	American Red Cross; Texas A&M University System			Savion, Naphtali/K-1013-2019; Prudovsky, Igor/GVU-1521-2022	Savion, Naphtali/0000-0001-8899-0624	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44336, HL32348] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKLAND P, 1990, NATURE, V343, P662; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDMAN S, 1992, BIOCHEM BIOPH RES CO, V198, P1203; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WONG S, 1992, ONCOGENE, V7, P2407; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; XU JM, 1992, J BIOL CHEM, V267, P17792; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221	22	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31720	31724						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527394				2022-12-25	WOS:A1994PX30300062
J	KAO, J; FAN, YG; HAEHNEL, I; BRETT, J; GREENBERG, S; CLAUSS, M; KAYTON, M; HOUCK, K; KISIEL, W; SELJELID, R; BURNIER, J; STERN, D				KAO, J; FAN, YG; HAEHNEL, I; BRETT, J; GREENBERG, S; CLAUSS, M; KAYTON, M; HOUCK, K; KISIEL, W; SELJELID, R; BURNIER, J; STERN, D			A PEPTIDE DERIVED FROM THE AMINO-TERMINUS OF ENDOTHELIAL-MONOCYTE-ACTIVATING POLYPEPTIDE-II MODULATES MONONUCLEAR AND POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS, DEFINES AN APPARENTLY NOVEL CELLULAR INTERACTION SITE, AND INDUCES AN ACUTE INFLAMMATORY RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; TUMOR-NECROSIS-FACTOR; VONWILLEBRAND ANTIGEN-II; RECEPTOR-BINDING; NEUTROPHIL CHEMOTAXIS; TISSUE FACTOR; CELLS; INTERLEUKIN-8; MACROPHAGES; GROWTH	Endothelial-monocyte-activating polypeptide II (EMAP II) is a novel mediator isolated from conditioned medium of methylcholanthrene A-induced tumor cells which modulates properties of endothelial cells, mononuclear phagocytes (MPs), and polymorphonuclear leukocytes (PMNs) in vitro and induces an acute inflammatory response in vivo. A synthetic peptide comprising 15 residues from the N-terminal region (residues 6-20) was shown to induce directional migration of MPs and PMNs, with half-maximal effect at almost-equal-to 200-250 pm, whereas a peptide from the C terminus of EMAP II, as well as other irrelevant peptides, were without effect. Modulation of cellular phenotype by EMAP II-derived peptide was suggested by peptide-induced elevation of cytosolic free calcium concentration in fura-2-loaded MPs and PMNs and by stimulation of peroxidase release in PMNs. Consistent with these in vitro data, EMAP II-derived N-terminal peptide-albumin conjugates injected into the mouse footpad elicited inflammatory cell tissue infiltration, whereas albumin alone or EMAP II-derived C-terminal peptide conjugated to albumin incited little response. Binding of I-125-labeled EMAP II-derived peptide (residues 12-20) to MPs was saturable (K(d) almost-equal-to 200 pm) and was blocked in a dose-dependent manner by the addition of intact EMAP II and unlabeled EMAP II-derived peptides (residues 6-20 and 12-20), whereas interleukin 1, tumor necrosis factor, formyl-methionyl-leucinyl-phenylalanine, or irrelevant peptides were without effect. Cross-linking of I-125-EMAP II-derived peptide (residues 12-20) by disuccinimidyl suberate to human MPs demonstrated a band, almost-equal-to 73 kDa, on reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis. I-125-EMAP II-derived peptide also demonstrated specific binding to human PMNs and murine RAW cells. These data indicate that the N-terminal region of EMAP II defines a biologically active locus of the molecule which interacts with target cells via a potentially novel cellular receptor.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; UNIV TROMSO,DEPT EXPTL PATHOL,N-9000 TROMSO,NORWAY; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOORGAN CHEM,S SAN FRANCISCO,CA 94080; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,BLOOD SYST RES FDN LAB,ALBUQUERQUE,NM 87131	Columbia University; UiT The Arctic University of Tromso; Roche Holding; Genentech; Roche Holding; Genentech; University of New Mexico	KAO, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,P&S 11-518,630 W 168TH ST,NEW YORK,NY 10032, USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249; Clauss, Matthias/0000-0001-5180-3899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL042507, R01HL042833] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42833, HL21006, HL42507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BARANY G, 1980, PEPTIDES, P281; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROCK TA, 1991, AM J PATHOL, V138, P213; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; DURUM SK, 1985, ANNU REV IMMUNOL, V3, P263; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; FLUKS AJ, 1981, J IMMUNOL METHODS, V41, P225, DOI 10.1016/0022-1759(81)90245-3; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAO J, 1992, J BIOL CHEM, V267, P20239; KARPATI RM, 1991, J IMMUNOL, V146, P2043; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KLOCZEWIAK M, 1987, BIOCHEMISTRY-US, V26, P6152, DOI 10.1021/bi00393a031; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; KONDO S, 1987, BLOOD, V70, P1947; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MENEGAZZI R, 1992, J LEUKOCYTE BIOL, V52, P619, DOI 10.1002/jlb.52.6.619; MING WJ, 1987, J IMMUNOL, V138, P1469; MONTESANO L, 1982, BIOCHEM BIOPH RES CO, V109, P7, DOI 10.1016/0006-291X(82)91558-3; MOSER B, 1993, J BIOL CHEM, V268, P7125; OLD L, 1987, TUMOR NECROSIS FACTO, P1; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SCOTT JP, 1981, BLOOD, V58, P1075; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHEN H, 1993, BLOOD, V81, P2767; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TIJBURG P, 1992, CIRCULATION, V86, P408; WAGNER DD, 1991, MAYO CLIN PROC, V66, P621, DOI 10.1016/S0025-6196(12)60522-9	50	78	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9774	9782						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7545917				2022-12-25	WOS:A1994NE05300060
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			COVALENT MODIFICATION OF HUMAN P-GLYCOPROTEIN MUTANTS CONTAINING A SINGLE CYSTEINE IN EITHER NUCLEOTIDE-BINDING FOLD ABOLISHES DRUG-STIMULATED ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED TRANSMEMBRANE DOMAIN; MULTIDRUG-RESISTANCE; ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; INSECT CELLS; MOUSE MDR1; TRANSPORTER; EXPRESSION; MUTATIONS; PROTEIN	The ATPase activity of P-glycoprotein is inactivated by N-ethylmaleimide (NEM), which is postulated to modify cysteine residues within either of the homology A consensus sequences for nucleotide binding (GNSGCGKS and GSSGCGKS, respectively) (Al-Shawi, M. K., Urbatsch, I. L., and Senior, A. E. (1994) J. Biol. Chem. 269, 8986-8992). To test this postulate as well as determine the contribution of either nucleotide-binding domain to function, a Cys-less mutant was constructed, and then a single cysteine residue was reintroduced back into each nucleotide binding consensus sequence. We then tested the sensitivity of the ATPase activity of each mutant to covalent modification by NEM, It was found that covalent modification of a single cysteine residue within either nucleotide-binding consensus sequence (Cys-431 and Cys-1074, respectively) with NEM inhibited drug-stimulated ATPase activity of P-glycoprotein. The concentrations of NEM required for half-maximal inactivation of ATPase activity were 7 and 35 mu M for mutants Cys-431 and Cys-1074, respectively. In both cases, inactivation of ATPase activity by NEM was prevented by ATP. These results suggest that both nucleotide-binding domains may need to bind ATP to couple drug binding to ATPase activity.	UNIV TORONTO,DEPT MED,MED RES COUNCIL GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V260, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GOTTESMAN MM, 1994, CURR TOP MEMBR, V41, P3, DOI 10.1016/S0070-2161(08)60451-7; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P7720; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO US, 1995, J BIOL CHEM, V270, P6686; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, J BIOL CHEM, V270, P10334, DOI 10.1074/jbc.270.17.10334; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHANG X, 1995, BIOL CHEM, V270, P5441; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	48	177	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22957	22961		10.1074/jbc.270.39.22957	http://dx.doi.org/10.1074/jbc.270.39.22957			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559432	hybrid			2022-12-25	WOS:A1995RY05400052
J	ROSSI, DL; ACEBRON, A; SANTISTEBAN, P				ROSSI, DL; ACEBRON, A; SANTISTEBAN, P			FUNCTION OF THE HOMEO AND PAIRED DOMAIN PROTEINS TTF-1 AND PAX-8 IN THYROID-CELL PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA-SYNTHESIS; THYROGLOBULIN PROMOTER; NUCLEAR-PROTEIN; GENE-EXPRESSION; CYCLIC-AMP; THYROTROPIN; CULTURE; INSULIN; MICROINJECTION	The thyroid transcription factors TTF-1 and Pax-8 are homeobox- and paired box-containing genes, respectively, that are responsible for thyroid-specific gene expression, thyroid development, and thyroid cell differentiation, However, it is not clear if such factors play a role in thyroid cell proliferation, The antisense oligonucleotide strategy was used in order to clarify this point, Treatment of quiescent FRTL-5 thyroid cells with TTF-l or Pax-8 antisense oligonucleotides caused a significant reduction in thyroid-stimulating hormone and insulin-like growth factor-I-stimulated cell proliferation, measured by DNA synthesis and cell counting, The same results were obtained with forskolin indicating that the TTF-1 or Pax-8 role in mediating the thyroid stimulating hormone growth effect occurred via the cAMP pathway, The effect was higher with TTF-1 as the blockage by this factor caused a 65% decrease in cell proliferation compared to the control, Pax-8 blocking lead only to a 30% decrease. The blocking of both thyroid transcription factors together did not result in an additive effect, These data provide direct evidence that both homeo and paired box gene expression is essential for FRTL-5 thyroid cell proliferation, with each one possibly playing a different regulatory role.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Santisteban, Pilar/E-7829-2016	Santisteban, Pilar/0000-0002-2758-796X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AZABLANC P, 1993, MOL ENDOCRINOL, V7, P1297, DOI 10.1210/me.7.10.1297; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CIVITAREALE D, 1993, MOL ENDOCRINOL, V7, P1589, DOI 10.1210/me.7.12.1589; Eggo MC, 1990, GROWTH FACTORS, V2, P99, DOI 10.3109/08977199009071497; FABBRO D, 1994, CANCER RES, V54, P4744; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GEHRING WJ, 1992, TRENDS BIOCHEM SCI, V17, P277, DOI 10.1016/0968-0004(92)90434-B; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; ISOZAKI O, 1987, MOL ENDOCRINOL, V1, P839, DOI 10.1210/mend-1-11-839; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LAMY F, 1993, J BIOL CHEM, V268, P8398; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PLACHOV D, 1990, DEVELOPMENT, V110, P643; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; SANTISTEBAN P, 1986, J BIOL CHEM, V262, P4048; SASSONECORSI P, 1989, GENE DEV, V2, P1529; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; TOMINAGA T, 1994, ENDOCRINOLOGY, V135, P1212, DOI 10.1210/en.135.3.1212; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, ENDOCRINOLOGY, V122, P127; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZANNINI S, 1994, J ENDOCRINOL INVE S1, V17, P63; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P913	37	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					23139	23142		10.1074/jbc.270.39.23139	http://dx.doi.org/10.1074/jbc.270.39.23139			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559458	hybrid			2022-12-25	WOS:A1995RY05400078
J	SCHLYER, BD; STEEL, DG; GAFNI, A				SCHLYER, BD; STEEL, DG; GAFNI, A			DIRECT KINETIC EVIDENCE FOR TRIPLET-STATE ENERGY-TRANSFER FROM ESCHERICHIA-COLI ALKALINE-PHOSPHATASE TRYPTOPHAN-109 TO BOUND TERBIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; ROOM-TEMPERATURE; LUMINESCENCE; PHOSPHORESCENCE; IONS; MOLECULES; SITES; BIOCHEMISTRY; MECHANISM; ELASTASE	The addition of excess Tb3+ to metal-depleted Escherichia coli alkaline phosphatase results in enhanced luminescence from enzyme-bound terbium, which increases with sample deoxygenation and exhibits a tryptophan-like excitation spectrum. Following pulsed excitation at 280 nm, the time-resolved terbium emission shows a negative prefactor associated with a submillisecond rise time, which is independent of the concentration of dissolved oxygen. The absence of a build-up phase and similarity in lifetime in the decay kinetics of directly excited (488 nm) terbium allows for the assignment of the submillisecond component in the 280 nm excited sample to bound terbium. The results of the steady state and time-resolved experiments suggest that the time evolution of alkaline phosphatase-bound terbium emission is determined by energy transfer (k(ET) similar to 360 and 120 s(-1)) from the triplet state of tryptophan to terbium followed by terbium decay. This model is based on the observations that 1) the tryptophan phosphorescence lifetime (previously assigned to Trp(109)) corresponds to the longer component of the terbium emission and 2) the long-lived emission is enhanced, as is the Trp(109) phosphorescence, by deoxygenation. An energy transfer mechanism involving the Trp(109) triplet state is shown to be inconsistent with a dipole-dipole process and is best understood as a through-space electron exchange over a donor acceptor distance of 9-10 Angstrom.	UNIV MICHIGAN, INST GERONTOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PHYS & ELECT ENGN, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON AGING [R01AG009761] Funding Source: NIH RePORTER; NIA NIH HHS [T32AG001114, AG09761] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENT DV, 1975, J AM CHEM SOC, V97, P2612, DOI 10.1021/ja00843a004; BHAUMIK ML, 1965, J CHEM PHYS, V42, P787, DOI 10.1063/1.1696007; BOSRON WF, 1977, BIOCHEMISTRY-US, V16, P610, DOI 10.1021/bi00623a009; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; BRUNO J, 1992, BIOCHEMISTRY-US, V31, P7016, DOI 10.1021/bi00146a002; CALHOUN DB, 1988, BIOCHEMISTRY-US, V27, P8466, DOI 10.1021/bi00422a026; CIONI P, 1992, J PHOTOCH PHOTOBIO B, V13, P289, DOI 10.1016/1011-1344(92)85068-6; CIONI P, 1989, EUR J BIOCHEM, V185, P573, DOI 10.1111/j.1432-1033.1989.tb15152.x; CROSBY GA, 1961, J CHEM PHYS, V34, P743, DOI 10.1063/1.1731670; DAWSON WR, 1966, J CHEM PHYS, V45, P2410, DOI 10.1063/1.1727955; DEHORROCKS W, 1981, J AM CHEM SOC, V103, P2856, DOI 10.1021/ja00400a061; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; DOMANUS J, 1980, PHOTOCHEM PHOTOBIOL, V31, P15, DOI 10.1111/j.1751-1097.1980.tb03676.x; DUPORTAIL G, 1980, BIOCHEMISTRY-US, V19, P1377, DOI 10.1021/bi00548a017; EBERSPACH I, 1988, BIOCHIM BIOPHYS ACTA, V952, P67, DOI 10.1016/0167-4838(88)90102-1; ENGLANDER SW, 1987, ANAL BIOCHEM, V161, P300, DOI 10.1016/0003-2697(87)90454-4; FALK MC, 1982, BIOCHEMISTRY-US, V21, P1471, DOI 10.1021/bi00536a001; FORSTER T, 1949, Z NATURFORSCH A, V4, P321; GALLEY WC, 1969, BIOCHEMISTRY-US, V8, P1831, DOI 10.1021/bi00833a008; HOGUE CWV, 1992, J BIOL CHEM, V267, P13340; HORROCKS WD, 1977, J AM CHEM SOC, V99, P2378, DOI 10.1021/ja00449a079; HORROCKS WD, 1979, J AM CHEM SOC, V101, P334, DOI 10.1021/ja00496a010; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIRK WR, 1993, J PHYS CHEM-US, V97, P10326, DOI 10.1021/j100142a011; KLEINERMAN M, 1968, J CHEM PHYS, V49, P3901, DOI 10.1063/1.1670698; LEVY ST, 1992, J PHOTOCH PHOTOBIO A, V66, P159, DOI 10.1016/1010-6030(92)85210-L; LUK CK, 1971, BIOCHEMISTRY-US, V10, P2838, DOI 10.1021/bi00791a006; MACMANUS JP, 1990, J BIOL CHEM, V265, P10358; MARRIOTT G, 1990, BIOCHEMISTRY-US, V29, P7004, DOI 10.1021/bi00482a008; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MARTINI JL, 1993, EUR J BIOCHEM, V211, P467, DOI 10.1111/j.1432-1033.1993.tb17572.x; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; PAPP S, 1989, PHOTOCHEM PHOTOBIOL, V49, P775, DOI 10.1111/j.1751-1097.1989.tb05576.x; PLOCKE DJ, 1962, BIOCHEMISTRY-US, V1, P373, DOI 10.1021/bi00909a001; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P4075; SCHLYER BD, 1994, BIOPHYS J, V67, P1192, DOI 10.1016/S0006-3495(94)80588-0; SIMPSON RT, 1968, BIOCHEMISTRY-US, V7, P4343, DOI 10.1021/bi00852a029; STRAMBINI GB, 1987, BIOPHYS J, V52, P23, DOI 10.1016/S0006-3495(87)83184-3; STRAMBINI GB, 1976, CHEM PHYS LETT, V39, P257, DOI 10.1016/0009-2614(76)80068-1; STRAMBINI GB, 1990, PHOTOCHEM PHOTOBIOL, V51, P643, DOI 10.1111/php.1990.51.6.643; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; [No title captured]	43	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22890	22894		10.1074/jbc.270.39.22890	http://dx.doi.org/10.1074/jbc.270.39.22890			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559424	hybrid			2022-12-25	WOS:A1995RY05400044
J	YBARRA, J; HOROWITZ, PM				YBARRA, J; HOROWITZ, PM			INACTIVE GROEL MONOMERS CAN BE ISOLATED AND REASSEMBLED TO FUNCTIONAL TETRADECAMERS THAT CONTAIN FEW BOUND PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE GROEL; BOVINE LIVER RHODANESE; AMINO-ACID CONTENT; ESCHERICHIA-COLI; SINGLE TRYPTOPHAN; PROTEIN; PURIFICATION; CPN60; CARBOXYLASE; ATP	For the first time, it has been shown that GroEL can be converted from tetradecamers (14-mers) to monomers under conditions commonly used for the preparation of this chaperonin. The essential requirements are the simultaneous presence of nucleotides such as MgATP or MgADP and a solid-phase anion exchange medium. The monomers that are formed are metastable in that they only reassemble to a small degree in the absence of additives, These results are in keeping with previous studies on high pressure dissociation that showed the separated monomers display conformational plasticity and can undergo conformational relaxation when relieved of the constraints of the quaternary structure in the oligomer (Gorovits, B,, Raman, C, S., and Horowitz, P, M, (1995) J. Biol. Chem. 270, 2061-2066). The monomers display greatly enhanced hydrophobic exposure to the probe 1,1'-bis(4-anilino)naphthalene-5,5'-disulfonic acid, although they are not active in folding functions, and they are unable to form complexes with partially folded rhodanese, The monomers can be completely re assembled to 14-mers by incubation in 1 M ammonium sulfate, There is no evidence of intermediates in the reassembly process, Compared with the original oligomers, the reassembled 14-mers have (a) very low levels of polypeptide contaminants and tryptophan-like fluorescence, two problems that previously hampered spectroscopic studies of GroEL structure and function; (b) functional properties that are very similar to the original material; (c) considerably decreased hydrophobic exposure in the native state; and (d) a similar triggered exposure of hydrophobic surfaces after treatment; with urea or spermidine, This study demonstrates that the quaternary structure of GroEL is more labile than previously thought. These results are consistent with suggestions that nucleotides can loosen subunit interactions and show that changes in quaternary structure can operate under conditions where GroEL function has been demonstrated.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; HAYERHARTL MK, 1993, FEBS LETT, V320, P83, DOI 10.1016/0014-5793(93)81663-K; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; Longworth JW, 1971, EXCITED STATES PROTE, P319; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; LUO GX, 1994, J BIOL CHEM, V269, P32151; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MENDOZA JA, 1995, J BIOL CHEM, V1247, P209; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; NEUHOFF V, 1986, ELECTROPHORESIS, V7, P56, DOI 10.1002/elps.1150070110; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PRICE NC, 1991, FEBS LETT, V292, P9, DOI 10.1016/0014-5793(91)80821-J; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TAGUCHI H, 1994, J BIOL CHEM, V269, P8529; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062	38	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22962	22967		10.1074/jbc.270.39.22962	http://dx.doi.org/10.1074/jbc.270.39.22962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559433	hybrid			2022-12-25	WOS:A1995RY05400053
J	KIM, JH; WOLLE, D; HARIDAS, K; PARRY, RJ; SMITH, JL; ZALKIN, H				KIM, JH; WOLLE, D; HARIDAS, K; PARRY, RJ; SMITH, JL; ZALKIN, H			STABLE CARBOCYCLIC ANALOG OF 5-PHOSPHORIBOSYL-1-PYROPHOSPHATE TO PROBE THE MECHANISM OF CATALYSIS AND REGULATION OF GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ASPARAGINE SYNTHETASE; CLONING; GENE; PURF; PHOSPHORIBOSYLTRANSFERASE; CYSTEINE; ENZYME	Glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase catalysis and regulation were studied using a new stable carbocyclic analog of PRPP, 1-alpha-pyrophosphoryl-2-alpha,3-alpha-dihydroxy-4-beta-cyclopentane-methanol-5-phosphate (cPRPP). Although cPRPP competes with PRPP for binding to the catalytic C site of the Escherichia coli enzyme, two lines of evidence demonstrate that cPRPP, unlike PRPP, does not promote an active enzyme conformation. First, cPRPP was not able to ''activate'' Cys(1) for reaction with glutamine or a glutamine affinity analog. The ring oxygen of PRPP may thus be necessary for the conformation change that activates Cys(1) for catalysis. Second, binding of cPRPP to the C site blocks binding of AMP and GMP, nucleotide end product inhibitors, to this site. However, the binding of nucleotide to the allosteric site was essentially unaffected by cPRPP in the C site. Since it is expected that nucleotide inhibitors would bind with low affinity to the active enzyme conformation, the nucleotide binding data support the conclusion that cPRPP does not activate the enzyme.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; RICE UNIV,DEPT CHEM,HOUSTON,TX 77251	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Rice University	KIM, JH (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024658, R01GM026569, R01GM024658] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42303] Funding Source: Medline; NIGMS NIH HHS [GM24658, GM26569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAYTON KA, 1994, J BIOL CHEM, V269, P5313; CLARK DV, 1994, GENETICS, V136, P547; DIXON M, 1979, ENZYMES, P3500; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; GU ZM, 1992, GENE, V119, P123, DOI 10.1016/0378-1119(92)90076-2; HERSHEY HV, 1986, GENE, V43, P287, DOI 10.1016/0378-1119(86)90218-0; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; ITO T, 1994, PLANT MOL BIOL, V26, P529, DOI 10.1007/BF00039565; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; KIM JH, 1995, PLANT J, V7, P77, DOI 10.1046/j.1365-313X.1995.07010077.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDIN KM, 1994, CURR GENET, V25, P465, DOI 10.1007/BF00351787; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MEI B, 1989, J BIOL CHEM, V264, P16613; MEI BG, 1990, J BACTERIOL, V172, P3512, DOI 10.1128/jb.172.6.3512-3514.1990; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; NAGANO H, 1970, J BIOL CHEM, V245, P3810; PARRY RJ, 1993, TETRAHEDRON LETT, V34, P7013, DOI 10.1016/S0040-4039(00)61584-8; RICHARDS NGJ, 1992, FEBS LETT, V313, P98, DOI 10.1016/0014-5793(92)81421-H; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; SCATCHARD G, 1909, ANN NY ACAD SCI, V51, P660; SHENG S, 1993, J BIOL CHEM, V268, P16771; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TSO JY, 1982, J BIOL CHEM, V257, P3525; WONG JY, 1981, BIOCHEMISTRY-US, V20, P5669, DOI 10.1021/bi00523a005; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZHOU GC, 1990, J BIOL CHEM, V265, P21152; ZHOU GC, 1993, J BIOL CHEM, V268, P10471; ZHOU GC, 1994, J BIOL CHEM, V269, P6784	32	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17394	17399		10.1074/jbc.270.29.17394	http://dx.doi.org/10.1074/jbc.270.29.17394			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542237	hybrid			2022-12-25	WOS:A1995RK68900056
J	ABRAHAMSEN, N; LUNDGREN, K; NISHIMURA, E				ABRAHAMSEN, N; LUNDGREN, K; NISHIMURA, E			REGULATION OF GLUCAGON RECEPTOR MESSENGER-RNA IN CULTURED PRIMARY RAT HEPATOCYTES BY GLUCOSE AND CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER; MODULATION; CALCIUM; CELL	Glucagon, the pancreatic hormone secreted in response to hypoglycemia, is a key regulator of hepatic glucose production, Since the number of specific glucagon receptors expressed on the cell surface affects the sensitivity of the liver to glucagon, we have examined the regulation of glucagon receptor mRNA levels in cultured primary rat hepatocytes, By ribonuclease protection assay we have identified glucose and intracellular cAMP as regulators of glucagon receptor mRNA expression in cultured rat hepatocytes, We observed a concentration-dependent increase in glucagon receptor mRNA expression when hepatocytes were cultured in the presence of increasing glucose, A a-fold induction in glucagon receptor mRNA levels was obtained in hepatocytes cultured for 24 h with 22.5 mM glucose as compared with 5.5 mM glucose. Factors such as 3-isobutyl-1-methylxanthine (IBMX), isoproterenol, and forskolin, which are known to raise intracellular cAMP levels, all caused a reduction in glucagon receptor mRNA expression, IBMX alone, IBMX together with isoproterenol, and forskolin reduced glucagon receptor mRNA expression to approximately 25, 10, and 50%, respectively, Glucagon was found to dose dependently decrease glucagon receptor mRNA expression in the hepatocytes with an approximately 70% reduction in response to 100 nm glucagon. Finally, me observed a marked reduction in the number of glucagon binding sites (35% of control) after hepatocytes were cultured with the combination of IBMX and isoproterenol. These results indicate that hepatic glucagon receptor mRNA levels can be regulated by glucose and intracellular cAMP and that this is also reflected at the protein level, Furthermore, the observed effects of cAMP and glucagon suggest that this may be a means by which glucagon can down-regulate its own receptor expression.	HAGEDORN RES INST,DEPT MOLEC ENDOCRINOL,DK-2820 GENTOFTE,DENMARK; NOVO NORDISK AS,DEPT BIOCHEM PHARMACOL,DK-2880 BAGSVAERD,DENMARK	Novo Nordisk; Hagedorn Research Institute; Novo Nordisk				Nishimura, Erica/0000-0001-5741-3648				ABRAHAMSEN N, 1995, ENDOCRINOLOGY, V270, P1572; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; BYGRAVE FL, 1993, BIOCHEM J, V296, P1; CHERRINGTON AD, 1981, GLUCAGON PHYSL PATHO, P221; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; EXTON JH, 1981, GLUCAGON PHYSL PATHO, P195; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; MENZEL S, 1994, GENOMICS, V20, P327, DOI 10.1006/geno.1994.1179; PREMONT RT, 1988, J BIOL CHEM, V263, P16087; Press WH, 1986, NUMERICAL RECIPES AR, P521; RODBELL M, 1983, GLUCAGON, V1, P263; SANTOS A, 1982, EUR J BIOCHEM, V121, P671, DOI 10.1111/j.1432-1033.1982.tb05838.x; SEGLEN PO, 1976, METHOD CELL BIOL, P29; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SNTOS A, 1982, DIABETOLOGIA, V22, P362; SOMAN V, 1978, NATURE, V272, P829, DOI 10.1038/272829a0; SRIKANT CB, 1977, J BIOL CHEM, V252, P7434; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; Unger RH, 1990, ELLENBERG RIFKINS DI, P104; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; Weir GC, 1994, JOSLINS DIABETES MEL, P240	22	49	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15853	15857		10.1074/jbc.270.26.15853	http://dx.doi.org/10.1074/jbc.270.26.15853			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541048	hybrid			2022-12-25	WOS:A1995RG53800063
J	ALAM, J; CAMHI, S; CHOI, AMK				ALAM, J; CAMHI, S; CHOI, AMK			IDENTIFICATION OF A 2ND REGION UPSTREAM OF THE MOUSE HEME OXYGENASE-1 GENE THAT FUNCTIONS AS A BASAL LEVEL AND INDUCER-DEPENDENT TRANSCRIPTION ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; C-JUN; ACTIVATION; INDUCTION; PROTEIN; PHOSPHORYLATION; INTERACTS; PROMOTER; INVITRO; SITES	A 161-base pair fragment (AB1) similar to 10 kilobase pairs upstream of the transcription start site of the mouse heme oxygenase-1 gene functions as a basal level and inducer-dependent enhancer. AB1/chloramphenicol acetyltransferase fusion genes stably transfected into mouse hepatoma (Hepa) cells or L929 fibroblasts were activated 7-8- or 17-22-fold, respectively, after treatment of the cells with either CdCl2 or heme. The AB1 fragment is composed largely of three tandem repeats containing two conserved core elements, A and B. Part of core element A (TCCGGAGCTGTG) resembles the consensus-binding site for transcription factor AP-4, whereas core element B (GCTGAGTCANGG) includes the consensus-binding site (TGAGTCA) for the AP-1 family of transcription factors, Nuclear proteins from Hepa cells did not bind to any of the core A elements, but bound to all three copies of the core B element, AB1 derivatives with one or two mutant AP-1-binding elements exhibited reduced but measurable inducer-dependent enhancer activity, but mutation of all three AP-1-binding sites abolished activation by CdCl2, and heme and also by mercury chloride, zinc chloride, H2O2, sodium arsenate, and 12-O-tetradecanoylphorbol-13-acetate. etate. Pretreatment of stably transfected L929 cells with protein kinase C inhibitors, but not with tyrosine kinase inhibitors or N-acetylcysteine, abrogated 12-O-tetradecanoylphorbol-13-acetate-dependent activation of the AB1/chloramphenicol acetyltransferase fusion gene. Induction by H2O2 was unaffected by the kinase inhibitors, but completely abolished by N-acetylcysteine. Heme-dependent induction was not significantly affected by any of these chemicals.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70121; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Louisiana State University System; Johns Hopkins University	ALAM, J (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT MOLEC GENET,1516 JEFFERSON HIGHWAY,NEW ORLEANS,LA 70121, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1991, BIOTECHNIQUES, V10, P423; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531; Maines M.D., 1992, HEME OXYGENASE CLIN; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V2, P771; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MITANI K, 1992, BLOOD, V79, P1255; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; NASCIMENTO ALTO, 1993, NUCLEIC ACIDS RES, V21, P1103, DOI 10.1093/nar/21.5.1103; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1989, J BIOL CHEM, V264, P10251; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TOMARO ML, 1991, ARCH BIOCHEM BIOPHYS, V286, P610, DOI 10.1016/0003-9861(91)90088-Z	37	189	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11977	11984		10.1074/jbc.270.20.11977	http://dx.doi.org/10.1074/jbc.270.20.11977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7538129	hybrid			2022-12-25	WOS:A1995QY73600047
J	ASA, D; RAYCROFT, L; MA, L; AEED, PA; KAYTES, PS; ELHAMMER, AP; GENG, JG				ASA, D; RAYCROFT, L; MA, L; AEED, PA; KAYTES, PS; ELHAMMER, AP; GENG, JG			THE P-SELECTIN GLYCOPROTEIN LIGAND FUNCTIONS AS A COMMON HUMAN-LEUKOCYTE LIGAND FOR P-SELECTINS AND E-SELECTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN GMP-140; ENDOTHELIAL VONWILLEBRAND-FACTOR; CARBOHYDRATE LIGAND; MYELOID CELLS; ADHESION MOLECULE-1; LECTIN DOMAIN; SIALYL-LEX; ELAM-1; RECOGNITION; SURFACE	P- and E-selectins belong to a family of Ca2+-dependent lectins and function as receptors for myeloid leukocytes, We have described a panel of monoclonal antibodies which recognize a sialoglycoprotein from human neutrophils and HL-60 promyelocytic cells and inhibit adhesion of these cells to P-selectin. In this study, we show that the E-selectin receptor-globulin (E-selectin Rg) affinity chromatography can isolate specifically only one glycoprotein from [H-3] glucosamine-labeled HL-60 cells in a Ca2+-dependent manner. This protein has a molecular mass of similar to 120 kDa under reducing conditions, which appears to be identical with the previously characterized glycoprotein ligand for P-selectin, The molecule can be cross-depleted by and cross-bound to the E- and P-selectin columns, The chromatographic profile of desialylated O-linked carbohydrates from molecules purified by P- and E-selectin affinity chromatography are identical, Both have five structures at 12.8, 9.8, 6.3, 3.5, and 2.5 glucose units, PL5 monoclonal antibody to the P-selectin sialoglycoprotein ligand, E-selectin Rg, and antiserum to P-selectin glycoprotein ligand-1 (PSGL-1) all recognize the purified P-selectin ligand on ligand blots and immunoblots. Furthermore, PL5 monoclonal antibody blocks adhesion of HL-60 cells and human neutrophils to E-selectin Rg, Taken together, our results demonstrate that the P- and E-selectin ligand defined in this study is PSGL-1 and suggest that this molecule is an important leukocyte ligand for both P- and E-selectins.	UPJOHN CO,UPJOHN LABS,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001; UPJOHN CO,UPJOHN LABS,BIOCHEM RES,KALAMAZOO,MI 49001	Pfizer; Pfizer								ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BONFANTI R, 1989, BLOOD, V73, P1109; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; CARLSON DM, 1968, J BIOL CHEM, V243, P616; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1991, J BIOL CHEM, V266, P22313; GENG JG, 1992, J BIOL CHEM, V267, P19846; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISENBERG WM, 1986, BLOOD CELLS, V12, P191; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MA L, 1994, J BIOL CHEM, V269, P27739; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MYADAS TN, 1993, CELL, V74, P541; NAGATA K, 1994, J BIOL CHEM, V269, P23290; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALCHECK B, 1993, J EXP MED, V178, P853, DOI 10.1084/jem.178.3.853; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	52	161	166	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11662	11670		10.1074/jbc.270.19.11662	http://dx.doi.org/10.1074/jbc.270.19.11662			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7538120	hybrid			2022-12-25	WOS:A1995QX86500089
J	JACOBSEN, L; HERMANN, M; VIEIRA, PM; SCHNEIDER, WJ; NIMPF, J				JACOBSEN, L; HERMANN, M; VIEIRA, PM; SCHNEIDER, WJ; NIMPF, J			THE CHICKEN OOCYTE RECEPTOR FOR LIPOPROTEIN DEPOSITION RECOGNIZES ALPHA(2)-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; BINDING-PROTEIN; FACTOR-XIII; COMPLEXES; VITELLOGENIN; INHIBITOR; LOCALIZATION	alpha(2)-Macroglobulin (alpha(2)M), a major plasma component in all vertebrates, is proposed to function as a broad spectrum protease inhibitor. The alpha(2)M-proteinase complex (activated alpha(2)M; alpha(2)M*) is removed rapidly by receptor-mediated endocytosis in the liver. Here we demonstrate by Western blotting that alpha(2)M is also present in the yolk of chicken oocytes. Plasma levels of alpha(2)M are increased by estrogen, and yolk alpha(2)M is partially proteolyzed, consistent with the action of cathepsin D on endocytosed alpha(2)M. Two known estrogen-induced ligands of the oocyte-specific 95-kDa very low density lipoprotein/vitellogenin receptor (OVR) are also fragmented by yolk cathepsin D (Retzek, H., Steyrer, E., Sanders, E. J., Nimpf, J., and Schneider, W. J. (1992) DNA Cell Biol. 11, 661-672). Since these findings suggested a common uptake mechanism for lipoproteins and alpha(2)M by oocytes, we investigated whether OVR, a member of the low density lipoprotein receptor family, functions in the metabolism of alpha(2)M. Ligand blotting of oocyte membrane extracts with chicken alpha(2)M* revealed that it binds to OVR. Surprisingly, the oocyte receptor also recognizes native alpha(2)M, in sharp contrast to the hepatic receptor, which only binds alpha(2)M*. Receptor interaction of both forms requires Ca2+; however, competition experiments suggest that alpha(2)M and alpha(2)M* interact with slightly different, or overlapping, sites on the receptor. Colocalization of alpha(2)M and OVR in coated vesicles isolated from growing oocytes, and internalization and degradation of methylamine-activated alpha(2)M by COS 7 cells transfected with OVR, strongly suggest that alpha(2)M is transported into growing oocytes via OVR. We propose that this multifunctional receptor mediates pathways at the metabolic crossroads of lipoproteins and protease inhibitor complexes.	UNIV VIENNA,DEPT MOLEC GENET,A-1030 VIENNA,AUSTRIA; BIOCTR VIENNA,A-1030 VIENNA,AUSTRIA	University of Vienna; Vienna Biocenter (VBC)				Hermann, Marcela/0000-0003-2298-4269; Nimpf, Johannes/0000-0002-9273-3492				ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; BARAKAT HA, 1985, J LIPID RES, V26, P1252; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; FELDMAN SR, 1984, ARCH BIOCHEM BIOPHYS, V235, P267, DOI 10.1016/0003-9861(84)90275-3; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERMIER D, 1985, BIOCHIM BIOPHYS ACTA, V836, P105, DOI 10.1016/0005-2760(85)90226-7; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOFER F, 1994, PNATL ACAD SCI US, V1, P1839; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; NIMPF J, 1991, J NUTR, V121, P1471, DOI 10.1093/jn/121.9.1471; NIMPF J, 1994, ANN NY ACAD SCI, V737, P145, DOI 10.1111/j.1749-6632.1994.tb44308.x; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OKA K, 1994, GENOMICS, V20, P2968; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1983, ANN NY ACAD SCI, V421, P41, DOI 10.1111/j.1749-6632.1983.tb18091.x; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STEYRER E, 1995, IN PRESS ANAL BIOCH; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VANLEUVEN F, 1982, BIOCHEM J, V203, P405, DOI 10.1042/bj2030405; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1994, SCIENCE, V264, P171	56	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6468	6475		10.1074/jbc.270.12.6468	http://dx.doi.org/10.1074/jbc.270.12.6468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7534764	hybrid			2022-12-25	WOS:A1995QQ85500010
J	CONOVER, CA; DURHAM, SK; ZAPF, J; MASIARZ, FR; KIEFER, MC				CONOVER, CA; DURHAM, SK; ZAPF, J; MASIARZ, FR; KIEFER, MC			CLEAVAGE ANALYSIS OF INSULIN-LIKE GROWTH-FACTOR (IGF)-DEPENDENT IGF-BINDING PROTEIN-4 PROTEOLYSIS AND EXPRESSION OF PROTEASE-RESISTANT IGF-BINDING PROTEIN-4 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; CELL-CONDITIONED MEDIUM; MOLECULAR-CLONING; HORMONAL-REGULATION; HUMAN-FIBROBLASTS; RAT; SEQUENCE	Cultured human fibroblasts and osteoblast-like cells secrete an insulin-like growth factor (IGF)-dependent protease that cleaves IGF-binding protein-4 (IGFBP-4) into two fragments of similar to 18 and 14 kDa. Edman degradation of the isolated proteins established the amino ter mini of the reaction products, Sequence analysis of the 14-kDa carboxyl terminal half of IGFBP-4 suggested cleavage after methionine at position 135 of the mature protein, Four variant IGPBP-4 molecules with single amino acid substitutions around this cleavage site were constructed and expressed, Wild-type and mutant IGFBPs-4 bound IGF-I and IGF-II with equivalent affinities and, in the intact state, were equally effective inhibitors of IGF-I action, However, the IGFEP-4 mutants were relatively resistant to IGF-dependent proteolysis, A 5-6-h incubation in human fibroblast conditioned medium in the presence of IGF-II was sufficient for near total hydrolysis of wild-type IGFBP-4, whereas the mutant IGFBPs-4 were only minimally affected at this time, After a 24-h incubation with IGF-II, all mutant IGFBPs-4 showed extensive proteolysis, generating 18- and 14-kDa fragments, Pre-exposure of human fibroblasts in serum-free conditioned medium to IGF-II for 5 h potentiated subsequent IGF-I stimulation of DNA synthesis, When added with IGF-II, the protease-resistant mutant IGFBPs-4, but not wild-type IGFBP-4, suppressed IGF-II enhancement of IGF-I-stimulated DNA synthesis, These biological studies suggest that the IGFBP-4/IGFBP-4 protease system may play a role modulating local cellular response to IGF-I.	UNIV ZURICH HOSP,DEPT MED,METAB UNIT,CH-8091 ZURICH,SWITZERLAND; CHIRON CORP,EMERYVILLE,CA 94608; LXR BIOTECHNOL INC,RICHMOND,CA 94804	University of Zurich; University Zurich Hospital; Novartis	CONOVER, CA (corresponding author), MAYO CLIN & MAYO FDN,DIV ENDOCRINOL & METAB,ENDOCRINE RES UNIT,5-164 W JOSEPH,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043258, T32DK007352, R01DK043258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43258, DK-07352] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; CHERNAUSEK SD, 1994, 3RD INT S INS LIK GR; CHEUNG PT, 1991, ENDOCRINOLOGY, V129, P1005; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1994, ENDOCRINOLOGY, V135, P76, DOI 10.1210/en.135.1.76; CONOVER CA, 1993, ENDOCRINOLOGY, V133, P1347, DOI 10.1210/en.133.3.1347; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; DURHAM SK, 1994, J BONE MINER RES, V9, P111; ERICKSON GF, 1992, ENDOCRINOLOGY, V130, P625, DOI 10.1210/en.130.2.625; FOWLKES J, 1992, ENDOCRINOLOGY, V131, P2071, DOI 10.1210/en.131.5.2071; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; PERKEL VS, 1990, J CLIN ENDOCR METAB, V71, P533, DOI 10.1210/jcem-71-2-533; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SHIMASAKI S, 1990, MOL ENDOCRINOL, V4, P1451, DOI 10.1210/mend-4-10-1451; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7	28	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4395	4400		10.1074/jbc.270.9.4395	http://dx.doi.org/10.1074/jbc.270.9.4395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533161	hybrid			2022-12-25	WOS:A1995QK08400035
J	LUSTINARASIMHAN, M; POWER, CA; ALLET, B; ALOUANI, S; BACON, KB; MERMOD, JJ; PROUDFOOT, AEI; WELLS, TNC				LUSTINARASIMHAN, M; POWER, CA; ALLET, B; ALOUANI, S; BACON, KB; MERMOD, JJ; PROUDFOOT, AEI; WELLS, TNC			MUTATION OF LEU(25) AND VAL(27) INTRODUCES CC CHEMOKINE ACTIVITY INTO INTERLEUKIN-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; FUNCTIONAL EXPRESSION; ACTIVATING FACTOR; RECEPTOR; FAMILY; RANTES; PURIFICATION; CYTOKINE; GENE; LYMPHOCYTES	Interleukin-8 (IL-8) is a member of the CXC branch of the chemokine superfamily and activates neutrophils but not monocytes. The related CC chemokine branch, which includes monocyte chemoattractant protein-1 (MCP-1) and RANTES are potent chemoattractants for monocytes but not neutrophils. Examination of the sequences of the CXC chemokines reveals that the highly conserved leucine, corresponding to Leu(25) in IL-8, is always replaced by tyrosine in CC chemokines, There is also a high degree of conservation among the CXC chemokines of the adjacent Val(27) residue, which points out from the same side of the beta-sheet as Leu(25). In RANTES, Val(27) is also replaced by a tyrosine. In order to investigate the role of these residues in controlling cell specificity, we have made the single mutants Leu(25) --> Tyr, Val(27) --> Tyr and the double mutant Leu(25) --> Tyr, Val(27) --> Tyr of IL-8. These proteins have been expressed in Escherichia colt and purified to homogeneity from inclusion body material, Ah three mutants have lower potency and efficacy in chemotaxis and calcium mobilization assays using neutrophils. The mutants also show lowered affinity to both IL-8 receptors A and B expressed recombinantly in HL-60 cells and to neutrophils in [(125)]IL-8 com petition assays. Additionally, the Leu(25) --> Tyr mutation introduces a novel monocyte chemoattractant activity into IL-8, We therefore studied the displacement of [I-125]MIP-1 alpha by IL-8 Leu(25) --> Tyr from the CC-CKR-1 receptor. The mutant displaces MIP-1 alpha ligand with an affinity only 12-fold less than MIP-1 alpha itself. This suggests that mutations in this region of IL-S are involved in receptor binding and activation and in the control of specificity between CC and CXC chemokines.	GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline				Wells, Timothy/0000-0001-9796-847X; Narasimhan, Manjulaa/0000-0003-0598-6887				ALAM R, 1993, J IMMUNOL, V150, P3442; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BEALL CJ, 1992, J BIOL CHEM, V267, P3455; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, PROTEIN ENG, V4, P263; FINCHAM NJ, 1988, J IMMUNOL, V140, P4294; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GAO JL, 1993, J EXP MED, V199, P1421; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HERMODSON M, 1977, J BIOL CHEM, V252, P6276; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LEATHERBARROW RJ, 1993, GRAFIT VERSION 3 01; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NIEWIAROWSKI S, 1981, PLATELETS BIOL PATHO, V2, P91; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SHAW JP, 1994, J MOL BIOL, V237, P349; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	42	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2716	2721		10.1074/jbc.270.6.2716	http://dx.doi.org/10.1074/jbc.270.6.2716			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7531692	hybrid			2022-12-25	WOS:A1995QF53500050
J	ARIMILLI, S; CARDOSO, C; MUKKU, P; BAICHWAL, V; NAG, B				ARIMILLI, S; CARDOSO, C; MUKKU, P; BAICHWAL, V; NAG, B			REFOLDING AND RECONSTITUTION OF FUNCTIONALLY ACTIVE COMPLEXES OF HUMAN-LEUKOCYTE ANTIGEN-DR2 AND MYELIN BASIC-PROTEIN PEPTIDE FROM RECOMBINANT-ALPHA AND RECOMBINANT-BETA POLYPEPTIDE-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; B-CELL LINE; ESCHERICHIA-COLI; T-CELLS; 3-DIMENSIONAL STRUCTURE; SCALE PURIFICATION; SURFACE EXPRESSION; HEAVY-CHAIN; MHC; BINDING	Major histocompatibility complex (MHC) class II molecules are cell surface heterodimeric glycoproteins consisting of one alpha and one beta polypeptide chain of similar size. These molecules play a critical role in immune recognition by displaying processed antigens to CD4-positive T helper cells. Several attempts to express the MHC class II molecules by recombinant methods in various systems resulted in either failure or poor recovery of the intact heterodimer. The present study describes our successful effort to refold and reconstitute HLA DR2 heterodimer from individually expressed alpha and beta polypeptide chains lacking the transmembrane hydrophobic regions in Escherichia coli, in the presence of an immunodominant epitope analog from human myelin basic protein (b-MBP(83-102)Y-83). The reconstituted DR2 heterodimer complex was selectively purified from unfolded alpha and beta chains using heterodimer-specific monoclonal antibody (L243) coupled to a solid support. The detection of two polypeptide chains in the purified refolded DR2-peptide complex preparations was accomplished by Western blot analysis and enzyme-linked immunosorbent assay using heterodimer- and chain-specific polyclonal antibodies, and the presence of equimolar amounts of both alpha chain and beta chain in the reconstituted complex preparation was confirmed by a double label experiment. The quantitation of the bound peptide in complex preparation was measured by incubating two chains in the presence of I-125-labeled peptide. An increase in the yield of refolded and reconstituted DR2-peptide complexes was observed with increasing peptide concentration in the reaction mixture. Finally, the functional activity of the reconstituted DR2 complexes was measured by their ability to stimulate gamma-interferon production by SS8T cloned T cells in an antigen-specific and dose-dependent manner. These results demonstrate that biologically active complexes of human DR2-b-MBP(83-102)Y-83 can be prepared by proper folding of human leukocyte antigen DR2 alpha and beta chains in the presence of antigenic peptide, The yield of such DR2 heterodimers with bound peptide is several thousand-fold higher over native DR2 purified from transformed B cells. Since purified MHC class II-peptide complexes have been shown to prevent autoimmune diseases in various animal models, reconstituted heterodimer complexes may have significant clinical relevance in antigen-specific treatment of various autoimmune diseases. In addition, such complexes with increased yield will provide better understanding of the trimolecular interactions between MHC-peptide and T cell receptor.	ANERGEN INC, REDWOOD CITY, CA 94063 USA									AGRAWAL B, 1994, J IMMUNOL, V152, P965; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; ALTMAN JD, 1993, P NATL ACAD SCI USA, V90, P10330, DOI 10.1073/pnas.90.21.10330; BABITT BP, 1985, NATURE, V317, P359; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUELOW R, 1993, EUR J IMMUNOL, V23, P69, DOI 10.1002/eji.1830230112; BUSS S, 1987, IMMUNOL REV, V98, P115; FAHENSTOCK ML, 1992, SCIENCE, V258, P1658; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1988, NATURE, V334, P530, DOI 10.1038/334530a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; NAG B, 1993, J BIOL CHEM, V268, P14360; NAG B, 1993, P NATL ACAD SCI USA, V90, P1604, DOI 10.1073/pnas.90.4.1604; NAG B, 1993, J IMMUNOL, V150, P1358; NAG B, 1994, J BIOL CHEM, V269, P10061; NAG B, 1994, MOL IMMUNOL, V31, P1161, DOI 10.1016/0161-5890(94)90030-2; NAG B, 1992, J IMMUNOL, V148, P369; PARHAM P, 1979, J BIOL CHEM, V254, P8709; PARKER KC, 1992, J BIOL CHEM, V267, P5451; PASSMORE D, 1992, J IMMUNOL METHODS, V155, P193, DOI 10.1016/0022-1759(92)90285-2; PICHLER WJ, 1994, IMMUNOL TODAY, V15, P312, DOI 10.1016/0167-5699(94)90078-7; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADEGYNASSERI S, 1991, NATURE, V13, P43; SCHEIRLE A, 1992, J IMMUNOL, V149, P1994; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TURKEWITZ AP, 1983, MOL IMMUNOL, V20, P1139, DOI 10.1016/0161-5890(83)90137-2; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; WITT SN, 1992, J AM CHEM SOC, V114, P3506, DOI 10.1021/ja00035a052; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	48	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					971	977		10.1074/jbc.270.2.971	http://dx.doi.org/10.1074/jbc.270.2.971			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529765	hybrid			2022-12-25	WOS:A1995QB81600073
J	HANDLEYGEARHART, PM; STEPHEN, AG; TRAUSCHAZAR, JS; CIECHANOVER, A; SCHWARTZ, AL				HANDLEYGEARHART, PM; STEPHEN, AG; TRAUSCHAZAR, JS; CIECHANOVER, A; SCHWARTZ, AL			HUMAN UBIQUITIN-ACTIVATING ENZYME, E1 - INDICATION OF POTENTIAL NUCLEAR AND CYTOPLASMIC SUBPOPULATIONS USING EPITOPE-TAGGED CDNA CONSTRUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATOR; MOLECULAR-CLONING; CELL-NUCLEUS; PROTEIN; GENE; LOCALIZATION; EXPRESSION; MUTANT	The ubiquitin-activating enzyme E1 catalyzes the first step in the ubiquitin conjugation pathway, Previously, we have cloned and sequenced the cDNA for human E1. Expression of the E1 cDNA in the ts20 cell line, which harbors a thermolabile E1, abrogated the phenotypic defects associated with this line. However, little is known of the cell biology of the E1 protein or the nature of the E1 doublet. Thus, we constructed epitope-tagged E1 cDNAs in which the HA monoclonal antibody epitope tag sequence (from influenza hemagglutinin and recognized by the 12CA5 monoclonal antibody) was fused to the amino terminus of E1. Because the amino-terminal amino acid sequence of E1 is unknown, three constructs were made in which the HA tag was placed at each of the first three ATGs in the open reading frame (HA-1E1, HA-2E1, and HA-3E1). Western analysis of HeLa cells transfected with the constructs revealed that HA-1E1 closely comigrated with the upper band of the E1 doublet, and HA-2E1 comigrated with the lower band of the E1 doublet; HA-3E1 appeared smaller than either of the E1 bands, Metabolic labeling with P-32 and immunoprecipitation with anti-HA antibody revealed that only the HA-1E1 protein product is phosphorylated; polyclonal anti-E1 antibody showed that only the upper band of the endogenous E1 doublet is phosphorylated, Each of the constructs was able to rescue the mutant phenotype of the ts20 cell line. Immunofluorescence studies showed that HA-2E1 and HA-3E1 were distributed in the cytoplasm with both negative and positive nuclei. This pattern of distribution has also been observed when immunostaining with a monoclonal antibody to E1 (1C5). However, the staining pattern associated with a polyclonal anti-E1 antibody (JJJ) is characterized by positive staining cytoplasm and nuclei in all cells. The HA-1E1 construct exhibited apparently exclusive nuclear distribution in HeLa cells. The difference between the staining patterns of the polyclonal and monoclonal anti-E1 antibodies can be explained by the existence of two subpopulations of E1: one cytoplasmic and partially nuclear, and one that is nuclear. Deletion of a small region at the amino terminus of the HA-1E1, including the basic sequence KKRR, transformed its immunostaining pattern to that observed with HA-2E1.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCRODT DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; TECHNION ISRAEL INST TECHNOL,FAC MED,RAPPAPORT FAMILY INST RES MED SCI,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,BIOCHEM UNIT,IL-31096 HAIFA,ISRAEL	Washington University (WUSTL); Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	HANDLEYGEARHART, PM (corresponding author), ST LOUIS CHILDRENS HOSP,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.		Stephen, Andrew/W-2636-2019; Ciechanover, Aaron J/C-9166-2017	Stephen, Andrew/0000-0002-8259-621X; 				ARNOLD JE, 1990, BIOCHEM J, V267, P751, DOI 10.1042/bj2670751; AYUSAWA D, 1992, CELL STRUCT FUNCT, V17, P113, DOI 10.1247/csf.17.113; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK JC, 1991, BIOCHEM BIOPH RES CO, V174, P564, DOI 10.1016/0006-291X(91)91454-K; COOK JC, 1992, J BIOL CHEM, V267, P24315; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRENFELL SJ, 1994, BIOCHEM J, V300, P701, DOI 10.1042/bj3000701; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KONG SK, 1992, J BIOL CHEM, V267, P14189; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KUDO M, 1991, EXP CELL RES, V192, P110, DOI 10.1016/0014-4827(91)90164-P; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENK SE, 1992, J CELL BIOL, V118, P301, DOI 10.1083/jcb.118.2.301; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; MAYER A, 1989, J BIOL CHEM, V264, P2060; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; NISHITANI H, 1992, BIOCHEM BIOPH RES CO, V184, P1015, DOI 10.1016/0006-291X(92)90692-E; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUSCH JS, 1993, AM J PHYSIOL, pC93; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	38	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33171	33178						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528747				2022-12-25	WOS:A1994QA63800067
J	HAYNES, PA; OKA, JA; WEIGEL, PH				HAYNES, PA; OKA, JA; WEIGEL, PH			THE RAT HEPATIC LECTIN-1 SUBUNIT OF THE RAT ASIALOGLYCOPROTEIN RECEPTOR IS A PHOSPHOPROTEIN AND CONTAINS PHOSPHOTYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; SIGNAL SEQUENCE; COATED PITS; TYROSINE PHOSPHORYLATION; GALACTOSYL RECEPTORS; ISOLATED HEPATOCYTES; RAPID ENDOCYTOSIS; PROTEIN-KINASE; CELL-MEMBRANES	The rat asialoglycoprotein receptor (ASGPR) is an integral transmembrane glycoprotein composed of three polypeptide subunits, designated rat hepatic lectins (RHL) 1, 2, and 3. Each subunit contains one or more Ser and Thr residues in its cytoplasmic domain that are potential sites of phosphorylation; in addition, RHL1 also contains one cytoplasmic Tyr. Based on [P-32]PO4 metabolic radiolabeling experiments, Takahashi et al. (Takahashi, T., Nakada, H., Okumura, T., Sawamura, T., and Tashiro, Y. (1985) Biochem. Biophys. Res. Commun. 126, 1054-1060) concluded that RHL2 and RHL3 are phosphoproteins but that RHL1 is not. We report here that RHL1 in active ASGPR is, in fact, a phosphoprotein. Western blot analysis using anti-Tyr(P) antibody identified Tyr(P) in RHL1 of affinity-purified ASGPRs. RHL2 and RHL3, which do not contain Tyr in their cytoplasmic domains, did not react with this antibody. When isolated hepatocytes were radiolabeled metabolically with [P-32]PO4, RHL1, RHL2, and RHL3 became radiolabeled. Each ASGPR subunit was radiolabeled to a similar extent in the presence or absence of the ligand asialo-orosomucoid, indicating that functioning of the ASGPR does not change its steady-state P-23-radiolabeling. Phosphoamino acid analysis of radiolabeled ASGPR subunits identified Ser(P) as the predominant (similar to 95%) and Thr(P) as a minor (similar to 5%) phosphoamino acid in each polypeptide and confirmed the presence of Tyr(P) (similar to 1%) in RHL1. Furthermore, treatment of hepatocytes with 3 mM vandate at 37 degrees C for 30 min doubled the steady-state level of Tyr(P) in RHL1.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695, R01GM030218] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49695, GM 30218] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EARP HS, 1983, FEBS LETT, V161, P180; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALLON RJ, 1992, EXP CELL RES, V203, P420, DOI 10.1016/0014-4827(92)90016-2; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HAYNES PA, 1994, IN PRESS J BIOL CHEM, V269, P33152; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCPHAUL M, 1987, MOL CELL BIOL, V7, P1841, DOI 10.1128/MCB.7.5.1841; MEDH JD, 1991, J BIOL CHEM, V266, P8771; OKA JA, 1991, ARCH BIOCHEM BIOPHYS, V289, P362, DOI 10.1016/0003-9861(91)90424-H; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; SANFORD JP, 1990, BIOCHIM BIOPHYS ACTA, V1087, P259, DOI 10.1016/0167-4781(90)90216-O; SCHWARTZ AL, 1984, BIOCHEM J, V223, P481, DOI 10.1042/bj2230481; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; TAMURA S, 1984, J BIOL CHEM, V259, P6650; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; WILLIAMS GM, 1974, EXP CELL RES, V89, P139, DOI 10.1016/0014-4827(74)90196-7; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	50	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33146	33151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528746				2022-12-25	WOS:A1994QA63800063
J	GILMER, T; RODRIQUEZ, M; JORDAN, S; CROSBY, R; ALLIGOOD, K; GREEN, M; KIMERY, M; WAGNER, C; KINDER, D; CHARIFSON, P; HASSELL, AM; WILLARD, D; LUTHER, M; RUSNAK, D; STERNBACH, DD; MEHROTRA, M; PEEL, M; SHAMPINE, L; DAVIS, R; ROBBINS, J; PATEL, IR; KASSEL, D; BURKHART, W; MOYER, M; BRADSHAW, T; BERMAN, J				GILMER, T; RODRIQUEZ, M; JORDAN, S; CROSBY, R; ALLIGOOD, K; GREEN, M; KIMERY, M; WAGNER, C; KINDER, D; CHARIFSON, P; HASSELL, AM; WILLARD, D; LUTHER, M; RUSNAK, D; STERNBACH, DD; MEHROTRA, M; PEEL, M; SHAMPINE, L; DAVIS, R; ROBBINS, J; PATEL, IR; KASSEL, D; BURKHART, W; MOYER, M; BRADSHAW, T; BERMAN, J			PEPTIDE INHIBITORS OF SRC SH3-SH2-PHOSPHOPROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTOR; SH3 DOMAINS; PHOSPHORYLATED PEPTIDES; TYROSINE KINASES; BINDING; PROTEINS; IDENTIFICATION; ASSOCIATION; RECOGNITION	Activated pp60(c-src) has been implicated in a number of human malignancies including colon carcinoma and breast adenocarcinoma. Association of the src SH2 do main with tyrosine-phosphorylated proteins plays a role in src-mediated signal transduction, Inhibitors of src SH2 domain-phosphoprotein interactions are, thus, of great interest in defining the role(s) of src in signal transduction pathways, To facilitate such studies, an enzyme-linked immunosorbent assay (ELISA) was developed to detect inhibitors of src SH2-phosphoprotein interactions, This assay measures inhibition of binding of a fusion construct (glutathione S-transferase src SH3-SH2) with autophosphorylated epidermal growth factor receptor tyrosine kinase domain, Activities of phosphopeptide segments derived from potential src SH2 cognate phosphoprotein partners were determined, with the focal adhesion kinase-derived segment VSETDDY*AEIIDE yielding the highest inhibitory activity, Structure activity studies starting from acetyl (Ac)-Y*EEIE have identified Ac-Y*Y*Y*IE as the most active compound screened ill the ELISA. This compound is at least all-fold more active than the parent peptide Ac-Y*EEIE. A high resolution (2 Angstrom) crystal structure of human src SH2 complexed with Ac-Y*EEIE was obtained and provided a useful framework for understanding the structure-activity relationships, Additionally, Ac-Y*EEIE was able to block interactions between src and its cellular phosphoprotein partners in vanadate-treated cell lysates from MDA-MB-468 breast carcinoma cells, However, it is unable to abrogate proliferation of MDA-MB-468 cells in culture, presumably because of poor cell penetration and/or lability of the phosphate group on tyrosine.	GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	GlaxoSmithKline								ALLEY MC, 1988, CANCER RES, V48, P589; ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DIXON WJ, 1953, BIOMETRICS, V9, P74, DOI 10.2307/3001634; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELDS GG, 1990, INT J PAPT PROT RES, V35, P151; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	166	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31711	31719						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7527393				2022-12-25	WOS:A1994PX30300061
J	LIN, M; HULTQUIST, KL; OH, DH; BAUER, EA; HOEFFLER, WK				LIN, M; HULTQUIST, KL; OH, DH; BAUER, EA; HOEFFLER, WK			INHIBITION OF COLLAGENASE TYPE-I EXPRESSION BY PSORALEN ANTISENSE OLIGONUCLEOTIDES IN DERMAL FIBROBLASTS	FASEB JOURNAL			English	Article						COLLAGENASE I; SKIN; ULTRAVIOLET LIGHT	HUMAN IMMUNODEFICIENCY VIRUS; GLOBIN MESSENGER-RNA; MATRIX METALLOPROTEINASES; CROSS-LINKING; EPIDERMOLYSIS-BULLOSA; TRANSLATION; INVITRO; AGENTS; DNA	Type I collagenase plays an important role in both tumor metastasis and the remodeling of connective tissue in normal human skin, during wound healing, for example, and may participate in the pathophysiology of some dermatological diseases such as skin cancer and a chronic blistering disease, recessive dystrophic epidermolysis bullosa. In an effort specifically to inhibit collagenase expression, we have designed phosphorothioate antisense oligonucleotides, linked at the 5' ends with photoreactive 4'-(hydroxyethoxymethyl)-4,5',8-trimethylpsoralen (HMT), and directed them against the 5' end of the collagenase mRNA, Two antisense-HMT molecules targeting a region overlapping the initiation codon were compared. Only one contained the HMT moiety targeting a 5'TpA on its complementary sense strand, and we observed greater than 50-fold improvement on the cross-linking of this antisense oligonucleotide to its target sequence after ultraviolet A (WA) irradiation. Likewise, sequence complementary to the 5'TpA target was also required to demonstrate specific inhibition of in vitro translation of collagenase mRNA, Tissue culture experiments, conducted by incubation of collagenase-specific antisense-HMT oligonucleotides with fibroblasts in monolayer or in 3-dimensional dermal equivalents, showed lowered collagenase levels 24 h after UVA irradiation as compared to controls. Initial screening of antisense oligomers for specific hybridization and photo-cross-linking is a useful step in the design of antisense oligonucleotides, and allowed us to design an HMT-linked antisense phosphorothioate oligonucleotide that specifically inhibits the expression of fibroblastic collagenase.	STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305	Stanford University				Hoeffler, Warren/0000-0001-8656-6651	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019537, R01AR019537] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR19537] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; BELL E, 1983, J INVEST DERMATOL, V81, pS2, DOI 10.1111/1523-1747.ep12539993; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; DENK W, 1990, SCIENCE, V248, P43; ECKES B, 1993, FEBS LETT, V318, P129, DOI 10.1016/0014-5793(93)80006-G; EMONARD H, 1990, CELL MOL BIOL, V36, P131; GASPARRO FP, 1988, PSORALEN DNA PHOTOBI, V2; GASPARRO FP, 1988, PSORALEN DNA PHOTOBI, V1; GHOSH MK, 1993, ANTI-CANCER DRUG DES, V8, P15; GOLDBERG GI, 1988, ARCH DERMATOL, V124, P737, DOI 10.1001/archderm.124.5.737; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HEARST JE, 1981, ANNU REV BIOPHYS BIO, V10, P691; HELENE C, 1994, EUR J CANCER, V30A, P1721, DOI 10.1016/0959-8049(93)E0352-Q; KEAN JM, 1988, BIOCHEMISTRY-US, V27, P9113, DOI 10.1021/bi00426a008; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LEE BL, 1987, BIOCHEMISTRY-US, V27, P3197; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MILLIGAN JF, 1994, ANN NY ACAD SCI, V716, P228, DOI 10.1111/j.1749-6632.1994.tb21715.x; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; PETERSEN MJ, 1992, J INVEST DERMATOL, V99, P440, DOI 10.1111/1523-1747.ep12616142; PIELES U, 1989, NUCLEIC ACIDS RES, V17, P285, DOI 10.1093/nar/17.1.285; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STETLERSTEVENSO.WG, 1993, FASEB J, V7, P1434; UHLMANN E, 1990, CHEM REV, V90, P544; UITTO J, 1992, J INVEST DERMATOL, V98, P391, DOI 10.1111/1523-1747.ep12499822; UNEMORI EN, 1994, EXP CELL RES, V211, P212, DOI 10.1006/excr.1994.1080; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WEBB TR, 1986, NUCLEIC ACIDS RES, V14, P7661, DOI 10.1093/nar/14.19.7661; WLASCHEK M, 1995, J INVEST DERMATOL, V104, P194, DOI 10.1111/1523-1747.ep12612751; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	33	13	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1995	9	13					1371	1377		10.1096/fasebj.9.13.7557028	http://dx.doi.org/10.1096/fasebj.9.13.7557028			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TA370	7557028				2022-12-25	WOS:A1995TA37000017
J	OHASHI, K; NAGATA, K; TOSHIMA, J; NAKANO, T; ARITA, H; TSUDA, H; SUZUKI, K; MIZUNO, K				OHASHI, K; NAGATA, K; TOSHIMA, J; NAKANO, T; ARITA, H; TSUDA, H; SUZUKI, K; MIZUNO, K			STIMULATION OF SKY RECEPTOR TYROSINE KINASE BY THE PRODUCT OF GROWTH ARREST-SPECIFIC GENE-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-S; EXPRESSION; THROMBIN; SYSTEM; CDNA	Sky (also called Rse, Brt, and Tyro3) is a member of a subfamily of related receptor tyrosine kinases, including Axl/Ufo/Ark. and c-Eyk/Mer. We obtained evidence that Case (the product of growth arrest-specific gene 6) is a ligand of the Sky receptor tyrosine kinase, Gas6, but not protein S (an anticoagulant protein structurally similar to Gas6), specifically bound to the soluble form of Sky (Sky-Fc), composed of the extracellular domain of Sky fused to the Fc domain of human immunoglobulin G1. The native and recombinant Case, but not protein S, stimulated tyrosine phosphorylation of Sky ectopically expressed in Chinese hamster ovary cells. Stimulation of Sky in response to Case was inhibited by Sky-Fc, The half-maximal concentration of Gas6 that stimulated Sky was about 1 nm. Thus, Case as a ligand for Sky specifically binds to and stimulates Sky receptor tyrosine kinase.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DEPT CLIN CHEM & LAB MED,FUKUOKA 812,JAPAN; SHIONOGI & CO LTD,SHIONOGI RES LABS,OSAKA 553,JAPAN; MIE UNIV,SCH MED,DEPT MOLEC PATHOBIOL,TSU,MIE 514,JAPAN	Kyushu University; Kyushu University; Shionogi & Company Limited; Mie University			Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HAYASHI T, 1994, BLOOD, V83, P683, DOI 10.1182/blood.V83.3.683.bloodjournal833683; HAYASHI T, 1995, THROMB HAEMOSTASIS, V73, P1259; ITO A, 1990, BIOCHEM INT, V22, P235; JAI R, 1994, J BIOL CHEM, V269, P1839; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; LAI C, 1994, ONCOGENE, V9, P2567; MALM G, 1994, BIOCHEM J, V802, P845; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARK MR, 1994, J BIOL CHEM, V269, P10720; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOCHEM, V117, P1267, DOI 10.1093/oxfordjournals.jbchem.a124854; OHASHI K, 1994, ONCOGENE, V9, P699; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RESCIGNO J, 1991, ONCOGENE, V6, P1909; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUZUKI K, 1983, J BIOCHEM-TOKYO, V94, P699, DOI 10.1093/oxfordjournals.jbchem.a134409; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	29	91	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22681	22684		10.1074/jbc.270.39.22681	http://dx.doi.org/10.1074/jbc.270.39.22681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559388	hybrid			2022-12-25	WOS:A1995RY05400008
J	LIU, L; CUTLER, RL; KRYSTAL, G				LIU, L; CUTLER, RL; KRYSTAL, G			IDENTIFICATION AND CHARACTERIZATION OF AN INTERLEUKIN-3 RECEPTOR-ASSOCIATED 110-KDA SERINE THREONINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE-PHOSPHORYLATED PROTEIN; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; SURFACE-RECEPTOR; CELL-LINE; RAPID PHOSPHORYLATION; CROSS-LINKING; IL-3 RECEPTOR; GENE FAMILY	We recently reported that interleukin-3 (IL-3) stimulation of the murine IL-3-responsive cell line, B6SUtA(1), results in the rapid phosphorylation of the beta subunit of the IL-3 receptor (IL-3R), not only on tyrosine residues but on serine/threonine (Ser/Thr) residues as well. Since this occurred even at 4 degrees C, it suggested that a Ser/Thr-specific kinase might be closely associated with the IL-3R. To test this possibility, IL-3R complexes were isolated with anti-IL-3R (alpha IL-3R) antibodies, and in vitro phosphorylation studies were undertaken. These revealed the presence of a 110-kDa protein that was heavily phosphorylated in vitro on serine and threonine residues and that bound selectively to gamma-ATP-Sepharose beads. Moreover, this protein, which was not the 110-kDa subunit of phosphatidylinositol 3-kinase, was tyrosine phosphorylated in response to IL-3 and was specifically labeled in vitro with azido-[P-32]ATP. These data, together with in vitro kinase inhibitor studies, suggest that an as yet uncharacterized H7- and staurosporine-sensitive 110-kDa Ser/Thr kinase may be constitutively associated with the IL-SR and activated following IL-3 stimulation. A comparison of IL-SR and erythropoietin receptor complexes suggests that this 110-kDa protein may be preferentially associated with the IL-3R.	BRITISH COLUMBIA CANC RES CTR, TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA	British Columbia Cancer Agency				Krystal, Gerald/0000-0002-1961-6281				CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; IHLE JN, 1994, BAILLIERE CLIN HAEM, V7, P17, DOI 10.1016/S0950-3536(05)80005-8; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JUBINSKY PT, 1993, BLOOD, V81, P587; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KROSL J, 1995, BLOOD, V85, P50, DOI 10.1182/blood.V85.1.50.bloodjournal85150; LAM K, 1994, J BIOL CHEM, V269, P20648; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; LIU L, 1994, J BIOL CHEM, V269, P16774; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; MAY WS, 1986, BIOCHEM BIOPH RES CO, V135, P870; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; MUI ALF, 1992, J BIOL CHEM, V267, P16523; MURTHY SC, 1990, EXP HEMATOL, V18, P11; NICOLA NA, 1986, J BIOL CHEM, V261, P2384; OKUDA K, 1991, BLOOD, V78, P1928; OKUDA K, 1992, BLOOD, V79, P2880; PARK LS, 1986, J BIOL CHEM, V261, P205; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POWIS G, 1994, CANCER RES, V54, P2419; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; SORENSEN PHB, 1989, BLOOD, V73, P406; STEVENS DA, 1991, J BIOL CHEM, V266, P4151; WOGNUM AW, 1990, BLOOD, V76, P697; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	51	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22422	22427		10.1074/jbc.270.38.22422	http://dx.doi.org/10.1074/jbc.270.38.22422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545678	hybrid			2022-12-25	WOS:A1995RW31400057
J	IKEDA, E; ACHEN, MG; BRIER, G; RISAU, W				IKEDA, E; ACHEN, MG; BRIER, G; RISAU, W			HYPOXIA-INDUCED TRANSCRIPTIONAL ACTIVATION AND INCREASED MESSENGER-RNA STABILITY OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN C6 GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN GENE; TUMOR ANGIOGENESIS; RHIZOBIUM-MELILOTI; PROTEIN-SYNTHESIS; OXYGEN SENSOR; EXPRESSION; DIFFERENTIATION; MITOGEN; BINDING; INVIVO	Vascular endothelial growth factor (VEGF) is an endothelial specific angiogenic mitogen secreted from various cell types including tumor cells. Increasing evidence suggests that VEGF is a major regulator of physiological and pathological angiogenesis, and the VEGF/VEGF receptor system has been shown to be necessary for glioma angiogenesis. Hypoxia seems to play a critical role in the induction of VEGF expression during glioma progression, C6 glioma cells provide an in vivo glioma model for the study of tumor angiogenesis, and the expression of VEGF in C6 cells has been shown to be up regulated by hypoxia in vitro. However, little is known about the molecular mechanism of hypoxic induction of VEGF. Here, we demonstrate that hypoxic induction of VEGF in C6 cells is due to both transcriptional activation and increased stability of mRNA. Nuclear run-on assays revealed a fast and lasting transcriptional activation, whereas the determination of mRNA half-life showed a slower increase of mRNA stability during hypoxia. Reporter gene studies revealed that hypoxia responsive transcription-activating elements were present in the 5'-flanking region of the VEGF gene, These results suggested that several distinct molecular mechanisms were involved in hypoxia-induced gene expression and were activated in a biphasic manner.	MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, MOLEK ZELLBIOL ABT, D-61231 BAD NAUHEIM, GERMANY	Max Planck Society			Breier, Georg/E-3580-2016	Breier, Georg/0000-0002-9467-780X; Achen, Marc/0000-0002-3791-803X				BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BREIER G, 1992, DEVELOPMENT, V114, P521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAQUIN WC, 1993, EXP HEMATOL, V21, P420; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KRANTZ SB, 1991, BLOOD, V77, P419; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MINCHENKO A, 1994, LAB INVEST, V71, P374; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; TISCHER E, 1991, J BIOL CHEM, V266, P11947	39	522	545	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19761	19766		10.1074/jbc.270.34.19761	http://dx.doi.org/10.1074/jbc.270.34.19761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544346	hybrid			2022-12-25	WOS:A1995RQ99100016
J	TAKAHASHI, K; PALADINI, RD; COULOMBE, PA				TAKAHASHI, K; PALADINI, RD; COULOMBE, PA			CLONING AND CHARACTERIZATION OF MULTIPLE HUMAN GENES AND CDNAS ENCODING HIGHLY RELATED TYPE-II KERATIN-6 ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-CELLS; EXPRESSION; SEQUENCE; EPITHELIA; HYPERPROLIFERATION; ORGANIZATION; PATTERNS; PROTEINS; SKIN; ACID	The human type II keratin 6 (K6; 56 kDa) is expressed in a heterogeneous array of epithelial tissues under normal conditions, but is better known for its strong induction in stratified epithelia that feature an enhanced cell proliferation rate or abnormal differentiation. Previous work has established the existence of two functional genes encoding K6 protein isoforms in the human genome, although only a partial cDNA clone is available for K6a, the dominant human K6 isoform in skin epithelial tissues (Tyner, A., and Fuchs, E. (1986) J. Cell Biol. 103, 1945-1955). We screened human genomic and skin cDNA libraries with probes derived from the K6b gene, and isolated clones containing the full-length gene and cDNA predicted to encode K6a. A thorough characterization of a large number of genomic (57) as well as cDNA (64) clones further revealed the existence of as many as six different human K6 protein isoforms that are highly related at the gene structure, nucleotide sequence, and predicted amino acid sequence levels. Based on the information accumulated to date we propose an evolutionary model in which the multiplicity of human K6 genes is explained by successive gene duplication events. We further demonstrate that K6a is clearly the dominant K6 isoform in skin tissue samples and cultured epithelial cell lines and that the various isoforms are differentially regulated within and between epithelial tissue types. Our findings have direct implications for an understanding of the regulation and function of K6 during hyperproliferation in stratified epithelia and the search for disease causing mutations in K6 sequences in the human population.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT DERMATOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAMS NIH HHS [R55-AR42047] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR042047] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bereiter-Hahn J., 1986, BIOL INTEGUMENT, P443; BESSHO Y, 1993, MOL BRAIN RES, V18, P201, DOI 10.1016/0169-328X(93)90190-Z; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BLUMENBERG M, 1988, J MOL EVOL, V27, P203, DOI 10.1007/BF02100075; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHOU CF, 1993, J BIOL CHEM, V268, P4465; COLLIN C, 1992, DIFFERENTIATION, V51, P137, DOI 10.1111/j.1432-0436.1992.tb00690.x; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; DEMARE S, 1990, ARCH DERMATOL RES, V282, P126, DOI 10.1007/BF00493471; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRANKE WW, 1978, CYTOBIOLOGIE, V17, P392; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1994, J INVEST DERMATOL, V103, pS25, DOI 10.1111/1523-1747.ep12398924; FUCHS E, 1993, J CELL SCI, P197; GILMARTIN ME, 1980, J INVEST DERMATOL, V75, P211, DOI 10.1111/1523-1747.ep12522887; GLASS C, 1988, J CELL BIOL, V107, P1337, DOI 10.1083/jcb.107.4.1337; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KIMONIS V, 1994, J INVEST DERMATOL, V103, P764, DOI 10.1111/1523-1747.ep12412771; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUSS S, 1990, GENE, V86, P241, DOI 10.1016/0378-1119(90)90285-Y; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; LANE EB, 1994, CURR OPIN GENET DEV, V4, P412, DOI 10.1016/0959-437X(94)90030-2; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MCLEAN WHI, 1995, NAT GENET, V9, P273, DOI 10.1038/ng0395-273; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MOLL R, 1983, DIFFERENTIATION, V23, P256; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; OUHAYOUN JP, 1985, DIFFERENTIATION, V30, P123; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; Schweizer Juergen, 1993, P33; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STEINERT PM, 1984, P NATL ACAD SCI-BIOL, V81, P5709, DOI 10.1073/pnas.81.18.5709; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; TYNER AL, 1986, J CELL BIOL, V103, P1945, DOI 10.1083/jcb.103.5.1945; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5; YATSUNAMI J, 1993, CANCER RES, V53, P992	58	99	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18581	18592		10.1074/jbc.270.31.18581	http://dx.doi.org/10.1074/jbc.270.31.18581			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7543104	hybrid			2022-12-25	WOS:A1995RM64200068
J	INASE, N; FUSHIMI, K; ISHIBASHI, K; UCHIDA, S; ICHIOKA, M; SASAKI, S; MARUMO, E				INASE, N; FUSHIMI, K; ISHIBASHI, K; UCHIDA, S; ICHIOKA, M; SASAKI, S; MARUMO, E			ISOLATION OF HUMAN AQUAPORIN-3 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNEL; PROTEINS; SEQUENCE; CLONING; FAMILY; CHIP; MIP	Human aquaporin 3 (AQP3) gene was isolated, and its structural organization was characterized. The gene appeared to exist as a single copy in the human genome and to comprise six exons distributing over 7 kilobases. The sizes of the exons are 171, 127, 138, 119, 218, and 1035 base pairs, and those of introns are approximately 3530, 300, 350, 330, and 90 base pairs, respectively. The initiation site of transcription was identified to locate 64 base pairs upstream of the first ATG codon by primer extension analysis and ribonuclease protection assay. The 5'-flanking region has a TATA box, two Sp1 sequences, and some consensus sequences including AP2 sites. With luciferase assay, the 5'-flanking region was demonstrated to have a promoter activity, which is up-regulated 4-fold by phorbol ester. These findings about the genomic clone of human AQP3 will contribute to elucidate the molecular mechanism of transcriptional regulation of AQP3.	TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)			Uchida, Shinichi/D-1111-2013					AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; FIASST S, 1992, NUCLEIC ACIDS RES, V20, P3; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; ISHIBASHI K, 1995, IN PRESS GENOMICS; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; MOON C, 1993, J BIOL CHEM, V268, P15772; PISANO MM, 1991, GENOMICS, V11, P981; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; UCHIDA S, 1994, J BIOL CHEM, V269, P23451	14	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17913	17916		10.1074/jbc.270.30.17913	http://dx.doi.org/10.1074/jbc.270.30.17913			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543093	hybrid			2022-12-25	WOS:A1995RM26600045
J	PELLETIER, AJ; KUNICKI, T; RUGGERI, ZM; QUARANTA, V				PELLETIER, AJ; KUNICKI, T; RUGGERI, ZM; QUARANTA, V			THE ACTIVATION STATE OF THE INTEGRIN ALPHA(IIB)BETA(3) AFFECTS OUTSIDE-IN SIGNALS LEADING TO CELL SPREADING AND FOCAL ADHESION KINASE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; GLYCOPROTEIN IIB/IIIA COMPLEX; MONOCLONAL-ANTIBODIES; VONWILLEBRAND-FACTOR; MODULATION; PLATELETS; AFFINITY; BINDING; IIIA; TRANSDUCTION	Integrins bind extracellular matrix and transduce signals mediating cell adhesion spreading, and migration. It is unclear how these distinct responses follow hom a common event: integrin clustering. We examined the relationship between integrin-mediated signals and the integrin's activation state using a cell line expressing alpha(IIb)beta(3) (Clone B) and a panel of monoclonal antibodies against this integrin. Nonactivating antibodies used to cluster alpha(IIb)beta(3) stimulated focal adhesion kinase (FAK) phosphorylation, regardless of affinity, subunit specificity, or ligand-blocking phenotype. Coated on plastic, these antibodies supported cell adhesion, spreading, and FAK phosphorylation. In contrast, clustering of alpha(IIb)beta(3) induced with activating antibodies, or binding of soluble fibrinogen to antibody activated alpha(IIb)beta(3), did not induce FAR phosphorylation. Thus, clustering of alpha(IIb)beta(3) on Clone B does not necessarily result in FAM phosphorylation. Coated on plastic, activating antibodies supported cell adhesion, but not spreading or FAK phosphorylation. Therefore, it appears the resting, not the active form of alpha(IIb)beta(3), induces cell spreading and FAR phosphorylation in Clone B. These data indicate that ''inside-out'' signals may alter not only the binding specificity of an integrin, but the ''outside-in'' biochemical signals that integrin initiates as well. This activation state linked signaling represents a novel mechanism, which may explain how diverse cellular responses are induced by integrin-matrix interactions.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute	PELLETIER, AJ (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.		Quaranta, Vito/G-6512-2016	Quaranta, Vito/0000-0001-7491-8672	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R01HL046979] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46979, HL48728] Funding Source: Medline; NIAID NIH HHS [AI07244] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ALTIERI DC, 1990, J IMMUNOL, V145, P662; BARKER PL, 1992, J MED CHEM, V35, P2040, DOI 10.1021/jm00089a014; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; DU XP, 1993, J BIOL CHEM, V268, P23087; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HANDA M, 1986, J BIOL CHEM, V261, P2579; HAWIGER J, 1991, ANN NY ACAD SCI, V614, P270, DOI 10.1111/j.1749-6632.1991.tb43709.x; HOGG N, 1993, AM REV RESPIR DIS, V148, pS55, DOI 10.1164/ajrccm/148.6_Pt_2.S55; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NIIYA K, 1987, BLOOD, V70, P475; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARISE LV, 1990, BLOOD, V75, P2363; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHATTIL S, 1991, CURR STUD HEMATOL BL, V58, P26; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHAW LM, 1993, J BIOL CHEM, V268, P11401; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273	36	55	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18133	18140		10.1074/jbc.270.30.18133	http://dx.doi.org/10.1074/jbc.270.30.18133			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543096				2022-12-25	WOS:A1995RM26600076
J	ORIORDAN, CR; ERICKSON, A; BEAR, C; LI, CH; MANAVALAN, P; WANG, KX; MARSHALL, J; SCHEULE, RK; MCPHERSON, JM; CHENG, SH; SMITH, AE				ORIORDAN, CR; ERICKSON, A; BEAR, C; LI, CH; MANAVALAN, P; WANG, KX; MARSHALL, J; SCHEULE, RK; MCPHERSON, JM; CHENG, SH; SMITH, AE			PURIFICATION AND CHARACTERIZATION OF RECOMBINANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FROM CHINESE-HAMSTER OVARY AND INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; EXPRESSION VECTORS; GENE; PHOSPHORYLATION; RECONSTITUTION; IDENTIFICATION; DELTA-F508; SECRETION; TRANSPORT; BILAYERS	We have developed procedures to purify highly functional recombinant cystic fibrosis transmembrane conductance regulator (CFTR) from Chinese hamster ovary (CHO) cells to high homogeneity. Purification of CHO-CFTR was achieved using a combination of alkali stripping, alpha-lysophosphatidylcholine extraction, DEAE ion-exchange, and immunoaffinity chromatography. Insect CFTR from Sf9 cells was purified using a modification of the method of Bear et al. (Bear, C. E., Li, C., Kartner, N., Bridges, R. J., Jensen, T. J., Ramjeesingh, M. and Riordan, J. R. (1992) Cell 68, 809-818), which included extraction with sodium dodecyl sulfate, hydroxyapatite, and gel filtration chromatography. Characterization of the properties of purified CFTR from both cell sources using a variety of electrophysiological and biochemical assays indicated that they were very similar. Both the purified CHO-CFTR and Sf9-CFTR when reconstituted into planar lipid bilayers exhibited a low pS, chloride-selective ion channel activity that was protein kinase A- and ATP-dependent. Both the purified CHO-CFTR and Sf9-CFTR were able to interact specifically with the nucleotide photoanalogue 8-N-3-[alpha-P-32]ATP with half-maximal binding at 25 and 50 mu M, respectively. These values compare well with those reported for 8-N-3-[alpha-P-32]ATP binding to CFTR in its native membrane form. Thus CFTR from either insect or CHO cells can be purified to high homogeneity with retention of many of the biochemical and electrophysiological characteristics of the protein associated in its native plasma membrane form. The availability of these reagents will facilitate further investigation and study of the structure and function of CFTR and its interactions with cellular proteins.	HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	ORIORDAN, CR (corresponding author), GENZYME CORP,1 MT RD,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869				ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARION WJ, 1970, J BIOL CHEM, V245, P5186; BAOT T, 1989, METABOLIC BASIS INHE, P2649; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P524; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HSIEH P, 1984, J BIOL CHEM, V259, P2375; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JONES OT, 1986, SOLUBILIZATION RECON; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1992, NEURON, V5, P821; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2	40	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17033	17043		10.1074/jbc.270.28.17033	http://dx.doi.org/10.1074/jbc.270.28.17033			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7542655	hybrid			2022-12-25	WOS:A1995RJ34700087
J	FAN, NS; RANK, KB; LEONE, JW; HEINRIKSON, RL; BANNOW, CA; SMITH, CW; EVANS, DB; POPPE, SM; TARPLEY, WG; ROTHROCK, DJ; TOMASSELLI, AG; SHARMA, SK				FAN, NS; RANK, KB; LEONE, JW; HEINRIKSON, RL; BANNOW, CA; SMITH, CW; EVANS, DB; POPPE, SM; TARPLEY, WG; ROTHROCK, DJ; TOMASSELLI, AG; SHARMA, SK			THE DIFFERENTIAL PROCESSING OF HOMODIMERS OF REVERSE TRANSCRIPTASES FROM HUMAN IMMUNODEFICIENCY VIRUSES TYPE-1 AND TYPE-2 IS A CONSEQUENCE OF THE DISTINCT SPECIFICITIES OF THE VIRAL PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HIV-1 PROTEASE; HTLV-III; ESCHERICHIA-COLI; RIBONUCLEASE-H; AIDS; PURIFICATION; DOMAIN; PROTEINASES; INHIBITORS; RETROVIRUS	Active, recombinant p68 reverse transcriptase (RT) from human immunodeficiency virus type 2 (HIV-2), with an NH2-terminal extension containing a hexahistidine sequence was isolated from extracts of Escherichia coli by immobilized metal affinity chromatography. Treatment of the purified p68/p68 homodimer of HIV-2 RT with recombinant HIV-2 protease generates stable, active heterodimer (p68/p58) that is resistant to further hydrolysis. Analysis of this p68/p58 HIV-2 RT heterodimer revealed that while one subunit is intact p68, the p58 subunit is COOP-terminally truncated by cleavage, not at Phe(440) as is seen in processing of the p66/p66 HIV-1 RT homodimer by HIV-1 protease, but at Met(484) The expected COOP-terminal p10 fragment resulting from hydrolysis of p68 at Met(484) is not released intact, but undergoes further cleavage at Asn(494), Met(503), and Tyr(532). Processing of p68/p68 HlV-2 RT with the HIV-1 protease led to cleavage of the phe(440)-Tyr(441) bond, exactly as is seen with p66/p66 HTV-1 RT, to give the analogous p53 subunit. Studies of a peptide substrate modeled after residues 437-444 in HIV-2 RT showed that while the HIV-1 protease was able to cleave the Phe(440) bond, this bond was resistant to cleavage by the HIV-2 enzyme. Our findings provide a rationale for the previous observation that the RT heterodimer isolated from HIV-P lysates is larger than that from HIV-1. We conclude that the p68/p58 HIV-2 RT heterodimer, containing the Met(484) truncated p58 subunit, is a biologically relevant form of the enzyme in vivo.	UPJOHN CO,KALAMAZOO,MI 49001	Pfizer					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025696] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI25696-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CHANDRA P, 1985, CANCER RES, V45, P4677; CHATTOPADHYAY D, 1992, J BIOL CHEM, V267, P14227; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; DEVICO AL, 1989, AIDS RES HUM RETROV, V5, P51, DOI 10.1089/aid.1989.5.51; EVANS DB, 1994, J BIOL CHEM, V269, P21741; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HOSTOMSKA Z, 1991, J BIOL CHEM, V266, P14697; HUI JO, 1993, J PROTEIN CHEM, V12, P321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEGRICE SFJ, 1988, J VIROL, V62, P2525, DOI 10.1128/JVI.62.7.2525-2529.1988; MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; MULLER B, 1991, J BIOL CHEM, V266, P14709; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SHAHARABANY M, 1992, J BIOL CHEM, V267, P3674; Sharma Satish K., 1992, Methods (Orlando), V4, P57, DOI 10.1016/1046-2023(92)90056-E; SHARMA SK, 1991, BIOTECHNOL APPL BIOC, V14, P69; SHARMA SK, 1994, FEBS LETT, V343, P125, DOI 10.1016/0014-5793(94)80303-X; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOMASSELLI AG, 1993, PROTEIN SCI, V2, P2167, DOI 10.1002/pro.5560021216; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WARREN TC, 1992, PROTEIN EXPRES PURIF, V3, P479, DOI 10.1016/1046-5928(92)90065-5; ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941	37	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13573	13579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7539431				2022-12-25	WOS:A1995RB43900091
J	BEVAN, AP; BURGESS, JW; DRAKE, PG; SHAVER, A; BERGERON, JJM; POSNER, BI				BEVAN, AP; BURGESS, JW; DRAKE, PG; SHAVER, A; BERGERON, JJM; POSNER, BI			SELECTIVE ACTIVATION OF THE RAT HEPATIC ENDOSOMAL INSULIN-RECEPTOR KINASE - ROLE FOR THE ENDOSOME IN INSULIN SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHORYLATED PROTEIN; MONOCLONAL-ANTIBODY; DOWN-REGULATION; LIVER; INVIVO; INTERNALIZATION; ASSOCIATION; COLCHICINE; PROLACTIN	Insulin administration activates the insulin receptor kinase (IRK) in both plasma membrane (PM) and endosomes (ENs) raising the possibility of transmembrane signaling occurring in the endosomal compartment, Peroxovanadium compounds activate the IRK by inhibiting IR-associated phosphotyrosine phosphatase(s). Following the administration of the phosphotyrosine phosphatase inhibitor bisperoxo(1,10-phenanthroline)oxovanadate (V) anion (bpV(phen)) activation of the hepatic IRK in ENs preceded that in PM by 5 min. When colchicine treatment preceded bpV(phen) administration IRK activation in ENs was unaffected but was totally abrogated in PM. Insulin receptor substrate-1 tyrosine phosphorylation followed the kinetics of IRK activation in ENs not PM and a hypoglycemic response similar to that achieved with a pharmacological dose of insulin ensued. These studies demonstrate that ENs constitute a site for IR-mediated signal transduction.	MCGILL UNIV,POLYPEPTIDE HORMONE LAB,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,DEPT CHEM,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3A 2B2,CANADA	McGill University; McGill University; McGill University			Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021	Bevan, Paul/0000-0002-0656-9164				ARMITAGE P, 1987, STATISTICAL METHODS; BACKER JM, 1993, J BIOL CHEM, V268, P8204; Bergeron J J, 1988, Adv Exp Med Biol, V234, P213; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERGERON JJM, 1983, J CELL BIOL, V96, P875, DOI 10.1083/jcb.96.3.875; BEVAN AP, 1995, AM J PHYSIOL-ENDOC M, V268, pE60, DOI 10.1152/ajpendo.1995.268.1.E60; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FAURE R, 1992, J BIOL CHEM, V267, P11215; FERRE P, 1985, BIOCHEM J, V228, P103, DOI 10.1042/bj2280103; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAY DG, 1986, J BIOL CHEM, V261, P8473; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Khan M N, 1993, Subcell Biochem, V19, P223; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KHAN MN, 1985, DIABETES, V34, P1025, DOI 10.2337/diabetes.34.10.1025; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAFONT F, 1994, NATURE, V372, P801; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LIPPINCOTTSCHWA, 1995, J CELL BIOL, V128, P293; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE194, DOI 10.1152/ajpendo.1991.260.2.E194; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PILCH PF, 1980, J BIOL CHEM, V255, P1722; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1994, J BIOL CHEM, V269, P4596; POSNER BI, 1982, J CELL BIOL, V93, P560, DOI 10.1083/jcb.93.3.560; REDMAN CM, 1975, J CELL BIOL, V66, P42, DOI 10.1083/jcb.66.1.42; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VULETIC N, 1973, CHEM SOC DA, P1137; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YIP CC, 1978, J BIOL CHEM, V253, P1743	47	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10784	10791		10.1074/jbc.270.18.10784	http://dx.doi.org/10.1074/jbc.270.18.10784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537739	hybrid			2022-12-25	WOS:A1995QW60100062
J	CHU, SC; WU, HP; BANKS, TC; EISSA, NT; MOSS, J				CHU, SC; WU, HP; BANKS, TC; EISSA, NT; MOSS, J			STRUCTURAL DIVERSITY IN THE 5'-UNTRANSLATED REGION OF CYTOKINE-STIMULATED HUMAN INDUCIBLE NITRIC-OXIDE SYNTHASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE REGULATOR GENE; MESSENGER-RNA TRANSCRIPTS; 5' UNTRANSLATED REGION; TRANSLATIONAL CONTROL; CYSTIC-FIBROSIS; CODING SEQUENCES; EXPRESSION; MODEL; GCN4; INDIVIDUALS	Inducible nitric oxide synthase, the critical enzyme responsible for the enhanced synthesis of nitric oxide in inflammatory states, is widely expressed in mammalian cells. To evaluate potential regulatory roles of the 5'-untranslated region (UTR) in the human inducible nitric oxide synthase gene, the transcription initiation sites and structure of the 5'-UTR of human inducible nitric oxide synthase were examined. Freshly isolated human alveolar macrophages, bronchial epithelial cells, and several types of cultured cells were evaluated following stimulation with cytokines (i.e. interferon-gamma, interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-6). The mRNA was analyzed by reverse transcription-polymerase chain reaction, Northern analysis, and 5'-rapid amplification of cDNA ends. Despite the presence of a TATA box in the promoter region, multiple transcription initiation sites were observed, some extending several hundred base pairs upstream from the main TATA-directed initiation site. Alternative splicing in the 5'-UTR of human inducible nitric oxide synthase mRNA resulted in further diversity. The TATA-independent inducible nitric oxide synthase mRNA transcripts were up-regulated by cytokines. The long and complex 5'-UTRs contain eight partially overlapping open reading frames upstream of the putative inducible nitric oxide synthase ATG, which may have an important role in translational regulation of human inducible nitric oxide synthase mRNA.			CHU, SC (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,BLDG 10,RM 6D03,10 CTR DR MSC 1590,BETHESDA,MD 20892, USA.							ABASTADO JP, 1991, NEW BIOL, V3, P511; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; EGGEN BJL, 1994, MOL BRAIN RES, V23, P221, DOI 10.1016/0169-328X(94)90229-1; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; HIRAOKA Y, 1991, MOL CELL ENDOCRINOL, V75, P71; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIN CS, 1993, J BIOL CHEM, V268, P2793; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARUYAMA M, 1994, J CLIN INVEST, V94, P368, DOI 10.1172/JCI117331; MILLER PF, 1989, GENE DEV, V3, P1217, DOI 10.1101/gad.3.8.1217; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NTHAN C, 1994, CELL, V78, P915; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SAITTA B, 1992, J BIOL CHEM, V267, P6188; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WEWERS MD, 1987, CELL IMMUNOL, V107, P479, DOI 10.1016/0008-8749(87)90255-3; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	39	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10625	10630		10.1074/jbc.270.18.10625	http://dx.doi.org/10.1074/jbc.270.18.10625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537735	hybrid			2022-12-25	WOS:A1995QW60100042
J	HIRASAWA, N; SCHARENBERG, A; YAMAMURA, H; BEAVEN, MA; KINET, JP				HIRASAWA, N; SCHARENBERG, A; YAMAMURA, H; BEAVEN, MA; KINET, JP			A REQUIREMENT FOR SYK IN THE ACTIVATION OF THE MICROTUBULE-ASSOCIATED PROTEIN-KINASE PHOSPHOLIPASE-A(2) PATHWAY BY FC-EPSILON-R1 IS NOT SHARED BY A G-PROTEIN-COUPLED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; TUMOR MAST-CELLS; TYROSINE PHOSPHORYLATION; RBL-2H3 CELLS; ANTIGEN RECEPTOR; HIGH-AFFINITY; SIGNAL TRANSDUCTION; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; 2H3 CELLS	Stimulation of the mast cell line, RBL-2H3, with antigen via the tetrameric (alpha beta gamma(2)) immunoglobulin E receptor (Fc epsilon R1) leads to the activation of cytosolic phospholipase A(2) and the release of arachidonic acid. This pathway is dependent on the activation of the mitogen-activated protein (MAP) kinase, In this paper, we show that the MAP kinase/cytosolic phospholipase A(2) pathway is linked to Fc epsilon R1 via the cytosolic tyrosine kinase, Syk, and that the GDP/GTP exchange factor, Vav, might be one candidate for accomplishing this link, Cross-linking of transmembrane chimeras containing the Fc epsilon R1 gamma motif, which is known to activate Syk, results in the tyrosine phosphorylation of Vav, activation of MAP kinase, and release of arachidonic acid. Cross-linking of chimeras containing the Fc epsilon R1 beta motif does not cause these events, Furthermore, stimulation of these events by antigen is enhanced by transient overexpression of a wild-type form of Syk and blocked by overexpression of a dominant negative form of Syk, By contrast, stimulation via the transfected, G protein-coupled, muscarinic mi receptor is not influenced by either form of Syk and does not result in tyrosine phosphorylation of Vav, These data establish unequivocally that the two types of receptor are independently linked to the MAP kinase/ cytosolic phospholipase A(2) pathway and demonstrate the existence of the Fc epsilon R1-Syk-MAP kinase pathway.	NHLBI,MOLEC IMMUNOL LAB,BETHESDA,MD 20892; NIAID,MOLEC ALLERGY & IMMUNOL SECT,BETHESDA,MD 20892; FUKUI MED SCH,DEPT BIOCHEM,FUKUI 91011,JAPAN	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Fukui				Hirasawa, Noriyasu/0000-0002-8062-4838				ALI H, 1989, J IMMUNOL, V143, P2626; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHOI OH, 1994, J BIOL CHEM, V269, P536; CHOI OH, 1993, J IMMUNOL, V151, P5586; EARL PL, 1987, CURRENT PROTOCOLS MO; EISEMAN E, 1992, NATURE, V355, P78; FRANKLIN RA, 1994, J CLIN INVEST, V93, P2134, DOI 10.1172/JCI117209; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HIRASAWA N, 1995, IN PRESS J IMMUNOL; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN PY, 1994, BIOCHEM J, V299, P109, DOI 10.1042/bj2990109; LIN PY, 1991, J IMMUNOL, V146, P1609; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANTINI F, 1993, J BIOL CHEM, V268, P22716; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TORDAI A, 1984, J BIOL CHEM, V269, P7538; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAMADA K, 1992, J IMMUNOL, V149, P1031; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	50	146	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10960	10967		10.1074/jbc.270.18.10960	http://dx.doi.org/10.1074/jbc.270.18.10960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537741	hybrid			2022-12-25	WOS:A1995QW60100086
J	RIVARD, N; MCKENZIE, FR; BRONDELLO, JM; POUYSSEGUR, J				RIVARD, N; MCKENZIE, FR; BRONDELLO, JM; POUYSSEGUR, J			THE PHOSPHOTYROSINE PHOSPHATASE PTP1D, BUT NOT PTP1C, IS AN ESSENTIAL MEDIATOR OF FIBROBLAST PROLIFERATION INDUCED BY TYROSINE KINASE AND G-PROTEIN-COUPLED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; SIGNAL TRANSDUCTION; SH2 DOMAIN; ACTIVATION; GENE	PTP1C and PTP1D are non-transmembrane protein-tyrosine phosphatases (PTPs), which contain two src homology-2 domains, These enzymes are believed to play a role in regulating downstream signaling from receptors with intrinsic tyrosine kinase activity. The present study describes the tyrosine phosphorylation and the catalytic activity of both PTPs in CCL39 cells, a Chinese hamster lung fibroblast cell line, upon addition of a variety of growth factors, We demonstrate that PTP1C activity was significantly stimulated by insulin and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate but was not influenced by serum, platelet derived growth factor (PDGF), or alpha-thrombin, However, tyrosine phosphorylation of PTP1C was increased in response to insulin, PDGF, and alpha-thrombin. PTP1D activity was slightly stimulated by insulin and 12-O-tetradecanoylphorbol-13-acetate but was significantly inhibited by serum, PDGF, and alpha-thrombin, although tyrosine phosphorylation is increased in response to these agonists, Mitogen-activated protein kinase phosphorylated PTP1C and PTP1D in in vitro kinase assays, suggesting that both PTPs are target proteins for mitogen-activated protein kinase, We also show that overexpression of PTP1C or PTP1D had no effect on DNA synthesis stimulated by different growth factors, However, a mutated inactive form of PTP1D strongly inhibited the stimulatory effects of both PDGF and alpha-thrombin on early gene transcription and DNA synthesis, These results demonstrate for the first time that PTP1C and PTP1D may participate in signal transduction but in different manners and that only PTP1D is a positive mediator of mitogenic signals induced by both tyrosine kinase receptors and G protein-coupled receptors in fibroblasts.			RIVARD, N (corresponding author), CTR BIOCHIM,CNRS,UMR 134,PARC VALROSE,F-06108 NICE 02,FRANCE.		Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRUNET A, 1994, ONCOGENE, V9, P3379; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN YH, 1994, J BIOL CHEM, V269, P27372; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LEICHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MELOCHE S, 1992, MOL ENDOCRINOL, V638, P845; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAWSON T, 1992, CELL, V30, P359; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Treisman R, 1990, Semin Cancer Biol, V1, P47; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANOBBERGHENSCH.E, 1991, MOL ENDOCRINOL, V5, P881; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	41	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					11017	11024		10.1074/jbc.270.18.11017	http://dx.doi.org/10.1074/jbc.270.18.11017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537742	hybrid			2022-12-25	WOS:A1995QW60100094
J	KITAZAWA, S; ROSS, FP; MCHUGH, K; TEITELBAUM, SL				KITAZAWA, S; ROSS, FP; MCHUGH, K; TEITELBAUM, SL			INTERLEUKIN-4 INDUCES EXPRESSION OF THE INTEGRIN ALPHA(V)BETA(3) VIA TRANSACTIVATION OF THE BETA(3) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTIC BONE-RESORPTION; VITRONECTIN RECEPTOR; MULTINUCLEATED CELLS; CHICKEN OSTEOCLASTS; MANNOSE RECEPTOR; INVITRO; ALPHA-V-BETA-3; MACROPHAGES; MICE; OSTEOPONTIN	Osteoclastic bone resorption is dependent upon cell-matrix recognition. This process is mediated by the integrin alpha(v) beta(3), whose expression is enhanced, in avian osteoclast precursors, by bone-seeking steroids. The purpose of this study was to determine if bone-modulating cytokines impact on gp, expression by mouse marrow macrophages (BMMs), known to differentiate into osteoclasts. Of the cytokines tested. Interleukin-4 (IL-4) is most effective in increasing beta(3) mRNA levels by a mechanism involving transactivation of the beta(3), gene. Moreover, IL-4 augmented beta(3) mRNA is mirrored by plasma membrane appearance of alpha(v) beta(3). As IL-4 induces beta(3) and not alpha(v) mRNA, the beta(3) chain appears to regulate surface expression of the heterodimer. The functional significance of IL-4-induced alpha v beta 3, is underscored by the fact that, while attachment to fibronectin is unaltered, treatment of EMMs with the cytokine enhances alpha(v) beta(3)- mediated binding to vitronectin 5-fold, Expression of this heterodimer by BMMs driven along a non-osteoclastic lineage suggests alpha(v) beta(3), may play a role in the inflammatory response of macrophages.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Kitazawa, Sohei/E-5602-2010	Kitazawa, Sohei/0000-0002-7466-7356; Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKASHI K, 1991, J CLIN INVEST, V88, P223, DOI 10.1172/JCI115281; AKATSU T, 1991, J BONE MINER RES, V6, P183; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; ASANO Y, 1988, J IMMUNOL, V140, P419; BISKOBING DM, 1993, ENDOCRINOLOGY, V132, P862, DOI 10.1210/en.132.2.862; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1988, J CELL PHYSIOL, V137, P476, DOI 10.1002/jcp.1041370312; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHIBA M, 1993, J BONE MINER RES, V8, P8144; CIEUTAT AM, 1993, BIOCHEM BIOPH RES CO, V193, P771, DOI 10.1006/bbrc.1993.1692; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; HORTON MA, 1993, J BONE MINER RES, V8, P239; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; LORENZO JA, 1987, J CLIN INVEST, V80, P160, DOI 10.1172/JCI113042; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; MIMURA H, 1994, ENDOCRINOLOGY, V134, P1061, DOI 10.1210/en.134.3.1061; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; PAUL WE, 1991, BLOOD, V77, P1859; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RIANCHO JA, 1993, J BONE MINER RES, V8, P1337; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; SHIOI A, 1991, J CELL BIOCHEM, V47, P272, DOI 10.1002/jcb.240470313; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	36	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4115	4120		10.1074/jbc.270.8.4115	http://dx.doi.org/10.1074/jbc.270.8.4115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7533159	hybrid			2022-12-25	WOS:A1995QH68800095
J	LIN, PH; SHENOY, S; GALITSKI, T; SHALLOWAY, D				LIN, PH; SHENOY, S; GALITSKI, T; SHALLOWAY, D			TRANSFORMATION OF MOUSE CELLS BY WILD-TYPE MOUSE C-SRC	ONCOGENE			English	Note						SRC; SPECIES-SPECIFIC; TRANSFORMATION	NIH 3T3 CELLS; PROTEIN-KINASE; V-SRC; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; TERMINAL REGION; PP60C-SRC; ACTIVATION; P60C-SRC; GENE	Previous studies in which chicken and human c-Src were overexpressed in chicken and rodent cells have indicated that overexpression of wild-type c-Src can not induce complete neoplastic transformation. However, studies with v-Src mutants have demonstrated that species-specific differences can play a significant role in transforming activity. Here we show that, in contrast to chicken c-Src, overexpressed mouse c-Src can induce significant anchorage-independent growth and tumori- genicity when transfected into NIH3T3 mouse cells. The biochemical cause for this difference is unknown. In particular, the protein-tyrosine kinase activities of chicken and mouse c-Src appear to be similar. This result is consistent with the hypothesis that v-Src-induced transformation results from perturbation of signalling pathways modulated by c-Src and highlights the need for caution in controlling for potential species-specific differences in studies of c-Src function.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University			Lin, Pei-Hui/I-3011-2015	Lin, Pei-Hui/0000-0002-3894-5099	NATIONAL CANCER INSTITUTE [R01CA008964, R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964, CA32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Potts W. M., 1989, ONCOGENE RES, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SHALLOWAY D, 1991, ADV CANCER RES, V57, P185; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	35	29	29	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					401	405						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530829				2022-12-25	WOS:A1995QC62400020
J	SHIMAMOTO, T; INOUYE, M; INOUYE, S				SHIMAMOTO, T; INOUYE, M; INOUYE, S			THE FORMATION OF THE 2',5'-PHOSPHODIESTER LINKAGE IN THE CDNA PRIMING REACTION BY BACTERIAL REVERSE-TRANSCRIPTASE IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; RNA-LINKED MSDNA; ESCHERICHIA-COLI; MYXOCOCCUS-XANTHUS; CLONED GENES; NUCLEOTIDE-SEQUENCE; LEVEL EXPRESSION; POLYMERASE; RETROELEMENT; BIOSYNTHESIS	Bacterial reverse transcriptase (RT) is responsible for synthesis of multicopy single-stranded DNA (msDNA) consisting of single-stranded DNA linked to an internal guanosine residue of RNA by an unusual 2',5'-phosphodiester linkage. Here we purified a bacterial RT to homogeneity from Escherichia coli harboring the RT gene from retron-Ec73. The purified RT-Ec73 was able to synthesize msDNA in a cell-free system using an RNA template produced in vitro by T7 RNA polymerase. The in vitro synthesized msDNA was released from the template RNA only when treated with yeast debranching enzyme DBR1, a specific nuclease for a 2',5'-phosphodiester linkage. The position of the branching G residue in the template RNA and the DNA sequence of the cell-free product were identical to those of msDNA-Ec73 synthesized in vivo. These results clearly demonstrate that the formation of the 2',5'-phosphodiester Linkage in msDNA synthesis is carried out by RT itself.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center			Shimamoto, Tadashi/A-7109-2018; Inouye, Sharon/R-7216-2019	Shimamoto, Tadashi/0000-0002-5538-0595; 	NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HSU MY, 1989, J BIOL CHEM, V264, P6214; INOUYE M, 1992, J BACTERIOL, V174, P2419, DOI 10.1128/jb.174.8.2419-2424.1992; INOUYE S, 1993, CURR OPIN GENET DEV, V3, P713, DOI 10.1016/S0959-437X(05)80088-7; INOUYE S, 1989, CELL, V56, P709, DOI 10.1016/0092-8674(89)90593-X; INOUYE S, 1993, REVERSE TRANSCRIPTAS, P391; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Maxam A M, 1980, Methods Enzymol, V65, P499; RICE SA, 1993, J BACTERIOL, V175, P4250, DOI 10.1128/JB.175.13.4250-4254.1993; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMADA M, 1994, J BIOL CHEM, V269, P14553; SHIMADA M, 1994, J BIOL CHEM, V269, P3925; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	27	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					581	588		10.1074/jbc.270.2.581	http://dx.doi.org/10.1074/jbc.270.2.581			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7529762	hybrid			2022-12-25	WOS:A1995QB81600015
J	SUGAHARA, K; TSUDA, H; YOSHIDA, K; YAMADA, S; DEBEER, T; VLIEGENTHART, JFG				SUGAHARA, K; TSUDA, H; YOSHIDA, K; YAMADA, S; DEBEER, T; VLIEGENTHART, JFG			STRUCTURE DETERMINATION OF THE OCTASACCHARIDE AND DECASACCHARIDE SEQUENCES ISOLATED FROM THE CARBOHYDRATE-PROTEIN LINKAGE REGION OF PORCINE INTESTINAL HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SWARM RAT CHONDROSARCOMA; CHONDROITIN SULFATE; FLAVOBACTERIUM-HEPARINUM; SUBSTRATE-SPECIFICITY; MAGNETIC-RESONANCE; NMR-SPECTROSCOPY; SHARK CARTILAGE; PROTEOGLYCANS; OLIGOSACCHARIDES	Previously we isolated a tetrasaccharide-serine and a hexasaccharide-serine from the carbohydrate-protein linkage region of porcine intestinal heparin after digestion with a mixture of Flavobacterium heparinase and heparitinases I and II (Sugahara, K., Yamada, S., Yoshida, K., de Waard, P., and Vliegenthart, J.F.G. (1992) J. Biol. Chem. 267, 1528-1533). In this study four longer carbohydrate sequences (I-IV) attached to Ser or a dipeptide (Ser-Gly or Gly-Ser), which accounted for at least 18.2% of the total linkage region, were isolated from the same heparin preparation after digestion with heparinase only. IV was successfully isolated only after subsequent digestion with glycuronate-2-sulfatase. Their structures were determined by chemical and enzymatic analyses and H-1 MMR spectroscopy and found to be the following octa- and decasaccharide sequences attached to Ser in a molar ratio of 1.1:2.3:1.0:1.3: Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4GlcA beta 1-4GlcNAc alpha 1-4-GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser (I), Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc alpha 1-4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser (II), Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc alpha 1-4Glca beta 1-4GlcNAc alpha 1-4GlcA beta 1-3Gal beta 1-3-gal beta 1-4Xyl beta 1-O-Ser (III), Delta Hex-A alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc(6S)alpha 1-4GlcA beta 1-3Gal beta 1-3Gal beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser (IV) (Delta HexA, GlcA, IdoA, and GlcN represent 4,5-unsaturated hexuronic acid, D-glucuronic acid, L-iduronic acid, and D-glucosamine, whereas 2S, 6S, and NS stand for 2-sulfate, 6-sulfate, and N-sulfate, respectively). I and II contained 1 mol of Gly in addition to Ser. The four structures indicate that sulfation in heparin chains takes place on the monosaccharide residues located in closer vicinity to the core protein than found for heparan sulfate chains and that there exist at least several heparin subclass chains with different linkage region structures. The significance of the isolated structures is discussed in relation to the biological functions and the biosynthetic mechanisms of heparin.	SEIKAGAKU CORP,TOKYO RES INST,TOKYO 207,JAPAN; UNIV UTRECHT,DEPT BIOORGAN CHEM,BIJVOET CTR,3508 UTRECHT,NETHERLANDS	Seikagaku Corporation; Utrecht University	SUGAHARA, K (corresponding author), KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN.							BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; FOLKMAN J, 1989, HEPARIN, P317; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; GALLAGHER JT, 1989, HEPARIN, P135; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HORNE A, 1991, CARBOHYD RES, V225, P43; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; LINDAHL U, 1966, BIOCHIM BIOPHYS ACTA, V130, P368, DOI 10.1016/0304-4165(66)90233-9; Lindahl U., 1989, HEPARIN CHEM BIOL PR, P25; Lindahl U., 1989, HEPARIN, P159; Lindahl U, 1972, CARBOHYDRATE PROTEIN, P491; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARCUM JA, 1989, HEPARIN, P275; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; NADER HB, 1990, J BIOL CHEM, V265, P16807; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROSENFELD L, 1988, J BIOL CHEM, V263, P262; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P1; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	52	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	1995	270	39					22914	22923		10.1074/jbc.270.39.22914	http://dx.doi.org/10.1074/jbc.270.39.22914			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY054	7559427	hybrid, Green Published			2022-12-25	WOS:A1995RY05400047
J	KO, YH; PEDERSEN, PL				KO, YH; PEDERSEN, PL			THE FIRST NUCLEOTIDE-BINDING FOLD OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CAN FUNCTION AS AN ACTIVE ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; SITE-SPECIFIC MUTAGENESIS; PHENOTYPIC SELECTION; SYNTHETIC PEPTIDE; MALTOSE-BINDING; PROTEIN; PHOSPHORYLATION; GENE; PURIFICATION; MUTATIONS	Cystic fibrosis is caused by mutations in the cell membrane protein called CFTR (cystic fibrosis transmembrane conductance regulator) which functions as a regulated Cl- channel. Although it is known that CFTR contains two nucleotide domains, both of which exhibit the capacity to bind ATP, it has not been demonstrated directly whether one or both domains can function as an active ATPase, To address this question, we have studied the first CFTR nucleotide binding fold (NBF1) in fusion with the maltose-binding protein (MBP), which both stabilizes NBF1 and enhances its solubility. Three different ATPase assays conducted on MBP-NBF1 clearly demonstrate its capacity to catalyze the hydrolysis of ATP. Significantly, the mutations K464H and K464L in the Walker A consensus motif of NBF1 markedly impair its catalytic capacity. MBP alone exhibits no ATPase activity and MBP-NBF1 fails to catalyze the release of phosphate from AMP or ADP. The V-max of ATP hydrolysis (similar to 30 nmol/min/mg of protein) is significant and is markedly inhibited by azide and by the ATP analogs 2'-(3')-O-(2,4,6-trinitrophenyl)-adenosine-5'- triphosphate and adenosine 5'-(beta, gamma-imido)triphosphate. As inherited mutations within NBF1 account for most eases of cystic fibrosis, results reported here are fundamental to our understanding of the molecular basis of the disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University								ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; ANDERSON MP, 1991, SCIENCE, V257, P1701; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CROUYCHANEL A, 1995, J BIOL CHEM, V270, P10571; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; EBEL RE, 1975, J BIOL CHEM, V250, P191; GOMORI GJ, 1962, J LAB CLIN MED, V27, P955; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; KO YH, 1993, J BIOL CHEM, V268, P24330; KO YH, 1994, J BIOL CHEM, V269, P14584; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; PEDERSEN PL, 1976, J BIOL CHEM, V251, P934; PENEFSKY HS, 1974, J BIOL CHEM, V249, P3579; RESIN IM, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799	35	96	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22093	22096		10.1074/jbc.270.38.22093	http://dx.doi.org/10.1074/jbc.270.38.22093			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7545672	hybrid			2022-12-25	WOS:A1995RW31400005
J	TAE, HJ; ZHANG, SY; KIM, KH				TAE, HJ; ZHANG, SY; KIM, KH			CAMP ACTIVATION OF CAAT ENHANCER-BINDING PROTEIN-BETA GENE-EXPRESSION AND PROMOTER-I OF ACETYL-COA CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE; 5' END; TRANSCRIPTION; DIFFERENTIATION; ELEMENT; PHOSPHORYLATION; PREADIPOCYTES; HETEROGENEITY; INHIBITORS	The acetyl-CoA carboxylase (ACC) gene contains two distinct promoters, denoted PI and PII, PI is responsible for the generation of class I ACC mRNAs which are induced in a tissue-specific manner under lipogenic conditions, PII generates class II AGC mRNAs which are expressed constitutively. During 30A5 preadipocyte differentiation, both promoters are activated; the preadipocytes must be pretreated with cAMP for this activation to occur. In this report, we present evidence that CAAT enhancer-binding protein-beta (C/EBP-beta) is induced and involved in the PI activation by cAMP. Expression of the reporter gene under the control of the PI promoter is activated within 3 h after treatment of 30A5 cells with a cyclic AMP analogue, 8-(4-chlorophenylthio)-adenosine 3',5'-cyclic monophosphate, and 3-isobutyl-1-methylxanthine, in association with the accumulation of C/EBP-beta mRNA and protein, These accumulations were inhibited in the presence of H8, a protein kinase inhibitor; H8 also inhibited activation of PI by cAMP. However, the induction of reporter gene expression and the increase of C/EBP-beta mRNA by cAMP were not affected by treatment with tumor necrosis factor alpha, which completely inhibited the accumulation of C/EBP-alpha mRNA. Overexpression of C/EBP-beta by transfection with the C/EBP-beta gene led to increased binding of C/EBP-beta to DNA and partial PI activation, cAMP did not affect the amount of C/EBP-beta binding to the DNA but did promote phosphorylation of C/EBP-beta and PI activation. As in the case of C/EBP-alpha, C/EBP-beta bound to the CCAAT box of the PI promoter. These results indicate that cAMP not only induces, but also activates, bound C/EBP-beta through phosphorylation for PI activation. Our studies also indicate that cAMP induces C/EBP-alpha. C/EBP-beta induction, however, precedes that of C/EBP-alpha.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA 46882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADHYA S, 1990, J BIOL CHEM, V265, P10797; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1476; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEVINE L, 1989, J IMMUNOL METHODS, V124, P239, DOI 10.1016/0022-1759(89)90360-8; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PARK EA, 1993, J BIOL CHEM, V268, P613; PARK KR, 1991, J BIOL CHEM, V266, P12249; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1984, J BIOL CHEM, V259, P5242; TAE HJ, 1994, J BIOL CHEM, V269, P10475; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZHU Z, 1989, J BIOL CHEM, V264, P6550	32	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21487	21494		10.1074/jbc.270.37.21487	http://dx.doi.org/10.1074/jbc.270.37.21487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545164	hybrid			2022-12-25	WOS:A1995RU75700014
J	VACHINO, G; CHANG, XJ; VELDMAN, GM; KUMAR, R; SAKO, D; FOUSER, LA; BERNDT, MC; CUMMING, DA				VACHINO, G; CHANG, XJ; VELDMAN, GM; KUMAR, R; SAKO, D; FOUSER, LA; BERNDT, MC; CUMMING, DA			P-SELECTIN GLYCOPROTEIN LIGAND-1 IS THE MAJOR COUNTER-RECEPTOR FOR P-SELECTIN ON STIMULATED T-CELLS AND IS WIDELY DISTRIBUTED IN NONFUNCTIONAL FORM ON MANY LYMPHOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; SIALYL-LEWIS-X; ENDOTHELIAL LIGAND; HOMING RECEPTOR; MYELOID CELLS; ANTIGEN; CD62; BIOSYNTHESIS; EXPRESSION; ACTIVATION	P-selectin glycoprotein ligand-1 (PSGL-1) is the high affinity counter-receptor for P-selectin on myeloid cells (Sako, D., Chang, X. J., Barone, K. M., Vachino, G., White, H. M., Shaw, G., Veldman, G. M., Bean, K. M., Ahern, T. J., Furie, B., Cumming, D. A., and Larsen, G. R. (1993) Cell 75, 1179-1186). Here we demonstrate that PSGL-1 is also widely distributed on T- and B-lymphocytic tumor cell lines, resting peripheral blood T and B cells, and on stimulated peripheral blood T cell and intestinal intraepithelial lymphocyte (IEL) lines. However, the majority of PSGL-1-positive resting peripheral blood lymphocytic cells and lymphoid tumor cell lines do not display significant P-selectin binding. In contrast, in vitro stimulated peripheral blood T cell and IEL lines avidly bind P-selectin, and PSGL-1 is the sole high affinity counter-receptor mediating this binding. During the course of in vitro stimulation, cell surface expression levels of PSGL-1 do not change as P-selectin binding increases. Rather, the activities of two glycosyltransferases reportedly involved in the production of functional PSGL-1 in myeloid cells are substantially higher in the stimulated T-lymphocytic lines than in resting T lymphocytes, consistent with the hypothesis that activation-dependent post-translational events contribute to the expression of functional PSGL-1 on lymphocytes.	GENET INST INC,DEPT MOLEC IMMUNOL,CAMBRIDGE,MA 02140; BAKER MED RES INST,DEPT VASC BIOL,PRAHRAN,VIC 3181,AUSTRALIA	Baker Heart and Diabetes Institute	VACHINO, G (corresponding author), GENET INST INC,SMALL MOLECULE DRUG DISCOVERY GRP,87 CAMBRIDGE PK DR,CAMBRIDGE,MA 02140, USA.		Berndt, Michael C/D-5580-2012	Vachino, Gloria/0000-0002-9193-9990				ALON R, 1994, J CELL BIOL, V127, P1485, DOI 10.1083/jcb.127.5.1485; ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BAUMHUETER S, 1994, BLOOD, V84, P2554; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CEPEK KL, 1993, J IMMUNOL, V150, P3459; DAMLE NK, 1992, EUR J IMMUNOL, V22, P1789, DOI 10.1002/eji.1830220718; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GROBER JS, 1993, J CLIN INVEST, V91, P2609, DOI 10.1172/JCI116500; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; IMAI Y, 1993, NATURE, V361, P555; ISHIKAWA T, 1993, BLOOD, V82, P1590; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KUBES P, 1994, J IMMUNOL, V152, P3570; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LUSCINSKAS FW, 1995, J EXP MED, V181, P1179, DOI 10.1084/jem.181.3.1179; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; OHMORI K, 1993, BLOOD, V82, P2797; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PILLER F, 1988, J BIOL CHEM, V263, P15146; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POSTIGO AA, 1994, J CLIN INVEST, V94, P1585, DOI 10.1172/JCI117500; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PUSSIER P, 1994, J EXDP MED, V180, P1185; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sambrook J, 1989, MOL CLONING LABORATO; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WASLEY LC, 1993, J BIOL CHEM, V268, P8458	43	144	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21966	21974		10.1074/jbc.270.37.21966	http://dx.doi.org/10.1074/jbc.270.37.21966			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7545173	hybrid			2022-12-25	WOS:A1995RU75700082
J	FUKAZAWA, T; REEDQUIST, KA; PANCHAMOORTHY, G; SOLTOFF, S; TRUB, T; DRUKER, B; CANTLEY, L; SHOELSON, SE; BAND, H				FUKAZAWA, T; REEDQUIST, KA; PANCHAMOORTHY, G; SOLTOFF, S; TRUB, T; DRUKER, B; CANTLEY, L; SHOELSON, SE; BAND, H			T-CELL ACTIVATION-DEPENDENT ASSOCIATION BETWEEN THE P85 SUBUNIT OF THE PHOSPHATIDYLINOSITOL 3-KINASE AND GRB2/PHOSPHOLIPASE C-GAMMA-1-BINDING PHOSPHOTYROSYL PROTEIN PP36/38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ANTIGEN RECEPTOR; SH2 DOMAINS; ZETA-CHAIN; GROWTH; CLONING; P59FYN; BIND; CD4	Tyrosine phosphorylation of cellular proteins is an early and an essential step in T cell receptor-mediated lymphocyte activation, Tyrosine phosphorylation of transmembrane receptor chains (such as zeta and CD3 chains) and membrane-associated proteins provides docking sites for SH2 domains of adaptor proteins and signaling enzymes, resulting in their recruitment in the vicinity of activated receptors, pp36/38 is a prominent substrate of early tyrosine phosphorylation upon stimulation through the T cell receptor, The tyrosine-phosphorylated form of pp36/38 is membrane-associated and directly interacts with phospholipase C-gamma l and Grb2, providing one mechanism to recruit downstream effecters to the cell membrane, Here, we demonstrate that in Jurkat T cells, pp36/38 associates with the p85 subunit of phosphatidylinositol 3-kinase (PI-S-K p85) in an activation-dependent manner, Association of pp36/38 with PI-3-K p85 was confirmed by transfection of a hemagglutinin-tagged p85 alpha cDNA into Jurkat cells followed by anti-hemagglutinin immunoprecipitation, In vitro binding experiments with glutathione S-transferase fusion proteins of PI-S-K p85 demonstrated that the SH2 domains, but not the SH3 domain, mediated binding to pp36/38, This binding was selectively abrogated by phosphopeptides that bind to p85 SH2 domains with high affinity, Filter binding assays demonstrated that association between pp36/38 and PI-3-K p85 SH2 domains was due to direct binding. These results strongly suggest the role of pp36/38 in recruiting PI-3-K to the cell membrane and further support the idea that pp36/38 is a multifunctional docking protein for SH2 domain-containing signaling proteins in T cells.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT IMMUNOL & RHEUMATOL,LYMPHOCYTE BIOL SECT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DEPT MED, DIV RES, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Oregon Health & Science University			Fukazawa, Takuya/GLR-7099-2022; Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Druker, Brian/0000-0001-8331-8206	NIAID NIH HHS [R29-AI28508] Funding Source: Medline; NIAMS NIH HHS [AR36308] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EXLEY M, 1994, J BIOL CHEM, V269, P15140; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1993, J BIOL CHEM, V268, P10780; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; THOMPSON PA, 1992, ONCOGENE, V7, P719; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WARD SG, 1992, J BIOL CHEM, V267, P23862; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20177	20182		10.1074/jbc.270.34.20177	http://dx.doi.org/10.1074/jbc.270.34.20177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7544353	hybrid			2022-12-25	WOS:A1995RQ99100074
J	ZHAO, JM; MILNE, JC; COLLIER, RJ				ZHAO, JM; MILNE, JC; COLLIER, RJ			EFFECT OF ANTHRAX TOXINS LETHAL FACTOR ON ION CHANNELS FORMED BY THE PROTECTIVE ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-ANTHRACIS; ADENYLATE-CYCLASE; DIPHTHERIA-TOXIN; BOTULINUM TOXIN; TETANUS TOXIN; LOW-PH; MEMBRANES; SEQUENCE; CELLS; MACROPHAGES	Protective antigen (PA), a component of anthrax toxin, mediates translocation of the toxin's lethal and edema factors (LF and EF, respectively) to the cytoplasm, via a pathway involving their release from an acidic intracellular compartment. PA(63), a 63-kDa proteolytic fragment of PG can be induced to form ion-conductive channels in the plasma membrane of mammalian cells by acidification of the medium. These channels are believed to be comprised of dodecyl sulfate resistant oligomers (heptameric rings) of PA(63) seen by electron microscopy of the purified protein. Here we report that the PA(63)-mediated efflux of Rb-86(+) from preloaded CHO-K1 cells under acidic conditions is strongly inhibited (greater than or equal to 70%) by LF or LF(N), a PA-binding fragment of LF. Control proteins caused no inhibition, Evidence is presented that the inhibition involves partial blockage of ion conductance by the PA(63), channel. Also, oligomer formation is slowed somewhat by LF at pH values near the pH threshold of channel formation (pH similar to 5.3), suggesting that channel formation may also be retarded under these conditions. The relevance of these results to the location of the LF-binding site on PA(63) and the mechanism of LF and EF translocation is discussed.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, SHIPLEY INST MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Collier, R John/0000-0002-2427-4239	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022021, R37AI022021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22021] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; FINKELSTEIN A, 1994, TOXICOLOGY, V87, P29, DOI 10.1016/0300-483X(94)90153-8; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Gill D., 1978, BACTERIAL TOXINS CEL, P291; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; HANNA PC, 1994, MOL MED, V1, P7; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; LEPPLA SH, 1991, P NATL ACAD SCI USA, P277; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; QUINN CP, 1991, J BIOL CHEM, V266, P20124; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SINGH Y, 1989, J BIOL CHEM, V264, P19103; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8	28	49	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18626	18630		10.1074/jbc.270.31.18626	http://dx.doi.org/10.1074/jbc.270.31.18626			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7543106	hybrid			2022-12-25	WOS:A1995RM64200073
J	SESSA, WC; GARCIACARDENA, G; LIU, JW; KEH, A; POLLOCK, JS; BRADLEY, J; THIRU, S; BRAVERMAN, IM; DESAI, KM				SESSA, WC; GARCIACARDENA, G; LIU, JW; KEH, A; POLLOCK, JS; BRADLEY, J; THIRU, S; BRAVERMAN, IM; DESAI, KM			THE GOLGI ASSOCIATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE IS NECESSARY FOR THE EFFICIENT SYNTHESIS OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELLS; CALCIUM; MEMBRANE; PROTEIN	The particulate enzyme, endothelial nitric oxide synthase (eNOS), produces nitric oxide to maintain normal vasodilator tone in blood vessels. In this study, we demonstrate that eNOS is a Golgi-associated protein in cultured endothelial cells and intact blood vessels. Using a heterologous expression system in HEK 293 cells, we show that wild-type myristoylated and palmitoylated eNOS, but not mutant, non-acylated eNOS targets to the Golgi. More importantly, HEK 293 cells expressing wildtype eNOS release substantially more NO than cells expressing the mutant, non-acylated enzyme. Thus, eNOS is a novel Golgi-associated protein, and Golgi compartmentalization is necessary for the enzyme to respond to intracellular signals and produce NO.	YALE UNIV, SCH MED, DEPT MOLEC CARDIOBIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06536 USA; ABBOTT LABS, ABBOTT PK, IL 60064 USA; UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN MED, DEPT MED, CAMBRIDGE CBZ 2QQ, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN MED, DEPT PATHOL, CAMBRIDGE CBZ 2QQ, ENGLAND	Yale University; Yale University; Abbott Laboratories; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	SESSA, WC (corresponding author), YALE UNIV, BOYER CTR MOLEC MED,SCH MED,DEPT PHARMACOL,RM 436D, 295 CONGRESS AVE, NEW HAVEN, CT 06536 USA.		Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Desai, Kaushik/0000-0001-9355-4528; Bradley, John/0000-0002-7774-8805	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009224, R29HL051948] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32-HL09224, R29-HL51948] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		BURNIER M, 1994, AM J PHYSIOL, V266, pC1118, DOI 10.1152/ajpcell.1994.266.4.C1118; CHANDRA S, 1989, P NATL ACAD SCI USA, V86, P1870, DOI 10.1073/pnas.86.6.1870; CHANDRA S, 1991, J CELL SCI, V100, P747; CHANDRA S, 1994, J BIOL CHEM, V269, P15186; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; GRIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; LIU JW, 1994, J BIOL CHEM, V269, P11691; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; NATHAN C, 1994, J BIOL CHEM, V269, P13725; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; SOLIMENA M, 1993, P NATL ACAD SCI USA, V90, P3073, DOI 10.1073/pnas.90.7.3073	23	226	230	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17641	17644		10.1074/jbc.270.30.17641	http://dx.doi.org/10.1074/jbc.270.30.17641			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7543089	hybrid			2022-12-25	WOS:A1995RM26600001
J	MARRERO, MB; SCHIEFFER, B; PAXTON, WG; SCHIEFFER, E; BERNSTEIN, KE				MARRERO, MB; SCHIEFFER, B; PAXTON, WG; SCHIEFFER, E; BERNSTEIN, KE			ELECTROPORATION OF PP60(C-SRC) ANTIBODIES INHIBITS THE ANGIOTENSIN-II ACTIVATION OF PHOSPHOLIPASE C-GAMMA-1 IN RAT AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; RECEPTOR; EXPRESSION; KINASES	Our previous study has shown that angiotensin II induces the rapid tyrosine phosphorylation and activation of phospholipase C-gamma 1 in cultured rat aortic smooth muscle (RASM) cells (Marrero, M. B,, Paxton, W, G,, Duff, J, L,, Berk, B, C,, and Bernstein, K, E, (1994) J, Biol, Chem, 269, 10935-10939), This signaling pathway is initiated by ligand binding to the AT(1) receptor, a cell surface G protein-coupled receptor, Antibodies to pp60(c-src) were introduced into RASM cells by electroporation. Angiotensin II-stimulated tyrosine phosphorylation of phospholipase C-gamma 1 was eliminated by the anti-pp60(c-src) antibodies but not by anti-mouse IgG or bovine serum albumin, Angiotensin II also induced the rapid tyrosine phosphorylation of pp120, a known pp60(c-src) kinase substrate, and this phosphorylation was also specifically inhibited by anti-pp60(c-src) antibodies, Electroporation of RASM cells with anti-pp60(c-src) antibodies had no effect on platelet-derived growth factor-stimulated tyrosine phosphorylation of PLC-gamma 1, Anti-pp60(c-src) also reduced the angiotensin II-stimulated inositol 1,4,5-trisphosphate production by 78%, while it had no effect on the platelet-derived growth factor-stimulated inositol 1,4,5-trisphosphate production, These data provide the first evidence for a direct involvement of pp60(c-src) kinase in angiotensin II-mediated PLC-gamma 1 phosphorylation and activation, Furthermore, it also describes a pathway in which a seven-transmembrane receptor can stimulate an intracellular tyrosine kinase.			MARRERO, MB (corresponding author), EMORY UNIV,DEPT PATHOL & LAB MED,ATLANTA,GA 30322, USA.			Bernstein, Kenneth/0000-0001-8097-3272	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039777, R37DK039777, R01DK044280, P50DK045215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39777, DK45215, DK44280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P59; CHIU AT, 1991, AM J HYPERTENS, V4, P282; DHAR A, 1994, J BIOL CHEM, V269, P9123; HOMMA Y, 1993, BIOCHEM J, V290, P649, DOI 10.1042/bj2900649; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; MALLOY CJ, 1993, J BIOL CHEM, V268, P7338; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SMITH JB, 1986, AM J PHYSIOL, V250, P759; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; WHAL MI, 1989, MOL CELL BIOL, V9, P2934; WONG PC, 1991, AM J HYPERTENS, V4, P288	24	162	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15734	15738		10.1074/jbc.270.26.15734	http://dx.doi.org/10.1074/jbc.270.26.15734			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541047	hybrid			2022-12-25	WOS:A1995RG53800047
J	MENDE, U; SCHMIDT, CJ; YI, F; SPRING, DJ; NEER, EJ				MENDE, U; SCHMIDT, CJ; YI, F; SPRING, DJ; NEER, EJ			THE G-PROTEIN GAMMA-SUBUNIT - REQUIREMENTS FOR DIMERIZATION WITH BETA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; MESSENGER-RNAS; COILED-COIL; TRANSDUCIN; CDNA; PRENYLATION; BINDING; FORM; ASSOCIATION; TRANSLATION	Guanine nucleotide-binding protein beta and gamma subunits form a tightly bound complex that can only be separated by denaturation, Assembly of beta and gamma subunits is a complicated process, The beta(1) and gamma(2) subunits can be synthesized in vitro in rabbit reticulocyte lysate and then assembled into dimers, but beta(1) cannot form beta gamma dimers when synthesized in a wheat germ extract, In contrast, gamma(2) translated in either system can dimerize with beta(1), suggesting that dimerization-competent gamma(2) can be synthesized without the aid of specific chaperonins or other cofactors. Dimerization-competent gamma(2) in solution forms an asymmetric particle with a Stokes radius of about 21 +/- 0.4 Angstrom (n = 4), s(20,w) of 0.9 S (range 0.8-1.0 S, n = 2), and frictional ratio of 1.57 (assuming no hydration), To define the part of gamma(2) that is needed for native beta gamma dimer formation, a series of N- and C-terminal truncations were generated, synthesized in vitro, and incubated with beta(1). Dimerization was assessed by stabilization of beta(1) to tryptic proteolysis. Truncation of up to 13 amino acids at the C terminus did not affect dimerization with B-1, whereas removal of 27 amino acids prevented it, Therefore, a region between residues 45 and 59 of gamma(2) is important for dimerization, Truncation of 15 amino acids from the N terminus greatly diminished the formation of beta gamma dimers, while removal of 25 amino acids entirely blocked it, Thus, another region important for forming native beta gamma is near the N terminus. Extension of the N terminus by 12 amino acids that include the influenza virus hemagglutinin epitope did not prevent beta gamma dimerization, Furthermore, in intact S-35-labeled COS cells, epitope-tagged gamma(2) coimmunoprecipitates with beta and alpha subunits. The N-terminal epitope tag must lie at the surface of the heterotrimer since it prevents neither heterotrimer formation nor access of the antibody.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	MENDE, U (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NIDDK NIH HHS [DK 07337] Funding Source: Medline; NIGMS NIH HHS [GM 36259] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CASEY PJ, 1992, J LIPID RES, V33, P1731; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P259; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; RUTHERFORD SL, 1994, CELL, V76, P1129; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; [No title captured]	41	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15892	15898		10.1074/jbc.270.26.15892	http://dx.doi.org/10.1074/jbc.270.26.15892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7541050	hybrid			2022-12-25	WOS:A1995RG53800069
J	KASAI, K; TAKAHASHI, S; MURAKAMI, K; NAKAYAMA, K				KASAI, K; TAKAHASHI, S; MURAKAMI, K; NAKAYAMA, K			STRAIN-SPECIFIC PRESENCE OF 2 TGN38 ISOFORMS AND ABSENCE OF TGN41 IN MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; INTEGRAL MEMBRANE-PROTEIN; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; BREFELDIN-A; COMPLEX; IDENTIFICATION; LOCALIZATION; EXPRESSION; CLATHRIN	TGN38 and TGN41 are isoforms of an integral membrane protein that is predominantly localized to the trans-Golgi network (TGN) in rat cells. They have been proposed to form a heterodimer and to be involved in the budding of exocytic transport vesicles from the TGN. By cDNA cloning and analysis using polymerase chain reaction, we found that there were two TGN38 isoforms in a strain of mouse (ICR), whereas other strains examined (BALB/c, DBA/2, and C57BL/6) had only one TGN38. The major difference between the two isoforms was: in the number of characteristic octapeptide repeats. Apart from this, there were several nucleotide substitutions between them. The two isoforms appeared to be derived from two distinct genes but not from one gene via alternative splicing. Furthermore, we failed to show the presence of TGN41 in all the strains examined. This result suggests that TGN38 may function as a monomer or a homodimer in mouse cells.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,CTR GENE EXPT,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba			Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183				BAUERFEIND R, 1993, CURR OPIN CELL BIOL, V6, P628; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1994, BIOMED RES-TOKYO, V15, P383, DOI 10.2220/biomedres.15.383; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REAVES B, 1992, BIOCHEM J, V283, P313, DOI 10.1042/bj2830313; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Stanley Keith K., 1993, Trends in Cell Biology, V3, P252, DOI 10.1016/0962-8924(93)90046-4; WONG SH, 1993, J BIOL CHEM, V268, P22853	24	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14471	14476		10.1074/jbc.270.24.14471	http://dx.doi.org/10.1074/jbc.270.24.14471			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7540170	hybrid			2022-12-25	WOS:A1995RD45500038
J	KUWAHARA, M; FUSHIMI, K; TERADA, Y; BAI, LQ; MARUMO, F; SASAKI, S				KUWAHARA, M; FUSHIMI, K; TERADA, Y; BAI, LQ; MARUMO, F; SASAKI, S			CAMP-DEPENDENT PHOSPHORYLATION STIMULATES WATER PERMEABILITY OF AQUAPORIN-COLLECTING DUCT WATER CHANNEL PROTEIN EXPRESSED IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRINSIC PROTEIN; RAT-KIDNEY; KINASE; NODULIN-26; MEMBRANE; CELLS; GENE	Among water channel proteins (aquaporins), aquaporin-collecting duct (AQP-CD) is the vasopressin-regulated water channel. Vasopressin causes cAMP production in the renal collecting duct cells, and this is believed to lead to exocytic insertion of water channel into the apical membrane (shuttle hypothesis). AQP-CD contains a consensus sequence for cAMP-dependent protein kinase, residues at positions 253-256 (Arg-Arg-Gln-Ser). To determine the role of this site, Ser-256 was substituted for Ala, Leu, Thr, Asp, or Glu by site-directed mutagenesis. In Xenopus oocytes injected with wild-type or mutated AQP-CD cRNAs, osmotic water permeability (Pf) was 4.8-7.7 times higher than Pf of water-injected oocytes. Incubation with cAMP plus forskolin or direct cAMP injection into the oocytes increased Pf of wildtype, but not mutated, AQP-CD-expressing oocytes, whereas the amounts of AQP-CD expression were similar in wild and mutated types as identified by Western blot analysis. In vitro phosphorylation studies of AQP-CD proteins expressed in oocyte showed that cAMP dependent protein kinase phosphorylated wildtype, but not mutated, AQP-CD proteins. Phosphoamino acid analysis revealed that this phosphorylation occurred at the serine residue, Moreover, phosphorylation of AQP-CD protein in intact rat kidney medulla tissues was stimulated by incubation with cAMP. Our data suggest that cAMP stimulates water permeability of AQP-CD by phosphorylation. This process may contribute to the vasopressin-regulated water permeability of collecting duct in addition to the apical insertion of AQP-CD by exocytosis.	TOKYO MED & DENT UNIV, SCH MED, DEPT INTERNAL MED 2, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Medical & Dental University (TMDU)								BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN D, 1991, SEMIN NEPHROL, V11, P478; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ECHEVARRIA M, 1993, J GEN PHYSIOL, V101, P827, DOI 10.1085/jgp.101.6.827; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EHRING GR, 1992, J MEMBRANE BIOL, V126, P75; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMURA I, 1993, BRIT J PHARMACOL, V110, P639, DOI 10.1111/j.1476-5381.1993.tb13859.x; LAMPE PD, 1990, EUR J BIOCHEM, V194, P541, DOI 10.1111/j.1432-1033.1990.tb15650.x; MIAO GH, 1992, J CELL BIOL, V118, P481, DOI 10.1083/jcb.118.2.481; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; PRESTON GM, 1993, J BIOL CHEM, V268, P17; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TERADA Y, 1994, J BIOL CHEM, V269, P31296; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x; WEAVER CD, 1992, BIOCHEMISTRY-US, V31, P8954, DOI 10.1021/bi00152a035	24	180	184	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10384	10387		10.1074/jbc.270.18.10384	http://dx.doi.org/10.1074/jbc.270.18.10384			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537730	hybrid			2022-12-25	WOS:A1995QW60100007
J	FUKS, B; HOMBLE, F				FUKS, B; HOMBLE, F			A VOLTAGE-DEPENDENT PORIN-LIKE CHANNEL IN THE INNER ENVELOPE MEMBRANE OF PLANT CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INTACT CHLOROPLASTS; MITOCHONDRIAL CHANNEL; CONDUCTING CHANNELS; ION-CHANNEL; STROMAL PH; VDAC; RECONSTITUTION; PHOTOSYNTHESIS; PURIFICATION	The electrical activity of a single channel of 525 +/- 12 picosiemens in 150 mM KCl was measured after fusion of the inner envelope membrane of the chloroplast with planar lipid bilayers. The reversal potentials measured in KCl gradients indicate that this channel is weakly anion selective (P-Cl/PK = 1.6 +/- 0.2). The gating mechanism of the pore is voltage dependent. The channel shifts from a fully open state to a substate at positive electrical potentials and remains closed at negative electrical potentials, Succinylation of the protein in creases the open probability of the fully open state and reverses the channel selectivity. Analysis of the single-channel conductance as a function of the salt concentration and of the open probability at various voltages suggests that this channel is a new membrane porin not previously identified.			FUKS, B (corresponding author), FREE UNIV BRUSSELS,FAC SCI,PHYSIOL VEGETALE LAB,CP 206-2,BLVD TRIOMPHE,B-1050 BRUSSELS,BELGIUM.		Homble, Fabrice/AAH-3780-2020	Homble, Fabrice/0000-0001-6031-136X				ADELSBERGERMANG.DM, 1987, J MEMBRANE BIOL, V98, P157; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BERRIER C, 1993, J MEMBRANE BIOL, V133, P119; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BERTL A, 1990, P NATL ACAD SCI USA, V87, P7824, DOI 10.1073/pnas.87.20.7824; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; CLINE K, 1985, PROTOPLASMA, V125, P111, DOI 10.1007/BF01297356; Cohen F. S., 1986, ION CHANNEL RECONSTI, P131; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DEMMIG B, 1983, PLANT PHYSIOL, V73, P169, DOI 10.1104/pp.73.1.169; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; FENG M, 1994, PLANT PHYSIOL, V105, P955; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; FLUGGE UI, 1992, RES PHOTOSYNTHESIS, V3, P667; FUKS B, 1994, BIOPHYS J, V66, P1404, DOI 10.1016/S0006-3495(94)80931-2; HEBER U, 1981, ANNU REV PLANT PHYS, V32, P139, DOI 10.1146/annurev.pp.32.060181.001035; HELDT HW, 1971, BIOCHIM BIOPHYS ACTA, V234, P83, DOI 10.1016/0005-2728(71)90133-2; HOWITZ KT, 1991, PLANT PHYSIOL, V96, P1060, DOI 10.1104/pp.96.4.1060; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KINALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99; Klotz I. M, 1967, METHOD ENZYMOL, V11, P576, DOI 10.1016/S0076-6879(67)11070-7; MANGAN PS, 1987, P NATL ACAD SCI USA, V84, P4896, DOI 10.1073/pnas.84.14.4896; MORAN O, 1990, J BIOL CHEM, V265, P908; PETERS JS, 1991, PLANT PHYSIOL, V95, P1229, DOI 10.1104/pp.95.4.1229; POTTOSIN II, 1992, FEBS LETT, V308, P87, DOI 10.1016/0014-5793(92)81057-S; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHWARZ M, 1994, J BIOL CHEM, V269, P29481; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V18, P127; WALKER DA, 1987, METHOD ENZYMOL, V148, P145; WANG XC, 1993, P NATL ACAD SCI USA, V90, P4981, DOI 10.1073/pnas.90.11.4981; WU WH, 1991, PLANT PHYSIOL, V97, P580, DOI 10.1104/pp.97.2.580; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X	36	17	18	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9947	9952		10.1074/jbc.270.17.9947	http://dx.doi.org/10.1074/jbc.270.17.9947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537272	hybrid			2022-12-25	WOS:A1995QV41700039
J	TAYLOR, SJ; ANAFI, M; PAWSON, T; SHALLOWAY, D				TAYLOR, SJ; ANAFI, M; PAWSON, T; SHALLOWAY, D			FUNCTIONAL INTERACTION BETWEEN C-SRC AND ITS MITOTIC TARGET, SAM-68	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; NUCLEIC-ACID; SH3 DOMAINS; BINDING; ACTIVATION; PROTEINS; ASSOCIATION; SH3-DOMAIN; PP60C-SRC; P60C-SRC	The c-Src tyrosine kinase phosphorylates and binds to a 68-kDa RNA-binding protein in mitotic cells. We have examined the mechanism and functional consequence of the interaction of c-Src with this protein, Sam 68 (Src associated in mitosis, 68 kDa). In whole cell homogenates, Sam 68 was the predominant substrate and binding partner of overexpressed c-Src. Mitotic, tyrosine-phosphorylated Sam 68 bound selectively to recombinant SH2 domains with significantly different affinities (c-Src approximate to Ras GTPase activating protein > p85 alpha (amino-terminal) > Grb2 much greater than p85 alpha (COOH-terminal)). In vitro translated Sam 68 also bound selectively to recombinant SH3 domains, with the highest affinity for the Src and p85 alpha SH3 domains. SH3 binding was inhibited by specific Sam 68 peptides, In vitro translated Sam 68 bound directly to immobilized poly(U), and this was inhibited by binding of Src and p85 SH3 domains to Sam 68. The results suggest that the selection of Sam 68 as a mitotic target by c-Src is the result of highly specific interaction with SH2 and SH3 domains and that this interaction may modulate the RNA binding activity of Sam 68.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	Cornell University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013		NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CHACKALAPARAMPI.I, 1988, CELL, V52, P801; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LIU XQ, 1993, ONCOGENE, V8, P1119; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OGAWA W, 1994, J BIOL CHEM, V269, P29602; OKADA M, 1993, J BIOL CHEM, V268, P18070; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1993, CURR BIOL, V3, P435; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	33	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10120	10124		10.1074/jbc.270.17.10120	http://dx.doi.org/10.1074/jbc.270.17.10120			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7537265	hybrid			2022-12-25	WOS:A1995QV41700062
J	CLARK, KJ; MURRAY, AW				CLARK, KJ; MURRAY, AW			EVIDENCE THAT THE BRADYKININ-INDUCED ACTIVATION OF PHOSPHOLIPASE-D AND OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE INVOLVE DIFFERENT PROTEIN-KINASE-C ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN FIBROBLASTS; PHOSPHATIDYLCHOLINE BREAKDOWN; 3T3 FIBROBLASTS; PHORBOL ESTERS; GROWTH-FACTOR; PC12 CELLS; ALPHA; OVEREXPRESSION; DIACYLGLYCEROL; BIOSYNTHESIS	The effect of alkylglycerol supplementation on protein kinase C (PKC) mediated signaling events has been studied in fibroblasts from Zellweger patients (SF 3271 cells), Western blotting analysis established that Zellweger fibroblasts express PKC alpha, epsilon, and zeta, Incubation with bradykinin induced a rapid transient translocation of PKC alpha and a more sustained translocation of PKC epsilon to the particulate fraction; translocation of PKC zeta was unaffected, Bradykinin-induced translocation and activation of PKC alpha, but not translocation of PKC epsilon, was blocked in SF 3271 cells which had been incubated with 1-O-hexadecylglycerol (1-O-HDG; 20 mu g/ml) for 24 h and then incubated in the absence of 1-O-HDG and serum for a further 24 h, Supplementation with 1-O-HDG increased the mass of ether-linked phospholipid. Bradykinin initiated a transient increase in cytosolic Ca2+ concentration in both control and 1-O-HDG supplemented cells, indicating that the initial receptor linked events were not affected by 1-O-HDG supplementation. Bradykinin also caused a rapid activation of phospholipase D (PLD), measured by phosphatidylbutanol accumulation, and mitogen-activated protein kinase (MAPK) determined by myelin basic protein phosphorylation of Mono Q fractions, Both events were blocked by preincubation of the cells with 12-O-tetradecanoylphorbol-13-acetate for 24 h to deplete PKC protein, 1-O-HDG supplementation prevented the bradykinin induced activation of PLD, but had no effect on the stimulation of MAPK activity, These results establish that modulation of the ether lipid composition of membranes can alter PKC isozyme translocation and indicate that a PKC isozyme other than PKC alpha, most likely PKC epsilon, is involved in MAPK activation.	FLINDERS UNIV S AUSTRALIA,SCH BIOL SCI,ADELAIDE,SA 5001,AUSTRALIA	Flinders University South Australia								ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDAR H, 1993, J BIOL CHEM, V268, P12560; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GODSON C, 1993, J BIOL CHEM, V268, P11946; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HA KS, 1993, J BIOL CHEM, V268, P10534; HARDY SJ, 1993, J NEUROCHEM, V62, P1546; HII CST, 1990, BIOCHIM BIOPHYS ACTA, V1052, P327, DOI 10.1016/0167-4889(90)90229-7; HORWITZ J, 1992, J NEUROCHEM, V59, P1474, DOI 10.1111/j.1471-4159.1992.tb08463.x; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KISS Z, 1993, FEBS LETT, V333, P229, DOI 10.1016/0014-5793(93)80659-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOIDL J, 1990, BIOCHIM BIOPHYS ACTA, V1049, P75; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MIZUNUMA M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P213; MUELLER HW, 1984, J LIPID RES, V25, P283; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SCHRAKAMP G, 1988, J LIPID RES, V29, P325; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	38	50	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7097	7103		10.1074/jbc.270.13.7097	http://dx.doi.org/10.1074/jbc.270.13.7097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7535766	hybrid			2022-12-25	WOS:A1995QQ43100016
J	DRACHMAN, JG; GRIFFIN, JD; KAUSHANSKY, K				DRACHMAN, JG; GRIFFIN, JD; KAUSHANSKY, K			THE C-MPL LIGAND (THROMBOPOIETIN) STIMULATES TYROSINE PHOSPHORYLATION OF JAK2, SHC, AND C-MPL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR RECEPTOR SUPERFAMILY; SIGNAL TRANSDUCTION; ERYTHROPOIETIN RECEPTOR; CYTOPLASMIC REGION; MOLECULAR-CLONING; BETA-SUBUNIT; SRC-FAMILY; GROWTH; INTERLEUKIN-3; PROTEIN	alpha-Mpl is a member of the cytokine receptor superfamily, expressed primarily on hematopoietic cells. Recently, the c-Mpl Ligand was cloned and found to have thrombopoietic activity. In this paper we report that ligand binding induced tyrosine phosphorylation in BaF3 cells engineered to express the murine Mpl receptor (BaF3/mMpl). Phosphorylation occurred within 1 min at cytokine concentrations sufficient for proliferation of receptor-bearing cells. Using specific antibodies for immunoprecipitation and Western blotting, several of these phosphorylated proteins were identified. Shc and Jak2, known cytokine signaling molecules, and the c-Mpl receptor were shown to be major substrates for tyrosine phosphorylation. In contrast, phospholipase C-gamma and phosphatidylinositol 3-kinase displayed little and no tyrosine phosphorylation, respectively, after thrombopoietin stimulation. Co-immunoprecipitation studies demonstrated that Jak2 became physically associated with c-Mpl relatively late in the observed time course (20-60 min), significantly later than tyrosine phosphorylation of Jak2 (15 min). These results suggest that c-Mpl induces signal transduction pathways similar to those of other known cytokines. Additionally, in light of its late physical association with c-Mpl following Ligand binding, Jak2 may not be the initiating tyrosine kinase in the thrombopoietin-induced signaling cascade.	UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; HARVARD UNIV,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02155	University of Washington; University of Washington Seattle; Harvard University; Dana-Farber Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043719] Funding Source: NIH RePORTER; NCI NIH HHS [CA31615] Funding Source: Medline; NIDDK NIH HHS [R01DK43719] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; DAMEN JE, 1993, BLOOD, V82, P2296; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; FUNG MR, 1991, J IMMUNOL, V147, P1253; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; HARPUR AG, 1992, ONCOGENE, V7, P1347; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; IHLE JN, 1994, BAILLIERE CLIN HAEM, V7, P17, DOI 10.1016/S0950-3536(05)80005-8; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MIYAJIMA A, 1993, BLOOD, V82, P1960; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUDA K, 1992, BLOOD, V79, P2880; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1994, J BIOL CHEM, V259, P1599; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TOJO A, 1987, EXP CELL RES, V171, P16, DOI 10.1016/0014-4827(87)90247-3; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YIN TG, 1994, EXP HEMATOL, V22, P467	45	195	201	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					4979	4982		10.1074/jbc.270.10.4979	http://dx.doi.org/10.1074/jbc.270.10.4979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7534285	hybrid			2022-12-25	WOS:A1995QL58000007
J	PALANIAPPAN, C; FAY, PJ; BAMBARA, RA				PALANIAPPAN, C; FAY, PJ; BAMBARA, RA			NEVIRAPINE ALTERS THE CLEAVAGE SPECIFICITY OF RIBONUCLEASE-H OF HUMAN-IMMUNODEFICIENCY-VIRUS-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDINONE DERIVATIVES; SELECTIVE INHIBITORS; ANGSTROM RESOLUTION; HIV-1 REPLICATION; CRYSTAL-STRUCTURE; TIBO DERIVATIVES; STRAND TRANSFER; BINDING-SITE; TYPE-1; DNA	The action of the dipyridodiazepinone nevirapine (BI-RG-587) on polymerization and RNase H activities of human immunodeficiency virus reverse transcriptase (RT) was examined. Substrates using heteropolymeric DNA primers hybridized to complementary RNA templates were employed. Challenged assays were performed that allowed measurement of activity of the RT resulting from a single round of binding of RT to substrate. Results demonstrated that nevirapine alters the cleavage specificity of the RNase H. Instead of a primary cleavage approximately 18 nucleotides upstream of the DNA 3' terminus, multiple cleavages were observed ahead of and behind this site. This indicated that the compound facilitates sliding of the RT away from the DNA primer terminus allowing cleavage at more sites. The change in specificity occurred whether the primer terminus was at the end or internal on the template. Experiments with RNA primers on circular DNA demonstrated a nevirapine-induced stimulation of RNase H activity beyond the increase expected from the change in cleavage specificity. Examination of polymerization showed that the compound decreased both the number of primers that underwent synthesis and the processive elongation of those primers, The significance of these results with respect to viral replication and recombination is discussed.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARROLL SS, 1993, J BIOL CHEM, V268, P276; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FU T, 1992, J VIROL, V66, P406; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P4110; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOPP EB, 1991, NUCLEIC ACIDS RES, V19, P3035, DOI 10.1093/nar/19.11.3035; LARDER BA, 1994, J GEN VIROL, V75, P951, DOI 10.1099/0022-1317-75-5-951; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NAKANE H, 1990, BIOCHEMISTRY-US, V29, P2841, DOI 10.1021/bi00463a029; OLSEN DB, 1994, NUCLEIC ACIDS RES, V22, P1437, DOI 10.1093/nar/22.8.1437; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; TAN GT, 1991, J BIOL CHEM, V266, P23529; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; TAYLOR PB, 1994, J BIOL CHEM, V269, P6325; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	38	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4861	4869		10.1074/jbc.270.9.4861	http://dx.doi.org/10.1074/jbc.270.9.4861			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7533167	hybrid			2022-12-25	WOS:A1995QK08400096
J	GHERZI, R; CARNEMOLLA, B; SIRI, A; PONASSI, M; BALZA, E; ZARDI, L				GHERZI, R; CARNEMOLLA, B; SIRI, A; PONASSI, M; BALZA, E; ZARDI, L			HUMAN TENASCIN GENE - STRUCTURE OF THE 5'-REGION, IDENTIFICATION, AND CHARACTERIZATION OF THE TRANSCRIPTION REGULATORY SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEXABRACHION TENASCIN; EXPRESSION; PROTEINS; INTRON; LOCALIZATION; HOMEODOMAIN; MOLECULE; HOMEOBOX; PROMOTER; BINDING	This report describes the genomic organization of the 5'-region of the human tenascin-C (TN) gene and the functional characterization of its promoter. Approximately 2300 base pairs of the TN gene 5'-flanking region have been cloned and sequenced. This genomic region contains several potential binding sites for transcription factors. By primer extension and S1 nuclease analysis we have localized the transcription start site. The first exon of the TN gene (179 base pairs long) is present in the two major TN transcripts, showing that the expression of these two mRNAs is regulated by a single promoter. The 220 bases upstream to the transcription start site are equally active in directing the expression of chloramphenicol acetyltransferase (CAT) reporter gene in TN producer and nonproducer cells. Using deletion fragments of the human 5'-flanking region we have shown the presence of putative ''silencer'' elements in the -220 to -2300 region active in both TN producer and nonproducer cell lines. Furthermore, we have demonstrated that the selective transcription in TN producing cells requires the presence of a 1.3-kilobase portion of the TN gene intron 1 in the CAT expression vectors. These findings indicate that complex mechanisms control the transcriptional regulation of TN gene.	IST NAZL RIC CANC, CELL BIOL LAB, I-16132 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST			Gherzi, Roberto/AAA-7256-2020; Ponassi, Marco/K-8000-2016	Gherzi, Roberto/0000-0001-8654-0611; Ponassi, Marco/0000-0002-5418-2458				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; BORSI L, 1994, CELL ADHES COMMUN, V1, P307, DOI 10.3109/15419069409097262; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHIQUET M, 1991, SEMIN NEUROSCI, V3, P341; CHIQUETEHRISMANN R, 1993, SEMIN CANCER BIOL, V4, P301; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; EDELMAN GM, 1992, TRENDS BIOCHEM SCI, V17, P228, DOI 10.1016/0968-0004(92)90383-K; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GHERZI R, 1994, EXP CELL RES, V213, P20, DOI 10.1006/excr.1994.1168; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HOLST BD, 1994, J BIOL CHEM, V269, P22245; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MATSUMOTO K, 1992, GENOMICS, V12, P485, DOI 10.1016/0888-7543(92)90438-X; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEUBERGER MS, 1988, NUCLEIC ACIDS RES, V16, P6713, DOI 10.1093/nar/16.14.6713; NIES DE, 1991, J BIOL CHEM, V266, P2818; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	47	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3429	3434		10.1074/jbc.270.7.3429	http://dx.doi.org/10.1074/jbc.270.7.3429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7531707	hybrid			2022-12-25	WOS:A1995QG47100080
J	REEVE, JG; GUADANO, A; XIONG, JY; MORGAN, J; BLEEHEN, NM				REEVE, JG; GUADANO, A; XIONG, JY; MORGAN, J; BLEEHEN, NM			DIMINISHED EXPRESSION OF INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING PROTEIN-5 AND ACTIVATION OF IGF-I-MEDIATED AUTOCRINE GROWTH IN SIMIAN-VIRUS 40-TRANSFORMED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOMEDIN-C; FACTOR RECEPTORS; TUMOR-ANTIGEN; CELLS; TRANSFORMATION; IDENTIFICATION; NOMENCLATURE; VARIABLES; SECRETION; GENE	The reduced growth factor requirements of murine fibroblasts transformed by simian virus 40 (SV 40) have been attributed to insulin-like growth factor (IGF)-I induction by T antigen and consequent activation of IGF-I receptor signaling. The present study shows that the autonomous growth of SV 40-transformed human fibroblasts also requires type-I IGF-I receptor activation but that this is not due to de novo induction of IGF-I gene expression since untransformed human fibroblasts, which fail to proliferate in the absence of serum, also showed IGF-I gene expression under serum-free conditions. DNA synthesis assays confirmed that untransformed cells were responsive to exogenous IGF and indicated that transformed cells were already maximally stimulated, In untransformed fibroblasts. IGF binding was principally to abundant membrane-associated IG FBP-5, whereas in transformed fibroblasts this protein was minimally expressed, and IGF binding was to IGF receptors. Loss of detectable membrane-associated IGFBP-5 in transformed cells was associated with diminished IGFBP-5 gene expression and with loss of IGF-II gene expression. Exogenous IGFBP-5 associated with the membranes of transformed cells and inhibited the autocrine growth of these cells. These findings suggest that loss of IGFBP-5 in SV 40 transformed fibroblasts facilitates interaction of endogenously produced IGF-I with the IGF-I receptor and increases their sensitivity to autocrine stimulation.			REEVE, JG (corresponding author), MRC, MRC CTR, CLIN ONCOL & RADIOTHERAPEUT UNIT, CAMBRIDGE CB2 2QH, ENGLAND.							BACH LA, 1994, GROWTH REGUL S1, V4, pI169; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BALLARD J, 1989, ACTA ENDOCRINOL-COP, V121, P751, DOI 10.1530/acta.0.1210751; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; Blat C, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008872; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1987, MOL ENDOCRINOL, V1, P339, DOI 10.1210/mend-1-5-339; CLEMMONS DR, 1991, J CLIN ENDOCR METAB, V73, P727, DOI 10.1210/jcem-73-4-727; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; COHEN P, 1991, ACTA ENDOCRINOL-COP, V124, P74; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; DEFENDI V, 1982, J CELL PHYSIOL, P131; DICKER P, 1981, EXP CELL RES, V135, P221, DOI 10.1016/0014-4827(81)90314-1; DROP SLS, 1992, ENDOCRINOLOGY, V130, P1736; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GOOLSBY CL, 1990, CANCER GENET CYTOGEN, V50, P231, DOI 10.1016/0165-4608(90)90183-B; Hill DJ, 1992, GROWTH FACTORS, V6, P315, DOI 10.3109/08977199209021543; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; IRMINGER JC, 1989, EUR J PEDIATR, V148, P620, DOI 10.1007/BF00441514; JANSEN M, 1985, FEBS LETT, V179, P243, DOI 10.1016/0014-5793(85)80527-5; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAPLAN PL, 1981, VIROLOGY, V108, P484, DOI 10.1016/0042-6822(81)90455-4; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KIEFER MC, 1993, GROWTH REGULAT, V3, P56; KULL FC, 1983, J BIOL CHEM, V258, P6561; Lamson G, 1991, Growth Factors, V5, P19, DOI 10.3109/08977199109000268; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; REEVE JG, 1993, CANCER RES, V53, P4680; REEVE JG, 1992, J NATL CANCER I, V84, P628, DOI 10.1093/jnci/84.8.628; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; SACH GH, 1981, IN VITRO, V17, P1; SCHOFIELD PN, 1991, BRIT J CANCER, V63, P687, DOI 10.1038/bjc.1991.156; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; STURM MA, 1989, ENDOCRINOLOGY, V124, P388, DOI 10.1210/endo-124-1-388; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731	48	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					135	142		10.1074/jbc.270.1.135	http://dx.doi.org/10.1074/jbc.270.1.135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529226	hybrid			2022-12-25	WOS:A1995QA28700025
J	VIRIYAKOSOL, S; KIRKLAND, TN				VIRIYAKOSOL, S; KIRKLAND, TN			A REGION OF HUMAN CD14 REQUIRED FOR LIPOPOLYSACCHARIDE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LPS-BINDING; 70Z/3 CELLS; PROTEIN; ENDOTOXIN; RESPONSES; RECEPTOR; ACTIVATION; EXPRESSION; CACHECTIN	CD14, a glycosylphosphatidylinositol-anchored protein on the surface of monocytes, macrophages, and polymorphonuclear leukocytes, is a receptor for lipopolysaccharide (LPS), CD14 binding of LPS is enhanced by serum proteins, especially lipopolysaccharide binding protein. The serum dependent binding of LPS to CD14 stimulates macrophages to make cytokines, which can cause septic shock in humans and animals. Here, we identify a region in human CD14 which is important in serum-dependent LPS binding and LPS-induced cellular activation. Four small regions (4-5 amino acids long) within the N-terminal 65 amino acids of CD14 were deleted singly or in combination. The deletion mutants were stably expressed in Chinese hamster ovary (CHO) cells. The mutants were characterized in three assays: reactivity with anti-CD14 monoclonal antibody, serum-dependent LPS binding, and LPS induced activation of NF-KB, Some of the mutants selectively lost reactivity with the anti-CD14 monoclonal antibody that inhibited serum-dependent LPS binding and cellular activation, All of the mutants bound much less LPS than wild type CD14 in the presence of serum, None of the mutants bound more LPS than control CD14-CHO cells in the absence of serum, CD14-CHO cells respond to LPS by activation of NP-kappa B. All of the deletion mutants were less active LPS receptors than wild type CD14-CHO cells. The Delta AVEVE mutant, the Delta DDED and Delta PQPD double mutant, and the Delta DDED, Delta PQPD, Delta AVEVE, and Delta DPRQY quadruple deletion mutants were essentially inactive LPS receptors in CHO cells. These studies suggest that the 65 N-terminal amino acids of CD14 are critical for serum-dependent binding of LPS to CD14 and subsequent signal transduction in CHO cells.	UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT PATHOL,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07036] Funding Source: Medline; NIGMS NIH HHS [GM-37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; COUTURIER C, 1991, J IMMUNOL, V147, P1899; FERRERO E, 1990, J IMMUNOL, V145, P331; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HEUMANN D, 1992, J IMMUNOL, V148, P3505; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KIRKLAND TN, 1988, J IMMUNOL, V141, P3208; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SKELLY RR, 1979, INFECT IMMUN, V23, P287, DOI 10.1128/IAI.23.2.287-293.1979; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	21	92	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					361	368		10.1074/jbc.270.1.361	http://dx.doi.org/10.1074/jbc.270.1.361			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7529231	hybrid			2022-12-25	WOS:A1995QA28700057
J	HEMPEL, SL; MONICK, MM; HE, B; YANO, T; HUNNINGHAKE, GW				HEMPEL, SL; MONICK, MM; HE, B; YANO, T; HUNNINGHAKE, GW			SYNTHESIS OF PROSTAGLANDIN-H SYNTHASE-2 BY HUMAN ALVEOLAR MACROPHAGES IN RESPONSE TO LIPOPOLYSACCHARIDE IS INHIBITED BY DECREASED CELL OXIDANT TONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCIBLE CYCLOOXYGENASE; HYDROGEN-PEROXIDE; BINDING-ACTIVITY; HUMAN MONOCYTES; G/H SYNTHASE; INTACT-CELLS; C-JUN; ACTIVATION; EXPRESSION	We previously demonstrated that lipopolysaccharide (LPS) increases expression of the prostaglandin H synthase-2 (PGHS-2) gene (Hempel, S. L,, Monick, M. M., and Hunninghake, G. W. (1994) J. Clin. Invest. 93, 391-396). In this study, the expression of the PGHS-2 gene in response to changes in cell oxidant tone was studied. During LPS exposure, inhibition of synthesis of the free radical, NO, resulted in a small decrease in prostaglandin E(2) synthesis that did not reach statistical significance. There was no effect on enzyme mass or mRNA. In contrast, incubation of alveolar macrophages in the presence of LPS plus the antioxidant pyrrolidine dithiocarbamate, the spin trap 5,5-dimethyl-1-pyrroline-N-oxide, or hypoxia, resulted in near complete inhibition of prostaglandin E(2) synthesis, PGHS-2 enzyme synthesis, and gene transcription of PGHS-2 mRNA. There was no evidence of cytotoxicity. These results demonstrate that synthesis of PGHS-2 in response to LPS is inhibited by agents that decrease cell oxidant tone.	UNIV IOWA, DEPT MED, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System					NHLBI NIH HHS [HL-37121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMSTAD PA, 1992, CANCER RES, V52, P3952; BARCHOWSKY A, 1987, BIOCHIM BIOPHYS ACTA, V927, P372, DOI 10.1016/0167-4889(87)90102-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOKTER WHA, 1993, BLOOD, V81, P337; HABIB A, 1993, J BIOL CHEM, V268, P23448; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMPEL SL, 1993, AM J PHYSIOL, V264, pC1448, DOI 10.1152/ajpcell.1993.264.6.C1448; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; IVANOV V, 1993, J IMMUNOL, V151, P4694; JONES DA, 1993, J BIOL CHEM, V268, P9049; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI Y, 1992, J BIOL CHEM, V267, P15097; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MENON SD, 1993, J BIOL CHEM, V268, P26805; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; POU S, 1989, BIOCHIM BIOPHYS ACTA, V991, P459, DOI 10.1016/0304-4165(89)90073-1; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SAMUNI A, 1986, P NATL ACAD SCI USA, V83, P7593, DOI 10.1073/pnas.83.20.7593; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STINSKI MF, 1983, J VIROL, V46, P1; TAYLOR L, 1983, J BIOL CHEM, V258, P6855; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402; ZAVALA DC, 1983, RECENT ADV RESPIRATO, V3; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986; [No title captured]	40	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32979	32984						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7528741				2022-12-25	WOS:A1994QA63800041
J	ABUSOUD, HM; YOHO, LL; STUEHR, DJ				ABUSOUD, HM; YOHO, LL; STUEHR, DJ			CALMODULIN CONTROLS NEURONAL NITRIC-OXIDE SYNTHASE BY A DUAL MECHANISM - ACTIVATION OF INTRADOMAIN AND INTERDOMAIN ELECTRON-TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME P-450 REDUCTASE; BRAIN; PURIFICATION; CALCIUM; IDENTIFICATION; HYDROGEN; SULFITE; ENZYME; FLAVIN; LIVER	In neuronal nitric-oxide synthase (NOS), electron transfer proceeds across domains in a linear sequence from NADPH to flavins to heme, with calmodulin (CaM) triggering the interdomain electron transfer to the heme (Abu-Soud, H. M., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 10769-10772). Here, we utilized a neuronal NOS devoid of its bound heme and tetrahydrobiopterin (apo NOS) to examine whether interdomain electron transfer is responsible for CaM's activation of NO synthesis, substrate-independent NADPH oxidation, and cytochrome c and ferricyanide reduction, Of the four activities, two (cytochrome c and ferricyanide reduction) were similarly stimulated by CaM in ape-NOS when compared with native NOS, indicating that activation occurs by a mechanism not involving flavin-to-heme electron transfer, Further analysis showed that CaM increased the rate of electron transfer from NADPH into the flavin centers by a factor of 20, revealing a direct activation of the NOS reductase domain by CaM. In contrast, CaM's activation of NO synthesis and substrate-independent NADPH oxidation appeared to involve flavin-to-heme electron transfer because these reactions were not activated in ape-NOS and were blocked in native NOS by agents that prevent heme iron reduction, Thus, CaM activates neuronal NOS at two points in the electron transfer sequence: electron transfer into the flavins and interdomain electron transfer between the flavins and heme. Activation at each point is associated with an up-regulation of domain-specific catalytic functions, The dual regulation by CaM is unique and represents a new means by which electron transfer can be controlled in a metalloflavoprotein.	CLEVELAND CLIN,DEPT IMMUNOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN L, 1991, BIOCHEM BIOPH RES CO, V180, P238, DOI 10.1016/S0006-291X(05)81282-3; DIGNAM JD, 1977, BIOCHEMISTRY-US, V16, P1116, DOI 10.1021/bi00625a014; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; POU S, 1992, J BIOL CHEM, V267, P24173; SANE PV, 1987, PHYTOCHEMISTRY, V26, P1289, DOI 10.1016/S0031-9422(00)81796-3; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WANG JL, 1993, J BIOL CHEM, V268, P22255; Williams C H Jr, 1979, Methods Enzymol, V62, P185; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	24	252	254	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32047	32050						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7528206				2022-12-25	WOS:A1994PX30400007
J	HJORTH, SA; ADELHORST, K; PEDERSEN, BB; KIRK, O; SCHWARTZ, TW				HJORTH, SA; ADELHORST, K; PEDERSEN, BB; KIRK, O; SCHWARTZ, TW			GLUCAGON AND GLUCAGON-LIKE PEPTIDE-1 - SELECTIVE RECEPTOR RECOGNITION VIA DISTINCT PEPTIDE EPITOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PIG SMALL-INTESTINE; EXPRESSION CLONING; PANCREAS; HORMONE; ANALOGS; BINDING; GENE	Glucagon and glucagon-like peptide 1 (GLP-1) are homologous peptide hormones that are recognized by likewise homologous, but highly selective receptors. Analogs of glucagon and GLP-1, in which the divergent residues were systematically exchanged, were employed to identify the structural requirements for their selective receptor recognition. Substitutions in the NH2-terminal part of the glucagon molecule with the corresponding GLP-1 residues, as for example in [Ala(2),Glu(3)]glucagon and [Val(10),Ser(12)]glucagon, reduced the binding affinity for the glucagon receptor several hundred-fold without increasing the affinity for the GLP-1 receptor. In contrast, introduction of GLP-1 residues into the far COOH-terminal part of the glucagon molecule, e.g. [Val(27),Lys(28),Gly(29),Arg(30)]glucagon, had a minimal effect on recognition of the glucagon receptor, but improved the affinity of the analog for the GLP-1 receptor up to 200-fold. Similarly, substitutions in especially the far COOH-terminal part of the GLP-1 molecule with the corresponding glucagon residues, e.g. des-Arg(30)-[Met(27)Asn(28), Thr(29)]GLP-1, decreased the affinity for the GLP-1 receptor several hundred-fold (IC50 = 0.4-190 nM) without increasing the affinity for the glucagon receptor. Conversely, substitutions in the NH2-terminal part of the GLP-1 molecule impaired the affinity for the GLP-1 receptor only moderately. We conclude that the selective recognition of the glucagon and GLP-1 receptors is determined by residues located at opposite ends of the homologous peptide ligands. This conclusion is supported by the observation that a ''chimeric'' peptide consisting of the NH2-terminal part of the glucagon molecule joined to the COOH-terminal part of the GLP-1 molecule was recognized with high affinity by both receptors.	RIGSHOSP 6321,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK; NOVO NORDISK AS,DIABET RES,DK-2880 BAGSVAERD,DENMARK	Rigshospitalet; Novo Nordisk				Hjorth, Siv Annegrethe/0000-0002-6470-650X; Schwartz, Thue W./0000-0002-0261-6904				ADELHORST K, 1994, J BIOL CHEM, V269, P6275; BRAND C, 1994, DIABETOLOGIA, V37; BRAND CL, 1994, DIABETES, V43, pA172; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; GALLWITZ B, 1990, J MOL ENDOCRINOL, V5, P33, DOI 10.1677/jme.0.0050033; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GOKE B, 1993, DIGESTION, V54, P339, DOI 10.1159/000201054; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOLST JJ, 1975, DIABETOLOGIA, V11, P211, DOI 10.1007/BF00422324; HRUBY VJ, 1986, BIOPOLYMERS, V25, P135; JACOBSEN CR, 1990, NEUROPEPTIDES THEIR, P403; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JORGENSEN JC, 1990, EUR J PHARMACOL, V186, P105, DOI 10.1016/0014-2999(90)94065-6; KAWAI K, 1991, DIABETES, V40, pA71; KOFOD H, 1988, AM J PHYSIOL, V254, pE454, DOI 10.1152/ajpendo.1988.254.4.E454; LIN MC, 1975, BIOCHEMISTRY-US, V14, P1559, DOI 10.1021/bi00679a002; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; ORSKOV C, 1987, DIABETOLOGIA, V30, P874; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; Schwartz TW, 1990, MOL BIOL ISLETS LANG, P153; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNSON CG, 1994, BIOCHEMISTRY-US, V33, P6884, DOI 10.1021/bi00188a018; UNSON CG, 1994, J BIOL CHEM, V269, P12548; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763	31	77	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30121	30124						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527026				2022-12-25	WOS:A1994PU52500015
J	AHMAD, F; LI, PM; MEYEROVITCH, J; GOLDSTEIN, BJ				AHMAD, F; LI, PM; MEYEROVITCH, J; GOLDSTEIN, BJ			OSMOTIC LOADING OF NEUTRALIZING ANTIBODIES DEMONSTRATES A ROLE FOR PROTEIN-TYROSINE-PHOSPHATASE 1B IN NEGATIVE REGULATION OF THE INSULIN ACTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-PHOSPHOTYROSINE ANTIBODIES; SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR RECEPTOR; HUMAN-PLACENTA; XENOPUS OOCYTES; PHOSPHORYLATION; CELLS; EXPRESSION; ACTIVATION; KINASE	Protein-tyrosine phosphatases (PTPases) have been postulated to balance the steady-state phosphorylation and the activation state of the insulin receptor and its substrate proteins. To explore whether PTP1B, a widely expressed, non-receptor type PTPase, regulates insulin signaling, we used osmotic shock to load rat KRC-7 hepatoma cells with affinity-purified neutralizing antibodies that immunoprecipitate and inactivate the enzymatic activity of recombinant rat PTP1B in vitro. In cells loaded with PTP1B antibody, insulin-stimulated DNA synthesis and phosphatidylinositol 3'-kinase activity were increased by 42% and 38%, respectively, compared with control cells loaded with preimmune IgG (p < 0.005). In order to characterize the potential site(s) of action of PTP1B in insulin signaling, we also determined that insulin-stimulated receptor autophosphorylation and insulin receptor substrate 1 tyrosine phosphorylation were increased 2.2- and 2.0-fold, respectively, and that insulin-stimulated receptor kinase activity toward an exogenous peptide substrate was increased by 57% in the PTP1B antibody loaded cells. Osmotic loading did not alter the cellular content of PTP1B protein, suggesting that the antibody acts in the cell by sterically blocking catalytic interactions between PTP1B and its physiological substrates. These studies demonstrate that PTP1B has a role in the negative regulation of insulin signaling and acts, at least in part, directly at the level of the insulin receptor. These results also show that insulin signaling can be enhanced by the inhibition of specific PTPases, a maneuver that has potential clinical relevance in the treatment of insulin resistance and Type II diabetes mellitus.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, DIV ENDOCRINOL & METAB, PHILADELPHIA, PA 19107 USA	Jefferson University			Khan, Faiyaz Ahmad/AAW-7944-2021		NIDDK NIH HHS [DK43396] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043396] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, BBA-PROTEIN STRUCT M, V1248, P57, DOI 10.1016/0167-4838(95)00003-D; AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BRAUTIGAN DL, 1993, MOL CELL BIOCHEM, V128, P121; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; GOLDSTEIN BJ, 1995, IN PRESS PHOSPHOPROT, V1; GOLDSTEIN BJ, 1995, IN PRESS DIABETES ME; GRUNBERGER G, 1983, BIOCHEM BIOPH RES CO, V115, P560, DOI 10.1016/S0006-291X(83)80181-8; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IDE R, 1994, BIOCHEM BIOPH RES CO, V201, P71, DOI 10.1006/bbrc.1994.1670; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SHIMIZU Y, 1986, J BIOL CHEM, V261, P7342; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WOODFORD TA, 1991, ADV PROTEIN PHOSPHAT, V6, P503; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	56	213	222	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20503	20508		10.1074/jbc.270.35.20503	http://dx.doi.org/10.1074/jbc.270.35.20503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7544790	hybrid			2022-12-25	WOS:A1995RR58400043
J	AMARATUNGA, A; FINE, RE				AMARATUNGA, A; FINE, RE			GENERATION OF AMYLOIDOGENIC C-TERMINAL FRAGMENTS DURING RAPID AXONAL-TRANSPORT IN-VIVO OF BETA-AMYLOID PRECURSOR PROTEIN IN THE OPTIC-NERVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PEPTIDE; CELLS; BRAIN; IDENTIFICATION; COMPARTMENTS; VESICLES; LOCALIZATION; DERIVATIVES; CLEAVAGE	The amyloid beta-protein (A beta) is a major component of extracellular deposits that are characteristic features of Alzheimer's disease. A beta is derived from the large transmembrane beta-amyloid precursor protein (beta APP). In the rabbit optic nerve/optic tract (ON), beta APP is synthesized in vivo in retinal ganglion cell perikarya, rapidly transported into the ON axons in small transport vesicles and is subsequently transferred to the axonal plasma membrane as well as to the presynaptic nerve terminals (Morin, P. J., Abraham, C. R., Amaratunga, A., Johnson, R. J., Huber, G., Sandell, J. H., and Fine, R. E. (1993) J. Neurochem. 61, 464-473). Present results indicate that there is rapid processing of beta APP in the ON to generate a 14-kDa C-terminal membrane-associated fragment that contains the A beta sequence. By using equilibrium sucrose density gradient fractionation, this fragment, as well as non-amyloidogenic C-terminal fragments and intact beta APP, are detected in at least two classes of transport vesicles destined for the plasma membrane and the presynaptic nerve terminal. The two classes of transported vesicles are distinguished by labeling kinetics as well as by density. In contrast to the ON, only non-amyloidogenic C-terminal fragments are generated in the retina, which contains the perikarya of retinal ganglion cells and glial (Muller) cells which also produce beta APP.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA; ELEANOR NORSE RODGERS VET ADM HOSP, BEDFORD, MA 01730 USA	Boston University					NATIONAL EYE INSTITUTE [R01EY008535] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 08535] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMARATUNGA A, 1995, J NEUROCHEM, V64, P2374; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; AUGENBRAUN E, 1993, EUR J CELL BIOL, V61, P34; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FERREIRA A, 1993, J NEUROSCI, V13, P3112; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MORIN PJ, 1991, J NEUROCHEM, V56, P415, DOI 10.1111/j.1471-4159.1991.tb08167.x; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MORIN PJ, 1991, ANN NY ACAD SCI, V632, P442, DOI 10.1111/j.1749-6632.1991.tb33150.x; MOYA KL, 1994, J NEUROCHEM, V63, P1971; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SAPIRSTEIN VS, 1994, J NEUROSCI RES, V37, P348, DOI 10.1002/jnr.490370307; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	40	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17268	17272		10.1074/jbc.270.29.17268	http://dx.doi.org/10.1074/jbc.270.29.17268			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7542234	hybrid			2022-12-25	WOS:A1995RK68900035
J	COLGAN, SP; PARKOS, CA; MCGUIRK, D; BRADY, HR; PAPAYIANNI, AA; FRENDL, G; MADARA, JL				COLGAN, SP; PARKOS, CA; MCGUIRK, D; BRADY, HR; PAPAYIANNI, AA; FRENDL, G; MADARA, JL			RECEPTORS INVOLVED IN CARBOHYDRATE-BINDING MODULATE INTESTINAL EPITHELIAL-NEUTROPHIL INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE; P-SELECTIN; MEL-14 ANTIGEN; LUNG INJURY; MONOLAYERS; MIGRATION; RECOGNITION; SPECIFICITY; LYMPHOCYTES; EXPRESSION	Neutrophil (polymorphonuclear neutrophil) migration across epithelial barriers is a common morphologic feature of many diseases. Previous studies show that PMN-epithelial interactions are dependent on the PMN beta(2)-integrin CD11b/18; however, nothing is known about surface carbohydrates and PMN epithelial interactions. Here we investigate the role of carbohydrates on PMN-epitehlial interactions using PMN and cultured monolayers of the intestinal epithelial cell line T84. Addition of the carbohydrates mannose 6-phosphate (Man-6-P) and glucose 6-phosphate (Glu-6-P), but not fructose 1-phosphate (Fru-1-P) inhibited transmigration by greater than or equal to 70%. Likewise, more complex carbohydrates, such as fucoidin and the Man-B-6-rich polysaccharide PPME selectively inhibited PMN transepithelial migration. These carbohydrates were found to be inhibitory in the apical-to-basolateral direction as well as the basolateral-to-apical direction, indicating a lack of polarity. This panel of related carbohydrates, however, was not effective in modulating short-term adhesion of PMN to epithelial monolayers, indicating that carbohydrate ligands may modulate different steps in the transmigration cascade. Finally, addition of functionally inhibitory monoclonal antibodies specific for the selectins (CD62E, CD62L, and CD62P) revealed no observable effect on PMN transmigration. These studies suggest that cell surface carbohydrates may play a role in inflammatory processes of the intestine.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,CTR DIGEST DIS,BOSTON,MA 02115; VET ADM MED CTR W ROXBURY,MED SERV,RENAL SECT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University	COLGAN, SP (corresponding author), BRIGHAM & WOMENS HOSP,DEPT ANESTHESIA,75 FRANCIS ST,BOSTON,MA 02115, USA.		Parkos, Charles a/B-3896-2009; Colgan, Sean P./B-4573-2009; Frendl, Gyorgy/AAE-5345-2020	Frendl, Gyorgy/0000-0001-8918-8553; Papagianni, Aikaterini/0000-0003-0437-5208	NIDDK NIH HHS [DK35932, DK33506, DK08777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035932, F32DK008777, P01DK033506, R37DK035932] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRADY HR, 1992, J IMMUNOL, V149, P2437; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; COLGAN SP, 1993, J CELL BIOL, V120, P785, DOI 10.1083/jcb.120.3.785; COLGAN SP, 1994, AM J PHYSIOL, V267, pC402, DOI 10.1152/ajpcell.1994.267.2.C402; DANA N, 1986, J IMMUNOL, V137, P3259; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, P6204; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KOIZUMI M, 1992, GASTROENTEROLOGY, V103, P840, DOI 10.1016/0016-5085(92)90015-Q; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEY K, 1993, BLOOD, V82, P1632; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; Madara JL, 1992, J TISS CULT METHODS, V14, P209; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NASH S, 1987, J CLIN INVEST, V80, P1104, DOI 10.1172/JCI113167; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PARKOS CA, 1995, AM J PHYSIOL-CELL PH, V268, pC472, DOI 10.1152/ajpcell.1995.268.2.C472; PARKOS CA, 1992, J CELL BIOL, V117, P757, DOI 10.1083/jcb.117.4.757; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PITELKA DR, 1983, J CELL BIOL, V96, P613, DOI 10.1083/jcb.96.3.613; SLODKI ME, 1973, BIOCHIM BIOPHYS ACTA, V304, P449, DOI 10.1016/0304-4165(73)90264-X; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1987, BLOOD, V70, P1842; TAKATA S, 1994, J CLIN INVEST, V93, P499, DOI 10.1172/JCI116999; TEDDER TF, 1990, J IMMUNOL, V144, P532; TEUFEL M, 1989, BIOL CHEM H-S, V370, P435, DOI 10.1515/bchm3.1989.370.1.435; YARDLEY JH, 1986, RECENT DEV THERAPY I, P3; YARDLEY JH, 1977, GASTROINTESTINAL TRA, P57; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725	38	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10531	10539		10.1074/jbc.270.18.10531	http://dx.doi.org/10.1074/jbc.270.18.10531			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7537733	hybrid			2022-12-25	WOS:A1995QW60100028
J	SCHWANINGER, M; BLUME, R; KRUGER, M; LUX, G; OETJEN, E; KNEPEL, W				SCHWANINGER, M; BLUME, R; KRUGER, M; LUX, G; OETJEN, E; KNEPEL, W			INVOLVEMENT OF THE CA2+-DEPENDENT PHOSPHATASE CALCINEURIN IN GENE-TRANSCRIPTION THAT BY STIMULATED BY CAMP THROUGH CAMP RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PANCREATIC-ISLET CELLS; BINDING PROTEIN; CYCLIC-AMP; MEMBRANE DEPOLARIZATION; CYCLOSPORINE-A; GLUCAGON GENE; FACTOR CREB; PHOSPHORYLATED CREB; CATALYTIC SUBUNIT	Gene transcription can be induced by cAMP and Ca2+ through distinct protein kinases phosphorylating the transcription factor CREB, which binds to cAMP response elements (CREs) in various genes. Induction of gene transcription by Ca2+ has been shown recently to depend on the Ca2+/calmodulin-dependent protein phosphatase calcineurin in pancreatic islet cells. This study investigates the role of calcineurin in CRE-directed gene transcription after stimulation by cAMP. Reporter fusion genes under the transcriptional control of CREs were transiently transfected into the cell line HIT. Pharmacological evidence suggests that cAMP stimulates CRE-mediated transcription through a Ca2+-dependent mechanism. The immunosuppressive drugs cyclosporin A and FK506 inhibited CRE-mediated transcription stimulated by cAMP. At the same concentrations they also inhibited calcineurin phosphatase activity. Reversal of calcineurin inhibition by rapamycin or overexpression of calcineurin led to disinhibition of CRE-mediated gene transcription. Immunoblots with a phosphoCREB-specific antibody showed that cyclosporin A and FK506 do not intrefere with CREB phosphorylation at serine 119 stimulated with cAMP or membrane depolarization. These results indicate that in HIT cells stimulation of CRE-mediated transcription depends not only on the activity of protein kinases phosphorylating CREB but also on the Ca2+/calmodulin-dependent protein phosphatase calcineurin that is necessary for the transcriptional competence of phosphorylated CREB.	UNIV GOTTINGEN,DEPT BIOCHEM PHARMACOL,D-37070 GOTTINGEN,GERMANY	University of Gottingen				Schwaninger, Markus/0000-0002-4510-9718				ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P1495, DOI 10.1210/me.7.11.1495; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JEFFERSON AB, 1991, J BIOL CHEM, V266, P1484; JOOST HG, 1979, HORM METAB RES, V11, P104, DOI 10.1055/s-0028-1092689; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; LI GD, 1992, MOL PHARMACOL, V42, P489; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OETJEN E, 1994, J BIOL CHEM, V269, P27036; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; REIK A, 1994, MOL ENDOCRINOL, V8, P490, DOI 10.1210/me.8.4.490; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SATIN LS, 1988, PFLUG ARCH EUR J PHY, V411, P401, DOI 10.1007/BF00587719; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SCHWANINGER M, 1993, N-S ARCH PHARMACOL, V348, P541; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUSSMAN KE, 1987, DIABETES, V36, P571, DOI 10.2337/diabetes.36.5.571; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647	50	77	77	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8860	8866		10.1074/jbc.270.15.8860	http://dx.doi.org/10.1074/jbc.270.15.8860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7536740	hybrid			2022-12-25	WOS:A1995QT44800072
J	STACHELHAUS, T; MARAHIEL, MA				STACHELHAUS, T; MARAHIEL, MA			MODULAR STRUCTURE OF PEPTIDE SYNTHETASES REVEALED BY DISSECTION OF THE MULTIFUNCTIONAL ENZYME GRSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAMICIDIN-S SYNTHETASE-2; OPEN READING FRAME; BACILLUS-SUBTILIS; NUCLEOTIDE-SEQUENCE; ACTIVATING FRAGMENT; PROTEIN TEMPLATES; GENE; BIOSYNTHESIS; SURFACTIN; DOMAINS	Analysis of the primary structure of peptide synthetases involved in non-ribosomal synthesis of peptide antibiotics revealed a highly conserved and ordered domain structure, These functional units, which are about 1000 amino acids in length, are believed to be essential for amino acid activation and thioester formation, To delineate the minimal extension of such a domain, we have amplified and cloned truncated fragments of the grsA gene, encoding the 1098-amino acid multifunctional gramicidin S synthetase 1, GrsA. The overexpressed His(6)-tagged GrsA derivatives were affinity-purified, and the catalytic properties of the deletion mutants were examined by biochemical studies including ATP-dependent amino acid activation, carboxyl thioester formation, and the ability to racemize the covalently bound phenylalanine from L- to the D-isomer, These studies revealed a core fragment (PheAT-His) that comprises the first 656 amino acid residues of GrsA, which restored all activities of the native protein, except racemization of phenylalanine. A further deletion of about 100 amino acids at the C-terminal end of the GrsA core fragment (PheAT-His), including the putative thioester binding motif LGGHSL, produced a 556-amino acid fragment (PheA-His) that shows a phenylalanine-dependent aminoacyl adenylation, but almost no thioester formation. A 291-amino acid deletion at the C terminus of the native GrsA, that contains a putative racemization site resulted in complete loss of racemization ability (PheATS-His), However, it retained the functions of specific amino acid activation and thioester formation, The results presented defined biochemically the minimum size of a peptide synthetase domain and revealed the locations of the functional modules involved in substrate recognition and ATP dependent activation as well as in thioester formation and racemization,	UNIV MARBURG,FACHBEREICH CHEM,D-35032 MARBURG,GERMANY	Philipps University Marburg								BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown T. A., 1991, MOL BIOL LABFAX; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; DSOUZA C, 1993, J BACTERIOL, V175, P3502, DOI 10.1128/jb.175.11.3502-3510.1993; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HOCHULI E, 1988, BIOTECHNOLOGY, V111, P1321; HORI K, 1991, J BIOCHEM-TOKYO, V110, P111, DOI 10.1093/oxfordjournals.jbchem.a123528; KITTELBERGER R, 1982, PEPTIDE ANTIBIOTICS, P209; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KRAUSE M, 1985, J BACTERIOL, V162, P1120, DOI 10.1128/JB.162.3.1120-1125.1985; KUROTSU T, 1991, J BIOCHEM-TOKYO, V109, P763, DOI 10.1093/oxfordjournals.jbchem.a123454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee S G, 1975, Methods Enzymol, V43, P585; LIPMANN F, 1971, ADV ENZYMOL RAMB, V35, P1; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PAVELAVRANCIC M, 1994, J BIOL CHEM, V269, P14962; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; Segel I. H., 1975, ENZYME KINETICS, P273; SKARPEID HJ, 1990, EUR J BIOCHEM, V187, P627, DOI 10.1111/j.1432-1033.1990.tb15346.x; SKARPEID HJ, 1990, EUR J BIOCHEM, V189, P517, DOI 10.1111/j.1432-1033.1990.tb15517.x; STEIN T, 1994, FEBS LETT, V340, P390; TOKITA K, 1993, J BIOCHEM-TOKYO, V114, P522, DOI 10.1093/oxfordjournals.jbchem.a124210; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; ULLRICH C, 1991, BIOCHEMISTRY-US, V30, P6503, DOI 10.1021/bi00240a022; VATER J, 1990, BIOCH PEPTIDE ANTIBI, P33; WEER G, 1994, CURR GENET, V26, P120; ZAMENHOF PJ, 1972, J BACTEIROL, V107, P171; Zuber Peter, 1993, P897	40	146	152	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6163	6169		10.1074/jbc.270.11.6163	http://dx.doi.org/10.1074/jbc.270.11.6163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7534306	hybrid			2022-12-25	WOS:A1995QM94500067
J	TRIANAALONSO, FJ; DABROWSKI, M; WADZACK, J; NIERHAUS, KH				TRIANAALONSO, FJ; DABROWSKI, M; WADZACK, J; NIERHAUS, KH			SELF-CODED 3'-EXTENSION OF RUN-OFF TRANSCRIPTS PRODUCES ABERRANT PRODUCTS DURING IN-VITRO TRANSCRIPTION WITH T7 RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; INVITRO TRANSCRIPTION; POLYINOSINIC ACID; POLYGUANYLIC ACID; DNA; BACTERIOPHAGE-T7; INITIATION; SEQUENCE; CLONING; MODEL	More than 70% of the RNA synthesized by T7 RNA polymerase during run-off transcription in vitro can be incorrect products, up to twice as long as the expected transcripts. Transcriptions with model templates indicate that false transcription is mainly observed when the correct product cannot form stable secondary structures at the 3'-end. Therefore, the following hypothesis is tested: after leaving the DNA template, the polymerase can bind a transcript to the template site and the 3'-end of the transcript to the product site and extend it, if the 3'-end is not part of a stable secondary structure. Indeed, incubation of purified transcripts with the polymerase in transcription conditions triggers a 3'-end prolongation of the RNA. When two RNAs of different lengths are added to the transcription mix, both generate distinct and specific patterns of prolonged RNA products without any interference, demonstrating the self-coding nature of the prolongation process, Furthermore, sequencing of the high molecular weight transcripts demonstrates that their 5'-ends are precisely defined in sequence, whereas the 3'-ends contain size-variable extensions which show complementarity to the correct transcript. Surprisingly, a reduction of the UTP concentration to 0.2-1.0 mM in the presence of 3.5-4.0 mM of the other NTPs leads to faithful transcription and good yields, irrespective of the nucleotide composition of the template.	MAX PLANCK INST MOLEC GENET, AG RIBOSOMEN, D-14195 BERLIN, GERMANY	Max Planck Society								ARNOTT S, 1974, BIOCHEM J, V141, P537, DOI 10.1042/bj1410537; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2235; Chamberlin M., 1982, ENZYMES, V15, P87; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; HAHN CS, 1989, METHOD ENZYMOL, V180, P121; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; KONARSKA MM, 1990, CELL, V63, P609, DOI 10.1016/0092-8674(90)90456-O; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; Lis J T, 1980, Methods Enzymol, V65, P347; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NEGRE D, 1989, P NATL ACAD SCI USA, V86, P4902, DOI 10.1073/pnas.86.13.4902; Neuhard, 1987, ESCHERICHIA COLI SAL, V1, P445; PADDOCK GV, 1989, BIOTECHNIQUES, V7, P856; Sambrook J, 1989, MOL CLONING LABORATO; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; WEITZMANN CJ, 1990, NUCLEIC ACIDS RES, V18, P3515, DOI 10.1093/nar/18.12.3515; WEITZMANN CJ, 1993, FASEB J, V7, P177, DOI 10.1096/fasebj.7.1.7916699; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	117	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6298	6307		10.1074/jbc.270.11.6298	http://dx.doi.org/10.1074/jbc.270.11.6298			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7534310	hybrid			2022-12-25	WOS:A1995QM94500088
